DAVID Y. IGE
GOVERNOR

MAJOR GENERAL KENNETH S. HARA
DIRECTOR OF EMERGENCY MANAGEMENT

LUKE P. MEYERS
ADMINISTRATOR OF EMERGENCY MANAGEMENT

PHONE (808) 733-4300
FAX (808) 733-4287

STATE OF HAWAII

DEPARTMENT OF DEFENSE
OFFICE OF THE DIRECTOR OF EMERGENCY MANAGEMENT
3949 DIAMOND HEAD ROAD
HONOLULU, HAWAII 96816-4495

STATE OF HAWAII
DEPARTMENT OF DEFENSE
HAWAII EMERGENCY MANAGEMENT AGENCY

TESTIMONY ON HOUSE BILL 1286 HD1,
RELATING TO TRAVEL

Before the House Committee on
JUDICIARY AND HAWAIIAN AFFAIRS

By

Luke P. Meyers

Administrator, Hawaii Emergency Management Agency (HI-EMA)

Aloha Chair Nakashima, Vice-Chair Matayoshi, and Members of the Committee:

House Bill 1286 exempts any person from the post-arrival mandatory self-quarantine if the person receives a negative test result prior to arrival. Allows the incident commander to establish conditions for exemption. Requires certain COVID-19 tests for travelers who do not have a test result upon arrival to avoid mandatory self-quarantine. Requires any person who does not obtain a negative test result for COVID-19 pre-arrival to be responsible for all costs associated with that person's mandatory self-quarantine. Repeals on 12/31/2021. Effective 7/1/2050. (HD1)

The Hawaii Emergency Management Agency (HI-EMA) **offers comments on** House Bill 1286.

While HI-EMA understands the challenges of the COVID-19 emergency, HI-EMA feels that this measure may not be necessary as the various counties already have a clear sense of how they wish to handle quarantines and testing requirements for travelers. This has also been addressed in the State emergency proclamations for this incident. As the incident evolves, similar discussions on vaccinations will be needed.

Thank you.

Luke P. Meyers: Luke.P.Meyers@hawaii.gov; 808-733-4300

DAVID Y. IGE
GOVERNOR OF HAWAII

ELIZABETH A. CHAR, M.D.
DIRECTOR OF HEALTH

STATE OF HAWAII
DEPARTMENT OF HEALTH
P. O. Box 3378
Honolulu, HI 96801-3378
doh.testimony@doh.hawaii.gov

Testimony COMMENTING on H.B. 1286 H.D. 1
RELATING TO TRAVEL

REP. MARK M. NAKASHIMA, CHAIR
HOUSE COMMITTEE ON JUDICIARY & HAWAIIAN AFFAIRS
Hearing Date: 2/17/2021 Room Number: VIA VIDEO CONFERENCE

Department Testimony: Thank you for the opportunity to provide comment on House Bill 1286 H.D. 1 which establishes COVID-19 testing requirements, exemptions to said requirements, and coverage of associated costs of post-arrival mandatory self-quarantining for travelers.

The Department of Health appreciates the amendments made to this bill which clarify that the Incident Commander will establish conditions when a person is automatically exempt from the mandatory self-quarantine, and that the State Safe Travels Program will be responsible for approving acceptable COVID-19 tests for purposes of the program. The Department of Health also appreciates the amendment to specify that any person who does not obtain a negative test result prior to arrival shall be responsible for securing and paying all costs associated with mandatory self-quarantine.

The question of how mandatory quarantine will be implemented and enforced and with what resources long term remains unclear. The Department recommends the bill specify that the Safe Travels program, administered by the incident commander, will manage implementation of travel-related quarantine.

The Governor's Eighteenth Emergency Proclamation provides exemption to "persons who, prior to departure to the State, upload into the State's Safe Travels program or otherwise provide written hard copy confirmation from a DOH approved COVID-19 testing facility ("Trusted Testing Partner") of a negative test result, using a DOH-approved form, from an observed test

administered to the traveler within 72 hours from the final leg of departure," and does not provide for exceptions for travelers who did not receive a test result upon arrival from the final leg of departure due to unforeseen circumstances through no fault of the person. This modification was made because of the excessive resources that were being directed to management of persons who arrived without a negative test already uploaded, and subsequently received a positive result. DOH is concerned that reinstatement of this exception will provide a "loophole" which will again drain resources of several state agencies, including DOH, Department of Transportation, and the Attorney General's office.

Regarding the merits of a pre-travel test only versus the addition of a post-arrival test, the Department of Health has always maintained that a post-travel test 3-5 days following arrival increases detection of travelers who may have tested negative prior to travel while still incubating COVID-19. Mandating self-quarantine until a post-travel test has been performed is likely to reduce importation and dissemination of COVID-19, including new variant strains, to Hawaii compared to only requiring a pre-travel test. DOH also acknowledges practical and resource limitations to implementing a statewide post-arrival testing program. However, allowing flexibility for implementation of more stringent quarantine mandates may be appropriate to provide improved protection in localities where such limitations can be overcome.

Thank you for the opportunity to testify on this measure.

HAWAI'I TOURISM AUTHORITY

Hawai'i Convention Center
1801 Kalākaua Avenue, Honolulu, Hawai'i 96815
kelepona tel 808 973 2255
kelepa'i fax 808 973 2253
kahua pa'a web hawaiitourismauthority.org

David Y. Ige
Governor

John De Fries
President and Chief Executive Officer

Statement of
JOHN DE FRIES

Hawai'i Tourism Authority
before the
HOUSE COMMITTEE ON JUDICIARY & HAWAIIAN AFFAIRS

Wednesday, February 17, 2021
2:00 PM
State Capitol, Conference Room #325
via videoconference

In consideration of
HOUSE BILL NO. 1286 HD1
RELATING TO TRAVEL

Chair Nakashima, Vice Chair Matayoshi, and members of the House Committee on Judiciary & Hawaiian Affairs: the Hawai'i Tourism Authority (HTA) is **providing comments** on House Bill 1286 HD1, which exempts any person from the post-arrival mandatory self-quarantine if the person receives a negative test result prior to arrival. It allows the incident commander to establish conditions for an exemption. It also requires certain COVID-19 tests for travelers who do not have a test result upon arrival to avoid mandatory self-quarantine. It also requires any person who does not obtain a negative test result for COVID-19 pre-arrival to be responsible for all costs associated with that person's mandatory self-quarantine.

This bill would standardize the protocols across the state for all travelers to Hawai'i and between the counties, which would help to make it less confusing for everyone. There are different protocols for trans-Pacific travelers and interisland travelers, which has been a challenge to navigate and understand. A consistent statewide policy for trans-Pacific and interisland travel that is based on protecting the people and communities of Hawai'i is a prudent approach.

Currently, trans-Pacific travelers must have their negative test results before they depart to Hawai'i. This bill would instead require the results upon arrival, giving travelers several extra hours to receive their test results. This bill would also allow those who don't get their negative test result by the time they arrive to then take another test upon arrival in Hawai'i. Currently, there is no post-arrival testing option, and sometimes, the travelers have delayed results through no fault of their

own. This bill would also create standardized quarantine exemption requirements across the state and counties.

The statistics show that the Safe Travels pre-travel testing program works as an extra layer of safety while also allowing travelers to fly to Hawai‘i without having to quarantine. The Safe Travels program is helping our visitor industry to recover, and we feel that this bill would help speed up the recovery efforts by making the rules easier to understand.

We appreciate this opportunity to provide comments on HB1286 HD1.

Council Chair
Alice L. Lee

Vice-Chair
Keani N.W. Rawlins-Fernandez

Presiding Officer Pro Tempore
Tasha Kama

Councilmembers
Gabe Johnson
Kelly Takaya King
Michael J. Molina
Tamara Paltin
Shane M. Sinenci
Yuki Lei K. Sugimura

Director of Council Services
Traci N. T. Fujita, Esq.

COUNTY COUNCIL

COUNTY OF MAUI
200 S. HIGH STREET
WAILUKU, MAUI, HAWAII 96793
www.MauiCounty.us

February 16, 2021

TO: Honorable Mark M. Nakashima, Chair
House Committee on Judiciary and Hawaiian Affairs

FROM: Alice L. Lee
Council Chair

DATE: February 17, 2021

SUBJECT: **OPPOSITION TO HB 1286, RELATING TO TRAVEL**

Thank you for the opportunity to testify in **opposition** to this important measure. The purpose of this measure is to exempt any person from the post-arrival mandatory self-quarantine if the person receives a negative test result prior to arrival.

The Maui County Council has not had the opportunity to take a formal position on this measure. Therefore, I am providing this testimony in my capacity as an individual member of the Maui County Council.

I oppose this measure for the following reasons:

1. State policy should set the minimum health standards while allowing the counties the flexibility to set the appropriate, stronger safety thresholds above that to reflect the unique capacity and needs of the individual islands even within a county.
2. This measure deprives the counties of self-rule and fails to appreciate the different challenges facing the different counties. It also fails protect rural communities, such as Hana, and their limited capacity to deal with surge cases.
3. While I appreciate and acknowledge the hardships the pandemic has caused everyone in Hawaii, especially the tourism industry and small businesses, the current system is working and allows counties to react to the needs of their relative communities.

For the foregoing reasons, I **OPPOSE** this measure.

ocs:proj:legis:21legis:21testimony:hb1286_paf21-008(31)a_jbf

COUNTY COUNCIL
Arryl Kaneshiro, Chair
Mason K. Chock, Vice Chair
Bernard P. Carvalho, Jr.
Felicia Cowden
Bill DeCosta
Luke A. Evslin
KipuKai Kualiʻi

OFFICE OF THE COUNTY CLERK

Jade K. Fountain-Tanigawa, County Clerk
Scott K. Sato, Deputy County Clerk

Telephone: (808) 241-4188
Facsimile: (808) 241-6349
E-mail: cokcouncil@kauai.gov

Council Services Division
4396 Rice Street, Suite 209
Līhuʻe, Kauaʻi, Hawaiʻi 96766

February 16, 2021

TESTIMONY OF FELICIA COWDEN
COUNCILMEMBER, COUNTY OF KAUAʻI
ON
HB 1286, HD1, RELATING TO TRAVEL
House Committee on Judiciary & Hawaiian Affairs
Wednesday, February 17, 2021
2:00 p.m.
Via Videoconference
Conference Room 325

Dear Chair Nakashima and Members of the Committee:

Thank you for this opportunity to provide testimony in opposition to HB 1286, HD1, Relating to Travel. My testimony is submitted in my individual capacity as a Member of the Kauaʻi County Council and Committee Chair of the Council's Public Safety & Human Services Committee.

I OPPOSE HB 1286, HD1, because this sets a precedent for managing future health crises beyond this virus, this governor, and these mayors. We are seeing increasing national political polarization, a wave of new island residents, and a national trend towards personality-based elections. Hawaiʻi Revised Statutes Section 127A-13 regarding Additional Powers in an Emergency Period authorizes a bone-chilling level of authority that could authorize and empower dictatorship reminiscent of World War II. This existing Emergency Management policy, which I opposed, passed in 2020. HB 1286, HD1, furthers the capacity for authoritarian mission creep by removing an important layer of county home rule. Population groups can be targeted with overwhelming force. The injustice visited upon our local Japanese population should never be allowed again. The wording of our Additional Powers allows for a range of injustices and more with the profound capabilities the governor now has "to protect" the State from an unclarified, undefined "infectious, communicable or other disease" that is "dangerous" in the governor's OPINION. It is not evident that a check or balance is in place were we to ever have a reckless governor.

Each island has unique medical, economic, and emergency circumstances in which the counties should be allowed the flexibility to set appropriate policies in a timely basis that are above the minimum set by the state. We need more county policy freedom, rather than less, in the times of emergency proclamations. The economic policy for counties in the COVID-19 time could be designed with more elegance and accountability if the mayors were allowed greater control.

Kauaʻi, Maui, and Hawaiʻi counties have had similar occupancy rates for January within 1% difference based on Hawaiʻi Tourism Authority (HTA) data, while Kauaʻi now rests at a one (1) COVID case/day average and relative freedom, whereas the other two neighbor island counties have the more difficult circumstance of poor visitor numbers coupled with lowered freedoms due to higher case counts.

Creating a bill to force Kauaʻi to open up to tourism beyond what our medical capacity can handle on the grounds of our five percent (5%) of the state population's economic cost is shortsighted. The larger implications of this bill are more profound than simply forcing compliance upon the smallest county. I humbly ask for your vote against HB 1286, HD1.

Thank you again for this opportunity to provide testimony. Should you have any questions, please feel free to contact me or Council Services Staff at (808) 241-4188 or via E-mail to cokcouncil@kauai.gov.

Sincerely,

Felicia Cowden

FELICIA COWDEN
Councilmember, Kauaʻi County Council

Mitchell D. Roth
Mayor

Lee E. Lord
Managing Director

Robert H. Command
Deputy Managing Director

County of Hawai'i
Office of the Mayor

25 Aupuni Street, Suite 2603 • Hilo, Hawai'i 96720 • (808) 961-8211 • Fax (808) 961-6553
KONA: 74-5044 Ane Keohokalole Hwy., Bldg C • Kailua-Kona, Hawai'i 96740
(808) 323-4444 • Fax (808) 323-4440

February 16, 2021

Chairman Mark M. Nakashima
Vice-Chairman Scott Z. Matayoshi
House Committee on Judiciary & Hawai'ian Affairs
Hawai'i State Legislature
415 S. Beretania Street
Honolulu, Hawai'i 96813

Subject: **H.B. 1286, HD 1, RELATING TO TRAVEL**
Hearing Date: Wednesday, February 17, 2021
Time/Place of Hearing: Rm. 325 via teleconference at 2:00 p.m.
Testimony In Oppositing to HB 1286, HD 1

Aloha Chair Nakashima, Vice Chair Matayoshi, and members of the House Committee on Judiciary & Hawai'ian Affairs,

The County of Hawai'i is expressing its firm **opposition** to House Bill 1286, HD 1, relating to Testing and Quarantine requirements under the Safe Travels Program.

While it appears well intended, the bill will result in sweeping provisions that create a "one size fits all" approach to addressing the health and safety of both our travelers and residents, without regard to the unique conditions faced by our island counties. Further, it usurps the authority of Mayor's to protect their communities in a manner that best serves them. Since counties already have measures in place to address testing and quarantines that are working, we find this bill to be unnecessary.

I am humbly asking for your committee's sincerest consideration of our opposition to this proposed legislation. Please feel free to contact me for any additional information.

Mahalo

Mitchell D. Roth
Mayor
County of Hawai'i

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

Council Chair
Alice L. Lee

Vice-Chair
Keani N.W. Rawlins-Fernandez

Presiding Officer Pro Tempore
Tasha Kama

Councilmembers
Riki Hokama
Kelly Takaya King
Michael J. Molina
Tamara Paltin
Shane M. Sinenci
Yuki Lei K. Sugimura

Director of Council Services
Traci N. T. Fujita, Esq.

COUNTY COUNCIL
COUNTY OF MAUI
200 S. HIGH STREET
WAILUKU, MAUI, HAWAII 96793
www.MauiCounty.us

February 17, 2021

COMMITTEE ON JUDICIARY & HAWAIIAN AFFAIRS
Rep. Mark M. Nakashima, Chair
Rep. Scot Z. Matayoshi, Vice Chair
February 17, 2021 at 2:00 pm

SUBJECT: TESTIMONY IN STRONG OPPOSITION OF HB1286 RELATING TO TRAVEL

Aloha a Luna Hoʻomalu Nakashima, e Hope Luna Hoʻomalu Matayoshi, a e honorable committee members,

Mahalo for this opportunity to testify on this measure. As the Councilmember from Molokai, I am in STRONG OPPOSITION of HB1286, related to travel.

This seems to be a political battle between those who appreciate Kauaʻi Mayor Kawakami's quick, decisive action to protect his County's health and wellbeing, and those who scoff at inconvenience.

While this particular bill would prevent mayors from having the option to opt out of the Safe Travels program, it has the potential to set a terrible precedent. It could further erode established County powers, flying in the face of Home Rule, which was established to ensure each County's unique challenges, resources, and needs can be adequately addressed independently.

Our residents' health and safety must be prioritized over the tourism industry and convenience, and each county should continue to be empowered to protect their own interests accordingly.

Mahalo, again, for this opportunity to testify in strong opposition.

Mahalo,

KEANI RAWLINS-FERNANDEZ
Council Vice-Chair

Chamber of Commerce HAWAII
The Voice of Business

Testimony to the Judiciary & Hawaiian Affairs
Wednesday, February 17, 2021 at 2:00 P.M.
Via Videoconference

RE: HB 1286, HD 1, RELATING TO TRAVEL

Chair Nakashima, Vice Chair Matayoshi, and Members of the Committee:

The Chamber of Commerce Hawaii ("The Chamber") **supports** HB 1286, HD 1 which establishes statewide approach to the safe travels program under the authority of the incident commander to take necessary action to protect public health as supported by risk-based and scientific approaches to contagion mitigation.

The Chamber is Hawaii's leading statewide business advocacy organization, representing 2,000+ businesses. Approximately 80% of our members are small businesses with less than 20 employees. As the "Voice of Business" in Hawaii, the organization works on behalf of members and the entire business community to improve the state's economic climate and to foster positive action on issues of common concern.

In a new Pulse of Business survey[1] conducted in partnership with Omnitrak and with the support of Central Pacific Bank Foundation, the Hawaii Chamber of Commerce Foundation found the economic impact of the COVID-19 pandemic continues to have dramatic consequences for local businesses. The Pulse of Business results are not surprising and that one primary issue facing businesses is the cost of paying higher unemployment taxes in 2020 while they continue to suffer from the economic impact of the COVID-19 pandemic.

The Pulse of Business survey found that:

- Many local businesses attributed a drastic drop in revenue to waning tourism, even if they were not directly involved in the visitor industry. A drop in visitor arrivals was the single most important factor impacting employee cutbacks.
- Island companies face a long road to recovery that they expect will extend into April 2022.
- Eighty percent of the businesses that participated in the survey are small businesses with 20 or fewer employees.

[1] Survey finds Hawaii businesses reeling from lost revenue, cutting jobs, and expecting a long road to recovery https://www.staradvertiser.com/2021/02/02/breaking-news/survey-finds-hawaii-businesses-reeling-from-lost-revenue-cutting-jobs-and-expecting-a-long-road-to-recovery/

- Revenues fell an average of 45% from 2019 to 2020, with no significant differences between Oahu and neighbor isles.
- Almost half (45%) reduced their workforce. The percentage would have been higher (63%) if businesses had not received federal Paycheck Protection Program funds.
- Businesses that had to cut jobs laid off a median of one in three workers in 2020. On neighbor isles, cuts were even greater, with five in nine employees laid off due to the pandemic.

Without tourists returning to the state, it is extremely clear that our economy will continue to wane with no relief in sight. Given our reliance on tourism, we must find a way to bring people back to our state and breathe life back to our local businesses.

Thank you for this opportunity to provide testimony.

An Independent Licensee of the Blue Cross and Blue Shield Association

February 17, 2021

The Honorable Mark M. Nakashima, Chair
The Honorable Scot Z. Matayoshi, Vice Chair
House Committee on Judiciary & Hawaiian Affairs

Re: HB 1286 HD1 – Relating to Travel

Dear Chair Nakashima, Vice Chair Matayoshi, and Committee Members:

Hawaii Medical Service Association (HMSA) appreciates the opportunity to testify on HB 1286, HD1, which exempts any person from the post-arrival mandatory self-quarantine if the person receives a negative test result prior to arrival. Allows the incident commander to establish conditions for exemption. Requires certain COVID-19 tests for travelers who do not have a test result upon arrival to avoid mandatory self-quarantine. Requires any person who does not obtain a negative test result for COVID-19 pre-arrival to be responsible for all costs associated with that person's mandatory self-quarantine. Repeals on 12/31/2021. Effective 7/1/2050.

HMSA appreciates the intent of this measure and we are supportive of efforts to safely allow for the reopening of Hawaii's economy. The efforts of this bill will contribute to the collaborative efforts within our State to continue the recovery of public health.

Thank you for allowing us to testify on HB 1286 HD1. Your consideration of our comments is appreciated.

Sincerely,

Matthew W. Sasaki
Director, Government Relations

HB-1286-HD-1
Submitted on: 2/14/2021 11:13:31 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Mary Taylor	Makanalani Kids	Support	No

Comments:

Thank you for the opportunity to submit testimony in support of HB1286.

My name is Mary Taylor, President of Makanalani Kids, a Hawaiian non profit organization. We provide a place for youth who may not have many other opportunities to experience and interact with farm animals, nature and others.

Due to the current quarantine requirements we have been unable to bring youth to Kauai and this has been a huge loss to these youth who would otherwise benefit from this life changing experience.

We ask that you please pass HB1286.

Thank you.

Mary Taylor

HB-1286-HD-1
Submitted on: 2/14/2021 12:41:06 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Miguel (Micco) Godinez	Kayak Kaua'i	Oppose	No

Comments:

Basically power should reside to respective counties to determine fate in all matters Covid and any other issues.

On Kaua'i see thing turning for the better....glacially...but can see light at the end of the tunnel.

Respective counties should be empowered to keep bearing their respective torches

Stay well.

Micco

HB-1286-HD-1
Submitted on: 2/15/2021 8:38:56 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Sean Cannard	Wyndham Destinations	Support	No

Comments:

Aloha-

On behalf of the six Wyndham-managed vacation resorts on Kauai comprising 741 rooms who have remained closed aside from skeleton crew oversight since mid-December 2020 (after only re-opening 10/15/20) when Kauai opted out of the State's Safe Travels program, we strongly desire "re-opening" Kauai to increased tourism by re-entering the State's Safe Travels program. As our resorts are not "bubble resorts" (where their occupancies are only very light at best) and we remain closed, we have furloughed for a second time in less than a year the majority of our resorts' 200+ associates, many of whom remain unable to successfully collect unemployment benefits; as we hear no updates regarding Kauai's potential re-opening to increased tourism, we have essentially been extending our resorts' closures/potential reopening dates by two week time periods, calling all arriving guests/owners within the next two week period to inform/cancel/rebook, etc.

From our perspectives, the unknown status of when and if Kauai may more fully reopen to increased tourism is frustrating as we cannot actively plan ahead to do so successfully, cannot schedule significant projects to be initiated/completed, cannot contemplate even partial re-openings with reduced occupancies and partial returns to active duty of some furloughed associates and can now no longer retain the majority of our furloughed associates as many are now desperately searching for next jobs/careers on-island to help get them by…additionally, we had placed a great deal of time, effort, energy and $$ into Kauai's 10/15/20 reopening, had been able to do so safely with new preventive measures and safeguards in place, only to have had to shut down again two months later.

More frustrating, what actual determinant(s) will flip the switch and allow Kauai to more fully reopen to tourism? We had thought it first to be the Tier system measuring active cases, average cases, etc., but that wasn't the case. Is it a percentage of Kauai's residents vaccinated? Is it 100% of the kupuna and front line/essential workers vaccinated? Is it all of Kauai's residents vaccinated? In late-November, we were

pleased to hear that negative COVID-19 test results would be required before traveling to Kauai, yet that announcement was given no time to be measured as potentially successful as Kauai opted out of the State's Safe Travels program almost immeditaley after that announcement took effect.

As we hear absolutely nothing from Kauai's leaders, despite repeated attempts to connect, reach out, participate and collaborate, it is now time to re-enter the State's Safe Travels program as we are confident that we can operate safely and successfully within the new normal, return our furloughed associates to work (once again), provide memorable, safe vacations to all and instill $$ into the dying economies of both the County and State.

HB-1286-HD-1
Submitted on: 2/15/2021 9:15:29 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Gregg Nelson	Napili Kai Beach Resort	Support	No

Comments:

Dear Chair and Committee Members, House Judiciary and Hawaiian Affairs,

I send you written testimony in favour of HB1286. My resort on Maui with 165 staff members and I support this bill which makes an effort towards standardizing the rules for travel into Hawaii. Allowing each County to establish its own individual rules related to travel over the past 11 months has proven to be a disorganized disaster for the tourism industry as we try to slowly recover from the government imposed shutdown of our economy back in April 2020.

I speak from experience when I say that many of our resort's returning guests have examined the Maui rules and stated to me, that it was all too confusing and daunting and therefore they cancelled their reservations. Still more who were potential first-time visitors mistook portions of the Kauai rules or Honolulu rules for Maui rules and again, just gave up and cancelled reservations.

If you are opposed to our economic recovery through tourism and would rather wait ten years or longer for an alternative to tourism then I guess you will vote no on this measure. However, if you recognize the importance tourism can play in the more immediiate revitalization of our economy, then hopefully you will see the need to simplify and standardize these travel rules and vote yes on HB1286. Mahalo for your consideration.

Gregg Nelson, General Manager, Napili Kai Beach Resort

HB-1286-HD-1
Submitted on: 2/15/2021 9:26:27 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Neil Ishida	ABC Stores	Support	No

Comments:

Good afternoon Chairperson Nakashima and members of the House Committee on Judiciary and Hawaiian Affairs. I am Neil Ishida Director of Government Affairs for ABC Stores.

ABC Stores **STRONGLY SUPPORTS** to HB 1286 Relating to Travel. We support keeping Hawaii safe and we believe that programs like Hawaii Safe Travels, testing before coming to our islands or mandatory quarantine if there is no testing done is working. Furthermore with more of our population being vaccinated, it will make Hawaii an even safer place.

We support HB 1286 intent to revitalize our visitor industry by allowing for less restrictions to mandatory quarantine rules. Also, having a statewide rule will alleviate much of the confusion surrounding travel to Hawaii. We have seen that every time a county changes its travel orders to stricter rules, the entire state suffers. Visitors view these county changes as being statewide or will be implemented shortly on all islands and therefore often cancel or postpone their travel plans. Some are unsure exactly what the rules are to come to Hawaii. And while Hawaii has seen large clusters due to COVID-19, the clusters were NOT due to visitors, but by social gatherings, care homes, and in our prison system.

We appreciate this opportunity to testify.

HAWAII FOOD INDUSTRY ASSOCIATION

1050 Bishop St. PMB 235 | Honolulu, HI 96813
P: 808-533-1292 | e: info@hawaiifood.com

Executive Officers
Joe Carter, Coca-Cola Bottling of Hawaii, *Chair*
Charlie Gustafson, Tamura Super Market, *Vice Chair*
Eddie Asato, The Pint Size Corp., *Secretary/Treas.*
Lauren Zirbel, HFIA, *Executive Director*
John Schlif, Rainbow Sales and Marketing, *Advisor*
Stan Brown, Acosta Sales & Marketing, *Advisor*
Paul Kosasa, ABC Stores, *Advisor*
Derek Kurisu, KTA Superstores, *Advisor*
Beau Oshiro, C&S Wholesale Grocers, *Advisor*
Toby Taniguchi, KTA Superstores, *Advisor*

TO:
Committee on Judiciary
Rep. Mark M. Nakashima, Chair
Rep. Scot Z. Matayoshi, Vice Chair

FROM: HAWAII FOOD INDUSTRY ASSOCIATION
Lauren Zirbel, Executive Director

DATE: February 17, 2021
TIME: 2pm
PLACE: Via Videoconference

RE: HB1286 HD1 Relating to Travel

Position: Support

The Hawaii Food Industry Association is comprised of two hundred member companies representing retailers, suppliers, producers, and distributors of food and beverage related products in the State of Hawaii.

HFIA is in support of this measure. This is a common-sense way to safely allow visitors and returning Hawaii residents to avoid unnecessary self-quarantine. Allowing travelers who receive a negative COVID-19 test to be exempt from self-quarantine will ease travel confusion and make the process smother and more efficient for everyone. Having clear manageable rules for testing and quarantine is an important step in safely opening up our economy.

Our local businesses and Hawaii residents have worked hard to keep our economy running and find ways to build a more diverse and resilient economy for the future. Right now, the most important step on the road to recovery and rebuilding is to find ways to safely welcome more visitors to our state. This measure can help make that happen. We thank you for the opportunity to testify.

HB-1286-HD-1
Submitted on: 2/15/2021 11:07:01 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Chip Bahouth	Sheraton Kauai Resort	Support	No

Comments:

As the General Manager of the Sheraton Kauai Resort, I have seen firsthand the devasting effects that the Kauai County travel restrictions have had on our island's economy.

The lack of tourism on Kauai has so severely impacted small businesses and the thousands of Kauai residents who rely on the tourism industry for some or all of their household income and employer-provided medical coverage. Through a survey of small businesses and lodging accommodations conducted by the Kauai Chapter of HLTA and the Kauai Chamber of Commerce, the Kauai hospitality industry is experiencing a 90% unemployment rate and over 60% of furloughed hospitality employees no longer have employer-subsidized health insurance. The number of employees losing employer subsidized health insurance continues to climb on a monthly basis. The Sheraton Resort Kauai has been unable to continue to provide health insurance for our furloughed employees and I have personally had conversations with several of these employees who have had to make the heartbreaking decision to forgo necessary medical treatment in order to put food on their tables for their children.

The County of Kauai references that these extensive restrictions are to ensure the safety and health of our community. I, and many other employers on the island, have employees or family member of employees, who are either suffering from untreated medical conditions, depression, anxiety and even suicide as a result of the pandemic. We cannot continue to measure the safety of our community solely through COVID case numbers when so many have lost everything because of our collapsing island economy.

The hospitality industry has taken extensive efforts to put safety measures in place to protect their employees, guests and our local community. The relatively low percentage of COVID transmission from visitor to resident during the six (6) weeks that Kauai participated in the Safe Travels program is a testament to the level of care that our hospitality industry took to ensure everyone's safety. The other Counties have been able to prove that the Safe Travels program works and I urge you to support HB1286 so Kauai's economy and the overall health of our residents can start to recover.

SPRINGBOARD
HOSPITALITY

Testimony of
Rob Robinson
Vice President
Springboard Hospitality

Committee on Judiciary and Hawaiian Affairs

House Bill 1286: Relating to Statewide Safe Travels Program; COVID 19

Chair Nakashima and members of the Committee,

Mahalo for the opportunity to submit testimony on behalf of Springboard Hospitality. Springboard Hospitality is a locally-owned company that operates 10 hotels across the Hawaiian Islands.

Springboard Hospitality strongly supports House Bill 1286 and the need for consistent, statewide guidelines to allow for tourism to restart safely and effectively. While we recognize the importance of "home rule" and allowing the county mayors to decide what is best for their communities, the lack of cohesion in rules for travelers and returning residents to Hawai'i has led to significant confusion, further harming an industry already suffering an unprecedented economic downturn. While we believe that the individual Mayors acted with the best interest of their constituents in mind, the efforts to re-boot tourism and safely allow inbound travel have failed to create even the beginnings of a meaningful recovery.

A recent special study issued by the Hawai'i Tourism Authority indicated that the single most prevalent reason that stopped travelers from visiting Hawai'i was that testing requirements were unreasonable. Moreover, the same study indicated that 21% of respondents had trouble sourcing a COVID-19 test from a Trusted Partner and 46% felt that the 72-hour window was troublesome. What was once perception has now become reality. The Washington Post recently ran an article titled "Hawaii wants tourists. Tourists want Hawaii. But the rules are complicated," which highlighted that our convoluted rules are serving as a deterrent to prospective visitors who are finding themselves navigating confusing requirements for both travel to the state and within the counties. Springboard is a strong proponent of a clear, statewide policy that provides clarity and simplicity for healthy travelers to come to Hawai'i. We have also been urging our local government to provide travelers with the option to take a second, rapid COVID-19 test upon arrival should they not receive their pre-arrival test result in time. The State has the tests and facilities needed to make this possible, and we also know that two counties are already providing rapid tests to travelers and have the facilities and know-how to execute this. **For these reasons, Springboard Hospitality strongly supports House Bill 1286.**

Further, we understand that the State just announced it is open to working towards a policy that would allow a quarantine exemption for certain vaccinated visitors. Our one recommendation for HB1286 HD1 is that it include a provision that would not pre-empt vaccinated visitors from a quarantine exemption should such a program or rule be implemented.

Thank you for the opportunity to offer this testimony.

Sincerely,
Rob Robinson
Springboard Hospitality

Kona-Kohala
CHAMBER OF COMMERCE

February 15, 2021

RE: HB1286 HD1 RELATING TO TRAVEL

Dear Chair Nakashima and the House Committee on Judiciary and Hawaiian Affairs,

The Kona-Kohala Chamber of Commerce supports HB1286 HD1 RELATING TO TRAVEL that exempts any person from the post-arrival mandatory self-quarantine if the person receives a negative test result prior to arrival. This bill also allows the incident commander to establish conditions for exemption and requires certain COVID-19 tests for travelers who do not have a test result upon arrival to avoid mandatory self-quarantine. In addition, any person who does not obtain a negative test result for COVID-19 pre-arrival is responsible for all costs associated with that person's mandatory self-quarantine.

With nearly 500 members, our chamber represents the business community in the Kona and Kohala districts on the West side of Hawai'i Island where tourism drives the local economy. Our community was especially hard hit in 2020 due to COVID-19 impacts that resulted in severe loss of business and mass employee layoffs. Initially, Governor Ige's stay-at-home order for non-essential workers and the mandatory 14-day quarantine for travelers made it so many businesses in our region were unable to operate. As reopening was allowed in the summer months, some of our businesses were able to open with limited capacity. For others, their customers – the visitors – were deterred by the restrictions in place and this meant these businesses continued to stay closed.

Based on the Hawai'i Tourism Authority's Monthly Reports, Hawai'i Island received 130,364 visitors in April 2019, but only 705 in April 2020. In August 2020, the visitor count was up to 3,729, but this was 87% down from the previous year and certainly not the volume that sustains our local economy.

In October 2020, the Safe Travels Hawai'i program was launched that allowed travelers to bypass the quarantine with a negative COVID-19 test result. This definitely helped our local businesses with visitor arrivals up to 48,134 in December 2020, however this was still 72% less than the prior year. For all of 2020, visitor arrivals fell 72.1% to 492,325. Based on the University of Hawai'i Economic Research Organization's Annual Hawai'i Forecast, Hawai'i Island's 2021 visitor count forecast is 766,100 – approximately one million less visitors than 2019.

Based on the state's continued low COVID-19 case counts, most agree that the Safe Travels Hawai'i program is successful in providing the needed safety precautions while allowing our customers to return. Moreover, as COVID-19 vaccinations are distributed in 2021, we anticipate this additional safety measure will prompt more people to travel once again.

As we navigate through this leg of our COVID-19 journey, we believe the Safe Travels Hawai'i program needs modifications to help streamline the process and improve the traveler experience. This includes standardizing the program statewide and stop the county-by-county mandates in regards to travel. This creates confusion for all travelers whether visitors from

Kona-Kohala Chamber of Commerce
75-5737 Kuakini Hwy. Suite 208 | Kailua-Kona, HI 96740
Ph. (808) 329-1758 Fax (808) 329-8564
info@kona-kohala.com | www.kona-kohala.com

outside of Hawai‘i or residents traveling inter-island. In addition, we've found little flexibility in trying to accommodate visitors and returning residents who have done everything "right" but who run into problems with timely test results. This legislation addresses these issues.

The Kona-Kohala Chamber of Commerce exists to provide leadership and advocacy for a successful business environment in West Hawai‘i. We support initiatives that safely reopen our visitor industry and put our community back to work. We support the Safe Travels Hawai‘i program and the modifications put forth in HB1286 HD1.

Mahalo for this opportunity to testify.

Sincerely,

Wendy J. Laros, President and CEO
Kona-Kohala Chamber of Commerce

Kona-Kohala Chamber of Commerce
75-5737 Kuakini Hwy. Suite 208 | Kailua-Kona, HI 96740
Ph. (808) 329-1758 Fax (808) 329-8564
info@kona-kohala.com | www.kona-kohala.com

HB-1286-HD-1
Submitted on: 2/15/2021 3:03:02 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Julia Kelly	Brennecke's Beach Broiler and Nukumoi Surf Co.	Support	No

Comments:

I'm writing to you with my most sincere concern for the future of our businesses here on Kauai. When we decided to participate in the Safe Travels program, it was the first glimmer of hope that many businesses had. We here at Brennecke's and Nukumoi Surf Co. were finally able to put money in the bank and start to pay off the massive amounts of debt we acquired during the previous months. Since opting out of Safe Travels, we have financially declined to a possible point of no return. For the first time in almost 40 years of being in business, we are looking at a very real possibility of closing our doors. The owners of Brennecke's and Nukumoi have always been very generous to our community, and it hurts me so much to see them doing everything in their power to keep our staff of over 50 people employed, even to the point of financially hurting themselves.

Please, on behalf of every struggling small business, please consider supporting this bill. While we can naturally expect to see a rise in cases, it can be maintained at a managable level with other health and safety precautions. With vaccinations available to so many, it seems only fair to start to ease back into a "normal" life.

HB-1286-HD-1
Submitted on: 2/15/2021 3:03:32 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Richard Albrecht	Club at Kukuiula	Support	No

Comments:

Aloha,

I am the President of the Club at Kukuiula, which is a resort on the South Shore of Kauai. We support the Bill to implement consistent rules for Covid testing and quarantine for travelers to all islands. The current variation in rules is confusing and unnecessarily complicated, and is creating unnecessary hardship for many people on Kauai. The Pre-travel testing is working effectively on other Islands, as we have seen over the past few months. Many small businesses on Kauai are experiencing extreme hardship for both the business owners and their employers and suppliers. Several months ago when we knew much less about the virus, the restrictions made more sense. We have had very few people hospitalized, and our hospital capacity was never threatened. Now that we understand the virus better, and vaccinations are progressing, and we have seen the effectiveness of pre-travel testing throughout the State, we need to implement more balanced rules to enable tourism to begin returning and supporting our local businesses and their employees.

Thank you. Richard Albrecht, President, Club at Kukuiula

Airlines for America®

We Connect the World

House Bill 1286
Testimony in SUPPORT

COMMITTEE ON JUDICIARY & HAWAIIAN AFFAIRS
Rep. Mark M. Nakashima, Chair
Rep. Scot Z. Matayoshi, Vice Chair

Chairs Nakashima, Vice Chair Matayoshi and members of the Committee on Judiciary and Hawaiian Affairs:

Thank you for allowing us the opportunity to provide industry testimony in support of House Bill 1286 with additional comments.

Airlines for America® (A4A) is the principal trade and service organization of the U.S. airline industry.[1] A4A members have gone to extensive lengths to protect the wellbeing and safety of our employees, customers and the communities in which we live, work and serve. U.S. airlines have relied on science throughout this crisis, and have undertaken hundreds of safety measures aimed at preventing virus transmission onboard aircraft. U.S. airlines began strictly enforcing face covering requirements in April 2020, long before the federal mandate. The layers of measures implemented by carriers also include pre-flight health acknowledgement forms, electrostatic and enhanced cleaning of aircraft and hospital-grade ventilation systems.

We are encouraged that rigorous scientific studies continue to confirm that the extensive layers of measures airlines have implemented effectively reduce the risk of transmission onboard aircraft. Studies by both the Harvard T.H. Chan School of Public Health's Aviation Initiative (APHI) and US TRANSCOM found that the risk of onboard transmission of COVID is very low. In fact, the research from Harvard concluded that being on an airplane as safe – if not safer than – other routine activities, such as grocery shopping or going to a restaurant. Similarly, a recent study in Canada found that travel was the smallest contributor to new COVID-19 infections and has remained extremely low throughout the crisis.

[1] The members of the association are Alaska Airlines, Inc.; American Airlines Group, Inc.; Atlas Air, Inc.;
Delta Air Lines, Inc.; Federal Express Corporation; Hawaiian Airlines; JetBlue; Southwest Airlines Co.; United Airlines Holdings, Inc.; and United Parcel Service Co. Air Canada is an associate
member.

Despite these efforts, U.S. airlines have endured a barrage of constantly changing restrictions and regulations regarding travel to and from destinations across the globe. In Hawaii, the challenge has not simply been the ever-evolving requirements for travel to and around the islands, but navigating changes that vary island-to-island. This has ultimately resulted in a patchwork of requirements that are difficult to navigate both for visitors and residents alike and as such is compounding the economic toll the pandemic has had on the State.

The industry remains committed to supporting risk-based, scientific approaches to contagion mitigation. A statewide policy, such as HB1286, that does not allow for differing local standards depending on what island you are on is welcomed, and allows those traveling to and within Hawai‘i the opportunity to adhere to uniform policies. This will let the private market find solutions that work; it helps the airline and travel industry partners to communicate clearly to travelers about what to expect and how to arrive travel-ready; and it helps travelers plan future travel without having to worry about last-minute policy changes.

While we are optimistic the sunset date will be the actual repeal of this measure, we recognize that this pandemic remains hard to predict. We remain hopeful the state will find a mechanism for vaccinations as a method to forgo testing in the near term. We are confident that it will continue to allow us dialogue with this body in hopes of removing some of the impediments to air travel, while ensuring Hawai‘i remains safe both for residents and for visitors, who are the lifeblood of our economy.

Sincerely,

Sean Williams
VP, State & Local Government Affairs
swilliams@airlines.org

HB-1286-HD-1
Submitted on: 2/15/2021 3:33:20 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Peggy Roberts	Lealani Corp. dba Brennecke's	Support	No

Comments:

I am in support of Bill#HB1286 as the purpose of this legislation is to create a statewide approach to the safe travels program while still allowing the Department of health to take necessary action to protect public health effective immediately and/or as soon as possible. I am asking that this legislation become law, so Kauai County will no longer be able to opt-out of the state's safe travels program.

I have been a resident of Kauai for 50 years and have worked in the tourist industry for 30 years. As we are facing the trials that Covid 19 has brought to the islands we realize we cannot sustain without visitors being allowed to travel safely to Kauai. We have experienced loss of jobs, businesses and poverty for many of our residents. Residents want to go back to work . This change will help stimulate the local economy and allow more of our residents to go back to their jobs. Please do not allow Kauai County to be able to place additional burdens on the traveling public and tourists. Our desire is to prosper, not suffer,living our lives to the fullest on this beautiful island of Kauai.

Sincerely,

Peggy Roberts

Office manager

Lealani Corporation dba Brennecke's

Kainoa Family Inc. dba Nukumoi Surf Co.

HAWAI'I LODGING & TOURISM ASSOCIATION

Testimony of
Mufi Hannemann
President & CEO
Hawai‘i Lodging & Tourism Association

Committee on Judiciary and Hawaiian Affairs
House Bill 1286, House Draft 1: Relating to Statewide Safe Travels Program Exemption; COVID-19; Quarantine

Chair Nakashima and members of the Committee, mahalo for the opportunity to submit testimony on behalf of the Hawai‘i Lodging & Tourism Association, the state's largest private sector visitor industry organization.

The Hawai‘i Lodging & Tourism Association—nearly 700 members strong, representing more than 50,000 hotel rooms and nearly 40,000 lodging workers —has long advocated for the adoption of statewide travel rules as they pertain to the COVID-19 pandemic and the Safe Travels program. While we recognize the importance of "home rule" and allowing the county mayors to decide what is best for their communities, the lack of cohesion in rules for travelers and returning residents to Hawai‘i has led to significant confusion, further harming an industry already suffering an unprecedented economic downturn. **As such, HLTA strongly supports House Bill 1286 House Draft 1.**

A recent special study issued by the Hawai‘i Tourism Authority indicated that the single most prevalent reason that stopped travelers from visiting Hawai‘i was that testing requirements were unreasonable. Moreover, the same study indicated that 21% of respondents had trouble sourcing a COVID-19 test from a Trusted Partner and 46% felt that the 72-hour window was troublesome. What was once perception has now become reality. The Washington Post recently ran an article titled "Hawaii wants tourists. Tourists want Hawaii. But the rules are complicated," which highlighted that our convoluted rules are serving as a deterrent to prospective visitors who are finding themselves navigating confusing requirements for both travel to the state and within the counties. HLTA has been a strong proponent of a clear, statewide policy that provides clarity and simplicity for healthy travelers to come to Hawai‘i. We have also been urging our local government to provide travelers with the option to take a second, rapid COVID-19 test upon arrival should they not receive their pre-arrival test result in time. The State has the tests and facilities needed to make this possible, and we also know that two counties are already providing rapid tests to travelers and have the facilities and know-how to execute this.

Further, we understand that the State just announced it is open to working towards a policy that would allow a quarantine exemption for certain vaccinated visitors. Our one recommendation for HB1286 HD1 is that it include a provision that would not pre-empt vaccinated visitors from a quarantine exemption should such a program or rule be implemented.

Thank you for the opportunity to offer this testimony.

Hawai`i Lodging & Tourism Association
2270 Kalakaua Avenue, Suite 1702, Honolulu, Hawai‘i 96815 · Phone: (808) 923-0407 · Fax: (808) 924-3843
info@hawaiilodging.org · www.hawaiilodging.org

Kohala Coast
RESORT ASSOCIATION

February 15, 2021

Representative Mark Nakashima, Chair
House Committee on Judiciary and Hawaiian Affairs
Representative Linda Ichiyama, Chair
House Committee on Pandemic and Disaster Preparedness

Support for HB1286 HD1

Dear Representative Nakashima and Members of the House Committees on Judiciary and Hawaiian Affairs

Thank you for the opportunity to provide comments on HB1286 HD1.

The Kohala Coast Resort Association supports the efforts to clarify and streamline the testing procedures for Hawaii's Safe Travels program. Since the program began, we have seen firsthand the impacts to visitors, who went through all of the required processes with pre-arrival testing to begin their travels to Hawaii, and who through no fault of their own, did not receive their results in time and were told they had to comply with the mandatory 10-day quarantine.

We understand and share the concerns of elected officials and the public that community safety is our first priority. We believe these processes will keep our community safe, while allowing us to rebuild the state's economic driver.

KCRA is a collection of master-planned resorts and hotels, situated north of the Kona International Airport which represents more than 3,500 hotel and timeshare accommodations and an equal number of resort residential units. This is approximately 35 percent of the visitor accommodations available on the Island of Hawai`i. KCRA member properties annually pay more than $25 million in TAT, $25 million in GET and $11 million in property taxes. KCRA members employ more than 5,000 Hawaii Island residents.

Mahalo for your consideration and support for this measure.

Sincerely,

Stephanie P. Donoho

Stephanie Donoho
Administrative Director

TESTIMONY OF TINA YAMAKI, PRESIDENT
RETAIL MERCHANTS OF HAWAII
February 17, 2021
Re: HB 1286 HD1 Relating to Travel

Good afternoon Chairperson Nakashima and members of the House Committee on Judiciary and Hawaiian Affairs. I am Tina Yamaki, President of the Retail Merchants of Hawaii and I appreciate this opportunity to testify.

The Retail Merchants of Hawaii was founded in 1901, RMH is a statewide, not for profit trade organization committed to the growth and development of the retail industry in Hawaii. Our membership represents small mom & pop stores, large box stores, resellers, luxury retail, department stores, shopping malls, local, national, and international retailers, chains, and everyone in between.

We are **STRONGLY SUPPORTS** to HB 1286 Relating to Travel. This measure exempts any person from the post-arrival mandatory self-quarantine if the person receives a negative test result prior to arrival; allows the incident commander to establish conditions for exemption; requires certain COVID-19 tests for travelers who do not have a test result upon arrival to avoid mandatory self-quarantine; requires any person who does not obtain a negative test result for COVID-19 pre-arrival to be responsible for all costs associated with that person's mandatory self-quarantine; and repeals on 12/31/2021. Effective 7/1/2050.

Retailers continue to be concerned about health and safety of not only our community and our employees, but our visitors coming to our islands as well. We have seen the devastation this pandemic has had on not only the community but on business as well. Hawaii's businesses and the community has been instrumental in ensuring that the health and safety by wearing masks, social distancing, constantly cleaning high touch areas and more since March 2020. We continue to support keeping Hawaii safe and we believe that programs like Hawaii Safe Travels, testing before coming to our islands or mandatory quarantine if there is no testing done is working. Furthermore, with more people around the world being vaccinated, it will make Hawaii an even safer place.

Having a statewide rule will alleviate much of the confusion surrounding travel to Hawaii. We have seen that every time a county changes its travel orders to stricter rules, the entire state suffers. Visitors view these county changes as being statewide or will be implemented shortly on all islands and therefore often cancel or postpone their travel plans. Some are unsure exactly what the rules are to come to Hawaii. And while Hawaii has seen large clusters due to COVID-19, it is our understanding that the clusters were NOT due to visitors, but by social gatherings for family gatherings and funerals, in care home and in our prison system.

Hawaii's economy depends on tourism. It is the story of the $20 bill – Visitor comes to Hawaii and pays for their hotel stay with at $20. The hotel uses that $20 to pay the hotel employee. The hotel employee purchases a plate lunch with that $20. The plate lunch wagon owner purchases vegetables from the local farmer with that $20. The local farmer pays the truck driver to deliver his vegetables to the grocery stores. The truck driver by shoes for his children with that $20. If there is a break in the link of the $20, Hawaii's economy will take an excruciating time to recover – and each week we see more and more retailers shutting their doors for good because they can no longer afford to do business in Hawaii without their customer base.

Mahalo again for this opportunity to testify.

3610 Waialae Ave • Honolulu, HI 96816 (808) 592-4200 tyamaki@rmhawaii.org

HB-1286-HD-1
Submitted on: 2/16/2021 8:24:07 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Cara Goodrich	Castle Hospitality Group	Support	No

Comments:

I am submitting written testimony on behalf of ALAN MATSON, PRESIDENT & CEO of CASTLE HOSPITALITY GROUP. Please see testimony in support of "HB 1286 H.D.1 Relating to Travel" attached.

Roberts Hawaii

February 15, 2021

phone 808.523.7750
fax 808.522.7866

Roberts Hawaii, Inc.
444 Niu Street, Suite 300
Honolulu, HI 96815

www.robertshawaii.com

Honorable Chair Nakashima and Members of the House Judiciary and Hawaiian Affairs Committee

Re: Testimony in Support of HB1286

Roberts Hawaii *strongly* supports House Bill 1286, which sets forth requirements to be applied across the state and counties for pre-arrival and post-arrival testing and mandatory quarantine, along with circumstances upon which travelers may be exempt.

As a company that directly engages with the visitors and the travel industry in Hawaii, we believe a uniform and consistent visitor arrival quarantine program needs to be adopted and applied across the State.

Hawaii's tourism industry has endured much hardship since mid-March 2020 when the entire industry was effectively completely shut down. Since then, the frequent state and county rule changes have created confusion for both visitors and residents. This bill seeks to establish a consistent approach to only the visitor arrival portion of Hawaii's total Covid 19 safety protocols. Each island mayor still regulates on island activities outside of this proposed consistent statewide visitor arrival quarantine program.

Passage of this bill will provide a ray of hope for the tens of thousands of residents impacted by the visitor industry shutdown. We have all learned to be adaptable and adjust to the changing environment. We should recognize the progress that we have made in dealing with the coronavirus, including the increasing vaccinations and the adoption of statewide covid safety protocols and now, we must look toward enhancing this progress by taking the next step to revive the visitor industry. Please support this next step by allowing a consistent statewide quarantine arrival experience.

Thank you for the opportunity to testify on this measure.

Sincerely,

Roy Pfund
President & Chief Executive Officer
Roberts Hawaii

LBD COFFEE, LLC

To: The Honorable Mark Nakashima, Chair, and Members of the House Committee on Judiciary & Hawaiian Affairs

Date: Wednesday, February 17, 2021

Time: 2:00 p.m.

Place: Via Videoconference

From: Tai Erum, Trevyn Pless, Les Drent for LBD Coffee, LLC

Re: HB 1286 (Relating to Travel)

Dear Mark Nakashima, Chair, and Members of the House Committee on Judiciary & Hawaiian Affairs

LBD Coffee, LLC **SUPPORTS** HB 1286.

For far too long the County of Kauai government has played the role of a draconian tyrant rather than allow its citizens the freedoms afforded to them under state law. HB 1286 is just another attempt to circumvent state's precedent.

Since the beginning of Covid-19 Kauai small businesses and farms on Kauai have suffered severe losses in revenue. Opting out of Hawaii's Safe Travels program has only made the matter worse on Kauai. Real Property values on farm land have increased 30%. New farmers have been priced completely out of the market, and existing local farmers are being displaced. All while the County of Kauai looks forward to increased real property tax collections from those moving to the island to hide and work behind a facade of increased safety and security. Nearly 29 million dollars was provided to Kauai through the CARES funding and how many icu beds were added on island?

Couple this rogue, and reckless behavior, and Kauai's overstepping of the Safe Travels Program, and also consider that since 2012 the County of Kauai has ignored Rule 57 in the HRS 632. This law was passed by the legislature to explicitly allow farmers the right to sell their value added products from within an enclosed structure on their farms. While they preach food to the people it is still illegal under the County of Kauai's Zoning Ordinance for a farmer to sell a mango from their land! *See attached County Bill No. 2804, and LBD testimony.*

At some point our state elected officials, and the courts of Hawaii need to stand up to those in Kauai government who seek to only further annex rather than unite Kauai with the rest of the state.

Thank you for your consideration.

Sincerely,

Tai Erum
Operations Manager

Trevyn Pless
Farm Manager

Les Drent
Owner

LBD Coffee, LLC
6200 Kawaihau Road, Unit B, Kapaa, HI 96746 USA
Ph: (808) 822-4495 Fax: (808) 822-9731
lbdcoffee.com

ORDINANCE NO. _____ BILL NO. _____

A BILL FOR AN ORDINANCE TO AMEND CHAPTER 8, KAUA'I COUNTY CODE 1987, AS AMENDED, RELATING TO USES IN THE AGRICULTURE ZONING DISTRICT

BE IT ORDAINED BY THE COUNCIL OF THE COUNTY OF KAUA'I, STATE OF HAWAI'I:

SECTION 1. Findings and purpose. The Council finds that the various lock-down measures in response to the Novel Coronavirus Disease 2019 (COVID-19) pandemic have halted economic activity in certain sectors and harshly disrupted others. Families who have lost employment income because of the COVID-19 pandemic have struggled to provide the basic needs of shelter and food.

The Council also finds that Kaua'i may experience further impacts as a result of steps taken by Young Brothers Hawaii to address financial challenges brought on by a 30% drop in cargo volumes due to the COVID-19 pandemic.

The Council further finds that nonprofit organizations and community members islandwide, including the County of Kaua'i and several business entities, have stepped up in many ways to help individuals and families in need and to provide and share a variety of resources at no cost to the recipient. The agriculture industry and agriculture community have been a major component and partner in efforts to provide families with food and fresh produce.

The Council finally finds that agriculture and agriculture-related activities must remain viable and continue to be a source towards accomplishing food security for the County of Kaua'i.

The purpose of this Ordinance is to amend the Comprehensive Zoning Ordinance to encourage and allow a multitude of agriculture and agriculture-related activities in the Agriculture Zoning District.

SECTION 2, Chapter 8, Kaua'i County Code 1987, as amended, is hereby amended by amending Sec. 8-1.5 Definitions by inserting, alphabetically, definitions for the following terms:

"'**Agricultural Retail Stand**' means a building or structure, not to exceed a gross floor area of 1,000 square feet, from which agricultural products produced on the subject property or the associated farm are sold.

'**Botanical Garden**' means a public or private facility for the demonstration and observation of the cultivation of flowers, fruits, vegetables, or ornamental plants.

'**Farmers Market**' means the offering of fresh agricultural products for sale directly to the consumer at an open-air market.

'**Food Processing and Packaging of agricultural products**' means facilities where raw and/or refined agricultural products are made suitable for human consumption and prepared for transport and sale.

'**Restaurant and food services**' means a retail business selling ready-to-eat food and/or beverages for on or off-premise consumption. These include eating establishments where customers are served from a walk-up ordering counter for either on or off-premise consumption ("counter service") and establishments where customers are served food at their tables for on premise consumption ("table service") that may also provide food for take-out, but does not include drive through services, which are separately defined and regulated.

'**Zoological Garden**' means a parklike area in which live animals are kept in cages or large enclosures for public exhibition."

SECTION 3. Chapter 8, Kaua'i County Code 1987, as amended, is hereby amended by amending Table 8-2.4 – Table of Uses, in pertinent part, as follows:

"**TABLE 8-2.4 Table of Uses**

Sec.	USE	ZONING DISTRICT								
		Residential			Commercial		Industrial			
		R-1 to R-6	R-10 to R-20	RR	CN	CG	IL	IG	AG	O
8-2.4(q)(1)	Accessory structures and uses								P	
8-2.4(q)(2)	Agriculture, Diversified and Specialized; and Nurseries								P	
8-2.4(q)(3)	Agriculture retail stand								P_2	
[8-2.4(q)(2)] 8-2.4(q)(4)	Aquaculture								P	
[8-2.4(q)(3)] 8-2.4(q)(5)	Diversified Agriculture								P	
8-2.4(q)(6)	Farm Dwelling								P	
8-2.4(q)(7)	Food processing and packaging of agriculture products								P_2	
[8-2.4(q)(4)] 8-2.4(q)(8)	Forestry								P	
[8-2.4(q)(6)] 8-2.4(q)(9)	Historic sites								P	
[8-2.4(q)(7)] 8-2.4(q)(10)	Intensive agriculture								P	
[8-2.4(q)(8)]	[Livestock, poultry, and piggeries, except as provided in Sec. 8-2.4(r)(11)]								[P]	
8-2.4(q)(11)	Livestock and grazing								P	
[8-2.4(q)(10)] 8-2.4(q)(12)	Orchards								P	

Sec.	USE	ZONING DISTRICT								
		Residential			Commercial		Industrial			
		R-1 to R-6	R-10 to R-20	RR	CN	CG	IL	IG	AG	O
[8-2.4(q)(11)] 8-2.4(q)(13)	Outdoor recreation								P	
[8-2.4(q)(12)] 8-2.4(q)(14)	Pet keeping and raising except as provided in Sec. 8-2.4(r)(12)								P	
8-2.4(q)(15)	Piggery, except as provided in Sec. 8-2.4(r)(13)								P	
8-2.4(q)(16)	Poultry Raising, except as provided in Sec. 8-2.4(r)(14)								P	
[8-2.4(q)(13)] 8-2.4(q)(17)	Public parks and monuments								P	
[8-2.4(q)(14)] 8-2.4(q)(18)	Resource Management								P	
[8-2.4(q)(15)] 8-2.4(q)(19)	Single family attached and detached dwellings								P	
[8-2.4(q)(16)] 8-2.4(q)(20)	Solar energy facilities placed within land with soil classified by the State of Hawai'i Land Study Bureau's detailed land classification as overall (master) productivity rating B, C, D, or E; those facilities placed within land with soil classified as overall productivity rating class B and C shall not occupy more than ten percent (10%) of the acreage of the parcel, or twenty (20) acres of land, whichever is less								P	
[8-2.4(q)(17)]	[Specialized Agriculture]								[P]	
[8-2.4(q)(18)] 8-2.4(q)(21)	Undeveloped campgrounds								P	
[8-2.4(q)(19)] 8-2.4(q)(22)	Warehousing, storage, and packing of plant products								P	
[8-2.4(q)(20)] 8-2.4(q)(23)	Wildlife management								P	
8-2.4(r)(1)	Animal hospitals								U	
8-2.4(r)(2)	Botanical and Zoological gardens								U	
[8-2.4(r)(2)] 8-2.4(r)(3)	Cemeteries								U	
[8-2.4(r)(3)] 8-2.4(r)(4)	Churches, temples and monasteries								U	
[8-2.4(r)(4)] 8-2.4(r)(5)	Commercial Recreation								U	
[8-2.4(r)(5)] 8-2.4(r)(6)	Construction and worker temporary housing								U	
[8-2.4(r)(6)] 8-2.4(r)(7)	Development campgrounds								U	
[8-2.4(r)(7)] 8-2.4(r)(8)	Farm worker housing								U	
[8-2.4(r)(8)] 8-2.4(r)(9)	Farmers Markets								U	
[8-2.4(r)(8)] 8-2.4(r)(10)	Golf courses								U	

Sec.	USE	ZONING DISTRICT								
		Residential			Commercial		Industrial			
		R-1 to R-6	R-10 to R-20	RR	CN	CG	IL	IG	AG	O
[8-2.4(r)(9)] 8-2.4(r)(11)	Mineral extraction and quarries								U	
[8-2.4(r)(10)] 8-2.4(r)(12)	Pet keeping and raising proposed within five hundred (500) feet of any Residential District								U	
8-2.4(r)(13)	Piggery, when to be located within three thousand (3,000) feet of any Use District								U	
[8-2.4(r)(11)] 8-2.4(r)(14)	Poultry [and piggeries] Raising, when to be located within three thousand (3,000) feet of any Use District								U	
[8-2.4(r)(13)] 8-2.4(r)(15)	Private and public utilities facilities								U	
8-2.4(r)(16)	Restaurants and food services								U	
8-2.4(r)(17)	Retail Sales								U	
[8-2.4(r)(13)] 8-2.4(r)(18)	Schools and day care centers								U	
[8-2.4(r)(14)] 8-2.4(r)(19)	Transportation terminals								U	
[8-2.4(r)(15)] 8-2.4(r)(20)	Any other use or structure which the Planning Director finds to be similar in nature to those listed in this Section and appropriate to the District								U	

Notes:

1 Requirements for Additional Dwelling Units (ADU) are contained in Article 15.

2 Only produce raised or grown on the property and/or associated farm or value-added goods derived primarily from produce or livestock raised on the subject property and/or associated farm.

KEY: U = Use Permit Required
P = Permitted Use or Structure (Zoning Permit may be required)"

SECTION 3. If any provision of this ordinance or application thereof to any person, persons, or circumstance is held invalid, the invalidity does not affect the other provisions or applications of this ordinance which can be given effect without the invalid provision or application, and to this end, the provisions of this ordinance are severable.

SECTION 4. Ordinance material to be repealed is bracketed. New ordinance material is underscored. When revising, compiling, or printing this ordinance for inclusion in the Kaua'i County Code 1987, as amended, the brackets, bracketed material, and underscoring shall not be included.

SECTION 5. This ordinance shall take effect upon its approval.

Introduced by:

ARRYL KANESHIRO

DATE OF INTRODUCTION:

Līhu'e, Kaua'i, Hawai'i
V:\BILLS\2018-2020 TERM\2020-306 AgricultureNew AK_AMK_mn.docx

LBD COFFEE, LLC

To: County of Kauai Planning Commission

Date: Tuesday, January 12, 2021
Time: 8:30 a.m.
Place: Teleconference

From: Les Drent
for LBD Coffee, LLC

Re: ZA-2021-1, A BILL FOR AN ORDINANCE TO AMEND CHAPTER 8, KAUAI COUNTY CODE 1987, AS AMENDED, RELATING TO USES (AGRICULTURAL RETAIL STAND) IN THE AGRICULTURE ZONING DISTRICT

Dear County of Kauai Planning Commission.

Takes a crisis, right?

After 18 years of being denied by the County of Kauai government it appears that the local overlords are finally going to allow farmers the right to retail their value added Hawaii grown products from their farms.

We find this all pretty incredible. Especially since we were first approved for value added retail on our farm in 2003, before being denied that right in the very same year. Near the completion of our coffee farm and agricultural processing room (Building Permit 03-596) that included every County, State and federal permit as well as a certified kitchen and value added retail space of about 400 square feet, we were told that it was an oversight, an error by the Planning Department's Plan Reviewers, who simply missed that retail aspect which was clearly called out on several pages of our approved building plans, and land use permit.

So let's not make any mistake here. This issue of agricultural retail on farm land operated by real farmers has been circulating for nearly two decades on Kauai and without any resolution, or consideration to help farmers.

In 2012 we applauded when the State legislature created Rule 57 in the HRS 632 which explicitely allows farmers the right to sell their value added products from within an enclosed structure on their farms. That law also stated that the Counties have the right to further define this law in their County Zoning Ordinances. While every other County in Hawaii either followed this state law, or further defined it, Kauai County, and much to the detriment of its farmers, remained completely silent on the matter. Kauai County has never listed agricultural retail stand in its table of land uses as either a permitted, not permitted or an activity that requires a Use or Special Use permit.

In 2017, and so completely fed up with Kauai County's position on the matter of agricultural retail LBD Coffee filed a declaratory judgement (Civil No. 17-1-0119) in the 5th circuit. Judge

LBD Coffee, LLC
6200 Kawaihau Road, Unit B, Kapaa, HI 96746 USA
Ph: (808) 822-4495 Fax: (808) 822-9731
lbdcoffee.com

Kathleen Watanabe in the fall of 2018 requested in chambers that Kauai County attorneys bring this matter before the Planning Commission. This was never done and a motion to reinstate the declaratory judgement was filed on April 16, 2019 and after the County's inaction to bring the matter before the Planning Commission.

Rather than wait any longer on the Declaratory Judgement LBD had its attorneys file for a Use Permit for agricultural retail and in a hearing in front of the Planning Commission was subjected to ten unwritten and unlawful conditions. In addition to these ten conditions we were hit with an 11th condition near the end of the hearing. This condition would prevent LBD from selling any agricultural product from a farm that does not either grow, and or manufacture that product on the permitted farm. This condition was completely nonsensical as we have numerous farms that we either own, or lease for our crop production.

At that point we chose to simply wait for the court's ruling on the matter, rather than subject ourselves to any more public scrutiny by non farming neighbors who oppose our activity, and a Planning Department who has been dead set against allowing us to sell our Hawaii grown valued added products.

No other County in Hawaii has exercised such blatant disregard for state law. Nor has any other County in Hawaii stripped its agricultural producers of their right to sell their goods like Kauai has.

In regards to the Kauai County Planning Department, their decision making in regards to land use and permitting has reeked of nepotism, cronyism, and favoritism for as long as I can remember. I've seen illegal use of agricultural land by persons and businesses that have zero association to farming, and this has occurred under a County government that has willingly turned a blind eye to these activities.

If this Covid-19 crisis, which is expected to end this summer, brings about meaningful change in allowing farmers to retail their value added products than so be it. But the damage this County has done to us and many others over the last two decades will not be forgotten, nor dismissed by your knee jerk reaction to agricultural retail under the guise of getting food to the people.

Respectfully submitted,

Les Drent
owner/farmer
LBD Coffee, LLC

LBD Coffee, LLC
6200 Kawaihau Road, Unit B, Kapaa, HI 96746 USA
Ph: (808) 822-4495 Fax: (808) 822-9731
lbdcoffee.com

P.O. Box 253, Kunia, Hawai'i 96759
Phone: (808) 848-2074; Fax: (808) 848-1921
e-mail info@hfbf.org; www.hfbf.org

February 17, 2021

HEARING BEFORE THE
HOUSE COMMITTEE ON JUDICIARY & HAWAIIAN AFFAIRS

TESTIMONY ON HB 1286, HD1
RELATING TO TRAVEL

Conference Room 325
10:00 AM

Aloha Chair Hashem, Vice-Chair Perusso, and Members of the Committee:

I am Brian Miyamoto, Executive Director of the Hawaii Farm Bureau (HFB). Organized since 1948, the HFB is comprised of 1,800 farm family members statewide and serves as Hawaii's voice of agriculture to protect, advocate and advance the social, economic, and educational interests of our diverse agricultural community.

The Hawaii Farm Bureau supports HB 1286, HD1, which exempts any person from the post-arrival mandatory self-quarantine if the person receives a negative test result prior to arrival. Allows the incident commander to establish conditions for exemption, requires certain COVID-19 tests for travelers who do not have a test result upon arrival to avoid mandatory self-quarantine, requires any person who does not obtain a negative test result for COVID-19 pre-arrival to be responsible for all costs associated with that person's mandatory self-quarantine.

HFB supports efforts to safely allow for the reopening of Hawaii's economy. We believe this bill is a reasonable way to safely allow visitors and returning Hawaii residents to avoid unnecessary self-quarantine. Allowing travelers who receive a negative COVID-19 test to be exempt from self-quarantine will ease travel confusion and make the process smoother and more efficient for everyone. Having clear manageable rules for testing and quarantine is an important step in safely opening up our economy.

Thank you for this opportunity to testify on this important subject.

HB-1286-HD-1
Submitted on: 2/16/2021 10:37:02 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Breana Grosz	International Market Place	Support	No

Comments:

Chair Ichiyama, Chair Onishi and member of the Committees, thank you for your ongoing efforts in protecting Hawai'i during this extraordinary time, and thank you for the opportunity to submit testimony in support of House Bill 1286.

International Market Place is home to over 80 stores and restaurants that employ over 2,000 kama'aina, of which about a quarter are working now due to the limited number of daily visitor arrivals, and pay millions of dollars in state and local taxes, in addition to providing a place for locals and visitors to shop and dine. A recent study issued by the Hawai'i Tourism Authority indicated that the number one reason that has stopped travelers from visiting Hawai'i were that testing requirements are unreasonable. Moreover, the same study indicated that 21% of respondents had trouble sourcing a COVID-19 test from a Trusted Partner and 46% felt that the 72-hour window was troublesome. The Washington Post recently ran an article titled "Hawaii wants tourists. Tourists want Hawaii. But the rules are complicated," which highlighted that rules are serving as a deterrent to prospective visitors who are finding themselves navigating confusing requirements for both travel to the state and within the counties.

Our tenants, employees, vendors, and shoppers will continue to suffer if we are not able to work together in the best interest of our community to strike the right balance and safely ease travel restrictions that are out of line with any other state. We strongly support a clear, statewide policy that provides clarity and simplicity for healthy travelers to come to Hawai'i. **We feel that House Bill 1286 achieves this balance and we fully support the Bill.** Thank you for the opportunity to offer this testimony.

Mahalo for your time and attention to this critical matter.

Breana Grosz
General Manager
International Market Place

SanHi
GOVERNMENT STRATEGIES
A LIMITED LIABILITY LAW PARTNERSHIP

DATE: February 16, 2021

TO: Representative Mark M. Nakashima
Chair, Committee on Judiciary & Hawaiian Affairs
Submitted Via Capitol Website

FROM: Matt Tsujimura

RE: **H.B. 1286, H.D. 1 – Relating to Travel**
Hearing Date: Wednesday, February 17, 2021 at 2:00 p.m.

Dear Chair Nakashima, Vice Chair Matayoshi, and Members of the Committee on Judiciary & Hawaiian Affairs:

We submit this testimony on behalf of Enterprise Holdings ("Enterprise"), which includes Enterprise Rent-A-Car, Alamo Rent-A-Car, National Car Rental, and Enterprise Commute (Van Pool).

Enterprise **supports** H.B. 1286, H.D. 1, which creates s statewide safe travels program exemption.

Enterprise favors uniformity through a single state policy, and believes H.B. 1286, H.D. 1, will help to accomplish that goal.

Thank you for the opportunity to submit this testimony.

First Hawaiian Center
999 Bishop Street, Suite 1400
Honolulu, HI 96813

T 808-539-0400
F 808-533-4945

HB-1286-HD-1
Submitted on: 2/16/2021 11:06:36 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Michael Palmer	Ho'okipa Partners, LLC	Support	No

Comments:

Chair Nakashima and members of the Committee,

Thank you for the opportunity to submit testimony on behalf of Ho'okipa Partners, LLC, in support of Bill HB1286 HD1. We strongly support this bill so as to encourage tourists to come visit Hawaii and get our economy going again. We operate a restaurant in Waikiki that employed over 150 team members this time last year. They are all eager to come back to work, but until tourism numbers increase it makes no logical sense to reopen our restaurant. The State has done a fantastic job of keeping Covid cases to a minimum, but now it is time to not only slowly open back up, but to facilitate the process to let visitors come. We can't open our business and hire back those 150 team members until we have confirmation of a significant increase in visitor counts. It is no secret that the restaurant industry has been one of the hardest hit in the nation, but people need to eat, and we want to feed them. But the numbers need to work. We stayed open until November 6th,2020 but it wasn't sustainable with the lack of visitors in Waikiki. With the approval of this bill, we hope to see the travel to Hawaii increase which will then make opeining for business sustainalble once again.

Mahalo Nui Loa for your time and consideration,

Michael Palmer,

Managing Partner

Ho'okipa Partners, LLC

HB-1286-HD-1
Submitted on: 2/16/2021 11:17:53 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Todd Hadley	Koloa Landing Resort at Poipu	Support	No

Comments:

Testimony of Todd N. Hadley, President, Koloa Landing Resort at Poipu

To: Committee on Judiciary and Hawaiian Affairs

RE: House Bill 1286 Relating to Statewide Safe Travels Program Exemption, COVID-19

Dear Chair Nakashima and Members of the committee,

On behalf of the Koloa Landing Resort at Poipu in Koloa, County of Kauai, Hawaii, we are in full support of House Bill 1286.

Our resort and our associates have been majorly impacted by the Covid pandemic and by the lack of tourism to the island. We feel it is important to get the tourism industry going for the island of Kauai and for the state at large. Significant economic impact has been done and we feel strongly that having a system in place with rules applying to all the Hawaiian Islands makes the most sense to begin the recovery process. We completely agree that by consolidating power and decision making authority at the state level is the best approach. This will help avoid confusion caused by the county mayors making separate rules that in our view are overreaching and lack merit. The state's Safe Travel program with Pre-testing requirement has proven to be an effective means of controlling the Covid virus spread.

We are anxious to get all of our Associates back to work and off of the state's unemployment benefits. We know our associates are much happier and are better citizens, and better mothers & fathers, we they have regular employment and feel they accomplishing things each day. This bill is a good thing for the island of Kauai.

We are extremely grateful to Speaker Saiki and to the other members of the house that introduced and are supporting this bill. Humbly we request the support from this committee as well.

Mahalo,

Todd N. Hadley

President, Koloa Landing Resort at Poipu

HB-1286-HD-1
Submitted on: 2/16/2021 11:18:30 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Charlee Abrams	Garden Island Rentals	Support	No

Comments:

I have resided on and owned a tourist related business on Kauai for over 40 years. Unlike in past, when faced by devastation and economic downturns - two hurricanes and economic rescessions, this time, small businesses have been "closed" by government! Simply put, we have no business becaue we have no customers! Like thousands on our island, our employees are on unemployment and suffering because of the same pandemic that has decimated Kauai's economy. In March of 2020, when orderd to close, we all thought the slump would be temporary, and we would be back to work by summer. Because our mayor has not allowed us to join the Safe Travels Program, the tourism engine of our economy is now suffering what looks to me like permenant damage. Because so much more has been learned about the virus, many are being vaccinated againse it, with few cases and only one death, it's time to join the Safe Travels Program for the sake our our island economy, allowing our people and small business like mine to get back to work! Please vote "yes," on HD1286HD1.

Testimony of
Dylan Ching
Vice President of Operations
T S Restaurants Oahu and Kauai

Committee on Judiciary and Hawaiian Affairs

House Bill 1286: Relating to Statewide Safe Travels Program Exemption; COVID-19; Quarantine

Chair Nakashima and members of the Committee, Mahalo for the opportunity to submit testimony on behalf of the T S Restaurants.

T S Restaurants owns and operates 8 restaurants in Oahu, Maui, and Kauai. Pre-COVID-19 we employed over 1,200 employees and have been in business for 44 years in Hawaii dating back to 1977. We are strong Community minded company that logged over 2,400 hrs. of volunteer work and $129,000 in food donation in 2019. Post COVID-19 we are only back to half of our 1,200 employees and under 50% of our total annual sales. We have done everything that has been asked of us and more to ensure our employees are safe, community supported, and our business survives. It is no surprise that even a successful and healthy company like ours finds our selves backed up against the wall. I have been in our buildings on the ground form March until today and have seen every kind of business imaginable. This has given me the ability to observe how the restrictions, closures, and travel bands have affected how people's moods and habits react to these issues. In addition, I was able to see how they affect the individual islands through a specific industry by comparing sales and guest counts in each of our three markets. **As such, T S Restaurants strongly supports House Bill 1286 House Draft 1.**

T S Restaurants understands the difficult job that our county leaders have and the decisions they must make. We appreciate the commitment to public safety and our communities have been cared for with respect and Aloha unmatched in our nation. I can and will only comment on my perspective and experience. Our businesses are struggling to survive and the single most important thing our government can do for us it to have a clear, consistent, and safe travels program. Our visitor industry can get us back on our feet so the dependence on government can switch to supporting our government. I understand that each island has its own challenges and strengths and are fighting to ensure their people are safe. As we operate in three of those counties we feel for each as they figure out how to survive. The stricter we are the less cases we have, but it is also true there is a balance of reopening that if allowed to open safely, our people can return to work and our economy can repair itself. Nothing that I have seen indicates that the Lt. Governor Greens program is not working in fact it seems to be preforming great. We have endured almost one full year of restrictions that have crippled our businesses and yet we still stand ready to fight another day. I say this humbly and with no disrespect to anyone who does not share our view, we need a consistent travel program.

In closing I want to thank you for the opportunity to offer this testimony and to give my perspective.

Mahalo Nui Loa,

Dylan Ching

Testimony of

Marleen Akau

VP, General Manager

Royal Hawaiian Center

Committee on Judiciary and Hawaiian Affairs

House Bill 1286: Relating to Statewide Safe Travels Program Exemption; COVID-19; Quarantine

Chair Nakashima and members of the Committee, thank you for the opportunity to submit testimony on behalf of the Royal Hawaiian Center, the largest shopping center in Waikiki.

The dramatic decline of visitor arrivals and expenditures has been a severe impact to our shopping center owners, as well as every tenant, ranging from locally owned and operated restaurants and retail shops to established global brands. Hundreds of employees that worked at our center for years have lost their jobs or are working reduced hours, while several owners are working extra shifts to contain their labor costs. As Waikiki continues to struggle, it is critical for tourism to have a clear statewide policy that provides consistent rules for all healthy travelers coming to Hawaii. As such, Royal Hawaiian Center strongly supports House Bill 1286 House Draft 1.

A clear statewide policy that provides consistent rules for all healthy travelers will benefit every island, while enhancing the Hawaii Tourism Authority marketing efforts to increase visitor arrivals to every island. Confusing requirements for both travel to the state and within the state have become complications for travelers and returning residents, which in turn have diminished visitor arrivals during these challenging times.

Thank you for the opportunity to offer this testimony.

Pono Hawai'i Initiative

Patrick Shea - Treasurer • Lena Mochimaru - Secretary
Nelson Ho • Summer Starr

Tuesday, February 16, 2021

Relating to Travel
Testifying in Strong Opposition

Aloha Chair and members of the committee,

The Pono Hawai'i Initiative (PHI) **strongly opposes HB1286, Relating to Travel.** This measure sets a ceiling for Covid-19 travel restrictions and bans Counties from imposing further restrictions on travelers.

Preventing any County from putting into place strong rules protecting its community's health and safety from the risks of expanded COVID infections is simply wrong.

There are 3 key elements to this proposal:

1) It is based on the premise that a universal COVID travel policy is best for the travel industry.

2) The policy that is proposed in **HB1286** requires each incoming traveler to have "a negative test result upon arrival from a state approved-COVID-19 test administered within seventy−two hours before departing from the final leg of departure." AND allows "the incident commander" (not the Governor, the Mayor, or the Director of Health) to determine who can be "automatically exempt from the pre-travel testing requirements and mandatory self-quarantine…" The present incident commander is Maj. General Kenneth Hara, Hawaii adjutant general and director of the Hawaii Emergency Management Agency.

3) If passed into law HB1286 will prevent any County government from having stricter rules - "this Act shall take precedence over all conflicting statutes concerning this subject matter and shall preempt all contrary laws, ordinances, rules, orders, or proclamations adopted by the State, a county, or any department or agency thereof."

All 3 of these elements are of course debatable. Most will likely agree that yes, a uniform travel policy is preferred. However, which policy is best and whether it should prevent a County from having stronger provisions are the key questions.

The policy now being proposed in HB1286 is woefully inadequate if the goal is to minimize the spread of travel related coronavirus infections in Hawaii. **The medical community is unanimous in agreement that a single test 72 hours prior to arrival is insufficient protection if the goal is to keep COVID infection and death rates as low as possible.** A second test is important and especially so when taking into consideration the rise of new and more dangerous strains such as the "Kent coronavirus variant" that U.K. experts have said may be up to 70 percent more infectious and about 30 percent more lethal than other variants.

The third policy element, that of "preempting" the right of a County to have stricter health protections is on its own, sufficient reason to oppose HB1286. **What's best for Honolulu is not necessarily what's best for every other County.**

State laws should be a "floor not a ceiling." If any County wants to pass stronger laws, rules, or regulations that reflect its particular circumstances, it should be allowed to do so. If the residents do not agree they can direct their voices to the County Council and Mayor, and/or they can elect new County leaders. If visitors do not like it and/or they are "confused" then perhaps they would be better served by spending their vacation days elsewhere.

It is important also to note that: "The CDC recommends that you do not travel at this time."

Finally - **Locking into law a statewide COVID travel policy based on a minimum level of protection will prevent the flexibility needed should the situation change for the worse** and increased testing and/or additional quarantine measures be needed to protect public health in the months ahead.

For these reasons, I strongly encourage Committee members to **vote NO on HB1826**.

Mahalo for the opportunity to testify,

Gary Hooser
Executive Director
Pono Hawai‘i Initiative

HB-1286-HD-1
Submitted on: 2/16/2021 12:31:36 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Andy Evers	Azul Hawaii Resorts	Support	No

Comments:

As an employer of over 225 associates on Kauai we are heavily impacted by the travel restrictions the County of Kauai has imposed on our island. We have laid off over 150 associates and may have to lay off more if these restrictions are kept on. To keep it short there has to be a balance between the health of our island residents and the re-opening of tourism. With less than a handful of active cases on Kauai we are being held hostage by these extreme restrictions. To make matters more challenging the constant creating and changing of the rules has severely impacted our associates and their families. The County (mayor) had a clear plan that had 4 stages that made sense initially, but then was just thrown out and our island has been locked down ever since.

The enhanced movement quarantine (EMQ/Bubble Resort) plan is not fair to businesses and creates an unfair business practice for our resort. Even given that, our resort has stayed open during the pandemic and done it safely and securely over the last 11 months. All of us have had to make huge sacrifices to ensure this happens. Kauai County has had plenty of time to come up with a better plan for our economy to re-open, for more ICU beds in our hospitals and to get our associates back to some semblance of work.

We are in major support of the HB1286 plan and hope that this step will create a better more seamless opportunity for our island as a whole to come together and function the way the other island have been able to.

Respectfully,

Andy Evers

General Manager/Koloa Landing Resort

TESTIMONY IN FAVOR OF HB 1286

While having lost more than $30 million based on business that was on the books prior to the pandemic, The Koloa Landing Resort is one of the more fortunate businesses on Kaua'i. Fortunate that we are still operating, but clearly and painfully aware of the economic devastation of the pandemic.

As an employer of 225 associates, we laid off 155 employees last March and the remaining employees suffered dramatic pay cuts of up to 50% of their normal salaries. When we initially participated in the Safe Travels program in October, business improved slightly and we were elated to bring back 50 associates with abbreviated schedules. Unfortunately, when Kauai County opted out of the Safe Travels program, occupancy dropped and we were forced to lay off those 50 associates and discontinue their medical benefits once again. This was heartbreaking to say the least.

The 155 associates, while no longer employed, are still considered our ohana. Our struggles and the fact that some of us are facing defaults on mortgages, are close to eviction, or cannot provide basic health care and food for our families continues to weigh as a very heavy burden on all of us.

Moreover, without visitors, our business partners such as Expedia, National Car Rental, several shops and restaurants in Kukuiula Village, attraction partners and dozens of small businesses across the island have closed – most, for good.

We have donated food, household items, and volunteered for food distribution events. We have offered our community a place to safely quarantine when they return from the mainland. We have cooperated with State efforts to ensure we are ensuring our associates and guests are maintaining safety and security protocols to ensure the health of all.

Mayor Kawakami, HVB, HTA & HLTA have done a far better job of communicating the necessary precautionary measures needed to mitigate the virus than the rest of the country. We've done so in a positive and respectful way with care and Aloha through positive and kind messaging. We have done our part and the community has done its part and I'm confident we can and will continue to do so as visitors return to support us.

For the good of the entire State, we feel that consistency and cohesion are needed to encourage more visitors to come at the right time with the appropriate pre-testing and screening. More options for approved pre-travel tests have helped. Post arrival testing would also be helpful. We are not expecting to encourage an influx of unhealthy visitors in mass to the detriment of our residents.

We feel strongly that more can be done to deter further economic erosion. Becoming less dependent on tourism is not a short-term option. It is time for us to stand together, as a State, to communicate consistency rather than confusion, and welcome tourism back in a healthy and effective way.

As such, Koloa Landing Resort strongly supports House Bill 1286 House Draft 1.

Koloa Landing Resort has been a strong proponent of a clear, statewide policy that provides clarity and simplicity for healthy travelers to come to Hawai‘i. We have also been urging our local government to provide travelers with the option to take a second, rapid COVID-19 test upon arrival should they not receive their pre-arrival test in time.

We also recommend HB1286 HD1 includes a provision that would not pre-empt vaccinated visitors from a quarantine exemption, should such a program or rule be implemented.

Thank you for the opportunity to offer this testimony.

Stacy Manzo

Director of Sales & Marketing

Koloa Landing Resort

HB-1286-HD-1
Submitted on: 2/16/2021 12:41:08 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Melissa Ragasa	Wyndham Ka'Eo Kai & Shearwater	Support	No

Comments:

I support bill HB 1286. It is time for Kauai to welcome back travelers with no quarantine restrictions and bring our associates back to work. This bill will help to streamline and clarify testing guidelines while keeping our residents safe. Mahalo!

Testimony for Lesli Reynolds
SVP Operations
Aqua-Aston Hospitality, Hawai'i

Committee Pandemic & Disaster Preparedness Committee on Labor & Tourism House Bill 1286:
Relating to Statewide Safe Travels Program Exemption; COVID-19; Quarantine

Chair Ichiyama, Chair Onishi, and members of the Committees, thank you for the opportunity to submit testimony on behalf of Aqua-Aston Hospitality. Aqua-Aston has over 30 hotels and resorts operating throughout Hawai'i. Covid-19 has had a devastating impact on our resorts and our staff has suffered greatly over the past year.

We continue to give our highest priority to ensuring the safety of our guests and associates as we strive to encourage travelers to return to their favorite vacation spot in Hawaii. Throughout this pandemic we have focused our efforts in supporting our local communities and ensuring full implementation and compliance with the mandates put in place by local governments.

At Aqua-Aston, we firmly believe that there is a clear need for a consistent pre-travel testing program for the State of Hawaii that will facilitate traveler's safe entry into the State and help eliminate confusion regarding requirements and a create greater degree of confidence when visiting our islands.

We therefore fully endorse the Hawai'i Lodging & Tourism Association's support of House Bill 1286 .

Management
Information
Consultants

February 16, 2021

Honorable Rep. Mark Nakashima, Chair
Honorable Rep. Scot Matayoshi, Vice-Chair
House Committee on Judicial and Hawaiian Affairs (JHA)
Hawaii State Capitol, Room 325
415 South Beretania Street
Honolulu, HI 96813

RE: Testimony in SUPPORT of HB1286HD1; Hearing Date: February 17, 2021 at 2:00 p.m. in House conference room 325; sent via Internet

Dear Rep. Nakashima, Chair, Rep. Matayoshi, Vice-Chair; Committee Members,

Thank you for the opportunity to provide testimony on this bill.

Our company is the only company that provides parliamentary and professional presiding services to Planned Community Associations and Condominium Associations (collectively called “Associations”) throughout the state of Hawaii. We have been in this business since 1983.

The COVID-19 pandemic has adversely affected these Association annual meetings. Most of them cannot conduct their mandated annual meetings electronically due to current statutory restrictions as well as technical restrictions related to proxy voting and secret ballots.

The patchwork of rules between the counties has been inconsistent, associations in the Counties of Oahu, Hawaii, and Kauai could meet, Maui could not. I was informed by legal counsel that Maui is now open for meetings. In all cases, there are CDC requirements that are met.

In most cases, these meetings last for 1-2 hours.

The problem is greater for individuals travelling to the neighbor islands from Oahu. Kauai had an absolute test, it was difficult to obtain results, and we simply could not serve any Associations on that island.

Currently, we’re involved in an Executive Branch Crossfire. We have an assistant arriving from the mainland for five weeks to go to several meetings on our behalf.

She has been scheduled to take 3 separate COVID tests today to ensure one comes before her arrival on Thursday. She took one this morning and another got cancelled because it was 23 degrees below zero and unsafe for people to wait outside for the test. Hopefully, she will have taken the second test by the time this testimony is submitted.

She will take an additional COVID test Friday for a Saturday meeting on Kauai. Now, it turns out that she may still have to quarantine even though she only has to go to a 2 hour meeting at one site.

Attempts to contact the Kauai County last week to make her assistance possible lead to:

a. A recording that takes no messages (241-1800) and keeps repeating;
b. E-mails to Kauai that results in a response referring us to the state website; and
c. E-mails sent to the state website that result in a referral to Kauai.

This morning, I arranged for another member of the company to go to Kauai. I still don't know if that request will be approved.

The inconsistency is not good for our economy. I have resided in Hawaii continuously since 1963 and our economic situation has never been this bad. Additionally, our own residents are frustrated with the pandemic and the sacrifices that they have made.

The inconsistency related to inter-island travel needs to be resolved, not just for my small company but for other legitimate travelers.

I respectfully ask that you pass this bill.

If you require any additional information, your call is most welcome. I may be contacted via phone: 423-6766 or through e-mail: Steveghi@Gmail.com. Thank you for the opportunity to present this testimony.

Sincerely,

Steve Glanstein

Steve Glanstein, Professional Registered Parliamentarian
President
SG:tbs

Testimony for Angela Nolan
Market General Manager
Marriott Vacations Worldwide Corporation, Hawai'i

Committee on Judiciary and Hawaiian Affairs
House Bill 1286: Relating to Statewide Safe Travels Program Exemption; COVID-19; Quarantine

Chair Nakashima and members of the Committees, mahalo for the opportunity to submit testimony on behalf of Marriott Vacations Worldwide Corporation (Marriott Vacations) . Marriott Vacations has 11 vacation ownership resorts on all Hawai'i islands. The impacts of covid-19 on our resorts and our staff have been staggering since the onset of this pandemic. We have remained steadfast in our efforts to support our respective communities, abide by and often times exceed the mandates put in place by local governments and excitedly look forward to safely welcoming back our owners and guests. In order to do so, we believe that a comprehensive and aligned pre-travel testing program for the State of Hawaii will substantially aid in our recovery, providing consistency for prospective travelers, eliminating confusion regarding requirements and creating greater confidence when visiting our islands.

As members of the Hawai'i Lodging & Tourism Association, we stand alongside our industry partners, fellow businesses and hotels in our support of House Bill 1286 . The Hawai'i Lodging & Tourism Association—nearly 700 members strong, representing more than 50,000 hotel rooms and nearly 40,000 lodging workers —has long advocated for the adoption of statewide travel rules as they pertain to the COVID-19 pandemic and the Safe Travels program. While we recognize the importance of "home rule" and allowing the county mayors to decide what is best for their communities, the lack of cohesion in rules for travelers and returning residents to Hawai'i has led to significant confusion, further harming an industry already suffering an unprecedented economic downturn.

Marriott Vacations, along with HLTA, strongly supports House Bill 1286. A recent special study issued by the Hawai'i Tourism Authority indicated that the single most prevalent reason that stopped travelers from visiting Hawai'i was that testing requirements were unreasonable. Moreover, the same study indicated that 21% of respondents had trouble sourcing a COVID-19 test from a Trusted Partner and 46% felt that the 72-hour window was troublesome. What was once perception has now become reality. The Washington Post recently ran an article titled "Hawaii wants tourists. Tourists want Hawaii. But the rules are complicated," which highlighted that our convoluted rules are serving as a deterrent to prospective visitors. These visitors are finding themselves navigating confusing requirements for both travel to the state and within the counties. Marriott Vacations is a strong proponent of a clear, statewide policy that provides clarity and simplicity for healthy travelers to come to Hawai'i. We along with HTLA have also been urging our local government to provide travelers with the option to take a second, rapid COVID-19 test upon arrival should they not receive their pre-arrival test result in time. The State has the tests and facilities needed to make this possible, and we also know that two counties are already providing rapid tests to travelers and have the facilities and know-how to execute this.

For these reasons, Marriott Vacations, alongside our hospitality colleagues and partners at HLTA strongly **support** House Bill 1286.

Testimony Before the House Committee on Judiciary & Hawaiian Affairs
Wednesday, February 17, 2021 at 2:00 PM
VIA VIDEOCONFERENCE
Conference Room 325
State Capitol
415 South Beretania Street

RE: Support for House Bill No. 1286 Relating to Travel

Dear Chair Nakashima, Vice Chair Matayoshi and Distinguished Members of the Committee:

The Kaua`i Chamber "Chamber" supports the passage of House Bill No. 1286, which would:

- exempt any person from the post-arrival mandatory self-quarantine if the person receives a negative test result prior to arrival,
- allow the incident commander to establish conditions for exemption,
- require certain COVID-19 tests for travelers who do not have a test result upon arrival to avoid mandatory self-quarantine, and
- require any person who does not obtain a negative test result for COVID-19 pre-arrival to be responsible for all costs associated with that person's mandatory self-quarantine.

According to a December 2020 poll conducted by the Chamber and the Kauai Chapter of the Hawaii Lodging and Tourism Association, 49 percent of respondents reported their business would likely shut down within three months without a significant return of tourists to Kauai.



Activity companies are the most at risk for closures, with 82 percent of respondents stating that they cannot survive past 90 days. This was followed by restaurants, with 79 percent of respondents stating that

they cannot survive past 90 days. Restaurants were also the highest at risk for closure within 30 days. Rounding out the top three, 56 percent of lodging respondents noted that they will have difficulties staying afloat past 90 days.

Additionally, the implementation of the 10-day quarantine and the withdrawal from Safe Travels resulted in furloughs of 70 percent of employees represented in the survey. In addition, respondents permanently laid off 20 percent of their staff, collectively. The impact to small businesses has been significant with activity companies and retailers furloughing 92 percent and 73 percent of their employee base, respectively. Based on survey results, this number may rise if a significant return of tourism does not occur.

Survey respondents held differing views regarding Kauai's participation in the state's Safe Travels Program.

- 56% of respondents feel Kauai should opt back into the Safe Travels program and allow visitors in without quarantine provided they test negative prior to arrival.
- 36% of respondents say the 3-Day mandatory quarantine at a resort bubble is a step in the right direction to reopening our island.
- 8% of respondents agree with Kauai's decision to opt out of the Safe Travels program.



While the Chamber appreciates the public's strong desire to maintain Kauai's record of safety regarding COVID-19, we also recognize the devastating impact the current COVID-19 policy is having on our residents. House Bill No. 1286 will help ensure the safety of our residents while allowing our economy to rebound. The status quo will result in a further diminished economy, which will have a detrimental effect on state and county operations as tax revenue continues to dry up and unemployment obligations increase. Even as visitors return, they will find boarded up and vacant commercial space, fewer restaurants and entertainment options, and less places to spend their tourist dollars in general. This means less tax revenue for the state and counties, which could lead to continued economic stagnation.

The Kauai Chamber has an active membership of over 400 Kauai businesses and organizations who give freely of their time and talents to advance the commercial, financial, industrial, civic, and social well-being of the County of Kauai and the State of Hawaii. The Chamber envisions a vibrant and resilient network of businesses that focus their collective power and unique strengths to make Kaua‘i a better place to live and work. Our mission is to champion economic prosperity by being the voice of business, promoting collaboration and helping our members thrive.

Thank you for your thoughtful leadership during this difficult time and for considering the Chamber’s position on this critical legislation.

Mahalo,

Mark Perriello
President & CEO
Kauai Chamber

HB-1286-HD-1
Submitted on: 2/16/2021 1:48:40 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Thomas Foti	HLTA	Support	No

Comments:

House Bill 1286: Relating to Statewide Safe Travels Program Exemption; COVID-19; Quarantine

Chair Nakashima and members of the Committee, mahalo for the opportunity to submit testimony on behalf of the Hawai‘i Lodging & Tourism Association, the state’s largest private sector visitor industry organization.

The Hawai‘i Lodging & Tourism Association—nearly 700 members strong, representing more than 50,000 hotel rooms and nearly 40,000 lodging workers —has long advocated for the adoption of statewide travel rules as they pertain to the COVID-19 pandemic and the Safe Travels program. While we recognize the importance of “home rule” and allowing the county mayors to decide what is best for their communities, the lack of cohesion in rules for travelers and returning residents to Hawai‘i has led to significant confusion, further harming an industry already suffering an unprecedented economic downturn. **As such, HLTA strongly supports House Bill 1286 House Draft 1.**

A recent special study issued by the Hawai‘i Tourism Authority indicated that the single most prevalent reason that stopped travelers from visiting Hawai‘i was that testing requirements were unreasonable. Moreover, the same study indicated that 21% of respondents had trouble sourcing a COVID-19 test from a Trusted Partner and 46% felt that the 72-hour window was troublesome. What was once perception has now become reality. The Washington Post recently ran an article titled “Hawaii wants tourists. Tourists want Hawaii. But the rules are complicated,” which highlighted that our convoluted rules are serving as a deterrent to prospective visitors who are finding themselves navigating confusing requirements for both travel to the state and within the counties. HLTA has been a strong proponent of a clear, statewide policy that provides clarity and simplicity for healthy travelers to come to Hawai‘i. We have also been urging our local government to provide travelers with the option to take a second, rapid COVID-19 test upon arrival should they not receive their pre-arrival test result in time.

The State has the tests and facilities needed to make this possible, and we also know that two counties are already providing rapid tests to travelers and have the facilities and know-how to execute this.

Further, we understand that the State just announced it is open to working towards a policy that would allow a quarantine exemption for certain vaccinated visitors. Our one recommendation for HB1286 HD1 is that it include a provision that would not pre-empt vaccinated visitors from a quarantine exemption should such a program or rule be implemented.

Thank you for the opportunity to offer this testimony.

Thomas Foti

Vice Chair, HLTA

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/16/2021 2:00:43 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Ike Cockett	Maui Seaside Hotel	Support	No

Comments:

Mahalo for the opportunity to submit testimony in support of HB1286 HD1 on behalf of the employees of the Maui Seaside Hotel. As a member of the Hawaii Lodging and Tourism Association, Maui County, the Maui Seaside Hotel is alligned in advocating for the adoption of Statewide Travel rules as they pertain to the CoVid19 pandemic and the Safe Travelers program. The lack of a unified system within the State has led to confusion amongst travelers making it less than "user friendly." Prior to the pandemic Maui Seaside Hotel employed approximately 80 employees. Currently, we employ 18. Like many of those in the Travel Industry, we have been impacted directly by the lack of visitors since March of 2020. Maui Seaside asks for your thoughtful consideration over this most urgent and important decision.

Mahalo for the opportuniy to offer this testimony.

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

PRINCE
WAIKIKI

House Bill 1286: Relating to Statewide Safe Travels Program Exemption; COVID-19; Quarantine

Aloha Chair Nakashima and members of the committee,

My name is Josh Hargrove and I'm the General Manager of the Prince Waikiki Hotel and the Hawaii Prince Golf Club. I will be testifying today in support of House Bill 1286.

This bill provides much needed clarity and simplification to our state's varied and confusing rules that differ county by county. In addition to clarity, this bill eliminates the unnecessary and punitive nature of the current policy that requires arriving guests to quarantine for the full 10 days despite being tested by a trusted partner, being tested within the 72 hour timeframe, but not receiving their test results in time due to no fault of their own.

Providing clarity and options to these "ideal travelers" who have followed all of our rules and made every effort to travel to our state the right way, is a good direction. We need policies that allow our economy to recover, and to recover without sacrificing safety. This bill accomplishes both of these criteria instead of choosing one or the other.

I strongly support this bill and believe the result will be more travelers to Hawaii with negative test results, more jobs for our staff, and more revenues to the many businesses that rely on tourism to survive.

Mahalo,

Josh Hargrove
General Manager
Prince Waikiki Hotel & Hawaii Prince Golf Club

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

Testimony of

Steve Yannarell
General Manager
Waikoloa Beach Marriott Resort and Ocean Club

Committee Pandemic & Disaster Preparedness
Committee on Labor & Tourism

House Bill 1286: Relating to Statewide Safe Travels Program Exemption; COVID-19; Quarantine

Chair Ichiyama, Chair Onishi, and members of the Committees, mahalo for the opportunity to submit testimony on behalf of the Waikoloa Beach Marriott Resort and Spa, a mixed use facility with 300 hotel rooms and 112 Marriott Vacation Club suites located along the beautiful Kohala Coast of Hawaii Island. We employ over 300 associates from across the island and are a member of the Hawaii Lodging and Tourism Association the largest private sector visitor industry organization in the state with 700 members, 170 of which are hotels managing 51,000 rooms and nearly 40,000 hotel associates.

The industry has long advocated for the adoption of statewide travel rules as they pertain to the COVID-19 pandemic and the Safe Travels program. While we recognize the importance of "home rule" and allowing the county mayors to decide what is best for their communities, the lack of cohesion in rules for travelers and returning residents to Hawai‘i has led to significant confusion, further harming an industry already suffering an unprecedented economic downturn. As such, I strongly support House Bill 1286.

A recent special study issued by the Hawai‘i Tourism Authority indicated that the single most prevalent reason that stopped travelers from visiting Hawai‘i was that testing requirements were unreasonable. Moreover, the same study indicated that 21% of respondents had trouble sourcing a COVID-19 test from a Trusted Partner and 46% felt that the 72-hour window was troublesome. What was once perception has now become reality. The Washington Post recently ran an article titled "Hawaii wants tourists. Tourists want Hawaii. But the rules are complicated," which highlighted that our convoluted rules are serving as a deterrent to prospective visitors who are finding themselves navigating confusing requirements for both travel to the state and within the counties. We need a clear statewide policy that provides clarity and simplicity for healthy travelers to come to Hawai‘i. We have also been urging our local government to provide travelers with the option to take a second, rapid COVID-19 test upon arrival should they not receive their pre-arrival test result in time. The State has the tests and facilities needed to make this possible, and we also know that two counties are already providing rapid tests to travelers and have the facilities and know-how to execute this.

For these reasons, I would strongly support House Bill 1286.

Thank you for the opportunity to offer this testimony.

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

Prince Resorts Hawaii

Testimony of
Kisan Jo
President
Prince Resorts Hawaii
Prince Waikiki – Mauna Kea Beach Hotel – The Westin Hapuna Beach Resort

Committee Pandemic & Disaster Preparedness
Committee on Labor & Tourism
House Bill 1286: Relating to Statewide Safe Travels Program Exemption; COVID-19; Quarantine

Chair Ichiyama, Chair Onishi, and members of the Committees,

Thank you for allowing us the opportunity to voice our concerns and support of House Bill 1286: Relating to Statewide Safe Travels Program Exemption; COVID-19; Quarantine

As you know the hotel industry, though open, is still seriously struggling to fill rooms and only able to bring back a fraction of our workers to their former positions. We have tried to make hotel reservations easy and worry free with extremely flexible (waived) cancellation policies, but still face major booking hesitancy with the confusion and uncertainty over testing and quarantine procedures. Having properties on Oahu and Hawaii Island, we can see firsthand how multi-island policy differences only add to the booking anxiety.

Please strongly consider House Bill 1286 as a way of simplifying statewide testing requirements and providing travelers with the option to take a second, rapid COVID-19 test upon arrival should they not receive their pre-arrival test result in time.

Thank you for the opportunity to offer this testimony.

Sincerely,

Kisan Jo
President | Prince Resorts Hawaii

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/16/2021 3:55:22 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Marc Bromley	Four Seasons Resort Maui	Support	No

Comments:

Dear Committee Members,

My name is Marc Bromley, and I am the General Manager of Four Seasons Resort Maui at Wailea. The Resort employs over 1000 Maui residents, all of whom have a vested interest in the visitor industry. My impetus in writing today is their livelihood. Thank you for the opportunity to testify.

House Speaker Scott Saiki's proposed measure, which is to be heard tomorrow in a joint hearing of the House Pandemic & Disaster Preparedness and Labor & Tourism Committees, provides necessary amendments to the Safe Travels program to alleviate pre-travel stress on visitors who wish to come safely to Hawai'i. House Bill 1286 is a critical measure for our entire industry and the local economy, as it will codify statewide travel rules and simplify the entire process. In addition to establishing statewide policy, HB1286 will also make available State-approved rapid testing upon arrival in Hawai'i for those that took a pre-arrival test within 72 hours of departure but did not get their results back in time.

The bill also adds further clarity for lodging operations in that it stipulates that visitors who end up testing positive while in Hawai'i are ultimately responsible for securing and paying for all arrangements related to their quarantine and isolation periods.

I stand in support of HB1286, and thank you for your consideration.

Sincerely,

Marc Bromley

General Manager

Four Seasons Resort Maui at Wailea

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

THE KAHALA
HOTEL & RESORT
Honolulu, Hawaii

Testimony of
Joe Ibarra
General Manager
The Kahala Hotel & Resort

Committee on Judiciary and Hawaiian Affairs

House Bill 1286: Relating to Statewide Safe Travels Program Exemption; COVID-19; Quarantine

Chair Nakashima and members of the Committee, mahalo for the opportunity to submit testimony on behalf of the Kahala Hotel & Resort, part of the state's largest private sector visitor industry.

The Kahala Hotel & Resort – representing 338 luxury hotel rooms, with six full service food and beverage operation outlets believes that adopting statewide travel rules as they pertain to the COVID-19 pandemic and the Safe Travels program is essential to the recovery of the economy and support of our Kahala Ohana.

The lack of cohesion in rules for travelers and returning residents to Hawai'i has led to significant confusion, further harming our business which is already suffering in an unprecedented economic downturn. We have assisted numerous visitors who were unclear to provisions, took incorrect tests from non-trusted partners, or did not get their results in time through no fault of their own.
As such, The Kahala Hotel & Resort strongly supports House Bill 1286 House Draft 1.

The Kahala Hotel & Resort has been in operation since 1964 and for 57 years and have many repeat and loyal guests. Due to the confusion and the complexity of the testing program and requirements many of our repeat guests are going to alternate destinations and avoiding Hawaii as a whole. We are a strong proponent of a clear, statewide policy that provides clarity and simplicity for healthy travelers to come to Hawai'i and The Kahala Hotel & Resort. We also believe that we should provide travelers with the option to take a second, rapid COVID-19 test upon arrival should they not receive their pre-arrival test result in time.

Further, we understand that the State just announced it is open to working towards a policy that would allow a quarantine exemption for certain vaccinated visitors. Our one recommendation for HB1286 HD1 is that it include a provision that would not pre-empt vaccinated visitors from a quarantine exemption should such a program or rule be implemented.

Thank you for the opportunity to offer this testimony.

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/16/2021 5:03:33 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Amber Coutsos	Maui Chamber of Commerce	Oppose	No

Comments:

Aloha Chair Nakashima, Vice-Chair Matayoshi and Members of the Committee on Judiciary & Hawaiian Affairs,

We understand the benefits of this bill and believe there is value in a statewide system. However, each county is unique, particularly our tri-island county, and we have seen situations where this could be problematic for Maui County. When we needed to travel between our islands within our county, we had to look at ways to do things differently. Therefore, we have to share our concerns given our situation. We hope to see continued dialogue between the Governor and Mayors to find workable solutions and unify where possible.

Mahalo for the opportunity to provide testimony.

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/16/2021 5:08:34 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Robert C Friedl	The Laylow	Support	No

Comments:

Aloha,

based on speaking with our guests and clients and many of my friends and family, a recent study issued by the HTA as well as an article published by the Washington post, it appears that most travelers are deterred from travelling to Hawaii due to the unreasonable and confusing testing requirements and rules.

We need a clear, statewide policy to simplify and clarify healthy travels to Hawaii as well as providing an option to travelers to take a second, rapid COVID-19 test upon arrival in case they have not received their pre-arrival test results in time.

We also suggest for HB1286, HD1 to include a provision that would not pre-empt vaccinated visitors from a quarantine exemption.

All these measures will be important steps to make travel to the Islands less confusing and more attractive and will assist in bringing travelers back to Hawaii in a safe and controlled manner. Our economy in general, and our industry in particular, are hurting and now is the time to take action to enable us to bring our associates back to work.

We therefor strongly support House Bill 1286.

Mahalo for your consideration,

Robert C. Friedl

General Manager

The Laylow

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

Testimony of
HIGHGATE Hotels in Hawaii

Committee on Judiciary and Hawaiian Affairs

House Bill 1286: Relating to Statewide Safe Travels Program Exemption; COVID-19; Quarantine

Chair Nakashima and members of the Committee, Mahalo for the opportunity to submit testimony on behalf of HIGHGATE. Our company manages seven (7) hotels in Waikiki which represents 3,172 rooms or 13% of the inventory in the Waikiki market. During normal business (pre-covid) we typically maintain a staff of 1000 + employees/workers.

We have long advocated for the adoption of statewide travel rules as they pertain to the COVID-19 pandemic and the Safe Travels program. While we recognize the importance of "home rule" and allowing the county mayors to decide what is best for their communities, the lack of cohesion in rules for travelers and returning residents to Hawai'i has led to significant confusion and difficulty for our visitors booking future stays, especially multi-island trips. This is further harming an industry already suffering an unprecedented economic downturn. **HIGHGATE strongly supports House Bill 1286 House Draft 1** because we are strong proponents of a clear, statewide policy that provides clarity and simplicity for healthy travelers to come to Hawai'i.

As you know, many returning residents, tourists, and business travelers have had trouble sourcing a COVID-19 test from a Trusted Partner or are not getting their test results back within the 72-hour window. This issue has served problematic for our visitors and has slowed the re-building of the tourism industry since opening the state to transpacific travel on October 15th. Hotels had started to re-open, airlines had restored flights, and travel partners have begun opening up sales to Hawai'i. Our industry spent millions in adapting to the new norm by implementing Health & Safety Standards that met CDC guidelines only to be hit by new and confusing rules that varied from county to county.

The Washington Post recently ran an article titled "Hawaii wants tourists. Tourists want Hawaii. But the rules are complicated," which highlighted that our convoluted protocols are serving as a deterrent to prospective visitors who are finding themselves navigating confusing requirements for both travel to the state and within the counties. HIGHGATE travel partners have confirmed as much, state unequivocally that Hawai'i is the most confusing destination to navigate given the different rules on each island. These travel partners sell packages to Hawaii, usually months in advance and have struggled to keep prospective travelers abreast of the various rule changes. Due to this, and to encourage future bookings, HIGHGATE had no choice but to launch our Pre-Travel COVID testing coordination and Safe Travels Hawai'i concierge service in partnership with V2 Solutions to assist guests of our HIGHGATE properties to navigate the requirements needed to travel to Hawai'i.

We understand that the State has just announced it is open to working towards a policy that would allow a quarantine exemption for certain vaccinated visitors. Our one recommendation for HB1286 HD1 is that it include a provision that would not pre-empt vaccinated visitors from a quarantine exemption should such a program or rule be implemented.

Thank you for the opportunity to offer this testimony.

Testimony of
HIGHGATE Hotels in Hawaii

Committee on Judiciary and Hawaiian Affairs

House Bill 1286: Relating to Statewide Safe Travels Program Exemption; COVID-19; Quarantine



Kelly Sanders
Senior Vice President, Operations –Hawaii
HIGHGATE

Cheryl Williams
Regional Vice President, Sales & Marketing-Hawaii
HIGHGATE

Matthew Grauso
General Manager
Alohilani Resort Waikiki Beach

Randy Diamond
General Manager
Aston Waikiki Beach Hotel

Stephen Hinck
General Manager
Hilton Garden Inn Waikiki Beach



Jim Paulon
General Manager
Courtyard by Marriott Waikiki

Brandon Kaya
General Manager
Pearl Hotel Waikiki
Ambassador Hotel Waikiki

Michael Troy
General Manager
Park Shore Waikiki

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/16/2021 5:29:43 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Glen Erickson	Ala Moana Hotel by Mantra	Support	No

Comments:

House Bill 1286: Relating to Statewide Safe Travels Program Exemption; COVID-19; Quarantine

Chair Nakashima and members of the Committee, mahalo for the opportunity to submit testimony on behalf of the Ala Moana Hotel by Mantra.

While the hotel strongly supports the need for visitors to produce a negative test result prior to arriving in Hawaii, the program needs consistency across the islands, provisions for vaccinated visitors along with greater availability of testing outside of those currently approved.

Throughout the pandemic, hotel team members on the front line have been responsible for explaining and enforcing the quarantine regulations to both those interested in booking travel to Hawaii and those who have arrived without a proper understanding. This confusion is being caused by the inconsistencies between counties within the state and a lack of understanding as to why some tests are approved and others are not.

While tourism is often the focal point of travel into the state of Hawaii, inter-island travel opens up an opportunity for more Hawaii residents to return to work in hotels, restaurants, bars and retail outlets. However, this segment is significantly impacted by the inconsistencies between counties in regards to pre-travel testing requirements.

Currently all international visitors arriving into the US require a negative Covid-19 test to enter the country. However, due to the limited approved tests by the State of Hawaii outside of the country, visitors are required to take a second test and therefore the majority of them are detracted from including Hawaii into their vacation itinerary.

Finally, our one recommendation for HB1286 HD1 is that it include a provision that would not pre-empt vaccinated visitors from a quarantine exemption should such a program or rule be implemented.

Thank you for the opportunity to offer this testimony.

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

BOARD OF DIRECTORS

Roy Yamaguchi
Chair

Alan Wong
Vice-Chair

Sharon Brown
Secretary

Meredith Ching
Treasurer

Vikram Garg
Director

Val Iwashita
Director

Warren Shon
Director

Mark Teruya
Director

Shep Gordon
Director

February 16, 2021

Testimony of
Denise Hayashi Yamaguchi
CEO
Hawaii Food & Wine Festival

Committee Judiciary and Hawaiian Affairs

House Bill 1286 HD1: Relating to Statewide Safe Travels Program Exemption; COVID-19; Quarantine

Chair Nakashima, Vice Chair Matayoshi and members of the Committees,

Thank you for the opportunity to submit testimony in support of House Bill 1286 HD1.

The Hawai'i Food & Wine Festival (HFWF) is a nonprofit organization that has worked over the last eleven years to support the visitor industry by putting a spotlight on Hawai'i as a culinary destination. There are thousands who benefit from the important work of the HFWF including, chefs, farmers, ranchers, fisherman, students, airlines, hotels, etc. by participating in event that uplifts and supports Hawaii's number one industry – tourism.

A recent special study issued by the Hawai'i Tourism Authority indicated that the number one reason that has stopped travelers to from visiting Hawai'i was that testing requirements are unreasonable. Moreover, the same study indicated that 21% of respondents had trouble sourcing a COVID-19 test from a Trusted Partner and 46% felt that the 72-hour window was troublesome. What was once perception has now become reality. The Washington Post recently ran an article titled "Hawaii wants tourists. Tourists want Hawaii. But the rules are complicated," which highlighted that rules are serving as a deterrent to prospective visitors who are finding themselves navigating confusing requirements for both travel to the state and within the counties.

Our businesses and our people will suffer if we are not able to work together in the best interest of our community. We strongly support a clear, statewide policy that provides clarity and simplicity for healthy travelers to come to Hawai'i. HFWF, in partnership with Hawaii Tourism Lodging Association (HLTA) has also been urging our local government to provide travelers with the option to take a second, rapid COVID-19 test upon arrival should they not receive their pre-arrival test result in time. The State has the tests and facilities needed to make this possible. For these reasons, we strongly support House Bill 1286 HD1.

Thank you for the opportunity to offer this testimony.

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

T S Restaurants
HAWAII & CALIFORNIA

February 9, 2021

To: Committee Pandemic & Disaster Preparedness
Committee Labor & Tourism

Fr: Jackie Reed
CEO, T S Restaurants

Re: Testimony House Bill 1286

Chair Ichiyama, Chair Onishi and member of the Committees,

Thank you for your steadfastness in protecting Hawaii during these extraordinary times. I recognize the enormity of the responsibility you carry, especially during a pandemic. I am grateful for your continued work to ensure the protection and sustainability of Hawaii's people and economy.

T S Restaurants was proudly founded in Hawaii in 1977. For the past 44 years, the company has grown and currently operates 13 restaurants; 8 of which are in Hawaii on the islands of Maui, Kauai and Oahu. Prepandemic, our restaurants proudly employed over 1,500 people throughout Hawaii with an additional 900 in California.

As you well know, the restaurant industry has been devastated by the coronavirus pandemic. Within our family of restaurants, we went from a proud T S 'ohana of almost 2,500 to only 10 employees actively working in April 2020. Like many in the hospitality industry, we had months of $0 revenue in 2020. We began our slow climb to recovery, but we still have a long way to go to recoup the millions of dollars in losses and the 65% revenue reduction in 2020.

Now, more than ever, we rely on our lawmakers to assist us in our recovery. We support and uphold all measures that will keep our employees, communities and guests safe. We have adjusted our business, reorganized our facility and implemented technology, policies and safety protocol to make our restaurants safer for all. Still, we hear time and time again that the varying testing requirements between counties is confusing and an obstacle for travelers. Therefore, we humbly ask for your help.

We want and need healthy travelers to be able to come to Hawaii in order to rebuild our tourism industry in a responsible way. We advocate for a clear, state-wide policy for testing all travelers to Hawaii. We also advocate for the option for travelers to take a rapid test at the airport if the pre-travel test results are delayed. These important initiatives are laid out in House Bill 1286 which we support for the aforementioned reasons.

Mahalo for your time and attention to this critical matter.

Jackie Reed
CEO, T S Restaurants

40 Kupuohi Street, Suite 206
Lahaina, Hawaii 96761
T 808.667.4800 • F 808.667.4842
TSRESTAURANTS.COM

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

WAIKĪKĪ IMPROVEMENT ASSOCIATION

Testimony of Rick Egged
Waikīkī Improvement Association
Before the
Committee on Judiciary and Hawaiian Affairs
Wednesday, February 17, 2021. 8:30am
In consideration, of HB 1286 Relating to Statewide Safe Travels Program

Aloha Chair Nakashima, Vice Chair Matayoshi and members of the Committee,

My name is Rick Egged, President of the Waikīkī Improvement Association (WIA). The WIA is a membership organization consisting of landowners, hotels, retailers and restaurants in Waikīkī, the businesses that serve them and those interested in the future of this important part of our community and economy.

WIA strongly supports House Bill 1286. WIA supports the adoption of statewide travel rules as they pertain to the COVID-19 pandemic and the Safe Travels program. While we recognize the importance of "home rule" and allowing the county mayors to decide what is best for their communities, the lack of cohesion in rules for travelers and returning residents to Hawai'i has led to significant confusion, further harming an industry already suffering an unprecedented economic downturn.

A recent special study issued by the Hawai'i Tourism Authority indicated that the single most prevalent reason that stopped travelers from visiting Hawai'i was that testing requirements were unreasonable. Moreover, the same study indicated that 21% of respondents had trouble sourcing a COVID-19 test from a Trusted Partner and 46% felt that the 72-hour window was troublesome. What was once perception has now become reality. The Washington Post recently ran an article titled "Hawaii wants tourists. Tourists want Hawaii. But the rules are complicated," which highlighted that our convoluted rules are serving as a deterrent to prospective visitors who are finding themselves navigating confusing requirements for both travel to the state and within the counties. WIA is a strong proponent of a clear, statewide policy that provides clarity and simplicity for healthy travelers to come to Hawai'i. We have also been urging our local government to provide travelers with the option to take a second, rapid COVID-19 test upon arrival should they not receive their pre-arrival test result in time. The State has the tests and facilities needed to make this possible, and we also know that two counties are already providing rapid tests to travelers and have the facilities and know-how to execute this. For these reasons, WIA strongly supports House Bill 1286.

Mahalo for the opportunity to testify.

Rick Egged
President of Waikīkī Improvement Association

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

PMG
PACIFIC MIRROR & GLASS

5675 Kawaihau Rd., Suite B2
PO Box 1366
Kapaa, HI 96746
Ph (808) 635-9696
Fax (808) 828-6273

To Whom it May Concern:

My name is Kahala Knopp and I'm a business owner of a glass construction company on Kauai. We have been in business for 20 years and have 11 employees.

I am writing in SUPPORT for Bill HB 1286 for the following reasons:

1. I agree with the statement on page 3 of the bill that "**public health is inextricably entwined with public health**." We cannot continue to focus on one aspect of health (COVID) while ignoring the devastating effects of poverty, drug & alcohol abuse, depression, suicide, and domestic abuse - ALL of which have increased in our community as a result of the economic shutdown.

2. If this act is not passed - when does this end? How can small businesses (i.e. Kauai families) begin to re-build their lives and futures when there is no end in sight? We must balance the risk that some in our community may contract COVID, with the fact that many lives will be ruined and lost if we continue on this path.

3. The bill allows for testing and appropriate safety measures to keep our community as safe as possible, while also allowing small businesses a fighting chance to stay alive and provide for their employees.

Small businesses are dying, leaving thousands of people without a job - while the people who "make the decisions" have not gone a day without a paycheck and still enjoy the benefits of full-time work.

Many, many people on Kauai are now wondering - "if the lawmakers and those in charge weren't getting paid either, would they make different decisions?" We wonder how they would vote. We wonder, if they didn't have health insurance and had to stand in line for food to feed their families - would they keep Hawaii and Kauai closed for so long and for such an indefinite period of time? We highly doubt you would.

Can we count on you to make the choice to fight for all us?

Sincerely,
Kahala Knopp

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

Waikiki
RESORT HOTEL

Testimony of
Glenn P. Vergara
Vice President & General Manager
Waikiki Resort Hotel

Committee on Pandemic & Disaster Preparedness
Committee on Labor & Tourism

Subject: **House Bill 1286: Relating to Statewide Safe Travels Program Exemption; COVID-19; Quarantine**

Chair Nakashima and members of the Committee,

Thank you for the opportunity to submit testimony on behalf of Waikiki Resort Hotel and its associates.

I am writing to express our **strong support** for House Bill 1286 House Draft 1.

Waikiki Resort Hotel employs 130 employees, of which 77% are still furloughed as we struggle to survive with occupancy levels in the 20-35% range. While health coverages for our furloughed members have since expired since the end of last year, they struggle to feed their families.

We are finding that since we reopened in December, many of those who originally were planning to visit our state are choosing instead to take the their travel plans to other destinations because of confusion and lack of confidence in our travel policies. Based on feedback from travel partners and prospective customers, they perceive Hawaii as generally “unfriendly” and view the state’s testing requirements as “unreasonable” reflected in current stringent and convoluted travel rules that are in place.

We are a strong proponent of a clear, uniform, statewide travel policy that provides clarity and simplicity for healthy travelers to come to Hawai‘i. With that said, we urge our local government to provide travelers with the option to take a second, rapid COVID-19 test upon arrival should they not receive their pre-arrival test result in time. The State has the tests and facilities needed to make this possible, and we also know that two counties are already providing rapid tests to travelers and have the facilities and know-how to execute this.

For these reasons, Waikiki Resort Hotel strongly supports House Bill 1286

FAIRMONT ORCHID, HAWAI`I
One North Kaniku Drive
Kohala Coast, Hawaii USA 96743
T +1 808 885 2000 F +1 808 885 5778

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

February 16, 2021

Committee on Judiciary and Hawaiian Affairs

RE: HB 1286: Relating to Statewide Safe Travels Program Exemption;
COVID-19; Quarantine

Aloha Chair Nakashima and members of the Committee,

On behalf of Fairmont Orchid, a resort located in Hawaii Island, we appreciate this opportunity to provide testimony in support of HB 1286.

Our property is one of the largest employers along the Kohala Coast of Hawaii Island, which typically employs in excess of 500 employees. When we temporarily suspended our operations for several months last year in support of local authorities and COVID-19 mandates, we created stringent health and safety protocols in alignment with the State and County of Hawaii's mandates to prioritize the wellbeing of our guests and colleagues. Our team also worked around the clock to keep our guests informed of the State and County of Hawaii's COVID-19 pre-travel testing requirements.

From the onset of resuming operations in November 2020, we have received frequent feedback from our guests in regards to the inconsistency of Hawaii's COVID-19 protocols for visitors. Guests have expressed confusion that testing requirements have frequently changed, they voiced frustration over the lack of cohesion between the Hawaiian Islands in regards to testing requirements, and many feared they would not receive their results in time from a Trusted Travel Partner and would have to quarantine as a result. We have heard concerns that inconsistent statewide travel rules have undermined our guest's willingness to follow through with a trip to Hawaii. As such, we strongly support House Bill 1286 House Draft 1. It is imperative that the state offers incoming travelers clarity, consistency and simplicity in its Safe Travels Program.

Furthermore, as many travelers have found it (a) hard to source a COVID-19 test from a trusted travel partner and (b) difficult to receive their tests on time, we request that our local government offers travelers the option of taking a second, rapid COVID-19 test upon arrival if they are unable to receive their pre-arrival results in time. We hope we can be equipped to make this happen and it would give incoming travelers peace of mind.

As we look forward to recovering from the devastating impact of COVID-19, we appreciate your efforts to pass HB 1286 and thank you for this opportunity to offer this testimony.

Sincerely,

Charles Head
General Manager

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/17/2021 8:58:14 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Anna Morozov	Aloha Festival	Support	No

Comments:

Please Open Kauai like the rest of Hawaii!

We support this Bill!

Mahalo!

We The People

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

OUTRIGGER
HOSPITALITY GROUP

Rep. Mark M. Nakashima
Chair, Committee on Judiciary and Hawaiian Affairs
Hawaii State Capitol, 415 South Beretania Street

Regarding: **Support for HB1286 HD1, Relating to Travel**

Aloha Chair Nakashima, Vice-Chair Matayoshi and honorable members of the House Committee on Judiciary and Hawaiian Affairs,

Please accept this testimony as Outrigger Hospitality Group's strong support for HB1286 HD1, Relating to Travel. This bill will facilitate the safe return of visitors to our islands without compromising the integrity of the health and welfare of the men and women who work in the visitor industry and those who live in and around the communities that we serve.

During this pandemic, Outrigger's investment in safety has been second to none. Across our network, we have implemented "Outrigger's Clean Commitment" - a comprehensive program of safety protocols and standards designed in partnership with Ecolab and local healthcare leaders, to keep our hotel employees, guests and the neighborhoods around our properties safe. Outrigger's Clean Commitment enabled our company to make the strategic decision to keep a few of our properties open throughout the pandemic in order to support the needs of our National Guardsmen, first responders, government employees and kama'aina in need of transient accommodations – despite the fact that the cost of keeping those properties open was substantially more than shutting down during the Statewide closure. As of the date of this testimony, not a single case of COVID-19 was attributed to our hotel operations. It is in this context of Outrigger's laser focus on safety and sanitation that we offer our endorsement of HB1286 HD1 and encourage your support for this measure.

In codifying the exemption from quarantine for persons who receive a negative test result prior to arrival to Hawaii, HB1286 HD1 establishes the market certainty needed for a safe, steady ramp-up of visitors returning to our islands. Equally important is the requirement contained in HB1286 that travelers who do not obtain a negative test be responsible for the costs associated with that person's mandatory self-quarantine. We know from experience that the best way to ensure our visitors are complying with the rules is to communicate those rules to our guests prior to the point of booking. As written, HB1286 HD1 outlines bright lines and safe harbors on the Statewide Safe Travels program that can be shared consistently across all channels of marketing and communication with our visitors.

Support for this measure will likely lead to the increase in visitor arrivals who have a negative COVID-19 test and will allow many more locals who work in the visitor industry to get back to work sooner, and safely.

Thank you for your continued leadership and for your consideration in support of HB1286 HD1.

Mahalo,

Sean Dee
Executive Vice President and Chief Marketing Officer

2375 Kūhiō Avenue, Honolulu, Hawai'i 96815 USA TEL +1 808 921-6600 FAX +1 808 921-6595 outrigger.com

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

Rental By Owner Awareness Association

The House of Representatives
The Hawaii State Legislature
Regular Session of 2021

To: Committee on Judiciary & Hawaiian Affairs

Date: February 17, 2021

Place: Conference Room 325 - Via Video Conference
Hawaii State Capitol
415 South Beretania Street
Honolulu, Hawaii 96813

RE: **HB1286, HD1 Relating to Travel**

Honorable Chair Mark Nakashima, Vice Chair Scot Matayoshi and Members of the Committee:

RBOAA **supports** HB1286, HD1 and would like to offer the offer the following**:**

There has been confusion on the travel requirements of the various Hawaiian islands and this bill will offer continuity while providing a clear framework for travel to and within the State of Hawaii.

We suggest that language be added to include an exemption for those who have received the COVID-19 vaccine at least two weeks prior to arrival. This would allow travelers to avoid certain restrictions and offer clearance to travel without the necessity for seeking a COVID-19 test beforehand.

This Bill may also start Hawaii on the pathway to economic recovery with the return of tourism and tourism-related employment.

Sincerely,

Meera Kohler
Rentals by Owner Awareness Association

29 S. KUKUI PLACE, KIHEI, HI 96753

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/17/2021 10:46:06 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Maha Conyers	mahana weddings maui	Support	No

Comments:

Strongy support HB1286 as it helps the economy to rebounce which is needed for the islands.

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/17/2021 11:04:41 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Katy Britzmann	Grand Hyatt Kauai Resort & Spa	Support	No

Comments:

Katy Britzmann Director of Sales & Marketing at the Grand Hyatt Kauai for over 20 years

I am in support HB 1286. While not perfect, I feel it presents the most viable plan at this time.

First of all let me say how genuinely proud I am of our County's low COVID rates, organized effort on contact tracing and the vaccination roll out. I have felt extremely privileged to be able to work and live on this safe and beautiful island. I am also proud of our marketing that promotes wellness and safety, along with our push to support our island businesses.

With that said, I believe that with an organized an expeditious vaccination effort, now is the time to come together with a consistent safe travels policy that serves all of the islands.

The Grand Hyatt Kauai originally closed our doors March 26 2020 and other than a 5 week period from November to early December, we have been completely shut down. As the largest private employer on the island, we are hyper committed and focused on the re-opening our 605 room resort. We employ 850 amazing employees whose unemployment is running out and whose medical coverage is in question from month to month. We directly support many small businesses from transportation companies, to entertainers, to food purveyors, restaurants, rental car companies and activities. In addition we provide tens of thousands of dollars and in-kind services to our island charities each year. We are all interconnected on this small island.

On our island, many couples are both dependent on hospitality and tourism, and I see some of our best people moving to other islands or to the mainland to find work. To lose our next generation of hospitality leaders saddens me.

I am here to support bringing the best employees in the world, SAFELY back to work, doing what they love. There is nothing profitable about the hotel business right now. This is about human being's survival. We need to begin the recovery in an industry that like it or not drives our economy.

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/17/2021 2:01:14 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Cara Flores	HALE Hawai'i	Oppose	No

Comments:

We oppose this bill; while well intentioned it can have huge unintended consequences.

1) We have new more contagious variants now in our state. If these variants spread and increase like they have elsewhere we may need to quickly pivot and change our travel protocol because our communities and hospitals are overwhelmed. This will hinder our ability to act quickly if our communities get inundated with a new more dangerous variant.

2) This bill treats all islands as if they are equal. This is unfair to the neighbor islands. All the neighbor islands have different levels of available medical infrastructure, different amounts of tourism, different budgets, and different school situations. I am on the island of Maui and very concerned.

a) Maui families have been very much harmed by the "Safe Travels" program. Our schools were in the green on DOH school metrics (in person school) for all of October now we have been in purple for over a month (learning from home).

b) Maui's cases per population is now equal to Portland, OR so the Safe Travels program is NOT working for Maui.

c) Maui hospital is strained and full regularly. It can quickly be completely overwhelmed which will cause people to unnecessarily die. This program can completely devastate our island if our hospital gets overwhelmed because there is no way to put on the breaks.

3) There are other plans that could allow tourism and keep residents safer. I would be happy to send some to you. If the whole state is going to adopt a plan it should be one that all the counties would be glad to adopt. The neighbor counties have all rejected the current program which is why there are different requirements. The Safe Travel program is not considered safe enough for counties with limited resources. It is not right to force a less safe plan onto counties without their consent. It is very Oahu-centric and very oppressive towards "neighbor" islands. This plan does not have aloha and is not very neighborly.

a) One plan that is widely supported as a better protocol by many renowned experts in Hawaii is the "Safer Travel" plan. It can be found here: https://halehawaii.cc/safertravels (I would be more than happy to explain it.)

b) Maybe this or a similar Safer program would be more acceptable to neighbor counties and would be voluntarily adopted.

c) Please consider the message this bill sends to neighbor counties. It sends a loud and clear message that residents in neighbor counties and our voices do not matter. This bill's purpose is to take apart plans and protocols that were painstakingly put together by counties despite opposition on all sides of the COVID-19 debate. The Safe Travels plan was considered and rejected by neighbor counties. To force more cases of COVID19 onto the neighbor counties with no ability to locally put on the brakes is very authoritarian and unethical. It will cause division and non-reversible resentment towards visitors and Oahu. Forcing counties to follow a plan that is already failing in Maui and widely rejected in Kauai and Hawai'i is not pono.

d) Our county Mayors and local DOH representatives can see what is happening on the ground here in real time and need to be able to respond to it quickly.

e) As a state we should only adopt and pursue a statewide plan that all county mayors would voluntarily gladly adopt. Otherwise we should let each county have a plan that fits their comfort level based on the local infrastructure and needs.

HB-1286-HD-1
Submitted on: 2/12/2021 6:20:08 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
James E Raymond	Individual	Oppose	No

Comments:

Aloha Committeepersons:

As a retired Deputy Attorney General, I can tell you this bill has a number of flaws, primarily in the form of ambiguities and unanticipated consequences.

But more importantly, it forces Kauai to follow the unSafe Travels program that has already been found to cause significant problems for that island -- why in the world would you want to spoil the only safe harbor in Hawaii?

Why would you want to gut the purpose of ch.127A, Emergency Powers and remove the authority of the Governor to act quickly during this pandemic -- especially when the impact of multiple variants has triggered alarms from the scientific community

This bill would also remove the option, provided by the Governor, for any other Mayor to opt out of the unSafe Travels program.

The bill represents the worst kind of special interest micro-managing by the legislature and ruins the ability of the Governor to react quickly and decisively to the pandemic - please kill this bill.

Respectfully,

James Raymond

(retired) Deputy Attorney General

HB-1286-HD-1
Submitted on: 2/12/2021 6:45:22 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Clayton Weber	Individual	Support	No

Comments:

To whom it may concern,

I live on Kauai and am in full support of this bill. The resort bubble isn't working and its obvious. I will post here visitor comparisions to show how little people are interested in such a model. So we need to accept that currently we are doing nothing to address the turmoil our small businesses are under and we are driving them to ruins. I want to keep our island healthy and protected, but we cannot completely jeapordize the livelihood of tens of thousands of people on the island in the process. We have to face facts and accept that we need to do a better job of working with tourists on Kauai.

The other islands are successfully managing their numbers currently and there is no reason to assume Kauai can't do the same.

The numbers on the other islands are extremely encouraging in both managing covid cases and visitors. Here they are as of today, 2/12/21:

Honolulu County - Visitors: approx. 45% / Covid 7-day average: 1.5% (Teir 4)

Hawaii County - Visitors: approx. 49% / Covid 7-day average: .5% (Teir 4)

Maui Coutny - Visitors: approx. 45% / Covid 7-day average: 2.2% (Teir 3)

Kauai County - Visitors: approx. <1% / Covid 7-day average: .1% (Teir 4)

Yes Kauai is out performing the others by a considerable ammount when it comes to covid, but it is paying an untenable price to do so in my opinion. There is no perfect answer when you are weighing two opposing needs. There must be give and take, and I believe we need to give more to the economy of our island.

Thank you to those who took the time to hear me and understand where I am coming from.

Clayton, Kilauea

HB-1286-HD-1
Submitted on: 2/12/2021 7:59:31 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Wendy Arbeit	Individual	Oppose	No

Comments:

I oppose this measure because the needs and resources of each county are different and therefore each county should be able to devise the restrictions and guidelines that best fit its requirements and desires.

HB-1286-HD-1
Submitted on: 2/13/2021 8:02:50 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Lauren Darrow	Individual	Support	No

Comments:

Aloha!

I live on Kauai and I support this bill because my job, like many others, is dependent on tourists. I like my job and am thankful for the work I get to do. I am also thankful for how protected the people of our island have been but we are at a moment where travel and interacting with people is becoming safer and safer by the day. Tourism resuming under good regulation for the sake of our businesses and jobs like mine is a good thing.

Mahalo!

Lauren

HB-1286-HD-1
Submitted on: 2/13/2021 10:26:43 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Matt Bailey	Individual	Support	No

Comments:

I think it's safe to say that the purpose of all the COVID rules and regulations throughout the state is to keep our citizens and visitors safe. When we lose sight of that purpose, we potentially do harm to our community and reputation. I recently had a family arrive to OGG with the intention of staying at the hotel I manage. The family of four all took their tests at the same time, from the same provider. Two members of the family received their results prior to arrival, two did not. The family was advised that they would all have to quarantine. As they walked to the rental car center, the two family members who had not received their test results received confirmation of a negative test. They walked back to the security area but were told that it didn't matter, they still had to quarantine for 14 days.

This is an example of ignoring the purpose of the rule merely to enforce the rule for enforcement's sake. Prior to the change in quarantine requirements, we had many guests who arrived with pending test results. Without exception, they followed the quarantine order until their results were received. There was not one who recieved a positive test result. The system worked well.

We need to get our economy running again. At my hotel, we laid off 85 associates and furloughed another almost 300, some of whom are still out. I worry that if we don't start seeing the benefits of tourism spend, the state and counties will try to tax themselves out of the hole we're in - largely due to the lack of belt tightening that should have happened while the state was essentially closed - and will look at the usual suspects - raising the TAT and property taxes on hotels.

Simplifying and standardizing the rules across all counties will be a good first step toward getting the economy moving.

Thank you for your time.

HB-1286-HD-1
Submitted on: 2/13/2021 10:44:08 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
David Szambelan	Individual	Support	No

Comments:

Aloha Honorable Legislators,

My wife and I purchased property on Kaua'i in March of 2020 right when Covid hit. To say it was bad timing is an understatement. We were looking forward to visiting as well as investing in the local ecomomy. When restrictions to the island were put into place it was understandable, at first. But as time went on we found ourselves unable to even occupy the property we legally purchased. Yet we were forced to continue paying in full all the fees and taxes required by the county and state while unable to freely enjoy our property. Our frustration only grew as restrictions became more intense and less uniform amongst all the islands. The lack of uniformity with regard to travel restrictions, especially on Kaua'i makes it nearly impossible to visit the beautiful state and island. As I'm sure you are aware a vast majority of visitors are tourists along with property owners. Generally folks such as ourselves would plan to visit the island for 7 days, on average. As it stands now on Kaua'i we would spend our entire visit quarantined in a room, that isn't ours, (bubble resorts, extra expense) and by the time we are free from quarantine it would be time to return home. I understand the other islands do not face these restrictions and we hope you would agree that this situation is unsustainable, not only for the visitors themselves but for the local economy as well. If something isn't done to put Kaua'i on a better course, we fear there might not be much to return to once if fully opens again. We support HB 1286 and a more comprehensive and uniform approach to implementing Covid restrictions.

Mahalo,

David and Sandra Szambelan of Spokane, WA and Kapa'a, HI

HB-1286-HD-1
Submitted on: 2/13/2021 12:38:37 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Daniel R Freund	Individual	Oppose	No

Comments:

"The legislature further finds that public health is inextricably entwined with economic health ..." Right. And **the public health situation in each island is unique**.

If Kauai, with it's limited hospital faciilities, becomes a death zone then it's economic health will suffer - perhaps for years to come as the bad publicity goes out to national and international media. **One size does NOT fit all.**

(And, really, have you no shame? What does the per capita spending have to do with either public or economic health. Why are you gratuitously sowing discord?)

- Dan Freund, 5609A Honua Rd., Kapaa 96746

HB-1286-HD-1
Submitted on: 2/13/2021 3:30:28 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Carl J. Berg	Individual	Oppose	No

Comments:

Each County must decide own regulations.

Keep Kauaqi safe.

HB 1286

This bill is intended to encourage travel and support the tourist industry by simplifying the requirements for interisland and interstate travel throughout Hawaii. Proposing a single set of testing and quarantine protocols for incoming travelers, whether visitors and residents, is definitely less confusing. Yes, if more people travel here it will generate more business.

Easing travel restrictions for the sake of business is counter-productive. It encourages travel from CONUS where COVID-19 is widespread and frankly uncontrolled. Travel doesn't automatically mean more infections but it does mean we need control it better. It means more accurate testing (or a second test!), stricter enforcement (which requires more staffing and less leniency), and <u>better contact tracing</u> (yes, more staffing, less leniency).

Rather than prevent Kauai from testing visitors with a second test, wouldn't it be better for the rest of the state to adopt their rules? Yes it's more expensive, more labor-intensive, more difficult. Maybe we can't staff it; there are just so many more people here. But look at Kauai's COVID-19 infection cases! We could be in Tier 3! We might even be able to <u>stay</u> in Tier 3.

And wouldn't that encourage the more cautious of travelers to come? You know, the type that follow the rules, respect the environment, pay attention. If we have better control and lower numbers, we can promote a safer experience for visitors and residents.

With the rise of COVID-19 variants that are more easily spread, isn't that even more important now BEFORE the variants become widespread?

We should continue to take advantage of Hawaii's natural boundaries. No other state could even begin to control travel across their borders and therefore the spread of COVID-19 and its variants from other states.

If we make a concerted, sustained, long-term effort to clamp down on the spread and stay the course, THEN we could open businesses and tourism. Not the other way around.

HB-1286-HD-1
Submitted on: 2/13/2021 6:38:42 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Gloria Stults	Individual	Support	No

Comments:

I Support this Bill

I'm in complete support of unifying travel restrictions and polices for the entire State. Kaua'i rules are out of control and one sided with no consideration for what they're doing to the local economy. The busineses that I supported daily are CLOSED. It is unknown if they will be able to reopen. My family on the mainland have been unable to travel to Kaua'i.The cost to travel, test, and stay in resort bubbles have made it impossible. I have been unable to work with resorts closed. There are NO jobs available. We are one state and should actaccordiingly.

Mahalo,

Gloria Stults

HB-1286-HD-1
Submitted on: 2/13/2021 11:27:10 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Will Caron	Individual	Oppose	No

Comments:

HB1286 is simply bad policy. State regulation should be a “floor and not a ceiling.” Each individual county has unique circumstances and should be allowed to implement stricter public health and safety standards if they believe that is in the best interest of their community.

HB-1286-HD-1
Submitted on: 2/14/2021 6:39:41 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Portia Igarashi	Individual	Oppose	No

Comments:

I am a Kauai resident who owns 3 vacation rentals on island. We only have 1 active case of Covid on island and that is because of the specific travel restrictions to Kauai. With only 9 ICU beds on island, Kauai cannot afford a Covid outbreak. Our mayor has made the island safe for our residents and visitors who meet the restrictions. We have seen outbreaks on the other 3 islands which have resulted in deaths and recovered Covid patients suffering from Long Covid (post long term symptoms). Because of our restrictions we are a healthy island; a healthy island is good for business, its residents and the future of Kauai. Restaurants, shops, museums, parks and beaches are all open. We are ready for when it is safe to travel freely again and visitors will be allowed on Kauai. With the nationwide curve improving and vaccinations occurring, now is not the time to lower our defenses against Covid because the tourist industry does not like them. It is right that our mayor will decide when it is safe to open Kauai to tourists because of our circumstances, not the legislature in Honolulu.

HB-1286-HD-1
Submitted on: 2/14/2021 7:27:00 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Elisabeth Dingus	Individual	Oppose	No

Comments:

Aloha,

I oppose bill HB 1286. I am a teacher and parent and strongly believe that our keiki have a better chance being back in school full time. And that is not going to happen until our island is safe and COVID is no longer spreading.

The CDC recommends NO travel beyond the absolute necessity. Cheap vacation flights are not a necessity! But our Mayor has made our island safe by enacting resort bubbles and quarantine rules that have kept our island healthy.

As a resident of a Kauai, I implore you to remember the differences between our islands in terms of size and ICU bed capability and reconsider classifying everything as the same. We are not, so should not be treated as such.

Please discard this bill or amend it so that these recommendations are the minimum but do not take my county's right to keep it me, my students and my children safe.

Thank you,

Elisabeth Dingus

HB-1286-HD-1
Submitted on: 2/14/2021 8:13:12 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Melinda Smith	Individual	Oppose	No

Comments:

Aloha, we, on Kauai, have a much different situation than the other Counties. We need to be able to protect ourselves from disease and over tourism. For example, as you know we only have a few ICU beds and opening us up like you would Waikiki is just not realistic. Thank you.

HB-1286-HD-1
Submitted on: 2/14/2021 8:32:42 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
umi martin	Individual	Oppose	No

Comments:

This a a power grab by the state to fuel the tourist addiction. What the powers to be don't understand is that we have made our decision on how to ha dle the covid pandemic. We have chosen our residents health over the economic impact of reduced tourism, and our protocols has proven to be safer than the state protocol. We understand, we are not stupid. The state should adopt iur policies. This is the tourism lobby that is fueling this power grab. Stop it

HB-1286-HD-1
Submitted on: 2/14/2021 8:43:39 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Molly McKenzie	Individual	Comments	No

Comments:

My husband and I are residents of Kauai and we do not approve of House Bill 1286. We believe it prevents Kauai County from putting into place rules to protect our communities health and safety from the risks of expanded COVID infections. Our mayor, Derek Kawakami has been forthright in keeping the residents of Kauai as safe as possible from the virus and it is our belief that this bill was introduced specifically to stop Kauai County from making those rules. We appreciate the virus has affected our economy however the choice Kauai County made was to keep it's citizen's safe and it has done that. So far we have only had one death and 210 affected with the virus. This is not a time to bow to the wishes of the Chamber of Commerce or the Hawaii Tourist Board. Therefor we do NOT approve the passing of this Bill. Mahalo.

February 14, 2021

Testimony in opposition to HB 1286 HD 1, Relating to Travel

Honorable Chair Nakashima and members of the Committee:

I am writing in opposition to HB 1286 HD1, Relating to Travel.

While economic health is important, even more than the economy, people depend on their government to take the steps that will protect the public health. And as these past months have demonstrated, until public health issues and COVID-19 are addressed, the economy cannot truly recover.

With this in mind, HB 1286 HD1 presents several concerns.

First, this bill would codify practices, which even now, do not reflect the latest guidance for safe travel. Please see for example, the CDC guidance at https://www.cdc.gov/coronavirus/2019-ncov/travelers/testing-air-travel.html.

However, concern also lies in the sweeping provisions of section 2(a) of the bill which require that the travel protocols in this bill precede and preempt all other laws, ordinances, rules, orders, or proclamations. Section 2(a) provides:

Notwithstanding chapter 127A or any other law to the contrary, this Act shall take precedence over all conflicting statutes concerning this subject matter and shall preempt all contrary laws, ordinances, rules, orders, or proclamations adopted by the State, a county, or any department or agency thereof.

Under this section, even as circumstances change, we may be locked into a protocol that is insufficient to protect the public health and lead to economic recovery. One consequence of section 2(a) is that counties will no longer have the flexibility to adjust their travel requirements to better protect their communities.

At present, the statewide requirements have provided for a floor, setting a level of protection across the state, but allowing a county, such as Kauai, to provide more protection with the governor's approval. This has allowed Kauai to stay at relatively low rates of infection and limit community spread. In contrast, Maui has gone from relatively few cases prior to October 15, to consistently higher numbers since then.

If this bill is passed, all counties will be tied to the protocols in the bill, and counties, such as Kauai, will no longer be able to adjust those practices to keep their people safer.

In addition, there is the possibility that this bill will take away flexibility from even state leaders to address a changing landscape. The language of section 2(a) of the bill appears to take away even the governor's emergency powers to adjust the travel protocols through emergency proclamation.

Our understanding of COVID-19 and how to protect against its transmission has been evolving over time. Now, we also see that the virus itself is changing and new variants, including the highly contagious UK variant, are coming into the state. It is therefore critical to maintain the ability to respond quickly to address the transmission of COVID-19. It would be foolish to deprive our leaders of the ability to quickly adjust travel protocols that may not reflect scientific advice at the time and that would harm our people and state.

For these reasons, I urge you to carefully consider, with the advice of your attorneys and health experts, if this bill will achieve what is best for our state, and I ask that you vote against this bill. Thank you for your consideration.

Sincerely,
Lynn Otaguro
Oahu, Hawaii

HB-1286-HD-1
Submitted on: 2/14/2021 10:58:41 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Mele Stokesberry	Individual	Oppose	No

Comments:

I strongly oppose House Bill 1286 because Maui county and the other Neighbor Island counties deserve to make our own rules to protect our citizens from COVID. It's obvious that there are more tourists arriving to O'ahu and more cases from travel and community spread on O'ahu. We are taking care of ourselves and we deserve to continue to make our own rules and decisions about COVID regulations.

Mele Stokesberry

51 Mano Drive, Kula, Hawaii 96790

HB-1286-HD-1
Submitted on: 2/14/2021 11:00:10 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Michael Stauber	Individual	Oppose	No

Comments:

Aloha,

I feel the people of Kauai deserve the protection of the County's current rules as implemented by our Mayor. It is NOT too confusing, it just takes effort to read and follow the rules. As shown when the rules were relaxed, Kauai experienced a massive growth in Covid cases. We currently have 1 active case and we want to keep our people safe.

HB-1286-HD-1
Submitted on: 2/14/2021 11:12:33 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Teri M Albert	Individual	Oppose	No

Comments:

Please respect the decisions made by the mayor of Kauai, and do not prevent Kauai County from safe guarding the island from Covid-19. Working in tandem with our health officials, our county has devised the most acceptable steps for allowing international and interisland travel. We currently have one case. Honestly, we could use this time to further analyze best practices for supporting our current population; conserving the environment unique to Kauai; addressing necessary economic growth in a studied, community-minded manner. Please do not pursue HB1286.

HB-1286-HD-1
Submitted on: 2/14/2021 11:19:09 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Debra Greene	Individual	Oppose	No

Comments:

Aloha Chair, Vice Chair and Committee Members,

Please oppose this bill. Each island is different and the unique needs of each island can best be met by honoring home rule and allowing local jurisdictions to make their own travel rules. Any interisland differences can easily be addressed with modern technology. Travelers can access websites and do their own due diligence before traveling. Airlines can support that. Please oppose a one-size-fits-all approach, because that may work on the mainland but doesn't work in or island state.

HB-1286-HD-1
Submitted on: 2/14/2021 11:22:37 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Adrian Bontje	Individual	Oppose	No

Comments:

Strongly oppose

HB-1286-HD-1
Submitted on: 2/14/2021 11:25:01 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Patricia Blair	Individual	Oppose	No

Comments:

Kauai has don't a good job protecting its citizens. The other Islands, not so much.

HB-1286-HD-1
Submitted on: 2/14/2021 11:38:37 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Douglas Shannon	Individual	Oppose	No

Comments:

As a resident of Kauai County, I am opposed to HB1286 because each island is different and therefore has different needs when it comes to fighting the Covid 19 virus. Under Mayor Kawakami's leadership, Kaua'i has the lowest COVID incidence in Hawai'i. As soon as we opened up under the so called "Safe Travels" policy our cases skyrocketed to a doubling of Covid cases in one month's time. After shutting down again in December, our numbers went back down. Compare this to Maui, which stuck with the Safe Travels plan, and has currently ballooned from 1% of the state's total cases to 18% today. The lieutenant governor's own Safe Travels Surveillance Study showed that the pre-departure test missed at least seven of 1,000 travelers — seven times the prediction of the state's travel plan. We need Mayor Kawakami's original plan of a second test to keep our island safe. One pre-travel negative test does not mean a traveler is safe. A significant number of travelers test positive AFTER arrival, causing spread in Hawai'i. I do not want to see Covid spreading like wildfire over a small island of 72,000 inhabitants with only 9 ICU beds. One reason for this bill is the misconception that the different rules for different islands is confusing, yet a poll by the Hawaiian Tourism Authority found that nearly 90% of visitors surveyed reported their visits were "excellent." This means that those travelers did not find anything about their trip to be "confusing". In addition, vaccine rollout is very slow here. I am 66 years old and will not receive my first vaccine shot until mid March! When will I receive my second, April or May? Sorry, I do not want to get sick and die in the name of tourism! 90% of the tourists I run into outside do not wear masks even though they are within 6 feet of you and think that since they tested they are Covid free and cannot be carriers. A better bill would be to require the HTA to place a brochure at every check in desk and TVR that explains our rules so that they are followed. Until this is done we are all at risk of becoming infected. I ask that you please vote "no" on this bill for those reasons. Mahalo for reading this testimony.

HB-1286-HD-1
Submitted on: 2/14/2021 11:44:12 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Sarah Biggs	Individual	Oppose	No

Comments:

Each county is different. Each county has different resources. Each county knows what's best for itself. It is not unreasonable to have different rules. Any reasonable traveler can look up what their destination's rules are before departing. The information is all there, one simply has to look for it. A simple Google search is not an undue burden on a traveler. It's the new normal.

HB-1286-HD-1
Submitted on: 2/14/2021 11:46:40 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
William Hackett	Individual	Oppose	No

Comments:

This is a bad bill. It ignores all the benefits of Mayor Kawakami's approach in deciding how to strike a balance between public health and economic health. The results on Kauai are impressive,compared to those on Oahu. Compare our results to those on Maui, which is following the state's Safe Travels program, with problematic results, and you can understand our concern with HB1286.
The so-called confusion to incoming visitors will benefit Oahu, where the state's Safe Travels program is more relaxed, resulting in 50 to 100 new cases of COVID-19 a day. For those visitors who are more concerned with exposure to Covid-19, and who do their homework, they will chose Kauai, which has zero to one new cases a day. This is all the more important with the new variants of Covid-19 emerging, which may be resistant to the current vaccines.
If you take the time to read the op-ed article in the Sunday, February 7, edition of The Garden Island, "Saiki's travel-policy bill unsafe for Kauai, Hawai'i" by JoAnn Yukimura, Robert Weiner, MD, and Chad K. Tanaguchi, you will understand why HB1286 is a bad bill.

Please don't overrun Kauai's and the neighbor islands ability to stay safe from Covid-19.

Mahalo,

William Hackett and Yvette Bambas

HB-1286-HD-1
Submitted on: 2/14/2021 12:07:05 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Judith Perino	Individual	Oppose	No

Comments:

Each county needs the flexibility to ascertain whatever restrictions or mandates that need to be made based on individual circumstances for that island. It is not one size fits all. I oppose this bill.

HB-1286-HD-1
Submitted on: 2/14/2021 12:17:19 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Gloria Bandsma	Individual	Oppose	No

Comments:

I live on Kauai and we want visitors to stay in a bubble resort for at least 3 days. We are not Oahu and do not have the resources to handle an influx of Covid 19 cases.

Let the mayors decide what happens on there island. They know us and what we want.

HB-1286-HD-1
Submitted on: 2/14/2021 12:46:31 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Linda Pascatore	Individual	Oppose	No

Comments:

Please oppose HB1286. Kauai has only 9 ICU beds, and is much more danger than Oahu for overrunning our hospital with COVID cases. Let our county have the autonomy to make our own rules. We have done exceptionally well with our mayor at the helm.

Linda Pascatore

MS, Licensed Speech Pathologist

resident of Hanapepe, Kauai, HI

HB-1286-HD-1
Submitted on: 2/14/2021 12:55:07 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Juan Wilson	Individual	Oppose	No

Comments:

Aloha House Members,

I am an architect and planner living on Kauai. I greatly appreciate the efforts of my county government to keep the people of Kauai safe and healthy. But the crises we are experiencing is not just about a viral pandemic.

We are facing a trifecta of disasters. One of those alone, namely global warming, is an existential threat to all life on Earth. We are also reaching a human overpopulation that is demanding resources that are in sharp decline.

Going ahead as if things are just fine is madness. "Growth" and "Tourism" are poison to life in Hawaii. Re-localisation is the solution to many of our problems. I'm going to get myself a "Derek for Governor!" label button.

HB-1286-HD-1
Submitted on: 2/14/2021 1:44:07 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Jill K. Reiner	Individual	Support	No

Comments:

We feel that for Kauai to open up that there needs to consistancy within the state of Hawaii and that this bill creates that. Therefore we are in 100% support of this bill.

Owner of Kahala 723 Kauai

Jii K. Reiner

HB-1286-HD-1
Submitted on: 2/14/2021 1:52:38 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Rozlyn Reiner	Individual	Oppose	No

Comments:

As a 43 year Hawai'i resident (40 years on Kauai) I STRONGLY oppose this bill. The policy now being proposed in HB1286 is woefully inadequate if the goal is to minimize the spread of travel-related coronavirus infections in Hawai‘i. The medical community is unanimous in agreement that a single test 72 hours prior to arrival is insufficient protection if the goal is to keep COVID infection and death rates as low as possible.

A second test is especially important when taking into consideration the rise of new and more dangerous strains such as the “Kent coronavirus variant” that U.K. experts have said may be up to 70% more infectious and about 30% more lethal than other variants.

The third policy element, that of “preempting” the right of a county to have stricter health protections, is on its own sufficient reason to oppose HB1286. This is yet-another example of the majority of the Legislature who live in Honolulu thinking that what’s best for Honolulu is best for everyone else, regardless of where they might live.

State laws should be a “floor, not a ceiling.” If any county wants to pass stronger laws, rules or regulations that reflect its particular circumstances, it should be allowed to do so. If the residents don’t agree, they can direct their voices to the County Council and mayor, and/or they can elect new county leaders. If visitors don’t like it and/or they are “confused,” then perhaps they would be better served by spending their vacation days in Honolulu. Or, better yet, perhaps non-essential travelers should abide by the CDC travel guidelines which are: “The CDC recommends that you do not travel at this time.”

Our Mayor & health officials here on Kauai know what protocols best serve the needs & safety of our community. Kauai needs to maintain more stringent rules for pre & post travel testing, & mandatory quarantine. We have only 9 ICU beds on our island & would be unable to effectively manage a Covid surge. We must maintain our more stringent testing & quarantine protocols to prevent travel-related spread of Covid (incoming travelers bringing Covid). I urge you to vote NO on HB 1286

Respectfully,

Rozlyn Reiner

Kekaha, Kauai

(808) 652-2373

HB-1286-HD-1
Submitted on: 2/14/2021 1:59:58 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Dr. Irene Sherman	Individual	Oppose	No

Comments:

Aloha Senators and Representatives,

As a full-time Kauai resident since 2006, I STRONGLY URGE YOU TO DEFEAT THIS BILL. Based upon the number of people who submitted testimony for the last hearing, there is keen interest in its outcome.

I have carefully read and considered all previous testimony. Without doing an exact count, it is obvious to me that the testimony can accurately be divided into two groups. The first consists of those who either own vacation rentals and live on the mainland or local business owners. Their concerns are focused on the economy and loss of income. The second group consists of those who actually live on Kauai and are concerned about the risk to their own health and lives as well as that of their families.

So far, Kauai has been spared an outbreak of COVID. This is not by chance, but due to the outstanding leadership of Mayor Kawakami and our County Council. It is absurd to compare the medical infrastructure of Oahu with that of Kauai. According to the most recent information, we only have 9 intensive care beds and 8 ventilators to serve a population of over 70,000 full-time citizens.

Only LOCAL, ELECTED OFFICIALS should be allowed to make decisions that will impact the safety and well-being of Kauaians. While I am not unsympathetic to economic hardship, in my opinion it borders on criminal, sociopathic behavior to put economic interests above life. Nothing is so easy as for those who will not suffer the consequences of their decisions. This cannot be allowed.

ONCE AGAIN, I IMPLORE YOU TO DEFEAT THIS BILL.

Sincerely,

Dr. Irene R. Sherman

HB-1286-HD-1
Submitted on: 2/14/2021 2:01:45 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Eric Taylor	Individual	Support	No

Comments:

1. am a resident of Kauai, and appreciate this opportunity to testify. have established several small businesses on Kauai. At this time, our operations include a farm that supplies produce directly to local restaurants, 3 shave ice stores and 3 restaurants. n normal times, we employ over 70 people on Kauai in permanent positions.

1. is noteworthy that we contribute all (all) of our profits from our small businesses towards enabling free camps for Hawaiian island kids, kids who otherwise would not be able to attend a camp. The camps were started in 2012 after years of building, and have always been free. The sole purpose of setting up our businesses on Kauai was to allow the camps to be free for island keiki and sustainable in the long term. In 2019 we had finally achieved our goal of fully funding the free camps through the profits of the small businesses, and in that year over 800 keiki from the islands attended those free camps.
2. the imposition of the mandatory quarantines, which continues to stop tourism on the island of Kauai, our small businesses have dropped down to less than 20% of 2019 revenue, we have lost most of our employees, and we have incurred and continue to incur huge losses. This continues today because of the policies in place on Kauai. Without visitors to the island, our businesses are not viable. To survive, we applied for aid available like PPP, and we have been selling off assets and real property to fund our losses and stay open, but that is not sustainable. While most of Hawaii welcomes visitors with negative Covid tests, Kauai governance has opted to keep our island closed despite the way it hurts businesses like ours. Besides causing confusion, this policy has directly hurt the employees and the viability of many small businesses on Kauai. A uniform Hawaiian policy will eliminate the present confusion, and will get us back to welcoming safe visitors.
3. has taken us many years of hard work and investment to build up our small businesses on Kauai, and to create good jobs on Kauai. That is all at risk.

1. strongly support the bill, and support a unified approach to visitors for all Hawaii. support decisions that are based on science instead of on privileged positions, or on groups of influencers, or on emotions.

Thank you for considering our view and for having the strength to make the right decision.

Eric Taylor

I am a resident of Kauai, and appreciate this opportunity to testify. I have established several small businesses on Kauai. At this time, our operations include a farm that supplies produce directly to local restaurants, 3 shave ice stores and 3 restaurants. In normal times, we employ over 70 people on Kauai in permanent positions.

It is noteworthy that we contribute all (all) of our profits from our small businesses towards enabling free camps for Hawaiian island kids, kids who otherwise would not be able to attend a camp. The camps were started in 2012 after years of building, and have always been free. The sole purpose of setting up our businesses on Kauai was to allow the camps to be free for island keiki and sustainable in the long term. In 2019 we had finally achieved our goal of fully funding the free camps through the profits of the small businesses, and in that year over 800 keiki from the islands attended those free camps.

Since the imposition of the mandatory quarantines, which continues to stop tourism on the island of Kauai, our small businesses have dropped down to less than 20% of 2019 revenue, we have lost most of our employees, and we have incurred and continue to incur huge losses. This continues today because of the policies in place on Kauai. Without visitors to the island, our businesses are not viable. To survive, we applied for aid available like PPP, and we have been selling off assets and real property to fund our losses and stay open, but that is not sustainable. While most of Hawaii welcomes visitors with negative Covid tests, Kauai governance has opted to keep our island closed despite the way it hurts businesses like ours. Besides causing confusion, this policy has directly hurt the employees and the viability of many small businesses on Kauai. A uniform Hawaiian policy will eliminate the present confusion, and will get us back to welcoming safe visitors.

It has taken us many years of hard work and investment to build up our small businesses on Kauai, and to create good jobs on Kauai. That is all at risk.

We strongly support the bill, and support a unified approach to visitors for all Hawaii. We support decisions that are based on science instead of on privileged positions, or on groups of influencers, or on emotions.

Thank you for considering our view and for having the strength to make the right decision.

Eric Taylor

HB-1286-HD-1
Submitted on: 2/14/2021 2:10:13 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Chris Holohan	Individual	Support	No

Comments:

Aloha, I manage several businesses (restaurants and shave ice shops) on the island, and we are desparately hurting due to the lack of travelers. We have laid off many people and applied for all the financial assistance we can. We have been hanging on for close to a year, and our time is running out. We have implemented every safety protocol the Department of Health has required, and then some. We are prepared to continue with all of our safety measures as long as needed, to help keep our community as safe as possible with the return of visitors. I am in support of this bill, and appreciate the chance to voice our struggles.

HB-1286-HD-1
Submitted on: 2/14/2021 2:16:15 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Amy Davis	Individual	Oppose	No

Comments:

The Hawaii Touism Board touts that each island is unique yet feels necessary to lump the islands into one "Safe Travels" program to benefit.....not the citizens of Kauai, obviously. The statistics speak for themselves. Please do not let this bill pass.

HB-1286-HD-1
Submitted on: 2/14/2021 2:23:12 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Rachel Holohan	Individual	Support	No

Comments:

As both a worker in the tourism industry, and a parent, I am in support of this bill. Despite our low Covid case numbers (one case on our entire island as of February 12th), our children have not been allowed to go back to school in a normal capacity, and they are struggling. In addition to that, my husband and I bring home the stress of watching the business we are managing struggle to survive. We care very much for our community, and we respectfully practice social distancing, we stress the importance of sanitizing to our kids, and we wear our masks. On the few days our kids are allowed to go to school, they also wear masks, remain socially distanced, and sanitize often. Kaua'i has been practicing all of these best practices since late March of 2020, and we are probably more prepared than most places to allow visitors back to our island. What is the point in having our kids continue to do distance learning with no community spread? If my kids are going to receive a lesser education in order to prevent community spread and keep others safe, then let it be for something. Opening the island with the pre-testing travel requirements gives us the chance to try and save the businesses that are dying while responsibly allowing visitors back to Kaua'i.

HB-1286-HD-1
Submitted on: 2/14/2021 2:39:24 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Bonnie Honma	Individual	Oppose	No

Comments:

Please allow our Mayor, in consultation with our Kauai Department of Health to continue their best efforts to keep our residents and visitors safe. As you already know, the neighbor islands have little capacity for Covid spread. Until residents are given an opportunity to get vaccinated, we must continue to use our wisdom to follow the CDC rules of limiting non-essential travel or enforcing quarantines and/or mandatory testing. I am against this bill.

Respectfully, Bonnie Honma

HB-1286-HD-1
Submitted on: 2/14/2021 2:50:05 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
David Hunt	Individual	Oppose	No

Comments:

HB 1286 should be SCUTTLED as the arrogant "WE politicians (that you elected) know better what's best for YOU than you do" garbage that it is.

HB1286 is simply disrespectful, over-reaching, and arrogant. If Kauai locals and county government need additional protections due to the size, health system capacity, and other unique characteristics - WHO ARE YOU to over-ride their needs, wishes, and decisions.

If Kauai has an unmanageable Covid-19 outbreak because YOU voted for HB1286 - WILL YOU also take FULL INDIVIDUAL / PERSONAL RESPONSIBILITY (legal, moral, and financial) for local illness, medical expenses, and deaths??

I imagine NOT... and IF NOT, then YOU need to VOTE THIS ARROGANCE DOWN.

HB-1286-HD-1
Submitted on: 2/14/2021 3:22:14 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Christine Heath	Individual	Oppose	No

Comments:

I am writing as opposed to HB 1286. I think that each Island has different circumstances that must be accounted for in setting resrtictions due to covid 19. Each island has different level of medical care that is available which might influence the requirements needed to keep the virus at bay. If there is an outbreak on one island, I would think it would not have the same requirments as those with a low incidence of infection. You may not realize how inadequate health care is on the neighbor islands and if we have to follow the same requirements as Oahu we could be decimated. Please vote no!

HB-1286-HD-1
Submitted on: 2/14/2021 3:36:25 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Lynn Murakami-Akatsuka	Individual	Oppose	No

Comments:

I strongly oppose HB 1286, HD 1 if it impacts the "home rule" of county mayors to decide the best couse of action for their community. In this particular case, the County of Kauai. The daily count of cases for Kauai has remained low or no active cases. Kauai is not Oahu. Kauai has one major hospital, Wilcox Hospital, on the island with only 7-8 ICU beds, few ventilators and staffing.

If Kauai was failing in its COVID response, I would welcome the opportunity for the state to come in and help put the standards as noted in HB 1286, HD 1 version. We are just months away from everyone who wants a vaccination to get one. This is NOT THE TIME to interfere with the system is working on Kauai or to override Mayor Kawakami's decisions for Kauai.

Thank you for the opportunity to testify in strong opposition of HB 1286, HD 1.

HB-1286-HD-1
Submitted on: 2/14/2021 4:09:02 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Jane Common	Individual	Support	No

Comments:

I support HB1286 100%. It has been very difficult for Hawaii visitors to understand and realize that each county's requirement is different. For example, if I want to go to New Zealand and learn that each state and each county has a different travel restriction, it will take a huge effort to plan. However, most likely, I will just go to Florida instead, knowing each county in Florida has the same travel restriction.

I would like to point out the conflict of interest of the Kauai mayor and his decision:

1. There is class warfare between working-class vs elderly (65+, the rich). There is > 20+% of elderly who do not work, do not pay Tourism tax, and have interest in keeping Kauai shutdown (less traffic, empty beach, peaceful). Kauai mayor expects to get re-election and therefore his main interest is in pleasing the senior to get re-election.
2. From March 2020- 2021, the number of 9 ICU beds is always be used to provide the reason why Kauai needs to have its own travel rule. With this limited bed supply, therefore Kauai is special and not able to accept visitors. Interestingly, instead of getting more ICU beds with the federal fund, The number of ICU beds remains the same number throughout the year. There is no transparency in the plan to increase the number of ICU. The number of ICU bed is the reason to have the most restriction in travel.
3. The bubble resort is the Kauai mayor's idea and he wants to implement it in Kauai. Even though the governor turned it down last year, the mayor still finds his way to implement it. The governor also points out that it would make confusion for Hawaii visitors. As of now, the bubble resort occupancy is ~ 7% (not 20% as he claims). The 20% data is calculated by excluding the # of empty hotels that did not participate to the resort bubbles. When we use the statistic number of visitors to Kauai, comparing between Jan 2020 vs Jan 2021. The # of hotel rooms in Kauai is the same, there is only 7% occupancy.

Please have a uniform travel restriction.

Best regards

HB-1286-HD-1
Submitted on: 2/14/2021 4:26:12 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Steve Marshall	Individual	Support	No

Comments:

Hello, my name is Steve Marshall and until March of 2020 I was a part-time resident of Kauai. We purchased our home on Kauai in late 2018 and spent about 20 weeks on-island during 2019 and about 4 weeks in 2020 until we left in mid-March due to impending travel restrictions as a result of the Covid 19 pandemic.

Since leaving the island, we have returned only once ... in late October 2020 for 6 days, when Kauai was participating in the Safe Travels program. Mayor Kawakami's decision to "temporarily" opt out of the Safe Travels program in early December 2020 has kept us from reoccupying our Kauai home since that time.

Mayor Kawakami's rules, while admirable in their intent, have kept us ... and other responsible like-minded Kauai property owners ... from visiting our homes on Kauai. We have followed all press releases and public comments since the "temporary" opt-out, and based on those releases and comments we are reasonably confident that Kauai may never reopen its borders to anyone other than permanent full-time local residents, despite the incredible and long-lasting economic damage being done as a result of the mayor's excessively harsh restrictions.

We understand the importance of keeping Covid-19 infections to an absolute minimum, but we also have to keep economic interests in mind. We are not suggesting that either is more important than the other, but we are suggesting that a balanced approach must be taken. Having said that, it is important to note that while we have been unable to occupy our Kauai home we have still been required to maintain all utility payments, HOA payments approaching $1000/month, and property tax payments ... the same costs all Kauai residents pay, but without the same benefits full-time Kauai locals receive. In total, we spend about $4000/month paying a mortgage, insurance utilities, HOA dues and property taxes. That means since March of 2020 we have spent about $44,000 in Kauai living costs without being afforded the opportunity to use our Kauai home in a reasonable manner.

I cannot speak for other 2nd homeowners on Kauai, but these costs are not insignificant to us and with no reasonable hope of returning to Kauai in its current lockdown state there is no real reason to continue paying these costs. The "bubble resort" (or EMQ) option does not create a reasonable opportunity to visit as the additional costs associated with these bubbles are designed to discourage all but the most affluent

people from participating. It is our understanding that only about 20 people per day are participating in these bubbles, and it is also our understanding that not one single Covid-19 positive test result has been reported from anyone participating in a resort bubble. That certainly underscores the success of Kauai's stringent rules, but it also underscores that responsible travelers are ensuring they are Covid-negative before attempting to visit Kauai.

We saved for more than twenty years to enjoy a part-time residence on Kauai and it is our belief that this effort was in vain. Mayor Kawakami seems intent on eliminating travel to Kauai without regard to any of the property owners who have experienced significant adverse effects as a result of his rules. This does not take into account the severe island-wide economic damage caused by his rules and the likely long-term (if ever) recovery from this damage. We are American citizens, the same as you and as all residents of Kauai. Responsible people can travel with minimal risk in this country as long as they take appropriate pre-travel steps to ensure they are virus-free.

I strongly urge the passage of this legislation and a uniform approach to travel across all of Hawaii. As a property owner and taxpayer, I believe we are entitled to the rights associated with our payment of the same taxes every other Kauai resident ... local or otherwise ... pays. Should the legislation fail, I believe it is appropriate to exempt all non-resident homeowners (both part-time homeowners and short term vacation rental owners) from payment of ANY property taxes on Kauai, and it is also appropriate to prohibit HOAs from collecting any dues from such property owners until such time as Mayor Kawakami chooses to reopen his island and rejoin the Safe Travels Program.

If the status quo remains the same, we will likely sell our property and relocate to a more friendly location. We LOVE Kauai and have been blessed to enjoy the island and its residents for many years. It will be with much regret that we give that blessing up. But it is important to us that we spend our time and our money in places where we feel welcomed and accepted. Kauai is clearly not welcoming or accepting of any non-locals at this time; further, from the press releases and social media comments it seems clear that this non-acceptance is becoming the norm and likely to continue well into the future. In fact, even if Kauai reopens its borders the predominately negative social media posts seem likely to discourage any significant number of travelers from returning anytime soon. For the well-being of Kauai, and Hawaii in general, I again urge the passage of this legislation.

Perhaps a reasonable alternative would be Kauai's return to the Safe Travels Program plus an additional rapid Covid test three days after arrival. The test could be performed by a stationary facility at a nominal cost, or for an additional cost a mobile testing unit that visits the residence of the recently-arrived person (it is my understanding that such mobile units are now visiting EMQ locations). Kauai is currently offering free testing to its residents, so the availability of tests should not be an issue. Further, a preset appointment for the 2nd test could be made a part of the Safe Travels website with significant penalties to anyone who does not upload the results of the 2nd test to the Safe Travels website in a timely manner. Perhaps the Safe Travels website could

collect a deposit from each traveler with the deposit refunded (less the cost of the test) after the 2nd test is completed.

Thank you for taking the time to read this statement. I apologize for being a less than eloquent writer; I am simply doing my best to express our thoughts in the most straightforward way possible.

HB-1286-HD-1
Submitted on: 2/14/2021 4:31:37 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Shannon Rudolph	Individual	Oppose	No

Comments:

Oppose. What's best for O'ahu may not be in alignment with what's best for neighbor islands. I'd prefer more local decision making.

HB-1286-HD-1
Submitted on: 2/14/2021 4:32:43 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Todd ziplow	Individual	Support	No

Comments:

Thank You for allowing me to just say how important it is for the state to take over. The Mayor of Kauai in destroying the enconomy on the island. The Mayor comes from a family whose's wife cares more about her Gucci purses that what the public needs. Without travel/tourism Hawaii dies.

People need to get back to work, we need tourists back and it's time to move forward. The Mayor should not have such a strong voice to control what's needed for the Island. It's time for the higher ups to take control.

Please support one system for all.

Thank You

Todd Ziplow

HB-1286-HD-1
Submitted on: 2/14/2021 9:05:02 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Dave Kisor	Individual	Oppose	No

Comments:

How qualified is your incident commander to make a medical decision? You want a cookie cutter set of regs, but I view this as stripping more protections away from the counties, just like the state did with Act 97. An individual county may have a higher standard than the state. There are times uniformity isn't all it's cracked up to be. Please reject HB1286.

HB-1286-HD-1
Submitted on: 2/14/2021 9:49:21 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
janice palma-glennie	Individual	Oppose	No

Comments:

aloha,

Top-down governance is not what counties (islands) need when it comes to deaing with covid-19. House Bill 1286 was introduced by House Speaker Scott Saiki, who represents District 26 which includes five hospitals: Queens, Kapiolani, Shriners, Straub and Kuakini. This is a far cry from the situation in Hawai`i Island or Kauai.

Allowing visitors to come without strict protocols is kissing tourist and tour industry okole at the behest of residents and common sense. it's already difficult and dangerous enough having to fly to Oahu to have routine medical procedures, no less under duress of covid.

i've spent many, many sleepless nights worrying about the health of my 97-year-old mother -- and her 68-year-old daugher (me!) before October when the state opened to tourists. After that it's been a crap shoot and lock down for residents who have to stop going to shops, stores and even b beaches to avoid tourists who are under-tested and over-pampered.

say "NO" to this bill to say "yes" to protecting the lives and long-tern livelihood of the people who live in Hawaii and who serve the tourists some legislators and businesses in this state are so overly-anxious to kowtow to.

mahalo and sincerely,

janice palma-glennie

kailua-kona

HB-1286-HD-1
Submitted on: 2/15/2021 6:00:39 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Joan Gannon	Individual	Oppose	No

Comments:

Joan Gannon from West Hawaii here asking you to please strick down HB1286. Each county should have the right to protect it's population from the COVID 19 virus.

Thank you

Joan Gannon

HB-1286-HD-1
Submitted on: 2/15/2021 6:32:25 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Anita Cionni	Individual	Oppose	No

Comments:

I strongly oppose the passage of house bill 1286.

I have called the State of Hawaii and the county of Kauai as my home for 20 years and I do not believe this bill is in the best interest of the state or Kauai.

Respectfully,

Anita Cionni RN/JD

HB-1286-HD-1
Submitted on: 2/15/2021 7:22:41 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Michal Fentin Stover	Individual	Oppose	No

Comments:

I oppose HB1286. The neighbor islands need the flexibility to impose covid-19 travel measures that their mayors and residents deem best suited to their needs. HB 1286 is about increasing travel industry profits, nothing more. Thank you.

HB-1286-HD-1
Submitted on: 2/15/2021 7:39:03 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
James Hoskinson	Individual	Oppose	No

Comments:

The ammendment prevents Kauai from continuing to be relatively successful in containing the current pandemic olely for the purposes of out of state tourists and the tourist industry.

The state legislature should not be creating legislation that preempts a county from following Centers for Disease Control guidelines to protect its population. To do so I unconscionable and the results will be squarely on the members who vote to support this measure.

The legislature should be maintaining a level of protection for our state that matches the CDC guidelines until such time as the state has vaccinated the majority of its population and then look at science based methods for resuming travel. Consider travel passports for vaccinated perople, a vaccinate and test procedure that has the effect of keeping the disease from reaching the community.

Who is benefitting from this? Is it really the citizens of Kauai? The citizens of Hawaii?

HB-1286-HD-1
Submitted on: 2/15/2021 8:32:24 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Maki Morinoue	Individual	Oppose	No

Comments:

Aloha

I strongly oppose Bill HB1286. It is astonishing to me, the gross negligence, lack of intelligence, lack of critical thinking, lack of care for any other surrounding Counties and their residence, lack of care to your own hospitals and essential workers and a Bill filled with arrogance, that one small little County in our state of Hawai'i feels more important, more special to disregard logical, scientific facts after so many people have died because of this virus spreading. All during a time when this virus mutates to become much more contagious.

I have family and friends in the ER as caregivers at Kona Hospital, LI Sloan Kettering, Mayo Clinic in MN supporting people with the Coronavirus.

I imagine you will not have our military blocking the road ways in and out of your County. So the lack of care for your own people and island disgusts me. Not Aloha, Not the Hawaiian way, but this Bill HB1286 only intends to service your monetary pockets. With great disregard to every single County in Kauai. The CDC and Governors rules should be unified across our islands more or less to protect our people and resources.

You don't get to go shirtless, pantlessless, shoeless or naked to a restaurant for health and safety reasons, you don't get to come to the island without a test, a second test, a mask and sanitized hands! It's called respect and prevention. My friend tested negative before getting on the plane and tested positive upon arrival. It's not perfect but they quarantined him and his family to stop the spread.

We have had acquaintances and loved ones die of this virus and some had to fight hard for their lives and the effects are long lasting at times beyond 6 months or more, or for life? We don't know.

I called it when Gov. Ige opened up in August to visitors. I was ok with residents wanting to come home, but safely wasn't a priority. Which is why locals spread it to locals. Big Island was at 0 here in Kona for over a month. We kept my son at home and opted in for 100% schooling because to open up wide in August and put kids in school at the same time lacks critical thinking and basic logic, or any care for Hawai'i residents in a place our economy survives off tourism and essential workers. We all called it here on

the island that our numbers would sky rocket and we would have community spread and we put ourselves on lock down before Ige did and that is exactly what happened to the Big Island, number spiked up, community spread occured, and our hospitals were maxed out. Our nurse friends having to intibate young children who fuaght for their lives.

Focus instead on vaccinating, educating and moving towards sustainability,
and diversifying our economy with an eco mindset.

The people that pass this have blood on your own hands if anyone becomes COVID positive or dies because of this Bill HB1286.

Aloha

HB-1286-HD-1
Submitted on: 2/15/2021 9:02:27 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Lynette Brooks	Individual	Oppose	No

Comments:

I live on Kauai and I strongly oppose HB1286. I have the same concerns of many that SafeTravels brought more cases to Kauai and that local government should be able to set stronger regulations than state government. I think, however, some important points have been missing from the testimony I have read.

Because Kauai has been careful, the residents are able to take better care of their health than otherwise might occur. Because of the few cases on Kauai, it is less stressful to take care of routine medical appointments and cancer screenings. We can visit a clinic without feeling like we could be exposed to COVID-19. If we need additional treatments, it is nice to know that we live on a safe island.

This bill does not consider that most people have not yet had an opportunity to be vaccinated, included anyone under 75, even if they have medical conditions that could make COVID-19 much more dangerous. There are people with asthma, diabetes, COPD, cancer, etc. that have not been vaccinated and will be forced to isolate when SafeTravels once again increases the number of cases on Kauai. Except they can't isolate. They must continue with medical care. I realize hospitals and clinics are trying very hard to be safe, but the added stress on non-COVID patients is detrimental to their health.

HB1286 also does not consider the positive impact on local economy because residents feel safe. We can visit the Farmers' Markets for fresh food and to support the local economy. We can visit and support local restaurants. If cases increase on the island, many residents will reduce their outings and their support of local businesses.

The financial strain is terrible for many people, but the low case numbers on Kauai are beneficial to the mental health of residents. We can meet with a few friends outdoors, we can have small outdoor family gatherings, and some children are in school.

HB1286 is a dangerous bill and should not be passed.

HB-1286-HD-1
Submitted on: 2/15/2021 9:28:14 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Elizabeth Scamahorn	Individual	Oppose	No

Comments:

I want my elected officials to remember that our state is **Different** and **Kauai** has the **lowest number Covid cases of any county in Hawaii. Our Mayor** has guided us successfully to this point and as a Kupuna I want the state to recognize that **autonomy is critical**! I have blood Ohana on Oahu and I'm so sad! But, We must be recognized and allowed to continue **our own travel restrictions. Now is the best time to honor the fact that we our *an Island State*.**

HB-1286-HD-1
Submitted on: 2/15/2021 9:29:55 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Bridget A Smith	Individual	Oppose	No

Comments:

I believe that each island has and knows it's own needs. Please don't vote to take that away from the people of each island.

HB-1286-HD-1
Submitted on: 2/15/2021 9:56:26 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Forest Frizzell	Individual	Oppose	No

Comments:

Aloha committee,

Thank you for taking on this important issue. I stand opposed to this bill in its current format. Visitors who don‘t follow CV testing protocols should not have loopholes to avoid quarantining. The health and safety of our community are more important, especially neighbor island communities with fewer resources.

Mahalo,

Forest

HB-1286-HD-1
Submitted on: 2/15/2021 9:59:46 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Richard E Griffiths	Individual	Oppose	No

Comments:

The proposed Bill is totally inadequate to protect the residents of Hawaii

from infection with SARS-CoV2, which causes the COVID-19 illness. In particular the

proposed 72 -hour period between testing and boarding the final leg of the flight to Hawaii does not guarantee that the arriving passenger is not infected upon arrival in Hawaii - the passenger could have visited a highly-infected community or location at any time in the intervening 72 hours or

been close to an infected person. The rapid-result test

should be performed upon arrival and should be paid for by the arriving passenger. If the arriving passenger is tested positive then they should be quarantined until tested negative.

HB-1286-HD-1
Submitted on: 2/15/2021 10:04:50 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
joan Levy	Individual	Oppose	No

Comments:

I have been a Kauai resident since 1992. Kauai has chosen safety over tourism needs. Clearly it is a hard choice. And many businesses are failing or have failed because of this choice. At the same time as a result of this choice, we have under 180 Covid Cases with only one death.

Each island is quite different here and I think each island should be allowed to make their decisions based on the particularities of life style and what they view as most important. This testimony takes away that right. Certainly the view plane from Honolulu cannot be generalized to the view plane of Kauai. And the view plane of big business should not supercede the needs of the residents of a locality.

I don't think the issue of visitors being confused really needs to be an issue. People who are interested in traveling to Hawaii can contact the mayor's office of their island of choice to find out what current Covid requirements are.

It has been clearly established that a single pretest , although it does help, it does not prevent the spread of Covid. If Kauai (and clearly this legislation is being aimed at Kauai) wants to have stronger measures than the State deems satisfactory, Kauai should have the right to exercise those stronger and safer measures.

Please vote no on HB 1286.

Sincerely, Joan Levy

HB-1286-HD-1
Submitted on: 2/15/2021 10:13:44 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
irene kloepfer	Individual	Oppose	No

Comments:

The health and welfare of the people should be in the hands of the people and their county officials, not the tourist industry. Waikiki has put up large banners for tourists, there is no way you can miss them, yet tourists are saying, I didn't see it....put people before profits. Ua mau ka ea o ka'aina ka pono, the life of the land is perpetuated in righteousness Mahalo for voting no on HB1286. Irene Kloepfer

HB-1286-HD-1
Submitted on: 2/15/2021 10:14:59 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Dylan Ramos	Individual	Oppose	No

Comments:

Aloha,

The following was brought to my attention by Kauaʻi's own Gary Hooser and I wanted to express my opinion in agreement:

"Despite strong testimony from neighbor-island residents and medical professionals in opposition, the PDP/LAT joint House Committee passed HB1286. This measure, introduced by House Speaker Scott Saiki and strongly supported by the travel industry, would prevent individual Counties from establishing their own COVID travel rules. Under the guise of needing a 'state-wide uniform travel policy.' **This measure requires every County to follow a 'one size fits all' and a 'one test' COVID travel policy.**

HB1286 is simply bad policy. **State regulation should be a 'floor and not a ceiling.'** An individual County due to its unique circumstances should be allowed to implement stricter standards if they believe that is in the best interest of their community."

Lee Cataluna also put it perfectly and succinctly: "The travel rules are not 'too confusing,' they’re exclusive. They exclude those who want easy and full access without personal responsibility or having to pay attention to the rules."

Please vote against this bill. Not only is it medically questionable and not guaranteed to significantly improve Kauaʻi's tourism industry, but it runs counter to our government's very structure. It would be one thing if a county sought to circumvent and weaken statewide policies, or even if the situation at hand was a clear, black-and-white moral choice, but given that that is not the case, no mayor should be steamrolled for trying to protect their jurisdiction using localized solutions.

Thank you,

Dylan Ramos

96816

HB-1286-HD-1
Submitted on: 2/15/2021 10:23:34 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Phyllis Robinson	Individual	Oppose	No

Comments:

I oppose this bill simply because it does not make scientific sense to allow anyone arriving here to be exempt from quarantine simply because they have tested negative. A person can test negative and still be a carrier. If a County wants to impose its own rules because they have proven they can keep their citizens safe based on good science, why should our Oahu centric government impose this on us.

HB-1286-HD-1
Submitted on: 2/15/2021 10:35:08 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Philip Keat	Individual	Support	No

Comments:

We should have done this from the start. If we had, many more people would still be working, earning income to support themselves and their families, and generated tax dollars for the financing of government services and union jobs.

HB-1286-HD-1
Submitted on: 2/15/2021 10:35:25 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Joan Langan	Individual	Oppose	No

Comments:

As a resident of Kauai I am most against a law that restricts the informed judgement of our mayor to protect the health of Kauai residents. It is obvious from the rules imposed by Kauai to strictly protect this island with very small resources from a pandemic that our mayor made very good rules regarding travelers. His need to have strict rules was clearly individualized to the population and resources of this particular island . It would be a very big mistake to ignore that each island of our state has unique and special features and needs. Please take this very seriously and look at the results of individual actions and why their judgement is so important. As noted in my first sentence I am strongly against law HB1286 . Please do not pass this bill. Sincerely, Joan Langan

HB-1286-HD-1
Submitted on: 2/15/2021 10:48:15 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Thomas Brandt	Individual	Oppose	No

Comments:

Oppose, strongly!

HB-1286-HD-1
Submitted on: 2/15/2021 10:50:07 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Jane Sezak	Individual	Oppose	No

Comments:

I strongly oppose Bill HB1286. Why would you even consider disempowering individual counties decisions for the well being of their people???? The legislature needs to honor each islands soveringty and listen to their needs, rather than lumping each island into one "corporate package of rules". It is not like Oahu is doing such a great job managing covid. The rules Kauai elects are not confusing, people are able to understand if they are communicated clearly. Mahalo for voting NO on Bill HB1286. Jane Sezak

February 15, 2021

Testimony from Melissa Mojo, 15-year resident of Kauai, regarding the HB1286 HD1bill:

The policy now being proposed in HB1286 is woefully inadequate if the goal is to minimize the spread of travel-related coronavirus infections in Hawai‘i. The medical community is unanimous in agreement that a single test 72 hours prior to arrival is insufficient protection if the goal is to keep COVID infection and death rates as low as possible.

A second test is especially important when taking into consideration the rise of new and more dangerous strains such as the “Kent coronavirus variant” that U.K. experts have said may be up to 70% more infectious and about 30% more lethal than other variants.

Kauai should NOT be made to adhere to this short-sighted and dangerous policy! Kauai is different. Kauai has had far fewer COVID-19 cases than the more populated islands and residents want to keep it that way.

The travel rules are not “too confusing,” they’re exclusive — and rightly so! We are a small rural community with a small hospital that has only 9 ICU beds. Kauai simply isn’t equipped to deal with widespread community disease.

Vacationers who want to visit Hawaii can find ample accommodations elsewhere on other islands that aren’t quite as worried about health and safety.

No matter how much it is argued that opening the doors wide to travelers is really and truly for Kauai residents’ health, the truth is that Kauai’s COVID-19 numbers have been down with the two-test program, went back up when the island was back on the statewide protocol, and have remained almost zero cases since the second-test protocol was reinstated.

According to Acting State Epidemiologist Dr. Sarah Kemble, who recently told members of the House Committee on Pandemic and Disaster Preparedness and the Labor and Tourism Committee at their joint meeting on Tuesday, the Kauai system of requiring a second test after arrival has merit, and that the state’s requirement of a single test taken before arrival cannot prevent people from arriving with the virus.

Kemble said, “An optimal system includes a post-travel test that occurs not at the time of arrival, but several days after arrival. From the standpoint of DOH, in terms of what would make the best public health sense, additional post-travel tests before releasing people from quarantine would be most effective.”

Do not take Kauai’s sovereignty away for the sake of the tourism industry — or for your own self aggrandizement! The system has been working here very well for a year, so why change it now? It makes much more sense to get through the vaccination phase and all the Covid variants before we open back up.

This is about people and the concerns of island residents. Yes, it’s been hard financially for many people this past year, but at least they have their lives. Opening up in the way you propose would put those at risk – for what? A few dollars? That will be cold comfort for the loved ones left behind.

Let Kauai officials make the decisions for Kauai. They’ve done a brilliant job for the past year. Instead of focusing on “confusing” rules, the visitor industry and everyone who supported this bill should be working to get vaccines into arms so this pandemic can finally come to an end. DO NOT PASS THE HB1286 HD1 bill!

HB-1286-HD-1
Submitted on: 2/15/2021 11:26:20 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Kennah Bunao	Individual	Support	No

Comments:

I highly support this bill because it will allow more people to be able to enter the state. And I think that it's what we need because many of our local businesses are suffering because they aren't making enough money to keep doors open without tourism. People hate to say it but Hawaii's economy runs off of tourism and without them we are suffering.

I believe that it's time to open the state up and not worry about the what if's and just take it as it is and deal with everything as we go. This bill is very beneficial and I don't think people are seeing that, they're only worried about people coming here and possibly spreading the virus to our people. But, I don't think that'll happen if they are required to test before arrival! And those who receive a positive test are required to quarantine! So I see no problem with this bill and that's why I support it.

HB-1286-HD-1
Submitted on: 2/15/2021 11:39:38 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Kameron Brown	Individual	Support	No

Comments:

I support this because I am involved in the tourism industry and I have seen many friends and families struggle during this time of separation from the rest of the islands/world. The pre-testing will allow for the island to safely re-open and allow for businesses to not suffer as they are currently. I fully support implementing this in the safest way, but prolonging this may cause harm to businesses, families, and the education of the keiki on the island.

HB-1286-HD-1
Submitted on: 2/15/2021 11:44:54 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Meredith Buck	Individual	Oppose	No

Comments:

Aloha, I strongly oppose HB1286 which would prohibit counties from implementing their own COVID travel rules. While this bill seems to target Kaua'i in particular, it would impact all islands, none of which have the capacity or infrastructure that O'ahu has for responding to rising case numbers. Even so, if all islands experience an uptick in critical COVID cases (which will almost certainly be the case if counties are unable to protect themselves), O'ahu will be overwhelmed with patients needing care. In turn, this puts O'ahu residents at risk, and a vicious cycle is perpetuated. The travel rules are not "too confusing", they're island-exclusive. That each county has the ability to tailor its regulations to serve its community is a major reason why Hawai'i has such low COVID numbers still today. In my hometown, I know we don't have the capacity to handle very many severe cases, and I fear that my elders who teach me lauhala weaving could be further exposed to and impacted by COVID if there are any fewer or weaker protections than we have right now. Please do not pass HB1286. Please allow counties to protect themselves from this global pandemic. Mahalo nui loa for your time.

HB-1286-HD-1
Submitted on: 2/15/2021 11:50:23 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Rhone Scoggins	Individual	Oppose	No

Comments:

Honorable legislators, I am against HB 1286. As you know, Kaua'i opted out of the Safe Travel 3-day program. Due to this our COVID cases dropped dramatically and remain very low. I urge you to vote against HB1286. Thank you, Rhone Scoggins

HB-1286-HD-1
Submitted on: 2/15/2021 12:03:11 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Gayle Borges Morrison	Individual	Oppose	No

Comments:

Kaua'i has been a success story during this pandemic. I liken it to New Zealand, which has been rated the no. 1 country in the world in terms of protecting its citizens. The statistics on covid-19 infections, hospitalizations, and deaths in Hawai'i show that Kaua'i's record is remarkable compared to the other islands--and Kaua'i also protects visitors who follow its rules, making it a safe place to visit. Especially in light of the uncertainties about how the emergence of variants will affect all of us, I strongly object to HB1286. This is no time to take away the ability of the counties to tailor their rules to local conditions and resources, which are strikingly different in each case.

It seems that it should be unnecessary to point out that the CDC still discourages unnecessary travel. Because our economy now relies so heavily on tourism (by definition, unnecessary travel), if we are to continue trying to make travel to Hawai'i relatively safe, Kaua'i's model is clearly more in line with CDC recommendations for pre-travel and post-travel testing than the Safe Travels program. If anything, the state should align its rules more closely to Kaua'i's, rather than trying to force Kaua'i to adhere to rules that have failed to prevent 423 deaths to date, as I write this, and nearly 27,000 cases.

Instead of accommodating pressure from the tourism industry, which will not recover fully *anywhere* until the covid is under control, you as our leaders should be taking this opportunity to seek ways to diversify our economy and to avoid the perils of overtourism. This is not going to be the last pandemic. The impacts of climate change on our islands are already being felt. We need to look beyond the immediate hardships to consider how to become more resilient in the future.

Mahalo for listening to my concerns.

HB-1286-HD-1
Submitted on: 2/15/2021 12:31:35 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Norris Thomlinson	Individual	Oppose	No

Comments:

As a Big Island resident, I've been grateful for the carefully devised, cautious rules restricting travel, which have largely protected us from COVID outbreaks. I'm disturbed by efforts at the state level to block each island from continuing necessary precautions, which are best judged at a local level. I'm extremely opposed to HB1286 or any similar moves to infringe on our rights of health and safety. Please scuttle this bill ASAP!

HB-1286-HD-1
Submitted on: 2/15/2021 12:50:35 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Mary Wijas	Individual	Oppose	No

Comments:

I strongly oppose this measure-just look at the rates of infection and death on Kauai compared to the other islands. People that have come to Kauai do not honor the quarantine they are required to maintain without a test and it is too labor intensive for the police department to follow up on all the tourists that may be in quarantine, let alone local residents who also do not comply. A travel restriction should have been installed in the very beginning of Covid (for locals and visitors) and maybe we wouldn't be in the current situation. Mainland cases are still high and they will only bring it here.

HB-1286-HD-1
Submitted on: 2/15/2021 1:39:50 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
marjorie Bennett	Individual	Oppose	No

Comments:

Uniformity is much easier to understand. However our government has long supported the right of individuality for States, counties and local municipalities. It's long been upheld that these individual groups are able to establish more stringent standards than those required by the federal government. The reason for this is to respect the uniqueness of local communities.

Our individual islands are cherished for their unique characteristics and personalities. The health arguments have been shared and they are very strongly support the opposition to this bill. In a very simplistic sense it may seem the uniformity would be beneficial for all.However when it comes to limited medical services, geographical isolation, and the will of its people, Kauai needs to remain independent and service the unique needs of our special home. Please defeat this measure.

HB-1286-HD-1
Submitted on: 2/15/2021 1:40:05 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Eileen K Nanni	Individual	Oppose	No

Comments:

Aloha

I strongly oppose Bill HB1286. It is astonishing to me, the gross negligence, lack of intelligence, lack of critical thinking, lack of care for any other surrounding Counties and their residence, lack of care to your own hospitals and essential workers and a Bill filled with arrogance, that one small little County in our state of Hawai'i feels more important, more special to disregard logical, scientific facts after so many people have died because of this virus spreading. All during a time when this virus mutates to become much more contagious.

I have family and friends in the ER as caregivers at Kona Hospital, LI Sloan Kettering, Mayo Clinic in MN supporting people with the Coronavirus.

I imagine you will not have our military blocking the road ways in and out of your County. So the lack of care for your own people and island disgusts me. Not Aloha, Not the Hawaiian way, but this Bill HB1286 only intends to service your monetary pockets. With great disregard to every single County in Kauai. The CDC and Governors rules should be unified across our islands more or less to protect our people and resources.

You don't get to go shirtless, pantlessless, shoeless or naked to a restaurant for health and safety reasons, you don't get to come to the island without a test, a second test, a mask and sanitized hands! It's called respect and prevention. My friend tested negative before getting on the plane and tested positive upon arrival. It's not perfect but they quarantined him and his family to stop the spread.

We have had acquaintances and loved ones die of this virus and some had to fight hard for their lives and the effects are long lasting at times beyond 6 months or more, or for life? We don't know.

I called it when Gov. Ige opened up in August to visitors. I was ok with residents wanting to come home, but safely wasn't a priority. Which is why locals spread it to locals. Big Island was at 0 here in Kona for over a month. We kept my son at home and opted in for 100% schooling because to open up wide in August and put kids in school at the same time lacks critical thinking and basic logic, or any care for Hawai'i residents in a place our economy survives off tourism and essential workers. We all called it here on

the island that our numbers would sky rocket and we would have community spread and we put ourselves on lock down before Ige did and that is exactly what happened to the Big Island, number spiked up, community spread occured, and our hospitals were maxed out. Our nurse friends had to intubate young children who fought for their lives.

Focus instead on vaccinating, educating and moving towards sustainability,
and diversifying our economy with an eco mindset.

The people that pass this have blood on your own hands if anyone becomes COVID positive or dies because of this Bill HB1286.

Aloha,

Eileen K Nanni

HB-1286-HD-1
Submitted on: 2/15/2021 1:42:46 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Robin Bon	Individual	Comments	No

Comments:

Aloha, While I am in favor of Oahu taking stronger measures to stem the spread of Covid, I strongly feel that our mayor, Derek Kawakami, is doing an excellent job for us on Kauai. I would like the counties to be able to instate their own regulations suited to the specific needs of that county. Our needs on Kauai differ from those of Oahu for example. I have every confidence in Mayor Kawakami and our council to continue to make good decisions and regulations to meet our needs. I do not believe a statewde regulation serves the individual counties or our specific needs.

Mahalo

HB-1286-HD-1
Submitted on: 2/15/2021 1:55:10 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Pamala Anderson	Individual	Oppose	No

Comments:

As a resident of this small island I feel it's important for us to have the extra security measures in place to prevent unnecessary infections of Covid. Obviously we want tourism to resume so we can go back to work. Unfortunately, I noticed many visitors didn't follow the necessary precautions when they were temporarily allowed to come visit. Please realize this island is not equipped to handle outbreaks. It takes so long already just to have a doctor visit.

Thank you

Pamala

HB-1286-HD-1
Submitted on: 2/15/2021 2:04:14 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Jennifer Rodwell	Individual	Oppose	No

Comments:

I strongly oppose this Bill as each county, with different resources and different needs must have the opportunity to protect their areas that cannot fit in a standard model. What works and is needed for Honolulu does not translate to other county. Please do what is pono and right for these islands that will give it a fighting chance to be an island worth visiting in many years to come. Mahalo!

HB-1286-HD-1
Submitted on: 2/15/2021 2:05:37 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
cynthia toth	Individual	Oppose	No

Comments:

I oppose HB 1286. Any decisions that impact our quality of life day to day in a negative manner should not be considered. Stop the bleeding heart attitude and hold visitors accountable for entry into our state and additional costs. Many other countries do this, and supposedly the U.S is supposed to be a leader, but i object in this case as we are not leaders, we are followers. Followers of the dollar. Let this be a wake up call to all that other industry needs to take root in hawaii other than tourism as it's not if this happens again, it's when it happens again and Hawaii won't be crippled.

HB-1286-HD-1
Submitted on: 2/15/2021 2:13:10 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Setsuko Morinoue	Individual	Oppose	No

Comments:

Aloha

I strongly oppose Bill HB1286. It is astonishing to me, the gross negligence, lack of intelligence, lack of critical thinking, lack of care for any other surrounding Counties and their residence, lack of care to your own hospitals and essential workers and a Bill filled with arrogance, that one small little County in our state of Hawai'i feels more important, more special to disregard logical, scientific facts after so many people have died because of this virus spreading. All during a time when this virus mutates to become much more contagious.

I have family and friends in the ER as caregivers at Kona Hospital, LI Sloan Kettering, Mayo Clinic in MN supporting people with the Coronavirus.

I imagine you will not have our military blocking the road ways in and out of your County. So the lack of care for your own people and island disgusts me. Not Aloha, Not the Hawaiian way, but this Bill HB1286 only intends to service your monetary pockets. With great disregard to every single County in Kauai. The CDC and Governors rules should be unified across our islands more or less to protect our people and resources.

You don't get to go shirtless, pantlessless, shoeless or naked to a restaurant for health and safety reasons, you don't get to come to the island without a test, a second test, a mask and sanitized hands! It's called respect and prevention. My friend tested negative before getting on the plane and tested positive upon arrival. It's not perfect but they quarantined him and his family to stop the spread.

We have had acquaintances and loved ones die of this virus and some had to fight hard for their lives and the effects are long lasting at times beyond 6 months or more, or for life? We don't know.

I called it when Gov. Ige opened up in August to visitors. I was ok with residents wanting to come home, but safely wasn't a priority. Which is why locals spread it to locals. Big Island was at 0 here in Kona for over a month. We kept my son at home and opted in for 100% schooling because to open up wide in August and put kids in school at the same time lacks critical thinking and basic logic, or any care for Hawai'i residents in a place our economy survives off tourism and essential workers. We all called it here on

the island that our numbers would sky rocket and we would have community spread and we put ourselves on lock down before Ige did and that is exactly what happened to the Big Island, number spiked up, community spread occured, and our hospitals were maxed out. Our nurse friends had to intubate young children who fought for their lives.

Focus instead on vaccinating, educating and moving towards sustainability,
and diversifying our economy with an eco mindset.

The people that pass this have blood on your own hands if anyone becomes COVID positive or dies because of this Bill HB1286.

Aloha,

Setsuko Morinoue

HB-1286-HD-1
Submitted on: 2/15/2021 2:17:37 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Samantha Woods	Individual	Support	No

Comments:

My name is Samantha Woods and I am employed by a Shave Ice business on the island of Kauai. Due to the affect of the Coronavirus and Kauai's mandatory quarantine, the tourism has drastically declined. My income is nothing that it would be with tourism. Besides just the personal affects that currently may cause me to have to leave island, I care about the business I am a part of and the other local businesses that we all know and love.. It would be a shame for this mandatory quarantine to go any longer and cause these business to suffer. We need tourism for the island economy to stay afloat. This outbreak is no longer the threat it began as, there is more and more research to show that we are safer than realized previously. Please open the island and allow for those with a negative test to come without quarantining. I miss my family and friends that haven't been able to visit. I miss the freedom to travel to a wedding and come back to work instead of worrying that in my island's situation I cannot go straight back to work. Please open the island. It's what the people what and we should be the governing body.

HB-1286-HD-1
Submitted on: 2/15/2021 2:42:25 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Chris Luff	Individual	Oppose	No

Comments:

I oppose HB1286 because each county has unique constraints and needs, forcing a one size fits all policy is bad policy. I understand the economic challenges and trying to find a balance, but it's upsetting to place money above lives.

Mahalo for your support and consideration,

Re: Testimony regarding HB 1286 (Against)

Statewide Safe Travels Program

Aloha Honorable Representatives:

I am writing from the island of Maui against this proposed bill.

This bill would strip mayors of their ability to protect their counties. Here are the reasons why I am against it:

1. All of the Hawaiian Islands are not in the same situation and therefore should not be treated the same. We have different resources—some islands do not have hospitals, while Maui has one. The one hospital that we do have has been of major concern to residents, as it has been the cause of several clusters here and has been completely full at times.

2. Maui has suffered terribly since mid-October, with cases rising steadily. Our dramatically rising numbers were ignored because the overall state numbers did not increase and news is very much Honolulu-centric. Our Mayor made a promise when he agreed not to opt out of the Safe Travels Plan that he would reinstate quarantine once cases rose to 4.99 per 100,000 (so 7.5 for Maui island). Once the numbers increased past that, he said that he had decided not to use the tier system (in other words, he reneged on his promise to his constituents). The target for re-instating quarantine kept moving as we reached higher numbers, and now he says that he won't do much unless the one hospital we have is overrun. At least we have that option. In this plan, even if the hospital is overrun, there would be no option of opting out of the Safe Travels Plan. Note that KITV reported on 2/1/21 that the hospital was indeed full, although I think that is no longer thew case.

3. Mayor Kawakami has been the best leader by far in the way he has handled this situation. He is the best advocate who cares about the residents of his island. He is my hero, and the majority of Maui residents wish that he was our mayor. This bill would strip him of his ability to protect Kauai, and is probably targeted specifically at him.

4. The bill calls to allow people to arrive here first and then test. This strategy was tried on all islands and failed. Maui had trailers to care for these people and contracted with a resort hotel here to take these people in. The bill calls for people to be responsible for their own quarantine costs, but that's not the way it works. When the visitor has a reservation at an Air B&B, they cannot go there if they test positive, so we become responsible to handle their lodging. Hotels will often not accept people they know are positive, and we become responsible for their lodging. The point of bringing visitors in for the profit is completely dashed, as now we are responsible to pay for their expenses.

5. A fifth reason that I oppose this measure is that not all the islands are being treated the same as far as vaccines. State leadership apparently decided on an 11% allotment for Maui, which did not cover our needs in any way, probably due to the high number of part-time residents, or snowbirds, we have. There were other issues such as the use of VAMS where tourists could and did sign up for the vaccine here. The online request system was very difficult and many seniors

were not able to manage it, however for others it was very easy to lie and many who got the vaccine should not have been eligible. The state is planning to finish tier 1b by the end of February, and we have no idea whether we will be back open for vaccines by then. What we do know is that we will be nowhere close to finishing up 1b along with the rest of the state. In other words, Maui will be even less protected than the rest of the state.

6. LG Green is proposing to waive tests for travelers who are vaccinated, believing that the vaccine causes sterilization immunity. The research is still being done on this, and opening up based on unproven research is not a good idea and endangers us unnecessarily.

7. Lastly, Maui's tourism numbers are much higher per capita. We have about 11% of the population but at least 36% of the tourists. Making decisions about travelers affects Maui much more than O'ahu, which we have seen with the Safe Travel Plan since mid-October.

Please vote against this bill. Think about the impact on the neighbor islands, which are part of the state. One size does not fit all!

HB-1286-HD-1
Submitted on: 2/15/2021 3:08:23 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Ethan Page	Individual	Support	No

Comments:

As a business owner and home owner on Kauai I would like to strongly plead with you to pass this bill and to bring a uniform policy to the state. The system on kauai is killing the local economy, The mayor thinks rvrything is ok because most workers are on unemployment insurance. But as of March 1st I know a lot of furloughed employees are going to lose medical insurance thru the large hotels (likr the Hyatt) wont that alone put a tremendous strain on the states resources?

Also the vacine is here. It works great look at Israel. theyve nicked down to 94% efficacy. We should be moving forward smartly and uniformly .

Thank You

Ethan Page

HB-1286-HD-1
Submitted on: 2/15/2021 3:26:04 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Loraine Lee Patch	Individual	Support	No

Comments:

Aloha from Kauai to all whom it may concern,

Please pass this bill for the people because it appears those who oppose it are opposing only for political means.

Kauai is dying on the vine, Kauaians have documented the detriment from the closing of businesses, the suicides and homelessness due to the government policies...

We need to strike a balance between protecting the most vulnerable and salvaging what is left of our tourism-based economy. The landscape is shifting, and the time has come to opt back in to the Safe Travels Program.

Thank you for making Kauai a safe haven from the pandemic over the past year. Through great uncertainty you have protected the people of our island with severely limited resources and infrastructure.

Now, almost one year in, circumstances continue to evolve. We begin to see the light at the end of the tunnel.

Covid cases on the Mainland, and more specifically in California (our largest visitor market), have declined dramatically from their peak. Many of our most vulnerable, our kupuna and our first responders, have been vaccinated. 17,000 doses have been administered to Kauai residents and many more will get vaccines over the coming months.

We now have several months of data from the Hawaii Safe Travels Program, and that data empirically shows that the program is a success.

In January the state had 227,337 domestic visitors. Of the 3027 statewide Covid cases last month, only 137 were non-resident travel related. Just .06% of non-resident visitors tested Covid positive while visiting here. That means that less than one out of every 1000 non-resident visitors tested positive for Covid.

Kauai typically gets about 10% of the total visitors to the state. We would expect to have about 10% of the visitor travel related Covid cases. In January that number would have

been around 14 visitor cases. That is about the number we saw in November. And we can expect as more people on the Mainland get vaccines, the numbers will drop further.

To be clear, there will be more Covid cases if we rejoin the Safe Travels Program.

But is our goal to have zero Covid cases? Or is it to limit severe cases and death from Covid? The first would maintain the current quarantine requirements and all but kill the remnants of our tourism-based economy. The second would allow us enough visitors to keep our economy on life-support. Even with the new Covid variants, vaccines have proven effective at preventing severe disease and death.

We cannot maintain the status quo without losing many more small businesses. Thousands of your constituents are unemployed because we have opted out of the Safe Travels Program. The other islands are running at around 25% of 2019 visitor numbers while Kauai is running at 3% of 2019 arrivals. Many of our businesses can survive at 25% arrival numbers. Virtually none can survive at current levels.

HB-1286-HD-1
Submitted on: 2/15/2021 3:27:24 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Jonathan McRoberts	Individual	Oppose	No

Comments:

Kauai has been an incredible success story. Do not take away the County's ability to set its own rules. There are plenty of States on the mainland where counties have different rules about all aspects of Covid. If tourists are not smart enough to check on the rules for the islands they plan to visit, then we probably do not want them on our roads or beaches.

Jonathna McRoberts

HB-1286-HD-1
Submitted on: 2/15/2021 3:29:54 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Cynthia Dazzi	Individual	Oppose	No

Comments:

I am a resident of Kaua'i and I strongly oppose this bill - which will severly remove our County's autonomy and ability to navigate our islands health and safe reopening. It is impossible to compare us to our neighbors - Oahu, Maui and Big Island. Our population alone is less than 1/2 of Maui, the 2nd smallest County ~ Our health care is not robust. I have had 6 doctors in 13 years, because they leave. I am currently searching for a new primary care as mine left Kaua'i last month. Our hospitals are small - our ICU beds are at 11 last I heard -

Beyond all of this - Kaua'i has shown that we can manage this disease and has done so throughout the pandemic. Our Mayor has shown true leadership by making hard decisions, some very unpopular. We have had vigourous testing and vaccinating and with the resort bubbles our numbers of disease prove that this works.

The Tourism industry should have a voice - but they absolutely must NOT have the loudest voice.

I work in the tourism industry. I was furloughed March 13, 2020 from my full time job and have luckily retained my part time job. We as a county and a state will get through this - we will become profitable again, but please do **not bend to the will of the tourism dollar** the driving force of this bill. Kaua'i is unique - Let us be just that, and don't try to fix what is not broken.

Mahalo

HB-1286-HD-1
Submitted on: 2/15/2021 3:35:27 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Sandy	Individual	Oppose	No

Comments:

I oppose HB 1286 because I think each county should be able to set their own rules.

HB-1286-HD-1
Submitted on: 2/15/2021 3:36:33 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Stephanie Austin	Individual	Oppose	No

Comments:

Please OPPOSE this irresponsible bill which harms the concept of home rule for neighbor islands, and puts the convenience of 'easily confused travelers' ahead of the health of island residents!

it is ESSENTIAL that each mayor is able to make import evaluations for their unique island: differences in the availability of medical care is enormous, just for a start!

Shame on those who sponsor and support this Oahu-centric, tourism sponsored bill!

The economy can and will recover: every life lost to Covid-19 is gone forever. On Maui, the majority of Kupuna over 75 who seek their FIRST vaccination have not yet been able to obtain it.

HB-1286-HD-1
Submitted on: 2/15/2021 3:44:29 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Bruce Silverglade	Individual	Support	No

Comments:

I support HB 1286. The Safe Travels Program provides Kauai residents like me (age 67) with sufficient public health protection. Kauai county's additional restrictions are unnecessary and detrimental to the island and permanent residents like myself. The public health costs, as well as potential benefits, must be considered in adding additional restrictions to the Safe Travels Program. When all health and well-being aspects of Kauai County's additional restrictions are considered, it is clear that such additional restrictions are not sufficiently beneficial to justify the costs.

Respectively Submitted,

Bruce Silverglade

HB-1286-HD-1
Submitted on: 2/15/2021 3:53:14 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Eileen McKee	Individual	Oppose	No

Comments:

I strongly oppose HB 1286. I believe these safe travel decisions should be left up to the counties.

Mahalo for considering my testimony.

Eileen McKee

Kihei, 96753

HB-1286-HD-1
Submitted on: 2/15/2021 3:53:50 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
judi glass	Individual	Oppose	No

Comments:

I am writing once again as this bill is not one to pass. As a travel advisor for over 20 years with Virtuoso I can attest to the danger of inadequate rules for travelers

We have seen a rise in cases on all the islands except for Kauai and logically ask yourselves why ? It is apparent that our mayor and islanders value respecting the science and it is obvious from our numbers that Kauai plan is working. The legislature should consdier adopting the more stringent rules of Kauai and not letting down; and please please let our islanders continue to be safe from the virus. Regarding travelers being confused about Hawaii, I can assure you that they understand. Travel to Hawaii comes up every day and we are able to patiently explain how to arrive on Kauai. We work with so many clients and are able to make this understaood if any quesitions arise. I think it more important to respect and follow our mayor than worry about tourists being confused. Seriously ? Keep in mind we have had many visitors and it is very possible to be on Kauai as part of a vacation. It is just not a good plan to try to arrive here first unless the resort bubble (which is a forward thinking and great idea) is an option. At Virtuoso we highlight those magical spots all over the world and Kauai is in the lead because of the handling of the virus I cannot understand why anyone would want to change this We are helping to support local busines as much as possible and ths will end soon and then we can open fully. The finish line is ahead and we have made it this far... I do not think the legislature would want to take the responsibility of destroying what we have worked so hard to achieve. Mahalo

HB-1286-HD-1
Submitted on: 2/15/2021 4:21:13 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Susan Zwirn	Individual	Oppose	No

Comments:

I **strongly oppose HB 1286.**

HB-1286-HD-1
Submitted on: 2/15/2021 4:21:17 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Lori H Fisher	Individual	Oppose	No

Comments:

I agree with Lee Cataluna “The travel rules are not “too confusing,” they’re exclusive. They exclude those who want easy and full access without personal responsibility or having to pay attention to the rules. Those vacationers can find ample accommodations elsewhere in a place that is not quite as worried about health and safety. Florida is beautiful this time of year.”

HB-1286-HD-1
Submitted on: 2/15/2021 4:25:25 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Isaac Moon	Individual	Support	No

Comments:

Support

HB-1286-HD-1
Submitted on: 2/15/2021 4:37:25 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Lila Metzger	Individual	Support	No

Comments:

I support this Bill as it gets us one step closer to opening back up and allowing United States citizens to exercise their right to freely move via domestic travel. We should open at least to US citizens ASAP to give citizens their constitutional right and to try to save the local business in Hawaii that still exist.

Mahalo,

Lila Metzger

HB-1286-HD-1
Submitted on: 2/15/2021 4:54:43 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Kuulei Ho	Individual	Oppose	No

Comments:

Aloha,

My family is against HB 1286. Our County of Kaua'i Mayor, along with his team, knows what is best for our Kaua'i and Ni'hau communities, and he should be able to make decisions that are appropriate for us, that protect us.

Returning visitors know that each island is different and should therefore understand that each island has different requirements. For the first-time visitors, if they really want to come they will read and figure out what they need to do.

We ask that these 2 important mana'o be kept in the forefront of everyone's minds, and changes will happen for the betterment of all:

1. The goal of herd immunity is on the horizon with the ongoing vaccinations and people practicing "wear masks, wash hands, social distance."

2. 'Ä€ina Aloha Economic Futures, www.ainaalohafutures. We must take care of our islands and people.

Mahalo nui,

Kuulei and 'ohana

HB-1286-HD-1
Submitted on: 2/15/2021 5:41:25 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
William Becker	Individual	Support	No

Comments:

I understand the desire to have mayoral autonomy, but there are some issues that beg for a statewide response. This state, both its business community and our fellow residents, rely on tourism and there is no way to have a healthy path to recovery without a consistent statewide set of policies. The reality, as we have seen, is that some mayors have been woefully over cautious, ensuring infection remains low (which other islands have also accomplished but with far less draconian measures) but at great cost to the livelihood of its citizens. It's time to elevate the decision making to one unified statewide authority. We CAN keep our community safe while also keeping our key industry alive at the same time. We have to do it together though. A unified voice.

HB-1286-HD-1
Submitted on: 2/15/2021 6:24:41 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Shyla Moon	Individual	Support	No

Comments:

Strongly support

HB-1286-HD-1
Submitted on: 2/15/2021 6:51:44 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
James Cherry	Individual	Support	No

Comments:

PLEASE SUPPORT HB 1286

I believe it is imperative to present a cohesive Covid-19 policy across all counties in the state of Hawaii. I live in Kauai and hear that many potential visitors to our island are avoiding the required quarantine and visiting the other islands instead due to our prohibitive restrictions. Our economy here is seriously damaged and will take years to recover. Please make it easier for Covid-free visitiors to come and help our economic recovery. HB 1286 is a safe and effective solution for residents and visitors! We need change NOW.

HB-1286-HD-1
Submitted on: 2/15/2021 6:59:53 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Juliana Cherry	Individual	Support	No

Comments:

I urge you to support HB 1286 which would welcome visitors to the state of Hawaii with a cohesive travel program. This will make the state of Hawaii a more attractive destination for travelers. Covid-19 pandemic procedures need to be consistent in all of the counties. I believe this protocol will keep our communities safe.

Kauai needs to be open to visitors without the current quarantine and double test requirements. All of us in Kauai that rely on the travel industry for our income, need to have the opportunity to receive visitors. I manage short term vacation rentals, and due to the current travel restrictions and the total uncertainty of when the mayor will open the island for travel, we have very few future bookings, and now people are cancelling summer reservations.

Our business is interconnected with MANY services and businesses on the island - cleaning companies, retail, restaurants, carpet cleaning, tour and activity companies, photographers, taxi drivers, produce growers. This is not just about big business - there are so many of us "little people" who want to work. And we need to get back to work! The state needs the tax revenue.

Residents need to be able to have their family visit them from the mainland!

HB 1286 refines the Safe Travel Program and offers clarity in timing and the option for the DOH to add further measures. **Please support HB 1286.**

HB-1286-HD-1
Submitted on: 2/15/2021 7:00:02 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Susan Pcola_Davis	Individual	Oppose	No

Comments:

I have to OPPOSE this bill as written.

If we just added the recommendation from the CDC it would be a SAFER TRAVELS BILL

Most importantly: **Get tested with a viral test 1-3 days before you travel. Keep a copy of your test results with you during travel in case you are asked for them. Do NOT travel if you test positive.**

Here it is:

If You Must Travel

If you must travel, take these steps to protect yourself and others from COVID-19:

- If you are eligible, get fully vaccinated for COVID-19. Wait 2 weeks after getting your second vaccine dose to travel—it takes time for your body to build protection after any vaccination.
- **Get tested with a viral test 1-3 days before you travel. Keep a copy of your test results with you during travel in case you are asked for them. Do NOT travel if you test positive.**
- Check travel restrictions before you go.
- Wear a mask over your nose and mouth when in public settings. Masks are required on planes, buses, trains, and other forms of public transportation traveling into, within, or out of the United States and in U.S. transportation hubs such as airports and stations.
- Avoid crowds and stay at least 6 feet/2 meters (about 2 arm lengths) from anyone who did not travel with you. It's important to do this everywhere — both indoors and outdoors.
- Wash your hands often or use hand sanitizer (with at least 60% alcohol).
- Bring extra supplies, such as masks and hand sanitizer.
- Avoid contact with anyone who is sick.
- Avoid touching your eyes, nose, and mouth.

Do NOT travel if you were exposed to COVID-19, you are sick or you test positive for COVID-19. Learn when it is safe for you to travel. Don’t travel with someone who is sick.

Honorable Senators, Representatives, Governor, Mayors, and Councilmembers:

In the four months prior to October 15th, when Hawai'i's 14-day-quarantine travel restrictions were lifted, the number of Kaua'i cases increased from **21** cases as of June 15th, to **59** cases as of October 15th -- **38** new cases in four months. In the four months since October 15th, the Kaua'i numbers have increased to **179** cases -- **120** new cases in four months. Kaua'i had a **two-week** period last month where **20** new cases were recorded (Jan 9-22); over these last two weeks we had **one** new case.

Here are Hawai'i's County populations per the 2010 US Census, for computing numbers below:

Hawai'i Island – 185,079
Kaua'i – 72,029
Lāna'i – 3,131
Māui – 154,834
Moloka'i – 7,345
O'ahu– 976,372

I updated the following numbers today from stats on the State of Hawai'i website: https://health.hawaii.gov/coronavirusdisease2019/what-you-should-know/current-situation-in-hawaii/
Statewide - **26, 889** cases, 895 in the past 14 days, and **426** total deaths.
Hawai'i Island has had **2,216 cases**, 45 in the past 14 days, and 53 deaths.
Kaua'i – **179** cases, 1 in the past 14 days, and 1 death.
Lāna'i – **108** cases, 2 in the past 14 days, and no deaths.
Māui – **1,947** cases, 198 in the past 14 days, and 29 deaths.
Moloka'i – **27** cases, 2 in the past 14 days, and no deaths.
O'ahu – **21,620** cases, 647 in the past 14 days, and 340 deaths.
Out of state – **792** cases and 3 deaths.

Per capita ratios by Island:

Hawai'i Island - 1 case per **84** residents
Kaua'i – 1 case per **402** residents
Lāna'i – 1 case per **29** residents
Māui – 1 case per **80** residents
Moloka'i – 1 case per **272** residents
O'ahu – 1 case per **45** residents

Instead of our **179** cases and **one** death, Kaua'i would have the following numbers using other Counties' stats:
Using **Big Island** per capita ratio, Kaua'i would have **862** cases and **21** deaths
Using **Lāna'i**, Kaua'i would have **2,485** cases (0 deaths)
Using **Māui**, Kaua'i would have **906** cases and **13** deaths
Using **Moloka'i**, Kaua'i would have **265** cases (0 deaths)
Using **O'ahu**, Kaua'i would have **1,595** cases and **25** deaths

As of this writing, the US population is 332,233,588, with 27,692,690 COVID-19 cases and 486,317 deaths. That ratio computes to **1 case for every 12 persons in the US** has been infected with COVID-19. **One** person for every **683** persons in the US **has died**. The US will surpass 500,000 COVID-19 deaths before the end of the month.

Our health care facilities and workers are limited and stretched to the max. Please vote to allow Kaua'i to continue with our travel regulations.

Mahalo for your consideration and service,
Susan Oakley, Kaua'i

HB-1286-HD-1
Submitted on: 2/15/2021 8:59:21 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Jonathan Dworkin, MD	Individual	Oppose	No

Comments:

As an infectious diseases doctor, I urge the legislature to decline this bill. Organizing ourselves into collective action is a fine goal, but the purpose should be to strengthen, not weaken, the state's fight against the pandemic.

We are now confronting the prospect of multiple mutant strains of virus, some of which may be resistant to common treatments like monoclonal antibodies. The possibility of vaccine escape - in which a circulating strain is resistant to vaccines - is real. I can tell you as a matter of basic fact that I am seeing people who enter this state with a negative pre-travel test and nonetheless become ill a week into their visit. A single test is a porous border system. This is certainly how the known mutant strains arrived here.

The goal of the legislature should be to protect the state and win the war against the virus. That means doing everything in our power to expand and intensify our vaccination program. Post-arrival testing, combined with vigorous quarantine enforcement, is absolutely the right thing to do until we know more about the mutant virus strains and have a higher rate of vaccine uptake.

I understand the legislature is under intense pressure from commercial interests to "open up," but we have a clear duty to protect these islands that should supersede commercial and political interests. Those of us on the front lines of this struggle are counting on each of you to do the right thing.

Mahalo for your time and for your service to this state.

Jonathan Dworkin, MD

Internal Medicine & Infectious Diseases

HB-1286-HD-1
Submitted on: 2/15/2021 9:25:02 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Max Castanera	Individual	Support	No

Comments:

Aloha,

Please consider passing HB 1286 to put into law COVID-19 travel testing/exemptions to protect our community as well as allow for the safe return of visitors. Mahalo for your time.

HB-1286-HD-1
Submitted on: 2/15/2021 9:46:56 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
David Gregorius	Individual	Oppose	No

Comments:

To the esteemed legislators of Hawaii-

I am an emergency medicine physician on the island of Kauai. I work at all three hospitals here and have been caring for the people of Kaua'i for almost 12 years now. I am writing in opposition of HB1286 HD1 for several reasons:

You CANNOT have one set of travel guidelines for all islands. This is ridiculous. Each island is so different to begin with, then has different covid loads, different hospital capabilities, and differences in public opinion on how to protect their Ä• ina. Please do not pass this law preventing each individual island to implement plans that work best for them.

State laws should serve as a MINIMUM travel/testing guideline, not the final/maximum guidelines.

A single pre-travel Covid test for travelers coming to Kaua'i is NOT sufficient to protect our island at this time. Immediately after Hawaii allowed travelers to start coming to our island with just one pre-travel test (on October 15), there was a surge, businesses that were starting to open had to close again, schools had to remain closed when it look like they had a chance to open. It did not work. There is no question that a 72 hour pretest is insufficient to keep Covid infections and death rates as low as possible. Every doctor I know agrees with this.
Our small hospital (and medical staffing) capabilities on Kaua'i cannot handle a massive surge of sick Covid patients and people WILL die waiting for transfer off island. This I am sure of. Our mayor made a very difficult and bold decision to require a second post travel test, and once again the island is mostly safe from Covid.

Also, considering these new more infectious Covid strains that are starting to circulate around the globe and in the United States Mainland, is this the best time to loosen travel guidelines?

Finally, The CDC is still recommending against non-essential travel as I write this.

Please do not pass this bill.
It will prevent each island from being able to do what's right for their particular situation

and it will likely result in unnecessary human fatalities.

Thank you

David Gregorius

HB-1286-HD-1
Submitted on: 2/15/2021 9:47:29 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Giselle Gregorius	Individual	Oppose	No

Comments:

Aloha and thank you for allowing me this opportunity to share my thoughts on this proposed bill. I realize that this topic is very polarized and there is no middle ground. I also respect the people whose livelihoods depend on the tourism industry returning, but I strongly oppose this Bill for several reasons.

1. All of our islands and counties are not equal. It does not make any sense to pass a bill that requires them all to have equal rules and guidelines. If we have learned anything this past year, it's the need to be flexible and adapt to change. As time goes on and each county's situation changes, there may be a need to increase or decrease travel restrictions accordingly. Taking this right away from each mayor puts every island potentially at risk.

2. We have proven that one negative pre-travel test is not sufficient if the goal is to keep the spread of Covid as low as possible.

3. The timing of this bill is terrible. It is wonderful that many of our citizens have been able to receive the vaccine, but why loosen the restrictions now before a majority have been vaccinated? And while there are new varients of the virus starting to spread that have been shown to be more infectious and more deadly than the existing virus? And while we currently have some schools open? And when businesses that are able to be open or able to be open freely? Loosening restrictions at this point is only setting us up for failure and aiming us towards another lock down.

I realize that there are many people and businesses that are itching to bring tourism back, but I ask that you not be swayed by by the tourism industry and rather be driven by data and health recommendations to keep our people safe. Please do sent a minimum standard for safe travel, but continue to allow each county to adjust additional

travel guidelines as necessary to accommodate their health system capabilities and to maintain healthy/safe communities.

With sincere gratitude,

Giselle

HB-1286-HD-1
Submitted on: 2/15/2021 11:36:31 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Marcia Kimura	Individual	Oppose	No

Comments:

Why are our the framers of HB1286 so blind to decency and prudence? It does not seem to matter to them that the safety and health of all our people must take precedence over all other concerns.

HB-1286-HD-1
Submitted on: 2/16/2021 1:20:38 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Paula Alquiza	Individual	Oppose	No

Comments:

I am testifying as a rightfully concerned citizen of Kauai speaking against HB1286. I fully believe that each island has unique qualities and resources, and that each is trying their best to bring business back to as normal as this new normal will allow. I see Kauai's businesses putting in the good fight to stay alive, please don't kill them off permanently with the possiblity of another shut down should our numbers go up too high and our hospitals ICU's become overwhelmed..

Requiring all islands to follow this state-wide rule that does not accomodate each one's ability to deal with a rise in Covid hospitalizations as a result of inadequate vetting of incoming travelers does not make sense right now. I have friends and family working in visitor related jobs. I do not want them at greater risk of becoming ill or to lose any of them because you feel that the confusion our rules may be causing is so terrible that you feel the need to change things for us.

Kauai's rules do not stop visitors from coming, they still do, and they too can feel safer out and about, with the normal precautions, once they've been cleared. Does the number of complaints warrant putting our island's whole population and industry at greater risk? At this time, I believe more effort should be done to highlight each island's differences in the rules of entry. For example, on the "GoHawaii" webpage, visitors have to click on and read through the Kauai.gov update to find out Kauai's rules. Adding the basics of the additional requirements for Kauai on the same page with the other islands' information will help make it clearer and easier to see. There can be secondary pages for more in-depth information. This may prove to be a benefit for the islands that have more relaxed rules when visitors can see the actual differences before deciding where to visit.

In theory, I would like to believe that the state will take appropriate, timely and effective action to mitigate an overrun of positive cases that could overwhelm our medical capabilities, but truth be told, I don't see that happening. This is not to say that I don't ever see Hawaii under a state-wide travel mandate, I just don't think it's the right for Kauai at this time.

I can fully support a state-wide rule going into effect possibly next year after most of our state and country's poplulations have had the chance to be vaccinated and the number

of new cases across the country and the world is no longer so alarmingly high. Is this too much to ask? Especially with the new variants coming in.

Please don't damage the progress Kauai is making by imposing this loss of county level control, at least for this session. The safety of our local economy and residents should be the priority over visitor complaints. With vaccines on the roll, we just need a little more time for the world to be a safer place. I know I speak for a lot of us who feel this way. We are a small island and we have too much at stake. Please do not pass HB1286.

Thank you for your time.

The Fauci/COVID-19 Dossier

This document is prepared for humanity by Dr. David E. Martin.

The Fauci/COVID-19 Dossier

This document is prepared for humanity by Dr. David E. Martin.

This work was supported, in part, by a fund-raising effort in which approximately 330 persons contributed funds in support of the New Earth technology team and Urban Global Health Alliance. *It is released under a Creative Commons license CC-BY-NC-SA. Any derivative use of this dossier must be made public for the benefit of others. All documents, references and disclosures contained herein are subject to an AS-IS representation. The author does not bear responsibility for errors in the public record or references therein. Throughout this document, uses of terms commonly accepted in medical and scientific literature do not imply acceptance or rejection of the dogma that they represent.*

Background:

Over the past two decades, my company – M·CAM – has been monitoring possible violations of the 1925 Protocol for the Prohibition of the Use in War of Asphyxiating, Poisonous, or other Gases, and of Bacteriological Methods of Warfare (the Geneva Protocol) 1972 Convention on the Prohibition of the Development, Production, and Stockpiling of Bacteriological and Toxin Weapons and Their Destruction (the BTWC). In our 2003-2004 ***Global Technology Assessment: Vector Weaponization*** M·CAM highlighted China's growing involvement in Polymerase Chain Reaction (PCR) technology with respect to joining the world stage in chimeric construction of viral vectors. Since that time, on a weekly basis, we have monitored the development of research and commercial efforts in this field, including, but not limited to, the research synergies forming between the United States Centers for Disease Control and Prevention (CDC), the National Institutes for Allergies and Infectious Diseases (NIAID), the University of North Carolina at Chapel Hill (UNC), Harvard University, Emory University, Vanderbilt University, Tsinghua University, University of Pennsylvania, many other research institutions, and their commercial affiliations.

The National Institute of Health's grant AI23946-08 issued to Dr. Ralph Baric at the University of North Carolina at Chapel Hill (officially classified as affiliated with Dr. Anthony Fauci's NIAID by at least 2003) began the work on synthetically altering the *Coronaviridae* (the coronavirus family) for the express purpose of general research, pathogenic enhancement, detection, manipulation, and potential therapeutic interventions targeting the same. As early as May 21, 2000, Dr. Baric and UNC sought to patent critical sections of the coronavirus family for their commercial benefit.[1] In one of the several papers derived from work sponsored by this grant, Dr. Baric published what he reported to be the full length cDNA of SARS CoV in which it was clearly stated that SAR CoV was based on a composite of DNA segments.

> *"Using a panel of contiguous cDNAs that span the entire genome, we have assembled a full-length cDNA of the SARS-CoV Urbani strain, and have rescued molecularly cloned SARS viruses (infectious clone SARS-CoV) that contained the expected marker mutations inserted into the component clones."*[2]

On April 19, 2002 – the Spring before the first SARS outbreak in Asia – Christopher M. Curtis, Boyd Yount, and Ralph Baric filed an application for U.S. Patent 7,279,372 for a method of producing recombinant coronavirus. In the first public record of the claims, they sought to patent a means of producing, "an infectious, replication defective, coronavirus." This work was supported by the NIH grant referenced above and GM63228. In short, the U.S. Department of Health and Human Services was involved in the funding of amplifying the infectious nature of coronavirus between 1999 and 2002 ***before SARS*** was ever detected in humans.

[1] U.S. Provisional Application No. 60/206,537, filed May 21, 2000

[2] https://www.pnas.org/content/100/22/12995

Against this backdrop, we noted the unusual patent prosecution efforts of the CDC, when on April 25, 2003 they sought to patent the SARS coronavirus isolated from humans that had reportedly transferred to humans during the 2002-2003 SARS outbreak in Asia. 35 U.S.C. §101 prohibits patenting nature. This legality did not deter CDC in their efforts. Their application, updated in 2007, ultimately issued as U.S. Patent 7,220,852 and constrained anyone not licensed by their patent from manipulating SARS CoV, developing tests or kits to measure SARS coronavirus in humans or working with their patented virus for therapeutic use. Work associated with this virus by their select collaborators included considerable amounts of chimeric engineering, gain-of-function studies, viral characterization, detection, treatment (both vaccine and therapeutic intervention), and weaponization inquiries.

In short, with Baric's U.S. Patent 6,593,111 (Claims 1 and 5) and CDC's '852 patent (Claim 1), no research in the United States could be conducted without permission or infringement.

We noted that gain-of-function specialist, Dr. Ralph Baric, was both the recipient of millions of dollars of U.S. research grants from several federal agencies but also sat on the World Health Organization's International Committee on Taxonomy of Viruses (ICTV) and the *Coronaviridae* Study Group (CSG). In this capacity, he was both responsible for determining "novelty" of clades of virus species but directly benefitted from determining declarations of novelty in the form of new research funding authorizations and associated patenting and commercial collaboration. Together with CDC, NIAID, WHO, academic and commercial parties (including Johnson & Johnson; Sanofi and their several coronavirus patent holding biotech companies; Moderna; Ridgeback; Gilead; Sherlock Biosciences; and, others), a powerful group of interests constituted what we would suggest are "interlocking directorates" under U.S. anti-trust laws.

These entities also were affiliated with the WHO's Global Preparedness Monitoring Board (GPMB) whose members were instrumental in the Open Philanthropy-funded global coronavirus pandemic "desk-top" exercise EVENT 201 in October 2019. This event, funded by the principal investor in Sherlock Biosciences and linking interlocking funding partner, the Bill and Melinda Gates Foundation into the GPMB mandate for a respiratory disease global preparedness exercise to be completed by September 2020 alerted us to anticipate an "epidemic" scenario. We expected to see such a scenario emerge from Wuhan or Guangdong China, northern Italy, Seattle, New York or a combination thereof, as Dr. Zhengli Shi and Dr. Baric's work on zoonotic transmission of coronavirus identified overlapping mutations in coronavirus in bat populations located in these areas.

This dossier is by no means exhaustive. It is, however, indicative the numerous criminal violations that may be associated with the COVID-19 terrorism. All source materials are referenced herein. An additional detailed breakdown of all the of individuals, research institutions, foundations, funding sources, and commercial enterprises can be accessed upon request.

CC-BY-NC-SA Dr. David E. Martin

Contents

35 U.S.C. § 101 5

18 U.S.C. §2339 C *et seq*. – Funding and Conspiring to Commit Acts of Terror 7

18 U.S.C. § 2331 §§ 802 – Acts of Domestic Terrorism resulting in death of American Citizens 10

18 U.S.C. § 1001 – Lying to Congress 12

15 U.S.C. §1-3 – Conspiring to Criminal Commercial Activity 16

15 U.S.C. §8 – Market Manipulation and Allocation 20

15 U.S.C. § 19 – Interlocking Directorates 21

35 U.S.C. §200 - 206 – Disclosure of Government Interest 23

21 C.F.R. § 50.24 et seq., Illegal Clinical Trial 25

The Commercial Actors 27

CC-BY-NC-SA Dr. David E. Martin

35 U.S.C. § 101

From Justice Clarence Thomas' opinion for the majority

Section 101 of the Patent Act provides: "Whoever invents or discovers any new and useful ... composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title." 35 U.S.C. § 101.

We have "long held that this provision contains an important implicit exception[:] Laws of nature, natural phenomena, and abstract ideas are not patentable." Mayo, 566 U.S., at ___, 132 S.Ct., at 1293 (internal quotation marks and brackets omitted). Rather, "`they are the basic tools of scientific and technological work'" that lie beyond the domain of patent protection. Id., at ___, 132 S.Ct., at 1293. As the Court has explained, without this exception, there would be considerable danger that the grant of patents would "tie up" the use of such tools and thereby "inhibit future innovation premised upon them." Id., at ___, 132 S.Ct., at 1301. This would be at odds with the very point of patents, which exist to promote creation. Diamond v. Chakrabarty, 447 U.S. 303, 309, 100 S.Ct. 2204, 65 L.Ed.2d 144 (1980) (Products of nature are not created, and "`manifestations... of nature [are] free to all men and reserved exclusively to none'").[3]

In their majority opinion in 2013, the U.S. Supreme Court made it abundantly clear that the Court had "long held" that nature was not patentable. Merely isolating DNA does not constitute patentable subject matter. In their patent, the CDC made false and misleading claims to the United States Patent & Trademark Office by stating that, "A newly isolated human coronavirus has been identified as the causative agent of SARS, and is termed SARS-CoV."[4] No "causal" data was provided for this statement.

When they filed their patent application on April 25, 2003 their first claim (and the only one that survived to ultimate issuance over the objection of the patent examiner in 2006 and 2007) was the genome for SARS CoV.

While this patent is clearly illegal under 35 U.S.C. §101, not only did the CDC insist on its granting over non-final and final rejections, but they also continued to pay maintenance fees on the patent after the 2013 Supreme Court decision confirmed that it was illegal.

In addition, the CDC patented the detection of SARS CoV using a number of methods including reverse transcription polymerase chain reaction (RT-PCR). With this patent, they precluded anyone outside of their licensed or conspiring interest from legally engaging in independent verification of their claim that they had isolated a virus, that it was a causative agent for SARS, or that any therapy could be effective against the reported pathogen.

It is important to note that the CDC's patent applications were also rejected in non-final and final rejections for ineligibility under 35 U.S.C. § 102 for being publicly disclosed prior to their own filing. In the first non-final rejection, the USPTO stated that the CDC's genome was published in four Genbank accession entries on April 14, 18, and 21, 2003 with identity ranging from 96.8% to 99.9% identical sequences.[5] Dr. Fauci knew, and failed to disclose evidence that the CDC patent was illegal, based on work he had funded in the years leading up to the SARS outbreak.

After seeking an illegal patent, petitioning to override the decision of an examiner to reject it, and ultimately prevailing with the patent's grant, the CDC lied to the public by stating they were controlling the patent so that it would be "publicly available".[6] Tragically, this public statement is falsified by the simple fact that their own publication in

[3] ***Association for Molecular Pathology v. Myriad Genetics, Inc.***, 569 U.S. 576 (2013)
[4] U.S. Patent 7,220,852
[5] USPTO Non-Final Rejection File #10822904, September 7, 2006, page 4.
[6] https://apnews.com/article/145b4e8d156cddc93e996ae52dc24ec0

CC-BY-NC-SA Dr. David E. Martin

Genbank had, in fact, made it public domain and thereby unpatentable. This fact, confirmed by patent examiners, was overridden by CDC in a paid solicitation to override the law.

While not covered under 35 U.S.C. §101, Dr. Fauci's abuse of the patent law is detailed below. Of note, however, is his willful and deceptive use of the term "vaccine" in patents and public pronouncements to pervert the meaning of the term for the manipulation of the public.

In the 1905 Jacobson v. Mass case, the court was clear that a PUBLIC BENEFIT was required for a vaccine to be mandated. Neither Pfizer nor Moderna have proved a disruption of transmission. In Jacobson v. Massachusetts, 197 U.S. 11 (1905), the court held that the context for their opinion rested on the following principle:

"This court has more than once recognized it as a fundamental principle that 'persons and property are subjected to all kinds of restraints and burdens in order to secure the general comfort, health, and prosperity of the state…"

The Moderna and Pfizer "alleged vaccine" trials have explicitly acknowledged that their gene therapy technology has no impact on viral infection or transmission whatsoever and merely conveys to the recipient the capacity to produce an S1 spike protein endogenously by the introduction of a synthetic mRNA sequence. Therefore, the basis for the Massachusetts statute and the Supreme Court's determination is moot in this case.
Further, the USPTO, in its REJECTION of Anthony Fauci's HIV vaccine made the following statement supporting their rejection of his bogus "invention"

Application/Control Number: 09/869,003 Page 5
Art Unit: 1648

These arguments are persuasive to the extent that an antigenic peptide stimulates an immune response that may produce antibodies that bind to a specific peptide or protein but is not persuasive in regards to a vaccine. The immune response produced by a vaccine must be more than merely some immune response but must be protective. As noted in the previous Office Action, the art recognizes the term "vaccine" to be a compound which prevents infection. Applicant has not demonstrated that the instantly claimed vaccine meets even the lower standard set forth in the specification, let alone the standard art definition, for being operative in this regards. Therefore, claims 5, 7, and 9 are not operative as an anti-HIV-1 vaccine and therefore lack patentable utility.

18 U.S.C. §2339 C *et seq*. – Funding and Conspiring to Commit Acts of Terror

Indirectly, unlawfully and willfully provides or collects funds with the intention that such funds be used, or with the knowledge that such funds are to be used, in full or in part, in order to carry out—

> **(A) an act which constitutes an offense within the scope of a treaty specified in subsection (e)(7), as implemented by the United States, or**
>
> **(B) any other act intended to cause death or serious bodily injury to a civilian, or to any other person not taking an active part in the hostilities in a situation of armed conflict, when the purpose of such act, by its nature or context, is to intimidate a population, or to compel a government or an international organization to do or to abstain from doing any act….**

By no later than April 11, 2005, Dr. Anthony Fauci was publicly acknowledging the association of SARS with bioterror potential. Leveraging the fear of the anthrax bioterrorism of 2001, he publicly celebrated the economic boon that domestic terror had directed towards his budget. He specifically stated that NIAID was actively funding research on a "SARS Chip" DNA microarray to rapidly detect SARS (something that was not made available during the current "pandemic") and two candidate vaccines focused on the SARS CoV spike protein.[7] Led by three Chinese researchers under his employment – Zhi-yong Yang, Wing-pui Kong, and Yue Huang – Fauci had at least one DNA vaccine in animal trials by 2004.[8] This team, part of the Vaccine Research Center at NIAID, was primarily focused on HIV vaccine development but was tasked to identify SARS vaccine candidates as well. Working in collaboration with Sanofi, Scripps Institute, Harvard, MIT and NIH, Dr. Fauci's decision to unilaterally promote vaccines as a primary intervention for several designated "infectious diseases" precluded ***proven therapies*** from being applied to the sick and dying.[9]

The CDC and NIAID led by Anthony Fauci entered into trade among States (including, but not limited to working with EcoHealth Alliance Inc.) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy of Sciences) through the 2014 *et seq* National Institutes of Health Grant R01AI110964 to exploit their patent rights. This research was known to involve surface proteins in coronavirus that had the capacity to directly infect human respiratory systems. In flagrant violation of the NIH moratorium on gain of function research, NIAID and Ralph Baric persisted in working with chimeric coronavirus components specifically to amplify the pathogenicity of the biologic material.

By October 2013, the Wuhan Institute of Virology 1 coronavirus S1 spike protein was described in NIAID's funded work in China. This work involved NIAID, USAID, and Peter Daszak, the head of EcoHealth Alliance. This work, funded under R01AI079231, was pivotal in isolating and manipulating viral fragments selected from sites across China which contained high risk for severe human response.[10]

By March 2015, both the virulence of the S1 spike protein and the ACE II receptor was known to present a considerable risk to human health. NIAID, EcoHealth Alliance and numerous researchers lamented the fact that the public was not sufficiently concerned about coronavirus to adequately fund their desired research.[11]

Dr. Peter Daszak of EcoHealth Alliance offered the following assessment:

---

[7] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320336/

[8] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095382/

[9] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1232869/

[10] Ge, XY., Li, JL., Yang, XL. *et al.* Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. *Nature* **503,** 535–538 (2013).

[11] Forum on Medical and Public Health Preparedness for Catastrophic Events; Forum on Drug Discovery, Development, and Translation; Forum on Microbial Threats; Board on Health Sciences Policy; Board on Global Health; Institute of Medicine; National Academies of Sciences, Engineering, and Medicine. Rapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships: Workshop Summary. Washington (DC): National Academies Press (US); 2016 Feb 12. 6, Developing MCMs for Coronaviruses. Available from: https://www.ncbi.nlm.nih.gov/books/NBK349040/

"*Daszak reiterated that, until an infectious disease crisis is very real, present, and at an emergency threshold, it is often largely ignored. To sustain the funding base beyond the crisis, he said, we need to increase public understanding of the need for MCMs such as a pan-influenza or pan-coronavirus vaccine. A key driver is the media, and the economics follow the hype. We need to use that hype to our advantage to get to the real issues. Investors will respond if they see profit at the end of process, Daszak stated*."[12]

Economics will follow the hype.

The CDC and NIAID entered into trade among States (including, but not limited to working with University of North Carolina, Chapel Hill) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy of Sciences represented by Zheng-Li Shi) through U19AI109761 (Ralph S. Baric), U19AI107810 (Ralph S. Baric), and National Natural Science Foundation of China Award 81290341 (Zheng-Li Shi) et al. 2015-2016. These projects took place during a time when the work being performed was prohibited by the United States National Institutes of Health.

The public was clearly advised of the dangers being presented by NIAID-funded research by 2015 and 2016 when the Wuhan Institute of Virology material was being manipulated at UNC in Ralph Baric's lab.

"The only impact of this work is the creation, in a lab, of a new, non-natural risk," agrees Richard Ebright, a molecular biologist and biodefence expert at Rutgers University in Piscataway, New Jersey. Both Ebright and Wain-Hobson are long-standing critics of gain-of-function research.

In their paper, the study authors also concede that funders may think twice about allowing such experiments in the future. "Scientific review panels may deem similar studies building chimeric viruses based on circulating strains too risky to pursue," they write, adding that discussion is needed as to "whether these types of chimeric virus studies warrant further investigation versus the inherent risks involved".

But Baric and others say the research did have benefits. The study findings "move this virus from a candidate emerging pathogen to a clear and present danger", says Peter Daszak, who co-authored the 2013 paper. Daszak is president of the EcoHealth Alliance, an international network of scientists, headquartered in New York City, that samples viruses from animals and people in emerging-diseases hotspots across the globe.

Studies testing hybrid viruses in human cell culture and animal models are limited in what they can say about the threat posed by a wild virus, Daszak agrees. But he argues that they can help indicate which pathogens should be prioritized for further research attention."[13]

Knowing that the U.S. Department of Health and Human Services (through CDC, NIH, NIAID, and their funded laboratories and commercial partners) had patents on each proposed element of medical counter measures and their funding, Dr. Fauci, Dr. Gao (China CDC), and Dr. Elias (Bill and Melinda Gates Foundation) conspired to commit acts of terror on the global population – including the citizens of the United States – when, in September 2019, they published the following mandate:

"Countries, donors and multilateral institutions must be prepared for the worst. A rapidly spreading pandemic due to a lethal respiratory pathogen (whether naturally emergent or accidentally or deliberately released) poses additional preparedness requirements. Donors and multilateral institutions must ensure adequate investment in developing innovative vaccines and therapeutics, surge manufacturing capacity, broad-spectrum antivirals and appropriate non-pharmaceutical interventions. All countries must develop a system for immediately sharing genome sequences of any

[12] *Ibid.*

[13] https://www.nature.com/news/engineered-bat-virus-stirs-debate-over-risky-research-%201.18787

new pathogen for public health purposes along with the means to share limited medical countermeasures across countries.

Progress indicator(s) by September 2020

> *• Donors and countries commit and identify timelines for: financing and development of a universal influenza vaccine, broad spectrum antivirals, and targeted therapeutics. WHO and its Member States develop options for standard procedures and timelines for sharing of sequence data, specimens, and medical countermeasures for pathogens other than influenza.*
>
> *• Donors, countries and multilateral institutions develop a multi-year plan and approach for strengthening R&D research capacity, in advance of and during an epidemic.*
>
> *• WHO, the United Nations Children's Fund, the International Federation of Red Cross and Red Crescent Societies, academic and other partners identify strategies for increasing capacity and integration of social science approaches and researchers across the entire preparedness/response continuum."*[14]

As if to confirm the utility of the September 2019 demand for "financing and development of" vaccine and the fortuitous SARS CoV-2 alleged outbreak in December of 2019, Dr. Fauci began gloating that his fortunes for additional funding were likely changing for the better. In a February 2020 interview in ***STAT***, he was quoted as follows:

""*The emergence of the new virus is going to change that figure, likely considerably, Fauci said. "I don't know how much it's going to be. But I think it's going to generate more sustained interest in coronaviruses because it's very clear that coronaviruses can do really interesting things*.""[15]

[14] https://apps.who.int/gpmb/assets/annual_report/GPMB_annualreport_2019.pdf (page 8)

[15] https://www.statnews.com/2020/02/10/fluctuating-funding-and-flagging-interest-hurt-coronavirus-research/

CC-BY-NC-SA Dr. David E. Martin

18 U.S.C. § 2331 §§ 802 – Acts of Domestic Terrorism resulting in death of American Citizens

Section 802 of the USA PATRIOT Act (Pub. L. No. 107-52) expanded the definition of terrorism to cover "domestic," as opposed to international, terrorism. A person engages in domestic terrorism if they do an act "dangerous to human life" that is a violation of the criminal laws of a state or the United States, if the act appears to be intended to: (i) intimidate or coerce a civilian population; (ii) influence the policy of a government by intimidation or coercion;

Dr. Anthony Fauci has intimidated and coerced a civilian population and sought to influence the policy of a government by intimidation and coercion.

With no corroboration, Dr. Anthony Fauci promoted[16] Professor Neil Ferguson's computer simulation derived claims that,

"The world is facing the most serious public health crisis in generations. Here we provide concrete estimates of the scale of the threat countries now face.

"We use the latest estimates of severity to show that policy strategies which aim to mitigate the epidemic might halve deaths and reduce peak healthcare demand by two-thirds, but that this will not be enough to prevent health systems being overwhelmed. More intensive, and socially disruptive interventions will therefore be required to suppress transmission to low levels. It is likely such measures – most notably, large scale social distancing – will need to be in place for many months, perhaps until a vaccine becomes available." [17]

Reporting to the President that as many as 2.2 million deaths may result from a pathogen that had not yet been isolated and could not be measured with any accuracy, Dr. Fauci intimidated and coerced the population and the government into reckless, untested, and harmful acts creating irreparable harm to lives and livelihoods.[18] Neither the Imperial College nor the "independent" Institute for Health Metrics and Evaluation (principally funded by the Bill and Melinda Gates Foundation)[19] had any evidence of success in estimating previous burdens from coronavirus but, without consultation or peer-review, Dr. Fauci adopted their terrifying estimates as the basis for interventions that are explicitly against medical advice.

- The imposition of social distancing was based on computer simulation and environmental models with NO disease transmission evidence whatsoever.
- The imposition of face mask wearing was directly against controlled clinical trial evidence and against the written policy in the Journal of the American Medical Association.

  > *"Face masks should not be worn by healthy individuals to protect themselves from acquiring respiratory infection because there is no evidence to suggest that face masks worn by healthy individuals are effective in preventing people from becoming ill."*[20]

- In both the Imperial College and the IHME simulations, ***quarantines were modeled for the sick, not the healthy.***

[16] https://www.cato.org/blog/did-mitigation-save-two-million-lives
[17] https://www.imperial.ac.uk/news/196234/covid-19-imperial-researchers-model-likely-impact/
[18] https://www.npr.org/2020/03/31/823916343/coronavirus-task-force-set-to-detail-the-data-that-led-to-extension-of-guideline
[19] https://www.gatesfoundation.org/Media-Center/Press-Releases/2017/01/IHME-Announcement
[20] https://jamanetwork.com/journals/jama/fullarticle/2762694?fbclid=IwAR2RE-c4V-fhUodui0JQRbiHRcgEJuDKG_21N4oL5zAfciQfWCyHAsetJmo

CC-BY-NC-SA Dr. David E. Martin

Insisting on vaccines while blockading the emergency use of proven pharmaceutical interventions may have contributed to the death of many patients and otherwise healthy individuals.[21]

Using the power of NIAID during the alleged pandemic, Dr. Anthony Fauci actively suppressed proven medical countermeasures used by, and validated in scientific proceedings, that offered alternatives to the products funded by his conspiring entities for which he had provided direct funding and for whom he would receive tangible and intangible benefit.

[21] https://www.reuters.com/investigates/special-report/health-coronavirus-usa-cost/

18 U.S.C. § 1001 – Lying to Congress

(a)Except as otherwise provided in this section, whoever, in any matter within the jurisdiction of the executive, legislative, or judicial branch of the Government of the United States, knowingly and willfully—

(1) falsifies, conceals, or covers up by any trick, scheme, or device a material fact;

(2) makes any materially false, fictitious, or fraudulent statement or representation; or

(3) makes or uses any false writing or document knowing the same to contain any materially false, fictitious, or fraudulent statement or entry;

shall be fined under this title, imprisoned not more than 5 years or, if the offense involves international or domestic terrorism (as defined in section 2331), imprisoned not more than 8 years, or both. If the matter relates to an offense under chapter 109A, 109B, 110, or 117, or section 1591, then the term of imprisonment imposed under this section shall be not more than 8 years.

On October 22, 2020, the United States Government Accountability Office (GAO) published a report entitled: ***BIOMEDICAL RESEARCH: NIH Should Publicly Report More Information about the Licensing of Its Intellectual Property***. In this document, the authors reported that the National Institutes of Health (NIH) received, "up to $2 billion in royalties from its contributions to 34 drugs sold from 1991-2019."[22]

A casual review of the NIH Office of Technology Transfer report of active licenses[23] appears to conflict with the GAO report on several important facts. Conspicuously absent from the GAO report are over 30 patents associated with active compounds generating billions of dollars in revenue. Why would it be that the GAO and the NIH couldn't agree on something as simple as drugs generating income for NIH?

Since the passage of the Bayh Dole Act (Pub. L. 96-517, December 12, 1980), federally funded research has been an economic bonanza for U.S. universities, federal agencies, and their selected patronage. For the first decade following Bayh Dole, NIH funding doubled from $3.4 billion to $7.1 billion. A decade later, it doubled again to $15.6 billion. In the wake of September 2001, the National Institute for Allergy and Infectious Diseases (NIAID) saw its direct budget increase over 300% without accounting for DARPA funds of as much as $1.7 billion annually from 2005 forward. In 2020, NIH's budget was over $41 billion.

What has become of the $763 billion of taxpayer funds allocated to making America healthier since inventors have been commercially incentivized? Who has been enriched?

The answer, regrettably, is that no accountability exists to answer these questions.

The NIH is the named owner of at least 138 patents since 1980.

The United States Department of Health and Human Services is the named owner of at least 2,600 patents.

NIAID grants or collaboration have resulted in 2,655 patents and patent applications of which only 95 include an assignment to the Department of Health and Human Services as an owner. Most of these patents are assigned to universities thereby making the ultimate commercial beneficiaries entirely opaque. One of the largest holders is SIGA Technologies (NASDAQ: SIGA) who, while publicly reporting close affiliation with NIAID, is not referenced in the NIH GAO report. SIGA's CEO, Dr. Phillip L. Gomez spent 9 years at NIAID developing its vaccine program for HIV, SARS, Ebola, West Nile Virus, and Influenza before exiting to commercial ventures. While their technology is clearly derived from NIAID science, the company reports revenue from NIAID but no royalty or commercial payments to NIH or any of its programs.

[22] https://www.gao.gov/products/GAO-21-52

[23] https://www.ott.nih.gov/reportsstats/hhs-license-based-vaccines-therapeutics

CC-BY-NC-SA Dr. David E. Martin

NIAID's Director, Dr. Anthony Fauci is listed as an inventor on 8 granted U.S. patents. None of them are reported in NIAID, NIH, or GAO reports of active licensing despite the fact that Dr. Fauci reportedly was compelled to get paid for his interleukin-2 "invention" – payments he reportedly donated to an unnamed charity.[24]

Of the 21 patents listed in the U.S. Food and Drug Administration's (FDA) Orange book itemized in the GAO report, none of Dr. Anthony Fauci's patents are listed. Furthermore, none of the NIAID patents are listed despite clear evidence that Gilead Sciences and Janssen Pharmaceuticals (a division of Johnson & Johnson) have generated over $2 billion annually from sales that were the direct result of NIAID funded science. Missing from the GAO report are 2 patents for Velclade® which has been generating sales in excess of $2.18 billion annually for several years. None of the patents for Yescarta® are listed in the GAO report. None of the Lumoxiti® patents are listed in the GAO report. None of the Kepivance® patents are listed in the GAO report. In violation of 37 USC §410.10 and 35 USC §202(a), over 13 of the 21 patents in the GAO report fail to disclose government interest despite being the direct result of NIH funding.

Dr. Anthony Fauci's Own Patent Track Record:

US Patent 6,190,656 and 6,548,055 **Immunologic enhancement with intermittent interleukin-2 therapy**

A method for activating a mammalian immune system entails a series of IL-2 administrations that are effected intermittently over an extended period. Each administration of IL-2 is sufficient to allow spontaneous DNA synthesis in peripheral blood or lymph node cells of the patient to increase and peak, and each subsequent administration follows the preceding administration in the series by a period of time that is sufficient to allow IL-2 receptor expression in peripheral or lymph node blood of the patient to increase, peak and then decrease to 50% of peak value. This intermittent IL-2 therapy can be combined with another therapy which targets a specific disease state, such as an anti-retroviral therapy comprising, for example, the administration of AZT, ddI or interferon alpha. In addition, IL-2 administration can be employed to facilitate in situ transduction of T cells in the context of gene therapy. By this approach the cells are first activated in vivo via the aforementioned IL-2 therapy, and transduction then is effected by delivering a genetically engineered retroviral vector directly to the patient.

This application is a continuation of U.S. patent application Ser. No. 08/487,075, filed Jun. 7, 1995, now abandoned, which is a continuation in part of U.S. patent application Ser. No. 08/063,315, filed May 19, 1993, now issued as U.S. Pat. No. 5,419,900, and U.S. patent application Ser. No. 08/452,440, filed May 26, 1995, now issued as U.S. Pat. No. 5,696,079, which is the National Stage filed under 35 USC 371 of PCT/US94/05397, filed May 19, 1994, the contents of which are incorporated herein by reference.

Filed May 19, 1993

Issued a Final Rejection January 20, 1998. Rejected after abandonment August 14, 1998 and April 12, 1999. Reduced and modified claims granted May 8, 2000.

*This family of patents was the basis of Fauci's lie to the **British Medical Journal** in which he falsely stated:*

"Dr Anthony Fauci told the BMJ that as a government employee he was required by law to put his name on the patent for the development of interleukin 2 and was also required by law to receive part of the payment the government received for use of the patent. He said that he felt it was inappropiate (sic) to receive payment and donated the entire amount to charity."[25]

He was not "required by law" to commit fraud on the patent office and then get paid for it!

[24] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC545012/
[25] *Ibid.*

US Patent 6,911,527 **HIV related peptides**

This invention is the discovery of novel specific epitopes and antibodies associated with long term survival of HIV-1 infections. These epitopes and antibodies have use in preparing vaccines for preventing HIV-1 infection or for controlling progression to AIDS.

Filed May 6, 1999

Rejected as unpatentable January 22, 2003. Issued with a final rejection on July 15, 2004 after submitting reconsideration requests. Modified and restricted claims allowed September 29, 2004.

US Patent 7,368,114 **Fusion protein including of CD4**

Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion or the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of the heavy chain of an IgA antibody ara tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4 fusion proteins.

Filed October 24, 2002

Rejected as unpatentable August 18, 2006. Paid appeal to overturn examiner's findings February 15, 2007. Rejected again May 11, 2007. On October 10, 2007 applicants further narrowed the construction of what was clearly not a patent and the USPTO granted less than half the claims that had been sought in the original filing.

US Patent 9,896,509, 9,193,790 and 9,441,041 **Use of antagonists of the interaction between HIV GP120 and .alpha.4.beta.7 integrin**

Methods are provided for the treatment of a HIV infection. The methods can include administering to a subject with an HIV infection a therapeutically effective amount of an agent that interferes with the interaction of gp120 and .alpha.4 integrin, such as a .alpha.4.beta.1 or .alpha.4.beta.7 integrin antagonist, thereby treating the HIV infection. In several examples, the .alpha.4 integrin antagonist is a monoclonal antibody that specifically binds to a .alpha.4, .beta.1 or .beta.7 integrin subunit or a cyclic hexapeptide with the amino acid sequence of CWLDVC. Methods are also provided to reduce HIV replication or infection. The methods include contacting a cell with an effective amount of an agent that interferes with the interaction of gp120 and .alpha.4 integrin, such as a .alpha.4.beta.1 or .alpha.4.beta.7 integrin antagonist. Moreover, methods are provided for determining if an agent is useful to treat HIV.

Rejected May 22, 2017 as Double Patenting. In their response, the applicants acknowledge the illegal act and seek only those components of their application that extend beyond the life of the issued patents. On October 11, 2017, the limited claims were issued.

A sample of the convoluted flow of funds that evades public disclosure.

U.S. Patent 8,999,351 was issued to Tekmira Pharmaceuticals Corporation in Burnaby, British Columbia. In their patent, they disclose that their research was supported by a grant from the National Institute of Allergy and Infectious Disease (Grant HHSN266200600012C). Ironically, this $23 million grant was awarded in 2006 to Alnylam Pharmaceuticals, Inc., not to Tekmira.[26]

[26] https://www.technologynetworks.com/genomics/news/alnylam-awarded-23-million-us-government-contract-to-develop-rnai-therapeutics-186097

In 2012, Alnylam agreed to pay Tekmira $65 million to settle legal disputes including a $1 billion damages claim for "relentless and egregious" misappropriation of Tekmira's trade secrets. From the patent filing's earliest priority of November 10, 2008, there is no public record stating Tekmira as the beneficiary of this NIAID grant. Notwithstanding, the lipid nanoparticle technology developed from this grant is the technology now used in the Moderna COVID-19 intervention. In their 10-Q filing, Alnylam reports to have a license to technology from Arbutus – formerly Tekmira – which has accused Acuitas of misappropriating trade secrets and licensing them to Moderna and Pfizer's collaboration with BioNTech.

Additional references can be found at:

https://www.ott.nih.gov/nih-and-its-role-technology-transfer
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/206288Orig1s000TAltr.pdf
https://www.gao.gov/assets/720/710287.pdf
https://grantome.com/search?q=%22National%20Institute%20of%20Allergy%20and%20Infectious%20Diseases%22

CC-BY-NC-SA Dr. David E. Martin

15 U.S.C. §1-3 – Conspiring to Criminal Commercial Activity

Every contract, combination in the form of trust or otherwise, or conspiracy, in restraint of trade or commerce among the several States, or with foreign nations, is declared to be illegal. Every person who shall make any contract or engage in any combination or conspiracy hereby declared to be illegal shall be deemed guilty of a felony, and, on conviction thereof, shall be punished by fine not exceeding $100,000,000 if a corporation, or, if any other person, $1,000,000, or by imprisonment not exceeding 10 years, or by both said punishments, in the discretion of the court.

The National Institute of Health's grant AI23946-08 issued to Dr. Ralph Baric at the University of North Carolina at Chapel Hill (officially classified as affiliated with Dr. Anthony Fauci's NIAID by at least 2003) began the work on synthetically altering the *Coronaviridae* (the coronavirus family) for the express purpose of general research, pathogenic enhancement, detection, manipulation, and potential therapeutic interventions targeting the same. As early as May 21, 2000, Dr. Baric and UNC sought to patent critical sections of the coronavirus family for their commercial benefit.[27] In one of the several papers derived from work sponsored by this grant, Dr. Baric published what he reported to be the full length cDNA of SARS CoV in which it was clearly stated that SAR CoV was based on a composite of DNA segments.

> *"Using a panel of contiguous cDNAs that span the entire genome, we have assembled a full-length cDNA of the SARS-CoV Urbani strain, and have rescued molecularly cloned SARS viruses (infectious clone SARS-CoV) that contained the expected marker mutations inserted into the component clones."*[28]

On April 19, 2002 – the Spring before the first SARS outbreak in Asia – Christopher M. Curtis, Boyd Yount, and Ralph Baric filed an application for U.S. Patent 7,279,372 for a method of producing recombinant coronavirus. In the first public record of the claims, they sought to patent a means of producing, "an infectious, replication defective, coronavirus." This work was supported by the NIH grant referenced above and GM63228. In short, the U.S. Department of Health and Human Services was involved in the funding of amplifying the infectious nature of coronavirus between 1999 and 2002 ***before SARS*** was ever detected in humans.

Against this backdrop, we noted the unusual patent prosecution efforts of the CDC, when on April 25, 2003 they sought to patent the SARS coronavirus isolated from humans that had reportedly transferred to humans during the 2002-2003 SARS outbreak in Asia. 35 U.S.C. §101 prohibits patenting nature. This legality did not deter CDC in their efforts. Their application, updated in 2007, ultimately issued as U.S. Patent 7,220,852 and constrained anyone not licensed by their patent from manipulating SARS CoV, developing tests or kits to measure SARS coronavirus in humans or working with their patented virus for therapeutic use. Work associated with this virus by their select collaborators included considerable amounts of chimeric engineering, gain-of-function studies, viral characterization, detection, treatment (both vaccine and therapeutic intervention), and weaponization inquiries.

In short, with Baric's U.S. Patent 6,593,111 (Claims 1 and 5) and CDC's '852 patent (Claim 1), no research in the United States could be conducted without permission or infringement.

We noted that gain-of-function specialist, Dr. Ralph Baric, was both the recipient of millions of dollars of U.S. research grants from several federal agencies but also sat on the World Health Organization's International Committee on Taxonomy of Viruses (ICTV) and the *Coronaviridae* Study Group (CSG). In this capacity, he was both responsible for determining "novelty" of clades of virus species but directly benefitted from determining declarations of novelty in the form of new research funding authorizations and associated patenting and commercial collaboration. Together with CDC, NIAID, WHO, academic and commercial parties (including Johnson & Johnson; Sanofi and their several coronavirus patent holding biotech companies; Moderna; Ridgeback; Gilead; Sherlock Biosciences; and, others), a powerful group of interests constituted what we would suggest are "interlocking directorates" under U.S. anti-trust laws.

[27] U.S. Provisional Application No. 60/206,537, filed May 21, 2000
[28] https://www.pnas.org/content/100/22/12995

CC-BY-NC-SA Dr. David E. Martin

1986-1990	NIAID Grant AI 23946 leading to patent U.S. 7,279,327 "Methods for Producing Recombinant Coronavirus" Filed 2002 and issued 2007 https://patents.google.com/patent/US7279327B2/ru The paper first published from the NIAID grant is https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7109931&blobtype=pdf
1990	Pfizer files U.S. Patent 6,372,224 on a vaccine for the *S*-protein on coronavirus November 14, 2000 which was abandoned April 2010 making it public domain.
1990s	Work focused on CoV association with cardiomyopathy (see above) Early reference to the "emergence" of CoV as a ***respiratory pathogen*** in https://link.springer.com/content/pdf/10.1007%2F978-1-4615-1899-0_91.pdf
2000	Ralph Baric AI23946 and GM63228 from the National Institutes of Health actively working recombinant CoV
2001	National Institute of Health, Allergy and Infectious diseases. "Reverse Genetics with a Coronavirus Infectious cDNA Construct." 4/1/2001-3/31/005 $1.0 million total costs/yr. RS Baric, PI
2002	Asia CoV SARS outbreak
2003	April 25, 2003 CDC Patent filed and ultimately becomes US7,220,852 (the patent on the RNA sequence) and 7,776,521 (the patent on the testing methodology. These patents give the U.S. Department of Health and Human Services the ability to control the commercial exploitation of SARS coronavirus. Dr. Anthony Fauci appointed to the Bill and Melinda Gates Foundation's Global Grand Challenges Scientific Advisory Board (served through 2010). April 28, 2003 Sequoia Pharmaceuticals $953K for pathogen response and patent US7,151,163 https://www.sbir.gov/node/305319 July 21, 2003 Ralph Baric's team (using AI23946 and GM63228) file U.S. Patent 7,618,802 which issued on November 17, 2009. https://patents.google.com/patent/US7618802B2 Dana Farber Cancer Institute files U.S. Patent 7,750,123 on a monoclonal antibody to neutralize SARS CoV. This research is supported by several NIH grants including National Institutes of Health Grants A128785, A148436, and A1053822.
2004	January 6, 2004 – ***SARS and Bioterrorism linked*** at Bioterrorism and Emerging Infectious Diseases: antimicrobials, therapeutics and immune modulators. https://tks.keystonesymposia.org/index.cfm?e=web.meeting.program&meetingid=706 ***At this conference, the term "The New Normal" was introduced by Merck*** ***FAUCI AND BARIC start making money!!!*** National Institutes of Health, Allergy and Infectious Diseases. SARS Reverse Genetics. AI059136-01. $1.7 million total costs, RS Baric, PI. 10% effort. 4/1/04- 3/31/09. The project develops a SARS-CoV full length infectious cDNA, the development of SARS-CoV replicon particles expressing heterologous genes, and seeks to adapt SARS-CoV to mice, producing a pathogenic mouse model for SARS-CoV infection.

National Institutes of Health, Allergy and Infectious Diseases. R01. Remodeling the SARS Coronavirus Genome Regulatory Network. RS Baric, PI 10% effort. 7/1/04-6/30/09. $2.1 million

November 22, 2004 University of Hong Kong patents SARS associated spike protein on CoV and pursues patent US 7,491,489

2005 DARPA gets in on the game Synthetic Coronaviruses. Biohacking: Biological Warfare Enabling Technologies, June 2005. Washington, DC. DARPA/MITRE sponsored event. Invited Speaker

Review timeline from https://www.youtube.com/watch?v=rO_EeYB0i0U and https://www.davidmartin.world/wp-content/uploads/2020/04/20APRBotWslides.pdf

2008 Biodefense Grant U54 AI057157 commences with $10,189,682 to UNC Chapel Hill https://taggs.hhs.gov/Detail/AwardDetail?arg_awardNum=U54AI057157&arg_ProgOfficeCode=104

2009 Biodefense Grant U54 AI057157 continues with $5,448,656 to UNC Chapel Hill (non-competitive grant from NIAID)

2010 Biodefense Grant U54 AI057157 continues with $8,747,142 to UNC Chapel Hill (non-competitive grant from NIAID)

Patent issuance for SARS coronavirus patents peak post the Asia outbreak at 391 issued patents.

August 6, 2010, Moderna (prior to its establishment) files U.S. Patent 9,447,164 which attracted the investment of (and "inventorship" for) venture capitalists at Flagship Ventures. This patent grew out of the work of Dr. Jason P. Schrum of Harvard Medical School supported by National Science Foundation Grant **#0434507. While the application claims priority to August 2010, the application didn't get finalized until October, 2015. On November 4, 2015, the USPTO issued a non-final rejection on this original patent rejecting all claims.**
https://www.nsf.gov/awardsearch/showAward?AWD_ID=0434507 with reference to the grant funding in
https://molbio.mgh.harvard.edu/szostakweb/publications/Szostak_pdfs/Schrum_et_al_JACS_2009.pdf

2011 Crucell joined the Janssen Pharmaceutical Companies of Johnson & Johnson in February taking with it all of its SARS technology.

Biodefense Grant U54 AI057157 continues with $7,344,820 to UNC Chapel Hill (non-competitive grant from NIAID)

2012 MERS isolated in Egypt

Biodefense Grant U54 AI057157 continues with $7,627,657 to UNC Chapel Hill (non-competitive grant from NIAID)

2013 Biodefense Grant U54 AI057157 continues with $7,226,237 to UNC Chapel Hill (non-competitive grant from NIAID)

2014 April 23, 2014, Moderna files patent on nucleic acid vaccine with Patents US9872900 and US10022435

CC-BY-NC-SA Dr. David E. Martin

2015	Moderna signs a vaccine development agreement with NIAID and executes it with the lead on the mRNA-1273 lead developer and inventor Guiseppe Ciaramella. https://www.documentcloud.org/documents/6935295-NIH-Moderna-Confidential-Agreements.html
2016	NIH through Scripps Institute and Dartmouth College file patent application WO 2018081318A1 "Prefusion Coronavirus Spike Proteins and their Use" disclosing mRNA technology that overlaps (and is used in tandem with) Moderna's technology. https://patents.google.com/patent/WO2018081318A1/en Lead Inventor Barney Scott Graham was well known to Moderna as he's the person at NIH that Moderna "e-mailed" to get the sequence for SARS CoV-2 according to Moderna's report here *("In January 2020, once it was discovered that the infection in Wuhan was caused by a novel coronavirus, Bancel quickly emailed Dr. Barney Graham, deputy director of the Vaccine Research Center at the National Institutes of Health, asking him to send the genetic sequence for the virus.")* https://www.wsws.org/en/articles/2020/05/26/vacc-m26.html In addition, co-inventor Jason McLellan worked with Graham on a vaccine patent jointly owned with the Chinese government filed in Australia in 2013 https://patents.google.com/patent/AU2014231357A1/en?inventor=Jason+MCLELLAN.
2017	August – Sanofi buys Protein Science Corp with considerable SARS patent holdings
2018	June – Sanofi buys Ablynx with considerable SARS patent holdings
2019	March, https://wyss.harvard.edu/news/sherlock-biosciences-licenses-wyss-technology-to-create-affordable-molecular-diagnostics/ funded by Open Philanthropy – the same organization that would be the financial sponsor of the Event 201 "table-top" exercise that laid out the entire "pandemic" plan in October 2019.

CC-BY-NC-SA Dr. David E. Martin

15 U.S.C. §8 – Market Manipulation and Allocation

Every combination, conspiracy, trust, agreement, or contract is declared to be contrary to public policy, illegal, and void when the same is made by or between two or more persons or corporations, either of whom, as agent or principal, is engaged in importing any article from any foreign country into the United States, and when such combination, conspiracy, trust, agreement, or contract is intended to operate in restraint of lawful trade, or free competition in lawful trade or commerce, or to increase the market price in any part of the United States of any article or articles imported or intended to be imported into the United States, or of any manufacture into which such imported article enters or is intended to enter. Every person who shall be engaged in the importation of goods or any commodity from any foreign country in violation of this section, or who shall combine or conspire with another to violate the same, is guilty of a misdemeanor, and on conviction thereof in any court of the United States such person shall be fined in a sum not less than $100 and not exceeding $5,000, and shall be further punished by imprisonment, in the discretion of the court, for a term not less than three months nor exceeding twelve months.

Through non-competitive grant awards to UNC Chapel Hill's Ralph Baric, to selection of the Bio-Safety Level 4 laboratory locations, to the setting of prices for Remdesivir and mRNA therapies from Moderna and Pfizer, NIAID, CDC, and the U.S. Department of Health and Human Services have been involved in allocating Federal funds to conspiring parties without independent review.

Around March 12, 2020, in an effort to enrich their own economic interests by way of securing additional funding from both Federal and Foundation actors, the CDC and NIAID's Dr Fauci elected to suspend testing and classify COVID-19 by capricious symptom presentation alone. Forcing the public to rely on The COVID Tracking Project – funded by the Bloomberg, Zuckerberg and Gates Foundation and presented by a media outlet (***The Atlantic***) – not a public health agency – Dr. Fauci used fraudulent testing technology (RT-PCR) to conflate "COVID cases" with positive PCR tests in the living while insisting that COVID deaths be counted by symptoms alone. This perpetuated a market demand for his desired vaccine agenda which was recited by him and his conspiring parties around the world until the present. Not surprisingly, this was necessitated by the apparent fall in cases that constituted Dr. Fauci's and others' criteria for depriving citizens of their 1st Amendment rights.

CC-BY-NC-SA Dr. David E. Martin

15 U.S.C. § 19 – Interlocking Directorates

(1) No person shall, at the same time, serve as a director or officer in any two corporations (other than banks, banking associations, and trust companies) that are—

(A) engaged in whole or in part in commerce; and

(B) by virtue of their business and location of operation, competitors, so that the elimination of competition by agreement between them would constitute a violation of any of the antitrust laws; if each of the corporations has capital, surplus, and undivided profits aggregating more than $10,000,000 as adjusted pursuant to paragraph (5) of this subsection.

Dr. Fauci is on the Leadership Council of the Bill and Malinda Gates Global Vaccine Action Plan

Dr. Fauci while controlling the economic dispensation of Federal research funding, Dr. Fauci has been, and continues to be, on the World Health Organization's Global Preparedness Monitoring Board. He is joined on this board by the conflicted donor from the Bill and Melinda Gates Foundation's Dr. Chris Elias and the State Council of China's Dr. George F. Gao of the Chinese CDC. This GPMB stipulated that all member states must take part in a global simulation of the release of a respiratory pathogen.

Dr. Baric is one of the primary beneficiaries of U.S. Federal funds, runs a BSL-4 facility and sits on the International Committee on Taxonomy of Virus *Coronaviridae* Working Group tasked to confirm the presence of absence of the pathogen for which he is directly compensated.

As referenced in the section covering violations of 18 U.S.C. § 1001 above, numerous undisclosed commercial relationships exist between funded researchers, their funding agencies, and commercial interests in which disclosed and undisclosed commercial terms exist. A complete list of all potential implicated parties is listed in the section below entitled "The Commercial Actors".

It appears that, during the period of patent enforcement and after the Supreme Court ruling confirming that patents on genetic material were illegal, the CDC and National Institute of Allergy and Infectious Diseases led by Anthony Fauci (hereinafter "NIAID" and "Dr Fauci", respectively) entered into trade among States (including, but not limited to working with Ecohealth Alliance Inc.) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy of Sciences) through the 2014 et seq National Institutes of Health Grant R01AI110964 to exploit their patent rights.

It further appears that, during the period of patent enforcement and after the Supreme Court ruling confirming that patents on genetic material was illegal, the CDC and National Institute of Allergy and Infectious Diseases (hereinafter "NIAID") entered into trade among States (including, but not limited to working with University of North Carolina, Chapel Hill) and with foreign nations (specifically, the Wuhan Institute of Virology and the Chinese Academy of Sciences represented by Zheng-Li Shi) through U19AI109761 (Ralph S. Baric), U19AI107810 (Ralph S. Baric), and National Natural Science Foundation of China Award 81290341 (Zheng-Li Shi) et al. 2015-2016.

It further appears that, during the period of patent enforcement and after the Supreme Court ruling confirming that patents on generic material was illegal, the CDC and NIAID entered into trade among States (including, but not limited to working with University of North Carolina, Chapel Hill) and with foreign nations to conduct chimeric construction of novel coronavirus material with specific virulence properties prior to, during, and following the determination made by the National Institutes for Health in October 17, 2014 that this work was not sufficiently understood for its biosecurity and safety standards.

In this inquiry, it is presumed that the CDC and its associates were: a) fully aware of the work being performed using their patented technology; b) entered into explicit or implicit agreements including licensing, or other consideration; and, c) willfully engaged one or more foreign interests to carry forward the exploitation of their proprietary technology

when the U.S. Supreme Court confirmed that such patents were illegal and when the National Institutes of Health issued a moratorium on such research.

Reportedly, in January 2018, the U.S. Embassy in China sent investigators to Wuhan Institute of Virology and found that, "During interactions with scientists at the WIV laboratory, they noted the new lab has a serious shortage of appropriately trained technicians and investigators needed to safely operate this high-containment laboratory." The Washington Post reported that this information was contained in a cable dated 19 January 2018. Over a year later, in June 2019, the CDC conducted an inspection of Fort Detrick's U.S. Army Medical Research Institute of Infectious Diseases (hereinafter "USAMRIID") and ordered it closed after alleging that their inspection found biosafety hazards. A report in the journal Nature in 2003 (423(6936): 103) reported cooperation between CDC and USAMRIID on coronavirus research followed by considerable subsequent collaboration. The CDC, for what appear to be the same type of concern identified in Wuhan, elected to continue work with the Chinese government while closing the U.S. Army facility.

The CDC reported the first case of SARS-CoV like illness in the United States in January 2020 with the CDC's Epidemic Intelligence Service reporting 650 clinical cases and 210 tests. Given that the suspected pathogen was first implicated in official reports on December 31, 2019, one can only conclude that CDC: a) had the mechanism and wherewithal to conduct tests to confirm the existence of a "novel coronavirus"; or, b) did not have said mechanism and falsely reported the information in January. It tests credulity to suggest that the WHO or the CDC could manufacture and distribute tests for a "novel" pathogen when their own subsequent record on development and deployment of tests has been shown to be without reliability

CC-BY-NC-SA Dr. David E. Martin

35 U.S.C. §200 - 206 – Disclosure of Government Interest

35 U.S.C. §202 (c)(6)

An obligation on the part of the contractor, in the event a United States patent application is filed by or on its behalf or by any assignee of the contractor, to include within the specification of such application and any patent issuing thereon, a statement specifying that the invention was made with Government support and that the Government has certain rights in the invention.

Over 5000 patents and patent applications have included reference to SARS Coronavirus dating back to priority dates of 1998. They are summarized below.



	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020		total
file	0	0	0	0	1	120	338	290	328	297	256	188	198	207	244	371	407	466	451	416	326	199	8	file	5111
issue	0	0	0	0	0	1	63	135	179	224	275	334	391	61	8	314	431	420	504	513	449	578	231	issue	5111
priority	10	12	29	38	129	506	487	408	335	370	279	256	303	279	322	330	348	342	208	95	25	0	0	priority	5111
total	10	12	29	38	129	627	888	833	842	891	810	778	892	547	574	1015	1186	1228	1163	1024	800	777	240	total	15333

On July 23, 2020, the Patent Trial and Appeal Board of the United States Patent and Trademark Office rejected Moderna's efforts to invalidate U.S. Patent 8,058,069. This patent, owned by Arbutus Biopharma Corp (principally owned by Roivant Science Ltd), covers the lipid nanoparticle (LNP) required to deliver an mRNA vaccine. Some of the core technology was based on work originally done at the University of British Columbia and was first licensed in 1998.

mRNA-1273 – the experimental vaccine developed by Moderna for COVID-19 – uses the LNP technology that Moderna thought it had licensed from Acuitas Therapeutics Inc., a firm developed by a former principal of Arbutus' prior company Tekmira. That license did not authorize Moderna to use the technology for the COVID-19 vaccine.

M·CAM and Knowledge Ecology International have independently confirmed that Moderna has violated U.S. law in failing to disclose the U.S. government's funding interest in their patents and patent applications. While this negligence impacts all of Moderna's over 130 granted U.S. patents, it is particularly problematic for U.S. Patent 10,702,600 ('600) which is the patent relating to, "a messenger ribonucleic acid (mRNA) comprising an open reading frame encoding a betacoronavirus (BetaCoV) S protein or S protein subunit formulated in a lipid nanoparticle." The specific claims addressing the pivot to the SARS Coronavirus were patented ***on March 28, 2019 – 9 months before the SARS CoV-2***

CC-BY-NC-SA Dr. David E. Martin

outbreak! Both the patent and the DARPA funding for the technology were disclosed in scientific publication (*New England Journal of Medicine*) but the government funds were not acknowledged in the patent.

In 2013, the Autonomous Diagnostics to Enable Prevention and Therapeutics (ADEPT) program awarded grant funding to Moderna Therapeutics for the development of a new type of vaccine based on messenger RNA. The initial DARPA grant was W911NF-13-1-0417. ***The company used that technology to develop its COVID-19 vaccine, currently undergoing Phase I clinical trials in conjunction with NIH***.[29]

Under the Federal Acquisition Regulation (FAR) rules, contractor to the Federal Government must provide information regarding intellectual property infringement issues as part of their contract. Under FAR §27.201-1(c) and (d), the Government both requires a notice of infringement or potential infringement as well as retention of economic liability for patent infringements. Specifically, in FAR §52.227.3 (a), the "Contractor shall indemnify the Government and its officers, agents, and employees against liability, including costs for infringement of any United States Patent…". In addition to the patents cited by the USPTO in their examination of '600, M·CAM has identified fourteen other issued patents preceding the '600 patent which were used by patent examiners to limit patents arising from the same funded research including patents sought by CureVac.

In short, while Moderna enjoys hundreds of millions of dollars of funding allegiance and advocacy from Anthony Fauci and his NIAID, since its inception, it has been engaged in illegal patent activity and demonstrated contempt for U.S. Patent law. To make matters worse, the U.S. Government has given it financial backing in the face of undisclosed infringement risks potentially contributing to the very infringement for which they are indemnified.

[29] https://crsreports.congress.gov/product/pdf/IN/IN11446

CC-BY-NC-SA Dr. David E. Martin

21 C.F.R. § 50.24 et seq., Illegal Clinical Trial

It is unlawful to conduct medical research (even in the case of emergency) without a series of steps taken to:

a. **Establish the research with a duly authorized and independent institutional review board;**
b. **Secure informed consent of all participants including a statement of risks and benefits; and,**
c. **Engage in consultation with the community in which the study is to be conducted.**

Dr. Anthony Fauci has forced upon the healthy population of the United States an unlawful clinical trial in which the U.S. Department of Health and Human Services are extrapolating epidemiologic data. No informed consent has been sought or secured for any of the "medical countermeasures" forced upon the population and no independent review board – as defined by the statute – has been empaneled.

Through April 2020, the official recommendation by the ***Journal of the American Medical Association*** was unambiguous.

"Face masks should not be worn by healthy individuals to protect themselves from acquiring respiratory infection because there is no evidence to suggest that face masks worn by healthy individuals are effective in preventing people from becoming ill."[30]

Part of that lack of evidence in fact showed that cloth facemasks actually increased influenza-linked illness.[31]

In contravention to established science, States, municipalities, and businesses have violated the legal requirements for the promulgation of medical counter measures during a public health emergency stating a "belief" that face masks limit the spread of SARS CoV-2. To date, not a single study has confirmed that a mask prevented the transmission of, or the infection by SARS CoV-2.

All parties mandating the use of facemasks are not only willfully ignoring established science but are engaging in what amounts to a whole population clinical trial. This conclusion is reached by the fact that facemask use and COVID-19 incidence are being reported in scientific opinion pieces promoted by the United States Centers for Disease Control and Prevention and others.[32]

Social distancing of up to 6 feet has been promoted as a means of preventing person-to-person transmission of influenza-like viruses. While one study hypothesized that infection could happen in a 6 foot range, the study explicitly states that person-to-person transfer was not tested and viability of the virus at 6 feet was not even a subject of the investigation.[33] That did not stop the misrepresentation of the study to be used as the basis for an unverified medical counter measure of social distancing. To date, no study has established the efficacy of social distancing to modify the transmission of SARS CoV-2. Public health officials have referenced:

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907354/#CR43

In contravention to established science, States, municipalities, and businesses have violated the legal requirements for the promulgation of medical counter measures during a public health emergency stating a "belief" that social distancing of a healthy population limits the spread of SARS CoV-2. To date, not a single study has confirmed that social distancing of any population prevented the transmission of, or the infection by SARS CoV-2.

---

[30] https://jamanetwork.com/journals/jama/fullarticle/2762694
[31] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4420971/
[32] https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover-guidance.html
[33] *Werner E. Bischoff, Katrina Swett, Iris Leng, Timothy R. Peters, Exposure to Influenza Virus Aerosols During Routine Patient Care,* The Journal of Infectious Diseases*, Volume 207, Issue 7, 1 April 2013, Pages 1037–1046,* ***https://doi.org/10.1093/infdis/jis773***

It is unlawful under the FTC Act, 15 U.S.C. § 41 et seq., to advertise that a product or service can prevent, treat, or cure human disease unless you possess competent and reliable scientific evidence, including, when appropriate, well-controlled human clinical studies, substantiating that the claims are true at the time they are made. As a result, every party promoting the use of face masks is violating the FTC Act.

All of these laws have been broken. All relevant authorities in the United States must cease and desist the use of face masks until the matters above are rectified.

CC-BY-NC-SA Dr. David E. Martin

The Commercial Actors

SARS coronavirus is a new topic for many individuals. Since 1999, the ability to manipulate and exploit coronavirus for a variety of purposes has attracted the attention of individuals, institutions and commercial organizations in public, private, and not-for-profit sectors. The following is the list of over 5,100 patents and patent applications filed for the express purpose of controlling some aspect of the SARS coronavirus.

PATENT	Title	Owner	Priority	Filed Date	Issue Date
US9995706	Amperometric gas sensor	Steris Corporation	25-Jun-12	30-Sep-14	12-Jun-18
US9995705	Amperometric gas sensor	Steris Corporation	25-Jun-12	30-Sep-14	12-Jun-18
US9994558	Multicyclic compounds and methods of using same	Karyopharm Therapeutics Inc.	20-Sep-13	19-Sep-14	12-Jun-18
US9994550	Heterocyclic modulators of lipid synthesis for use against cancer and viral infections	3-V Biosciences, Inc.	7-Jan-14	7-Jan-15	12-Jun-18
US9993543	Immunogenic compositions comprising silicified virus and methods of use	Portland State University	31-Jan-13	31-Jan-14	12-Jun-18
US9982257	Chiral control	WAVE LIFE SCIENCES LTD.	13-Jul-12	12-Jul-13	29-May-18
US9982241	Recombinant HCMV and RHCMV vectors and uses thereof	Oregon Health & Science University	14-May-10	1-Oct-15	29-May-18
US9982025	Monomeric griffithsin tandemers	The United States of America, as represented by the Secretary, Department of Health and Human Services	5-Jun-13	5-Jun-14	29-May-18
US9981036	Compositions, comprising improved Il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	12-Dec-11	26-Feb-16	29-May-18
US9975885	Broad-spectrum non-covalent coronavirus protease inhibitors	PURDUE RESEARCH FOUNDATION	28-Apr-16	28-Apr-17	22-May-18
US9974850	Immunogenic compositions and uses thereof	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM	25-Mar-15	25-Mar-16	22-May-18
US9974848	Tetanus toxoid and CCL3 improve DC vaccines	Duke University	14-Nov-13	14-Nov-14	22-May-18
US9974845	Combination of vaccination and inhibition of the PD-1 pathway	CureVac AG	22-Feb-13	21-Feb-14	22-May-18
US9970061	Bioagent detection oligonucleotides	IBIS BIOSCIENCES, INC.	27-Dec-11	27-Dec-12	15-May-18
US9969793	Compositions and methods for the treatment of immunodeficiency	ADMA Biologics, Inc.	28-Oct-14	13-Nov-17	15-May-18
US9963718	LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus-producing cells for the therapy of tumors	VIRATHERAPEUTICS GMBH	8-Oct-08	7-Apr-17	8-May-18
US9963611	Composition for use in decreasing the transmission of human pathogens	Innonix Technologies, Incorporated	29-May-09	21-May-10	8-May-18
US9963427	Dithiol mucolytic agents	PARION SCIENCES, INC.	23-Aug-13	11-Mar-16	8-May-18
US9962439	Injectable vaccine composition	NITTO DENKO CORPORATION	3-Oct-13	2-Oct-14	8-May-18
US9957302	Treating cancer with viral nucleic acid	Mayo Foundation for Medical Education and Research	20-Feb-07	6-Jul-15	1-May-18
US9957300	Virus-like particles, methods of preparation, and immunogenic compositions	Emory University	17-May-02	4-May-15	1-May-18
US9957238	Arylalkyl-and aryloxyalkyl-substituted epithelial sodium channel blocking compounds	Parion Sciences, Inc.	13-Dec-13	1-Mar-17	1-May-18
US9951317	Highly efficient influenza matrix (M1) proteins	NOVAVAX, INC.	11-Jul-03	6-Oct-16	24-Apr-18

CC-BY-NC-SA Dr. David E. Martin

US9951124	Antibody producing non-human mammals	MERUS N.V.	27-Jun-08	25-Jan-13	24-Apr-18
US9951122	Antibodies against influenza virus and methods of use thereof	BURNHAM INSTITUTE FOR MEDICAL RESEARCH	6-Dec-07	12-Aug-13	24-Apr-18
US9950062	Compounds and compositions as TLR activity modulators	GLAXOSMITHKLINE BIOLOGICALS SA	2-Sep-09	1-Sep-10	24-Apr-18
US9945856	Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics	AMSTERDAM INSTITUTE OF VIRAL GENOMICS B.V.	18-Aug-03	13-Aug-14	17-Apr-18
US9945780	Use of a fluorescent material to detect failure or deteriorated performance of a fluorometer	GEN-PROBE INCORPORATED	14-Jun-12	7-Jun-13	17-Apr-18
US9944928	Construction of pool of interfering nucleic acids covering entire RNA target sequence and related compositions	York Yuan Yuan Zhu	23-Jul-07	2-Jul-15	17-Apr-18
US9944695	Antibody producing non-human mammals	Merus N.V.	27-Jun-08	30-Apr-14	17-Apr-18
US9944686	Treatment of tumors with recombinant interferon alpha	SUPERLAB FAR EAST LIMITED	28-Feb-01	5-Sep-13	17-Apr-18
US9944649	Compounds and compositions as toll-like receptor 7 agonists	Novartis Ag	1-May-14	29-Apr-15	17-Apr-18
US9943614	Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods	BRIGHAM YOUNG UNIVERSITY	17-Jun-08	16-Jun-09	17-Apr-18
US9938300	Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors	Forma Therapeutics, Inc.	5-Feb-15	4-Feb-16	10-Apr-18
US9938275	Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines	3M Innovative Properties Company	18-Jun-04	23-Jan-17	10-Apr-18
US9938258	Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof	Karyopharm Therapeutics Inc.	29-Nov-12	27-Nov-13	10-Apr-18
US9932351	Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors	Forma Therapeutics, Inc.	5-Feb-15	4-Feb-16	3-Apr-18
US9932323	Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones	Rutgers, The State University of New Jersey	11-Sep-12	13-Jan-17	3-Apr-18
US9931316	Antiviral activity from medicinal mushrooms and their active constituents	Not Available	31-Mar-15	14-Sep-15	3-Apr-18
US9926340	NAD analogs and methods of using said NAD analogs in determining ribosylation of proteins with PARP mutants	Biolog Life Science Institute Forshungslabor und Biochemica-Vertrieb GmbH	8-Apr-15	1-Apr-16	27-Mar-18
US9925215	Anionically modified polyallylamine derivative, use of anionically modified polyallylamine derivative as medicine, particularly for propylaxis and treatment of infections of respiratory tract caused by human metapneumovirus (hMPV), human rhinoviruses (HRV), and infection by influenza virus type A (IAV) and pharmaceutical composition comprising the anionically modified polyallylamine derivative	UNIWERSYTET JAGIELLONSKI	29-Jul-14	25-Oct-17	27-Mar-18
US9920314	Compositions for and methods of identifying antigens	President and Fellows of Harvard College	21-Feb-06	6-May-15	20-Mar-18
US9920128	Synthetic antiserum for rapid-turnaround therapies	The Johns Hopkins University	28-Jan-15	20-Jan-16	20-Mar-18
US9919034	Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group V	TAMIR BIOTECHNOLOGY, INC.	28-Mar-14	10-Jun-15	20-Mar-18
US9915613	Systems and methods for distinguishing optical signals of different modulation frequencies in an optical signal detector	GEN-PROBE INCORPORATED	24-Feb-11	21-Mar-14	13-Mar-18
US9914976	Methods and compositions for prostate cancer metastasis	FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (FA	25-Mar-11	27-May-16	13-Mar-18
US9913801	Treatment of evolving bacterial resistance diseases including Klebsiella pneumoniae with liposomally formulated glutathione	YOUR ENERGY SYSTEMS, LLC	15-Feb-13	15-Mar-13	13-Mar-18
US9909176	Efficient deep sequencing and rapid genomic speciation of RNA viruses (vRNAseq)	The Johns Hopkins University	8-Sep-14	1-Sep-15	6-Mar-18
US9908946	Generation of binding molecules	Merus N.V.	26-Sep-11	16-Sep-15	6-Mar-18
US9908675	Powdered pouch and method of making same	MONOSOL, LLC	16-Apr-12	19-Jul-16	6-Mar-18

US9907796	Methods of treating tumoral diseases, or bacterial or viral infections	INHIBIKASE THERAPEUTICS, INC.	4-Oct-12	15-Sep-16	6-Mar-18
US9895692	Sample-to-answer microfluidic cartridge	Micronics, Inc.	29-Jan-10	5-Aug-15	20-Feb-18
US9895411	Analogs of C5a and methods of using same	BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA	29-Jun-10	29-Jun-11	20-Feb-18
US9895341	Inflammation and immunity treatments	Ocean Spray Cranberries, Inc.	1-Apr-11	30-Mar-12	20-Feb-18
US9894888	Transgenic immunodeficient mouse expressing human SIRP-alpha	INSTITUT PASTEUR	26-Mar-12	26-Mar-13	20-Feb-18
US9890419	Nanoreporters and methods of manufacturing and use thereof	NanoString Technologies, Inc.	23-Dec-05	20-May-16	13-Feb-18
US9890408	Multiple displacement amplification	IBIS BIOSCIENCES, INC.	15-Oct-09	15-Oct-10	13-Feb-18
US9890362	Compositions, methods and uses for inducing viral growth	Takeda Vaccines, Inc.	5-Dec-08	19-Sep-14	13-Feb-18
US9890361	Methods for increasing the infectivity of viruses utilizing alkyne-modified fatty acids	LIFE TECHNOLOGIES CORPORATION	26-Jan-12	25-Jan-13	13-Feb-18
US9890206	H1N1 flu virus neutralizing antibodies	Medigen Biotechnology Corporation	20-Aug-15	20-Aug-15	13-Feb-18
US9890169	Triazolinone compounds as HNE inhibitors	CHIESI FARMACEUTICI S.P.A.	14-Dec-15	12-Dec-16	13-Feb-18
US9890124	Benzazepine sulfonamide compounds	Hoffmann-La Roche Inc.	15-Dec-15	14-Jun-17	13-Feb-18
US9889194	Immunogenic composition for MERS coronavirus infection	New York Blood Center, Inc.	1-Mar-13	28-Feb-14	13-Feb-18
US9885092	Materials and methods for detection of HPV nucleic acids	QIAGEN GAITHERSBURG INC.	24-Feb-11	23-Feb-12	6-Feb-18
US9885082	Embodiments of a probe and method for targeting nucleic acids	University of Idaho	19-Jul-11	19-Jul-12	6-Feb-18
US9885037	Chiral control	WAVE LIFE SCIENCES LTD.	13-Jul-12	12-Jul-13	6-Feb-18
US9884895	Methods and compositions for chimeric coronavirus spike proteins	The University of North Carolina at Chapel Hill	20-Mar-14	20-Mar-15	6-Feb-18
US9884876	Anti-viral compounds, pharmaceutical compositions, and methods of use thereof	Kineta, Inc.	9-May-14	8-May-15	6-Feb-18
US9884129	Release of agents from cells	The Brigham and Women's Hospital, Inc.	15-Oct-09	5-Jan-15	6-Feb-18
US9884032	Esters of short chains fatty acids for use in the treatment of immunogenic disorders	PROPONENT BIOTECH GMBH	3-Oct-12	3-Mar-16	6-Feb-18
US9884026	Modular particles for immunotherapy	YALE UNIVERSITY	1-Nov-13	31-Oct-14	6-Feb-18
US9880151	Method of determining, identifying or isolating cell-penetrating peptides	Phylogica Limited	23-May-11	23-May-12	30-Jan-18
US9879026	Substituted spirocycles	Boehringer Ingelheim International GmbH	12-Sep-14	29-Nov-16	30-Jan-18
US9879003	Host targeted inhibitors of dengue virus and other viruses	Dana-Farber Cancer Institute, Inc.	11-Apr-12	15-Mar-13	30-Jan-18
US9878988	Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases	PARION SCIENCES, INC.	29-May-12	5-Jan-16	30-Jan-18
US9873678	Chemical compounds	AstraZeneca AB	18-Mar-14	17-Mar-15	23-Jan-18
US9873674	C-Rel inhibitors and uses thereof	CORNELL UNIVERSITY	21-Sep-12	19-Sep-13	23-Jan-18
US9872900	Nucleic acid vaccines	ModernaTX, Inc.	23-Apr-14	5-Apr-16	23-Jan-18
US9872898	Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome	Ohio State Innovation Founation	24-Apr-12	3-Oct-16	23-Jan-18
US9872895	TLR5 ligands, therapeutic methods, and compositions related thereto	Emory University	24-Sep-10	20-Sep-11	23-Jan-18

CC-BY-NC-SA Dr. David E. Martin

US9868952	Compositions and methods for â€œresistance-proofâ€ SiRNA therapeutics for influenza	Sirnaomics, Inc.	8-Jul-12	7-Jul-13	16-Jan-18
US9868740	Pyrimidinone compounds which are HNE inhibitors	CHIESI FARMACEUTICI S.p.A.	12-Jun-14	12-Jun-14	16-Jan-18
US9868736	Deubiquitinase inhibitors and methods for use of the same	THE REGENTS OF THE UNIVERSITY OF MICHIGAN	10-Oct-13	10-Oct-14	16-Jan-18
US9867882	Carbohydrate conjugates as delivery agents for oligonucleotides	Alnylam Pharmaceuticals, Inc.	4-Dec-07	25-Aug-15	16-Jan-18
US9867877	Methods for preparing squalene	NOVARTIS AG	12-May-10	22-Nov-16	16-Jan-18
US9862706	Compounds	CHIESI FARMACEUTICI S.p.A.	31-May-16	26-May-17	9-Jan-18
US9861614	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	9-May-12	23-Jun-15	9-Jan-18
US9856254	Alkoxy substituted imidazoquinolines	3M Innovative Properties Company	3-Oct-03	13-Jun-16	2-Jan-18
US9856241	Substituted benzofuranyl and benzoxazolyl compounds and uses thereof	Karyopharm Therapeutics Inc.	3-Jul-13	3-Jul-14	2-Jan-18
US9856228	Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors	PROZYMEX A/S	9-Sep-13	8-Sep-14	2-Jan-18
US9856224	Stable sodium channel blockers	PARION SCIENCES, INC.	30-Jun-14	30-Jan-17	2-Jan-18
US9855287	Anti-viral azide containing compounds	LIFE TECHNOLOGIES CORPORATION	28-Jul-10	20-Aug-15	2-Jan-18
US9855284	Pharmaceutical compositions and methods	Pop Test Oncology LLC	3-Aug-15	6-Dec-16	2-Jan-18
US9849143	Broad spectrum antiviral and methods of use	The Burlington HC Research Group, Inc.	17-Apr-06	16-Feb-17	26-Dec-17
US9845342	Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria	Spogen Biotech Inc.	17-Sep-14	17-Sep-15	19-Dec-17
US9840731	Preservation of biological materials in non-aqueous fluid media	Gentegra, LLC	14-Mar-13	14-Mar-14	12-Dec-17
US9840719	Variant AAV and compositions, methods and uses for gene transfer to cells, organs and tissues	The Children's Hospital of Philadelphia	22-Jul-13	22-Jul-14	12-Dec-17
US9840491	Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors	FORMA Therapeutics, Inc.	5-Feb-15	4-Feb-16	12-Dec-17
US9839687	Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule	SUZHOU M-CONJ BIOTECH CO., LTD.	15-Jul-15	15-Jul-15	12-Dec-17
US9834812	Probe kit for detecting a single strand target nucleotide sequence	Fondazione Istituto Italiano Di Tecnologia	27-Dec-12	27-Dec-13	5-Dec-17
US9834791	CRISPR-related methods and compositions with governing gRNAS	Editas Medicine, Inc.	7-Nov-13	7-Nov-14	5-Dec-17
US9834757	Hand, foot, and mouth vaccines and methods of manufacture and use thereof	Takeda Vaccines, Inc.	7-Nov-14	6-Nov-15	5-Dec-17
US9834595	Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases	Ablynx N.V.	5-Jun-08	29-Oct-15	5-Dec-17
US9833504	Virus-like particles and process for preparing same	Folia Biotech Inc.	13-May-11	1-May-12	5-Dec-17
US9833492	Combinations of a caspase inhibitor and an antiviral agent	Centre National de la Recherche Scientifique	2-Nov-07	15-May-15	5-Dec-17
US9832998	Antiviral compositions	Long Island University	30-May-07	19-Mar-15	5-Dec-17
US9828382	Pyrimidinone compounds as human neutrophil elastase inhibitors	Chiesi Farmaceutici S.p.A.	18-Dec-12	10-May-16	28-Nov-17
US9828379	Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof	ABIDE THERAPEUTICS, INC.	3-Jul-13	1-Jul-14	28-Nov-17
US9828370	Compositions and methods for inhibiting kinases	INHIBIKASE THERAPEUTICS, INC.	23-Apr-15	22-Apr-16	28-Nov-17
US9828346	N-myristoyl transferase inhibitors	University of Dundee	2-Sep-08	31-Aug-15	28-Nov-17

CC-BY-NC-SA Dr. David E. Martin

US9828342	Isatin derivatives, pharmaceutical compositions thereof, and methods of use thereof	CITY OF HOPE	24-Feb-12	25-Feb-13	28-Nov-17
US9827190	Intradermal delivery of immunological compositions comprising toll-like receptor 7 agonists	GLAXOSMITHKLINE BIOLOGICALS SA	1-Feb-13	30-Jan-14	28-Nov-17
US9822339	Means and methods for influencing the stability of antibody producing cells	ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM	9-Dec-05	26-Aug-15	21-Nov-17
US9822173	Heterodimeric immunoglobulins	AMGEN INC.	21-Nov-12	21-Nov-13	21-Nov-17
US9822165	Hydrocarbon stapled stabilized alpha-helices of the HIV-1 GP41 membrane proximal external region	DANA-FARBER CANCER INSTITUTE, INC.	18-Jun-09	18-Jun-10	21-Nov-17
US9822155	Method of preventively treating a subject at the risk of developing infections of a respiratory virus	Xiangxue Group (Hong Kong) Company Limited	9-May-13	23-Aug-16	21-Nov-17
US9822127	GAK modulators as antivirals	The Board of Trustees of the Leland Stanford Junior University	23-Jul-14	23-Jul-15	21-Nov-17
US9822065	Benzazepine dicarboxamide compounds	Hoffmann-La Roche Inc.	6-Mar-15	14-Feb-17	21-Nov-17
US9821052	Reverse genetics systems	Seqirus UK Limited	31-Jul-09	30-Jul-10	21-Nov-17
US9821051	Reducing hospitalization in elderly influenza vaccine recipients	Seqirus UK Limited	28-Oct-10	21-Oct-11	21-Nov-17
US9816078	Compositions for increasing polypeptide stability and activity, and related methods	SOLIS BIODYNE OÃœ	19-Nov-09	11-Mar-16	14-Nov-17
US9815886	Compositions and methods for the treatment of immunodeficiency	ADMA BIOLOGICS, INC.	28-Oct-14	8-Jan-15	14-Nov-17
US9815805	Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors	ASTRAZENECA AB	24-Jan-14	8-Nov-16	14-Nov-17
US9814777	Targeting lipids	Arbutus Biopharma Corporation	4-Dec-07	22-Oct-13	14-Nov-17
US9810683	Use of live cell inteferometry with reflective floor of observation chamber to determine changes in mass of mammalian cells	The Regents of the University of California	6-May-09	25-Nov-13	7-Nov-17
US9809845	Methods and reagents for amplifying nucleic acids	The United States of America, as represented by the Secretary, Department of Health and Human Services	6-Aug-12	6-Aug-12	7-Nov-17
US9809796	Animal protein-free media for cultivation of cells	Baxalta GmbH	29-Oct-04	18-May-17	7-Nov-17
US9809632	Universal protein tag for double stranded nucleic acid delivery	University of Washington Through its Center for Commercialization	23-Oct-13	22-Oct-14	7-Nov-17
US9809591	Heterocyclic modulators of lipid synthesis	3-V Biosciences, Inc.	8-Mar-11	5-Oct-15	7-Nov-17
US9808490	Induced hepatocytes and uses thereof	ACCELERATED BIOSCIENCES CORP.	26-Nov-14	25-Nov-15	7-Nov-17
US9803236	Microarray-based assay integrated with particles for analyzing molecular interactions	CapitalBio Corporation	6-Aug-10	6-Aug-10	31-Oct-17
US9803197	Particle-nucleic acid conjugates and therapeutic uses related thereto	Emory University	25-Jun-12	27-Feb-13	31-Oct-17
US9802937	Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors	ORIGENIS GMBH	21-Apr-11	23-Apr-12	31-Oct-17
US9802919	Compounds	CHIESI FARMACEUTICI S.p.A.	31-May-16	26-May-17	31-Oct-17
US9801948	Antimicrobial compositions and methods of use thereof	Yale University	21-Sep-11	21-Sep-12	31-Oct-17
US9801947	Methods and compositions for enhancing immune response	3M INNOVATIVE PROPERTIES COMPANY	10-Apr-03	6-Oct-14	31-Oct-17
US9801935	Soluble needle arrays for delivery of influenza vaccines	SEQIRUS UK LIMITED	20-Aug-10	11-Oct-16	31-Oct-17
US9801897	Delivery of RNA to trigger multiple immune pathways	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul-10	6-Jul-11	31-Oct-17
US9797000	Non-target amplification method for detection of RNA splice-forms in a sample	QIAGEN GAITHERSBURG INC.	1-May-09	30-Apr-10	24-Oct-17
US9796979	Oligonucleotide modulators of the toll-like receptor pathway	Quark Pharmaceuticals Inc.	3-Mar-11	28-Jul-16	24-Oct-17

US9796735	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	20-Jun-07	7-Nov-14	24-Oct-17
US9795669	Lipidated immune response modifier compound compositions, formulations, and methods	3M INNOVATIVE PROPERTIES COMPANY	17-Aug-10	15-Dec-15	24-Oct-17
US9795668	Delivery of self-replicating RNA using biodegradable polymer particles	GlaxoSmithKline Biologicals S.A.	6-Jul-10	23-Nov-15	24-Oct-17
US9795666	High-yield transgenic mammalian expression system for generating virus-like particles	Academia Sinica	5-Sep-06	11-Feb-15	24-Oct-17
US9791437	Multianalyte assay	Nexus Dx, Inc.	30-Apr-07	15-Jun-15	17-Oct-17
US9789180	D-amino acid derivative-modified peptidoglycan and methods of use thereof	The Regents of the University of California	30-Nov-12	31-Mar-16	17-Oct-17
US9786050	Stain-free histopathology by chemical imaging	The Board of Trustees of the University of Illinois	15-Mar-13	14-Mar-14	10-Oct-17
US9783595	Neutralizing GP41 antibodies and their use	The United States of America, as represented by the Secretary, Department of Health and Human Services	7-Nov-11	2-Aug-16	10-Oct-17
US9782470	Method of obtaining thermostable dried vaccine formulations	Merck Sharp & Dohme Corp.	16-Oct-13	13-Oct-14	10-Oct-17
US9782434	Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution	Sonoma Pharmaceuticals, Inc.	20-Jan-06	7-Jul-15	10-Oct-17
US9770504	Generating peptoid vaccines	The Board of Regents of the University of Texas System	3-May-13	2-May-14	26-Sep-17
US9770463	Delivery of RNA to different cell types	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul-10	7-Jun-11	26-Sep-17
US9765395	System and method for DNA sequencing and blood chemistry analysis	Nanomedical Diagnostics, Inc.	28-Apr-14	10-Apr-15	19-Sep-17
US9765133	Antibody producing non-human mammals	Merus N.V.	27-Jun-08	29-Apr-14	19-Sep-17
US9765071	Substituted imidazo ring systems and methods	3M INNOVATIVE PROPERTIES COMPANY	25-Nov-03	14-Mar-16	19-Sep-17
US9764027	Outer membrane vesicles	GLAXOSMITHKLINE BIOLOGICALS SA	18-Sep-12	18-Sep-13	19-Sep-17
US9759723	B-cell antigen presenting cell assay	University of Pittsburghâ€"Of the Commonwealth System of Higher Education	8-Apr-10	21-Mar-16	12-Sep-17
US9758840	Parasite detection via endosymbiont detection	IBIS BIOSCIENCES, INC.	14-Mar-10	11-Mar-11	12-Sep-17
US9758820	Organism identification panel	BioFire Diagnostics, LLC	2-Apr-07	1-Apr-08	12-Sep-17
US9758775	TAL effector-mediated DNA modification	Iowa State University Research Foundation, Inc.	10-Dec-09	14-Apr-14	12-Sep-17
US9758568	Oligopeptide-free cell culture media	Baxalta GmbH	4-Jan-06	16-Nov-15	12-Sep-17
US9758553	Yeast strain for the production of proteins with terminal alpha-1,3-linked galactose	MERCK SHARP & DOHME CORP.	30-May-08	2-Jul-14	12-Sep-17
US9757478	Mutant protease biosensors with enhanced detection characteristics	Promega Corporation	11-May-10	7-Jan-16	12-Sep-17
US9757470	Peptides for assisting delivery across the blood brain barrier	Children's Medical Center Corporation	22-May-06	30-Apr-14	12-Sep-17
US9757446	Influenza virus vectors and uses therefor	FLUGEN, INC.	17-Mar-14	13-Mar-15	12-Sep-17
US9757407	Treatment of viral infections by modulation of host cell metabolic pathways	The Trustees of Princeton University	1-Jun-07	21-Dec-15	12-Sep-17
US9751945	Sortase-modified VHH domains and uses thereof	Whitehead Institute for Biomedical Research	13-Apr-12	15-Apr-13	5-Sep-17
US9750798	Bunyaviruses with segmented glycoprotein precursor genes and methods for generating these viruses	STICHTING WAGENINGEN RESEARCH	21-May-13	21-May-14	5-Sep-17
US9750797	Sustained release vaccine composition	VIRBAC CORPORATION	16-Jun-04	16-Jun-05	5-Sep-17
US9750690	Circulation of components during microfluidization and/or homogenization of emulsions	NOVARTIS AG	3-Dec-09	5-Sep-14	5-Sep-17

CC-BY-NC-SA Dr. David E. Martin

US9746985	System and method for detecting, collecting, analyzing, and communicating event-related information	Georgetown University	25-Feb-08	20-Apr-11	29-Aug-17
US9746459	Antigen presenting cell assay	University of Pittsburghâ€"Of the Commonwealth System of Higher Education	8-Apr-10	11-Oct-13	29-Aug-17
US9745306	2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1H-pyrazolo[3,4-D]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl) quinazolin-4(3H)-one derivatives and their use as phosphoinositide 3-kinase inhibitors	Respivert Limited	15-Mar-13	14-Mar-14	29-Aug-17
US9744231	Quality control methods for oil-in-water emulsions containing squalene	NOVARTIS AG	8-Nov-06	27-Aug-13	29-Aug-17
US9744229	Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	4-Apr-08	28-Apr-14	29-Aug-17
US9744183	Nucleic acid prodrugs and methods of use thereof	WAVE LIFE SCIENCES LTD.	6-Jul-09	6-Jul-10	29-Aug-17
US9738894	Short interfering RNA (siRNA) analogues	Roche Innovation Center Copenhagen A/S	21-Mar-03	28-Mar-16	22-Aug-17
US9738624	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	21-Jun-13	20-Jun-14	22-Aug-17
US9737618	Adeno-associated virus (AAV) glades, sequences, vectors containing same, and uses therefor	The Trustees of the University of Pennsylvania	30-Sep-03	20-Jul-15	22-Aug-17
US9737593	Carbon nanotube compositions and methods of use thereof	Yale University	19-Mar-08	15-Mar-13	22-Aug-17
US9730997	Alphavirus vectors for respiratory pathogen vaccines	Novartis Vaccines and Diagnostics, Inc.	21-May-04	20-Aug-14	15-Aug-17
US9730912	Pharmaceutical compounds	ASTEX THERAPEUTICS LIMITED	12-Oct-06	12-Oct-07	15-Aug-17
US9727810	Spatially addressable molecular barcoding	Cellular Research, Inc.	27-Feb-15	26-Feb-16	8-Aug-17
US9726607	Systems and methods for detecting multiple optical signals	GEN-PROBE INCORPORATED	10-Mar-05	3-Mar-14	8-Aug-17
US9725770	Methods and compositions for identification of source of microbial contamination in a sample	The Regents of the University of California	6-Mar-12	6-Mar-13	8-Aug-17
US9725487	Compositions and methods for measles virus inhibition	Autoimmune Technologies, LLC	4-Nov-03	13-May-15	8-Aug-17
US9719106	Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof	The Trustees of the University of Pennsylvania	29-Apr-13	29-Apr-14	1-Aug-17
US9719083	Bioagent detection methods	IBIS BIOSCIENCES, INC.	8-Mar-09	8-Mar-10	1-Aug-17
US9718774	Indole carboxamide derivatives as P2X7 receptor antagonist	IDORSIA PHARMACEUTICALS LTD	12-Dec-12	11-Dec-13	1-Aug-17
US9717755	Method of treating inflammation	Cytosorbents Corporation	1-Apr-10	1-Apr-11	1-Aug-17
US9717749	Production of stable non-polyadenylated RNAs	Massachusetts Institute of Technology	16-Oct-12	16-Oct-13	1-Aug-17
US9717732	Drug combination	VERONA PHARMA PLC	15-Mar-13	17-Mar-14	1-Aug-17
US9714411	Animal protein-free media for cultivation of cells	Baxalta GmbH	29-Oct-04	30-Nov-15	25-Jul-17
US9714283	Compositions and methods for the treatment of immunodeficiency	ADMA BIOLOGICS, INC.	28-Oct-14	2-Jul-15	25-Jul-17
US9714226	Hydrazide containing nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	29-Jul-11	13-Nov-15	25-Jul-17
US9713641	Anti-TIGIT antigen-binding proteins and methods of use thereof	Potenza Therapeutics, Inc.	13-Feb-17	13-Feb-17	25-Jul-17
US9713606	Methods for treating pulmonary emphysema using substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C	Boehringer Ingelheim International GmbH	14-Mar-13	1-Dec-15	25-Jul-17
US9708375	Inhibitory polypeptides specific to WNT inhibitors	Amgen Inc.	15-Mar-13	14-Mar-14	18-Jul-17
US9707278	Methods of modulating immune responses by modifying Akt3 bioactivity	Augusta University Research Institute, Inc.	17-Apr-14	17-Apr-15	18-Jul-17

US9701736	Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection	New York Blood Center, Inc.	20-Oct-10	9-Oct-14	11-Jul-17
US9701638	Therapeutic hydroxyquinolones	Rutgers, The State University of New Jersey	9-Nov-12	8-Nov-13	11-Jul-17
US9700616	Arranging interaction and back pressure chambers for microfluidization	NOVARTIS AG	3-Dec-09	22-Mar-16	11-Jul-17
US9700614	Intranasal vaccination dosage regimen	Eurocine Vaccines AB	17-Dec-12	17-Dec-13	11-Jul-17
US9700558	Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist	VERONA PHARMA PLC	15-Mar-13	17-Mar-14	11-Jul-17
US9696247	Sample fixation and stabilisation	RNASSIST LTD.	1-Mar-13	28-Feb-14	4-Jul-17
US9695445	Method for production of reprogrammed cell using chromosomally unintegrated virus vector	ID Pharma Co., Ltd.	16-Jul-08	29-Jul-15	4-Jul-17
US9695135	Therapeutic catechols	Rutgers, The State University of New Jersey	12-May-14	11-May-15	4-Jul-17
US9695134	3,5-diamino-6-chloro-N-(n-(4-phenylbutyl)carbamimidoyl)pyrazine-2-carboxamide compounds	Parion Sciences, Inc.	17-Dec-12	8-Jan-15	4-Jul-17
US9689018	Mixed cell diagnostic systems for detection of respiratory, herpes and enteric viruses	Diagnostic Hybrids, Inc.	24-Apr-98	4-Aug-14	27-Jun-17
US9688982	Methods and compositions for the treatment of cancer or other diseases	CITY OF HOPE	26-Jan-07	11-Oct-13	27-Jun-17
US9687536	Methods and compositions for intranasal delivery	SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.	15-Apr-10	15-Apr-11	27-Jun-17
US9683256	Biological specimen collection and transport system	Longhorn Vaccines and Diagnostics, LLC	1-Oct-07	15-Dec-15	20-Jun-17
US9683017	Inhibitory peptides of viral infection	UNIVERSITY TENNESSEE RESEARCH FOUNDATION	17-Jul-14	16-Jul-15	20-Jun-17
US9682133	Disrupted adenovirus-based vaccine against drugs of abuse	CORNELL UNIVERSITY	17-Mar-10	17-Mar-11	20-Jun-17
US9677089	Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor	The Trustees of the University of Pennsylvania	17-Dec-01	30-Mar-16	13-Jun-17
US9676867	Chimeric T cell receptor comprising carbonic anhydrase IX (G250) antibody	Dana-Farber Cancer Institute Inc.	2-Dec-05	8-May-13	13-Jun-17
US9676857	Soluble engineered monomeric Fc	The United States of America, as represented by the Secretary, Department of Health and Human Services	16-Mar-12	14-Mar-13	13-Jun-17
US9676727	Myxovirus therapeutics, compounds, and uses related thereto	Children's Healthcare of Atlanta, Inc.	24-Oct-11	7-Jul-16	13-Jun-17
US9675550	Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM	26-Jul-10	25-Jan-13	13-Jun-17
US9670507	Directed evolution and in vivo panning of virus vectors	The University of North Carolina at Chapel Hill	30-Apr-08	28-Jun-16	6-Jun-17
US9670166	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	6-Feb-13	5-Aug-16	6-Jun-17
US9669092	Antagonism of the VIP signaling pathway	Emory University	2-Feb-11	31-Jan-12	6-Jun-17
US9669089	Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen	CureVac AG	15-Feb-12	15-Feb-13	6-Jun-17
US9669088	Vaccination with multiple clades of H5 influenza A virus	Seqirus UK Limited	26-Nov-07	25-Nov-08	6-Jun-17
US9661856	Synergy of plant antimicrobials with silver	The Arizona Board of Regents on Behalf of The University of Arizona	24-Aug-12	26-Aug-13	30-May-17
US9657278	Methods to produce bunyavirus replicon particles	Stichting Dienst Landbouwkundig Onderzoek	20-Sep-10	10-Jul-15	23-May-17
US9657076	GM-CSF and IL-4 conjugates, compositions, and methods related thereto	Children's Healthcare of Atlanta, Inc.	23-Oct-12	23-Oct-13	23-May-17
US9657048	Enantiomers of the 1â€²,6â€²-isomer of neplanocin A	Auburn University	4-Aug-14	4-Aug-15	23-May-17

CC-BY-NC-SA Dr. David E. Martin

US9657015	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	31-Jul-14	27-Jul-15	23-May-17
US9655896	Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity	PARION SCIENCES, INC.	27-Jun-11	12-Jan-15	23-May-17
US9655845	Oil-in-water emulsions that contain nucleic acids	GlaxoSmithKline Biologicals, S.A.	6-Jul-11	6-Jul-12	23-May-17
US9655367	Disinfecting composition and wipes with reduced contact time	LONZA, INC.	6-Nov-13	4-Nov-14	23-May-17
US9651543	Malaria antigen screening method	The United States of America as Represented by the Secretary of the Navy	31-Aug-05	19-Apr-13	16-May-17
US9650685	Selective detection of human rhinovirus	The United States of America, as represented by the Secretary, Department of Health and Human Services	5-Dec-08	15-Dec-14	16-May-17
US9650649	LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus-producing cells for the therapy of tumors	VIRATHERAPEUTICS GMBH	8-Oct-08	8-Oct-09	16-May-17
US9649324	Use of tylvalosin as antiviral agent	CAMBRIDGE UNIVERSITY TECHNICAL SERVICES	13-Jul-06	8-Jun-15	16-May-17
US9649309	Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activity	The University of North Carolina at Chapel Hill	11-Apr-14	3-Apr-15	16-May-17
US9644180	Synthetic membrane-receiver complexes	RUBIUS THERAPEUTICS, INC.	18-Nov-13	12-Jun-15	9-May-17
US9642876	Method of preventing or treating sinusitis with oxidative reductive potential water solution	SONOMA PHARMACEUTICALS, INC.	30-Dec-03	27-Oct-15	9-May-17
US9642873	Combinations of TGFÎ² and COX-2 inhibitors and methods for their therapeutic application	Sirnaomics, Inc.	4-May-10	4-May-11	9-May-17
US9637524	Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector	The Regents of the University of California	27-Feb-09	5-Nov-14	2-May-17
US9637491	Pyrazolo[4,3-D]pyrimidines as kinase inhibitors	ORIGENIS GMBH	19-Oct-12	18-Oct-13	2-May-17
US9636410	Cationic oil-in-water emulsions	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul-11	6-Jul-12	2-May-17
US9636397	Adjuvant compositions and related methods	Vaxliant, LLC	24-Mar-15	24-Mar-16	2-May-17
US9636370	AAV vectors targeted to oligodendrocytes	The University of North Carolina at Chapel Hill	28-Sep-12	27-Sep-13	2-May-17
US9629907	Compositions for and methods of inducing mucosal immune responses	The Trustees of the University of Pennsylvania	19-Nov-04	28-Oct-11	25-Apr-17
US9624173	Heterocyclic modulators of lipid synthesis	3-V Biosciences, Inc.	8-Mar-11	19-Mar-15	18-Apr-17
US9623040	Immunomodulation by controlling expression levels of microRNAs in dendritic cells	The Board of Trustees of the Leland Stanford Junior University	14-Jul-14	10-Jul-15	18-Apr-17
US9618508	Flow cytometry analysis of materials adsorbed to metal salts	GlaxoSmithKline Biologicals SA	14-Dec-10	14-Dec-11	11-Apr-17
US9618476	System and method for electronic biological sample analysis	NANOMEDICAL DIAGNOSTICS, INC.	28-Apr-14	28-Apr-14	11-Apr-17
US9618429	Polymer stabilization of chromogen solutions	Ventana Medical Systems, Inc.	23-Jan-12	18-Jan-13	11-Apr-17
US9611481	Chimeric polynucleotides and polypeptides enabling the secretion of a polypeptide of interest in combination with exosomes and uses thereof	UNIVERSITE DE MONTPELLIER	24-Sep-09	23-Sep-10	4-Apr-17
US9611474	Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof	QUARK PHARMACEUTICALS, INC.	12-Sep-12	12-Sep-13	4-Apr-17
US9605276	Replication defective adenovirus vector in vaccination	Etubics Corporation	24-Aug-12	15-Mar-13	28-Mar-17
US9603864	Substituted nucleosides, nucleotides and analogs thereof	Alios BioPharma, Inc.	24-Jun-14	22-Jun-15	28-Mar-17
US9603850	MerTK-specific pyrazolopyrimidine compounds	The University of North Carolina at Chapel Hill	11-Apr-14	3-Apr-15	28-Mar-17
US9599606	ADP-ribose detection reagents	The Board of Regents of the University of Texas System	10-Jun-14	9-Jun-15	21-Mar-17
US9598459	Pharmaceutical compositions and methods	Pop Test Oncology LLC	3-Aug-15	28-Jul-16	21-Mar-17

US9597333	Benzazepine dicarboxamide compounds	Hoffmann-La Roche Inc.	6-Mar-15	28-Sep-16	21-Mar-17
US9593334	Use of the chromosome 19 microRNA cluster (C19MC) for treating viral disease and promoting authophagy	University of Pittsburghâ€"Of the Commonwealth System of Higher Education	7-Mar-12	6-Mar-13	14-Mar-17
US9593331	Double-stranded nucleic acid molecule for gene expression control	Osaka City University	2-Nov-11	1-Nov-12	14-Mar-17
US9593084	Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity	Parion Sciences, Inc.	17-Dec-12	13-Dec-13	14-Mar-17
US9592284	Immunization regimen with E4-deleted adenovirus prime and E1-deleted adenovirus boost	The Trustees of the University of Pennsylvania	28-Apr-04	27-Apr-05	14-Mar-17
US9592277	Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases	Avirid, Inc.	14-Apr-04	14-Apr-05	14-Mar-17
US9588069	Methods for performing thermal melt analysis	GEN-PROBE INCORPORATED	31-Jul-12	31-Jul-13	7-Mar-17
US9587250	Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor	Trustees of the University of Pennsylvania	17-Dec-01	16-Jan-15	7-Mar-17
US9586998	Methods of propagating monkey adenoviral vectors	GenVec, Inc.	9-Nov-09	4-Aug-15	7-Mar-17
US9586911	Arylalkyl- and aryloxyalkyl-substituted epthelial sodium channel blocking compounds	Parion Sciences, Inc.	13-Dec-13	19-Dec-14	7-Mar-17
US9586910	3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide	Parion Sciences, Inc.	27-Jun-11	18-Dec-13	7-Mar-17
US9585968	Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom	3M Innovative Properties Company	3-Jun-11	14-Aug-15	7-Mar-17
US9585953	Immunogenic compositions in particulate form and methods for producing the same	MUCOSIS B.V.	22-Mar-11	22-Mar-12	7-Mar-17
US9585874	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	9-May-12	6-Jan-16	7-Mar-17
US9585849	Broad spectrum antiviral and methods of use	The Burlington HC Research Group, Inc.	17-Apr-06	17-Apr-07	7-Mar-17
US9580474	Polyionic papilloma virus-like particle (VLP) vaccines	THE JOHNS HOPKINS UNIVERSITY	8-Sep-10	8-Sep-11	28-Feb-17
US9580468	Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells	CENTRE DE INVESTIGACION BIOMEDICA EN RED BIOINGENIERA BIOMATERIALS Y NANOMEDICINA (CIBER BBN)	13-Jan-11	13-Jan-12	28-Feb-17
US9580429	Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy	AstraZeneca AB	6-Dec-04	15-Sep-14	28-Feb-17
US9574189	Enzymatic encoding methods for efficient synthesis of large libraries	Nuevolution A/S	1-Dec-05	1-Dec-06	21-Feb-17
US9574181	Influenza virus reassortment method	Seqirus UK Limited	21-May-10	24-Oct-14	21-Feb-17
US9573955	Compounds	Chiese Farmaceutici S.p.A.	16-Dec-13	16-Dec-14	21-Feb-17
US9573938	Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones	Rutgers, The State University of New Jersey	11-Sep-12	11-Sep-13	21-Feb-17
US9572899	Compositions for enhancing transport of molecules into cells	AVI BIOPHARMA, INC.	29-Apr-03	5-Nov-08	21-Feb-17
US9572864	Compositions and uses of lectins	Emory University	12-Feb-10	11-Dec-15	21-Feb-17
US9572823	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16-Feb-05	5-Apr-16	21-Feb-17
US9567336	Conjugated TLR7 and/or TLR8 and TLR2 agonists	INVIVOGEN	19-Nov-12	15-Mar-13	14-Feb-17
US9566326	Adjuvanted influenza vaccines for pediatric use	Seqirus UK Limited	22-Feb-08	21-Jun-13	14-Feb-17
US9566291	Nutritional composition comprising indigestible oligosaccharides	N.V. Nutricia	24-Aug-04	24-Aug-05	14-Feb-17
US9566290	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16-Feb-05	20-Apr-16	14-Feb-17

US9566289	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16-Feb-05	17-Feb-16	14-Feb-17
US9565857	Antimicrobial solutions	Board of Regents, The University of Texas System	10-Sep-10	9-Sep-11	14-Feb-17
US9562110	Bispecific antibody	Wuhan YZY Biopharma Co., Ltd.	21-Nov-12	21-Nov-12	7-Feb-17
US9561263	Treatment of inflammatory illnesses with ACE2	Apeiron Biologics AG	18-Dec-07	18-Dec-08	7-Feb-17
US9556237	Antiviral rift valley fever virus peptides and methods of use	The United States of America, as represented by the Secretary of the Army, on behalf of the U.S. Army Medical Research Institute of Infectious Diseases	6-Dec-12	4-Jun-15	31-Jan-17
US9556229	Modification of peptides using a bis(thioether)arylbridge approach	The Regents of the University of California	18-May-12	17-May-13	31-Jan-17
US9556184	Phosphoinositide 3-kinase inhibitors	Respivert, Ltd.	15-Mar-13	4-Dec-15	31-Jan-17
US9556117	Indole carboxamide derivatives as P2X7 receptor antagonists	ACTELION PHARMACEUTICALS LTD.	18-Dec-12	17-Dec-13	31-Jan-17
US9555031	Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity	The University of North Carolina at Chapel Hill	11-Apr-14	3-Apr-15	31-Jan-17
US9555030	Therapeutic uses of selected pyrazolopyrimidine compounds with anti-Mer tyrosine kinase activity	The University of North Carolina at Chapel Hill	11-Apr-14	3-Apr-15	31-Jan-17
US9550773	Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines	3M Innovative Properties Company	18-Jun-04	13-Apr-15	24-Jan-17
US9550757	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	5-Mar-10	28-Jun-13	24-Jan-17
US9549949	Antiviral agent	NBC MESHTEC, INC.	3-Sep-08	31-Aug-09	24-Jan-17
US9549938	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16-Feb-05	11-Mar-16	24-Jan-17
US9546371	Chimeric polynucleotides and polypeptides enabling secretion of a polypeptide of interest in association with exosomes and use thereof for the production of immunogenic compositions	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE	18-Mar-08	18-Mar-09	17-Jan-17
US9546184	Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines	3M INNOVATIVE PROPERTIES COMPANY	13-Aug-08	8-Jun-15	17-Jan-17
US9546150	Substituted quinazolin-4-ones for inhibiting ubiquitin specific protease 7	HYBRIGENICS SA	2-Sep-11	29-Aug-12	17-Jan-17
US9545440	Methods for preparing squalene	NOVARTIS AG	12-May-10	23-Oct-15	17-Jan-17
US9540373	Substituted spirocycles	Boehringer Ingelheim International GmbH	12-Sep-14	10-Sep-15	10-Jan-17
US9539321	HMGB1-derived peptides enhance immune response to antigens	The Regents of the University of California	27-Jul-10	9-Mar-15	10-Jan-17
US9539217	Nanoparticle compositions	Allertein Therapeutics, LLC	3-Apr-13	3-Apr-14	10-Jan-17
US9533978	Pyrimidine derivatives and their use in the treatment of cancer and further diseases	Sumitomo Dainippon Pharma Co., Ltd	21-May-09	26-Aug-14	3-Jan-17
US9533037	Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes	Declion Holdings LLC	16-Oct-07	16-Oct-08	3-Jan-17
US9529974	System and method for detecting, collecting, analyzing, and communicating event-related information	Georgetown University	25-Feb-08	27-Jul-11	27-Dec-16
US9527903	Engineered antibody constant domain molecules	The United States of America, as represent by the Secretary, Department of Health and Human Services	31-Jan-08	1-Oct-13	27-Dec-16
US9526803	Diagnostic chewing gum for pathogens	Julius-Maximilians-Universitaet Wuerzburg	8-Mar-12	8-Mar-13	27-Dec-16
US9526700	Composition for inactivating an enveloped virus	VIROBLOCK SA	19-May-06	17-Nov-14	27-Dec-16
US9522962	Peptides, conjugates and method for increasing immunogenicity of a vaccine	Academisch Ziekenhuis Leiden h.o.d.n. LUMC	15-Mar-10	15-Mar-11	20-Dec-16
US9522894	Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors	AstraZeneca AB	24-Jan-14	21-Jan-15	20-Dec-16

CC-BY-NC-SA Dr. David E. Martin

US9522171	EV576 for use in the treatment of viral infections of the respiratory tract	Volution Immuno Pharmaceuticals SA	8-Jan-10	2-Jan-15	20-Dec-16
US9518093	Topical formulation of arginine-rich cyclic antimicrobial peptides	NOVABIOTICS LIMITED	24-Feb-06	9-Nov-15	13-Dec-16
US9518083	Gadd45beta targeting agents	Imperial Innovations Limited	22-Oct-09	10-Feb-15	13-Dec-16
US9517263	Benzonaphthyridine-containing vaccines	GlaxoSmithKline Biologicals SA	10-Jun-09	10-Jun-10	13-Dec-16
US9517205	Soluble needle arrays for delivery of influenza vaccines	Seqirus UK Limited	20-Aug-10	19-Aug-11	13-Dec-16
US9512471	Methods and kits for detecting human papillomavirus	DIACARTA Inc	30-Jun-10	30-Jun-10	6-Dec-16
US9512443	Recombinant expression of multiprotein complexes using polygenes	ETH ZURICH	8-Nov-05	6-Nov-06	6-Dec-16
US9512181	Fusion proteins of ciliate granule lattice proteins, granular protein particles thereof, and uses therefor	Tetragenetics, Inc.	27-May-11	29-May-12	6-Dec-16
US9511070	Heterocyclyl carboxamides for treating viral diseases	NovaDrug, LLC	31-Aug-12	30-Aug-13	6-Dec-16
US9506063	SiRNA compositions and methods for treatment of HPV and other infections	Sirnaomics, Inc.	29-Jul-10	29-Jan-13	29-Nov-16
US9504747	Lipids and lipid compositions for the delivery of active agents	Novartis AG	8-Mar-13	7-Mar-14	29-Nov-16
US9504673	Agent for the prophylaxis and treatment of highly pathogenic infectious diseases	LTD â€œValenta-Intellektâ€	21-May-09	10-May-10	29-Nov-16
US9504255	Physical antimicrobial method	NMS TECHNOLOGIES CO., LTD.	1-Aug-12	16-Jul-13	29-Nov-16
US9499799	Cells and methodology to generate non-segmented negative-strand RNA viruses	Centre National De La Recherche Scientifique	22-Dec-06	15-Oct-13	22-Nov-16
US9499535	Kinase inhibitors	ORIGENIS GMBH	21-Apr-11	23-Apr-12	22-Nov-16
US9499489	Myxovirus therapeutics, compounds, and uses related thereto	Children's Healthcare of Atlanta, Inc.	24-Oct-11	24-Oct-12	22-Nov-16
US9498548	Method of using oxidative reductive potential water solution in dental applications	Oculus Innovative Sciences, Inc.	2-May-05	2-May-06	22-Nov-16
US9498544	Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents	Tissue Regeneration Therapeutics Inc.	21-Apr-08	13-Mar-15	22-Nov-16
US9498527	Vaccine composition	NITTO DENKO CORPORATION	4-Apr-12	3-Apr-13	22-Nov-16
US9494571	Methods of testing for intracellular pathogens	Novartis AG	8-Mar-10	7-Mar-11	15-Nov-16
US9493788	Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor	The Trustees of the University of Pennsylvania	17-Dec-01	16-Jan-15	15-Nov-16
US9493572	GITR antibodies and methods of inducing or enhancing an immune response	GITR, Inc.	25-Mar-05	23-Mar-15	15-Nov-16
US9493518	Compositions and methods for treating clostridium difficile-associated diseases	National Health Research Institutes	14-Mar-13	13-Mar-14	15-Nov-16
US9492528	Influenza virus-like particles (VLPS) comprising hemagglutinin	MEDICAGO INC.	13-Jul-07	2-Jul-09	15-Nov-16
US9492413	Use of salt of an acetylsalicylic acid for the treatment of viral infections	Ventaleon GMBH	14-Jan-08	14-Jan-09	15-Nov-16
US9489495	System and method for detecting, collecting, analyzing, and communicating event-related information	GEORGETOWN UNIVERSITY	25-Feb-08	28-Aug-08	8-Nov-16
US9487838	Oligonucleotide probe for the detection of adenovirus	QIAGEN HAMBURG GMBH	28-Dec-10	28-Dec-10	8-Nov-16
US9487837	Exosome-mediated diagnosis of hepatitis virus infections and diseases	MOREHOUSE SCHOOL OF MEDICINE	6-Oct-08	21-Jan-14	8-Nov-16
US9487778	Oligonucleotide modulators of the toll-like receptor pathway	QUARK PHARMACEUTICALS, INC.	3-Mar-11	1-Mar-12	8-Nov-16
US9487749	Use of methylsulfonylmethane (MSM) to modulate microbial activity	Biogenic Innovations, LLC	30-Oct-09	12-Aug-14	8-Nov-16

US9487528	Compounds	Chiesi Farmaceutici S.p.A.	9-Jun-14	5-Jun-15	8-Nov-16
US9486479	Antimicrobial solutions containing dichloride monoxide and methods of making and using the same	Oculus Innovative Sciences, Inc.	13-Mar-07	21-Jul-14	8-Nov-16
US9481912	Compositions and methods for detecting and identifying nucleic acid sequences in biological samples	Longhorn Vaccines and Diagnostics, LLC	12-Sep-06	8-Oct-13	1-Nov-16
US9481724	hDC-sign binding peptides	Sloan-Kettering Institute for Cancer Research	19-Dec-11	10-Dec-12	1-Nov-16
US9481630	Ingenane-type diterpene compound, and pharmaceutical composition for treating or preventing viral infectious diseases containing same	KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY	19-Oct-11	28-Sep-12	1-Nov-16
US9476090	Signal propagation biomolecules, devices and methods	STC.UNM	21-May-13	21-May-14	25-Oct-16
US9476032	Attenuated viruses useful for vaccines	The Research Foundation for The State University of New York	30-Mar-07	31-Mar-08	25-Oct-16
US9475872	Nucleic acid molecules encoding moonoclonal antibodies speceific for IL17F	ImmunoQure AG	28-Dec-11	2-Jan-13	25-Oct-16
US9475862	Neutralizing GP41 antibodies and their use	The United States of America, as represented by the Secretary, Department of Health and Human Services	7-Nov-11	7-Nov-12	25-Oct-16
US9475832	Phosphonates with reduced toxicity for treatment of viral infections	The Regents of the University of California	14-Apr-10	29-Sep-14	25-Oct-16
US9475804	Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom	3M Innovative Properties Company	3-Jun-11	1-Jun-12	25-Oct-16
US9475779	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	31-Jul-14	27-Jul-15	25-Oct-16
US9475775	Benzazepine dicarboxamide compounds	Hoffmann-La Roche Inc.	6-Mar-15	4-Mar-16	25-Oct-16
US9474844	Methods for pathogen inactivation in blood using UV irradiation while minimizing heat transfer thereto	Hemalux LLC	22-Oct-14	29-Dec-15	25-Oct-16
US9474759	Broad-spectrum antivirals against 3C or 3C-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronaviruses	Kansas State University Research Foundation	27-Sep-11	27-Sep-12	25-Oct-16
US9469876	Circulating biomarkers for metastatic prostate cancer	Caris Life Sciences Switzerland Holdings GmbH	6-Apr-10	6-Apr-11	18-Oct-16
US9464276	Highly efficient influenza matrix (M1) proteins	Novavax, Inc.	11-Jul-03	23-Feb-15	11-Oct-16
US9464123	Peptides having activity of inhibiting infections of respiratory viruses and use of the same	XIANGXUE GROUP (HONG KONG) COMPANY LIMITED	9-May-13	21-Feb-14	11-Oct-16
US9463240	Arranging interaction and back pressure chambers for microfluidization	NOVARTIS AG	3-Dec-09	11-Jul-14	11-Oct-16
US9459247	Quantitative measurement of nano/micro particle endocytosis with cell mass spectrometry	Academia Sinica	29-Mar-10	29-Mar-11	4-Oct-16
US9459233	Amperometric gas sensor	Steris Corporation	25-Jun-12	26-Feb-13	4-Oct-16
US9458492	Methods and cells for identifying RIG-I pathway regulators	Kineta, Inc.	25-Feb-11	23-Feb-12	4-Oct-16
US9458470	Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin	MEDICAGO INC.	21-Jan-08	23-Jan-13	4-Oct-16
US9458184	Compositions of TLR7 and/or TLR8 agonists conjugated to lipids	INVIVOGEN	15-Jun-12	15-Mar-13	4-Oct-16
US9458113	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	31-Jul-14	27-Jul-15	4-Oct-16
US9457074	Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome	Ohio State Innovation Foundation	24-Apr-12	23-Feb-15	4-Oct-16
US9453043	Nucleic acid chemical modifications	ALNYLAM PHARMACEUTICALS, INC.	2-Mar-09	22-Jan-15	27-Sep-16
US9452973	Modulators of the relaxin receptor 1	THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES	4-May-12	15-Mar-13	27-Sep-16
US9452210	Influenza virus-like particles (VLPS) comprising hemagglutinin produced within a plant	MEDICAGO INC.	13-Jul-07	4-Jan-13	27-Sep-16

CC-BY-NC-SA Dr. David E. Martin

US9447462	Methods for concurrent identification and quantification of an unknown bioagent	IBIS BIOSCIENCES, INC.	18-Feb-04	27-Jan-14	20-Sep-16
US9447132	Highly active nucleoside derivative for the treatment of HCV	Achillion Pharmaceuticals, Inc.	12-Apr-13	14-Apr-14	20-Sep-16
US9447097	4-amino-imidazoquinoline compounds	Hoffmann-La Roche Inc.	22-Apr-14	7-Apr-16	20-Sep-16
US9446062	Methods of treating ischemia-reperfusion injury with siRNAs	Quark Pharmaceuticals, Inc.	25-Oct-06	8-Jan-15	20-Sep-16
US9442107	Antibody-nanoparticle conjugates and methods for making and using such conjugates	Ventana Medical Systems, Inc.	27-Apr-10	21-Apr-15	13-Sep-16
US9441247	TC-83-derived alphavirus vectors, particles and methods	ALPHAVAX, INC.	18-May-04	6-Jul-15	13-Sep-16
US9440960	Substituted oxetanes and their use as inhibitors of cathepsin C	Boehringer Ingelheim International GmbH	1-Aug-14	31-Jul-15	13-Sep-16
US9440930	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	31-Jul-14	27-Jul-15	13-Sep-16
US9435795	Enhanced deposition of chromogens utilizing pyrimidine analogs	Ventana Medical Systems, Inc.	30-Dec-10	6-Oct-14	6-Sep-16
US9435000	Primate T-lymphotropic viruses	Johns Hopkins University	21-Feb-05	20-Sep-13	6-Sep-16
US9434997	Methods, compounds and systems for detecting a microorganism in a sample	Lawrence Livermore National Security, LLC	24-Aug-07	21-Aug-08	6-Sep-16
US9434769	Peptide compositions and methods for inhibiting herpesvirus infection	The Administrators of the Tulane Educational Fund	30-Oct-09	9-Jul-14	6-Sep-16
US9433672	Compositions and methods for activating innate and allergic immunity	ID Biomedical Corporation of Quebec	26-Apr-12	28-Apr-14	6-Sep-16
US9430610	Re-sequencing pathogen microarray	The United States of America, as represented by the Secretary of the Navy	2-Jul-04	10-Apr-08	30-Aug-16
US9428739	Norovirus and Sapovirus antigens	NOVARTIS VACCINES AND DIAGNOSTICS, INC.	24-Mar-01	27-Nov-12	30-Aug-16
US9428574	Polypeptides and uses thereof for treatment of autoimmune disorders and infection	COMPUGEN LTD.	30-Jun-11	1-Jul-12	30-Aug-16
US9428571	Antibodies and processes for preparing the same	TAIGA BIOTECHNOLOGIES, INC.	16-May-08	18-Mar-15	30-Aug-16
US9428490	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	29-Jul-11	26-Jul-12	30-Aug-16
US9428439	Hydrobenzamide derivatives as inhibitors of Hsp90	ASTEX THERAPEUTICS LTD.	12-Oct-06	7-Jan-14	30-Aug-16
US9426989	Organic peroxide compounds for microorganism inactivation	NOVARTIS AG	6-May-10	6-May-11	30-Aug-16
US9422367	Antigenic GM-CSF peptides and antibodies to GM-CSF	Morphotek, Inc.	7-Feb-06	26-Nov-13	23-Aug-16
US9421254	Immunostimulatory combinations of TLR ligands and methods of use	The United States of America, as represented by the Secretary, Department of Health and Human Services	24-Sep-07	24-Sep-08	23-Aug-16
US9416416	Biological specimen collection/transport compositions and methods	Longhorn Vaccines and Diagnostics, LLC	1-Oct-07	16-Dec-11	16-Aug-16
US9416409	Capture primers and capture sequence linked solid supports for molecular diagnostic tests	IBIS BIOSCIENCES, INC.	31-Jul-09	30-Jul-10	16-Aug-16
US9416396	Covalently linked thermostable kinase for decontamination process validation	The Secretary of State for Health	20-Feb-08	18-Feb-09	16-Aug-16
US9415392	Slip chip device and methods	The University of Chicago	24-Mar-09	23-Mar-10	16-Aug-16
US9415087	Compositions and methods for treating coronavirus infection	Ludwig-Maximilians-Universitaet Muenchen	11-Mar-14	8-May-15	16-Aug-16
US9415033	Esters of short chains fatty acids for use in the treatment of immunogenic disorders	PROPONENT BIOTECH GMBH	3-Oct-12	3-Oct-13	16-Aug-16
US9409987	Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer	COMPUGEN LTD	15-Apr-11	16-Apr-12	9-Aug-16
US9409917	Heterocyclic amide derivatives as P2X7 receptor antagonists	ACTELION PHARMACEUTICALS LTD.	20-Jan-12	18-Jan-13	9-Aug-16

CC-BY-NC-SA Dr. David E. Martin

US9409870	Compounds	CHIESI FARMACEUTICI S.p.A.	15-Dec-14	27-Nov-15	9-Aug-16
US9408908	Combination adjuvant formulation	Not Available	16-Oct-08	15-Feb-13	9-Aug-16
US9408907	Homogenous suspension of immunopotentiating compounds and uses thereof	GlaxoSmithKline Biologicals SA	15-Dec-09	15-Dec-10	9-Aug-16
US9404160	Methods for the detection of microorganisms	Becton, Dickinson and Company	22-Dec-09	21-Dec-10	2-Aug-16
US9403868	Crystalline tripeptide epoxy ketone protease inhibitors	Onyx Therapeutics, Inc.	20-Mar-09	5-Mar-15	2-Aug-16
US9402921	Directed evolution and in vitro panning of virus vectors	The University of North Carolina at Chapel Hill	30-Apr-08	22-Oct-14	2-Aug-16
US9402878	Depsipeptide and uses thereof	NovoBiotic Pharmaceuticals, LLC	3-Dec-12	1-Jul-15	2-Aug-16
US9402812	Methods for the preparation of liposomes	Indu Javeri	23-Sep-09	23-Sep-10	2-Aug-16
US9394092	Powdered pouch and method of making same	MONOSOL, LLC	16-Apr-12	14-Mar-13	19-Jul-16
US9393564	Bioagent detection systems, devices, and methods	IBIS BIOSCIENCES, INC.	30-Mar-09	30-Mar-10	19-Jul-16
US9393295	Nanoparticles for use in pharmaceutical compositions	Novartis AG	28-Apr-08	28-Apr-09	19-Jul-16
US9393215	Nanoparticles for use in immunogenic compositions	Novartis AG	2-Dec-05	1-Dec-06	19-Jul-16
US9388429	Method for propagating adenoviral vectors encoding inhibitory gene products	GenVec, Inc.	10-Nov-05	28-May-14	12-Jul-16
US9388234	Systems and methods for identifying Replikin Scaffolds and uses of said Replikin Scaffolds	Not Available	6-Jun-03	19-Jun-13	12-Jul-16
US9388198	Heterocyclic amide derivatives as P2X7 receptor antagonists	ACTELION PHARMACEUTICALS LTD.	21-Jan-14	21-Jan-14	12-Jul-16
US9388197	Heterocyclic amide derivatives as P2X7 receptor antagonists	ACTELION PHARMACEUTICALS LTD.	22-Jan-13	21-Jan-14	12-Jul-16
US9387242	Chimeric viruses presenting non-native surface proteins and uses thereof	Icahn School of Medicine at Mount Sinai	2-Dec-05	1-Dec-06	12-Jul-16
US9382590	Methods and compositions for prostate cancer metastasis	FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (FAMU)	25-Mar-11	20-May-15	5-Jul-16
US9382545	CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity	COLEY PHARMACEUTICAL GMBH	27-Sep-06	4-Oct-13	5-Jul-16
US9382288	Derivatives of steroid benzylamines, having an antiparasitic antibacterial, antimycotic and/or antiviral action	Justus-Liebig-Universitat Giessen	6-Oct-10	6-Oct-11	5-Jul-16
US9381244	VISTA modulators for diagnosis and treatment of cancer	KING'S COLLEGE LONDON	7-Sep-12	9-Sep-13	5-Jul-16
US9381239	VLPS derived from cells that do not express a viral matrix or core protein	Novavax, Inc.	25-May-07	14-Apr-14	5-Jul-16
US9381226	Methods and compositions related to inhibition of viral entry	UNIVERSITY OF UTAH RESEARCH FOUNDATION	8-Feb-07	8-Feb-08	5-Jul-16
US9381220	Sceletium extract and uses thereof	H. L. Hall & Sons Limited	20-Mar-09	15-Jul-14	5-Jul-16
US9380785	Antiviral resin member	NBC MESHTEC, INC.	6-Jul-11	6-Jul-12	5-Jul-16
US9376486	Human monoclonal antibody with specificity for Dengue virus serotype 1 E protein and uses thereof	DSO National Laboratories	14-Dec-10	14-Dec-11	28-Jun-16
US9376398	Carboxylic acid compounds	Astrazeneca Aktiebolag	18-May-12	17-May-13	28-Jun-16
US9375465	Conjugates of GM-CSF and IL-7, compositions and methods related thereto	Children's Healthcare of Atlanta, Inc.	14-Nov-11	13-Nov-12	28-Jun-16
US9372156	System for processing contents of a receptacle to detect an optical signal emitted by the contents	GEN-PROBE INCORPORATED	10-Mar-05	22-Feb-11	21-Jun-16
US9371563	Nanoreporters and methods of manufacturing and use thereof	NanoString Technologies, Inc.	23-Dec-05	11-Mar-13	21-Jun-16

US9370582	Carbohydrate conjugates as delivery agents for oligonucleotides	ALNYLAM PHARMACEUTICALS, INC.	4-Dec-07	11-Jul-14	21-Jun-16
US9370581	Carbohydrate conjugates as delivery agents for oligonucleotides	ALNYLAM PHARMACEUTICALS, INC.	4-Dec-07	11-Jul-14	21-Jun-16
US9370570	Polychlorinated biphenyls and squalene-containing adjuvants	Novartis AG	28-Dec-07	10-Dec-13	21-Jun-16
US9370531	Method of providing patient specific immune response in amyloidoses and protein aggregation disorders	New York University	31-Aug-07	1-Sep-08	21-Jun-16
US9365577	Pyrimidinone compounds as human neutrophil elastase inhibitors	Chiesi Farmaceutici S.p.A.	18-Dec-12	17-Dec-13	14-Jun-16
US9365567	Alkoxy substituted imidazoquinolines	3M Innovative Properties Company	3-Oct-03	30-Sep-14	14-Jun-16
US9365523	Imidazolyl amide compounds and uses related thereto	Children's Healthcare of Atlanta, Inc.	31-Mar-11	28-Mar-12	14-Jun-16
US9365506	Compounds and compositions as TLR2 agonists	NOVARTIS AG	23-Mar-10	9-Jul-14	14-Jun-16
US9364511	Antiviral preparations obtained from a natural cinnamon extract	RAMOT AT TEL-AVIV UNIVERSITY LTD.	24-Dec-03	22-Jun-06	14-Jun-16
US9359360	TLR agonists	The Regents of The University of California	22-Aug-05	20-Nov-12	7-Jun-16
US9358280	Decreasing potential iatrogenic risks associated with influenza vaccines	Novartis AG	9-Sep-04	11-Jan-13	7-Jun-16
US9353133	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16-Feb-05	7-Mar-14	31-May-16
US9352048	Carbohydrate conjugates as delivery agents for oligonucleotides	ALNYLAM PHARMACEUTICALS, INC.	4-Dec-07	22-Jul-14	31-May-16
US9347055	Method and kit for preparation of sample for use in nucleic acid amplification	EIKEN KAGAKU KABUSHIKI KAISHA	5-Nov-07	5-Nov-08	24-May-16
US9346866	Inhibition of tace activity with cyclic peptides	The Regents of the University of California	2-Jun-11	19-Sep-14	24-May-16
US9346794	Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	23-Aug-12	29-Dec-15	24-May-16
US9346769	Tetrazolones as inhibitors of fatty acid synthase	Infinity Pharmaceuticals, Inc.	5-May-10	23-Aug-13	24-May-16
US9346753	Dithiol mucolytic agents	PARION SCIENCES, INC.	23-Aug-13	13-Aug-14	24-May-16
US9345760	IPNV-ISAV bivalent vaccine using a virus-like particle-based platform and methods of using the same	Advanced Bionutrition Corporation	9-Sep-11	7-Sep-12	24-May-16
US9340507	Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	23-Aug-12	2-Sep-15	17-May-16
US9339561	Mutant protease biosensors with enhanced detection characteristics	PROMEGA CORPORATION	11-May-10	5-May-14	17-May-16
US9339525	Inhibition of biofilm organisms	Novabiotics Limited	31-Mar-09	31-Mar-10	17-May-16
US9334268	4-amino-imidazoquinoline compounds	HOFFMAN-LA ROCHE INC.	22-Apr-14	22-Apr-15	10-May-16
US9328110	Substituted imidazo ring systems and methods	3M INNOVATIVE PROPERTIES COMPANY	25-Nov-03	11-Mar-14	3-May-16
US9328093	Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applications	HYBRIGENICS SA	15-Jan-10	17-Sep-14	3-May-16
US9326972	Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression	Ohio University	16-Mar-04	9-Feb-12	3-May-16
US9322827	B-cell antigen presenting cell assay	University of Pittsburgh - Of the Commonwealth System of Higher Education	8-Apr-10	8-Apr-11	26-Apr-16
US9321999	Compositions for increasing polypeptide stability and activity, and related methods	SOLIS BIODYNE OÃœ	19-Nov-09	19-Nov-10	26-Apr-16
US9321847	Activatable toxin complexes comprising a cleavable inhibitory peptide	RAMOT at Tel Aviv University Ltd.	20-Sep-10	22-Aug-11	26-Apr-16

CC-BY-NC-SA Dr. David E. Martin

US9321831	RSV-specific binding molecules and means for producing them	MedImmune Limited	1-Jun-07	13-Sep-13	26-Apr-16
US9320784	Peptides shared among lethal cancers and therapeutic compositions comprising said peptides	Not Available	7-Aug-09	19-Jul-12	26-Apr-16
US9320748	Immunologically useful arginine salts	Novartis AG	7-Mar-12	7-Mar-13	26-Apr-16
US9315530	Adsorption of immunopotentiators to insoluble metal salts	Novartis AG	1-Sep-10	1-Sep-11	19-Apr-16
US9310375	Luminophore-labeled molecules coupled with particles for microarray-based assays	CapitalBio Corporation	27-Oct-10	27-Oct-10	12-Apr-16
US9310088	Device and method for reducing spread of microorganisms and airborne health hazardous matter and/or for protection from microorganisms and airborne health hazardous matter	Technical University of Denmark	17-Jul-09	14-Jul-10	12-Apr-16
US9309325	Antibodies and methods of use thereof	The Regents of the University of California	7-May-09	4-May-10	12-Apr-16
US9303068	D-amino acid derivative-modified peptidoglycan and methods of use thereof	The Regents of the University of California	30-Nov-12	27-Nov-13	5-Apr-16
US9303000	Olefin containing nuclear transport modulators and uses thereof	KARYOPHARM THERAPEUTICS INC.	17-Jan-11	16-Jan-12	5-Apr-16
US9297010	Short interfering RNA (siRNA) analogues	Roche Innovation Center Copenhagen A/S	21-Mar-03	11-Feb-14	29-Mar-16
US9295732	Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists	INVIVOGEN	22-Feb-13	22-Feb-13	29-Mar-16
US9295708	Modified release formulations for oprozomib	Onyx Therapeutics, Inc.	24-Oct-12	24-Oct-13	29-Mar-16
US9295646	Cationic oil-in-water emulsions	Novartis AG	6-Jul-10	18-Sep-11	29-Mar-16
US9291628	Direct clone analysis and selection technology	Dublin City University	13-Jul-10	13-Jul-11	22-Mar-16
US9291597	Detecting targets using mass tags and mass spectrometry	VENTANA MEDICAL SYSTEMS, INC.	2-Jul-10	1-Jul-11	22-Mar-16
US9290794	Mutant protease biosensors with enhanced detection characteristics	PROMEGA CORPORATION	11-May-10	12-Nov-12	22-Mar-16
US9290786	Monoclonal antibody production by EBV transformation of B cells	Institute for Research in Biomedicine	26-Feb-03	25-Apr-13	22-Mar-16
US9290760	Modified iRNA agents	ALNYLAM PHARMACEUTICALS, INC.	15-Sep-10	14-Sep-11	22-Mar-16
US9290745	Luciferase biosensor	PROMEGA CORPORATION	10-Oct-03	14-Feb-14	22-Mar-16
US9290545	Compositions and methods for the treatment of viral infections	Dana-Farber Cancer Institute, Inc.	23-Jan-08	23-Jul-10	22-Mar-16
US9290459	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	6-Feb-13	9-Nov-15	22-Mar-16
US9290457	Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	31-Jul-14	27-Jul-15	22-Mar-16
US9289487	II-key/antigenic epitope hybrid peptide vaccines	Antigen Express, Inc.	14-Sep-99	11-Jan-05	22-Mar-16
US9284560	Application of highly conserved domain sequences from viral genome as template to design therapeutic sliRNAs	Biocross Institute of Molecular Medicine (Nantong) Co., Ltd.	19-Sep-11	19-Sep-11	15-Mar-16
US9278128	Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same	The Trustees of the University of Pennsylvania	14-Sep-09	6-Jan-14	8-Mar-16
US9278126	Influenza vaccines with reduced amounts of squalene	Seqirus UK Limited	10-Feb-09	10-Feb-10	8-Mar-16
US9272024	Compositions, comprising improved IL-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same	The Trustees of the University of Pennsylvania	12-Dec-11	11-Dec-12	1-Mar-16
US9271494	Shelf stable, reduced corrosion, ready to use peroxycarboxylic acid antimicrobial compositions	Ecolab USA, Inc.	30-Aug-07	30-Aug-07	1-Mar-16
US9266844	Suppression of SARS replication by SARS helicase inhibitors	The Curators of the University of Missouri	15-Jun-12	17-Jun-13	23-Feb-16

US9266843	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	9-May-12	9-May-13	23-Feb-16
US9265876	Systems and methods for pathogen inactivation in blood using UV irradiation while minimizing heat transfer thereto	Hemalux Technologies LLC	22-Oct-14	22-Oct-14	23-Feb-16
US9260398	Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases	PARION SCIENCES, INC.	29-May-12	9-Dec-14	16-Feb-16
US9255144	Anti-IL-18 antibodies and their uses	MedImmune Limited	20-Dec-10	20-Dec-11	9-Feb-16
US9255140	Adjuvancy and immune potentiating properties of natural products of Onchocerca volvulus	NEW YORK BLOOD CENTER, INC.	15-Jun-04	23-Mar-09	9-Feb-16
US9254315	Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds	Not Available	28-Apr-04	3-Feb-10	9-Feb-16
US9254265	Small liposomes for delivery of immunogen encoding RNA	NOVARTIS AG	31-Aug-10	31-Aug-11	9-Feb-16
US9249427	Recombinant HCMV and RHCMV vectors and uses thereof	Oregon Health & Science University	14-May-10	14-Nov-12	2-Feb-16
US9249195	Reovirus vaccines and methods of use therefor	Vanderbilt University	7-Apr-10	4-Apr-11	2-Feb-16
US9248201	Mutant protease biosensors with enhanced detection characteristics	PROMEGA CORPORATION	11-May-10	5-May-14	2-Feb-16
US9248178	Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimens	Not Available	8-Jun-09	8-Jun-10	2-Feb-16
US9242980	Lipidated immune response modifier compound compositions, formulations, and methods	3M Innovative Properties Company	17-Aug-10	16-Aug-11	26-Jan-16
US9238809	Compositions, methods, and kits for isolating and analyzing nucleic acids using an anion exchange material	QIAGEN GAITHERSBURG, INC.	24-Sep-09	5-Aug-10	19-Jan-16
US9234175	Creating bioengineered lymph nodes	H. Lee Moffitt Cancer Center and Research Institute, Inc.	17-Nov-09	16-Nov-10	12-Jan-16
US9233148	Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenza	Not Available	9-Jan-09	16-Oct-09	12-Jan-16
US9227977	Phosphoinositide 3-kinase inhibitors	Respivert Ltd.	15-Mar-13	14-Mar-14	5-Jan-16
US9222075	Animal protein-free media for cultivation of cells	Baxalta GmbH	29-Oct-04	2-May-14	29-Dec-15
US9221832	Heterocyclic amide derivatives as P2X7 receptor antagonists	ACTELION PHARMACEUTICALS LTD.	22-Jul-11	20-Jul-12	29-Dec-15
US9221807	Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	21-Feb-14	12-Feb-15	29-Dec-15
US9220768	Decreasing potential iatrogenic risks associated with influenza vaccines	Novartis AG	9-Sep-04	14-Oct-11	29-Dec-15
US9217745	Arrayed detector system for measurement of influenza immune response	University of Rochester	2-May-08	11-Jul-13	22-Dec-15
US9217157	Recombinant influenza viruses and uses thereof	Icahn School of Medicine at Mount Sinai	27-Jul-09	27-Jul-10	22-Dec-15
US9216192	Toll-like receptor agonist formulations and their use	VentiRx Pharmaceuticals, Inc.	1-Aug-08	16-Jul-12	22-Dec-15
US9213027	Lipoparticles comprising proteins, methods of making, and using the same	Integral Molecular, Inc.	30-Jul-03	1-Nov-13	15-Dec-15
US9212399	Biological specimen collection and transport system and method of use	Longhorn Vaccines and Diagnostics, LLC	1-Oct-07	7-Jan-14	15-Dec-15
US9212205	Nucleic acid binding compounds and methods of use	University of Rochester	26-Jul-07	28-Jul-08	15-Dec-15
US9206396	Methods and devices for quantitative viral assays	Wisconsin Alumni Research Foundation	16-Nov-05	16-Nov-06	8-Dec-15
US9206158	Hydrazide containing nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	29-Jul-11	10-Jun-15	8-Dec-15
US9200329	Rapid epidemiologic typing of bacteria	BioFire Diagnostics, LLC	19-May-08	18-May-09	1-Dec-15

CC-BY-NC-SA Dr. David E. Martin

US9200287	Phosphate-modified oligonucleotide analogs with enhanced immunostimulatory activity	AdiuTide Pharmaceuticals GmbH	18-May-07	15-May-08	1-Dec-15
US9200280	Methods and compositions for the treatment of cancer or other diseases	CITY OF HOPE	26-Jan-07	9-Jun-14	1-Dec-15
US9200279	Methods and compositions for the treatment of cancer or other diseases	CITY OF HOPE	26-Jan-07	14-Jan-14	1-Dec-15
US9200074	Antibodies to IL-1 R1 and methods of making them	MEDIMMUNE LIMITED	7-Nov-08	16-Apr-14	1-Dec-15
US9199981	Compounds and compositions as C-kit kinase inhibitors	NOVARTIS AG	1-Sep-11	27-Aug-12	1-Dec-15
US9199897	Methods for preparing squalene	NOVARTIS AG	12-May-10	12-May-11	1-Dec-15
US9198927	Targeting opposite strand replication intermediates of single-stranded viruses by RNAI	ALNYLAM PHARMACEUTICALS, INC.	24-Sep-04	1-Mar-10	1-Dec-15
US9193780	Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases	Ablynx N.V.	5-Jun-08	5-Jun-09	24-Nov-15
US9192661	Delivery of self-replicating RNA using biodegradable polymer particles	Novartis AG	6-Jul-10	7-Jun-11	24-Nov-15
US9187748	Compositions and methods for silencing ebola virus gene expression	Not Available	20-Jul-09	28-Mar-14	17-Nov-15
US9187426	Organic compounds	Novartis AG	27-Jun-08	25-Jun-09	17-Nov-15
US9186419	Directed evolution and in vitro panning of virus vectors	The University of North Carolina at Chapel Hill	30-Apr-08	17-Jan-14	17-Nov-15
US9186399	Immune stimulatory oligonucleotide analogs containing modified sugar moieties	AdiutTide Pharmaceuticals GmbH	9-Oct-07	29-Sep-08	17-Nov-15
US9181303	Treatment of bacterial infections with cyclic antimicrobial peptides	NovaBiotics Limited	22-Dec-05	20-Jun-14	10-Nov-15
US9181290	Inhibition of biofilm formation by 1,2,3,4,6-penta-O-galloyl-D-glucopyranose	CHANG GUNG UNIVERSITY	17-Jun-11	19-Sep-11	10-Nov-15
US9175047	Peptidomimetic macrocycles	Aileron Therapeutics, Inc.	14-Jan-09	14-Jan-10	3-Nov-15
US9174925	Phorbol type diterpene compound, pharmaceutical composition for treatment or prevention of viral infectious diseases including same	KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY	26-Oct-11	28-Sep-12	3-Nov-15
US9169318	Neutralizing molecules to viral antigens	Sea Lane Biotechnologies, Inc.	28-Mar-08	18-Jul-11	27-Oct-15
US9168318	Oxidative reductive potential water solution and methods of using the same	Oculus Innovative Sciences, Inc.	30-Dec-03	11-Aug-04	27-Oct-15
US9168299	Methods for treating juvenile arthritis with ant-bile salt-stimulated lipase (BSSL) antibodies	LIPUM AB	8-Apr-09	30-Oct-13	27-Oct-15
US9168269	Inhibitors of long and very long chain fatty acid metabolism as broad spectrum anti-virals	THE TRUSTEES OF PRINCETON UNIVERSITY	18-Feb-10	18-Feb-11	27-Oct-15
US9163222	Mutations in OAS1 genes	Kineta Two, LLC	4-May-05	14-Nov-12	20-Oct-15
US9163065	Depsipeptide and uses thereof	NovoBiotic Pharmaceuticals, LLC	3-Dec-12	3-Dec-13	20-Oct-15
US9161976	Immunotherapy comprising TLR9 ligand and CD40 ligand	Trustees of Dartmouth College	30-Dec-02	22-Oct-12	20-Oct-15
US9156811	N-myristoyl transferase inhibitors	Univeristy of Dundee	2-Sep-08	29-Aug-09	13-Oct-15
US9155309	Virus inactivating sheet	NBC MESHTEC, INC.	2-Oct-09	4-Oct-10	13-Oct-15
US9149473	Targeted whole genome amplification method for identification of pathogens	IBIS BIOSCIENCES, INC.	14-Sep-06	14-Sep-07	6-Oct-15
US9149445	Inhibition of glycerol-3-phosphate acyltransferase (GPAT) and associated enzymes for treatment of viral infections	THE TRUSTEES OF PRINCETON UNIVERSITY	27-Jul-09	27-Jul-10	6-Oct-15
US9145588	Generation of binding molecules	MERUS BIOPHARMACEUTICALS B.V.	26-Sep-11	26-Sep-12	29-Sep-15

CC-BY-NC-SA Dr. David E. Martin

US9145585	Method for using permuted nucleic acid probes	Ventana Medical Systems, Inc.	1-Sep-06	5-Aug-14	29-Sep-15
US9145410	Pyrazolopyridines and analogs thereof	3M Innovative Properties Company	3-Oct-03	26-Jan-12	29-Sep-15
US9144575	Anti-viral azide containing compounds	LIFE TECHNOLOGIES CORPORATION	28-Jul-10	28-Jul-11	29-Sep-15
US9139833	Modified small interfering RNA molecules and methods of use	Arrowhead Research Corporation	26-Jul-02	12-Mar-13	22-Sep-15
US9139647	Diagnosis and treatment of cancer using anti-TM4SF20 antibody	FORERUNNER PHARMA RESEARCH CO., LTD.	25-Dec-08	25-Dec-09	22-Sep-15
US9139620	Feline morbillivirus and uses thereof	THE GOVERNMENT OF THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE'S REPUBLIC OF CHINA	20-Jan-12	22-Jan-13	22-Sep-15
US9138472	CD40L vaccines, compositions, and methods related thereto	EMORY UNIVERSITY	28-Sep-10	28-Sep-11	22-Sep-15
US9134247	Method and apparatus for two-step surface-enhanced raman spectroscopy	REAL-TIME ANALYZERS, INC.	16-Dec-11	16-Dec-11	15-Sep-15
US9133248	Methods of propagating monkey adenoviral vectors	GenVec, Inc.	9-Nov-09	9-Nov-10	15-Sep-15
US9132423	Sample-to-answer microfluidic cartridge	Micronics, Inc.	29-Jan-10	28-Jan-11	15-Sep-15
US9132175	Bacillus based delivery system and methods of use	The Curators of the University of Missouri	18-Apr-11	18-Apr-11	15-Sep-15
US9128101	Biomarkers for theranostics	Caris Life Sciences Switzerland Holdings GmbH	1-Mar-10	1-Mar-11	8-Sep-15
US9127256	Method for production of reprogrammed cell using chromosomally unintegrated virus vector	DNAVEC CORPORATION	16-Jul-08	16-Jul-09	8-Sep-15
US9127251	Means and methods for influencing the stability of antibody producing cells	ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM	9-Dec-05	8-Dec-06	8-Sep-15
US9127028	Substrates for chromogenic detection and methods of use in detection assays and kits	Ventana Medical Systems, Inc.	16-Aug-10	12-Aug-11	8-Sep-15
US9125952	Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes	Industry Academic Cooperation Foundation, Hallym University	17-Jul-09	13-Aug-14	8-Sep-15
US9115093	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	4-Mar-13	20-Feb-14	25-Aug-15
US9115065	Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with Arenaviruses	Kineta, Inc.	6-Dec-04	26-Feb-13	25-Aug-15
US9109199	Methods to produce bunyavirus replicon particles	STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK	20-Sep-10	20-Sep-11	18-Aug-15
US9107970	Method and a filter for capturing airborne agents	Not Available	15-Jul-08	13-Jul-09	18-Aug-15
US9107958	Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom	3M Innovative Properties Company	3-Jun-11	1-Jun-12	18-Aug-15
US9107906	Compositions and methods for the treatment of immunodeficiency	ADMA BIOLOGICS, INC.	28-Oct-14	8-Jan-15	18-Aug-15
US9107904	Immunostimulatory compositions and methods of use thereof	Massachusetts Institute of Technology	5-Apr-12	15-Mar-13	18-Aug-15
US9102938	2â€² and 5â€² modified monomers and oligonucleotides	ALNYLAM PHARMACEUTICALS, INC.	31-Mar-11	31-Mar-11	11-Aug-15
US9102911	High density self-contained biological analysis	BioFire Diagnostics, LLC	15-May-09	28-Jan-13	11-Aug-15
US9102741	GAS57 mutant antigens and GAS57 antibodies	Novartis AG	12-Sep-07	13-Oct-14	11-Aug-15
US9102740	Cna-B domain antigens in vaccines against gram positive bacteria	NOVARTIS AG	12-Jan-09	7-Jun-13	11-Aug-15
US9102633	Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds	Parion Sciences, Inc.	13-Dec-13	13-Dec-13	11-Aug-15
US9102624	Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	23-Aug-12	20-Aug-13	11-Aug-15

CC-BY-NC-SA Dr. David E. Martin

US9101597	Immunoprotective primary mesenchymal stem cells and methods	Autoimmune Technologies, LLC	14-Mar-13	14-Mar-13	11-Aug-15
US9101582	Use of a pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a pathogen	The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention	31-Jul-08	27-Mar-13	11-Aug-15
US9096585	Antiviral compounds and uses thereof	Icahn School of Medicine at Mount Sinai	28-May-10	31-May-11	4-Aug-15
US9096543	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	9-May-12	9-May-13	4-Aug-15
US9090897	Production of IFN-lambda by conventional dendritic cells	Bavarian Nordic A/S	18-Dec-09	17-Dec-10	28-Jul-15
US9085641	Peptides regulating the surface expression of the T cell receptor	Max-Delbruck-Centrum Fur Molekulare Medizin	23-Jun-06	23-Jun-07	21-Jul-15
US9084808	Modified small interfering RNA molecules and methods of use	Arrowhead Research Corporation	1-Oct-04	9-May-14	21-Jul-15
US9084758	Antiviral compositions comprising ethanol extract of Tetracera scandens and use thereof	The Catholic University of Korea Industry-Academic Cooperation Foundation	24-Jul-12	25-Aug-14	21-Jul-15
US9080209	Non-mass determined base compositions for nucleic acid detection	IBIS BIOSCIENCES, INC.	6-Aug-09	6-Aug-10	14-Jul-15
US9080204	Compositions and methods for rapid, real-time detection of influenza a virus (H1N1) Swine 2009	Longhorn Vaccines and Diagnostics, LLC	12-Sep-06	30-Dec-11	14-Jul-15
US9079965	Bispecific antibody	Wuhan YZY Biopharma Co., LTD.	21-Nov-12	13-Mar-14	14-Jul-15
US9079943	TC-83-derived alphavirus vectors, particles and methods	ALPHAVAX, INC.	18-May-04	28-Mar-14	14-Jul-15
US9079865	Hydrazide containing nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	29-Jul-11	29-Jul-12	14-Jul-15
US9078885	Respiratory disease treatment	Pulmagen Therapeutics (Inflammation) Limited	7-Aug-08	7-Apr-14	14-Jul-15
US9078868	Therapeutic agent for accelerating recovery of animal under medical treatment	DAIICHI SANKYO COMPANY, LIMITED	15-Jan-10	14-Jan-11	14-Jul-15
US9073869	Method of using substituted 2-Aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C	Boehringer Ingelheim International GmbH	14-Mar-13	11-Sep-14	7-Jul-15
US9072738	Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity	PARION SCIENCES, INC.	27-Jun-11	27-Jun-12	7-Jul-15
US9072726	Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution	Oculus Innovative Sciences, Inc.	20-Jan-06	21-Dec-09	7-Jul-15
US9072702	Reverse genetics using non-endogenous pol I promoters	Novartis AG	21-May-09	21-May-10	7-Jul-15
US9067873	Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses	Kineta Four, LLC	6-Dec-04	19-Dec-13	30-Jun-15
US9066964	Use of tylvalosin as antiviral agent	Cambridge University Technical Services	13-Jul-06	13-Jul-07	30-Jun-15
US9063150	Method for detection of antigen-specific antibodies in biological samples	The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control Prevention	2-Sep-08	25-Aug-09	23-Jun-15
US9061001	Combination adjuvant formulation	Dalhousie University	16-Oct-08	15-Oct-09	23-Jun-15
US9056900	Compositions and methods for coronavirus inhibition	Autoimmune Technologies, LLC.	4-Nov-03	8-Aug-13	16-Jun-15
US9056898	Attenuated RNA virus and applications thereof	Washington University	20-Sep-07	22-Sep-08	16-Jun-15
US9056071	Compounds and methods for preventing or treating a viral infection	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)	2-Nov-07	19-Jun-13	16-Jun-15
US9051619	Methods and compositions for prostate cancer metastasis	FLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (FAMU)	25-Mar-11	23-Mar-12	9-Jun-15
US9051564	Compositions for and methods of identifying antigens	President and Fellows of Harvard College	21-Feb-06	21-Feb-07	9-Jun-15
US9051353	Crystalline tripeptide epoxy ketone protease inhibitors	Onyx Therapeutics, Inc.	20-Mar-09	24-Sep-13	9-Jun-15

CC-BY-NC-SA Dr. David E. Martin

US9050376	Conjugates of synthetic TLR agonists and uses therefor	The Regents of the University of California	7-Feb-07	19-Jun-14	9-Jun-15
US9046523	Rapid bioluminescence detection system	THE SECRETARY OF STATE FOR HEALTH	7-Jan-09	2-Aug-13	2-Jun-15
US9045855	Anti-viral member	NBC Meshtec, Inc.	26-Dec-08	28-Dec-09	2-Jun-15
US9045727	Virus-like particles, methods of preparation, and immunogenic compositions	EMORY UNIVERSITY	17-May-02	4-Apr-06	2-Jun-15
US9045472	Imidazoquinoline compounds	ASTRAZENECA AB	16-Dec-10	16-Dec-11	2-Jun-15
US9045470	Compounds and compositions as TLR activity modulators	IRM LLC	2-Sep-09	1-Sep-10	2-Jun-15
US9044420	Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses	IMMUNE DESIGN CORP.	8-Apr-11	6-Apr-12	2-Jun-15
US9040310	Antibody-nanoparticle conjugates and methods for making and using such conjugates	Ventana Medical Systems, Inc.	27-Apr-10	27-Apr-11	26-May-15
US9034646	Virally-inactivated growth factors-containing platelet lysate depleted of PDGF and VEGF and preparation method thereof	ZHENG YANG BIOMEDICAL TECHNOLOGY CO., LTD.	25-May-10	26-Nov-12	19-May-15
US9034313	Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the same	Inovio Pharmaceuticals, Inc.	8-Feb-10	8-Feb-11	19-May-15
US9029413	Treatment of viral infections by modulation of host cell metabolic pathways	The Trustees of Princeton University	1-Jun-07	3-Apr-12	12-May-15
US9029382	3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds	Parion Sciences, Inc.	17-Dec-12	13-Dec-13	12-May-15
US9029315	Soluble PD-1 variants, fusion constructs, and uses thereof	The University of Hong Kong	11-Nov-10	11-Nov-11	12-May-15
US9028841	Synergistic bacterial compositions and methods of production and use thereof	Seres Health, Inc.	23-Nov-12	20-Mar-14	12-May-15
US9028837	Methods and compositions for poxvirus A35R protein	East Carolina University	7-Jun-12	20-Dec-12	12-May-15
US9028823	Methods of inducing or enhancing an immune response in a subject by administering agonistic GITR binding antibodies	GITR, Inc.	25-Mar-05	1-Mar-13	12-May-15
US9024001	Alphavirus replicon packaging constructs	Novartis Vaccines and Diagnostics, Inc.	25-May-04	20-May-05	5-May-15
US9023855	Compounds	Chiesi Farmaceutici S.p.A.	14-Sep-11	11-Feb-14	5-May-15
US9023839	Compounds and compositions as c-kit kinase inhibitors	IRM LLC	1-Sep-11	22-Apr-14	5-May-15
US9017699	Adjuvancy and immune potentiating properties of natural products of Onchocerca volvulus	New York Blood Center, Inc.	15-Jun-04	18-Feb-10	28-Apr-15
US9017696	Adenovirus vectors	Isis Innovation Limited	10-Apr-07	10-Apr-08	28-Apr-15
US9012622	Compositions and methods using siRNA molecules and siRNA cocktails for the treatment of breast cancer	Not Available	31-Dec-08	31-Dec-09	21-Apr-15
US9011767	Transportable vacuum assisted decontamination unit and decontamination process	STERIS Inc.	1-Apr-13	31-Mar-14	21-Apr-15
US9006264	Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines	3M Innovative Properties Company	18-Jun-04	9-Sep-13	14-Apr-15
US9006194	Compositions and methods for diminishing viral infection and inflammation associated with viral infection	Drexel University	19-Dec-08	17-Dec-09	14-Apr-15
US9005974	Means and methods for influencing the stability of cells	Academish Medisch Centrum Bij de Universiteit van Amsterdam	9-Dec-05	9-Dec-05	14-Apr-15
US9005665	Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome	Ohio State Innovation Foundation	24-Apr-12	24-Apr-13	14-Apr-15
US9005599	Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agents	Tissue Regeneration Therapeutics Inc.	21-Apr-08	20-Apr-09	14-Apr-15
US8999996	Hydrazide containing nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	29-Jul-11	19-Mar-14	7-Apr-15

CC-BY-NC-SA Dr. David E. Martin

US8999975	Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C	Boehringer Ingelheim International GmbH	19-Sep-11	14-Sep-12	7-Apr-15
US8999678	Method of increasing the function of an AAV vector	The Trustees of the University of Pennsylvania	7-Apr-05	7-Apr-06	7-Apr-15
US8999349	HMGB1-derived peptides enhance immune response to antigens	The Regents of the University of California	27-Jul-10	27-Jul-11	7-Apr-15
US8999316	Antiviral compounds	Long Island University	30-May-07	30-May-08	7-Apr-15
US8993717	Gadd45beta targeting agents	Imperial Innovations Limited	22-Oct-09	22-Oct-10	31-Mar-15
US8993581	Methods for treating viral disorders	Trustees of Boston University	24-Sep-09	11-Jun-13	31-Mar-15
US8993295	Methods, compositions, and kits for the selective activation of protoxins through combinatorial targeting	The General Hospital Corporation	20-Jul-06	20-Jul-07	31-Mar-15
US8992939	Highly efficient influenza matrix (M1) proteins	Novavax, Inc.	11-Jul-03	24-Oct-11	31-Mar-15
US8987249	Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C	Boehringer Ingelheim International GmbH	14-Mar-13	12-Mar-14	24-Mar-15
US8987191	Bioactive peptides and methods of using same	Compugen Ltd.	12-Jul-07	21-Jun-13	24-Mar-15
US8986933	Selective detection of human rhinovirus	The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control	5-Dec-08	5-Dec-08	24-Mar-15
US8986926	Compositions comprising oriented, immobilized macromolecules and methods for their preparation	NanoString Technologies, Inc.	23-Dec-05	22-Dec-06	24-Mar-15
US8986702	Antibodies and processes for preparing the same	Taiga Biotechnologies, Inc.	16-May-08	18-May-09	24-Mar-15
US8980898	Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases	Parion Sciences, Inc.	29-May-12	29-May-13	17-Mar-15
US8980338	Sceletium extract and uses thereof	H.L. Hall & Sons Limited	20-Mar-09	16-Mar-10	17-Mar-15
US8980281	High-yield transgenic mammalian expression system for generating virus-like particles	Academia Sinica	5-Sep-06	12-Feb-10	17-Mar-15
US8975389	Nucleic acid chemical modifications	Alnylam Pharmaceuticals, Inc.	2-Mar-09	2-Mar-10	10-Mar-15
US8969362	9-substituted 8-oxoadenine compound	AstraZeneca Aktiebolag	26-Mar-04	21-Oct-13	3-Mar-15
US8969350	Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient	Astrazeneca AB	18-Dec-08	17-Dec-09	3-Mar-15
US8962580	Chemical modifications of monomers and oligonucleotides with cycloaddition	Alnylam Pharmaceuticals, Inc.	23-Sep-08	23-Sep-09	24-Feb-15
US8962332	Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor	The Trustees of the University of Pennsylvania	17-Dec-01	13-Sep-13	24-Feb-15
US8962330	Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor	The Trustees of the University of Pennsylvania	17-Dec-01	31-Oct-07	24-Feb-15
US8961983	Mucosal vaccine using cationic nanogel	National University Corporation Tokyo Medical and Dental University	31-Oct-08	5-Sep-14	24-Feb-15
US8961477	Delivery of immune response modifier compounds	3M Innovative Properties Company	25-Aug-03	25-Aug-04	24-Feb-15
US8956863	Agents from cells	The Brigham and Women's Hospital, Inc.	15-Oct-09	15-Oct-10	17-Feb-15
US8956616	Constructs binding to phosphatidylserine and their use in disease treatment	Board of Regents, The University of Texas System	24-Jan-05	24-Jan-06	17-Feb-15
US8951768	Mutations in OAS1 genes	Kineta Two, LLC	4-May-05	11-Jul-11	10-Feb-15
US8951528	Immune response modifier conjugates	3M Innovative Properties Company	22-Feb-06	21-Feb-07	10-Feb-15
US8945943	Personal glucose meters for detection and quantification of a broad range of analytes	The Board of Trustees of the University of Illinois	26-May-10	26-May-11	3-Feb-15
US8945904	Influenza virus reassortment	Novartis AG	21-May-10	20-May-11	3-Feb-15

US8945610	Condensation products based on bicyclic or polycyclic aromatics or heteroaromatics	BASF SE	14-Nov-07	11-Nov-08	3-Feb-15
US8940864	Stabilized therapeutic small helical antiviral peptides	New York Blood Center, Inc.	5-Oct-06	2-Oct-07	27-Jan-15
US8940501	Methods for ligation and uses thereof	Whitehead Institute for Biomedical Research	30-Jan-09	1-Feb-10	27-Jan-15
US8937154	Stabilized therapeutic small helical antiviral peptides	New York Blood Center, Inc.	5-Oct-06	2-Feb-12	20-Jan-15
US8933210	Label-free functional nucleic acid sensors for detecting target agents	The Board of Trustees of the University of Illinois	6-Oct-10	6-Oct-11	13-Jan-15
US8933019	Antiviral cell-penetrating peptides	New York Blood Center, Inc.	6-May-08	31-Oct-12	13-Jan-15
US8916552	Pharmaceutical combinations	Astex Therapeutics Limited	12-Oct-06	12-Oct-07	23-Dec-14
US8916340	Method for identifying and validating dominant T helper cell epitopes using an HLA-DM-assisted class II binding assay	The John Hopkins University	6-Jan-06	8-Jan-07	23-Dec-14
US8906872	Antisense antiviral compound and method for treating ssRNA viral infection	Sarepta Therapeutics, Inc.	16-Sep-04	22-Dec-11	9-Dec-14
US8906863	Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector	The Regents of the University of California	27-Feb-09	1-Sep-11	9-Dec-14
US8906862	Multiple antigen delivery system using hepatitis E virus-like particle	National Institute of Infectious Disease	27-Feb-09	29-Aug-11	9-Dec-14
US8901071	Compounds and their use	Novabiotics Limited	31-Mar-10	30-Mar-11	2-Dec-14
US8900585	Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infection	New York Blood Center, Inc.	20-Oct-10	20-Oct-11	2-Dec-14
US8895629	Circulation of components during homogenization of emulsions	Novartis AG	3-Dec-09	3-Dec-10	25-Nov-14
US8895577	Compounds and compositions as TLR activity modulators	Not Available	3-Mar-08	22-Apr-13	25-Nov-14
US8895570	Purine derivatives	AstraZeneca AB	17-Dec-10	14-Dec-11	25-Nov-14
US8895534	Boron containing small molecules	Anacor Pharmaceuticals, Inc.	20-Jun-07	30-Jul-10	25-Nov-14
US8895295	High density self-contained biological analysis	Biofire Diagnostics, LLC	15-Nov-06	14-Nov-07	25-Nov-14
US8889708	Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C	Boehringer Ingelheim International GmbH	14-Mar-13	12-Mar-14	18-Nov-14
US8889692	Pyrazinone derivatives, pharmaceutically acceptance salts thereof and their uses	AstraZeneca AB	27-Jun-07	14-Sep-12	18-Nov-14
US8889656	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16-Feb-05	30-Apr-13	18-Nov-14
US8889398	Composition for inactivating an enveloped virus	Viroblock SA	19-May-06	18-May-07	18-Nov-14
US8889181	Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopes	Industry Academic Cooperation Foundation, Hallym University	17-Jul-09	16-Jun-10	18-Nov-14
US8889118	Anticancer agent containing dendritic cell having RNA virus transferred thereinto	DNA VEC Research Inc.	24-Jun-04	28-Apr-05	18-Nov-14
US8889117	Modular nanoparticles for adaptable vaccines	Yale University	15-Feb-07	15-Feb-08	18-Nov-14
US8884020	Indole compounds	Ironwood Pharmaceuticals, Inc.	7-Aug-06	7-Aug-07	11-Nov-14
US8883790	Pharmaceutical combinations	Astex Therapeutics Limited	12-Oct-06	12-Oct-07	11-Nov-14
US8883500	Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherapy	Northeastern University	5-Dec-08	7-Dec-09	11-Nov-14
US8883481	Reverse genetics methods for virus rescue	Novartis AG	20-Oct-09	20-Oct-10	11-Nov-14
US8883477	Oligoadenylate synthetase (OAS)	Kineta Two, LLC	23-Nov-05	14-Jun-13	11-Nov-14

CC-BY-NC-SA Dr. David E. Martin

US8882484	Methods and compositions for production of recombinant protein in HBX-expressing mammalian cells	Bayer HealthCare LLC	28-May-08	27-May-09	11-Nov-14
US8881040	System and method for detecting, collecting, analyzing, and communicating event-related information	Georgetown University	28-Aug-08	2-Dec-09	4-Nov-14
US8877775	Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C	Boehringer Ingelheim International GmbH	14-Mar-13	12-Mar-14	4-Nov-14
US8877187	Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseases	Avianax, LLC	25-Jul-05	23-Nov-10	4-Nov-14
US8877060	Methods for removing pathogens from a platelet preparation	Biovec Transfusion, LLC	23-Nov-10	31-Oct-11	4-Nov-14
US8871816	Methods for producing vaccine adjuvants	Novartis AG	3-Dec-09	3-Dec-10	28-Oct-14
US8871790	Heterocyclic modulators of lipid synthesis	3-V Biosciences, Inc.	8-Mar-11	8-Mar-12	28-Oct-14
US8871783	Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano-methyl)-amides inhibitors of cathepsin C	Boehringer Ingelheim International GmBh	14-Mar-13	12-Mar-14	28-Oct-14
US8871782	Alkoxy substituted imidazoquinolines	3M Innovative Properties Company	3-Oct-03	1-Oct-04	28-Oct-14
US8871503	Construct	Isis Innovation Limited	28-Mar-06	28-Mar-07	28-Oct-14
US8871487	Compositions, methods and uses for inducing viral growth	Takeda Vaccines, Inc.	5-Dec-08	4-Dec-09	28-Oct-14
US8871442	Enhanced deposition of chromogens	Ventana Medical Systems, Inc.	30-Dec-10	28-Dec-11	28-Oct-14
US8865865	N-terminally modified tetrapeptide derivatives having a C-terminal arginine mimetic	Philipps-Universitat Marburg	29-Oct-08	29-Oct-09	21-Oct-14
US8865166	Antibodies to IL-17A and uses thereof	MedImmune Limited	23-Jun-06	22-Jun-07	21-Oct-14
US8859568	Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapy	Astrazeneca AB	6-Dec-04	3-Nov-10	14-Oct-14
US8859251	Oligoadenylate synthetase (OAS)	Kineta Two, LLC	23-Nov-05	1-Jul-13	14-Oct-14
US8858958	Adjuvant comprising aluminum, oligonucleotide and polycation	Novartis AG	27-Aug-09	27-Aug-10	14-Oct-14
US8858957	GAS57 mutant antigens and GAS57 antibodies	Novartis AG	12-Sep-07	14-Mar-13	14-Oct-14
US8854617	Compounds and markers for surface-enhanced Raman scattering	Julius-Maximilians-Universitat Wurzburg	24-Sep-07	24-Sep-08	7-Oct-14
US8853382	Expression of antibody or a fragment thereof in lactobacillus	Hera Pharmaceuticals, Inc.	5-Aug-10	4-Aug-11	7-Oct-14
US8846710	Method of preferentially inducing the biosynthesis of interferon	3M Innovative Properties Company	23-Feb-05	22-Feb-06	30-Sep-14
US8846697	Purine analogs	The Regents of the University of California	31-May-06	23-Apr-07	30-Sep-14
US8846643	Phosphonates with reduced toxicity for treatment of viral infections	The Regents of the University of California	14-Apr-10	11-Oct-12	30-Sep-14
US8846051	Modulation of replicative fitness by deoptimization of synonymous codons	The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention	8-Oct-04	7-Oct-05	30-Sep-14
US8841100	Use of methylsulfonylmethane (MSM) to modulate microbial activity	Biogenic Innovations, LLC	30-Oct-09	16-Feb-11	23-Sep-14
US8840899	Use of mTOR inhibitors to enhance T cell immune responses	Emory University	5-Aug-08	5-Aug-09	23-Sep-14
US8840890	Rapid expression cloning of human monoclonal antibodies from memory B cells	University of Maryland, Baltimore	12-Nov-08	12-Nov-09	23-Sep-14
US8840873	Method of treating second and third degree burns using oxidative reductive potential water solution	Oculus Innovative Sciences, Inc.	23-Mar-05	23-Mar-06	23-Sep-14
US8840774	Electrochemistry and electrogenerated chemiluminescence with a single faradaic electrode	Board of Regents of the University of Texas System	3-Jun-05	28-Oct-13	23-Sep-14
US8835107	Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics	Amsterdam Institute of Viral Genomics B.V.	18-Aug-03	26-Jul-10	16-Sep-14

US8834445	Methods of treating or preventing peritonitis with oxidative reductive potential water solution	Oculus Innovative Sciences, Inc.	20-Jan-06	30-Mar-12	16-Sep-14
US8828962	SiRNA compositions and methods for potently inhibiting viral infection	Xiangxue Group (Hong Kong) Company Limited	11-Dec-08	12-Dec-11	9-Sep-14
US8828956	Carbohydrate conjugates as delivery agents for oligonucleotides	Alnylam Pharmaceuticals, Inc.	4-Dec-07	4-Dec-12	9-Sep-14
US8828940	Method of treating an ischemia-reperfusion injury-related disorder by administering GPCR ligands	Compugen Ltd.	18-Sep-06	14-Dec-10	9-Sep-14
US8828929	Cytotoxic T cell epitope peptide for SARS coronavirus, and use thereof	Japan as Represented by Director-General of National Institute of Infectious Diseases	28-Nov-08	27-Nov-09	9-Sep-14
US8828673	Mixed cell diagnostic systems for detection of respiratory, herpes and enteric viruses	Diagnostic Hybrids Inc	24-Apr-98	1-Mar-12	9-Sep-14
US8828659	Method for producing nucleic acid probes	Ventana Medical Systems, Inc.	1-Sep-06	11-Mar-13	9-Sep-14
US8828407	Chimaeric protein	The Pirbright Institute	7-Jul-09	5-Jul-10	9-Sep-14
US8828406	Influenza viruses and uses thereof	Icahn School of Medicine at Mount Sinai	30-Jul-09	29-Jul-10	9-Sep-14
US8822512	Crystalline tripeptide epoxy ketone protease inhibitors	Onyx Therapeutics, Inc.	20-Mar-09	20-Sep-11	2-Sep-14
US8822409	Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewith	Phylogica Limited	20-Jun-07	20-Jun-08	2-Sep-14
US8821897	Viral adjuvants	The University of North Carolina at Chapel Hill	9-Jul-04	24-Nov-10	2-Sep-14
US8816089	Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity	Masatoshi Hagiwara	26-Dec-03	19-Nov-12	26-Aug-14
US8816053	Methods for treating viral infection using IL-28 and IL-29 cysteine mutants	ZymoGenetics, Inc.	2-Apr-04	7-Sep-12	26-Aug-14
US8815837	Respiratory disease treatment	Pulmagen Therapeutics (Inflammation) Limited	7-Aug-08	29-Jun-12	26-Aug-14
US8815831	Treatment of Acinetobacter with alginate oligomers and antibiotics	Algipharma AS	3-Jun-09	3-Jun-10	26-Aug-14
US8815611	Surface for label independent detection and method thereof	Corning Incorporated	10-Apr-08	3-Apr-09	26-Aug-14
US8815249	Ii-key/antigenic epitope hybrid peptide vaccines	Antigen Express, Inc.	4-Sep-99	26-Jul-10	26-Aug-14
US8815244	Method for production of antibody using ostrich	Japan Science and Technology Agency	29-Aug-05	16-Aug-11	26-Aug-14
US8809377	Deubiquitinase inhibitors and methods for use of the same	The Regents of the University of Michigan	24-Sep-10	23-Sep-11	19-Aug-14
US8808703	Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc	Not Available	23-Mar-10	23-Mar-11	19-Aug-14
US8808686	Adjuvant-sparing multi-dose influenza vaccination regimen	Novartis AG	15-Jun-06	19-Sep-11	19-Aug-14
US8802853	Arylalkenyl and arylalkynyl substituted imidazoquinolines	3M Innovative Properties Company	29-Dec-03	17-Dec-04	12-Aug-14
US8802647	Materials and methods for prevention and treatment of RNA viral diseases	University of South Florida	30-Apr-02	17-Sep-12	12-Aug-14
US8802106	Peptide compositions and methods for inhibiting herpesvirus infection	The Administrators of the Tulane Educational Fund	30-Oct-09	29-Oct-10	12-Aug-14
US8796423	Anti-TSG101 antibodies and their uses for treatment of viral infections	Eli Lilly and Company	15-Nov-06	18-Apr-08	5-Aug-14
US8790655	Conjugates of synthetic TLR agonists and uses therefor	The Regents of The University of California	7-Feb-07	8-Jan-13	29-Jul-14
US8785408	Compositions and methods for reducing or protecting against delayed graft function (DGF)	Quark Pharmaceuticals, Inc.	27-Jun-07	26-Jun-08	22-Jul-14
US8785375	Cyclic antimicrobial peptides for treating bacterial infections	Novabiotics Ltd.	22-Dec-05	22-Aug-12	22-Jul-14

US8784900	Antimicrobial solutions containing dichlorine monoxide and methods of making and using the same	Oculus Innovative Sciences, Inc.	13-Mar-07	13-Mar-08	22-Jul-14
US8779132	Pharmaceutical compounds	Astex Therapeutics Limited	12-Oct-06	12-Oct-07	15-Jul-14
US8778963	Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines	3M Innovative Properties Company	25-Nov-03	24-Nov-04	15-Jul-14
US8778846	Composition, device and associated method	General Electric Company	4-Dec-06	1-Mar-07	15-Jul-14
US8778845	Composition, device and associated method	Genral Electric Company	15-Dec-05	1-Mar-07	15-Jul-14
US8778358	Immunogenic compositions for gram positive bacteria such as Streptococcus agalactiae	Novartis Vaccines and Diagnostics, Inc.	29-Jul-04	18-Oct-10	15-Jul-14
US8778275	Methods for producing vaccine adjuvants	Novartis AG	3-Dec-09	3-Dec-10	15-Jul-14
US8772471	Targeted delivery of siRNA	Immune Disease Institute	26-Jan-07	25-Jan-08	8-Jul-14
US8765939	Pyrimidline derivatives having immune modulating properties that act via TLR7 for the treatment of viral or allergic diseases and cancers	AstraZeneca AB	22-Nov-07	16-Aug-12	1-Jul-14
US8765704	Modified small interfering RNA molecules and methods of use	Novartis AG	28-Feb-08	14-Dec-11	1-Jul-14
US8765643	Composition, device and associated method	General Electric Company	4-Dec-06	1-Mar-07	1-Jul-14
US8765146	Adenoviral vector-based malaria vaccines	GenVec, Inc.	31-Aug-05	31-Aug-06	1-Jul-14
US8765138	Antiviral and antibacterial activity from medicinal mushrooms	Not Available	6-Jan-04	24-Sep-08	1-Jul-14
US8765133	Method of producing anti-CD166 antibody in ostrich	Japan Science and Technology Agency	29-Aug-05	16-Aug-11	1-Jul-14
US8759307	Oligonucleotide compound and method for treating nidovirus infections	Sarepta Therapeutics, Inc.	24-Dec-03	25-Apr-08	24-Jun-14
US8758763	Archaeal polar lipid aggregates for administration to animals	National Research Council of Canada	15-Dec-06	23-Jan-13	24-Jun-14
US8758680	Method and device for cleaning air	Not Available	29-Sep-10	27-Sep-11	24-Jun-14
US8754071	Compounds and compositions as c-kit kinase inhibitors	Not Available	1-Sep-11	19-Sep-13	17-Jun-14
US8754015	Modified phage for displaying post-translationally modified proteins and uses thereof	University of Rochester	21-Nov-06	20-Nov-07	17-Jun-14
US8748567	Method for delivery across the blood brain barrier	Children's Medical Center Corporation	22-May-06	22-May-07	10-Jun-14
US8748464	Use of SIRT1 activators or inhibitors to modulate an immune response	The J. David Gladstone Institutes	7-Feb-08	16-Jul-10	10-Jun-14
US8748405	Methods and compositions for the treatment of cancer or other diseases	City of Hope	26-Jan-07	9-Sep-11	10-Jun-14
US8748156	Animal protein-free media for cultivation of cells	Baxter Healthcare SA	29-Oct-04	16-Apr-13	10-Jun-14
US8741813	Composition, device and associated method	General Electric Company	15-Dec-05	28-Feb-07	3-Jun-14
US8741653	Single recombination system and methods of use	Emergent Product Development GmbH	22-Dec-08	16-Dec-09	3-Jun-14
US8741604	Nucleic acid molecule encoding a specific IL-1R1 antibody	Medimmune Limited	7-Nov-08	14-Sep-12	3-Jun-14
US8741564	Quantitative nuclease protection assay (QNPA) and sequencing (QNPS) improvements	HTG Molecular Diagnostics, Inc.	4-May-11	26-Apr-12	3-Jun-14
US8741311	Methods and compositions for immunization against virus	Academia Sinica	27-Mar-09	26-Mar-10	3-Jun-14
US8735567	Multi-targeted RNAi therapeutics for scarless wound healing of skin	Not Available	6-Nov-07	6-Nov-08	27-May-14
US8735559	Mutant protease biosensors with enhanced detection characteristics	Promega Corporation	11-May-10	11-May-11	27-May-14

US8735421	Imidazoquinolinyl sulfonamides	3M Innovative Properties Company	30-Dec-03	23-Dec-04	27-May-14
US8735410	Quinazoline derivatives as tyrosine kinase inhibitors	AstraZeneca AB	26-Feb-05	24-Feb-06	27-May-14
US8735348	Casein derived peptides and uses thereof	Peptera Ltd.	1-Mar-00	5-Sep-12	27-May-14
US8734823	Device including altered microorganisms, and methods and systems of use	The Invention Science Fund I, LLC	14-Dec-05	28-May-10	27-May-14
US8728793	Amphipathic alpha-helical peptide compositions as antiviral agents	The Board of Trustees of the Leland Stanford Junior University	19-Jul-07	14-Jul-08	20-May-14
US8722917	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16-Feb-05	23-Jan-12	13-May-14
US8722741	Biphenyloxyacetic acid derivatives for the treatment of respiratory disease	AstraZeneca AB	24-Aug-04	6-Dec-11	13-May-14
US8722725	Caffeoylquinic acid derivatives containing nitrogen, and preparation method, pharmaceutical composition and usage thereof	Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory	23-Mar-07	21-Mar-08	13-May-14
US8718948	Systems and methods for distinguishing optical signals of different modulation frequencies in an optical signal detector	Gen-Probe Incorporated	24-Feb-11	24-Feb-12	6-May-14
US8716464	Compositions and methods for silencing Ebola virus gene expression	Not Available	20-Jul-09	20-Jul-10	6-May-14
US8716461	Human parvovirus	Blood Systems, Inc.	24-May-04	24-May-05	6-May-14
US8710224	Heterocyclic compounds as CCR2B antagonists	AstraZeneca AB	24-Dec-04	13-Sep-13	29-Apr-14
US8709730	Methods of preventing and treating viral infections by inhibiting the deISGylation activity of OTU domain-containing viral proteins	Icahn School of Medicine at Mount Sinai	5-Apr-07	7-Apr-08	29-Apr-14
US8709496	Use of deuterium oxide for the treatment of virus-based diseases of the respiratory tract	D2 Bioscience Group Ltd.	6-Jan-10	23-May-12	29-Apr-14
US8709447	Compositions and methods for activating innate and allergic immunity	ID Biomedical Corporation of Quebec	22-Oct-03	26-Apr-12	29-Apr-14
US8709441	TC-83-derived alphavirus vectors, particles and methods	Alphavax, Inc.	18-May-04	6-Jul-10	29-Apr-14
US8704169	Direct impact ionization (DII) mass spectrometry	The United States of America, as represented by the Secretary, Department of Health and Human Services	11-Oct-11	11-Oct-11	22-Apr-14
US8703748	Cleaning composition for treating tissue for transplantation derived from human/animal	CG BIO Co., Ltd.	11-Feb-09	10-Feb-10	22-Apr-14
US8703467	Inactivation of a pathogen in a sample by a treatment with formalin and UV light	Baxter Healthcare SA	27-May-04	26-May-05	22-Apr-14
US8702958	Electrochemistry and electrogenerated chemiluminescence with a single faradaic electrode	Board of Regents of the University of Texas System	3-Jun-05	31-May-12	22-Apr-14
US8697873	Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines	3M Innovative Properties Company	24-Mar-04	24-Mar-05	15-Apr-14
US8697853	TAL effector-mediated DNA modification	Iowa State University Research Foundation, Inc.	10-Dec-09	10-Jan-13	15-Apr-14
US8697659	Analogues of glycolipids useful as immunoadjuvants	Luigi Panza	12-Oct-07	10-Oct-08	15-Apr-14
US8697140	Virucidal disinfectant	B. Braun Medical AG	28-Jan-05	28-May-09	15-Apr-14
US8697088	VLPs derived from cells that do not express a viral matrix or core protein	Novavax, Inc.	25-May-07	27-May-08	15-Apr-14
US8697087	Influenza vaccines including combinations of particulate adjuvants and immunopotentiators	Novartis AG	4-Nov-05	6-Nov-06	15-Apr-14
US8691837	Substituted imidazo ring systems and methods	3M Innovative Properties Company	25-Nov-03	24-Nov-04	8-Apr-14
US8691826	Compounds	Chiesi Farmaceutici S.p.A.	14-Sep-11	13-Sep-12	8-Apr-14
US8691781	Compositions for treating respiratory viral infections and their use	Sirnaomics, Inc.	5-Nov-04	4-Nov-05	8-Apr-14

CC-BY-NC-SA Dr. David E. Martin

US8691777	Combination therapy	Emory University	27-Jan-11	25-Jan-12	8-Apr-14
US8686152	4,4-disubstituted piperidine derivatives useful as inhibitors of dipeptidyl peptidase-1 (DPP-1)	Janssen Pharmaceutica NV	10-Mar-10	9-Mar-11	1-Apr-14
US8682619	Device including altered microorganisms, and methods and systems of use	The Invention Science Fund I, LLC	14-Dec-05	28-May-10	25-Mar-14
US8679839	Cell line from rousettus as host cell for pathogen amplification	Probiogen AG	4-Mar-08	4-Mar-09	25-Mar-14
US8678184	Methods for producing vaccine adjuvants	Novartis AG	3-Dec-09	3-Dec-10	25-Mar-14
US8678002	Devices and methods for decreasing human pathogen transmission	Filligent Limited	26-Jun-07	25-Jun-08	25-Mar-14
US8673983	Melanins synthesized chemically or via enzyme catalysis	Loyola University Chicago	21-Dec-07	22-Dec-08	18-Mar-14
US8673932	Oxime substituted imidazo-containing compounds	3M Innovative Properties Company	12-Aug-03	12-Aug-04	18-Mar-14
US8673907	Pharmaceutically acceptable salts of methyl (3-{ [[3-(6-amino- 2-butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl) propyl] (3-morpholin-4-ylpropyl) amino] methyl }phenyl) acetate and their use in therapy	AstraZeneca AB	17-Dec-07	16-Dec-08	18-Mar-14
US8673904	Epoxide inhibitors of cysteine proteases	The Board of Trustees of the Leland Stanford Junior University	13-Jun-06	13-Jun-07	18-Mar-14
US8673558	Luciferase biosensor	Promega Corporation	10-Oct-03	24-Apr-12	18-Mar-14
US8673331	Composition with sterilizing activity against bacteria, fungus and viruses, application thereof and method for preparation thereof	GP&E	18-Nov-11	18-Nov-11	18-Mar-14
US8669263	Use of TAM receptor inhibitors as antimicrobials	Salk Institute for Biological Studies	9-Nov-07	8-Mar-13	11-Mar-14
US8669262	3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide	Parion Sciences, Inc.	27-Jun-11	26-Jun-12	11-Mar-14
US8669240	Biological specimen collection and transport system and method of use	Longhorn Vaccines & Diagnostics, LLC	1-Oct-07	19-Mar-13	11-Mar-14
US8664274	Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses	Siga Technologies, Inc.	6-Dec-04	6-Jul-11	4-Mar-14
US8664218	Pharmaceutical compounds	Astex Therapeutics Ltd.	11-Apr-08	30-Jan-13	4-Mar-14
US8664188	siRNA compositions and methods for potently inhibiting viral infection	Xiangxue Group (Hong Kong) Company Limited	11-Dec-08	11-Dec-09	4-Mar-14
US8663922	Systems and methods for detecting multiple optical signals	Gen-Probe Incorporated	10-Mar-05	1-Jun-10	4-Mar-14
US8658767	Lipidated polyepitope vaccines	National Health Research Institutes	15-Nov-10	15-Nov-11	25-Feb-14
US8658697	Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses	Siga Technologies, Inc.	6-Dec-04	26-Oct-10	25-Feb-14
US8658666	Substituted imidazoquinolines and imidazonaphthyridines	3M Innovative Properties Company	11-Feb-05	10-Feb-06	25-Feb-14
US8658178	Carbon nanotube compositions and methods of use thereof	Yale University	19-Mar-08	19-Mar-09	25-Feb-14
US8653252	Short interfering RNA (siRNA) analogues	Santaris Pharma A/S	21-Mar-03	22-Mar-04	18-Feb-14
US8653084	Hydrobenzamide derivatives as inhibitors of Hsp90	Astex Therapeutics Ltd.	12-Oct-06	12-Oct-07	18-Feb-14
US8653034	Compositions and methods comprising phosphatidylethanolamine-binding peptide derivatives	Board of Regents, The University of Texas System	15-Jul-02	8-May-08	18-Feb-14
US8652836	Defective ribosomal products in blebs (DRibbles) and methods of use to stimulate an immune response	Providence Health System	29-Jul-05	27-Jul-06	18-Feb-14

CC-BY-NC-SA Dr. David E. Martin

US8652782	Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids	Longhorn Vaccines & Diagnostics, LLC	12-Sep-06	26-Apr-11	18-Feb-14
US8652533	Durable biocides and disinfectants	Mitsui Norin Co., Ltd.	7-Jul-04	5-Jul-05	18-Feb-14
US8648076	Cysteine protease inhibitors and their therapeutic applications	Hybrigenics SA	5-Aug-05	26-Jul-06	11-Feb-14
US8647676	Antimicrobial composition from copepods	Nofima Ingrediens	28-Oct-08	28-Oct-09	11-Feb-14
US8642596	Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena viruses	Siga Technologies, Inc.	6-Dec-04	6-Dec-05	4-Feb-14
US8642260	Single quantum-dot based aptameric nanosensors	The Research Foundation of the City University of New York	21-Oct-08	21-Oct-09	4-Feb-14
US8633322	Alkynyl derivatives useful as DPP-1 inhibitors	Janssen Pharmaceutica NV	29-Oct-09	28-Oct-10	21-Jan-14
US8633308	Compounds for preventing or treating viral infections and methods of use thereof	The Governors of The University of Alberta	28-Feb-07	27-Feb-08	21-Jan-14
US8632764	Directed evolution and in vivo panning of virus vectors	University of North Carolina at Chapel Hill	30-Apr-08	29-Apr-09	21-Jan-14
US8629283	Compounds that modulate negative-sense, single-stranded RNA virus replication and uses thereof	Icahn School of Medicine at Mount Sinai	6-Mar-08	6-Mar-09	14-Jan-14
US8629271	Compounds	AstraZeneca AB	6-Feb-08	2-Apr-12	14-Jan-14
US8629098	Compositions and methods for adoptive and active immunotherapy	Yale University	15-Jan-08	14-Jan-09	14-Jan-14
US8628786	Polychlorinated biphenyls and squalene-containing adjuvants	Novartis AG	28-Dec-07	2-Dec-11	14-Jan-14
US8624011	Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same	The Trustees of the University of Pennsylvania	14-Sep-09	14-Sep-10	7-Jan-14
US8623419	Technology for preparation of macromolecular microspheres	Ansun Biopharma, Inc.	24-Jan-06	4-Nov-11	7-Jan-14
US8623382	Immunogenic compositions for inducing an immune response to HIV	Wyeth LLC	17-Jun-04	18-Jan-11	7-Jan-14
US8623364	Antigenic GM-CSF peptides and antibodies to GM-CSF	Morphotek, Inc.	8-Feb-06	24-Oct-12	7-Jan-14
US8617838	Fluorescent proteins and related methods and compounds	University of Massachusetts	20-Sep-04	20-Sep-05	31-Dec-13
US8615368	Method for determining the amount of an analyte in a sample	Gen-Probe Incorporated	10-Mar-05	10-Mar-06	24-Dec-13
US8609370	Highly active glycoproteins-process conditions and an efficient method for their production	Glycotope GmbH	13-Feb-04	14-Feb-05	17-Dec-13
US8609101	Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodies	Theraclone Sciences, Inc.	23-Apr-09	23-Apr-10	17-Dec-13
US8604215	Crystalline tripeptide epoxy ketone protease inhibitors	Onyx Therapeutics, Inc.	20-Mar-09	22-Mar-10	10-Dec-13
US8603469	Methods of treating cancer with human monoclonal antibodies against interleukin 8	Genmab A/S	16-Dec-02	27-Dec-11	10-Dec-13
US8599383	Optical cytometry	The Regents of the University of California	6-May-09	6-May-09	3-Dec-13
US8598192	Hydroxylamine substituted imidazoquinolines	3M Innovative Properties Company	14-Nov-03	12-Nov-04	3-Dec-13
US8598134	RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof	South Alabama Medical Science Foundation	22-Oct-04	23-Jul-10	3-Dec-13
US8598116	Treatment of influenza virus infection	Educational Fund and Autoimmune Technologies, LLC	4-Nov-03	29-May-12	3-Dec-13
US8598106	Anti-microbial composition exhibiting residual anti-microbial properties on a surface	Byotrol PLC	17-Sep-07	5-Jul-11	3-Dec-13
US8597650	Methods for treating rheumatoid arthritis with anti-bile salt-stimulated lipase (BSSL) antibodies	HERNELL OLLE	8-Apr-09	6-Apr-10	3-Dec-13

CC-BY-NC-SA Dr. David E. Martin

US8592567	Vaccines and immunotherapeutics using codon-optimized IL-15 and methods for using the same	The Trustees of the University of Pennsylvania	13-Jan-06	3-May-12	26-Nov-13
US8592391	Method for therapeutic, clinical and veterinary use poly-ICLC	SALAZAR ANDRES	1-Jul-03	17-Oct-08	26-Nov-13
US8586770	Unsaturated steroid compounds	Harbor Therapeutics, Inc.	29-Sep-04	18-Feb-11	19-Nov-13
US8586364	Cells and methodology to generate non-segmented negative-strand RNA viruses	Institut Pasteur	22-Dec-06	21-Dec-07	19-Nov-13
US8586363	TAL effector-mediated DNA modification	Iowa State University Research Foundation, Inc.	10-Dec-09	10-Dec-10	19-Nov-13
US8581584	Membrane proteins, mechanisms of action and uses thereof	Florida State University Research Foundation	26-May-10	26-May-11	12-Nov-13
US8580927	Engineered antibody constant domain molecules	The United States of America, as represented by the Secretary, Department of Health and Human Services	31-Jan-08	30-Jan-09	12-Nov-13
US8580268	CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity	Coley Pharmaceutical GmbH	27-Sep-06	27-Sep-07	12-Nov-13
US8569283	Compounds and compositions as c-Kit kinase inhibitors	LIU XIAODONG	1-Sep-11	29-Aug-12	29-Oct-13
US8562996	RSV-specific binding molecules and means for producing them	MedImmune Limited	1-Jun-07	30-May-08	22-Oct-13
US8562943	Quality control methods for oil-in-water emulsions containing squalene	Novartis AG	8-Nov-06	6-Nov-07	22-Oct-13
US8560339	System and method to predict the global spread of infectious agents via commercial air travel	Kamran Khan	2-Apr-07	2-Apr-08	15-Oct-13
US8557767	Synthetic apolipoprotein E mimicking polypeptides and methods of use	UAB Research Foundation	28-Aug-07	27-Aug-08	15-Oct-13
US8557248	Methods and compositions for treating malaria	Cyvax, Inc.	9-Aug-10	9-Aug-11	15-Oct-13
US8552051	Use of pharmaceutical compositions containing mesembrenone	H. L. Hall & Sons Limited	20-Mar-09	16-Mar-10	8-Oct-13
US8552032	Bicyclic derivatives useful as inhibitors of DPP-1	Janssen Pharmaceutica NV	18-Dec-09	16-Dec-10	8-Oct-13
US8551968	Methods for generation of antibodies	National Jewish Health	13-Mar-07	13-Mar-08	8-Oct-13
US8551756	Avian influenza chimeric VLPS	Novavax, Inc.	11-Jul-03	19-Jan-10	8-Oct-13
US8551750	Device including bone cage and method for treatment of disease in a subject	The Invention Science Fund I, LLC	23-Apr-09	28-Jul-09	8-Oct-13
US8551749	Device including bone cage and method for treatment of disease in a subject	The Invention Science Fund I, LLC	23-Apr-09	23-Apr-09	8-Oct-13
US8551738	Systems and methods for rapid identification of nucleic acid variants	Ibis Biosciences, Inc.	21-Jul-05	11-Nov-09	8-Oct-13
US8551469	Treatment of tumors and viral diseases with recombinant interferon alpha	Superlab Far East Limited	28-Feb-01	6-Oct-08	8-Oct-13
US8546432	Tetrazolones as inhibitors of fatty acid synthase	Infinity Pharmaceuticals, Inc.	5-May-10	5-May-11	1-Oct-13
US8546383	Chiral fused [1,2]imidazo[4,5-c] ring compounds	3M Innovative Properties Company	30-Dec-04	25-May-12	1-Oct-13
US8546082	Methods for identification of sepsis-causing bacteria	Ibis Biosciences, Inc.	11-Sep-03	25-May-07	1-Oct-13
US8541568	Compositions and methods using siRNA molecules for treatment of gliomas	BIGNER DARELL D	24-May-08	26-May-09	24-Sep-13
US8541457	Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors	Xenon Pharmaceuticals Inc.	3-Jun-05	5-Jun-06	24-Sep-13
US8541438	Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines	3M Innovative Properties Company	18-Jun-04	21-Dec-10	24-Sep-13
US8541221	Primate T-lymphotropic viruses	Johns Hopkins University	21-Feb-05	1-Jul-10	24-Sep-13
US8541003	Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using	Protein Sciences Corporation	20-Jun-03	21-Jun-04	24-Sep-13

US8529968	Decontaminating composition having simultaneously bactericidal, fungicidal and virocidal properties, methods for obtaining and using said composition	Hightech Bio-Activities Holding GmbH	29-Mar-04	29-Mar-05	10-Sep-13
US8524715	Phenoxyacetic acid derivatives useful for treating respiratory diseases	Astrazeneca AB	23-Nov-04	22-Nov-05	3-Sep-13
US8524488	Methods and devices for determining a cell characteristic, and applications employing the same	The Regents of the University of California	10-Sep-02	9-Mar-05	3-Sep-13
US8524241	Fusion proteins comprising a fragment of Vibrio cholerae exotoxin A	The General Hospital Corporation	20-Jul-07	18-Jul-08	3-Sep-13
US8519106	Monoclonal human tumor-specific antibody	University of Zurich	13-Mar-07	13-Mar-08	27-Aug-13
US8507545	Cytotoxic T cell activator comprising EP4 agonist	National University Corporation, Hamamatsu University School of Medicine	8-May-07	7-May-08	13-Aug-13
US8507544	Bi-aryl amide compounds as CRTh2 receptor modulators	Astrazeneca AB	5-Jul-07	3-Jul-08	13-Aug-13
US8507455	Folate conjugates	Alnylam Pharmaceuticals, Inc.	4-Dec-07	4-Dec-08	13-Aug-13
US8506968	SARS vaccine compositions and methods of making and using them	Eli Lilly and Company	29-Jun-00	28-Dec-09	13-Aug-13
US8506966	Adjuvanted influenza vaccines for pediatric use	Novartis AG	22-Feb-08	20-Feb-09	13-Aug-13
US8501746	Organic compounds	Novartis AG	5-Jun-06	4-Jun-07	6-Aug-13
US8501699	Bicyclic nucleosides and nucleotides as therapeutic agents	Biota Scientific Management Pty Ltd	3-Jul-08	7-Sep-12	6-Aug-13
US8501461	System for performing multi-formatted assays	Gen-Probe Incorporated	10-Mar-05	3-Dec-09	6-Aug-13
US8497405	Process for dispersing vaporous hydrogen peroxide	STERIS Inc.	6-Mar-07	28-Feb-13	30-Jul-13
US8497112	Method for producing viral vaccines	Baxter Healthcare SA	28-Aug-07	28-Aug-08	30-Jul-13
US8494781	Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds	BOGOCH ELENORE S	6-Jun-03	10-Dec-10	23-Jul-13
US8492329	Bioactive peptides and methods of using same	Compugen Ltd.	12-Jul-07	11-Jul-08	23-Jul-13
US8486959	Dibenzo[f,h]isoquinoline derivatives	National Health Research Institutes	14-Jan-10	14-Jan-11	16-Jul-13
US8486678	Pharmaceutical compositions for the treatment of virus infection	Kineta Two, LLC	23-Nov-05	1-Feb-12	16-Jul-13
US8486619	Arrayed imaging reflectometry (air) sensor chip comprising influenza hemagglutinin (HA) polypeptides suitable for the detection of antiviral immune responses	University of Rochester	2-May-08	1-May-09	16-Jul-13
US8486420	Live virus vaccines	Children's Hospital, Inc.	15-Feb-05	15-Feb-06	16-Jul-13
US8481547	Substituted benzothiazole and benzoxazole derivatives useful as inhibitors of DPP-1	Janssen Pharmaceutica NV	18-Dec-09	16-Dec-10	9-Jul-13
US8481270	Method for chromogenic detection of two or more target molecules in a single sample	Ventana Medical Systems, Inc.	22-Aug-08	21-Aug-09	9-Jul-13
US8481255	Scytovirin domain 1 related polypeptides	The United States of America, as represented by the Secretary, Department of Health and Human Services	25-May-05	30-Sep-11	9-Jul-13
US8476292	Amide and carbamate derivatives of N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c] quinolin-1-Yl]-1,1-dimethylethyl}methanesulfonamide and methods	3M Innovative Properties Company	9-Sep-05	8-Sep-06	2-Jul-13
US8476288	Salts 756	AstraZeneca AB	21-May-09	20-May-10	2-Jul-13
US8476265	Compounds-801	AstraZeneca AB	30-Jul-10	14-Sep-12	2-Jul-13
US8470771	Method and medicament for inhibiting the infection of influenza virus	Institute of Microbiology, Chinese Academy of Sciences	14-Nov-07	18-Dec-07	25-Jun-13
US8470769	Method of treatment of bacterial infection by administration of poly-lysine	Novabiotics, Ltd.	18-Aug-04	30-Nov-11	25-Jun-13

CC-BY-NC-SA Dr. David E. Martin

US8470346	Anti-viral pharmaceutical compositions	Mast Therapeutics, Inc.	10-Dec-03	19-May-11	25-Jun-13
US8470335	Recombinant SARS-CoV nsp12 and the use of thereof and the method for producing it	Industry-Academic Cooperation Foundation, Yonsei University Kookmin University Industry Academy Cooperation Foundation	13-Jun-08	13-Jun-08	25-Jun-13
US8466284	Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase	Astra Zeneca AB	6-Nov-07	5-Nov-08	18-Jun-13
US8466167	Compounds and compositions as TLR activity modulators	IRM LLC	3-Mar-08	27-Feb-09	18-Jun-13
US8466124	RNA sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profiles	Coley Pharmaceutical GmbH	13-Aug-07	12-Jun-12	18-Jun-13
US8465751	Cnaâ€"B domain antigens in vaccines against gram positive bacteria	Novartis AG	12-Jan-09	12-Jan-10	18-Jun-13
US8461125	Compositions and methods to treat asthma	The Children's Hospital of Philadelphia	14-Feb-08	13-Aug-10	11-Jun-13
US8460914	Decreasing potential iatrogenic risks associated with vaccines and vaccine antigens	Novartis AG	9-Sep-04	10-Jan-13	11-Jun-13
US8460605	Decontaminant dispenser suitable for use as a projectile	STERIS Inc.	6-Mar-07	20-Feb-08	11-Jun-13
US8455483	Compoundsâ€"801	AstraZeneca AB	31-Jul-09	30-Jul-10	4-Jun-13
US8450471	TAL effector-mediated DNA modification	Iowa State University Research Foundation, Inc.	10-Dec-09	22-Mar-12	28-May-13
US8450467	Carbohydrate conjugates as delivery agents for oligonucleotides	Alnylam Pharmaceuticals, Inc.	4-Dec-07	14-Dec-11	28-May-13
US8450350	Triazoles as inhibitors of fatty acid synthase	Infinity Pharmaceuticals, Inc.	5-May-10	5-May-11	28-May-13
US8450284	Coiled-coil lipopeptide helical bundles and synthetic virus-like particles	Universitaet Zuerich	9-Dec-06	6-Dec-07	28-May-13
US8450055	Malaria antigen screening method	The United States of America as Represented by the Secretary of the Navy	31-Aug-05	25-Aug-06	28-May-13
US8445650	Mutant botulinum neurotoxin serotype A polypeptide and uses thereof	Thomas Jefferson University	25-Sep-07	25-Sep-08	21-May-13
US8445447	B7-DC variants immunogenic compositions and methods of use thereof	The Johns Hopkins University	13-Jul-07	7-Mar-12	21-May-13
US8444961	RNA virus infection inhibitor, method for inhibition of infection by RNA virus, RNA virus infection-inhibiting product, and use as RNA virus infection inhibitor	Sekisui Chemical Co., Ltd.	16-Jun-09	16-Jun-10	21-May-13
US8440704	Quercetin-containing compositions	Quercegen Pharmaceuticals LLC	17-Jul-06	16-Dec-09	14-May-13
US8440649	Phenanthroindolizidine analogues	National Health Research Institutes	24-Feb-09	11-Feb-10	14-May-13
US8440642	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16-Feb-05	1-Sep-11	14-May-13
US8440432	Tal effector-mediated DNA modification	Iowa State University Research Foundation, Inc.	10-Dec-09	22-Mar-12	14-May-13
US8440431	TAL effector-mediated DNA modification	Iowa State University Research Foundation, Inc.	10-Dec-09	22-Mar-12	14-May-13
US8440408	Animal protein-free media for cultivation of cells	Baxter Healthcare S.A.	29-Oct-04	10-Dec-10	14-May-13
US8436178	Imidazoquinolines with immuno-modulating properties	AstraZeneca AB	8-May-07	6-May-08	7-May-13
US8436024	2-pyridone compounds	Astrazeneca AB	2-Oct-09	1-Oct-10	7-May-13
US8431160	Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions	Novartis AG	24-Feb-06	24-Feb-07	30-Apr-13
US8431134	Use of a pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a pathogen	The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention	31-Jul-08	31-Jul-09	30-Apr-13
US8426565	Dendritic cell marker and uses thereof	Walter and Eliza Hall Institute of Medical Research	30-Aug-07	29-Aug-08	23-Apr-13
US8420798	Method for producing nucleic acid probes	Ventana Medical Systems, Inc.	1-Sep-06	31-Aug-07	16-Apr-13

CC-BY-NC-SA Dr. David E. Martin

US8420784	Interleukin 10 receptor, (IL-10R) antibodies	Kyowa Hakko Kirin Co., Ltd.	27-May-08	27-May-09	16-Apr-13
US8420096	Cell-penetrating SOCS polypeptides that inhibit cytokine-induced signaling	Vanderbilt University	4-Mar-04	4-Mar-05	16-Apr-13
US8420094	Fusion proteins comprising a fragment of Vibrio cholerae exotoxin A	The General Hospital Corporation	20-Jul-07	18-Jul-08	16-Apr-13
US8415394	Biphenyloxyacetic acid derivatives for the treatment of respiratory disease	Astrazeneca AB	6-Oct-05	21-Dec-11	9-Apr-13
US8415361	Use of TAM receptor inhibitors as antimicrobials	The Salk Institute for Biological Studies	9-Nov-07	7-Nov-08	9-Apr-13
US8415330	Biological specimen collection and transport system and method of use	Longhorn Vaccines & Diagnostics, LLC	1-Oct-07	1-Oct-12	9-Apr-13
US8415309	Bicyclic nucleosides and nucleotides as therapeutic agents	Biota Scientific Managment Pty Ltd	1-Jul-09	11-Jan-12	9-Apr-13
US8415118	Porcine DC-SIGN, ICAM-3 and LSECtin and uses thereof	Virginia Tech Intellectual Properties, Inc.	29-Oct-07	29-Oct-08	9-Apr-13
US8415102	Methods and computer systems for identifying target-specific sequences for use in nanoreporters	NanoString Technologies, Inc.	10-Apr-07	10-Apr-08	9-Apr-13
US8410149	Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses	Siga Technologies Inc.	6-Dec-04	28-Oct-10	2-Apr-13
US8410114	2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial	AstraZeneca AB	8-May-06	6-Jan-12	2-Apr-13
US8409589	Mutant forms of streptolysin O	Novartis AG	21-Dec-07	14-Sep-11	2-Apr-13
US8399651	Nucleic acids encoding GAS57 mutant antigens	Novartis AG	12-Sep-07	10-Sep-12	19-Mar-13
US8398992	Methods and compositions for polytopic vaccination	Polytopos LLC	29-Apr-05	22-Dec-11	19-Mar-13
US8394986	Phenoxiacetic acid derivatives	AstraZeneca AB	21-Aug-03	26-Jul-11	12-Mar-13
US8394945	Compositions for use in identification of bacteria	Ibis Biosciences, Inc.	11-Sep-03	7-Mar-07	12-Mar-13
US8394386	Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrations	The Trustees of the University of Pennsylvania	28-Apr-04	27-Apr-05	12-Mar-13
US7829712	Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturase	Xenon Pharmaceuticals Inc.	20-Sep-04	20-Sep-05	9-Nov-10
US7829707	Pyrrolo [3,2-d]pyrimidin-4-one derivatives and their use in therapy	AstraZeneca AB	6-Dec-04	5-Dec-05	9-Nov-10
US7829302	Method for detecting the specificity of activated lymphocyte	HU JUN	8-Dec-03	7-Dec-04	9-Nov-10
US7820210	Methods and apparatus to prevent, treat, and cure the symptoms of nausea caused by chemotherapy treatments of human cancers	Inhalation, Inc.	3-Apr-00	18-Mar-08	26-Oct-10
US7812135	GITR-binding antibodies	TOLERRX, Inc.	25-Mar-05	27-Mar-06	12-Oct-10
US7803918	Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics	Amsterdam Institute of Viral Genomics B.V.	18-Aug-03	18-Aug-04	28-Sep-10
US7803796	Homopiperazine compounds that inhibit ribosomal frameshifting by binding to RNA pseudoknot structure of SARS coronavirus	Sungkyunkwan University Foundation For Corporate Collaboration	22-Dec-06	20-Dec-07	28-Sep-10
US7803765	Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom	Phylogica Limited	20-Feb-04	20-Feb-04	28-Sep-10
US7799800	Lipid-modified immune response modifiers	3M Innovative Properties Company	30-Oct-03	12-Aug-04	21-Sep-10
US7794998	Primate T-lymphotropic viruses	Johns Hopkins University	21-Feb-05	24-Feb-07	14-Sep-10
US7794659	Signal measuring system having a movable signal measuring device	Gen-Probe Incorporated	10-Mar-05	10-Mar-06	14-Sep-10
US7790878	RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof	Alnylam Pharmaceuticals, Inc.	22-Oct-04	25-Jun-09	7-Sep-10

US7790449	Adeno-associated virus (AAV) serotype 8 sequences, vectors containing the same, and uses therefor	The Trustees of the University of Pennsylvania	17-Dec-01	6-Sep-07	7-Sep-10
US7790159	Methods, combinations and kits for treating viral infections using immunoconjugates and antibodies to aminophospholipids	Board of Regents, The University of Texas System	15-Jul-02	15-Aug-03	7-Sep-10
US7786290	Double-stranded ribonucleic acid with increased effectiveness in an organism	Alnylam Pharmaceuticals, Inc.	13-Jun-03	14-Jun-04	31-Aug-10
US7785775	Human virus causing severe acute respiratory syndrome (SARS) and uses thereof	Versitech Limited	24-Mar-03	8-Jun-07	31-Aug-10
US7785612	Polyamino acid for use as adjuvant	Masanori Baba	20-Apr-05	19-Apr-06	31-Aug-10
US7781226	Particle on membrane assay system	The Board of Regents of the University of Texas System	27-Feb-04	22-Dec-04	24-Aug-10
US7781203	Supports for assaying analytes and methods of making and using thereof	Corning Incorporated	29-Dec-05	7-Jun-06	24-Aug-10
US7777036	Heterocyclic derivatives and their use as therapeutic agents	Xenon Pharmaceuticals Inc.	20-Sep-04	20-Sep-05	17-Aug-10
US7777022	Bioinformatically detectable group of novel regulatory viral and viral associated oligonucleotides and uses thereof	Rosetta Genomics, Ltd.	26-Nov-02	26-May-04	17-Aug-10
US7776521	Coronavirus isolated from humans	The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention	25-Apr-03	14-May-07	17-Aug-10
US7767817	Water soluble boronic acid fluorescent reporter compounds and methods of use thereof	FANG HAO	5-Sep-03	7-Sep-04	3-Aug-10
US7767677	Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors	Xenon Pharmaceuticals Inc.	20-Sep-04	20-Sep-05	3-Aug-10
US7767658	Vaccine composition	Aventis Pasteur SA	17-Nov-03	9-Jan-08	3-Aug-10
US7767657	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16-Feb-05	16-Aug-06	3-Aug-10
US7767210	RNA virus vaccines and methods	The Board of Regents of the University of Oklahoma	14-Dec-05	14-Dec-06	3-Aug-10
US7763618	Pyridyl derivatives and their use as therapeutic agents	Xenon Pharmaceuticals Inc.	29-Jul-03	29-Jul-04	27-Jul-10
US7758868	Modified polymerases and attenuated viruses and methods of use thereof	The Penn State Research Foundation	22-Dec-06	24-Dec-07	20-Jul-10
US7754711	Pyridazine derivatives and their use as therapeutic agents	Xenon Pharmaceuticals Inc.	30-Jul-03	9-Feb-05	13-Jul-10
US7750123	Antibodies against SARS-CoV and methods of use thereof	Dana Farber Cancer Institute, Inc.	25-Nov-03	24-Nov-04	6-Jul-10
US7749445	Method and apparatus for analyzing bioprocess fluids	BioScale, Inc.	2-May-05	19-Dec-06	6-Jul-10
US7745486	Quercetin-containing compositions	Quercegen Pharma LLC	17-Jul-06	16-Jul-07	29-Jun-10
US7745442	Methods of reducing risk of infection from pathogens	Parion Sciences, Inc.	20-Aug-03	18-Aug-04	29-Jun-10
US7745147	Methods and uses of antibodies in the purification of interferon	ViraNative AB	12-Feb-05	13-Feb-06	29-Jun-10
US7745119	System for detecting polynucleotides	Investigen, Inc.	20-May-03	21-Nov-05	29-Jun-10
US7745118	Comparative genomic resequencing	Roche Nimblegen, Inc.	8-Apr-04	8-Apr-05	29-Jun-10
US7741450	Antibodies to GM-CSF	Morphotek Inc.	8-Feb-06	8-Feb-07	22-Jun-10
US7741360	Bi-aryl or aryl-heteroaryl substituted indoles	AstraZeneca AB	26-May-06	25-May-07	22-Jun-10
US7740858	SARS-CoV-specific B-cell epitope and applications thereof	National Taiwan University	21-Sep-04	21-Sep-04	22-Jun-10
US7737135	Biphenyloxyacetic acid derivatives for the treatment of respiratory disease	AstraZeneca AB	24-Aug-04	22-Aug-05	15-Jun-10
US7736850	Strain of SARS-associated coronavirus and applications thereof	Centre National de la Recherche Scientifique	2-Dec-03	2-Dec-04	15-Jun-10

CC-BY-NC-SA Dr. David E. Martin

US7732177	Oligoadenylate Synthetase (OAS)	Illumigen Biosciences, Inc.	23-Nov-05	17-Nov-06	8-Jun-10
US7731978	Mutant forms of streptolysin O	Novartis AG	21-Dec-07	19-Dec-08	8-Jun-10
US7728110	Antibodies to SARS coronavirus	Amgen, Inc.	19-May-06	21-May-07	1-Jun-10
US7725565	System and method for detecting, collecting, analyzing, and communicating event related information	Georgetown University	25-Feb-08	19-Nov-08	25-May-10
US7723570	Edible vaccines expressed in soybeans	SoyMeds, Inc.	12-Oct-04	12-Oct-05	25-May-10
US7723041	Assay for SARS coronavirus by amplification and detection of the replicase sequence	Becton, Dickinson and Company	12-Sep-03	3-Feb-09	25-May-10
US7722886	Compositions and methods for treatment of severe acute respiratory syndrome (SARS)	Wyeth	20-May-04	20-May-04	25-May-10
US7714109	Combinations and kits for cancer treatment using selected antibodies to aminophospholipids	Board of Regents, The University of Texas System	15-Jul-02	15-Aug-03	11-May-10
US7713515	Methods and compositions for use in diagnosing and characterizing diseases involving abnormal apoptosis	R.E.D. Laboratories N.V.	27-May-03	26-May-04	11-May-10
US7709521	Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases	AstraZeneca AB	18-Aug-03	16-Aug-04	4-May-10
US7709511	Benzothiazolone derivatives	AstraZeneca AB	9-Aug-05	3-Aug-06	4-May-10
US7709188	Multi-allelic detection of SARS-associated coronavirus	Birch Biomedical Research LLC	22-Aug-03	13-Aug-04	4-May-10
US7700782	Compounds 569	AstraZeneca AB	19-Dec-07	19-Dec-07	20-Apr-10
US7700728	Use of chimeric receptors in a screening assay for identifying agonists and antagonists of cell receptors	Schering Corporation	24-Mar-05	24-Mar-06	20-Apr-10
US7700727	Compositions and kits for detecting pathogen infection	Biokit, S.A.	23-Dec-03	27-Apr-05	20-Apr-10
US7700273	Peptidomimetics that mimic a conformational-dependent neutralizing epitope of the human immunodeficiency virus (HIV) CCR5 coreceptor	The United States of America as represented by the Department of Health and Human Services	9-Apr-04	11-Apr-05	20-Apr-10
US7700120	Adjuvancy and immune potentiating properties of natural products of Onchocerca volvulus	New York Blood Center	15-Jun-04	15-Jun-05	20-Apr-10
US7696406	Expression of a recombinant transgene	Board of Trustees Operating Michigan State University	3-Jul-03	2-Jul-04	13-Apr-10
US7696330	Binding molecules against SARS-coronavirus and uses thereof	Crucell Holland B.V.	22-Jul-03	20-Jan-06	13-Apr-10
US7691877	Pharmaceuticals	Pfizer Inc.	17-Feb-06	16-Feb-07	6-Apr-10
US7691646	Hazardous substance removing method, hazardous substance removing material used therein such as air filter, mask, wipe sheet, and the like, and storage method thereof	Daikin Industries, Ltd.	28-Mar-03	21-Nov-08	6-Apr-10
US7691599	Mammalian genes involved in viral infection and tumor suppression	Zirus, Inc.	2-May-02	2-May-03	6-Apr-10
US7691390	Viral protein	CHANG MING-FU	2-Mar-04	19-Sep-07	6-Apr-10
US7687535	Substituted 3-sulfur indoles	AstraZeneca AB	27-May-03	25-May-04	30-Mar-10
US7687475	RNA interference in respiratory epithelial cells	University of Iowa Research Foundation	9-Jul-04	16-Oct-07	30-Mar-10
US7682688	Microporous materials, methods, and articles for localizing and quantifying analytes	University of Utah Research Foundation	26-Nov-02	20-Nov-03	23-Mar-10
US7678774	Treating severe acute respiratory syndrome	Hemispherx Biopharma	16-May-03	26-Jan-07	16-Mar-10
US7678386	Liposomes coated with selected antibodies that bind to aminophospholipids	Board of Regents the University of Texas	15-Jul-02	15-Aug-03	16-Mar-10
US7674795	Fluorene derivatives, composition containing said derivatives and the use thereof	Aventis Pharma SA	19-May-05	14-Nov-07	9-Mar-10

US7670807	RNA-dependent DNA polymerase from Geobacillus stearothermophilus	East Tennessee State Univ. Research Foundation	10-Mar-04	10-Mar-04	2-Mar-10
US7670565	Building decontamination with vaporous hydrogen peroxide	Steris Inc	31-Jan-03	3-Mar-08	2-Mar-10
US7666996	Casein derived peptides and uses thereof	Peptera Pharmaceuticals Ltd	1-Mar-00	1-Mar-04	23-Feb-10
US7666592	Methods for concurrent identification and quantification of an unknown bioagent	Ibis Biosciences, Inc.	18-Feb-04	17-Feb-05	23-Feb-10
US7662860	3D-structure model of SARS coronavirus 3CL protease and anti-SARS drugs	Shanghai Institute of Materia Medica, Chinese Academy of Sciences	4-Jun-03	2-Dec-05	16-Feb-10
US7648997	Hydroxylamine substituted imidazoquinolines	Coley Pharmaceutical Group, Inc.	12-Aug-03	12-Aug-04	19-Jan-10
US7648844	Method and apparatus for detection of analyte using an acoustic device	BioScale, Inc.	2-May-05	2-May-06	19-Jan-10
US7645881	Methods for treating hepatitis C	PTC Therapeutics, Inc.	22-Jul-04	14-Jul-05	12-Jan-10
US7642350	Purine derivatives	Pfizer Limited	4-May-05	3-May-06	5-Jan-10
US7636637	Variable length probe selection	Roche NimbleGen, Inc.	18-Jun-04	20-Jun-05	22-Dec-09
US7635557	Enzymatic diagnostic test for SARS and other viral diseases	MND Diagnostic Ltd.	23-Jun-03	23-Jun-04	22-Dec-09
US7635485	Method of accelerated vaccination against Ebola viruses	The United States of America as represented by the Department of Health and Human Services	1-Aug-03	17-Jan-06	22-Dec-09
US7632638	Methods and apparatus for detecting viruses using an acoustic device	BioScale, Inc.	2-May-05	2-May-06	15-Dec-09
US7629443	Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus	New York Blood Center, Inc.	2-Jun-04	8-Feb-06	8-Dec-09
US7629385	Sphingolipid-derived pharmaceutical compositions	Jado Technologies GmbH	29-Jun-04	29-Jun-05	8-Dec-09
US7629137	Methods and apparatus for detecting bacteria using an acoustic device	BioScale, Inc.	2-May-05	2-May-06	8-Dec-09
US7629114	Method of collecting nasopharyngeal cells and secretions for diagnosis of viral upper respiratory infections and screening for nasopharyngeal cancer	World Sense Technology Limited	26-Aug-03	20-Aug-04	8-Dec-09
US7625563	Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids	Board of Regents, The University of Texas System	15-Jul-02	15-Aug-03	1-Dec-09
US7625492	Charge-based water filtration systems	The University of Wyoming Research Corporation	28-Jan-03	28-Jan-04	1-Dec-09
US7625428	Bioagent air filtration systems	The University of Wyoming Research Corporation	28-Jan-03	28-Jan-04	1-Dec-09
US7623997	Computer-implemented biological sequence identifier system and method	The United States of America as represented by the Secretary of the Navy	2-Jul-04	6-Jun-06	24-Nov-09
US7622559	Human monoclonal antibodies against interleukin 8 (IL-8)	Genmab A/S	16-Dec-02	27-Jun-07	24-Nov-09
US7622125	Polycistronic HIV vector constructs	Novartis Vaccines and Diagnostics, Inc.	5-May-04	5-May-05	24-Nov-09
US7622118	Cancer treatment methods using selected antibodies to aminophospholipids	Board of Regents, The University of Texas System	15-Jul-02	15-Aug-03	24-Nov-09
US7622112	Anti-SARS monoclonal antibodies	Not Available	5-Dec-03	6-Dec-04	24-Nov-09
US7619067	Evolved interferon-alpha polypeptides	Maxygen, Inc.	18-May-05	17-May-06	17-Nov-09
US7618802	Compositions of coronaviruses with a recombination-resistant genome	The University of North Carolina at Chapel Hill	21-Jul-03	19-Jan-06	17-Nov-09
US7618788	Proteome epitope tags and methods of use thereof in protein modification analysis	Millipore Corporation	10-May-02	5-Feb-04	17-Nov-09
US7618635	Super-antigen fusion proteins and the use thereof	Healthbanks Biotech Co., Ltd.	21-Jul-04	19-Jul-05	17-Nov-09
US7615381	Method and apparatus for detecting estradiol and metabolites thereof using an acoustic device	BioScale, Inc.	2-May-05	2-May-06	10-Nov-09

CC-BY-NC-SA Dr. David E. Martin

US7615223	Selected immunoconjugates for binding to aminophospholipids	Board of Regents, The University of Texas System	15-Jul-02	15-Aug-03	10-Nov-09
US7611908	Method and apparatus for therapeutic drug monitoring using an acoustic device	BioScale, Inc.	2-May-05	2-May-06	3-Nov-09
US7611704	Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids	Board of Regents, The University of Texas System	15-Jul-02	15-Aug-03	3-Nov-09
US7605161	Pyridyl derivatives and their use as therapeutic agents	Xenon Pharmaceuticals Inc.	30-Jul-03	29-Jul-04	20-Oct-09
US7605135	Baicalin as a treatment for SARS infection	The University of Hong Kong	10-Nov-03	8-Nov-04	20-Oct-09
US7604960	Transient protein expression methods	Crucell Holland B.V.	15-Apr-99	1-Jun-07	20-Oct-09
US7604801	Methods for detecting parvovirus infections	The Research Foundation of State University of New York	5-May-03	16-Oct-08	20-Oct-09
US7598382	Aryl substituted imidazoquinolines	Coley Pharmaceutical Group, Inc.	20-Dec-02	13-Jan-06	6-Oct-09
US7598094	Methods and apparatus for detecting cardiac injury markers using an acoustic device	BioScale, Inc.	2-May-05	2-May-06	6-Oct-09
US7598072	Assay to detect viral uncoating	Wisconsin Alumni Research Foundation	9-Dec-03	8-Dec-04	6-Oct-09
US7597936	Method of producing a pigmented composite microporous material	University of Utah Research Foundation	26-Nov-02	26-May-04	6-Oct-09
US7595381	Method for detecting SARS coronavirus	Eiken Kagaku Kabushiki Kaisha	27-Jun-03	10-Jun-08	29-Sep-09
US7595163	Method for detecting SARS coronavirus	Eiken Kagaku Kabushiki Kaisha	27-Jun-03	10-Jun-08	29-Sep-09
US7592343	Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitors	Xenon Pharmaceuticals Inc.	20-Sep-04	20-Sep-05	22-Sep-09
US7592322	RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof	Alnylam Pharmaceuticals, Inc.	22-Oct-04	14-Jun-05	22-Sep-09
US7592008	Membrane scaffold proteins	The Board of Trustees of the University of Illinois, a body corporate and politic of the State of Illinois	20-Nov-00	11-Jan-05	22-Sep-09
US7589092	Prodrugs of heteroaryl compounds	Koronis Pharmaceuticals, Incorporated	20-Jun-03	27-Dec-06	15-Sep-09
US7585647	Nucleic acid encoding recombinant interferon	WEI GUANGWEN	28-Aug-03	26-Aug-04	8-Sep-09
US7582740	Methods and kits for detecting SARS-associated coronavirus	The Trustees of Columbia University In the City of New York	17-Apr-03	23-Jan-04	1-Sep-09
US7582621	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	16-Feb-05	16-Feb-06	1-Sep-09
US7579396	Polymer composite	Eastman Kodak Company	31-Jan-07	31-Jan-07	25-Aug-09
US7579359	1-alkoxy 1H-imidazo ring systems and methods	3M Innovative Properties Company	2-Sep-04	1-Sep-05	25-Aug-09
US7572621	Detection, characterization and treatment of viral infection and methods thereof	Canadian Blood Services	9-Apr-03	11-Oct-05	11-Aug-09
US7572448	Combined cancer treatment methods using selected antibodies to aminophospholipids	Board of Regents, The University of Texas System	15-Jul-02	15-Aug-03	11-Aug-09
US7572442	Selected antibody compositions for binding to aminophospholipids	Board of Regents, The University of Texas System	15-Jul-02	15-Jul-03	11-Aug-09
US7569536	Method for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity	Masatoshi Hagiwara	26-Dec-03	24-Dec-04	4-Aug-09
US7569384	Albumin fusion proteins	Human Genome Sciences, Inc.	9-Feb-04	8-Aug-06	4-Aug-09
US7550140	Antibody to the human OX40 receptor	Crucell Holland B.V.	13-Jun-02	13-Jun-03	23-Jun-09
US7547698	Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coadesaturase (SCD)	Xenon Pharmaceuticals Inc.	20-Sep-04	20-Sep-05	16-Jun-09
US7547516	Method for reducing the presence of amplification inhibitors in a reaction receptacle	Gen-Probe Incorporated	10-Mar-05	10-Mar-06	16-Jun-09

CC-BY-NC-SA Dr. David E. Martin

US7547512	High-throughput diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)	The University of Hong Kong	24-Mar-03	24-Mar-04	16-Jun-09
US7544697	Pyrazolopyridines and analogs thereof	Coley Pharmaceutical Group, Inc.	3-Oct-03	1-Apr-05	9-Jun-09
US7541436	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	19-May-04	4-May-07	2-Jun-09
US7541163	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	19-May-04	14-Aug-07	2-Jun-09
US7531630	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	19-May-04	13-Sep-06	12-May-09
US7531324	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	19-May-04	13-Sep-06	12-May-09
US7521424	Albumin fusion proteins	Human Genome Sciences, Inc.	22-Jan-03	7-Jul-05	21-Apr-09
US7521185	Assay for SARS coronavirus by amplification and detection of the replicase sequence	Becton, Dickinson and Company	12-Sep-03	13-Sep-04	21-Apr-09
US7514436	Pyridazine derivatives and their use as therapeutic agents	Xenon Pharmaceuticals Inc.	30-Jul-03	29-Jul-04	7-Apr-09
US7511124	Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents	Board of Regents, The University of Texas System	15-Jul-02	15-Aug-03	31-Mar-09
US7504384	Use of lipid conjugates in the treatment of infection	Yissum Research Development Company of the Hebrew University of Jerusalem	10-Jan-00	8-Sep-05	17-Mar-09
US7504382	Protease inhibitors for coronaviruses and SARS-CoV and the use thereof	Cytovia, Inc.	6-May-03	6-May-04	17-Mar-09
US7504205	Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP-dependent kinase and a target for SARS therapy	The Burnham Institute	17-May-04	17-May-05	17-Mar-09
US7504097	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	18-Nov-02	30-Oct-06	17-Mar-09
US7498409	Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists	Schering Corporation	24-Mar-05	23-Mar-06	3-Mar-09
US7498152	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	18-Nov-02	30-Oct-06	3-Mar-09
US7495011	Anti-coronavirus drug	aRigen Pharmaceuticals, Inc.	15-Jul-03	14-Jul-04	24-Feb-09
US7491793	Influenza virus inhibiting peptides	The Administrators of the Tulane Educational Fund	4-Nov-03	3-Nov-04	17-Feb-09
US7491706	Artificial cpg single-stranded oligodeoxynucleotide and antiviral use thereof	Changchun Huapu Biotechnology Co., Ltd.	25-Jul-03	26-Jul-04	17-Feb-09
US7491508	Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses	The Trustees of the University of Pennsylvania	20-Jun-03	15-Jun-04	17-Feb-09
US7491489	Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof	The University of Hong Knog	22-Nov-04	28-Oct-05	17-Feb-09
US7491397	Receptor binding polypeptides	National Health Research Institutes	9-Jan-04	10-Jan-05	17-Feb-09
US7488801	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	18-Nov-02	30-Oct-06	10-Feb-09
US7488589	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	18-Nov-02	30-Oct-06	10-Feb-09
US7488473	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	18-Nov-02	30-Oct-06	10-Feb-09
US7485432	Selective modulation of TLR-mediated biological activity	3M Innovative Properties Company	27-Feb-03	27-Feb-04	3-Feb-09
US7482334	Therapeutic treatment methods	Hollis-Eden Pharmaceuticals, Inc.	28-Aug-02	12-Feb-07	27-Jan-09
US7482149	Inhibition of SARS coronavirus infection with clinically approved antiviral drugs	Genome Institute of Singapore	9-Jun-03	9-Jun-04	27-Jan-09
US7479484	Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity	Takeda Pharmaceutical Company Limited	25-Jun-03	25-Jun-04	20-Jan-09
US7470666	Use of Ulinastatin and its pharmaceutical composition for treating severe acute respiratory syndrome	Guangdong Techpool Biochem. Pharma. Co., Ltd.	26-May-03	25-May-04	30-Dec-08

CC-BY-NC-SA Dr. David E. Martin

US7470548	Hazardous substance removing method, hazardous substance removing material used therein such as air filter, mask, wipe sheet, and the like, and storage method thereof	Daikin Industries, Ltd.	28-Mar-03	26-Mar-04	30-Dec-08
US7468418	Compositions for enhancing transport of molecules into cells	AVI BioPharma., Inc.	29-Apr-03	29-Apr-04	23-Dec-08
US7465836	Hydrolytically-resistant boron-containing therapeutics and methods of use	Anacor Pharmaceuticals, Inc.	16-Jun-03	15-Jun-04	16-Dec-08
US7462615	Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications	Hybrigenics SA	8-Dec-05	8-Dec-05	9-Dec-08
US7460960	Proteome epitope tags and methods of use thereof in protein modification analysis	Epitome Biosystems, Inc.	10-May-02	13-Nov-03	2-Dec-08
US7456180	Piperazine derivatives and their use as therapeutic agents	Xenon Pharmaceuticals Inc.	30-Jul-03	29-Jul-04	25-Nov-08
US7455833	Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids	Board of Regents, The University of Texas System	15-Jul-02	15-Aug-03	25-Nov-08
US7452542	Live attenuated coronavirus vaccines	Vanderbilt University	21-May-04	23-May-05	18-Nov-08
US7445889	Methods for detecting parvovirus infections	The Research Foundation of State University of New York	5-May-03	5-May-04	4-Nov-08
US7442761	Replikin peptides and uses thereof	BOGOCH ELENORE S	6-Jun-03	4-Jun-04	28-Oct-08
US7442508	Methods for detection and production of influenza viruses	Diagnostic Hybrids, Inc.	24-Apr-98	28-Apr-06	28-Oct-08
US7439349	Method for preparation of large volume batches of poly-ICLC with increased biological potency; therapeutic, clinical and veterinary uses thereof	Not Available	3-Jul-02	1-Jul-03	21-Oct-08
US7439052	Method of making modified immunodeficiency virus particles	Lipid Sciences	29-Jun-00	10-Apr-06	21-Oct-08
US7435588	Systems for detection and production of respiratory, herpes and enteric viruses	Diagnostic Hybrids, Inc.	20-Sep-05	28-Apr-06	14-Oct-08
US7435538	High throughput screening method of drug for physiologically active protein	CellFree Sciences Co., Ltd.	8-Sep-03	8-Sep-04	14-Oct-08
US7432045	Method of inhibiting influenza infection with antiviral peptides	Wisconsin Alumni Research Foundation	1-Dec-03	1-Dec-04	7-Oct-08
US7429656	Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference	The University of Hong Kong	19-May-03	14-Jun-06	30-Sep-08
US7427479	Methods and kits for identifying target nucleotides in mixed populations	Applera Corporation	30-Apr-04	29-Apr-05	23-Sep-08
US7424370	Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential	Council of Scientific and Industrial Research	20-Jul-04	7-Feb-05	9-Sep-08
US7407663	Modified immunodeficiency virus particles	Lipid Sciences, Inc.	29-Jun-00	20-Jun-03	5-Aug-08
US7407662	Modified viral particles with immunogenic properties and reduced lipid content	Lipid Sciences, Inc.	29-Jun-00	21-Jun-04	5-Aug-08
US7405207	Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof	Epigenesis Pharmaceuticals, Inc.	17-Jun-02	17-Jun-03	29-Jul-08
US7405046	Compositions and methods for treatment of rhinovirus	The Quigley Corporation	6-Aug-01	27-Oct-06	29-Jul-08
US7399588	Method for detecting SARS coronavirus	Eiken Kagaku Kabushiki Kaisha	27-Jun-03	15-Jun-04	15-Jul-08
US7396914	SARS nucleic acids, proteins, antibodies, and uses thereof	University of Massachusetts	4-Aug-03	4-Aug-04	8-Jul-08
US7393856	Anti-viral uses of borinic acid complexes	Anacor Pharmaceuticals, Inc.	14-Jun-04	14-Jun-05	1-Jul-08
US7393638	Assay system and methods for detecting SARS-CV	AsiaGEN Corporation	1-Jul-03	1-Jul-03	1-Jul-08
US7387271	Immunostimulatory combinations	3M Innovative Properties Company	30-Dec-02	30-Dec-03	17-Jun-08

CC-BY-NC-SA Dr. David E. Martin

US7384909	Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents	Board of Regents, The University of Texas System	15-Jul-02	15-Aug-03	10-Jun-08
US7378386	Anti-viral treatment methods using phosphatidylethanolamine-binding peptide derivatives	Board of Regents, The University of Texas System	15-Jul-02	15-Aug-03	27-May-08
US7375210	PCR primer set for detecting severe acute respiratory syndrome (SARS)-Coronavirus, method and kit for detecting SARS-Coronavirus using the same	Samsung Electronics Co., Ltd.	12-Dec-03	24-Nov-04	20-May-08
US7375202	Human virus causing severe acute respiratory syndrome (SARS) and uses thereof	The University of Hong Kong	24-Mar-03	24-Mar-04	20-May-08
US7375180	Methods and compositions related to IRM compounds and Toll-like receptor 8	3M Innovative Properties Company	13-Feb-03	12-Feb-04	20-May-08
US7374883	Method and kit for the detection of a novel coronoavirus associated with the severe acute respiratory syndrome (SARS)	QIAGEN Diagnostics GmbH	30-Apr-03	30-Apr-04	20-May-08
US7371850	Method and composition for reducing expression of ROCK-II	Myriad Genetics, Inc.	20-Aug-03	20-Aug-04	13-May-08
US7371837	Human virus causing respiratory tract infection and uses thereof	The University of Hong Kong	21-Jul-04	16-May-05	13-May-08
US7371525	Compositions and methods for diagnosing and treating severe acute respiratory syndrome (SARS)	The Chinese University of Hong Kong	29-Jul-03	28-Jul-04	13-May-08
US7361747	Isolation and characterization of the precursor virus of human SARS virus: SARS-associated corona virus-like virus	The University of Hong Kong	22-May-03	24-May-04	22-Apr-08
US7361304	Building decontamination with vaporous hydrogen peroxide	Steris Inc.	31-Jan-03	29-Jan-04	22-Apr-08
US7358068	Antiviral oligonucleotides	Replicor, Inc.	13-Sep-02	12-Sep-03	15-Apr-08
US7354908	Materials and methods for prevention and treatment of RNA viral diseases	University of South Florida	30-Apr-02	30-Apr-03	8-Apr-08
US7354551	Room decontamination with hydrogen peroxide vapor	Steris Inc	8-Jul-04	8-Jul-04	8-Apr-08
US7344740	Methods and apparatus to prevent, treat, and cure the symptoms of nausea caused by chemotherapy treatments of human cancers	Inhalation, Inc.	3-Apr-00	27-Nov-04	18-Mar-08
US7344720	Vaccine composition	Sanofi Pasteur SA	17-Nov-03	15-Nov-04	18-Mar-08
US7339051	Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)	Isis Pharmaceuticals, Inc.	28-Apr-03	26-Apr-04	4-Mar-08
US7335658	Pyridazine derivatives and their use as therapeutic agents	Xenon Pharmaceuticals Inc.	30-Jul-03	29-Jul-04	26-Feb-08
US7332475	Preventive or therapeutic composition for viral infectious disease	Kyowa Hakko Kogyo Co., Ltd.	22-Jul-03	22-Jul-04	19-Feb-08
US7332294	CXCL10-based diagnosis and treatment of respiratory illnesses	University Health Network	17-Aug-04	17-Aug-04	19-Feb-08
US7320857	Characterization of the earliest stages of the severe acute respiratory syndrome (SARS) virus and uses thereof	Chinese National Human Genome Center at Shanghai	9-Jul-04	9-Jul-04	22-Jan-08
US7318918	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	19-May-04	18-May-05	15-Jan-08
US7314613	Interferon-alpha polypeptides and conjugates	Maxygen, Inc.	18-Nov-02	19-May-04	1-Jan-08
US7312036	Compositions for use in identification of viral hemorrhagic fever viruses	ISIS Pharmaceuticals, Inc.	22-Mar-04	21-Mar-05	25-Dec-07
US7297786	RNA interference in respiratory epitheial cells	University of Iowa Research Foundation	9-Jul-04	11-Jul-05	20-Nov-07
US7291498	Methods of generating chimeric adenoviruses and uses for such chimeric adenoviruses	The Trustees of the University of Pennsylvania	20-Jun-03	20-Jun-03	6-Nov-07
US7282568	Human monoclonal antibodies against interleukin 8 (IL-8)	Genmab A/S	16-Dec-02	16-Dec-03	16-Oct-07
US7282199	Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor	The Trustees of the University of Pennsylvania	17-Dec-01	25-Apr-03	16-Oct-07
US7267942	Diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)	The University of Hong Kong	24-Mar-03	24-Mar-04	11-Sep-07

US7261867	Production of silver sulfate grains using organo-sulfate or organo-sulfonate additives	Eastman Kodak Company	7-Apr-06	7-Apr-06	28-Aug-07
US7247303	Selected antibody CDRs for binding to aminophospholipids	Board of Regents, The University of Texas System	15-Jul-02	15-Aug-03	24-Jul-07
US7244732	Prodrugs of heteroaryl compounds	Koronis Pharmaceuticals, Incorporated	20-Jun-03	31-Mar-04	17-Jul-07
US7223787	Prenylation inhibitors reduce host cell permissiveness to viral replication	Board of Regents, The University of Texas System	21-Oct-03	21-Oct-03	29-May-07
US7220852	Coronavirus isolated from humans	The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention	25-Apr-03	12-Apr-04	22-May-07
US7183300	Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof	AGARWAL ATUL	11-Nov-04	10-Nov-05	27-Feb-07
US7166435	Compositions and methods for reducing the transmissivity of illnesses	The Quigley Corporation	6-Aug-01	14-Dec-04	23-Jan-07
US7163947	1-Amino 1H-imidazoquinolines	3M Innovative Properties Company	7-Mar-03	3-Sep-04	16-Jan-07
US7151163	Antiviral agents for the treatment, control and prevention of infections by coronaviruses	Sequoia Pharmaceuticals, Inc.	28-Apr-03	28-Apr-04	19-Dec-06
US7151091	Compositions and methods for preventing infection	La Jolla Biosciences LLC	20-Sep-02	22-Sep-03	19-Dec-06
US7148248	Method of treating or inhibiting the development of brain inflammation and sepsis	NOZAKI MASAKO	29-Nov-02	26-Nov-03	12-Dec-06
US7129223	Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference	The University of HongKong	19-May-03	19-May-04	31-Oct-06
US7129042	Compositions and methods for detecting severe acute respiratory syndrome coronavirus	Diagnostic Hybrids, Inc.	3-Nov-03	3-Nov-03	31-Oct-06
US7115563	Composition and its therapeutic use	Insignion Holding Limited	29-May-02	29-May-03	3-Oct-06
US7091214	Aryl substituted Imidazoquinolines	3M Innovative Properties Co.	20-Dec-02	18-Dec-03	15-Aug-06
US7048953	Methods and apparatus to prevent, treat and cure infections of the human respiratory system by pathogens causing severe acute respiratory syndrome (SARS)	Inhalation, Inc.	3-Apr-00	2-May-03	23-May-06
US7023593	Apparatus for forming nano-grating device	Industrial Technology Research Institute	28-Nov-03	17-Mar-04	4-Apr-06
US6946291	Mixed cell diagnostic systems	Diagnostic Hybrids, Inc.	24-Apr-98	30-Mar-04	20-Sep-05
US20200176079	METHODS AND DEVICES FOR NUCLEIC ACID-BASED REAL-TIME DETERMINATION OF DISEASE STATES	Not Available	19-Jul-17	18-Jul-18	4-Jun-20
US20200173925	MICROSCOPIC BODY ENCLOSING METHOD, MICROSCOPIC BODY DETECTION METHOD, AND MICROSCOPIC BODY DETECTION DEVICE	JAPAN SCIENCE AND TECHNOLOGY AGENCY	29-Mar-17	28-Mar-18	4-Jun-20
US20200172883	COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND ACTIVITY, AND RELATED METHODS	Not Available	19-Nov-09	13-Sep-19	4-Jun-20
US20200172879	DHFR TUNABLE PROTEIN REGULATION	Not Available	3-Mar-17	2-Sep-19	4-Jun-20
US20200172600	RSV F PROTEIN COMPOSITIONS AND METHOD FOR MAKING SAME	GLAXOSMITHKLINE BIOLOGICALS, SA	15-Jul-09	16-Aug-17	4-Jun-20
US20200172513	DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDS	Hoffmann-La Roche Inc.	12-Jun-16	5-Feb-20	4-Jun-20
US20200172480	CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS	HANGZHOU DAC BIOTECH CO., LTD.	12-Jul-12	5-Feb-20	4-Jun-20
US20200171085	Method of Treating Respiratory Tract Infection	Not Available	19-May-17	18-May-18	4-Jun-20
US20200171060	FLEX-NUCLEOSIDE ANALOGUES, NOVEL THERAPEUTICS AGAINST FILOVIRUSES AND FLAVIVIRUSES	Not Available	31-Jul-17	26-Jan-18	4-Jun-20
US20200166505	METHOD AND DEVICE FOR DETECTING ANTIGEN-SPECIFIC ANTIBODIES IN A BIOLOGICAL FLUID SAMPLE BY USING NEODYMIUM MAGNETS	The U.S.A., as represented by the Secretary, Department of Health and Human Services	1-Sep-15	30-Jan-20	28-May-20
US20200165632	ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTION	Spark Therapeutics, Inc.	7-Jun-17	6-Jun-18	28-May-20

US20200165630	COMPOSITIONS FOR THE TREATMENT OF DISEASE	Not Available	29-Apr-16	28-Apr-17	28-May-20
US20200165613	VIRUS LIKE PARTICLE	The University of Leeds	1-Jun-17	31-May-18	28-May-20
US20200165594	CRISPR SYSTEM BASED ANTIVIRAL THERAPY	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	7-Jul-17	6-Jul-18	28-May-20
US20200165585	NEW CHIMERIC ENZYMES AND THEIR APPLICATIONS	Not Available	27-Jul-17	27-Jul-18	28-May-20
US20200165357	CARBONIC ANHYDRASE IX (G250) ANTIBODIES AND METHODS OF USE THEREOF	Not Available	2-Dec-05	21-Oct-19	28-May-20
US20200164334	MICROSPOTTING DEVICE	Not Available	18-Apr-12	11-Oct-19	28-May-20
US20200164067	Methods and Compositions for Inhibiting Akt3	Not Available	15-Jan-16	5-Feb-20	28-May-20
US20200164058	TRIMERIC S1-CD40L FUSION PROTEIN VACCINE AGAINST MIDDLE EAST RESPIRATORY SYNDROME-CORONAVIRUS	King Abdulaziz University	27-Nov-18	27-Nov-18	28-May-20
US20200164020	PUM 1 PROTEIN AS TARGET FOR VIRUS INHIBITION	Not Available	12-Apr-17	12-Apr-17	28-May-20
US20200163878	LIPID NANOPARTICLE MRNA VACCINES	Not Available	26-Oct-16	26-Oct-17	28-May-20
US20200157600	METHODS AND COMPOSITIONS FOR WHOLE TRANSCRIPTOME AMPLIFICATION	Not Available	19-Nov-18	19-Nov-18	21-May-20
US20200157222	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	Not Available	29-Mar-18	29-Mar-19	21-May-20
US20200157221	ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES	Not Available	30-Jun-16	28-Jan-20	21-May-20
US20200155704	ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR	Not Available	30-Sep-03	30-Jan-20	21-May-20
US20200155699	MODIFIED VIRUS-LIKE PARTICLES OF CMV	Not Available	22-Oct-14	26-Nov-19	21-May-20
US20200155667	VACCINE COMPOSITIONS	Not Available	27-Jul-17	24-Jan-20	21-May-20
US20200155664	INFLUENZA VACCINES WITH REDUCED AMOUNTS OF SQUALENE	Not Available	10-Feb-09	26-Jun-19	21-May-20
US20200155662	COMBINATION IMMUNOTHERAPIES COMPRISING IL-15 SUPERAGONISTS	Not Available	26-May-17	25-May-18	21-May-20
US20200155660	COMPOSITIONS AND METHODS FOR MODIFIED DENDRIMER NANOPARTICLE DELIVERY	Not Available	23-Sep-15	22-Nov-19	21-May-20
US20200155646	EV576 For Use in the Treatment of Viral Infections of the Respiratory Tract	Volution Immuno Pharmaceuticals SA	8-Jan-10	7-Jun-19	21-May-20
US20200149062	ENGINEERED TSC2	Not Available	14-Jul-17	13-Jul-18	14-May-20
US20200149048	Transbiotic Regulation of Bacterial Gene Expression	Not Available	22-May-17	22-May-18	14-May-20
US20200148749	ANTIBODIES AND PROCESSES FOR PREPARING THE SAME	Not Available	16-May-08	10-Oct-19	14-May-20
US20200147203	VACCINATION OF IMMUNOCOMPROMISED SUBJECTS	Not Available	26-Sep-14	10-Jan-20	14-May-20
US20200147193	COMPOSITIONS AND METHODS FOR TUMOR VACCINATION AND IMMUNOTHERAPY INVOLVING HER ANTIGENS	Not Available	2-Jun-17	2-Jun-18	14-May-20
US20200147171	COMPOSITIONS OF CRACC FUSIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE AGAINST CANCERS, INFECTIONS DISEASES AND DISORDERS	Not Available	18-Sep-18	18-Sep-19	14-May-20
US20200140547	MULTIFUNCTIONAL ANTIBODY-LIGAND TRAPS TO MODULATE IMMUNE TOLERANCE	Not Available	26-May-17	25-May-18	7-May-20
US20200140493	Engineering Virus-like Nanocarriers for Biomolecule Delivery	Not Available	26-Oct-18	25-Oct-19	7-May-20
US20200140398	HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS	AZIENDA OSPEDALIERA UNIVERSITARIA SENESE	13-Feb-15	6-Jan-20	7-May-20

CC-BY-NC-SA Dr. David E. Martin

US20200138937	Genetically Attenuated Nucleic Acid Vaccine	Not Available	2-Jun-17	1-Jun-18	7-May-20
US20200138936	Phenotypically Wild-Type and Genetically Attenuated Viruses	Not Available	2-Jun-17	1-Jun-18	7-May-20
US20200138818	METHODS OF TREATING PAIN AND/OR INFLAMMATORY DISORDERS USING LAPATINIB	Not Available	7-Nov-18	6-Nov-19	7-May-20
US20200138780	METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C	Not Available	14-Mar-13	19-Dec-19	7-May-20
US20200131518	CONTROL OF TOTAL AFUCOSYLATED GLYCOFORMS OF ANTIBODIES PRODUCED IN CELL CULTURE	Not Available	14-Mar-17	14-Mar-18	30-Apr-20
US20200129487	CHEMOTHERAPY FOR CANCER USING AZABICYCLO COMPOUND	TAIHO PHARMACEUTICAL CO., LTD.	30-Jun-17	29-Jun-18	30-Apr-20
US20200127954	RNA TARGETING METHODS AND COMPOSITIONS	Salk Institute for Biological Studies	22-Aug-17	31-Dec-18	23-Apr-20
US20200124599	ACCURATE, RAPID AND CONVENIENT SINGLE-STEP DISEASE DIAGNOSTIC METHOD USING SELF-AMPLIFICATION PRINCIPLE OF DETECTION SIGNAL	CELLEMEDY CO., LTD	13-Apr-17	13-Apr-18	23-Apr-20
US20200123233	AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF VIRAL DISEASES	Ablynx N.V.	5-Jun-08	1-Aug-19	23-Apr-20
US20200123205	Inhibition Of TCR Signaling With Peptide Variants	Not Available	22-Oct-18	18-Dec-19	23-Apr-20
US20200123203	COMPOSITIONS COMPRISING CURONS AND USES THEREOF	FLAGSHIP PIONEERING INNOVATIONS V, INC.	13-Jun-17	13-Jun-18	23-Apr-20
US20200115448	CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOF	Not Available	26-Apr-17	22-Oct-19	16-Apr-20
US20200115434	ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOF	Not Available	23-Oct-15	29-Oct-19	16-Apr-20
US20200113996	CHIMERIC VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTIGEN-SPECIFIC REDIRECTORS OF IMMUNE RESPONSES	Not Available	23-Jun-17	21-Jun-18	16-Apr-20
US20200113967	PEPTIDES AND USES THEREFOR AS ANTIVIRAL AGENTS	Not Available	26-May-17	26-May-17	16-Apr-20
US20200113831	LIPOSOMES HAVING USEFUL N:P RATIO FOR DELIVERY OF RNA MOLECULES	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul-11	16-Dec-19	16-Apr-20
US20200113830	PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING RNA	GLAXOSMITHKLINE BIOLOGICALS S.A.	31-Aug-11	16-Dec-19	16-Apr-20
US20200109403	IN VIVO DELIVERY OF OLIGONUCLEOTIDES	Not Available	12-Dec-11	18-Dec-19	9-Apr-20
US20200108136	METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES	Not Available	6-Apr-07	22-Nov-19	9-Apr-20
US20200102558	TRANSKINGDOM PLATFORM FOR THERAPEUTIC NUCLEIC ACID DELIVERY	Not Available	3-Apr-17	3-Oct-19	2-Apr-20
US20200102550	TAL EFFECTOR-MEDIATED DNA MODIFICATION	Not Available	10-Dec-09	28-Aug-19	2-Apr-20
US20200102544	POXVIRUS-PLASMODIUM RECOMBINANTS, COMPOSITIONS CONTAINING SUCH RECOMBINANTS, USES THEREOF, AND METHODS OF MAKING AND USING THE SAME	Not Available	30-Dec-13	11-Sep-19	2-Apr-20
US20200102362	TUMOR NECROSIS FACTOR RECEPTOR (TNFR) BINDING PROTEIN COMPLEX WITH IMPROVED BINDING AND BIOACTIVITY	Not Available	6-Apr-17	5-Apr-18	2-Apr-20
US20200102292	SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF	Not Available	3-Jul-13	10-Jul-19	2-Apr-20
US20200101158	ANTI-TIGIT ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF	Not Available	1-Oct-15	22-Oct-19	2-Apr-20
US20200101153	MVA-BN AND AD26.ZEBOV OR AD26.FILO PRIME-BOOST REGIMEN	Not Available	6-Apr-17	6-Apr-18	2-Apr-20
US20200101142	PDE5 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPY	Not Available	12-Jun-17	12-Jun-18	2-Apr-20

CC-BY-NC-SA Dr. David E. Martin

US20200101119	METHODS OF TREATMENT OF INFECTIONS USING BACTERIA	Not Available	27-Sep-18	26-Sep-19	2-Apr-20
US20200101087	PHARMACEUTICAL COMPOSITIONS AND METHODS	Not Available	3-Aug-15	21-Nov-19	2-Apr-20
US20200100480	TRAIT SELECTION IN AVIANS	Not Available	31-May-17	31-May-18	2-Apr-20
US20200095324	ANTI-TIGIT ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOF	Not Available	30-Mar-17	30-Mar-18	26-Mar-20
US20200093919	MODIFIED PEDV SPIKE PROTEIN	Not Available	20-Sep-18	18-Sep-19	26-Mar-20
US20200093909	PLASMODIUM SPOROZOITE NPDP PEPTIDES AS VACCINE AND TARGET NOVEL MALARIA VACCINES AND ANTIBODIES BINDING TO	Not Available	19-Apr-17	19-Apr-18	26-Mar-20
US20200093855	ENHANCED IMMUNE RESPONSE UPON TREATMENT WITH NITRIC OXIDE	Not Available	11-Sep-17	3-Jun-19	26-Mar-20
US20200093841	Broad Spectrum Antiviral and Methods of Use	Not Available	17-Apr-06	30-Apr-19	26-Mar-20
US20200087655	PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM OXIDES	Not Available	14-Jul-15	22-Nov-19	19-Mar-20
US20200087646	OPTIMIZED HUMAN CLOTTING FACTOR IX GENE EXPRESSION CASSETTES AND THEIR USE	Not Available	31-May-17	31-May-18	19-Mar-20
US20200087630	INFLUENZA VIRUS AND TYPE 1 DIABETES	Istituto Zooprofilattico Sperimentale delle Venezie	10-Oct-12	25-Jul-19	19-Mar-20
US20200087359	GRIFFITHSIN MUTANTS	The United States of America,as represented by the Secretary,Department of Health and Human Services	10-Feb-15	27-Nov-19	19-Mar-20
US20200087313	NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	29-Jul-11	25-Apr-19	19-Mar-20
US20200087298	Imidazo[4,5-c] Ring Compounds Containing Guanidine Substituted Benzamide Groups	Not Available	1-Mar-17	27-Feb-18	19-Mar-20
US20200087280	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5-Feb-15	25-Nov-19	19-Mar-20
US20200086324	DEVICES AND METHODS FOR NUCLEIC ACID EXTRACTION	Not Available	30-Jun-16	27-Dec-18	19-Mar-20
US20200085984	APPARATUS, METHOD AND SYSTEM FOR SELECTIVELY AFFECTING AND/OR KILLING A VIRUS	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	7-Mar-11	25-Nov-19	19-Mar-20
US20200085947	VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER	Not Available	7-Sep-12	14-May-19	19-Mar-20
US20200085943	PHARMACEUTICAL COMPOSITION COMPRISING A POLYMERIC CARRIER CARGO COMPLEX AND AT LEAST ONE PROTEIN OR PEPTIDE ANTIGEN	CureVac AG	31-Jan-12	29-Aug-19	19-Mar-20
US20200085872	IMMUNE CELLS EXPRESSING ENGINEERED ANTIGEN RECEPTORS	Not Available	19-Apr-17	19-Apr-18	19-Mar-20
US20200085852	EPIDERMAL MRNA VACCINE	Not Available	5-Aug-15	5-Aug-16	19-Mar-20
US20200085756	NANOPARTICLE VACCINE ADJUVANT AND METHODS OF USE THEREOF	Not Available	14-Sep-18	12-Jul-19	19-Mar-20
US20200080141	METHODS AND COMPOSITIONS FOR ENRICHMENT OF AMPLIFICATION PRODUCTS	Not Available	11-Dec-13	19-Nov-19	12-Mar-20
US20200080111	Methods for Autocatalytic Genome Editing and Neutralizing Autocatalytic Genome Editing and Compositions Thereof	Not Available	18-Sep-15	19-Sep-16	12-Mar-20
US20200079820	DERIVATIVES OF AMANITA TOXINS AND THEIR CONJUGATION TO A CELL BINDING MOLECULE	Hangzhou DAC Biotech Co., Ltd.	20-Apr-16	20-Apr-16	12-Mar-20
US20200079781	Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases	Not Available	5-Sep-18	1-Aug-19	12-Mar-20
US20200078335	COMPOSITIONS AND METHODS TO REDUCE PATHOGENESIS	Not Available	1-May-17	1-May-18	12-Mar-20
US20200072836	MEDIA ELABORATED WITH NEWLY SYNTHESIZED ANTIBODIES (MENSA) AND USES THEREOF	Not Available	5-May-14	2-Apr-19	5-Mar-20
US20200071723	RNA-BASED DELIVERY SYSTEMS WITH LEVELS OF CONTROL	Not Available	30-Aug-18	29-Aug-19	5-Mar-20

CC-BY-NC-SA Dr. David E. Martin

US20200071421	BISPECIFIC ANTIBODY	Not Available	20-Nov-13	8-Apr-19	5-Mar-20
US20200069814	CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGE	Hangzhou DAC Biotech Co., Ltd.	6-Apr-17	6-Apr-17	5-Mar-20
US20200062764	ALKYL PYRROLOPYRIMIDINE ANALOGS AND METHODS OF MAKING AND USING SAME	Not Available	17-Nov-16	17-Nov-17	27-Feb-20
US20200061187	METHODS FOR PREPARING SQUALENE	Not Available	12-May-10	4-Nov-19	27-Feb-20
US20200061185	PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USE	The Scripps Research Institute	25-Oct-16	25-Oct-17	27-Feb-20
US20200060981	CATIONIC NANOPARTICLES FOR ENHANCING INFECTIOUS CAPACITY OF LIVE VIRUSES	Not Available	9-Dec-16	11-Dec-17	27-Feb-20
US20200056221	METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING ADSORPTION MEDIA	Not Available	8-Nov-13	25-Oct-19	20-Feb-20
US20200056159	NOVEL ADENO-ASSOCIATED VIRUS (AAV) CLADE F VECTOR AND USES THEREFOR	Not Available	28-Feb-17	27-Feb-18	20-Feb-20
US20200055927	MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION	Not Available	8-Sep-16	25-Oct-19	20-Feb-20
US20200055926	MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION	Not Available	8-Sep-16	25-Oct-19	20-Feb-20
US20200054731	IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF	Not Available	7-Jan-14	15-Jul-19	20-Feb-20
US20200054660	DNA METHYLATION PROFILING FOR T-CELL IMMUNOTHERAPY	St. Jude Children's Research Hospital	9-Dec-16	7-Dec-17	20-Feb-20
US20200054259	HIGH DENSITY ANALOG MULTIPEXING	EnLiSense, LLC	17-Aug-18	16-Aug-19	20-Feb-20
US20200048722	METHODS FOR REAL-TIME MULTIPLEX ISOTHERMAL DETECTION AND IDENTIFICATION OF BACTERIAL, VIRAL, AND PROTOZOAN NUCLEIC ACIDS	Not Available	8-May-15	24-Aug-19	13-Feb-20
US20200048649	VIRUS-LIKE PARTICLES AND USES THEREOF	Not Available	13-Mar-17	13-Mar-18	13-Feb-20
US20200048636	IMMUNISATION OF LARGE MAMMALS WITH LOW DOSES OF RNA	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul-10	18-Oct-19	13-Feb-20
US20200046865	DECONTAMINATION DEVICE AND METHOD USING ULTRASONIC CAVITATION	Not Available	29-Dec-17	22-Aug-19	13-Feb-20
US20200046826	METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST VIRUS	Academia Sinica	27-Mar-09	4-Jun-19	13-Feb-20
US20200046692	SPECIFIC AKT3 INHIBITOR AND USES THEREOF	Not Available	15-Jan-16	2-Oct-19	13-Feb-20
US20200040408	HANDHELD NUCLEIC ACID-BASED ASSAY FOR RAPID IDENTIFICATION	Not Available	8-Feb-16	6-May-19	6-Feb-20
US20200040042	CHIMERIC MOLECULES AND USES THEREOF	Not Available	30-Mar-17	29-Mar-18	6-Feb-20
US20200038871	DEVICES, PROCESSES, AND SYSTEMS FOR DETERMINATION OF NUCLEIC ACID SEQUENCE, EXPRESSION, COPY NUMBER, OR METHYLATION CHANGES USING COMBINED NUCLEASE, LIGASE, POLYMERASE, AND SEQUENCING REACTIONS	Not Available	29-Mar-17	29-Mar-18	6-Feb-20
US20200038373	NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	9-May-12	16-May-19	6-Feb-20
US20200033343	EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES	Not Available	6-Oct-08	14-Oct-19	30-Jan-20
US20200032255	METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES	Not Available	26-Jan-07	6-Mar-19	30-Jan-20
US20200031871	NOVEL DEPSIPEPTIDES AND USES THEREOF	Not Available	4-Apr-17	30-Mar-18	30-Jan-20
US20200031819	COMPOSITIONS AND METHODS FOR INHIBITING KINASES	Not Available	23-Apr-15	26-Jun-19	30-Jan-20
US20200030441	Lipidated Immune Response Modifier Compound Compositions, Formulations, and Methods	Not Available	17-Aug-10	8-Jul-19	30-Jan-20

CC-BY-NC-SA Dr. David E. Martin

US20200030432	ZOONOTIC DISEASE RNA VACCINES	ModernaTX, Inc.	17-Mar-17	16-Mar-18	30-Jan-20
US20200030422	COMBINATION OF VACCINATION AND OX40 AGONISTS	CureVac AG	9-Sep-16	15-Apr-19	30-Jan-20
US20200024616	NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH ENHANCED HUMAN PANCREATIC TROPISM	Not Available	30-Mar-18	29-Mar-19	23-Jan-20
US20200024310	NOVEL DEPSIPEPTIDE AND USES THEREOF	Not Available	3-Dec-12	1-Aug-19	23-Jan-20
US20200020420	Method for Establishing Machine Learning Model for Predicting Toxicity of siRNA to Certain Type of Cells and Application Thereof	Not Available	8-Dec-16	7-Dec-17	16-Jan-20
US20200017926	CELL-FREE NUCLEIC ACIDS FOR THE ANALYSIS OF THE HUMAN MICROBIOME AND COMPONENTS THEREOF	Not Available	7-Nov-13	28-Aug-19	16-Jan-20
US20200017832	COMPOSITIONS FOR REPROGRAMMING CELLS INTO DENDRITIC CELLS OR ANTIGEN PRESENTING CELLS, METHODS AND USES THEREOF	Not Available	5-Apr-17	5-Apr-18	16-Jan-20
US20200017588	MODULAR TETRAVALENT BISPECIFIC ANTIBODY PLATFORM	Not Available	14-Oct-16	16-Oct-17	16-Jan-20
US20200017554	SELF-ASSEMBLING PROTEIN NANOPARTICLES WITH BUILT-IN SIX-HELIX BUNDLE PROTEINS	Not Available	23-Mar-17	22-Mar-18	16-Jan-20
US20200017514	ADAMANTANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION	Not Available	12-Jul-18	12-Jul-18	16-Jan-20
US20200017455	CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS	Not Available	24-Jan-14	19-Mar-19	16-Jan-20
US20200016589	LOADING VIALS	Not Available	10-Nov-11	24-Sep-19	16-Jan-20
US20200016286	Production of Immune-Response-Stimulating Aerosols By Non-Thermal Plasma Treatment Of Airborne Pathogens	Not Available	13-Jul-18	12-Jul-19	16-Jan-20
US20200016280	Compositions For Enhancing Transport Of Molecules Into Cells	Not Available	29-Apr-03	9-Apr-19	16-Jan-20
US20200016161	METHODS FOR TREATING VIRAL DISORDERS	TRUSTEES OF BOSTON UNIVERSITY	24-Sep-09	22-Jul-19	16-Jan-20
US20200010883	METHODS AND COMPOSITIONS FOR ENRICHMENT OF AMPLIFICATION PRODUCTS	Not Available	9-Oct-15	7-Jun-19	9-Jan-20
US20200010519	NUCLEASE FUSIONS FOR ENHANCING GENOME EDITING BY HOMOLOGY-DIRECTED TRANSGENE INTEGRATION	Not Available	10-Mar-17	9-Mar-18	9-Jan-20
US20200009244	NANOPARTICLE VACCINES WITH NOVEL STRUCTURAL COMPONENTS	Not Available	13-Jun-18	13-Jun-19	9-Jan-20
US20200002674	ERYTHROID CELLS COMPRISING PHENYLALANINE HYDROXYLASE	Not Available	18-Nov-13	16-Sep-19	2-Jan-20
US20200000931	SYNTHETIC NANOPARTICLES FOR DELIVERY OF IMMUNOMODULATORY COMPOUNDS	Not Available	15-Jul-16	10-Apr-19	2-Jan-20
US20190391150	COMPOSITIONS AND METHODS FOR CAPTURING EXOSOMES	Not Available	1-May-15	10-Sep-19	26-Dec-19
US20190390249	BIOLOGICAL SPECIMEN COLLECTION AND TRANSPORT SYSTEM	Longhorn Vaccines and Diagnostics, LLC	1-Oct-07	19-Jun-17	26-Dec-19
US20190390229	GENE EDITING REAGENTS WITH REDUCED TOXICITY	Not Available	21-Apr-16	20-Apr-17	26-Dec-19
US20190390179	SYNTHETIC REVERSE TRANSCRIPTASES AND USES THEREOF	Not Available	12-Apr-16	12-Apr-17	26-Dec-19
US20190390176	NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH ENHANCED HUMAN SKELETAL MUSCLE TROPISM	Not Available	2-Dec-15	3-Jul-19	26-Dec-19
US20190389816	ANTIVIRAL COMPOUNDS AND METHODS	Biotron Limited	26-Jun-03	29-Aug-19	26-Dec-19
US20190388473	METHODS AND COMPOSITIONS FOR IMMUNOMODULATION	Not Available	1-Apr-14	30-Aug-19	26-Dec-19
US20190382799	VIRAL METHODS OF MAKING GENETICALLY MODIFIED CELLS	Not Available	27-Oct-16	19-Apr-19	19-Dec-19

CC-BY-NC-SA Dr. David E. Martin

US20190382433	GLYCOLIPIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THERAPY	THE UNIVERSITY OF NOTTINGHAM	4-Apr-14	25-Jul-19	19-Dec-19
US20190381180	HYBRID CARRIERS FOR NUCLEIC ACID CARGO	Not Available	9-Jun-16	9-Jun-17	19-Dec-19
US20190381162	PAN FILOVIRUS VACCINE COMPOSITIONS AND METHODS OF MAKING	Not Available	28-Mar-16	27-Mar-17	19-Dec-19
US20190381155	COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY	CureVac AG	22-Feb-13	29-Aug-19	19-Dec-19
US20190380995	PREVENTION AND TREATMENT OF VIRAL INFECTIONS	Not Available	2-Jun-16	3-Jul-19	19-Dec-19
US20190380891	MOBILE CLINICS	Baylor College of Medicine	12-Nov-14	28-Aug-19	19-Dec-19
US20190376151	MODIFIED OLIGONUCLEOTIDES COMPRISING THIOL FUNCTIONS AND USE THEREOF FOR DETECTING NUCLEIC ACIDS	Not Available	4-Apr-12	8-Feb-19	12-Dec-19
US20190376034	PLATELETS COMPRISING EXOGENOUS POLYPEPTIDES AND USES THEREOF	Not Available	18-Nov-13	23-Aug-19	12-Dec-19
US20190375801	HSP FUSION PROTEIN WITH ANTI-CHEMOREPELLANT AGENT FOR TREATMENT OF INFECTIOUS DISEASE	Not Available	9-Sep-16	8-Sep-17	12-Dec-19
US20190374650	COMPOSITIONS AND METHODS FOR DELIVERY OF POLYMER/BIOMACROMOLECULE CONJUGATES	Not Available	22-Feb-17	21-Feb-18	12-Dec-19
US20190374610	MEDICAL USE OF INTERFERON-LAMBDA FOR THE TREATMENT OF FIBROSIS	Not Available	20-Dec-16	20-Dec-17	12-Dec-19
US20190374576	VIRAL METHODS OF T CELL THERAPY	Not Available	27-Oct-16	19-Apr-19	12-Dec-19
US20190370834	SYSTEM FOR DETERMINING PUBLIC SENTIMENT TOWARDS PATHOGENS	Not Available	1-Jun-18	1-Jun-18	5-Dec-19
US20190367553	COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1	Not Available	27-Oct-17	26-Apr-19	5-Dec-19
US20190367525	PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	30-Dec-14	19-Jul-19	5-Dec-19
US20190367453	CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS	HANGZHOU DAC BIOTECH CO., LTD.	12-Jul-12	13-Aug-19	5-Dec-19
US20190365925	AAV VECTORS TARGETED TO THE CENTRAL NERVOUS SYSTEM	Not Available	21-Nov-14	13-Jun-19	5-Dec-19
US20190365756	PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS	Not Available	4-Jun-18	3-Jun-19	5-Dec-19
US20190359990	VIRAL SYNTHETIC NUCLEIC ACID SEQUENCES AND USE THEREOF	Not Available	25-Jan-17	25-Jan-18	28-Nov-19
US20190359635	ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5-Feb-15	18-Jul-19	28-Nov-19
US20190359629	THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5-Feb-15	18-Jul-19	28-Nov-19
US20190358335	STOMACH ACID-STABLE AND MUCIN-BINDING PROTEIN-POLYMER CONJUGATES	Not Available	12-Jan-17	12-Jan-18	28-Nov-19
US20190358312	ANTIGEN-ADJUVANT COUPLING REAGENTS AND METHODS OF USE	Not Available	19-Dec-17	19-Dec-18	28-Nov-19
US20190358304	ORAL DELIVERY OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) OR ANGIOTENSIN-(1-7)-BIOENCAPSULATED IN PLANT CELLS ATTENUATES PULMONARY HYPERTESNIONS, CARDIAC DYSFUNCTION AND DEVELOPMENT OF AUTOIMMUNE AND EXPOERIMENTALLY INDUCED OCULAR DISORDERS	Not Available	18-Oct-13	29-May-19	28-Nov-19
US20190358170	Lipids and Lipid Compositions for the Delivery of Active Agents	Not Available	19-Dec-13	12-Aug-19	28-Nov-19
US20190352639	GENOME EDITING REAGENTS AND THEIR USE	Not Available	10-Feb-17	12-Feb-18	21-Nov-19
US20190352615	METHOD FOR PURIFYING VIRUS	Not Available	22-Dec-16	21-Dec-17	21-Nov-19

CC-BY-NC-SA Dr. David E. Martin

US20190352608	CD137 ENRICHMENT FOR EFFICIENT TUMOR INFILTRATING LYMPHOCYTE SELECTION	Not Available	16-Sep-13	30-Jan-19	21-Nov-19
US20190352357	HELIX-GRAFTED PROTEINS AS INHIBITORS OF DISEASE-RELEVANT PROTEIN-PROTEIN INTERACTIONS	Colorado State University Research Foundation	7-Nov-14	7-Aug-19	21-Nov-19
US20190346443	EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES	Not Available	6-Oct-08	28-Jun-19	14-Nov-19
US20190345504	ARTIFICIAL NUCLEIC ACID MOLECULES	CureVac AG	30-Dec-14	26-Jul-19	14-Nov-19
US20190345503	CIRCULAR RNAS AND THEIR USE IN IMMUNOMODULATION	Not Available	20-Jun-16	15-Jun-17	14-Nov-19
US20190345481	PURIFICATION OF NUCLEIC ACIDS USING METAL-TITANIUM OXIDES	Not Available	14-Jul-15	5-Jul-19	14-Nov-19
US20190345221	BROAD SPECTRUM VACCINE, PREPARING METHOD AND APPLICATION THEREOF	Tianjin Dongya Biological Technology Co., Ltd.	9-May-18	9-May-18	14-Nov-19
US20190345166	COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS	Not Available	1-May-14	24-Jul-19	14-Nov-19
US20190343862	DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS	GLAXOSMITHKLINE BIOLOGICALS, SA	6-Jul-10	16-Jul-19	14-Nov-19
US20190337990	POLYPEPTIDES FOR ENGINEERING INTEGRASE CHIMERIC PROTEINS AND THEIR USE IN GENE THERAPY	Not Available	13-Feb-15	5-Jun-19	7-Nov-19
US20190336969	PARALLELIZED SAMPLE HANDLING	Not Available	19-Apr-13	27-Mar-19	7-Nov-19
US20190336611	HYBRID CARRIERS FOR NUCLEIC ACID CARGO	CureVac AG	9-Jun-16	9-Jun-17	7-Nov-19
US20190336608	CATIONIC CARRIERS FOR NUCLEIC ACID DELIVERY	CureVac AG	9-Jun-16	9-Jun-17	7-Nov-19
US20190336597	METHODS OF GENERATING ROBUST PASSIVE AND ACTIVE IMMUNE RESPONSES	Not Available	8-Jan-13	17-May-19	7-Nov-19
US20190336456	USE OF XIBORNOL AS ACTIVE AGENT IN THE TREATMENT OF VIRAL INFECTIONS	ABIOGEN PHARMA S.P.A.	15-Jul-16	13-Jul-17	7-Nov-19
US20190330618	ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES	Not Available	1-Dec-05	22-Jan-19	31-Oct-19
US20190330572	CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF	Not Available	8-Sep-16	21-Jun-19	31-Oct-19
US20190330245	Boron-Containing Small Molecules	Anacor Pharmaceuticals, Inc.	16-Feb-05	12-Jul-19	31-Oct-19
US20190330187	Chemical Compounds	Not Available	18-Mar-14	10-May-19	31-Oct-19
US20190330164	HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	29-Jul-11	28-Nov-18	31-Oct-19
US20190330149	CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS	HANGZHOU DAC BIOTECH CO., LTD.	12-Jul-12	9-May-19	31-Oct-19
US20190328869	IMMUNOTHERAPEUTIC PRODUCT AND MDSC MODULATOR COMBINATION THERAPY	Transgene SA	10-Oct-16	10-Oct-17	31-Oct-19
US20190328865	IMMUNOGENIC COMPOSITION FOR MERS CORONAVIRUS INFECTION	Not Available	28-Jul-14	17-Nov-17	31-Oct-19
US20190328804	AAV Vectors Targeted to Oligodendrocytes	Not Available	28-Sep-12	15-Jul-19	31-Oct-19
US20190323068	PCR Ready Compositions and Methods for Screening Biological Samples	Longhorn Vaccines and Diagnostics, LLC	12-Sep-06	28-Jun-19	24-Oct-19
US20190322989	PRODUCTION OF VIRUSES IN CELL CULTURE	Not Available	24-Nov-15	25-Jan-19	24-Oct-19
US20190322725	COMPOSITIONS COMPRISING AAV EXPRESSING DUAL ANTIBODY CONSTRUCTS AND USES THEREOF	Not Available	13-May-14	2-Jul-19	24-Oct-19
US20190321481	IMMUNOMODULATORY COMPOSITIONS, PROCESSES FOR MAKING THE SAME, AND METHODS FOR INHIBITING CYTOKINE STORMS	NantBio, Inc.	11-Nov-16	9-Nov-17	24-Oct-19
US20190321403	ENGINEERED B CELLS AND RELATED COMPOSITIONS AND METHODS	Juno Therapeutics, Inc.	2-Dec-16	30-Nov-17	24-Oct-19

US20190316109	COMPOSITION COMPRISING A GENE VECTOR THAT SELECTIVELY DEPLETES P16 POSITIVE SENESCENT CELLS	Not Available	17-Apr-12	10-Jun-19	17-Oct-19
US20190316091	ERYTHROID CELLS COMPRISING ARGINASE	Not Available	18-Nov-13	30-May-19	17-Oct-19
US20190316090	ERYTHROID CELLS COMPRISING ARGININE DEIMINASE	RUBIUS THERAPEUTICS, INC.	18-Nov-13	30-May-19	17-Oct-19
US20190316089	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13	10-May-19	17-Oct-19
US20190315840	ANTI-DENGUE VIRUS ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT FC REGIONS, AND METHODS OF USE	Not Available	16-Sep-16	10-Jun-19	17-Oct-19
US20190315807	VIRUS-LIKE PARTICLES WITH HIGH-DENSITY COATING FOR INDUCING THE EXPRESSION OF ANTIBODIES	Not Available	27-Jul-16	26-Jul-17	17-Oct-19
US20190314496	POLYMERIC CARRIER CARGO COMPLEX FOR USE AS AN IMMUNOSTIMULATING AGENT OR AS AN ADJUVANT	CureVac AG	1-Apr-14	18-Jun-19	17-Oct-19
US20190314483	Vaccines Including Antigen From Four Strains of Influenza Virus	Not Available	6-Dec-06	30-Nov-18	17-Oct-19
US20190314482	VACCINES AGAINST INFECTIOUS DISEASES CAUSED BY POSITIVE STRANDED RNA VIRUSES	Medigen, Inc.	28-Nov-16	21-Nov-17	17-Oct-19
US20190314480	IMMUNOGENIC COMPOSITIONS AND USES THEREOF	Not Available	25-Mar-15	23-Apr-19	17-Oct-19
US20190314471	MOLECULAR VACCINES FOR INFECTIOUS DISEASE	Not Available	2-Oct-08	27-Jun-19	17-Oct-19
US20190314455	CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES	Not Available	3-Aug-17	7-Jun-19	17-Oct-19
US20190314372	PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPS	Not Available	5-Dec-16	25-Mar-19	17-Oct-19
US20190310168	AIRBORNE AGENT COLLECTORS, METHODS, SYSTEMS AND DEVICES FOR MONITORING AIRBORNE AGENTS	Not Available	22-Jul-14	4-Mar-19	10-Oct-19
US20190309357	CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	9-Dec-16	25-Feb-19	10-Oct-19
US20190309262	ERYTHROID CELLS COMPRISING SERINE DEHYDRATASE	Not Available	18-Nov-13	4-Jun-19	10-Oct-19
US20190309261	ERYTHROID CELLS COMPRISING LYSINE OXIDASE	Not Available	18-Nov-13	4-Jun-19	10-Oct-19
US20190309048	Optimized Human Clotting Factor VIII Gene Expression Cassettes and Their Use	Not Available	6-Feb-15	20-May-19	10-Oct-19
US20190309039	CRYPTIC POLYPEPTIDES AND USES THEREOF	Not Available	29-Jan-15	22-Apr-19	10-Oct-19
US20190308980	PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	30-Dec-14	24-Jun-19	10-Oct-19
US20190308969	HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS	Not Available	11-Nov-16	13-Nov-17	10-Oct-19
US20190308943	3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS	Parion Sciences, Inc.	17-Dec-12	13-Mar-19	10-Oct-19
US20190307878	IMMUNE COMPLEX	The Rockefeller University	20-Mar-15	10-May-19	10-Oct-19
US20190307722	ANTIVIRAL COMPOSITIONS FOR THE TREATMENT OF INFECTIONS LINKED TO CORONAVIRUSES	Not Available	21-Oct-16	20-Oct-17	10-Oct-19
US20190298824	ALBUMIN-BINDING IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF	THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Serv	4-May-16	4-May-17	3-Oct-19
US20190298752	METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR)	Invirsa, Inc.	27-Mar-18	26-Mar-19	3-Oct-19
US20190298750	Nucleotide and Nucleoside Therapeutic Compositions and Uses Related Thereto	Not Available	11-Sep-13	21-Nov-18	3-Oct-19
US20190293656	NON-RADIOACTIVE CYTOTOXICITY ASSAYS	Not Available	19-Sep-16	19-Sep-17	26-Sep-19
US20190292580	DNA LOGIC-GATED PROXIMITY ASSEMBLY CIRCUIT FOR BIOCHEMICAL SENSING	Rutgers, The State University of New Jersey	23-Mar-18	22-Mar-19	26-Sep-19

CC-BY-NC-SA Dr. David E. Martin

US20190292563	ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR	The Trustees of the University of Pennsylvania	17-Dec-01	8-Apr-19	26-Sep-19
US20190292561	SCALABLE METHODS FOR PRODUCING RECOMBINANT ADENO-ASSOCIATED VIRAL (AAV) VECTOR IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM SUITABLE FOR CLINICAL USE	SPARK THERAPEUTICS, INC.	1-Dec-15	1-Dec-16	26-Sep-19
US20190292236	MODULATION OF IFI16 AND STING ACTIVITY	Not Available	9-Aug-16	9-Aug-17	26-Sep-19
US20190292216	Cyclic Di-Nucleotide Induction of Type I Interferon	Not Available	3-May-13	19-Feb-19	26-Sep-19
US20190292178	HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES	Dana-Farber Cancer Institute, Inc.	11-Apr-12	26-Jan-18	26-Sep-19
US20190290674	Composition for Promoting Production of Immunostimulatory Factor	Kyoto University	2-Aug-16	31-Jul-17	26-Sep-19
US20190285632	METABALOMICS AND VIRAL DIAGNOSTICS SUITE	Excision Biotherapeutics, Inc.	24-May-16	24-May-17	19-Sep-19
US20190284575	REVERSE GENETICS USING NON-ENDOGENOUS POL I PROMOTERS	Not Available	21-May-09	30-Jan-19	19-Sep-19
US20190284531	DETECTION OF T CELL EXHAUSTION OR LACK OF T CELL COSTIMULATION AND USES THEREOF	Not Available	15-May-15	24-May-19	19-Sep-19
US20190284230	ASSEMBLED GLYCOPROTEINS	Not Available	29-Sep-16	22-Sep-17	19-Sep-19
US20190282694	IMMUNOPROTECTIVE PRIMARY MESENCHYMAL STEM CELLS AND METHODS	AUTOIMMUNE TECHNOLOGIES, LLC	14-Mar-13	30-May-19	19-Sep-19
US20190282608	Method Of Treating Inflammation	Not Available	1-Apr-10	29-May-19	19-Sep-19
US20190276523	COMPOSITION AND METHODS OF TREATING B CELL DISORDERS	Not Available	2-Sep-16	5-Sep-17	12-Sep-19
US20190275519	SYSTEM FOR THE PRODUCTION OF CELLS AND/OR CELL PRODUCTS	Not Available	8-Nov-16	8-Nov-17	12-Sep-19
US20190275101	STRUCTURE OF GII.4 NOROVIRUS PROTEASE - DESIGN OF BROAD-SPECTRUM PROTEASE INHIBITORS	Not Available	5-Oct-16	5-Oct-17	12-Sep-19
US20190269694	HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS	Not Available	8-Mar-11	11-Oct-18	5-Sep-19
US20190269672	Specific Akt3 Inhibitor and Uses Thereof	Not Available	15-Jan-16	20-May-19	5-Sep-19
US20190264267	PHASING	Wave Life Sciences Ltd.	25-Jul-16	24-Jul-17	29-Aug-19
US20190264177	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13	10-May-19	29-Aug-19
US20190263934	FC VARIANTS WITH ENHANCED BINDING TO FCRN AND PROLONGED HALF-LIFE	Not Available	26-Jan-18	25-Jan-19	29-Aug-19
US20190262448	Cationic Oil-In-Water Emulsions	GLAXOSMITHKLINE BIOLOGICALS, SA	18-Sep-11	7-Mar-19	29-Aug-19
US20190262371	METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONS	Not Available	20-Oct-16	20-Oct-17	29-Aug-19
US20190256585	ANTIBODY SPECIFICALLY BINDING TO AN ISOLATED PEPTIDE DERIVED FROM VIMENTIN OR A FRAGMENT BINDING TO THE PEPTIDE	Not Available	10-Jun-15	10-Jun-16	22-Aug-19
US20190256579	MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE	The U.S.A., as represented by the Secretary, Department of Health and Human Services	24-Feb-15	3-May-19	22-Aug-19
US20190255085	METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS	Not Available	16-Sep-15	1-Feb-19	22-Aug-19
US20190254968	OIL-IN-WATER EMULSIONS THAT CONTAIN NUCLEIC ACIDS	GLAXOSMITHKLINE BIOLOGICALS S.A.	6-Jul-11	2-May-19	22-Aug-19
US20190250153	MULTI-CONFIGURABLE SENSING ARRAY AND METHODS OF USING SAME	Board of Regents, The University of Texas System	20-Oct-16	19-Oct-17	15-Aug-19
US20190248883	HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)	Not Available	16-Dec-02	20-Feb-19	15-Aug-19
US20190248866	POLYPEPTIDES AND USES THEREOF FOR TREATMENT OF AUTOIMMUNE DISORDERS AND INFECTION	Not Available	30-Jun-11	30-Apr-18	15-Aug-19

US20190248865	ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOF	Not Available	23-Oct-15	21-Oct-16	15-Aug-19
US20190247529	METHOD AND SYSTEM FOR DECONTAMINATING SMALL ENCLOSURES	Not Available	29-Dec-17	23-Apr-19	15-Aug-19
US20190247489	ADJUVANTED INFLUENZA B VIRUS VACCINES FOR PEDIATRIC PRIMING	Not Available	20-Oct-11	16-Nov-18	15-Aug-19
US20190247485	Dimethyl Fumarate and Vaccination Regimens	Biogen MA Inc.	14-Mar-14	23-Apr-19	15-Aug-19
US20190247440	METHODS AND COMPOSITIONS FOR IMMUNOMODULATION	Not Available	1-Apr-14	12-Apr-19	15-Aug-19
US20190247367	TREATMENT OF INFECTIOUS DISEASES	CHILDREN'S MEDICAL CENTER CORPORATION	26-Jan-15	23-Apr-19	15-Aug-19
US20190241646	ANTI-PNEUMOCOCCAL HYPERIMMUNE GLOBULIN FOR THE TREATMENT AND PREVENTION OF PNEUMOCOCCAL INFECTION	Not Available	15-Mar-17	15-Apr-19	8-Aug-19
US20190241618	INHIBITION OF TCR SIGNALING WITH PEPTIDE VARIANTS	Not Available	30-Sep-09	22-Oct-18	8-Aug-19
US20190240317	HPIV3 RNA VACCINES	ModernaTX, Inc.	22-Oct-15	28-Mar-19	8-Aug-19
US20190233447	PROTEIN PROXIMITY ASSAY IN FORMALIN FIXED PARAFFIN EMBEDDED TISSUE USING CAGED HAPTENS	Not Available	28-Aug-15	25-Feb-19	1-Aug-19
US20190232282	METHODS AND COMPOSITIONS FOR DETECTING ANALYTES	Not Available	23-Sep-16	20-Sep-17	1-Aug-19
US20190231004	MASK	NBC MESHTEC INC.	17-Oct-16	13-Oct-17	1-Aug-19
US20190225986	GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA VIRUS SPIKE PROTEIN	Not Available	28-Oct-05	30-Nov-18	25-Jul-19
US20190225971	METHOD OF INCREASING THE REPLICATION OF A CIRCULAR DNA MOLECULE	Not Available	10-Aug-15	4-Aug-16	25-Jul-19
US20190224339	COMPOSITIONS FOR THE TREATMENT OF DISEASE	Not Available	29-Apr-16	28-Apr-17	25-Jul-19
US20190223445	ANTIMICROBIAL GEOPOLYMER COMPOSITIONS	Not Available	14-Jul-16	13-Jul-17	25-Jul-19
US20190220524	DETERMINING EXPLANATIONS FOR PREDICTED LINKS IN KNOWLEDGE GRAPHS	Not Available	16-Jan-18	29-Mar-18	18-Jul-19
US20190219563	Assay for Detecting TH1 and TH2 Cell Populations	Not Available	16-May-14	17-Dec-18	18-Jul-19
US20190218574	METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR	The Trustees of the University of Pennsylvania	2-Oct-07	28-Mar-19	18-Jul-19
US20190218277	ANTI-DENGUE VIRUS ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT FC REGIONS, AND METHODS OF USE	Not Available	16-Sep-16	15-Sep-17	18-Jul-19
US20190218207	3-(Pyridin-3-yl)-Acrylamide and N-(Pyridin-3-yl)-Acrylamide Derivatives and Their Use as PAK or NAMPT Modulators	Not Available	17-Aug-15	17-Aug-16	18-Jul-19
US20190216951	METHOD FOR INCREASING EXPRESSION OF RNA-ENCODED PROTEINS	CureVac AG	21-Aug-13	1-Apr-19	18-Jul-19
US20190216917	HMPV RNA VACCINES	ModernaTX, Inc.	22-Oct-15	28-Mar-19	18-Jul-19
US20190216915	TRANSGENIC VERO-CD4/CCR5 CELL LINE	Not Available	2-Oct-15	15-Feb-19	18-Jul-19
US20190216841	Regimens and Compositions for AAV-Mediated Passive Immunization of Airborne Pathogens	Not Available	20-Apr-11	20-Mar-19	18-Jul-19
US20190211361	COMPOSITIONS COMPRISING CURONS AND USES THEREOF	Not Available	13-Jun-17	27-Mar-19	11-Jul-19
US20190211355	DNA MOLECULES PRODUCING CUSTOM DESIGNED REPLICATING AND NON-REPLICATING NEGATIVE STRANDED RNA VIRUSES AND USES THERE OF	Not Available	5-Jan-15	4-Jan-16	11-Jul-19
US20190211024	SMALL MOLECULES HAVING ANTIVIRAL PROPERTIES	General Research Laboratory	19-Aug-16	19-Aug-17	11-Jul-19

CC-BY-NC-SA Dr. David E. Martin

US20190209678	MANUFACTURE OF SURFACTANT-CONTAINING COMPOSITIONS WITH ENHANCED STABILITY	Not Available	2-Dec-14	12-Mar-19	11-Jul-19
US20190209604	OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOF	WAVE LIFE SCIENCES LTD.	3-Jun-16	2-Jun-17	11-Jul-19
US20190207890	RNA TARGETING METHODS AND COMPOSITIONS	Salk Institute for Biological Studies	22-Aug-17	31-Dec-18	4-Jul-19
US20190204330	APPLICATION OF CLICK CHEMISTRY FOR SIGNAL AMPLIFICATION IN IHC AND ISH ASSAYS	Not Available	28-Jun-16	19-Dec-18	4-Jul-19
US20190203268	LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) BASED ASSAY FOR DETECTING MICROBES	Not Available	2-Jan-18	31-Dec-18	4-Jul-19
US20190203186	PRODUCTION OF VIRUSES IN AVIAN EGGS	Not Available	24-Nov-15	25-Jan-19	4-Jul-19
US20190203170	Avian Cells for Improved Virus Production	Not Available	5-Jun-13	21-Dec-18	4-Jul-19
US20190202929	COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF AML USING USP10 BIOMARKERS AND MODULATORS	Not Available	20-Sep-16	20-Sep-17	4-Jul-19
US20190202868	CORONAVIRUS PROTEINS AND ANTIGENS	Phibro Animal Health Corporation	7-Feb-14	15-Mar-19	4-Jul-19
US20190202854	ENANTIOMERS OF THE 1',6'-ISOMER OF NEPLANOCIN A	Not Available	4-Aug-14	8-Mar-19	4-Jul-19
US20190201565	DECONTAMINATION DEVICE AND METHOD USING ULTRASONIC CAVITATION	Not Available	29-Dec-17	11-Sep-18	4-Jul-19
US20190201564	DECONTAMINATION DEVICE AND METHOD USING ULTRASONIC CAVITATION	Not Available	29-Dec-17	29-Dec-17	4-Jul-19
US20190201552	Aptamer Compositions and Methods of Use Thereof	Not Available	28-Dec-17	28-Dec-18	4-Jul-19
US20190201433	2'-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENT	Atea Pharmaceuticals, Inc.	7-Sep-16	5-Mar-19	4-Jul-19
US20190201352	DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER NUCLEOSIDE ANALOGUES HAVING ANTI-CORONAVIRUS ACTIVITY	Not Available	30-Jan-15	12-Mar-19	4-Jul-19
US20190201337	HYDROPHILIC FILTRATION DURING MANUFACTURE OF VACCINE ADJUVANTS	Not Available	3-Dec-09	3-Jan-19	4-Jul-19
US20190194728	Systemic inflammatory and pathogen biomarkers and uses therefor	Not Available	24-Aug-16	24-Aug-17	27-Jun-19
US20190194717	METHOD AND KIT FOR DETECTING PATHOGENIC MICROORGANISM	JAPAN SCIENCE AND TECHNOLOGY AGENCY	5-Sep-16	4-Sep-17	27-Jun-19
US20190194628	METHODS FOR PRODUCING VIRUS FOR VACCINE PRODUCTION	Takeda Pharmaceutical Company Limited	1-Sep-16	1-Sep-17	27-Jun-19
US20190194322	IDENTIFICATION OF VSIG3/VISTA AS A NOVEL IMMUNE CHECKPOINT AND USE THEREOF FOR IMMUNOTHERAPY	BIO-TECHNE CORPORATION	3-Aug-16	3-Aug-17	27-Jun-19
US20190194299	MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF	Not Available	25-Apr-14	19-Nov-18	27-Jun-19
US20190194226	FUSED [1,2]IMIDAZO[4,5-C] RING COMPOUNDS SUBSTITUTED WITH GUANIDINO GROUPS	Not Available	26-Aug-16	1-Aug-17	27-Jun-19
US20190194150	COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTION	Arrakis Therapeutics, Inc.	1-Jul-16	30-Jun-17	27-Jun-19
US20190192691	REGULATED BIOCIRCUIT SYSTEMS	Not Available	11-Apr-16	11-Apr-17	27-Jun-19
US20190192581	Methods of Populating a Gastrointestinal Tract	Not Available	4-Feb-13	1-Aug-18	27-Jun-19
US20190187151	ASSAY FOR QUANTITATION OF PROTEINS AND PEPTIDES USING STABLE ISOTOPE STANDARDS	UVic Industry Partnerships Inc.	6-Jun-16	7-Apr-17	20-Jun-19
US20190187130	COLORS FOR CHROMOGENIC IHC AND ISH STAINING WITH MULTI-DYE QUINONE METHIDE AND TYRAMIDE CONJUGATES	Not Available	28-Jun-16	19-Dec-18	20-Jun-19
US20190185922	LUMINOPHORE-LABELED MOLECULES COUPLED WITH PARTICLES FOR MICROARRAY-BASED ASSAYS	CapitalBio Corporation	5-Dec-13	20-Nov-18	20-Jun-19

CC-BY-NC-SA Dr. David E. Martin

US20190185832	DIET CONTROLLED EXPRESSION OF A NUCLEIC ACID ENCODING CAS9 NUCLEASE AND USES THEREOF	Not Available	3-Jun-16	2-Jun-17	20-Jun-19
US20190184067	MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS	Not Available	1-Nov-15	28-Feb-19	20-Jun-19
US20190184018	CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES	Not Available	4-Dec-07	20-Nov-18	20-Jun-19
US20190183968	METHODS AND REAGENTS FOR EFFICIENT AND TARGETED DELIVERY OF THERAPEUTIC MOLECULES TO CXCR4 CELLS	Not Available	13-Jan-11	27-Feb-19	20-Jun-19
US20190183918	SYSTEMIC IN VIVO DELIVERY OF OLIGONUCLEOTIDES	Not Available	12-Jun-13	29-Oct-18	20-Jun-19
US20190177739	RECOMBINANT INFLUENZA VIRUS-LIKE PARTICLES (VLPS) PRODUCED IN TRANSGENIC PLANTS	Not Available	21-Jan-08	13-Dec-18	13-Jun-19
US20190175716	Adenoviral Vector	Not Available	23-Jun-16	23-Jun-17	13-Jun-19
US20190175528	INHIBITION OF BIOFILM ORGANISMS	Not Available	31-Mar-09	13-Feb-19	13-Jun-19
US20190169677	PORTABLE MOLECULAR DIAGNOSTIC DEVICE AND METHODS FOR THE DETECTION OF TARGET VIRUSES	Click Diagnostics, Inc.	9-Nov-17	9-Nov-18	6-Jun-19
US20190169639	CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS	EDITAS MEDICINE, INC.	7-Nov-13	24-Jan-19	6-Jun-19
US20190169595	RNA TARGETING METHODS AND COMPOSITIONS	Salk Institute for Biological Studies	22-Aug-17	25-Jan-19	6-Jun-19
US20190167787	Methods and Compositions for Inhibiting Akt3	Not Available	15-Jan-16	6-Feb-19	6-Jun-19
US20190167786	EMULSIONS WITH FREE AQUEOUS-PHASE SURFACTANT FOR ADJUVANTING SPLIT INFLUENZA VACCINES	Not Available	4-Nov-05	9-Jul-18	6-Jun-19
US20190167636	METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C	Not Available	14-Mar-13	8-Feb-19	6-Jun-19
US20190166866	METHOD FOR PRODUCING A PROTEIN PHOSPHOLIPID COMPLEX FROM A CRUSTACEAN CATCH	Not Available	4-Dec-17	30-Nov-18	6-Jun-19
US20190160129	Novel Polygonum Cuspidatum Extracts and Their Use as Photodynamic Inactivating Agents	Not Available	1-Oct-15	1-Feb-19	30-May-19
US20190160063	NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	31-Dec-15	30-Dec-16	30-May-19
US20190154687	DETECTION DEVICE AND DETECTION METHOD	Kabushiki Kaisha Toshiba	17-Nov-17	7-Mar-18	23-May-19
US20190154550	BIOAEROSOL DETECTION SYSTEMS AND METHODS OF USE	Not Available	6-Apr-16	6-Apr-17	23-May-19
US20190153471	COMPOSITIONS FOR THE TREATMENT OF DISEASE	Not Available	29-Apr-16	28-Apr-17	23-May-19
US20190153086	Heterodimeric Immunoglobulins	Not Available	21-Nov-12	5-Feb-19	23-May-19
US20190151844	DEVICES AND METHODS FOR THE DETECTION OF MOLECULES USING A FLOW CELL	Click Diagnostics, Inc.	29-Jun-16	21-Dec-18	23-May-19
US20190151474	RNA-BASED LOGIC CIRCUITS WITH RNA BINDING PROTEINS, APTAMERS AND SMALL MOLECULES	Kyoto University	8-Sep-14	8-Sep-15	23-May-19
US20190144930	ENHANCED METHODS OF RIBONUCLEIC ACID HYBRIDIZATION	Not Available	6-Dec-13	9-Jan-19	16-May-19
US20190144929	DEVICES FOR CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS	Not Available	15-Mar-17	15-Mar-18	16-May-19
US20190144827	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	RUBIUS THERAPEUTICS, INC.	18-Nov-13	19-Nov-18	16-May-19
US20190144556	ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIES	Not Available	13-May-16	12-May-17	16-May-19
US20190144484	ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO	Not Available	28-Apr-16	28-Apr-17	16-May-19

CC-BY-NC-SA Dr. David E. Martin

US20190142929	INFLUENZA VACCINE REGIMENS FOR PANDEMIC ASSOCIATED STRAINS	Not Available	10-Feb-09	15-Oct-18	16-May-19
US20190142927	LOW-ADDITIVE INFLUENZA VACCINES	Not Available	27-Jun-07	26-Jun-18	16-May-19
US20190136226	DEVICES AND METHODS FOR NUCLEIC ACID EXTRACTION	Not Available	11-May-16	9-Nov-18	9-May-19
US20190136215	Replication Conditional Virus that Specifically Kills Senescent Cells	Not Available	17-Apr-12	6-Jul-18	9-May-19
US20190135875	TRI-SEGMENTED PICHINDE VIRUSES AS VACCINE VECTORS	Not Available	18-May-16	17-May-17	9-May-19
US20190135873	COMPOSITIONS AND METHODS FOR TREATING DISEASES BY INHIBITING EXOSOME RELEASE	Not Available	19-Dec-16	19-Dec-18	9-May-19
US20190135788	DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDS	Hoffmann-La Roche Inc.	12-Jun-16	7-Dec-18	9-May-19
US20190134214	GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof	Not Available	6-May-16	4-May-17	9-May-19
US20190134193	USE OF TAM RECEPTOR INHIBITORS AS IMMUNOENHANCERS AND TAM ACTIVATORS AS IMMUNOSUPPRESSORS	SALK INSTITUTE FOR BIOLOGICAL STUDIES	9-Nov-07	9-Aug-18	9-May-19
US20190134186	INFLUENZA VACCINES WITH REDUCED AMOUNT OF EMULSION ADJUVANT	Not Available	4-Nov-05	10-Jul-18	9-May-19
US20190134062	PHARMACEUTICAL COMPOSITIONS AND METHODS	Not Available	3-Aug-15	8-Jan-19	9-May-19
US20190128893	QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION	Not Available	24-Feb-14	7-Nov-18	2-May-19
US20190128810	SYSTEM FOR MEASURING OPTICAL SIGNAL DETECTOR PERFORMANCE	Not Available	31-Dec-15	13-Dec-18	2-May-19
US20190127441	METHODS AND COMPOSITIONS FOR REDUCING VIRUS INFECTIVITY	University of Vermont and State Agricultural College	13-Apr-16	13-Apr-17	2-May-19
US20190127405	QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION	Not Available	24-Feb-14	7-Nov-18	2-May-19
US20190127401	CHARGED LINKERS AND THEIR USES FOR CONJUGATION	HANGZHOU DAC BIOTECH CO., LTD.	12-Aug-16	20-Dec-18	2-May-19
US20190127400	CHARGED LINKERS AND THEIR USES FOR CONJUGATION	HANGZHOU DAC BIOTECH CO., LTD.	12-Aug-16	20-Dec-18	2-May-19
US20190127399	CHARGED LINKERS AND THEIR USES FOR CONJUGATION	HANGZHOU DAC BIOTECH CO., LTD.	12-Aug-16	20-Dec-18	2-May-19
US20190125858	COLD ADAPTED AND VIRULENCE FACTOR DELETED LIVE ATTENUATED VACCINE SUITABLE FOR MUCOSAL DELIVERY	Not Available	18-Apr-16	18-Apr-17	2-May-19
US20190125806	Antimicrobial and Antiviral Agent, Antimicrobial and Antiviral Member, and Method for Producing Antimicrobial and Antiviral Agent	Murata Manufacturing Co., Ltd.	13-Jun-16	13-Dec-18	2-May-19
US20190125724	PREVENTION AND TREATMENT OF VIRAL INFECTIONS	Not Available	2-Jun-16	27-Nov-18	2-May-19
US20190119744	CAPTURE PRIMERS AND CAPTURE SEQUENCE LINKED SOLID SUPPORTS FOR MOLECULAR DIAGNOSTIC TESTS	Not Available	31-Jul-09	5-Nov-18	25-Apr-19
US20190119743	COMPOSITIONS AND METHODS FOR DETECTING RARE SEQUENCE VARIANTS	Not Available	15-Aug-16	26-Oct-18	25-Apr-19
US20190119701	METHODS FOR IMPROVED HOMOLOGOUS RECOMBINATION AND COMPOSITIONS THEREOF	Not Available	8-Sep-17	7-Sep-18	25-Apr-19
US20190119266	COMPOSITIONS AND METHODS FOR INHIBITING KINASES	Not Available	23-Apr-15	24-Oct-18	25-Apr-19
US20190119220	CARBOXYLIC ACID COMPOUNDS	Sumitomo Dainippon Pharma Co., Ltd.	18-May-12	23-Oct-18	25-Apr-19
US20190117793	MODULAR NANODEVICES FOR SMART ADAPTABLE VACCINES	Not Available	15-Feb-07	1-Oct-18	25-Apr-19
US20190117702	USE OF ASC AND ASC-CM TO TREAT ARDS, SARS, AND MERS	Indiana University Research and Technology Corporation	6-May-14	31-Oct-18	25-Apr-19
US20190112596	TAL-EFFECTOR ASSEMBLY PLATFORM, CUSTOMIZED SERVICES, KITS AND ASSAYS	Not Available	4-Apr-12	12-Apr-18	18-Apr-19
US20190112394	USING SORTASES TO INSTALL CLICK CHEMISTRY HANDLES FOR PROTEIN LIGATION	Whitehead Institute for Biomedical Research	28-Jun-11	24-Sep-18	18-Apr-19

CC-BY-NC-SA Dr. David E. Martin

US20190111141	A PEPTIDE WITH ABILITY TO PENETRATE CELL MEMBRANE	Ewha University - Industry Collaboration Foundation	6-Apr-16	6-Apr-17	18-Apr-19
US20190105653	PORTABLE PATHOGEN ANALYSIS SYSTEM FOR DETECTING WATERBORNE PATHOGENS	Not Available	5-Oct-17	5-Oct-18	11-Apr-19
US20190105381	METHOD FOR PREPARING VIRAL PARTICLES WITH CYCLIC DINUCLEOTIDE AND USE OF SAID PARTICLES FOR TREATING CANCER	Not Available	16-Mar-16	16-Mar-16	11-Apr-19
US20190105334	Anti-Viral Azide Containing Compounds	Not Available	28-Jul-10	3-Dec-18	11-Apr-19
US20190100586	Humanized Anti-Claudin-1 Antibodies and Uses Thereof	Chu Strasbourg, Les HÃ´pitaux Universitaires de Strasbourg	22-Mar-16	21-Mar-17	4-Apr-19
US20190099493	Targeting Lipids	Arbutus Biopharma Corporation	4-Dec-07	10-Oct-17	4-Apr-19
US20190099479	RECOMBINANT HCMV AND RHCMV VECTORS AND USES THEREOF	Not Available	14-May-10	27-Apr-18	4-Apr-19
US20190094224	METHODS AND COMPOSITIONS FOR DETECTING SINGLE T CELL RECEPTOR AFFINITY AND SEQUENCE	Not Available	11-Apr-16	6-Apr-17	28-Mar-19
US20190091329	CATIONIC OIL-IN-WATER EMULSIONS	GLAXOSMITHKLINE BIOLOGICALS, SA	6-Jul-11	6-Dec-18	28-Mar-19
US20190091221	METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS	TRUSTEES OF BOSTON UNIVERSITY	11-Mar-10	23-Apr-18	28-Mar-19
US20190085057	MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION	Not Available	8-Sep-16	15-Nov-18	21-Mar-19
US20190085024	Alpha-Ketoamide Inhibitors Of Cysteine Proteases	Not Available	15-Sep-17	17-Sep-18	21-Mar-19
US20190085013	NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO	Not Available	7-Mar-16	7-Mar-17	21-Mar-19
US20190084943	CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY	Parion Sciences, Inc.	17-Dec-12	23-Aug-18	21-Mar-19
US20190083602	METHOD FOR PRODUCING RNA MOLECULE COMPOSITIONS	Not Available	22-Dec-15	22-Dec-16	21-Mar-19
US20190083592	IMMUNOSTIMULATORY COMBINATIONS	Not Available	30-Dec-02	22-Oct-18	21-Mar-19
US20190083569	MICROBICIDAL COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS	Not Available	11-Jun-15	24-Jul-18	21-Mar-19
US20190083525	COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONS	Not Available	11-Jul-17	10-Jul-18	21-Mar-19
US20190083520	N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto	Not Available	10-Mar-16	10-Mar-17	21-Mar-19
US20190083408	CONTROLLED-RELEASE PEPTIDE COMPOSITIONS AND USES THEREOF	Not Available	2-Dec-11	4-Dec-18	21-Mar-19
US20190083397	OIL-IN-WATER EMULSIONS INCLUDING RETINOIC ACID	NOVARTIS AG	23-Dec-15	21-Dec-16	21-Mar-19
US20190078060	DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES	Novartis AG	9-Sep-04	8-Nov-18	14-Mar-19
US20190078051	Animal Protein-Free Media for Cultivation of Cells	Baxalta GmbH	29-Oct-04	29-Oct-18	14-Mar-19
US20190077847	AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF VIRAL DISEASES	Ablynx N.V.	5-Jun-08	17-Oct-17	14-Mar-19
US20190077764	BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH SECONDARY AMIDE FUNCTION	Hoffmann-La Roche Inc.	23-May-16	13-Nov-18	14-Mar-19
US20190077763	BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH TERTIARY AMIDE FUNCTION	Hoffmann-La Roche Inc.	23-May-16	13-Nov-18	14-Mar-19
US20190076520	VACCINES AND IMMUNOTHERAPEUTICS USING IL-28 AND COMPOSITIONS AND METHODS OF USING	Not Available	4-Apr-08	11-Sep-18	14-Mar-19
US20190076468	ENHANCED IMMUNE RESPONSE UPON TREATMENT WITH NITRIC OXIDE	Not Available	11-Sep-17	11-Sep-17	14-Mar-19

CC-BY-NC-SA Dr. David E. Martin

US20190071423	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5-Feb-15	2-Nov-18	7-Mar-19
US20190071422	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5-Feb-15	2-Nov-18	7-Mar-19
US20190071421	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5-Feb-15	2-Nov-18	7-Mar-19
US20190071420	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5-Feb-15	2-Nov-18	7-Mar-19
US20190071419	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5-Feb-15	2-Nov-18	7-Mar-19
US20190071418	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5-Feb-15	2-Nov-18	7-Mar-19
US20190062785	MULTIVALENT VACCINES FOR RABIES VIRUS AND CORONOVIRUSES	Not Available	4-Apr-16	31-Mar-17	28-Feb-19
US20190062724	RNA TARGETING METHODS AND COMPOSITIONS	Salk Institute for Biological Studies	22-Aug-17	27-Mar-18	28-Feb-19
US20190062713	HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS	Not Available	11-Jul-03	22-Mar-18	28-Feb-19
US20190062408	CONSERVED HEMAGGLUTININ EPITOPE, ANTIBODIES TO THE EPITOPE, AND METHODS OF USE	Not Available	25-Aug-08	20-Jun-18	28-Feb-19
US20190062380	FUSION PROTEINS FOR PROMOTING AN IMMUNE RESPONSE, NUCLEIC ACIDS ENCODING SAME, AND METHODS OF MAKING AND USE THEREOF	Not Available	7-Sep-12	28-Aug-18	28-Feb-19
US20190062326	2-PHENYL-3-(PIPERAZINOMETHYL)IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS BLOCKERS OF TASK-1 AND TASK-2 CHANNELS, FOR THE TREATMENT OF SLEEP-RELATED BREATHING DISORDERS	BAYER PHARMA AKTIENGESELLSCHAFT	10-Dec-15	7-Dec-16	28-Feb-19
US20190062323	PI-Kinase Inhibitors with Anti-Infective Activity	Not Available	26-Feb-16	24-Feb-17	28-Feb-19
US20190060435	PEPTIDE VACCINE FORMULATIONS AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSE	The United States of America, as represented by the Secretary, Dept of Health and Human Service	27-Feb-16	27-Feb-17	28-Feb-19
US20190060364	INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY	Not Available	31-Jul-15	6-Nov-18	28-Feb-19
US20190060363	INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY	Not Available	31-Jul-15	6-Nov-18	28-Feb-19
US20190060262	ENHANCED EXPRESSION OF RNA VECTORS	UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH	25-Mar-13	5-Sep-18	28-Feb-19
US20190060239	Technology for the Preparation of Microparticles	Not Available	24-Jul-07	17-Oct-18	28-Feb-19
US20190056122	Clean Rooms Having Dilute Hydrogen Peroxide (DHP) Gas and Methods of Use Thereof	Synexis LLC	20-Apr-15	20-Apr-16	21-Feb-19
US20190055256	ANTI-VIRAL DRUG	DORING INTERNATIONAL GMBH	24-Feb-16	24-Feb-17	21-Feb-19
US20190055241	GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS	Not Available	31-Aug-15	22-Oct-18	21-Feb-19
US20190055234	COMPOSITIONS AND METHODS FOR INHIBITING KINASES	Not Available	23-Apr-15	24-Oct-18	21-Feb-19
US20190054188	ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR	Not Available	30-Sep-03	2-Oct-18	21-Feb-19
US20190054127	ANTIVIRAL AGENT AND ANTIVIRAL FOOD	EDUCATIONAL CORPORATION MUKOGAWA GAKUIN	4-Mar-16	22-Nov-16	21-Feb-19
US20190054122	INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY	Not Available	31-Jul-15	5-Nov-18	21-Feb-19
US20190049378	CONTINUOUS PROCESS FOR PERFORMING MULTIPLE NUCLEIC ACID AMPLIFICATION ASSAYS	Not Available	10-Mar-05	21-Jun-18	14-Feb-19
US20190048344	CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION	Not Available	23-Sep-08	16-Aug-18	14-Feb-19
US20190048082	PSEUDOTYPED ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES	Not Available	30-Jun-16	25-Oct-18	14-Feb-19

US20190048049	CARGOMERS	CERENIS THERAPEUTICS HOLDING SA	10-Aug-17	10-Aug-18	14-Feb-19
US20190048026	Boron-Containing Small Molecules	Anacor Pharmaceuticals, Inc.	16-Feb-05	18-Oct-18	14-Feb-19
US20190046690	MATERIALS WITH IMPROVED PROPERTIES	Not Available	1-Nov-15	2-Nov-16	14-Feb-19
US20190046654	ALBUMIN BINDING PEPTIDE CONJUGATES AND METHODS THEREOF	Not Available	9-Aug-17	9-Aug-18	14-Feb-19
US20190046635	COMPOSITION FOR IMMUNITY INDUCTION PROMOTION AND VACCINE PHARMACEUTICAL COMPOSITION	NITTO DENKO CORPORATION	2-Feb-16	1-Feb-17	14-Feb-19
US20190040451	FULLY INTEGRATED HAND-HELD DEVICE TO DETECT SPECIFIC NUCLEIC ACID SEQUENCES	Not Available	8-Jan-16	9-Jan-17	7-Feb-19
US20190040378	NOVEL NUCLEIC ACID MOLECULES	Not Available	4-Jul-17	3-Jul-18	7-Feb-19
US20190040370	TRACKING AND MANIPULATING CELLULAR RNA VIA NUCLEAR DELIVERY OF CRISPR/CAS9	Not Available	23-Nov-15	3-Aug-18	7-Feb-19
US20190040105	Method for Preventing and Treating Hyperpermeability	Not Available	5-Mar-09	19-Oct-18	7-Feb-19
US20190038742	MESENCHYMAL STEM CELLS AS VACCINE ADJUVANTS AND METHODS FOR USING THE SAME	Longeveron LLC	4-Feb-16	2-Feb-17	7-Feb-19
US20190032077	ARTIFICIAL NUCLEIC ACID MOLECULES	CureVac AG	30-Dec-13	9-Jul-18	31-Jan-19
US20190032041	COMPOSITIONS FOR AND METHODS OF IDENTIFYING ANTIGENS	Not Available	21-Feb-06	12-Feb-18	31-Jan-19
US20190031740	COMPOSITIONS COMPRISING AAV EXPRESSING DUAL ANTIBODY CONSTRUCTS AND USES THEREOF	Not Available	13-May-14	15-Oct-18	31-Jan-19
US20190031679	NOVEL MONOTHIOL MUCOLYTIC AGENTS	Not Available	30-Jan-15	5-Sep-18	31-Jan-19
US20190031605	TETRAHYDRONAPHTHALENE DERIVATIVE	ONO PHARMACEUTICAL CO., LTD.	29-Jan-16	27-Jan-17	31-Jan-19
US20190030187	sirna/Nanoparticle Formulations for Treatment of Middle-East Respiratory Syndrome Coronaviral Infection	Sirnaomics, Inc.	8-Sep-15	7-Sep-16	31-Jan-19
US20190030094	BACTERIAL STRAIN AS AGENTS FOR PREVENTING AND/OR TREATING RESPIRATORY DISORDERS	Not Available	27-Jan-16	27-Jan-17	31-Jan-19
US20190025292	ANTIGEN PRESENTING CELL ASSAY	University of Pittsburgh - Of the Commonwealth System of Higher Education	8-Apr-10	25-Sep-18	24-Jan-19
US20190024096	PROCESS FOR THE IN VIVO PRODUCTION OF RNA IN A HOST CELL	Not Available	7-Aug-15	7-Aug-15	24-Jan-19
US20190023799	GITR Antibodies And Methods Of Inducing Or Enhancing An Immune Response	Not Available	25-Mar-05	28-Jun-18	24-Jan-19
US20190023779	METHOD OF PROVIDING MONOCLONAL AUTO-ANTIBODIES WITH DESIRED SPECIFICITY	Not Available	28-Dec-11	5-Oct-18	24-Jan-19
US20190023769	COMPOSITIONS AND METHODS FOR INHIBITING PATHOGEN INFECTION	Not Available	29-Oct-12	21-Sep-18	24-Jan-19
US20190022249	ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR	Not Available	30-Sep-03	2-Oct-18	24-Jan-19
US20190022216	ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOF	Not Available	23-Oct-15	4-Sep-18	24-Jan-19
US20190022214	Attenuated Infectious Bronchitis Virus	Not Available	27-Jan-16	26-Jan-17	24-Jan-19
US20190022213	MERS-CoV Vaccine	Not Available	29-Nov-13	29-Jun-18	24-Jan-19
US20190022116	N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related Thereto	Not Available	26-Dec-14	16-Dec-15	24-Jan-19
US20190017112	METHOD OF DIRECT TARGET SEQUENCING USING NUCLEASE PROTECTION	HTG Molecular Diagnostics, Inc.	11-Feb-16	10-Feb-17	17-Jan-19
US20190017068	ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR	Not Available	17-Dec-01	26-Sep-18	17-Jan-19

CC-BY-NC-SA Dr. David E. Martin

US20190017000	CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF	Not Available	8-Sep-16	19-Sep-18	17-Jan-19
US20190016785	ANTIBODIES THAT POTENTLY NEUTRALIZE HEPATITIS B VIRUS AND USES THEREOF	Not Available	7-Oct-15	7-Oct-16	17-Jan-19
US20190016772	GM-CSF and IL-4 Conjugates, Compositions, and Methods Related Thereto	Not Available	23-Oct-12	2-Oct-18	17-Jan-19
US20190016710	MULTICYCLIC COMPOUNDS AND USES THEREOF	Not Available	31-Dec-15	29-Dec-16	17-Jan-19
US20190016690	NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	31-Dec-15	30-Dec-16	17-Jan-19
US20190015527	ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR	Not Available	30-Sep-03	25-Jul-18	17-Jan-19
US20190015522	IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF	Not Available	5-Apr-12	19-Jul-18	17-Jan-19
US20190015501	NUCLEIC ACID VACCINES	ModernaTX, Inc.	23-Apr-14	27-Sep-18	17-Jan-19
US20190015432	Lipid Disulfide Prodrugs and Uses Related Thereto	Not Available	13-Jul-17	13-Jul-18	17-Jan-19
US20190010469	ATTENUATED VIRUSES USEFUL FOR VACCINES	Not Available	30-Mar-07	16-Jul-18	10-Jan-19
US20190010240	COMPOSITION COMPRISED OF ANTIGEN LINKED TO A TNF SUPERFAMILY LIGAND	Not Available	15-Mar-13	2-Aug-18	10-Jan-19
US20190010132	ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS	Parion Sciences, Inc.	13-Dec-13	4-Apr-18	10-Jan-19
US20190008954	NEGATIVELY CHARGED NUCLEIC ACID COMPRISING COMPLEXES FOR IMMUNOSTIMULATION	CureVac AG	31-Jan-12	11-Jun-18	10-Jan-19
US20190008948	NUCLEIC ACID VACCINES	ModernaTX, Inc.	23-Apr-14	16-Jul-18	10-Jan-19
US20190008833	NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	9-May-12	17-Jul-18	10-Jan-19
US20190004061	DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY	Not Available	2-Jul-10	4-Aug-18	3-Jan-19
US20190002477	ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF	Kineta, Inc.	9-May-14	31-Jan-18	3-Jan-19
US20190002448	SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF	Not Available	31-Dec-15	29-Dec-16	3-Jan-19
US20190002393	Lipids and Lipid Compositions for the Delivery of Active Agents	Not Available	5-Sep-14	19-Sep-18	3-Jan-19
US20190001010	ADDITIVE COMPOSITIONS FOR PIGMENTED DISINFECTION AND METHODS THEREOF	Not Available	8-Dec-14	13-Jul-18	3-Jan-19
US20190000959	NUCLEIC ACID VACCINES	ModernaTX, Inc.	23-Apr-14	27-Jul-18	3-Jan-19
US20190000745	POLYMER-BASED ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF	eXion labs Inc.	28-Jul-16	4-Sep-18	3-Jan-19
US20180372747	METHODS OF IDENTIFYING IMMUNE CELLS IN PD-L1 POSITIVE TUMOR TISSUE	Not Available	22-Nov-15	21-May-18	27-Dec-18
US20180372733	ANTIBODY-NANOPARTICLE CONJUGATES AND METHODS FOR MAKING AND USING SUCH CONJUGATES	Not Available	27-Apr-10	21-Jun-18	27-Dec-18
US20180371536	METHODS FOR RNA QUANTIFICATION	Not Available	1-Jun-15	26-May-16	27-Dec-18
US20180371461	APTAMERS, NUCLEIC ACID MOLECULES, POLYNUCLEOTIDES, SYNTHETIC ANTIBODIES COMPOSITIONS FOR DETECTING PRRS VIRUSES AND TREATING PRRS VIRUS INFECTION	Not Available	10-Dec-15	1-Dec-16	27-Dec-18
US20180371410	MEANS AND METHODS FOR INFLUENCING THE STABILITY OF CELLS	Not Available	4-Dec-09	28-Aug-18	27-Dec-18
US20180369386	LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS	Not Available	8-Mar-13	29-Aug-18	27-Dec-18
US20180369364	RECOMBINANT VIRUS LIKE PARTICLES USING BOVINE IMMUNODEFICIENCY VIRUS GAG PROTEIN	Not Available	2-Jul-15	1-Jul-16	27-Dec-18

CC-BY-NC-SA Dr. David E. Martin

US20180368417	ANTIMICROBIAL COMPOSITIONS AND METHODS	Not Available	23-Sep-14	19-Jun-18	27-Dec-18
US20180365375	METHODS AND SYSTEMS FOR MULTIPLE TAXONOMIC CLASSIFICATION	Not Available	24-Apr-15	4-Oct-17	20-Dec-18
US20180363027	STABILIZING COMPOSITIONS AND METHODS FOR EXTRACTION OF RIBONUCLEIC ACID	Not Available	6-Oct-06	15-May-18	20-Dec-18
US20180362625	REGULATION OF CYTOKINE PRODUCTION	Not Available	4-Dec-15	2-Dec-16	20-Dec-18
US20180360877	METHODS FOR EXPANDING A POPULATION OF ALVEOLAR MACROPHAGES IN A LONG TERM CULTURE	Not Available	8-Dec-15	8-Dec-16	20-Dec-18
US20180360736	FILM DOSAGE FORM WITH EXTENDED RELEASE MUCOADHESIVE PARTICLES	Intelgenx Corp.	2-Dec-13	23-Aug-18	20-Dec-18
US20180355017	COMPOSITIONS AND METHODS FOR INTERNALIZING ENZYMES	Not Available	7-Jun-17	6-Jun-18	13-Dec-18
US20180353594	METHOD FOR INACTIVATING VIRUSES USING ELECTRON BEAMS	Not Available	26-Jul-13	21-Aug-18	13-Dec-18
US20180346574	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	Not Available	13-Jun-16	9-Aug-18	6-Dec-18
US20180346573	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	Not Available	13-Jun-16	9-Aug-18	6-Dec-18
US20180346522	HUMAN RESPIRATORY SYNCYTIAL VIRUS CONSENSUS ANTIGENS, NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM, AND METHODS OF USING THE SAME	Not Available	10-Apr-12	6-Aug-18	6-Dec-18
US20180346516	PEPTIDES AND USES THEREFOR AS ANTIVIRAL AGENTS	Not Available	27-Nov-15	28-Nov-16	6-Dec-18
US20180346485	ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5-Feb-15	27-Feb-18	6-Dec-18
US20180346480	THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5-Feb-15	1-Mar-18	6-Dec-18
US20180344877	RECOMBINANT PROMOTERS AND VECTORS FOR PROTEIN EXPRESSION IN LIVER AND USE THEREOF	Children's Healthcare of Atlanta, Inc.	16-Apr-15	8-Aug-18	6-Dec-18
US20180344832	METHODS AND COMPOSITIONS FOR COMBINATION IMMUNOTHERAPY	Not Available	20-Apr-15	20-Apr-16	6-Dec-18
US20180344751	Broad Spectrum Antiviral and Methods of Use	Not Available	17-Apr-06	26-Dec-17	6-Dec-18
US20180340219	CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	9-Dec-16	9-Mar-18	29-Nov-18
US20180340218	CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	9-Dec-16	9-Mar-18	29-Nov-18
US20180340215	SAMPLE ANALYSIS, PRESENCE DETERMINATION OF A TARGET SEQUENCE	Not Available	28-Aug-15	26-Aug-16	29-Nov-18
US20180340154	PRODUCTION OF VIRUSES IN AVIAN EGGS	Not Available	24-Nov-15	23-Nov-16	29-Nov-18
US20180340153	PRODUCTION OF VIRUSES IN CELL CULTURE	Not Available	24-Nov-15	23-Nov-16	29-Nov-18
US20180339991	PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	30-Dec-14	24-May-18	29-Nov-18
US20180339988	PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	30-Dec-14	18-Jan-18	29-Nov-18
US20180339014	PEPTIDOMIMETIC MACROCYCLES	Not Available	14-Jan-09	7-Jun-18	29-Nov-18
US20180334480	CORONAVIRUSES EPITOPE-BASED VACCINES	RAMOT AT TEL-AVIV UNIVERSITY LTD.	17-Sep-15	15-Sep-16	22-Nov-18
US20180333485	Compositions, Comprising Improved Il-12 Genetic Constructs And Vaccines, Immunotherapeutics And Methods Of Using The Same	Not Available	12-Dec-11	9-May-18	22-Nov-18
US20180327800	MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION OF B CELLS	Not Available	26-Feb-03	21-May-18	15-Nov-18

US20180327738	STABILIZED REAGENTS FOR GENOME MODIFICATION	Not Available	20-Nov-15	18-Nov-16	15-Nov-18
US20180327697	CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF	Not Available	8-Sep-16	12-Jun-18	15-Nov-18
US20180327484	RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM	Not Available	1-Jun-07	23-Jul-18	15-Nov-18
US20180326070	CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES	Not Available	4-Dec-07	20-Nov-17	15-Nov-18
US20180326051	LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS	Not Available	17-Aug-10	24-Jul-18	15-Nov-18
US20180326045	COMBINATION PIV3/HMPV RNA VACCINES	ModernaTX, Inc.	22-Oct-15	20-Jul-18	15-Nov-18
US20180326044	NSP10 SELF-ASSEMBLING FUSION PROTEINS FOR VACCINES, THERAPEUTICS, DIAGNOSTICS AND OTHER NANOMATERIAL APPLICATIONS	Not Available	13-Oct-15	13-Oct-16	15-Nov-18
US20180326039	VACCINE COMPOSITIONS	Not Available	16-Sep-15	16-Sep-16	15-Nov-18
US20180325076	ANTIMICROBIAL COMPOSITIONS AND METHODS WITH NOVEL POLYMERIC BINDING SYSTEM	OXISCIENCE, LLC	28-Aug-14	24-Jul-18	15-Nov-18
US20180321242	VIRAL BIOMARKERS AND USES THEREFOR	Not Available	6-Nov-15	4-Nov-16	8-Nov-18
US20180319811	DERIVATIVES OF PORPHYRINS, THEIR PROCESS OF PREPARATION AND THEIR USE FOR TREATING VIRAL INFECTIONS	Not Available	30-Oct-15	28-Oct-16	8-Nov-18
US20180319779	SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF	Not Available	3-Jul-13	4-Dec-17	8-Nov-18
US20180318447	COMPOSITIONS AND METHODS FOR IMPROVING VIRAL VECTOR EFFICIENCY	Not Available	3-Dec-15	30-Nov-16	8-Nov-18
US20180318366	METHOD OF TREATMENT USING ONCOLYTIC VIRUSES	Not Available	15-Jun-15	15-Jun-16	8-Nov-18
US20180318350	Immune Cells with DNMT3A Gene Modifications and Methods Related Thereto	Not Available	4-Nov-15	4-Nov-16	8-Nov-18
US20180312575	ANTIBODIES AGAINST INFLUENZA VIRUS AND METHODS OF USE THEREOF	Not Available	6-Dec-07	20-Mar-18	1-Nov-18
US20180312545	OPTIMIZED NUCLEIC ACID MOLECULES	Not Available	9-Nov-15	9-Nov-16	1-Nov-18
US20180312544	RECOMBINANT HUMAN/BOVINE PARAINFLUENZA VIRUS 3 (B/HPIV3) EXPRESSING A CHIMERIC RSV/BPIV3 F PROTEIN AND USES THEREOF	The United States of America, as represented by the Secretary, Dept. of Health and Human Services	20-Jan-15	20-Jan-16	1-Nov-18
US20180311338	MICRONEEDLE COMPOSITIONS AND METHODS OF USING SAME	Not Available	11-Jan-16	11-Jul-18	1-Nov-18
US20180311273	Method of Treating Inflammation	Not Available	1-Apr-10	26-Jun-18	1-Nov-18
US20180305773	CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS FOR MALARIA DETECTION	Not Available	12-Apr-17	12-Apr-18	25-Oct-18
US20180305760	Pathogen biomarkers and uses therefor	Not Available	30-Sep-15	30-Sep-16	25-Oct-18
US20180305451	HIDE1 COMPOSITIONS AND METHODS	Not Available	13-Jul-15	13-Jul-16	25-Oct-18
US20180305412	COMPOSITIONS AND METHODS FOR TREATING DISEASES BY INHIBITING EXOSOME RELEASE	Not Available	19-Dec-16	9-Jul-18	25-Oct-18
US20180305357	IMMUNE RESPONSE MODIFIER COMPOSITIONS AND METHDOS	Not Available	22-Dec-06	25-Jun-18	25-Oct-18
US20180305356	NOVEL KINASE INHIBITORS	Not Available	19-Oct-12	18-May-18	25-Oct-18
US20180303874	Compositions and Methods for the Prevention of Microbial Infections	Not Available	10-Nov-11	30-Nov-17	25-Oct-18
US20180303768	DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER NUCLEOSIDE ANALOGUES HAVING ANTI-CORONAVIRUS ACTIVITY	Not Available	30-Jan-15	2-Jul-18	25-Oct-18
US20180303090	TREATMENT COMPOSITIONS PROVIDING AN ANTIMICROBIAL BENEFIT	Not Available	30-Oct-15	17-Oct-16	25-Oct-18

CC-BY-NC-SA Dr. David E. Martin

US20180267031	METHOD AND DEVICE FOR DETECTING ANTIGEN-SPECIFIC ANTIBODIES IN A BIOLOGICAL FLUID SAMPLE BY USING NEODYMIUM MAGNETS	The U.S.A., as represented by the Secretary, Department of Health and Human Services	1-Sep-15	8-Aug-16	20-Sep-18
US20180265847	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13	29-Mar-18	20-Sep-18
US20180265822	LIQUID LOADING COMPOSITION, METHOD OF MAKING AND USE THEREOF	Not Available	8-Sep-16	21-May-18	20-Sep-18
US20180265574	Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection	Not Available	15-Mar-17	15-Mar-17	20-Sep-18
US20180265507	HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES	Dana-Farber Cancer Institute, Inc.	11-Apr-12	26-Jan-18	20-Sep-18
US20180264098	MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF SYNONYMOUS CODONS	The Government of the USA as represented by the Secretary of the Dept. of Health and Human Service	8-Oct-04	31-May-18	20-Sep-18
US20180258162	Methods Of Treating Inflammation Associated Airway Diseases And Viral Infections	Not Available	2-Jan-15	22-May-18	13-Sep-18
US20180258160	Optimized Crosslinkers for Trapping a Target on a Substrate	Not Available	13-Nov-15	11-May-18	13-Sep-18
US20180258159	COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY	Not Available	28-Oct-14	14-May-18	13-Sep-18
US20180258151	RECOMBINANT SUPER-COMPOUND INTERFERON AND USES THEREOF	Not Available	28-Feb-01	2-Mar-18	13-Sep-18
US20180251737	COMPOSITIONS, METHODS AND USES FOR INDUCING VIRAL GROWTH	Not Available	5-Dec-08	28-Dec-17	6-Sep-18
US20180251540	HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)	Not Available	16-Dec-02	30-Apr-18	6-Sep-18
US20180251436	CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS	Not Available	24-Jan-14	19-Sep-17	6-Sep-18
US20180250602	PAPAYA MOSAIC VIRUS COMPOSITIONS AND USES THEREOF FOR STIMULATION OF THE INNATE IMMUNE RESPONSE	Not Available	11-Feb-14	1-May-18	6-Sep-18
US20180250381	SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES	Not Available	20-Aug-10	12-Oct-17	6-Sep-18
US20180245056	COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND ACTIVITY, AND RELATED METHODS	Not Available	19-Nov-09	9-Oct-17	30-Aug-18
US20180245053	VIRAL VACCINES AND METHODS OF FORMING THE SAME	Not Available	27-Feb-17	27-Feb-18	30-Aug-18
US20180244759	NOVEL METHODS OF GENERATING ANTIBODIES	Rutgers, The State University of New Jersey	19-Aug-15	18-Aug-16	30-Aug-18
US20180244756	MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USE	The United States of America, as Represented by the Secretary, Dept. of Health and Human Services	24-Feb-15	24-Feb-16	30-Aug-18
US20180244669	IMIDAZO[4,5-c] RING COMPOUNDS CONTAINING SUBSTITUTED GUANIDINE GROUPS	Not Available	31-Aug-15	26-Aug-16	30-Aug-18
US20180244660	CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE INHIBITORS	Not Available	17-Aug-15	17-Aug-16	30-Aug-18
US20180243347	IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF	Not Available	25-Aug-15	22-Aug-16	30-Aug-18
US20180237835	METHODS OF ANALYZING VIRUS-DERIVED THERAPEUTICS	American International Biotechnology, LLC	31-Jul-15	29-Jul-16	23-Aug-18
US20180237788	IMPROVEMENTS IN OR RELATING TO DNA RECOMBINATION	The Regents of the University of California	8-Aug-15	5-Aug-16	23-Aug-18
US20180237786	ARTIFICIAL NUCLEIC ACID MOLECULES	CUREVAC AG	28-Aug-15	22-Aug-16	23-Aug-18
US20180237502	PAN-EBOLA AND PAN-FILOVIRUS PROTECTIVE EPITOPES, ANTIBODIES, AND ANTIBODY COCKTAILS	Integrated BioTherapeutics, Inc.	11-Mar-15	11-Mar-16	23-Aug-18
US20180237435	GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS	Not Available	31-Aug-15	26-Aug-16	23-Aug-18
US20180236058	REVERSE GENETICS SYSTEMS	Not Available	31-Jul-09	16-Oct-17	23-Aug-18
US20180236054	Tetanus Toxoid and CCL3 Improve DC Vaccines	Duke University	14-Nov-13	19-Apr-18	23-Aug-18

US20180235948	(S,E)-3-(6-AMINOPYRIDIN-3-YL)-N-((5-(4-(3-FLUORO-3-METHYLPYRROLIDINE-1-CARBONYL)PHENYL)-7-(4-FLUOROPHENYL)BENZOFURAN-2-YL)METHYL)ACRYLAMIDE FOR THE TREATMENT OF CANCER	Not Available	18-Aug-15	18-Aug-16	23-Aug-18
US20180230521	BIOAGENT DETECTION OLIGONUCLEOTIDES	Not Available	27-Dec-11	13-Apr-18	16-Aug-18
US20180230447	ACTIVE LOW MOLECULAR WEIGHT VARIANTS OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2)	Northwestern University	24-Jan-17	24-Jan-18	16-Aug-18
US20180228695	DEVICES, SYSTEM AND METHOD TO CONTROL THE DELIVERY OF ORAL MEDICATIONS TO ENSURE THEY ARE EFFICACIOUS , TAKEN AS PRESCRIBED, AND TO AVOID UNWANTED SIDE EFFECTS	Not Available	11-Aug-15	11-Aug-16	16-Aug-18
US20180223290	METHOD FOR PROPAGATING ADENOVIRAL VECTORS ENCODING INHIBITORY GENE PRODUCTS	GenVec, Inc.	10-Nov-05	7-Sep-17	9-Aug-18
US20180222906	SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES	3M Innovative Properties Company	18-Jun-04	9-Apr-18	9-Aug-18
US20180221464	IMMUNOGENIC COMPOSITIONS, ANTIGEN SCREENING METHODS, AND METHODS OF GENERATING IMMUNE RESPONSES	Not Available	3-Aug-15	3-Aug-16	9-Aug-18
US20180216164	HIGH DENSITY SELF-CONTAINED BIOLOGICAL ANALYSIS	Not Available	15-Nov-06	19-Mar-18	2-Aug-18
US20180216067	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13	29-Mar-18	2-Aug-18
US20180215831	Antibody Derivatives with Conditionally Enabled Effector Function	Not Available	27-Jul-15	27-Jul-16	2-Aug-18
US20180215801	CRYPTIC POLYPEPTIDES AND USES THEREOF	Not Available	29-Jan-15	29-Jan-16	2-Aug-18
US20180215794	TREATING CANCER WITH VIRAL NUCLEIC ACID	Mayo Foundation for Medical Education and Research	20-Feb-07	27-Mar-18	2-Aug-18
US20180214430	Selective Inhibitors Of i-NOS For Use Against Viral Infection	UCL Business PLC	17-Jul-15	15-Jul-16	2-Aug-18
US20180209960	Method of Determining, Identifying or Isolating Cell-Penetrating Peptides	Not Available	23-May-11	11-Dec-17	26-Jul-18
US20180208897	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13	19-Mar-18	26-Jul-18
US20180208659	ANTI-PD-L1 ANTIBODIES AND USES THEREOF	Not Available	13-Jun-16	13-Jun-17	26-Jul-18
US20180208653	METHODS FOR ENHANCING AN IMMUNE RESPONSE	Not Available	20-Jan-17	19-Jan-18	26-Jul-18
US20180207258	ADJUVANTED INFLUENZA VACCINES FOR PEDIATRIC USE	Not Available	22-Feb-08	5-Mar-18	26-Jul-18
US20180207145	PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES	GlaxoSmithKline Intellectual Property (No. 2) Limited	12-May-14	19-Mar-18	26-Jul-18
US20180201998	COMPOSITIONS AND METHODS FOR DETECTION OF GENETIC DEAFNESS GENE MUTATION	CapitalBio Corporation	14-Jul-15	14-Jul-15	19-Jul-18
US20180201907	METHODS FOR INCREASING THE INFECTIVITY OF VIRUSES	Not Available	26-Jan-12	13-Mar-18	19-Jul-18
US20180201687	ANTIBODIES HAVING SPECIFICITY TO MYOSIN 18A AND USES THEREOF	Not Available	7-Jul-15	7-Jul-16	19-Jul-18
US20180200365	Methods and Compositions for Inhibiting Akt3	Not Available	17-Jan-17	20-Feb-18	19-Jul-18
US20180200364	LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS	3M Innovative Properties Company	17-Aug-10	27-Nov-17	19-Jul-18
US20180200224	Antiviral Activity from Medicinal Mushrooms and Their Active Constituents	Not Available	31-Mar-15	12-Mar-18	19-Jul-18
US20180200196	Modular Particulars for Immunotherapy	Not Available	1-Nov-13	3-Jan-18	19-Jul-18
US20180196061	INFLUENZA POTENCY ASSAYS	Not Available	7-Jul-15	7-Jul-16	12-Jul-18
US20180195048	METHODS FOR PRODUCING VIRUS FOR VACCINE PRODUCTION	Takeda Vaccines, Inc.	13-Feb-15	12-Feb-16	12-Jul-18

US20180194850	ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIES	Not Available	15-May-15	13-May-16	12-Jul-18
US20180194829	POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR TREATMENT OF IMMUNE RELATED DISORDERS AND CANCER	Not Available	15-Apr-11	13-Nov-17	12-Jul-18
US20180194735	Sulfinylphenyl or Sulfonimidoylphenyl Benzazepines	Hoffmann La-Roche Inc.	17-Sep-15	8-Mar-18	12-Jul-18
US20180193477	DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTS	Not Available	15-Jul-15	15-Jul-16	12-Jul-18
US20180187213	Variant AAV and Compositions, Methods and Uses for Gene Transfer to Cells, Organs and Tissues	The Children's Hospital of Philadelphia	22-Jul-13	6-Dec-17	5-Jul-18
US20180187211	METHODS AND COMPOSITIONS FOR COMBINATION IMMUNOTHERAPY	Not Available	9-Jan-15	7-Jan-16	5-Jul-18
US20180187165	HAND, FOOT, AND MOUTH VACCINES AND METHODS OF MANUFACTURE AND USE THEREOF	Takeda Vaccines, Inc.	7-Nov-14	27-Oct-17	5-Jul-18
US20180187154	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13	20-Feb-18	5-Jul-18
US20180187153	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13	20-Feb-18	5-Jul-18
US20180187131	DISINFECTING AQUEOUS FOAM, PROCESS FOR PREPARING SAME AND USE THEREOF	COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES	16-Jun-15	15-Jun-16	5-Jul-18
US20180186897	NOVEL VACCINES IN PREVENTION AND TREATMENT OF MALARIA	Not Available	26-Jun-15	24-Jun-16	5-Jul-18
US20180186821	PROTEIN PROXIMITY ASSAY IN FORMALIN FIXED PAFFAFIN EMBEDDED TISSUE USING CAGED HAPTENS	Not Available	28-Aug-15	28-Feb-18	5-Jul-18
US20180186802	COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS	Not Available	1-May-14	27-Feb-18	5-Jul-18
US20180186792	HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM	3M Innovative Properties Company	3-Jun-11	26-Feb-18	5-Jul-18
US20180186534	Powdered Pouch And Method Of Making Same	MONOSOL, LLC	16-Apr-12	29-Dec-17	5-Jul-18
US20180185469	COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME	Not Available	24-Apr-12	14-Dec-17	5-Jul-18
US20180185392	Pharmaceutical Compositions and Methods	Not Available	3-Aug-15	29-Nov-17	5-Jul-18
US20180185345	METHODS AND COMPOSITIONS FOR TREATING HERPESVIRUS INDUCED CONDITIONS	Not Available	19-Jun-15	17-Jun-16	5-Jul-18
US20180180544	USE OF A FLUORESCENT MATERIAL TO DETECT FAILURE OR DETERIORATED PERFORMANCE OF A FLUOROMETER	Not Available	14-Jun-12	22-Feb-18	28-Jun-18
US20180179300	GENERATION OF BINDING MOLECULES	Merus N.V.	26-Sep-11	22-Nov-17	28-Jun-18
US20180179274	PROTEINS COMPRISING A MUTATED LAIR-1 FRAGMENT AND USES THEREOF	Not Available	26-Jun-15	24-Jun-16	28-Jun-18
US20180177863	METHODS OF MAKING AND USING LIVE ATTENUATED VIRUSES	Not Available	23-Sep-15	31-Oct-17	28-Jun-18
US20180177862	ANTIGENICALLY MATCHED INFLUENZA VACCINES	Not Available	26-Jun-15	24-Jun-16	28-Jun-18
US20180177860	VACCINE CONTAINING VIRUS INACTIVATED BY GREEN TEA EXTRACT, AND PREPARATION METHOD THEREFOR	Not Available	11-Jun-15	7-Jun-16	28-Jun-18
US20180163182	PROCESSES FOR PRODUCTION AND PURIFICATION OF NUCLEIC ACID-CONTAINING COMPOSITIONS	Human Services	10-Jun-15	10-Jun-16	14-Jun-18
US20180162838	Chemical Compounds	Not Available	18-Mar-14	13-Dec-17	14-Jun-18
US20180162835	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5-Feb-15	11-Dec-17	14-Jun-18
US20180161425	NOVEL PROTEIN STRUCTURE USED FOR EFFICIENT ANTIBODY PRODUCTION IN IMMUNIZATION	Not Available	10-Dec-14	10-Dec-15	14-Jun-18

CC-BY-NC-SA Dr. David E. Martin

US20180161422	NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC ANTIGEN	CureVac AG	15-Feb-12	8-Feb-18	14-Jun-18
US20180161279	GASTRO-RETENTIVE MODIFIED RELEASE DOSAGE FORMS FOR OPROZOMIB AND PROCESS TO MAKE THEREOF	Not Available	14-Dec-16	13-Dec-17	14-Jun-18
US20180160662	Transgenic Immunodeficient Mouse Expressing Human SIRP-alpha	Institut Pasteur	26-Mar-12	25-Jan-18	14-Jun-18
US20180149659	DIAGNOSIS AND TREATMENT OF MERS-RELATED RENAL DISEASE	Not Available	4-Jun-15	3-Jun-16	31-May-18
US20180148727	ARTIFICIAL NUCLEIC ACID MOLECULES	Not Available	30-Dec-14	29-Dec-15	31-May-18
US20180142239	METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES	Not Available	26-Jan-07	14-Jun-17	24-May-18
US20180142198	DELIVERY OF BIOMOLECULES TO IMMUNE CELLS	Not Available	31-Oct-14	30-Oct-15	24-May-18
US20180142006	ANTIBODY PRODUCING NON-HUMAN ANIMALS	Merus N.V.	27-Jun-08	12-Jan-18	24-May-18
US20180142005	ANTIBODY PRODUCING NON-HUMAN ANIMALS	Merus N.V.	27-Jun-08	12-Jan-18	24-May-18
US20180142004	ANTIBODY PRODUCING NON-HUMAN ANIMALS	Merus N.V.	27-Jun-08	11-Jan-18	24-May-18
US20180142003	ANTIBODY PRODUCING NON-HUMAN ANIMALS	Merus N.V.	27-Jun-08	9-Jan-18	24-May-18
US20180142002	ANTIBODY PRODUCING NON-HUMAN ANIMALS	Merus N.V.	27-Jun-08	5-Jan-18	24-May-18
US20180140659	ANALOGS OF C5a AND METHODS OF USING SAME	Not Available	29-Jun-10	12-Jan-18	24-May-18
US20180140625	PRODUCTION OF STABLE NON-POLYADENYLATED RNAS	Massachusetts Institute of Technology	16-Oct-12	31-Jul-17	24-May-18
US20180140580	METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF BRAIN INFLAMMATION AND SEPSIS	Not Available	29-Nov-02	23-Oct-17	24-May-18
US20180135099	NANOREPORTERS AND METHODS OF MANUFACTURING AND USE THEREOF	Not Available	23-Dec-05	2-Jan-18	17-May-18
US20180135012	MEMBRANE-RECEIVER COMPLEX THERAPEUTICS	Not Available	13-May-15	13-May-16	17-May-18
US20180134783	HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)	Not Available	16-Dec-02	26-Apr-16	17-May-18
US20180134770	ANTIBODY PRODUCING NON-HUMAN ANIMALS	Merus N.V.	27-Jun-08	12-Jan-18	17-May-18
US20180133246	INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES	Not Available	7-Mar-12	1-Nov-17	17-May-18
US20180127836	IMPROVED COMPOSITIONS AND METHODS FOR DETECTION OF VIRUSES	Not Available	7-May-15	6-May-16	10-May-18
US20180127783	CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS	EDITAS MEDICINE, INC.	7-Nov-13	29-Nov-17	10-May-18
US20180127384	HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	29-Jul-11	21-Jun-17	10-May-18
US20180125965	HAND, FOOT, AND MOUTH VACCINES AND METHODS OF MANUFACTURE AND USE THEREOF	Takeda Vaccines, Inc.	7-Nov-14	6-Nov-15	10-May-18
US20180125952	PRIME-BOOST REGIMENS INVOLVING ADMINISTRATION OF AT LEAST ONE mRNA CONSTRUCT	Not Available	15-May-15	13-May-16	10-May-18
US20180125883	INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES	Not Available	7-Mar-12	20-Sep-17	10-May-18
US20180112270	C-CBL MUTATIONS AND USES THEREOF	Not Available	4-Jun-10	22-Mar-16	26-Apr-18
US20180111991	MODULATORS OF ACTIVIN AND METHODS FOR MODULATING IMMUNE RESPONSES AND T FOLLICULAR HELPER CELLS	Not Available	2-Dec-14	2-Jun-17	26-Apr-18

CC-BY-NC-SA Dr. David E. Martin

US20180111907	DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES	Not Available	29-May-12	20-Dec-17	26-Apr-18
US20180110845	METHOD OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN AMYLOIDOSES AND PROTEIN AGGREGATION DISORDERS	Not Available	31-Aug-07	18-Dec-17	26-Apr-18
US20180105815	Bivalent siRNA Chimeras and Methods of Use Thereof	Not Available	18-Oct-16	6-Oct-17	19-Apr-18
US20180105596	ANTI-TYRO3 ANTIBODIES AND USES THEREOF	Not Available	17-Apr-15	15-Apr-16	19-Apr-18
US20180105514	HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORS	Not Available	7-Apr-16	3-Jan-18	19-Apr-18
US20180104241	CHEMICALLY AND METABOLICALLY STABLE DIPEPTIDE POSSESSING POTENT SODIUM CHANNEL BLOCKER ACTIVITY	PARION SCIENCES, INC.	27-Jun-11	15-Dec-17	19-Apr-18
US20180100181	METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAME	Not Available	17-Apr-15	15-Apr-16	12-Apr-18
US20180099999	FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA	Not Available	17-Sep-14	14-Dec-17	12-Apr-18
US20180098972	TREATMENT OF INFECTIOUS DISEASES	CHILDREN'S MEDICAL CENTER CORPORATION	26-Jan-15	26-Jan-16	12-Apr-18
US20180092932	Anti-Viral Azide Containing Compounds	Not Available	28-Jul-10	7-Dec-17	5-Apr-18
US20180087049	MAXIMIZING DNA YIELD OF BLOOD SPECIMENS COLLECTED IN RAPID CLOT TUBES	Not Available	27-Sep-16	7-Sep-17	29-Mar-18
US20180086818	COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY	Not Available	28-Oct-14	13-Nov-17	29-Mar-18
US20180085457	ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOF	Not Available	23-Oct-15	1-Dec-17	29-Mar-18
US20180085432	STING (Stimulator of Interferon Genes), A Regulator of Innate Immune Responses	Not Available	4-Aug-08	15-Sep-17	29-Mar-18
US20180085388	DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS	GLAXOSMITHKLINE BIOLOGICALS, SA	6-Jul-10	5-Oct-17	29-Mar-18
US20180079746	HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS	Not Available	19-Mar-15	15-Mar-16	22-Mar-18
US20180078625	COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS	Not Available	25-Mar-15	25-Mar-16	22-Mar-18
US20180078532	IMMEDIATE RELEASE FORMULATIONS FOR OPROZOMIB	AMGEN INC.	21-Sep-16	18-Sep-17	22-Mar-18
US20180078507	BIODEGRADABLE POLYMERIC PARTICLES ENCAPSULATING AN ACTIVE AGENT, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF	Not Available	16-Sep-16	15-Sep-17	22-Mar-18
US20180073073	METHODS AND COMPOSITIONS FOR LABELING TARGETS AND HAPLOTYPE PHASING	Not Available	18-Mar-15	16-Mar-16	15-Mar-18
US20180072813	CARBONIC ANHYDRASE IX (G250) ANTIBODIES AND METHODS OF USE THEREOF	Not Available	2-Dec-05	9-May-17	15-Mar-18
US20180072796	MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTION	Not Available	8-Sep-16	17-Nov-17	15-Mar-18
US20180072752	COUMARIN DERIVATIVE AS ANTIVIRAL AGENT, PHARMACEUTICAL COMPOSITION THEREOF, ITS PREPARATION AND USE	Not Available	30-Mar-15	2-Feb-16	15-Mar-18
US20180071219	Technology for Preparation of Macromolecular Microspheres	Not Available	24-Jan-06	25-Sep-17	15-Mar-18
US20180067299	ENDOSCOPIC APPARATUS FOR THERMAL DISTRIBUTION MONITORING	ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE	7-Sep-16	31-May-17	8-Mar-18
US20180066228	Detection of T Cell Exhaustion or Lack of T Cell Costimulation and Uses Thereof	Not Available	15-May-15	15-Nov-17	8-Mar-18
US20180066216	CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOF	Not Available	8-Sep-16	6-Sep-17	8-Mar-18
US20180065981	HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR	Not Available	26-Mar-15	21-Mar-16	8-Mar-18

US20180064790	Composition for Treatment or Prevention of Infectious Inflammatory Diseases, or Composition for Immune Enhancement, Comprising Tryptophanyl-tRNA Synthetase as an Active Ingredient	Not Available	26-Feb-15	25-Aug-17	8-Mar-18
US20180064752	ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE, USE OF ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE AS MEDICINE, PARTICULARLY FOR PROPYLAXIS AND TREATMENT OF INFECTIONS OF RESPIRATORY TRACT CAUSED BY HUMAN METAPNEUMOVIRUS (HMPV), HUMAN RHINOVIRUSES (HRV), AND INFECTION BY INFLUENZA VIRUS TYPE A (IAV) AND PHARMACEUTICAL COMPOSITION COMPRISING THE ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE	Not Available	29-Jul-14	25-Oct-17	8-Mar-18
US20180058988	SAMPLE FIXATION AND STABILISATION	Not Available	1-Mar-13	14-Aug-17	1-Mar-18
US20180057871	COMPOSITIONS AND METHODS FOR DETECTING RARE SEQUENCE VARIANTS	Not Available	15-Aug-16	1-Nov-17	1-Mar-18
US20180057841	METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR	Not Available	7-Apr-05	27-Oct-17	1-Mar-18
US20180057817	Particle-Nucleic Acid Conjugates and Therapeutic Uses Related Thereto	Not Available	25-Jun-12	9-Oct-17	1-Mar-18
US20180057594	PSEUDOTYPED ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES	Not Available	30-Jun-16	29-Sep-17	1-Mar-18
US20180057509	ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES	Not Available	9-Feb-05	2-Nov-17	1-Mar-18
US20180057488	COMPOSITIONS AND METHODS FOR INHIBITING KINASES	Not Available	23-Apr-15	7-Nov-17	1-Mar-18
US20180055925	DISPLAY PLATFORM FROM BACTERIAL SPORE COAT PROTEINS	The United States of America, as represented by the Secretary, Department of Health and Human Serv	3-Mar-15	7-Aug-15	1-Mar-18
US20180055769	CIRCULATION OF COMPONENTS DURING MICROFLUIDIZATION AND/OR HOMOGENIZATION OF EMULSIONS	Not Available	3-Dec-09	26-Jun-17	1-Mar-18
US20180051267	TAL EFFECTOR-MEDIATED DNA MODIFICATION	Not Available	10-Dec-09	5-Oct-17	22-Feb-18
US20180051266	TAL EFFECTOR-MEDIATED DNA MODIFICATION	Not Available	10-Dec-09	21-Aug-17	22-Feb-18
US20180050059	DELIVERY OF RNA TO DIFFERENT CELL TYPES	GLAXOSMITHKLINE BIOLOGICALS, SA	6-Jul-10	30-Aug-17	22-Feb-18
US20180044687	ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION	Not Available	12-Dec-14	11-Dec-15	15-Feb-18
US20180044328	PEPTIDYL NITRIL COMPOUNDS AS DIPEPTIDYL PEPTIDASE I INHIBITORS	Prozymex A/S	5-Mar-15	4-Mar-16	15-Feb-18
US20180043007	INFLUENZA VIRUS VECTORS AND USES THEREFOR	Not Available	17-Mar-14	21-Aug-17	15-Feb-18
US20180037952	SYSTEM AND METHOD FOR DNA SEQUENCING AND BLOOD CHEMISTRY ANALYSIS	Nanomedical Diagnostics, Inc.	28-Apr-14	21-Aug-17	8-Feb-18
US20180037942	ENZYME-INDEPENDENT MOLECULAR INDEXING	Not Available	3-Aug-16	1-Aug-17	8-Feb-18
US20180037871	CANCER INITIATING CELL AND USE THEREOF	Not Available	8-Aug-16	8-Aug-16	8-Feb-18
US20180037636	STRUCTURED VIRAL PEPTIDE COMPOSITIONS AND METHODS OF USE	DANA-FARBER CANCER INSTITUTE, INC.	18-Jun-09	21-Sep-17	8-Feb-18
US20180037634	ENGINEERED POLYPEPTIDES AND USES THEREOF	Not Available	2-Aug-16	2-Aug-17	8-Feb-18
US20180037617	METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING A DISEASE OR DISORDER ASSOCIATED WITH ABNORMAL LEVEL AND/OR ACTIVITY OF THE IFP35 FAMILY OF PROTEINS	Institute of Biophysics, Chinese Academy of Sciences	22-Aug-14	21-Aug-15	8-Feb-18
US20180036398	FLAVIVIRUS REPLICONS	Not Available	27-Feb-15	25-Feb-16	8-Feb-18

CC-BY-NC-SA Dr. David E. Martin

US20180036237	OIL/SURFACTANT MIXTURES FOR SELF-EMULSIFICATION	GLAXOSMITHKLINE BIOLOGICALS, SA	23-Feb-15	23-Feb-16	8-Feb-18
US20180031555	METHOD FOR SELECTING A SINGLE CELL EXPRESSING A HETEROGENEOUS COMBINATION OF ANTIBODIES	Merus N.V.	27-Jun-08	18-Jul-17	1-Feb-18
US20180030429	Polypeptide Assemblies and Methods for the Production Thereof	Not Available	27-Feb-15	29-Feb-16	1-Feb-18
US20180030411	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13	13-Oct-17	1-Feb-18
US20180028677	Peptides for Assisting Delivery Across the Blood Brain Barrier	Children's Medical Center Corporation	22-May-06	30-Jun-17	1-Feb-18
US20180028626	IMMUNOTHERAPEUTIC VACCINE AND ANTIBODY COMBINATION THERAPY	Transgene SA	13-Feb-15	12-Feb-16	1-Feb-18
US20180028562	METHODS OF TREATING OR PREVENTING INFLAMMATION AND HYPERSENSITIVITY WITH OXIDATIVE REDUCTIVE POTENTIAL WATER SOLUTION	SONOMA PHARMACEUTICALS, INC.	20-Jan-06	10-Oct-17	1-Feb-18
US20180028449	Technology for the Preparation of Microparticles	Not Available	24-Jul-07	27-Jun-17	1-Feb-18
US20180028431	POLYMER-BASED ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOF	eXion labs Inc.	28-Jul-16	27-Jul-17	1-Feb-18
US20180023048	ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS	Not Available	29-Oct-04	22-Sep-17	25-Jan-18
US20180022781	POLYPEPTIDES FOR ENGINEERING INTEGRASE CHIMERIC PROTEINS AND THEIR USE IN GENE THERAPY	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)	13-Feb-15	12-Feb-16	25-Jan-18
US20180021448	Conjugates of Cell Binding Molecules with Cytotoxic Agents	Hangzhou DAC Biotech Co., Ltd.	12-Jul-12	16-Apr-14	25-Jan-18
US20180016307	GRIFFITHSIN MUTANTS	The United States of America, as represented by the Secretary, Department of Health and Human Serv	10-Feb-15	10-Feb-16	18-Jan-18
US20180016285	Boron-Containing Small Molecules	Not Available	20-Jun-07	28-Sep-17	18-Jan-18
US20180016243	HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTS	Not Available	13-Feb-15	12-Feb-16	18-Jan-18
US20180015174	SYNTHETIC NANOPARTICLES FOR DELIVERY OF IMMUNOMODULATORY COMPOUNDS	Not Available	15-Jul-16	14-Jul-17	18-Jan-18
US20180015052	DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER NUCLEOSIDE ANALOGUES HAVING ANTI-CORONAVIRUS ACTIVITY	Not Available	30-Jan-15	28-Jan-16	18-Jan-18
US20180010167	ORGANISM IDENTIFICATION PANEL	Not Available	2-Apr-07	26-Jul-17	11-Jan-18
US20180010125	DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4 AND METHODS OF USE THEREOF	Quark Pharmaceuticals Inc.	12-Sep-12	15-Feb-17	11-Jan-18
US20180009787	NOVEL COMPOUNDS	CHIESI FARMACEUTICI S.P.A.	31-May-16	22-Sep-17	11-Jan-18
US20180008689	RNA VIRUS ATTENUATION BY ALTERATION OF MUTATIONAL ROBUSTNESS AND SEQUENCE SPACE	Not Available	28-Jan-15	28-Jan-16	11-Jan-18
US20180002743	FLUOROGENIC PROBES AND THEIR USE IN QUANTITATIVE DETECTION OF TARGET RNA SEQUENCES	Not Available	18-Jun-16	16-Jun-17	4-Jan-18
US20180002406	NEUTRALIZING GP41 ANTIBODIES AND THEIR USE	The United States of America, as represented by the Secretary, Department of Health and Human	7-Nov-11	8-Sep-17	4-Jan-18
US20180000929	D-AMINO ACID DERIVATIVE-MODIFIED PEPTIDOGLYCAN AND METHODS OF USE THEREOF	Not Available	30-Nov-12	14-Sep-17	4-Jan-18
US20180000926	METHODS OF INDUCING AN IMMUNE RESPONSE TO HEPATITIS C VIRUS	Not Available	15-Jan-15	15-Jan-16	4-Jan-18
US20180000868	Induced Hepatocytes and Uses Thereof	Not Available	26-Nov-14	15-Sep-17	4-Jan-18
US20180000724	METHODS FOR INDUCING AN IMMUNE RESPONSE VIA BUCCAL AND/OR SUBLINGUAL ADMINISTRATION OF A VACCINE	Not Available	26-Jul-10	10-May-17	4-Jan-18
US20170369843	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13	29-Mar-17	28-Dec-17
US20170369470	Cyclic Compounds and Uses Thereof	Not Available	16-Dec-14	16-Dec-15	28-Dec-17

CC-BY-NC-SA Dr. David E. Martin

US20170368203	Compositions For Enhancing Transport Of Molecules Into Cells	Not Available	29-Apr-03	10-Jan-17	28-Dec-17
US20170368201	SCALABLE MANUFACTURING PROCESS TO PRODUCE RECOMBINANT LENTIVIRAL VECTORS IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM	The Children's Hospital of Philadelphia	15-Mar-13	8-Sep-17	28-Dec-17
US20170368167	COMPOSITIONS AND METHODS RELATED TO NEUROLOGICAL DISORDERS	Not Available	21-Aug-12	6-Jun-16	28-Dec-17
US20170362300	OLIGOPEPTIDE-FREE CELL CULTURE MEDIA	Not Available	4-Jan-06	7-Aug-17	21-Dec-17
US20170362297	CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOF	Not Available	19-Dec-14	21-Dec-15	21-Dec-17
US20170362187	3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS	Parion Sciences, Inc.	17-Dec-12	29-Jun-17	21-Dec-17
US20170362170	HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS	Not Available	3-Aug-07	29-Jun-17	21-Dec-17
US20170360962	NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS RESISTANT TO PRE-EXISTING HUMAN NEUTRALIZING ANTIBODIES	Not Available	16-Feb-16	18-Aug-17	21-Dec-17
US20170360960	AAV Vectors Targeted to the Central Nervous System	Not Available	21-Nov-14	20-Nov-15	21-Dec-17
US20170360908	VACCINE PHARMACEUTICAL COMPOSITION FOR CELL-MEDIATED IMMUNITY CONTAINING BISPHOSPHONATES	NITTO DENKO CORPORATION	3-Sep-14	2-Sep-15	21-Dec-17
US20170360881	PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF	Not Available	17-Jun-16	16-Jun-17	21-Dec-17
US20170360875	METHODS FOR TREATING IMMUNE-MEDIATED VIRAL INFECTIONS	MIDDLE TENNESSEE STATE UNIVERSITY	22-Dec-14	22-Dec-15	21-Dec-17
US20170358082	STAIN-FREE HISTOPATHOLOGY BY CHEMICAL IMAGING	Not Available	15-Mar-13	2-Aug-17	14-Dec-17
US20170354727	MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF SYNONYMOUS CODONS	Not Available	8-Oct-04	23-Aug-17	14-Dec-17
US20170348433	NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS RESISTANT TO PRE-EXISTING HUMAN NEUTRALIZING ANTIBODIES	The Board of Trustees of the Leland Stanford Junior University	16-Feb-16	16-Feb-17	7-Dec-17
US20170348402	SYSTEM AND METHOD FOR DELIVERING GENETIC MATERIAL OR PROTEIN TO CELLS	Not Available	30-Jul-14	30-Jul-15	7-Dec-17
US20170348369	Plant Extract and Its Therapeutic Use	Not Available	16-May-08	18-Jul-17	7-Dec-17
US20170342442	RECOMBINANT SELF-REPLICATING POLYCISTRONIC RNA MOLECULES	GLAXOSMITHKLINE BIOLOGICALS, SA	11-Oct-11	15-Aug-17	30-Nov-17
US20170342405	MOLECULAR INDEXING OF INTERNAL SEQUENCES	Not Available	31-May-16	16-May-17	30-Nov-17
US20170342056	NOVEL COMPOUNDS	CHIESI FARMACEUTICI S.P.A.	31-May-16	26-May-17	30-Nov-17
US20170340735	Anti-TIGIT Antigen-Binding Proteins and Methods of Use Thereof	Not Available	1-Oct-15	19-Jun-17	30-Nov-17
US20170340725	COMBINATION PIV3/HMPV RNA VACCINES	ModernaTX, Inc.	22-Oct-15	11-Aug-17	30-Nov-17
US20170340721	METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSES	Not Available	3-Sep-14	3-Sep-15	30-Nov-17
US20170340611	NOVEL COMPOUNDS	CHIESI FARMACEUTICI S.P.A.	31-May-16	26-May-17	30-Nov-17
US20170337459	SPATIALLY ADDRESSABLE MOLECULAR BARCODING	Not Available	27-Feb-15	2-Aug-17	23-Nov-17
US20170336412	Multiplex Immuno Screening Assay	Institut Pasteur	4-May-12	19-Jul-17	23-Nov-17
US20170336411	B-CELL ANTIGEN PRESENTING CELL ASSAY	The University of Pittsburgh - Of the Commonwealth System of Higher Education	8-Apr-10	9-Aug-17	23-Nov-17
US20170335408	Methods and Systems of Multi-Assay Processing and Analysis	Not Available	15-Mar-16	15-Mar-17	23-Nov-17

CC-BY-NC-SA Dr. David E. Martin

US20170335374	METHODS AND COMPOSITIONS FOR IDENTIFICATION OF SOURCE OF MICROBIAL CONTAMINATION IN A SAMPLE	Not Available	6-Mar-12	6-Jul-17	23-Nov-17
US20170334984	HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)	Not Available	16-Dec-02	26-Apr-16	23-Nov-17
US20170334973	NON-HUMAN PRIMATE-DERIVED PAN-EBOLA AND PAN-FILOVIRUS MONOCLONAL ANTIBODIES DIRECTED AGAINST ENVELOPE GLYCOPROTEINS	Not Available	28-Oct-14	27-Oct-15	23-Nov-17
US20170334941	2',2'-DIHALO NUCLEOSIDE ANALOGS FOR TREATMENT OF THE FLAVIVIRIDAE FAMILY OF VIRUSES AND CANCER	Not Available	31-Oct-14	30-Oct-15	23-Nov-17
US20170334919	2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1 -YL)METHYL)-3-(2-(TRIFLUORO-METHYL)BENZYL)QUINAZOLIN-4(3H)-ONE DERIVATIVES AND THEIR USE AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS	RESPIVERT LTD.	15-Mar-13	27-Jul-17	23-Nov-17
US20170334864	3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6-PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL) CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE	Parion Sciences, Inc.	27-Jun-11	1-Mar-17	23-Nov-17
US20170333586	ADDITIVE COMPOSITIONS FOR PIGMENTED DISINFECTION AND METHODS THEREOF	Not Available	8-Dec-14	23-May-15	23-Nov-17
US20170333553	LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS	Not Available	21-May-13	1-Aug-17	23-Nov-17
US20170333494	PROBIOTIC THERAPEUTIC APPLICATIONS	Not Available	10-Nov-14	9-Nov-15	23-Nov-17
US20170333457	Anti-Viral Azide Containing Compounds	Not Available	28-Jul-10	8-Aug-17	23-Nov-17
US20170333267	MOBILE CLINICS	Baylor College of Medicine	12-Nov-14	11-Nov-15	23-Nov-17
US20170328819	SAMPLE FIXATION AND STABILISATION	Not Available	1-Mar-13	30-May-17	16-Nov-17
US20170327543	POLYIONIC PAPILLOMA VIRUS-LIKE PARTICLE (VLP) VACCINES	Not Available	8-Sep-10	31-Jan-17	16-Nov-17
US20170327472	CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY	Parion Sciences, Inc.	17-Dec-12	7-Mar-17	16-Nov-17
US20170327439	DIHYDRONAPHTHALENE DERIVATIVE	ONO PHARMACEUTICAL CO., LTD.	3-Dec-14	3-Dec-14	16-Nov-17
US20170326256	RECOMBINANT PROMOTERS AND VECTORS FOR PROTEIN EXPRESSION IN LIVER AND USE THEREOF	Children's Healthcare of Atlanta, Inc.	16-Apr-15	15-Apr-16	16-Nov-17
US20170326123	Throat solution for treatment of cold, flu and sore throat	Not Available	12-May-16	12-May-16	16-Nov-17
US20170322682	SYSTEM AND METHOD FOR DETECTING, COLLECTING, ANALYZING, AND COMMUNICATING EVENT-RELATED INFORMATION	Georgetown University	25-Feb-08	27-Jul-17	9-Nov-17
US20170322201	ANTIGEN PRESENTING CELL ASSAY	University of Pittsburgh - Of the Commonwealth System of Higher Education	8-Apr-10	20-Jul-17	9-Nov-17
US20170321192	Recombinant RNA Viruses and Uses Thereof	Icahn School of Medicine at Mount Sinai	6-Jun-10	6-Apr-17	9-Nov-17
US20170319712	METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSE	3M INNOVATIVE PROPERTIES COMPANY	10-Apr-03	27-Jul-17	9-Nov-17
US20170319673	TRI-SEGMENTED ARENAVIRUSES AS VACCINE VECTORS	Not Available	13-Nov-14	12-Nov-15	9-Nov-17
US20170319551	NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	9-May-12	24-Jan-17	9-Nov-17
US20170313765	DIRECT EXPRESSION OF ANTIBODIES	Not Available	29-Oct-14	28-Oct-15	2-Nov-17
US20170313685	BROAD-SPECTRUM NON-COVALENT CORONAVIRUS PROTEASE INHIBITORS	Purdue Research Foundation	28-Apr-16	28-Apr-17	2-Nov-17
US20170312371	MODIFIED VIRUS-LIKE PARTICLES OF CMV	SAIBA GMBH	22-Oct-14	20-Oct-15	2-Nov-17

CC-BY-NC-SA Dr. David E. Martin

US20170312357	MANUFACTURE OF SURFACTANT-CONTAINING COMPOSITIONS	Not Available	2-Dec-14	2-Dec-15	2-Nov-17
US20170308679	BIOSECURITY SCREENING SYSTEM AND METHOD	Not Available	16-Oct-14	12-Oct-15	26-Oct-17
US20170307562	CHEMICALLY DIFFERENTIATED SENSOR ARRAY	Nanomedical Diagnostics, Inc.	28-Apr-14	8-May-17	26-Oct-17
US20170306354	ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR	Not Available	17-Dec-01	1-May-17	26-Oct-17
US20170306293	MEANS AND METHODS FOR INFLUENCING THE STABILITY OF ANTIBODY PRODUCING CELLS	Not Available	9-Dec-05	2-Jun-17	26-Oct-17
US20170306001	CHIMERIZATION AND CHARACTERIZATION OF A MONOCLONAL ANTIBODY WITH POTENT NEUTRALIZING ACTIVITY ACROSS MULTIPLE INFLUENZA A H5N1 CLADES	NATIONAL UNIVERSITY OF SINGAPORE	27-Mar-14	27-Mar-15	26-Oct-17
US20170305868	ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS	Parion Sciences, Inc.	13-Dec-13	1-Mar-17	26-Oct-17
US20170304829	PRINTED CIRCUIT BOARD HEATER FOR AN AMPLIFICATION MODULE	Click Diagnostics, Inc.	22-Apr-16	21-Apr-17	26-Oct-17
US20170304466	AAV-Based Gene Therapy	Not Available	6-Oct-14	6-Oct-15	26-Oct-17
US20170304459	METHODS AND COMPOSITIONS FOR INHALATION DELIVERY OF CONJUGATED OLIGONUCLEOTIDE	Not Available	10-Oct-14	7-Oct-15	26-Oct-17
US20170304429	VACCINATION OF IMMUNOCOMPROMISED SUBJECTS	Not Available	26-Sep-14	25-Sep-15	26-Oct-17
US20170304420	POLYMER ADJUVANT	Oxford University Innovation Limited	10-Oct-14	9-Oct-15	26-Oct-17
US20170304354	TREATMENT OF DISEASE WITH POLY-N-ACETYLGLUCOSAMINE NANOFIBERS	Marine Polymer Technologies, Inc.	15-Apr-11	13-Mar-17	26-Oct-17
US20170299591	EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES	Not Available	6-Oct-08	13-Dec-16	19-Oct-17
US20170298100	ANTI-VIRAL PEPTIDES	Not Available	1-Oct-14	30-Sep-15	19-Oct-17
US20170296663	Conjugates of Cell Binding Molecules with Cytotoxic Agents	Hangzhou DAC Biotech Co., Ltd.	16-Apr-14	16-Apr-14	19-Oct-17
US20170296574	Method of Treating Inflammation	Not Available	1-Apr-10	28-Jun-17	19-Oct-17
US20170292132	TISSUE PREFERENTIAL CODON MODIFIED EXPRESSION CASSETTES, VECTORS CONTAINING SAME, AND USES THEREOF	Not Available	29-Apr-13	20-Jun-17	12-Oct-17
US20170290909	METHODS AND COMPOSITIONS FOR INTRA-NASAL IMMUNIZATION WITH RECOMBINANT MVA ENCODING FLAGELLIN	Bavarian Nordic A/S	26-Sep-14	25-Sep-15	12-Oct-17
US20170281966	Device to Kill Micro-Organisms Inside the Respiratory Tract	Not Available	1-Apr-16	28-Mar-17	5-Oct-17
US20170281759	BISPHOSPHONATE-CONTAINING VACCINE PHARMACEUTICAL COMPOSITION FOR HUMORAL IMMUNITY	NITTO DENKO CORPORATION	3-Sep-14	2-Sep-15	5-Oct-17
US20170275621	CHIRAL CONTROL	Not Available	13-Jul-12	17-Mar-17	28-Sep-17
US20170275592	CULTURE MEDIUM	Koninklijke Nederlandse Akademie Van Wetenschappen	27-Nov-14	27-Nov-15	28-Sep-17
US20170275323	GLYCOLIPIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THERAPY	THE UNIVERSITY OF NOTTINGHAM	4-Apr-14	7-Apr-15	28-Sep-17
US20170275253	BENZAZEPINE SULFONAMIDE COMPOUNDS	Hoffmann-La Roche Inc.	18-Dec-14	14-Jun-17	28-Sep-17
US20170275243	Lipids and Lipid Compositions for the Delivery of Active Agents	Novartis AG	5-Sep-14	4-Sep-15	28-Sep-17
US20170274064	MODIFIED BAT INFLUENZA VIRUSES AND THEIR USES	Not Available	5-Sep-14	4-Sep-15	28-Sep-17
US20170274024	AAV Vectors Targeted to Oligodendrocytes	Not Available	28-Sep-12	17-Apr-17	28-Sep-17

CC-BY-NC-SA Dr. David E. Martin

US20170267969	Animal Protein-Free Media for Cultivation of Cells	Baxalta GmbH	29-Oct-04	18-May-17	21-Sep-17
US20170267722	INHIBITORY PEPTIDES OF VIRAL INFECTION	Not Available	17-Jul-14	25-May-17	21-Sep-17
US20170267649	STABLE SODIUM CHANNEL BLOCKERS	PARION SCIENCES, INC.	30-Jun-14	30-Jan-17	21-Sep-17
US20170266272	TRANSGENIC VERO-CD4/CCR5 CELL LINE	Not Available	2-Oct-15	6-Apr-17	21-Sep-17
US20170266190	DRUG COMBINATION	Not Available	15-Mar-13	5-Jun-17	21-Sep-17
US20170266160	METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C	Not Available	14-Mar-13	6-Jun-17	21-Sep-17
US20170261431	CONTINUOUS PROCESS FOR PERFORMING MULTIPLE NUCLEIC ACID AMPLIFICATION ASSAYS	Not Available	10-Mar-05	19-May-17	14-Sep-17
US20170260223	ENANTIOMERS OF THE 1',6'-ISOMER OF NEPLANOCIN A	Not Available	4-Aug-14	17-May-17	14-Sep-17
US20170260147	ANTIVIRAL COMPOUNDS AND METHODS	Biotron Limited	26-Jun-03	23-May-17	14-Sep-17
US20170259976	DEGRADABLE MATERIALS AND PACKAGING MADE FROM SAME	MONOSOL, LLC	3-Oct-14	2-Oct-15	14-Sep-17
US20170258904	Antagonism of the VIP Signaling Pathway	Not Available	2-Feb-11	22-May-17	14-Sep-17
US20170258893	MERS-CoV Vaccine	Not Available	29-Nov-13	26-Nov-14	14-Sep-17
US20170253861	HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS	Not Available	11-Jul-03	6-Oct-16	7-Sep-17
US20170252430	POLYMERIC CARRIER CARGO COMPLEX FOR USE AS AN IMMUNOSTIMULATING AGENT OR AS AN ADJUVANT	Not Available	1-Apr-14	1-Apr-15	7-Sep-17
US20170252417	PROTEIN-CHAPERONED T-CELL VACCINES	Not Available	7-Mar-16	7-Mar-17	7-Sep-17
US20170247688	ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES	NUEVOLUTION A/S	1-Dec-05	12-Dec-16	31-Aug-17
US20170247453	SOLUBLE ENGINEERED MONOMERIC FC	The United States of America, as represented by the Secretary, Department of Health and Human Serv	16-Mar-12	9-May-17	31-Aug-17
US20170247423	STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES TO TREAT INFECTION	Not Available	29-Feb-16	28-Feb-17	31-Aug-17
US20170246347	MATERIALS WITH IMPROVED PROPERTIES	Not Available	1-Nov-15	5-May-17	31-Aug-17
US20170241998	METHOD FOR THE IMMOBILIZATION OF BIOMOLECULES	Not Available	22-Feb-16	17-Feb-17	24-Aug-17
US20170240639	ACTRII ANTAGONISTS FOR USE IN INCREASING IMMUNE ACTIVITY	Not Available	22-Feb-16	22-Feb-17	24-Aug-17
US20170239397	MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS	Not Available	1-Nov-15	5-May-17	24-Aug-17
US20170239364	METHODS AND COMPOSITIONS RELATED TO INHIBITION OF VIRAL ENTRY	Not Available	28-Mar-11	2-Mar-17	24-Aug-17
US20170239349	COMPOSITIONS AND METHODS RELATED TO NEUROLOGICAL DISORDERS	Not Available	20-Feb-15	6-Jun-16	24-Aug-17
US20170239291	METHOD OF PREVENTING OR TREATING SINUSITIS WITH OXIDATIVE REDUCTIVE POTENTIAL WATER SOLUTION	SONOMA PHARMACEUTICALS, INC.	30-Dec-03	9-May-17	24-Aug-17
US20170234781	MEMBRANE-ASSISTED PURIFICATION	Accelerate Diagnostics, Inc.	7-Mar-11	3-May-17	17-Aug-17
US20170226593	HANDHELD NUCLEIC ACID-BASED ASSAY FOR RAPID IDENTIFICATION	Not Available	8-Feb-16	8-Feb-16	10-Aug-17
US20170226511	APTAMERS FOR BINDING FLAVIVIRUS PROTEINS	National University of Singapore	13-Nov-13	13-Nov-14	10-Aug-17
US20170226232	MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONS	Not Available	1-Nov-15	2-Nov-16	10-Aug-17

CC-BY-NC-SA Dr. David E. Martin

US20170226222	BISPECIFIC ANTIBODY	Not Available	20-Nov-13	18-Jan-17	10-Aug-17
US20170226173	GM-CSF and IL-4 Conjugates, Compositions, and Methods Related Thereto	Not Available	23-Oct-12	19-Apr-17	10-Aug-17
US20170224813	VACCINE PHARMACEUTICAL COMPOSITION FOR SUPPRESSING APOPTOSIS OF CTL OR INHIBITING SUPPRESSION OF INDUCTION OF CTL	NITTO DENKO CORPORATION	4-Aug-14	4-Aug-15	10-Aug-17
US20170224812	LIQUID IMMUNITY INDUCTION-PROMOTING COMPOSITION AND VACCINE PHARMACEUTICAL COMPOSITION THAT INCLUDE THROMBOSIS TREATMENT DRUG	NITTO DENKO CORPORATION	4-Aug-14	4-Aug-15	10-Aug-17
US20170224616	OIL-IN-WATER EMULSIONS THAT CONTAIN NUCLEIC ACIDS	GLAXOSMITHKLINE BIOLOGICALS SA	6-Jul-11	24-Apr-17	10-Aug-17
US20170219560	MALARIA ANTIGEN SCREENING METHOD	United States of America as Represented by the Secretary of the Navy	31-Aug-05	10-Apr-17	3-Aug-17
US20170216431	VACCINE PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL ADMINISTRATION	NITTO DENKO CORPORATION	2-Oct-14	1-Oct-15	3-Aug-17
US20170216430	IMMUNE-INDUCTION-PROMOTING COMPOSITION INCLUDING NUCLEAR RECEPTOR LIGAND, AND VACCINE PHARMACEUTICAL COMPOSITION	NITTO DENKO CORPORATION	4-Aug-14	4-Aug-15	3-Aug-17
US20170216429	COMPOSITION FOR ENHANCING INDUCTION OF HUMORAL IMMUNITY, AND VACCINE PHARMACEUTICAL COMPOSITION	NITTO DENKO CORPORATION	4-Aug-14	4-Aug-15	3-Aug-17
US20170216427	Coronavirus	Not Available	23-Jul-14	23-Jul-15	3-Aug-17
US20170216348	METAL NANOCLUSTERS AND USES THEREOF	Not Available	7-Aug-14	7-Aug-15	3-Aug-17
US20170216347	ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE, USE OF ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE AS MEDICINE, PARTICULARLY FOR PROPYLAXIS AND TREATMENT OF INFECTIONS OF RESPIRATORY TRACT CAUSED BY HUMAN METAPNEUMOVIRUS (HMPV), HUMAN RHINOVIRUSES (HRV), AND INFECTION BY INFLUENZA VIRUS TYPE A (IAV) AND PHARMACEUTICAL COMPOSITION COMPRISING THE ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE	UNIWERSYTET JAGIELLONSKI	29-Jul-14	29-Jul-15	3-Aug-17
US20170212116	BIOSENSORS FOR THE DETECTION OF INFECTION AND ASSOCIATED MALADIES	ULISSE BIOMED SRL	31-Jan-14	26-Jan-15	27-Jul-17
US20170212019	POLYMER STABILIZATION OF CHROMOGEN SOLUTIONS	Not Available	23-Jan-12	10-Apr-17	27-Jul-17
US20170211096	LCMV-GP-VSV-Pseudotyped Vectors and Tumor-Infiltrating Virus-Producing Cells for the Therapy of Tumors	Not Available	29-Jun-11	7-Apr-17	27-Jul-17
US20170211069	USE OF THE CHROMOSOME 19 MICRORNA CLUSTER (C19MC) FOR TREATING MICROBIAL DISEASE AND PROMOTING AUTHOPHAGY	University of Pittsburgh - Of the Commonwealth System of Higher Education	7-Mar-12	27-Jan-17	27-Jul-17
US20170211058	METHOD AND APPARATUS FOR AUTOMATED PROCESSING OF POOLED SAMPLES	Not Available	6-Aug-14	5-Aug-15	27-Jul-17
US20170209844	MICROSPOTTING DEVICE	Not Available	18-Apr-12	5-Jan-17	27-Jul-17
US20170209595	DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELL-BINDING MOLECULE	Suzhou M-Conj Biotech Co., Ltd.	15-Jul-15	5-Apr-17	27-Jul-17
US20170209590	METHODS AND REAGENTS FOR EFFICIENT AND TARGETED DELIVERY OF THERAPEUTIC MOLECULES TO CXCR4 CELLS	Not Available	13-Jan-11	10-Jan-17	27-Jul-17
US20170209570	Carbon Nanotube Compositions and Methods of Use Thereof	Not Available	19-Mar-08	17-Mar-17	27-Jul-17
US20170209376	COMPOSITIONS WITH MODIFIED NUCLEASES TARGETED TO VIRAL NUCLEIC ACIDS AND METHODS OF USE FOR PREVENTION AND TREATMENT OF VIRAL DISEASES	Not Available	14-Apr-04	10-Mar-17	27-Jul-17
US20170205399	POLYMERS AND CONJUGATES COMPRISING THE SAME	Not Available	2-Oct-14	31-Mar-17	20-Jul-17

CC-BY-NC-SA Dr. David E. Martin

US20170204143	Constrained proteins and uses therefor	Not Available	21-Jul-14	21-Jul-15	20-Jul-17
US20170204083	THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES	RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY	11-Sep-12	13-Jan-17	20-Jul-17
US20170202975	DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELL-BINDING MOLECULE	Suzhou M-Conj Biotech Co., Ltd.	15-Jul-15	5-Apr-17	20-Jul-17
US20170202960	CATIONIC OIL-IN-WATER EMULSIONS	GLAXOSMITHKLINE BIOLOGICALS, SA	6-Jul-11	23-Mar-17	20-Jul-17
US20170202959	ADJUVANT COMPOSITIONS AND RELATED METHODS	Not Available	24-Mar-15	23-Mar-17	20-Jul-17
US20170202956	Methods and Compositions for Inhibiting Akt3	Not Available	15-Jan-16	17-Jan-17	20-Jul-17
US20170202955	Adjuvanted Influenza Vaccines for Pediatric Use	Not Available	22-Feb-08	30-Dec-16	20-Jul-17
US20170202949	DEFECTIVE RIBOSOMAL PRODUCTS IN BLEBS (DRIBBLES) AND METHODS OF USE TO STIMULATE AN IMMUNE RESPONSE	Providence Health & Services - Oregon	29-Jul-05	29-Dec-16	20-Jul-17
US20170202829	Specific Akt3 Inhibitor and Uses Thereof Cross-Reference to Related Applications	Not Available	15-Jan-16	17-Jan-17	20-Jul-17
US20170196979	LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS	Novartis AG	8-Mar-13	27-Sep-16	13-Jul-17
US20170196954	PRIME-BOOST REGIMENS WITH A TLR4 AGONIST ADJUVANT AND A LENTIVIRAL VECTOR	Not Available	15-Jul-14	14-Jul-15	13-Jul-17
US20170191933	Systems and Methods for Analyzing a Sample and for Monitoring the Performance of an Optical Signal Detector	Not Available	31-Dec-15	23-Dec-16	6-Jul-17
US20170191079	METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR	Not Available	7-Apr-05	18-Jan-17	6-Jul-17
US20170190770	HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)	CORMORANT PHARMACEUTICALS AB	16-Dec-02	26-Apr-16	6-Jul-17
US20170189521	LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS	3M Innovative Properties Company	17-Aug-10	19-Aug-16	6-Jul-17
US20170175140	METHODS FOR USING A 5'-EXONUCLEASE TO INCREASE HOMOLOGOUS RECOMBINATION IN EUKARYOTIC CELLS	Not Available	16-Dec-15	14-Dec-16	22-Jun-17
US20170173585	POINT OF CARE POLYMERASE CHAIN REACTION DEVICE FOR DISEASE DETECTION	Not Available	11-Jul-14	10-Jul-15	22-Jun-17
US20170173176	ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING MOLECULE	SUZHOU M-CONJ BIOTECH CO., LTD.	15-Jul-15	3-Mar-17	22-Jun-17
US20170173168	ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING MOLECULE	SUZHOU M-CONJ BIOTECH CO., LTD.	15-Jul-15	3-Mar-17	22-Jun-17
US20170173164	HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM	Not Available	3-Jun-11	6-Mar-17	22-Jun-17
US20170168052	EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES	Not Available	6-Oct-08	13-Dec-16	15-Jun-17
US20170168044	QUANTITATIVE ANALYSIS METHOD BASED ON AIR PRESSURE MEASURING	XIAMEN UNIVERSITY	9-Jun-14	24-Sep-14	15-Jun-17
US20170166574	NOVEL COMPOUNDS	CHIESI FARMACEUTICI S.P.A.	14-Dec-15	12-Dec-16	15-Jun-17
US20170165366	Anti-TIGIT Antigen-Binding Proteins and Methods of Use Thereof	Not Available	1-Oct-15	13-Feb-17	15-Jun-17
US20170165359	IMMUNOSTIMULATORY COMBINATIONS OF TLR LIGANDS AND METHODS OF USE	Not Available	11-Aug-10	23-Aug-16	15-Jun-17
US20170165341	REPLICATION DEFECTIVE ADENOVIRUS VECTOR IN VACCINATION	Not Available	24-Aug-12	15-Feb-17	15-Jun-17
US20170165230	USE OF GSK-3 INHIBITORS OR ACTIVATORS WHICH MODULATE PD-1 OR T-BET EXPRESSION TO MODULATE T CELL IMMUNITY	Not Available	9-Apr-14	9-Apr-15	15-Jun-17
US20170160218	APPARATUS AND SYSTEM FOR PERFORMING THERMAL MELT ANALYSES AND AMPLIFICATIONS	Not Available	31-Jul-12	23-Feb-17	8-Jun-17

CC-BY-NC-SA Dr. David E. Martin

US20170159027	ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR	Not Available	30-Sep-03	15-Feb-17	8-Jun-17
US20170159026	Novel Recombinant Adeno-Associated Virus Capsids with Enhanced Human Skeletal Muscle Tropism	Not Available	2-Dec-15	2-Dec-16	8-Jun-17
US20170158752	MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF	Not Available	25-Apr-14	27-Apr-15	8-Jun-17
US20170157262	CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTS	Not Available	12-Jul-12	12-Jul-12	8-Jun-17
US20170157151	Broad Spectrum Antiviral and Methods of Use	Not Available	17-Apr-06	16-Feb-17	8-Jun-17
US20170152274	CHARGED LINKERS AND THEIR USES FOR CONJUGATION	Hangzhou DAC Biotech Co., Ltd.	28-Feb-14	28-Feb-14	1-Jun-17
US20170152271	GAK MODULATORS AS ANTIVIRALS	Katholieke Universiteit Leuven	23-Jul-14	23-Jul-15	1-Jun-17
US20170151346	DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELL-BINDING MOLECULE	SUZHOU M-CONJ BIOTECH CO., LTD.	15-Jul-15	13-Feb-17	1-Jun-17
US20170151291	SYNERGISTIC BACTERIAL COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF	Not Available	25-Nov-13	25-Nov-14	1-Jun-17
US20170145394	TRACKING AND MANIPULATING CELLULAR RNA VIA NUCLEAR DELIVERY OF CRISPR/CAS9	Not Available	23-Nov-15	22-Nov-16	25-May-17
US20170144984	MODULATORS OF THE RELAXIN RECEPTOR 1	Not Available	4-May-12	25-Aug-16	25-May-17
US20170143845	ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING MOLECULE	SUZHOU M-CONJ BIOTECH CO., LTD	15-Jul-15	3-Feb-17	25-May-17
US20170143820	IMMUNOGENIC COMBINATIONS	GLAXOSMITHKLINE SA	13-Jun-14	12-Jun-15	25-May-17
US20170143758	INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES	Advanced Inhalation Therapies (AIT) Ltd.	11-Sep-13	4-Jan-17	25-May-17
US20170143749	SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF	Not Available	24-Jun-14	2-Feb-17	25-May-17
US20170137527	GITR ANTIBODIES AND METHODS OF INDUCING OR ENHANCING AN IMMUNE RESPONSE	Not Available	25-Mar-05	7-Nov-16	18-May-17
US20170137430	Nuclear Transport Modulators And Uses Thereof	Not Available	29-Jul-11	22-Jul-16	18-May-17
US20170136118	NEUTRALIZING MOLECULES TO VIRAL ANTIGENS	Not Available	28-Mar-08	8-Jun-16	18-May-17
US20170136043	THERAPEUTIC USES OF SELECTED PYRROLOPYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY	The University of North Carolina at Chapel Hill	11-Apr-14	30-Jan-17	18-May-17
US20170131271	ANTIBODY-NANOPARTICLE CONJUGATES AND METHODS FOR MAKING AND USING SUCH CONJUGATES	Not Available	27-Apr-10	12-Sep-16	11-May-17
US20170130200	INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPY	Not Available	31-Jul-15	29-Jul-16	11-May-17
US20170129947	REGULATING THE INTERACTION BETWEEN TAM LIGANDS AND LIPID MEMBRANES WITH EXPOSED PHOSPHATIDYL SERINE	Kolltan Pharmaceuticals, Inc.	25-Jul-12	20-Sep-16	11-May-17
US20170129891	SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES	Not Available	18-Jun-04	23-Jan-17	11-May-17
US20170128465	Pharmaceutical Compositions and Methods	Not Available	3-Aug-15	6-Dec-16	11-May-17
US20170122853	PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN VIVO	THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV	8-Aug-14	7-Aug-15	4-May-17
US20170121372	NOVEL DEPSIPEPTIDE AND USES THEREOF	Not Available	3-Dec-12	15-Jun-16	4-May-17
US20170119872	SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES	Not Available	20-Aug-10	11-Oct-16	4-May-17
US20170119871	LOW-ADDITIVE INFLUENZA VACCINES	Not Available	27-Jun-07	24-Jun-16	4-May-17
US20170119820	MODIFIED CELLS AND METHODS OF THERAPY	Not Available	31-Jul-15	29-Jul-16	4-May-17

CC-BY-NC-SA Dr. David E. Martin

US20170119786	HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS	Not Available	8-Mar-11	11-Nov-16	4-May-17
US20170119734	TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE	Not Available	5-May-10	22-Apr-16	4-May-17
US20170118995	MINERAL FUNCTIONAL WATER, METHOD FOR PRODUCING THE SAME, AND METHOD FOR CONTROLLING UNICELLULAR ORGANISMS AND/OR VIRUSES	Riken Techno System Co., Ltd.	17-Sep-14	6-Dec-16	4-May-17
US20170114053	HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF	The United States of America, as represented by the Secretary, Department of Health and Human Serv	12-Jun-14	12-Jun-15	27-Apr-17
US20170112929	VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER	Not Available	7-Sep-12	6-Jun-16	27-Apr-17
US20170107254	Modified Antimicrobial Peptides	Not Available	2-Apr-14	2-Apr-15	20-Apr-17
US20170107195	Chemical Compounds	AstraZeneca AB	18-Mar-14	17-Mar-15	20-Apr-17
US20170106077	INFLUENZA VIRUS VECTORS AND USES THEREFOR	Not Available	17-Mar-14	13-Mar-15	20-Apr-17
US20170101459	CLEAVAGE AND EXCHANGE OF MAJOR HISTOCOMPATIBILITY COMPLEX LIGANDS EMPLOYING AZOBENZENE-CONTAINING PEPTIDES	Not Available	6-Jun-14	5-Jun-15	13-Apr-17
US20170101413	NOVEL COMPOUNDS	CHIESI FARMACEUTICI S.p.A.	12-Jun-14	12-Jun-14	13-Apr-17
US20170100474	METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES	Not Available	6-Apr-07	22-Jul-16	13-Apr-17
US20170100385	PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASES	GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED	12-May-14	8-May-15	13-Apr-17
US20170096646	Modified Adenovirus Hexon Protein and Uses Thereof	Not Available	28-Apr-06	20-Dec-16	6-Apr-17
US20170096455	METHODS AND COMPOSITIONS FOR CHIMERIC CORONAVIRUS SPIKE PROTEINS	The University of North Carolina at Chapel Hill	20-Mar-14	20-Mar-15	6-Apr-17
US20170096441	PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS	Not Available	14-Apr-10	9-Sep-16	6-Apr-17
US20170096417	Multicyclic Compounds And Methods Of Using Same	Karyopharm Therapeutics Inc.	20-Sep-13	19-Sep-14	6-Apr-17
US20170095818	INTEGRATED MICROFLUIDIC DEVICE FOR TARGET AMPLIFICATION AND MICROARRAY DETECTION	CapitalBio Corporation	31-Mar-14	31-Mar-15	6-Apr-17
US20170095521	Novel Polygonum Cuspidatum Extracts and Their Use as Photodynamic Inactivating Agents	Not Available	1-Oct-15	30-Sep-16	6-Apr-17
US20170089911	QUINONE METHIDE ANALOG SIGNAL AMPLIFICATION	Not Available	24-Feb-14	24-Aug-16	30-Mar-17
US20170088858	ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR	Not Available	17-Dec-01	20-Oct-16	30-Mar-17
US20170088848	Recombinant Influenza Virus-Like Particles (VLPs) Produced in Transgenic Plants Expressing Hemagglutinin	Medicago Inc.	21-Jan-08	2-Sep-16	30-Mar-17
US20170088559	ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES	Not Available	9-Feb-05	12-Dec-16	30-Mar-17
US20170086463	ANTIVIRAL AGENT	Not Available	3-Sep-08	12-Dec-16	30-Mar-17
US20170082608	Assay for Detecting TH1 and TH2 Cell Populations	Not Available	16-May-14	15-May-15	23-Mar-17
US20170082607	MALARIA ANTIGEN SCREENING METHOD	Not Available	31-Aug-05	19-Apr-13	23-Mar-17
US20170081655	PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM OXIDES	Not Available	14-Jul-15	13-Jul-16	23-Mar-17
US20170081393	ENGINEERED ANTIBODY CONSTANT DOMAIN MOLECULES	The U.S.A., as represented by the Secretary, Department of Health and Human Services	31-Jan-08	2-Dec-16	23-Mar-17
US20170081392	COMPOSITIONS COMPRISING AAV EXPRESSING DUAL ANTIBODY CONSTRUCTS AND USES THEREOF	Not Available	13-May-14	13-May-15	23-Mar-17

CC-BY-NC-SA Dr. David E. Martin

US20170080084	OIL/SURFACTANT MIXTURES FOR SELF-EMULSIFICATION	Not Available	17-Mar-14	17-Mar-15	23-Mar-17
US20170080079	METHODS OF MAKING AND USING LIVE ATTENUATED VIRUSES	Not Available	23-Sep-15	23-Sep-16	23-Mar-17
US20170080078	COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME	Not Available	24-Apr-12	3-Oct-16	23-Mar-17
US20170079920	Technology for the Preparation of Microparticles	Not Available	24-Jul-07	5-Dec-16	23-Mar-17
US20170079916	COMPOSITIONS AND METHODS FOR MODIFIED DENDRIMER NANOPARTICLE DELIVERY	Not Available	23-Sep-15	23-Sep-16	23-Mar-17
US20170079253	TRANSGENIC MICE HAVING A HUMAN MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) PHENOTYPE, EXPERIMENTAL USES AND APPLICATIONS	INSTITUT PASTEUR	30-Jul-03	17-Jul-12	23-Mar-17
US20170073738	Compositions and Methods for Detecting and Quantifying Nucleic Acid Sequences in Blood Samples	Longhorn Vaccines and Diagnostics, LLC	1-Oct-07	25-Nov-16	16-Mar-17
US20170073730	METHODS AND COMPOSITIONS FOR LIBRARY NORMALIZATION	Not Available	11-Sep-15	8-Sep-16	16-Mar-17
US20170073727	METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING ADSORPTION MEDIA	Not Available	8-Nov-13	2-Nov-16	16-Mar-17
US20170073390	Method for Identifying and Validating Dominant T Helper Cell Epitopes Using an HLA-DM-Assisted Class II Binding Assay	Not Available	6-Jan-06	5-Dec-14	16-Mar-17
US20170073352	NOVEL SUBSTITUTED SPIROCYCLES	Not Available	12-Sep-14	29-Nov-16	16-Mar-17
US20170072053	METHODS FOR PREPARING SQUALENE	Not Available	12-May-10	22-Nov-16	16-Mar-17
US20170071980	METHOD OF USING OXIDATIVE REDUCTIVE POTENTIAL WATER SOLUTION IN DENTAL APPLICATIONS	OCULUS INNOVATIVE SCIENCES, INC.	2-May-05	22-Nov-16	16-Mar-17
US20170071964	METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONS	Not Available	16-Sep-15	16-Sep-16	16-Mar-17
US20170071867	NOVEL NANOPARTICLE COMPOSITIONS	Not Available	3-Apr-13	28-Nov-16	16-Mar-17
US20170067030	ATTENUATED VIRUSES USEFUL FOR VACCINES	Not Available	30-Mar-07	7-Sep-16	9-Mar-17
US20170067021	MODIFIED CELLS AND METHODS OF THERAPY	Not Available	31-Jul-15	2-Sep-16	9-Mar-17
US20170066788	BORON-CONTAINING SMALL MOLECULES	Not Available	16-Feb-05	18-Nov-16	9-Mar-17
US20170066787	BORON-CONTAINING SMALL MOLECULES	Not Available	16-Feb-05	18-Nov-16	9-Mar-17
US20170066731	SMALL MOLECULE FATTY ACID SYNTHASE INHIBITORS	Not Available	7-Mar-14	5-Mar-15	9-Mar-17
US20170065706	METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONS	Not Available	2-Jul-07	14-Sep-16	9-Mar-17
US20170065693	Sequential administration of a replication defective adenovirus vector in vaccination protocols	Not Available	2-Jul-07	14-Sep-16	9-Mar-17
US20170065677	EV576 FOR USE IN THE TREATMENT OF VIRAL INFECTIONS OF THE RESPIRATORY TRACT	Volution Immuno Pharmaceuticals SA	8-Jan-10	22-Jul-16	9-Mar-17
US20170065636	MODIFIED CELLS AND METHODS OF THERAPY	Not Available	31-Jul-15	29-Aug-16	9-Mar-17
US20170058430	BACTERIAL IDENTIFICATION IN CLINICAL INFECTIONS	Not Available	18-Feb-14	18-Feb-15	2-Mar-17
US20170058365	SYSTEMS AND METHODS FOR ANALYZING VIRAL NUCLEIC ACIDS	Not Available	1-Sep-15	3-Feb-16	2-Mar-17
US20170057978	ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF	Kineta, Inc.	9-May-14	8-May-15	2-Mar-17
US20170057968	COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS	NOVARTIS AG	1-May-14	29-Apr-15	2-Mar-17
US20170057938	CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS	Not Available	24-Jan-14	8-Nov-16	2-Mar-17

CC-BY-NC-SA Dr. David E. Martin

US20170052190	Covalently Linked Thermostable Kinase for Decontamination Process Validation	Not Available	20-Feb-08	8-Jul-16	23-Feb-17
US20170051053	METHOD OF PROVIDING MONOCLONAL AUTO-ANTIBODIES WITH DESIRED SPECIFICITY	Not Available	28-Dec-11	7-Sep-16	23-Feb-17
US20170051046	H1N1 FLU VIRUS NEUTRALIZING ANTIBODIES	MEDIGEN BIOTECHNOLOGY CORPORATION	20-Aug-15	20-Aug-15	23-Feb-17
US20170051022	ADENOVIRUS COMPRISING AN ALBUMIN-BINDING MOIETY	Not Available	30-Apr-14	30-Apr-15	23-Feb-17
US20170051007	PHARMACEUTICAL COMPOSITIONS AND METHODS	Not Available	3-Aug-15	28-Jul-16	23-Feb-17
US20170049813	ANTIMICROBIAL SOLUTIONS CONTAINING DICHLORINE MONOXIDE AND METHODS OF MAKING AND USING THE SAME	OCULUS INNOVATIVE SCIENCES, INC.	13-Mar-07	8-Nov-16	23-Feb-17
US20170044603	CAPTURE PRIMERS AND CAPTURE SEQUENCE LINKED SOLID SUPPORTS FOR MOLECULAR DIAGNOSTIC TESTS	Not Available	31-Jul-09	15-Aug-16	16-Feb-17
US20170044595	PCR Ready Compositions and Methods for Detecting and Identifying Nucleic Acid Sequences	Longhorn Vaccines and Diagnostics, LLC	24-Aug-07	26-Oct-16	16-Feb-17
US20170044237	ANTIBODIES AND PROCESSES FOR PREPARING THE SAME	Not Available	16-May-08	23-Aug-16	16-Feb-17
US20170044168	COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTS	NOVARTIS AG	1-May-14	29-Apr-15	16-Feb-17
US20170042994	COMPOSITIONS HAVING MEANS FOR TARGETING AT LEAST ONE ANTIGEN TO DENDRITIC CELLS	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS	22-Jul-11	29-Jul-16	16-Feb-17
US20170042898	METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS	HEMAQUEST PHARMACEUTICALS, INC.	11-Mar-10	27-Oct-16	16-Feb-17
US20170039316	Compositions, processes and algorithms for microbial detection	Not Available	12-Nov-03	25-Oct-04	9-Feb-17
US20170039314	BIOINFORMATIC PROCESSES FOR DETERMINATION OF PEPTIDE BINDING	IOGENETICS, LLC	23-Mar-10	13-Sep-12	9-Feb-17
US20170038085	AIR CURTAIN DEVICE	Not Available	7-Aug-15	19-Nov-15	9-Feb-17
US20170037457	NUCLEIC ACID DETECTION OR QUANTIFICATION METHOD USING MASK OLIGONUCLEOTIDE, AND DEVICE FOR SAME	Not Available	5-Feb-14	29-Jan-15	9-Feb-17
US20170037379	CHIMERIC VIRUSES PRESENTING NON-NATIVE SURFACE PROTEINS AND USES THEREOF	Icahn School of Medicine at Mount Sinai	2-Dec-05	3-Mar-16	9-Feb-17
US20170037376	METHOD FOR PREPARING INDUCED PLURIPOTENT STEM CELL, COMPOSITION USED IN METHOD, AND USES THEREOF	GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES	15-Nov-13	12-Nov-14	9-Feb-17
US20170037090	RECOMBINANT EXPRESSION OF MULTIPROTEIN COMPLEXES USING POLYGENES	Not Available	8-Nov-05	26-Oct-16	9-Feb-17
US20170037045	HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM	3M Innovative Properties Company	3-Jun-11	24-Oct-16	9-Feb-17
US20170035878	Multi-Functional Mucosal Vaccine Platform	Not Available	11-Feb-14	11-Feb-15	9-Feb-17
US20170035845	Compositions and Methods for Inhibiting Pro-Inflammatory Cytokine Gene Expression	Not Available	7-Aug-15	5-Aug-16	9-Feb-17
US20170029877	POLYTAG PROBES	Not Available	26-Feb-10	31-Mar-16	2-Feb-17
US20170029847	ARTIFICIAL NUCLEIC ACID MOLECULES	CureVac AG	30-Dec-13	28-Jun-16	2-Feb-17
US20170029489	HUMAN MONOCLONAL ANTIBODY WITH SPECIFICITY FOR DENGUE VIRUS SEROTYPE 1 E PROTEIN AND USES THEREOF	Not Available	14-Dec-10	1-Jun-16	2-Feb-17
US20170028082	ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR	Not Available	30-Sep-03	3-Aug-16	2-Feb-17
US20170028054	VACCINE COMPOSITION	NITTO DENKO CORPORATION	4-Apr-12	11-Oct-16	2-Feb-17
US20170027975	Methods of Treating Coronavirus Infection	United States Government as represented by the Secretary, Department of Health and Human Services	7-Apr-14	7-Apr-15	2-Feb-17

CC-BY-NC-SA Dr. David E. Martin

US20170027944	METHODS FOR TREATING VIRAL DISORDERS	Not Available	24-Sep-09	18-Feb-15	2-Feb-17
US20170022577	METHODS OF TESTING FOR INTRACELLULAR PATHOGENS	Novartis AG	8-Mar-10	23-Sep-16	26-Jan-17
US20170022242	NOVEL ANTIVIRAL AND ANTITUMORAL COMPOUNDS	KATHOLIEKE UNIVERSITEIT LEUVEN, KU LEUVEN R&D	17-Apr-14	17-Apr-15	26-Jan-17
US20170021013	D-AMINO ACID DERIVATIVE-MODIFIED PEPTIDOGLYCAN AND METHODS OF USE THEREOF	Not Available	30-Nov-12	31-Mar-16	26-Jan-17
US20170020926	METHODS AND COMPOSITIONS FOR IMMUNOMODULATION	Not Available	1-Apr-14	13-Mar-15	26-Jan-17
US20170016048	COMPOSITIONS AND METHODS FOR ENRICHING POPULATIONS OF NUCLEIC ACIDS	Not Available	18-May-15	17-May-16	19-Jan-17
US20170015716	STABILIZED ANTI-MICROBIAL PEPTIDES	Not Available	2-Jul-15	1-Jul-16	19-Jan-17
US20170014496	COMBINATION OF VACCINATION AND OX40 AGONISTS	Not Available	12-Mar-14	12-Mar-14	19-Jan-17
US20170014423	Benzazepine Dicarboxamide Compounds	Hoffmann-La Roche Inc.	6-Mar-15	28-Sep-16	19-Jan-17
US20170011131	SYSTEM AND METHOD FOR DETECTING, COLLECTING, ANALYZING, AND COMMUNICATING EVENT RELATED INFORMATION	Georgetown University	25-Feb-08	23-Sep-16	12-Jan-17
US20170010264	EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES	Not Available	6-Oct-08	20-Sep-16	12-Jan-17
US20170009237	Short Interfering RNA (siRNA) Analogues	Not Available	21-Mar-03	28-Mar-16	12-Jan-17
US20170007577	METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF BRAIN INFLAMMATION AND SEPSIS	Not Available	29-Nov-02	19-Sep-16	12-Jan-17
US20170002042	PEPTIDOMIMETIC MACROCYCLES	Not Available	1-Jul-15	1-Jul-16	5-Jan-17
US20170000878	CONSTRAINED IMMUNOGENIC COMPOSITIONS AND USES THEREFOR	Not Available	23-Jun-10	9-Aug-16	5-Jan-17
US20170000873	Dimethyl Fumarate and Vaccination Regimens	Not Available	14-Mar-14	13-Mar-15	5-Jan-17
US20160376596	COMPOSITIONS AND METHODS FOR INDUCING AN ENHANCED IMMUNE RESPONSE USING POXVIRUS VECTORS	Bavarian Nordic A/S	28-Nov-13	25-Nov-14	29-Dec-16
US20160376321	A NOVEL SARS IMMUNOGENIC COMPOSITION	BAYLOR COLLEGE OF MEDICINE	26-Nov-13	21-Nov-14	29-Dec-16
US20160375137	TARGETING LIPIDS	Tekmira Pharmaceuticals Corporation	4-Dec-07	22-Oct-13	29-Dec-16
US20160375132	HOMOGENOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF	Not Available	15-Dec-09	5-Jul-16	29-Dec-16
US20160369268	TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) LIBRARIES AND METHODS OF SYNTHESIS AND USE	The Board of Regents of the University of Texas System	1-Jul-13	25-Jun-14	22-Dec-16
US20160368956	METHOD OF PREVENTIVELY TREATING A SUBJECT AT THE RISK OF DEVELOPING INFECTIONS OF A RESPIRATORY VIRUS	Not Available	9-May-13	23-Aug-16	22-Dec-16
US20160368904	SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF	Not Available	3-Jul-13	3-Jul-14	22-Dec-16
US20160367587	Systemic In Vivo Delivery of Oligonucleotides	OncoImmunin, Inc.	12-Jun-13	12-Jun-14	22-Dec-16
US20160367188	ORAL SENSOR ALERTING AND COMMUNICATION SYSTEM AND DEVELOPERS' TOOL KIT	Not Available	17-Jun-15	10-Sep-15	22-Dec-16
US20160363557	AMPEROMETRIC GAS SENSOR	Not Available	25-Jun-12	25-Aug-16	15-Dec-16
US20160362730	PHOTO-SELECTIVE METHOD FOR BIOLOGICAL SAMPLE ANALYSIS	Not Available	26-Feb-14	26-Aug-16	15-Dec-16
US20160362454	Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses	Not Available	7-Oct-11	10-Jun-16	15-Dec-16
US20160361382	MICROBICIDAL COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS	Not Available	11-Jun-15	13-Jun-16	15-Dec-16

CC-BY-NC-SA Dr. David E. Martin

US20160361259	Methods for the Preparation of Liposomes	Not Available	23-Sep-09	2-Aug-16	15-Dec-16
US20160354451	METHOD OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN AMYLOIDOSES AND PROTEIN AGGREGATION DISORDERS	Not Available	31-Aug-07	9-Jun-16	8-Dec-16
US20160354428	METHODS AND COMPOSITIONS RELATED TO INHIBITION OF VIRAL ENTRY	Not Available	8-Feb-07	2-Jun-16	8-Dec-16
US20160354347	Nuclear Transport Modulators and Uses Thereof	Not Available	9-May-12	6-Jan-16	8-Dec-16
US20160348153	EXTRACTION AND PRESERVATION OF NUCLEIC ACID MOLECULES FROM PATHOGENS	THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Serv	29-May-15	31-May-16	1-Dec-16
US20160348132	TC-83-DERIVED ALPHAVIRUS VECTORS, PARTICLES AND METHODS	Not Available	18-May-04	11-Aug-16	1-Dec-16
US20160348115	CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity	Not Available	27-Sep-06	26-May-16	1-Dec-16
US20160348110	NUCLEIC ACID CHEMICAL MODIFICATIONS	Not Available	2-Mar-09	11-Aug-16	1-Dec-16
US20160347816	POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR TREATMENT OF IMMUNE RELATED DISORDERS AND CANCER	Not Available	15-Apr-11	29-Feb-16	1-Dec-16
US20160347814	VSTM5 POLYPEPTIDES AND USES THEREOF AS A DRUG FOR TREATMENT OF CANCER, INFECTIOUS DISEASES AND IMMUNE RELATED DISEASES	Not Available	11-Sep-13	10-Mar-16	1-Dec-16
US20160347784	NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOF	Not Available	6-Jul-09	27-May-16	1-Dec-16
US20160346309	TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS	Not Available	1-Jun-07	21-Dec-15	1-Dec-16
US20160340713	STABILIZING COMPOSITIONS AND METHODS FOR EXTRACTION OF RIBONUCLEIC ACID	Not Available	6-Oct-06	20-May-16	24-Nov-16
US20160340319	SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY	Not Available	6-Feb-13	5-Aug-16	24-Nov-16
US20160339097	CORONAVIRUS PROTEINS AND ANTIGENS	MJ Biologics, Inc.	7-Feb-14	4-Aug-16	24-Nov-16
US20160338998	HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF	3-V Biosciences, Inc.	20-Dec-13	19-Dec-14	24-Nov-16
US20160333356	OLIGONUCLEOTIDE MODULATORS OF THE TOLL-LIKE RECEPTOR PATHWAY	Not Available	3-Mar-11	28-Jul-16	17-Nov-16
US20160333089	Antigenic GM-CSF Peptides and Antibodies to GM-CSF	Not Available	8-Feb-06	18-Jul-16	17-Nov-16
US20160333076	NEUTRALIZING GP41 ANTIBODIES AND THEIR USE	The United States of America, as represented by the Secretary, Department of Health and Human Serv	7-Nov-11	2-Aug-16	17-Nov-16
US20160331828	NUCLEIC ACID VACCINES	Moderna Therapeutics, Inc.	23-Apr-14	5-Apr-16	17-Nov-16
US20160331816	ORAL DELIVERY OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) OR ANGIOTENSIN-(1-7) BIOENCAPSULATED IN PLANT CELLS ATTENUATES PULMONARY HYPERTENSION, CARDIAC DYSFUNCTION AND DEVELOPMENT OF AUTOIMMUNE AND EXPERIMENTALLY INDUCED OCULAR DISORDERS	Not Available	18-Oct-13	18-Apr-16	17-Nov-16
US20160331758	TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE	Not Available	1-Aug-08	21-Dec-15	17-Nov-16
US20160327506	CAPACITIVE LIQUID CRYSTAL BIOSENSORS	Not Available	6-May-15	5-May-16	10-Nov-16
US20160327484	A METHOD OF PREDICTING A PERFORMANCE CHARACTERISTIC OF A PLANT OR YEAST HYDROLYSATE AND ITS USE	Not Available	30-Dec-13	18-Dec-14	10-Nov-16
US20160326598	METHODS AND COMPOSITIONS FOR PROSTATE CANCER METASTASIS	Not Available	25-Mar-11	27-May-16	10-Nov-16
US20160326325	POWDERED POUCH AND METHOD OF MAKING SAME	Not Available	16-Apr-12	19-Jul-16	10-Nov-16

CC-BY-NC-SA Dr. David E. Martin

US20160326233	NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES AGAINST HEPATITIS B VIRUS SURFACE ANTIGEN	Not Available	16-Jan-14	15-Jan-15	10-Nov-16
US20160326141	HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS FOR USE AGAINST CANCER AND VIRAL INFECTIONS	Not Available	7-Jan-14	7-Jan-15	10-Nov-16
US20160325283	BIOAGENT DETECTION SYSTEMS, DEVICES, AND METHODS	Not Available	30-Mar-09	18-Jul-16	10-Nov-16
US20160324834	Use of mTOR Inhibitors to Enhance T Cell Immune Responses	Not Available	5-Aug-08	16-May-16	10-Nov-16
US20160320390	COMPOSITIONS AND METHODS FOR CAPTURING EXOSOMES	Not Available	1-May-15	1-May-15	3-Nov-16
US20160318985	Chimeric Virus-Like Particles Incorporating Fusion GPI Anchored GM-CSF and IL-4 Conjugates	Not Available	29-Apr-15	29-Apr-16	3-Nov-16
US20160318861	NOVEL PRODRUGS OF DITHIOL MUCOLYTIC AGENTS	PARION SCIENCES, INC.	30-Apr-15	2-May-16	3-Nov-16
US20160317647	NUCLEIC ACID VACCINES	Moderna Therapeutics, Inc.	23-Apr-14	1-Apr-16	3-Nov-16
US20160317637	IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOF	Not Available	7-Jan-14	7-Jan-15	3-Nov-16
US20160317496	METHODS OF TREATING CANCER AND OTHER DISORDERS	Not Available	12-Nov-10	27-Jun-16	3-Nov-16
US20160317458	Lipids and Lipid Compositions for the Delivery of Active Agents	Not Available	19-Dec-13	17-Dec-14	3-Nov-16
US20160312276	METHODS AND COMPOSITIONS FOR WHOLE TRANSCRIPTOME AMPLIFICATION	Not Available	23-Apr-15	21-Apr-16	27-Oct-16
US20160311886	Constructs Binding to Phosphatidylserine and Their Use in Disease Treatment and Imaging	Not Available	24-Jan-05	12-Jul-16	27-Oct-16
US20160311835	NOVEL ANTIBIOTICS	Not Available	26-May-11	30-Nov-15	27-Oct-16
US20160311816	COMPOSITIONS AND METHODS FOR INHIBITING KINASES	Not Available	23-Apr-15	22-Apr-16	27-Oct-16
US20160311759	Lipids and Lipid Compositions for the Delivery of Active Agents	Not Available	19-Dec-13	17-Dec-14	27-Oct-16
US20160310511	Myxovirus Therapeutics, Compounds, and Uses Related Thereto	Not Available	24-Oct-11	7-Jul-16	27-Oct-16
US20160305936	DIRECT CLONE ANALYSIS AND SELECTION TECHNOLOGY	Not Available	13-Jul-10	18-Feb-16	20-Oct-16
US20160304954	COMPOSITIONS AND METHODS FOR DETECTING RARE SEQUENCE VARIANTS	Not Available	11-Dec-13	11-Dec-14	20-Oct-16
US20160304942	Enhanced Methods of Ribonucleic Acid Hybridization	Not Available	6-Dec-13	5-Dec-14	20-Oct-16
US20160304904	Directed Evolution and In Vivo Panning of Virus Vectors	Not Available	30-Apr-08	28-Jun-16	20-Oct-16
US20160304883	ARTIFICIAL NUCLEIC ACID MOLECULES	CureVac AG	30-Dec-13	28-Jun-16	20-Oct-16
US20160304882	METHOD FOR PROPAGATING ADENOVIRAL VECTORS ENCODING INHIBITORY GENE PRODUCTS	GenVec, Inc.	10-Nov-05	27-Jun-16	20-Oct-16
US20160304586	PROCESS FOR PREPARING INFLUENZA VACCINES	Crucell Holland B.V.	5-Dec-13	4-Dec-14	20-Oct-16
US20160304579	POLYPEPTIDES AND USES THEREOF FOR TREATMENT OF AUTOIMMUNE DISORDERS AND INFECTION	Not Available	30-Jun-11	29-Feb-16	20-Oct-16
US20160304472	Hydrazide Containing Nuclear Transport Modulators and Uses Thereof	Not Available	29-Jul-11	13-Nov-15	20-Oct-16
US20160303194	Compositions And Method For Treatment Of Inflammatory Bowel Disease	Not Available	2-Jun-11	21-Apr-16	20-Oct-16
US20160303052	MODULAR PARTICLES FOR IMMUNOTHERAPY	Not Available	1-Nov-13	31-Oct-14	20-Oct-16
US20160299141	NAD ANALOGS AND METHODS OF USING SAID NAD ANALOGS IN DETERMINING RIBOSYLATION OF PROTEINS WITH PARP MUTANTS	Biolog Life Science Institute Forschungslabor und Biochemica-Vertrieb GmbH	8-Apr-15	1-Apr-16	13-Oct-16
US20160298179	LUMINOPHORE-LABELED MOLECULES COUPLED WITH PARTICLES FOR MICROARRAY-BASED ASSAYS	CapitalBio Corporation	5-Dec-13	2-Dec-14	13-Oct-16

US20160296617	Immunogenic Composition for MERS Coronavirus Infection	Not Available	1-Mar-13	28-Feb-14	13-Oct-16
US20160296616	IMMUNOGENIC COMPOSITIONS AND USES THEREOF	Not Available	25-Mar-15	25-Mar-16	13-Oct-16
US20160295844	GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS OF USE THEREOF	Not Available	13-Apr-15	12-Apr-16	13-Oct-16
US20160292393	SYSTEMS AND METHODS FOR ORDERING LABORATORY TESTS AND PROVIDING RESULTS THEREOF	Not Available	24-Oct-13	13-Apr-16	6-Oct-16
US20160289740	METHODS AND COMPOSITIONS FOR COMBINATORIAL BARCODING	Not Available	30-Mar-15	29-Mar-16	6-Oct-16
US20160289191	ORGANIC COMPOUNDS	NOVARTIS AG	27-Jun-08	9-Oct-15	6-Oct-16
US20160288121	Slip Chip Device and Methods	Not Available	24-Mar-09	25-May-16	6-Oct-16
US20160287697	INJECTABLE VACCINE COMPOSITION	NITTO DENKO CORPORATION	3-Oct-13	2-Oct-14	6-Oct-16
US20160287622	COMPOSITIONS AND METHODS FOR TREATING IMMUNE AND VIRAL DISORDERS AND MODULATING PROTEIN-RNA INTERACTION	Massachusetts Institute of Technology	18-Nov-13	7-Nov-14	6-Oct-16
US20160281109	GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA VIRUS SPIKE PROTEIN	Not Available	28-Oct-05	10-Jun-16	29-Sep-16
US20160280707	ALKOXY SUBSTITUTED IMIDAZOQUINOLINES	Not Available	3-Oct-03	13-Jun-16	29-Sep-16
US20160279237	ADJUVANT COMPOSITIONS AND RELATED METHODS	Not Available	24-Mar-15	24-Mar-16	29-Sep-16
US20160279193	IMMUNOSUPPRESSIVE AGENTS AND THEIR USE IN THERAPY	Not Available	6-Nov-13	6-Nov-14	29-Sep-16
US20160279165	PULSE INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES	Not Available	24-Mar-15	24-Mar-16	29-Sep-16
US20160279163	Method of Treating Inflammation	Not Available	1-Apr-10	3-Jun-16	29-Sep-16
US20160278349	Immunocompromised Ungulates	Not Available	27-Oct-08	23-Mar-15	29-Sep-16
US20160272707	VSTM5 ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER, INFECTIOUS DISEASES AND IMMUNE RELATED DISEASES	Not Available	11-Sep-13	11-Sep-14	22-Sep-16
US20160271241	BUNYAVIRUSES WITH SEGMENTED GLYCOPROTEIN PRECURSOR GENES AND METHODS FOR GENERATING THESE VIRUSES	Stichting Dienst Landbouwkundig Onderzoek	21-May-13	21-May-14	22-Sep-16
US20160271240	Tetanus Toxoid and CCL3 Improve DC Vaccines	Duke University	14-Nov-13	14-Nov-15	22-Sep-16
US20160271137	INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID METABOLISM AS BROAD SPECTRUM ANTI-VIRALS	Not Available	18-Feb-10	27-Oct-15	22-Sep-16
US20160267244	METHODS OF PREDICTING CANCER LETHALITY USING REPLIKIN COUNTS	Not Available	8-Aug-08	19-May-16	15-Sep-16
US20160265025	NANOREPORTERS AND METHODS OF MANUFACTURING AND USE THEREOF	Not Available	23-Dec-05	20-May-16	15-Sep-16
US20160264971	COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS GENE EXPRESSION	Not Available	20-Jul-09	9-Oct-15	15-Sep-16
US20160264962	TAL-EFFECTOR ASSEMBLY PLATFORM, CUSTOMIZED SERVICES, KITS AND ASSAYS	Not Available	4-Apr-12	28-Jul-15	15-Sep-16
US20160263156	RED BLOOD CELL MEMBRANE-DERIVED MICROPARTICLES AND THEIR USE FOR THE TREATMENT OF LUNG DISEASE	University of Pittsburgh - Of the Commonwealth System of Higher Education	7-Nov-13	6-Nov-14	15-Sep-16
US20160258949	CHIPS, DETECTION SYSTEMS, AND METHODS FOR MULTIPLEX PNEUMOCOCCUS SEROLOGY	Not Available	9-Oct-13	9-Oct-14	8-Sep-16
US20160257932	GENETICALLY ENGINEERED ENUCLEATED ERYTHROID CELLS COMPRISING A PHENYLALANINE AMMONIA LYASE RECEIVER POLYPEPTIDE	Not Available	18-Nov-13	17-May-16	8-Sep-16
US20160257653	Benzazepine Dicarboxamide Compounds	Hoffmann-La Roche Inc.	6-Mar-15	4-Mar-16	8-Sep-16

CC-BY-NC-SA Dr. David E. Martin

US20160256870	Slip Chip Device and Methods	Not Available	24-Mar-09	25-May-16	8-Sep-16
US20160256541	Cationic Oil-In-Water Emulsions	Not Available	6-Jul-10	11-Mar-16	8-Sep-16
US20160253584	SPATIALLY ADDRESSABLE MOLECULAR BARCODING	Not Available	27-Feb-15	26-Feb-16	1-Sep-16
US20160251637	COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND ACTIVITY, AND RELATED METHODS	Not Available	19-Nov-09	11-Mar-16	1-Sep-16
US20160251631	DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES	Novartis AG	9-Sep-04	9-May-16	1-Sep-16
US20160251399	PEPTIDOMIMETIC MACROCYCLES	Not Available	14-Jan-09	7-Apr-16	1-Sep-16
US20160251362	NOVEL COMPOUNDS	CHIESI FARMACEUTICI S.P.A.	18-Dec-12	10-May-16	1-Sep-16
US20160251319	CARBOXYLIC ACID COMPOUNDS	Astrazeneca Aktiebolag	18-May-12	11-May-16	1-Sep-16
US20160250326	Conjugates of GM-CSF and IL-7, and Compositions Thereof	Not Available	14-Nov-11	18-May-16	1-Sep-16
US20160250278	PEPTIDOMIMETIC MACROCYCLES	Not Available	14-Jan-09	7-Apr-16	1-Sep-16
US20160250168	ESTERS OF SHORT CHAINS FATTY ACIDS FOR USE IN THE TREATMENT OF IMMUNOGENIC DISORDERS	Not Available	3-Oct-12	3-Mar-16	1-Sep-16
US20160238601	METHODS AND COMPOSITIONS FOR CORONAVIRUS DIAGNOSTICS AND THERAPEUTICS	Not Available	14-Oct-13	14-Oct-14	18-Aug-16
US20160238600	METHOD FOR SELECTING A SINGLE CELL EXPRESSING A HETEROGENEOUS COMBINATION OF ANTIBODIES	Merus B.V.	30-May-03	27-Apr-16	18-Aug-16
US20160237455	CRISPR-RELATED METHODS AND COMPOSITIONS	Editas Medicine, Inc.	27-Sep-13	26-Sep-14	18-Aug-16
US20160237123	COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS	Not Available	23-Jan-08	4-May-16	18-Aug-16
US20160237082	DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAME	Not Available	10-Oct-13	10-Oct-14	18-Aug-16
US20160235840	Compositions, Comprising Improved Il-12 Genetic Constructs And Vaccines, Immunotherapeutics And Methods Of Using The Same	Not Available	12-Dec-11	26-Feb-16	18-Aug-16
US20160235837	THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR MIDDLE EAST RESPIRATORY SYNDROME VIRUS (MERS CoV)	Not Available	16-Oct-13	16-Oct-14	18-Aug-16
US20160235835	INFLUENZA VACCINES WITH REDUCED AMOUNTS OF SQUALENE	Seqirus UK Limited	10-Feb-09	27-Jan-16	18-Aug-16
US20160235675	Technology for the Preparation of Microparticles	Not Available	24-Jul-07	24-Mar-16	18-Aug-16
US20160230190	Lentiviral Vectors Having a Mutated Integrase Protein and uses Thereof	Not Available	17-Sep-13	17-Sep-14	11-Aug-16
US20160229904	Optimized Human Clotting Factor VIII Gene Expression Cassettes and Their Use	Not Available	6-Feb-15	5-Feb-16	11-Aug-16
US20160229872	ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5-Feb-15	4-Feb-16	11-Aug-16
US20160229864	THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5-Feb-15	4-Feb-16	11-Aug-16
US20160229833	QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	5-Feb-15	4-Feb-16	11-Aug-16
US20160228540	NASAL MUCOSAL VACCINE COMPOSITION	NITTO DENKO CORPORATION	3-Oct-13	2-Oct-14	11-Aug-16
US20160228533	Use of EGFR Pathway Inhibitors to Increase Immune Responses to Antigens	Emory University	23-Sep-13	23-Sep-14	11-Aug-16
US20160228532	METHOD OF OBTAINING THERMOSTABLE DRIED VACCINE FORMULATIONS	Merck Sharp & Dohme Corp.	16-Oct-13	13-Oct-14	11-Aug-16
US20160228463	BORON-CONTAINING SMALL MOLECULES	Not Available	16-Feb-05	20-Apr-16	11-Aug-16

CC-BY-NC-SA Dr. David E. Martin

US20160222414	CONSTRUCTS AND METHODS FOR DELIVERING MOLECULES VIA VIRAL VECTORS WITH BLUNTED INNATE IMMUNE RESPONSES	Not Available	14-Mar-13	15-Apr-16	4-Aug-16
US20160222072	Universal Protein Tag for Double Stranded Nucleic Acid Delivery	Not Available	23-Oct-13	22-Oct-14	4-Aug-16
US20160222023	NOVEL MONOTHIOL MUCOLYTIC AGENTS	PARION SCIENCES, INC.	30-Jan-15	29-Jan-16	4-Aug-16
US20160222010	4-AMINO-IMIDAZOQUINOLINE COMPOUNDS	Hoffmann-La Roche Inc.	22-Apr-14	7-Apr-16	4-Aug-16
US20160221994	Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof	Not Available	29-Nov-12	27-Nov-13	4-Aug-16
US20160220664	ANTIGEN AND METHOD FOR PRODUCTION THEREOF	Not Available	13-Sep-13	12-Sep-14	4-Aug-16
US20160220595	NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO	Not Available	11-Sep-13	10-Sep-14	4-Aug-16
US20160220536	USE OF PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND TAUTOMERIC CYCLIC THIONES FOR THE TREATMENT OF AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLL-LIKE RECEPTOR OVEREXPRESSION	Not Available	16-Mar-04	19-Feb-16	4-Aug-16
US20160215282	SYNTHETIC ANTISERUM FOR RAPID-TURNAROUND THERAPIES	Not Available	28-Jan-15	20-Jan-16	28-Jul-16
US20160215262	CD137 ENRICHMENT FOR EFFICIENT TUMOR INFILTRATING LYMPHOCYTE SELECTION	Not Available	16-Sep-13	16-Sep-14	28-Jul-16
US20160213776	ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS	GlaxoSmithKline Biologicals SA	1-Sep-10	7-Apr-16	28-Jul-16
US20160213773	MUCOSAL VACCINE COMPOSITION	NITTO DENKO CORPORATION	3-Oct-13	2-Oct-14	28-Jul-16
US20160213761	CARBON NANOTUBE COMPOSITIONS AND METHODS OF USE THEREOF	Not Available	19-Mar-08	5-Apr-16	28-Jul-16
US20160213647	COMPOSITIONS AND METHODS FOR INHIBITING VIRAL INFECTION	Not Available	28-Jan-15	27-Jan-16	28-Jul-16
US20160213610	MODIFIED RELEASE FORMULATIONS FOR OPROZOMIB	Not Available	24-Oct-12	28-Jan-16	28-Jul-16
US20160207980	FC-CONTAINING MOLECULES EXHIBITING PREDICTABLE, CONSISTENT, AND REPRODUCIBLE GLYCOFORM PROFILES	AMGEN INC.	5-Sep-13	5-Sep-14	21-Jul-16
US20160207949	NOVEL CYTOTOXIC AGENTS FOR CONJUGATION TO A CELL BINDING MOLECULE	Hangzhou DAC Biotech Co., Ltd	2-Sep-13	2-Sep-13	21-Jul-16
US20160207900	PEPTIDYL NITRIL COMPOUNDS AS DIPEPTIDYL PEPTIDASE I INHIBITORS	PROZYMEX A/S	9-Sep-13	8-Sep-14	21-Jul-16
US20160206729	IMMUNOGENIC MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS (MERS-CoV) COMPOSITIONS AND METHODS	Not Available	19-Sep-13	19-Sep-14	21-Jul-16
US20160206719	COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY	CureVac AG	22-Feb-13	5-Apr-16	21-Jul-16
US20160206638	BORON-CONTAINING SMALL MOLECULES	Not Available	16-Feb-05	5-Apr-16	21-Jul-16
US20160206575	Inhibition of Biofilm Organisms	NOVABIOTICS LIMITED	31-Mar-09	28-Mar-16	21-Jul-16
US20160202258	B-CELL ANTIGEN PRESENTING CELL ASSAY	University of Pittsburgh - Of the Commonwealth System of Higher Education	8-Apr-10	21-Mar-16	14-Jul-16
US20160201110	DIAGNOSIS AND TREATMENT OF INCIPIENT DIABETES	Not Available	9-Jan-15	17-Nov-15	14-Jul-16
US20160201088	ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR	Not Available	17-Dec-01	30-Mar-16	14-Jul-16
US20160199486	ARRANGING INTERACTION AND BACK PRESSURE CHAMBERS FOR MICROFLUIDIZATION	Not Available	3-Dec-09	22-Mar-16	14-Jul-16
US20160199449	METHOD OF REDUCING ANTIGENIC DRIFT OR REASSORTMENT OF VIRUSES IN A HOST ANIMAL USING ALPHA INTERFERON	Hemispherx Biopharma, Inc.	21-Aug-13	21-Aug-14	14-Jul-16

CC-BY-NC-SA Dr. David E. Martin

US20160199416	Induced Hepatocytes and Uses Thereof	Not Available	26-Nov-14	25-Nov-15	14-Jul-16
US20160199407	HALIDES IN THE TREATMENT OF PATHOGENIC INFECTION	THE UNIVERSITY OF IOWA RESEARCH FOUNDATION	25-Jan-08	17-Dec-15	14-Jul-16
US20160194387	Methods Of Treating Inflammation Associated Airway Diseases And Viral Infections	Not Available	2-Jan-15	31-Dec-15	7-Jul-16
US20160194322	SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS	Not Available	25-Nov-03	14-Mar-16	7-Jul-16
US20160194278	DITHIOL MUCOLYTIC AGENTS	PARION SCIENCES, INC.	23-Aug-13	11-Mar-16	7-Jul-16
US20160193603	SAMPLE-TO-ANSWER MICROFLUIDIC CARTRIDGE	Not Available	29-Jan-10	5-Aug-15	7-Jul-16
US20160193327	MUCOSAL VACCINE COMPOSITION	NITTO DENKO CORPORATION	3-Oct-13	2-Oct-14	7-Jul-16
US20160193321	MAKING INFLUENZA VIRUS VACCINES WITHOUT USING EGGS	Novartis AG	11-Sep-06	5-Nov-15	7-Jul-16
US20160193315	PEPTIDES SHARED AMONG LETHAL CANCERS AND THERAPEUTIC COMPOSITIONS COMPRISING SAID PEPTIDES	Not Available	7-Aug-09	17-Mar-16	7-Jul-16
US20160192658	HYDROGEN-CONTAINING ANTIMICROBIAL AGENT	Not Available	13-Aug-13	5-Aug-14	7-Jul-16
US20160185786	PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	30-Dec-14	29-Dec-15	30-Jun-16
US20160185785	PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS	Not Available	30-Dec-14	29-Dec-15	30-Jun-16
US20160184424	INTRANASAL VACCINATION DOSAGE REGIMEN	Not Available	17-Dec-12	17-Dec-13	30-Jun-16
US20160184334	BORON-CONTAINING SMALL MOLECULES	Not Available	16-Feb-05	11-Mar-16	30-Jun-16
US20160177337	METHOD FOR PRODUCTION OF REPROGRAMMED CELL USING CHROMOSOMALLY UNINTEGRATED VIRUS VECTOR	Not Available	16-Jul-08	8-Mar-16	23-Jun-16
US20160177336	Expression Tools for Multiprotein Applications	Not Available	9-Mar-04	11-Dec-15	23-Jun-16
US20160175433	LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS	Not Available	17-Aug-10	15-Dec-15	23-Jun-16
US20160175394	Compositions and Uses of Lectins	Emory University	12-Feb-10	11-Dec-15	23-Jun-16
US20160175387	Use of Immune Suppressive Domains as Medicaments	Not Available	10-Apr-13	10-Apr-14	23-Jun-16
US20160174631	PROTECTIVE MASKS WITH COATING COMPRISING DIFFERENT ELECTROSPUN FIBERS INTERWEAVED WITH EACH OTHER, FORMULATIONS FORMING THE SAME, AND METHOD OF PRODUCING THEREOF	Not Available	23-Dec-14	10-Dec-15	23-Jun-16
US20160168203	Cyclic Antimicrobial Peptides	NOVABIOTICS LIMITED	24-Feb-06	9-Nov-15	16-Jun-16
US20160168101	NOVEL COMPOUNDS	CHIESI FARMACEUTICI S.p.A.	15-Dec-14	27-Nov-15	16-Jun-16
US20160166710	METHOD FOR INCREASING EXPRESSION OF RNA-ENCODED PROTEINS	CureVac AG	21-Aug-13	19-Feb-16	16-Jun-16
US20160166676	Use of Immune Suppressive Peptides as Adjuvants	Not Available	10-Apr-13	10-Apr-14	16-Jun-16
US20160160258	MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION OF B CELLS	Not Available	26-Feb-03	8-Feb-16	9-Jun-16
US20160160178	IMMUNOTHERAPY USING STEM CELLS	Not Available	9-Dec-14	2-Dec-15	9-Jun-16
US20160159927	IDENTIFICATION OF VSIG8 AS THE PUTATIVE VISTA RECEPTOR (V-R) AND USE THEREOF TO PRODUCE VISTA/VSIG8 AGONISTS AND ANTAGONISTS	Not Available	5-Dec-14	7-Dec-15	9-Jun-16
US20160158341	PREPARATION OF INFLUENZA VIRUS VACCINE ANTIGENS	Novartis AG	18-Mar-08	7-Dec-15	9-Jun-16

US20160158340	INFLUENZA VACCINES CONTAINING HEMAGGLUTININ AND MATRIX PROTEINS	Not Available	27-Jan-06	4-Dec-15	9-Jun-16
US20160158339	METHOD FOR INACTIVATING VIRUSES USING ELECTRON BEAMS	Not Available	26-Jul-13	24-Jul-14	9-Jun-16
US20160158308	TREATMENT OF MULTIPLE EVOLVING BACTERIAL RESISTANCE DISEASES WITH LIPOSOMALLY FORMULATED GLUTATHIONE	CHILDREN'S HEALTHCARE OF ATLANTA, INC.	12-Nov-13	14-Aug-14	9-Jun-16
US20160158294	Methods of Populating a Gastrointestinal Tract	Not Available	4-Feb-13	4-Feb-14	9-Jun-16
US20160158154	PROTEIN VESICLES AND METHODS OF MAKING AND USING THEREOF	Not Available	5-Dec-14	7-Dec-15	9-Jun-16
US20160153034	Rapid Epidemiologic Typing of Bacteria	Not Available	19-May-08	11-Nov-15	2-Jun-16
US20160152693	AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF VIRAL DISEASES	Ablynx N.V.	5-Jun-08	29-Oct-15	2-Jun-16
US20160152676	HELIX-GRAFTED PROTEINS AS INHIBITORS OF DISEASE-RELEVANT PROTEIN-PROTEIN INTERACTIONS	COLORADO STATE UNIVERSITY RESEARCH FOUNDATION	7-Nov-14	9-Nov-15	2-Jun-16
US20160152667	COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS	Not Available	23-Jan-08	9-Feb-16	2-Jun-16
US20160152596	Nuclear Transport Modulators and Uses Thereof	Karyopharm Therapeutics Inc.	21-Jun-13	20-Jun-14	2-Jun-16
US20160151399	BORON-CONTAINING SMALL MOLECULES	Not Available	16-Feb-05	17-Feb-16	2-Jun-16
US20160146806	RECEPTORS FOR B7-H4	Not Available	17-May-13	19-May-14	26-May-16
US20160146786	Method of monitoring cellular trafficking of peptides	Not Available	26-Jun-13	26-Jun-14	26-May-16
US20160145246	NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	9-May-12	23-Jun-15	26-May-16
US20160144061	Compositions and Imaging Methods Comprising Detectably Labeled Phosphatidylethanolamine-Binding Peptides	Not Available	15-Jul-02	4-Feb-16	26-May-16
US20160139143	DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY	Not Available	2-Jul-10	28-Dec-15	19-May-16
US20160137702	GAS57 MUTANT ANTIGENS AND GAS57 ANTIBODIES	Not Available	12-Sep-07	7-Aug-15	19-May-16
US20160137649	PYRROLO-PYRROLE CARBAMATE AND RELATED ORGANIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF	Not Available	3-Jul-13	1-Jul-14	19-May-16
US20160135453	SHELF STABLE, REDUCED CORROSION, READY TO USE PEROXYCARBOXYLIC ACID ANTIMICROBIAL COMPOSITIONS	Not Available	30-Aug-07	20-Jan-16	19-May-16
US20160130367	GENERATION OF BINDING MOLECULES	Merus B.V.	26-Sep-11	16-Sep-15	12-May-16
US20160130345	COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY	Not Available	22-Feb-13	21-Feb-14	12-May-16
US20160130265	SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY	Not Available	23-Aug-12	29-Dec-15	12-May-16
US20160129110	IMMUNOPROTECTIVE PRIMARY MESENCHYMAL STEM CELLS AND METHODS	AUTOIMMUNE TECHNOLOGIES, LLC	14-Mar-13	17-Jul-15	12-May-16
US20160129104	HAND, FOOT, AND MOUTH VACCINES AND METHODS OF MANUFACTURE AND USE THEREOF	Not Available	7-Nov-14	6-Nov-15	12-May-16
US20160129095	Immunostimulatory Combinations	Not Available	30-Dec-02	10-Sep-15	12-May-16
US20160128937	CIRCULATION OF COMPONENTS DURING MICROFLUIDIZATION AND/OR HOMOGENIZATION OF EMULSIONS	Novartis AG	3-Dec-09	5-Sep-14	12-May-16
US20160122412	COMPOSITION COMPRISED OF ANTIGEN LINKED TO A TNF SUPERFAMILY LIGAND	Not Available	15-Mar-13	16-Mar-14	5-May-16

CC-BY-NC-SA Dr. David E. Martin

US20160122397	REPLIKIN-BASED COMPOUNDS FOR PREVENTION AND TREATMENT OF INFLUENZA AND METHODS OF DIFFERENTIATING INFECTIVITY AND LETHALITY IN INFLUENZA	Not Available	23-Apr-09	2-Dec-15	5-May-16
US20160122312	ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF	Not Available	16-Jul-13	16-Jul-14	5-May-16
US20160122306	DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES	PARION SCIENCES, INC.	29-May-12	5-Jan-16	5-May-16
US20160116462	ANTIBODY-NANOPARTICLE CONJUGATES AND METHODS FOR MAKING AND USING SUCH CONJUGATES	Not Available	27-Apr-10	21-Apr-15	28-Apr-16
US20160115522	MUTANT PROTEASE BIOSENSORS WITH ENHANCED DETECTION CHARACTERISTICS	Not Available	11-May-10	7-Jan-16	28-Apr-16
US20160115221	COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY	Not Available	28-Oct-14	2-Jul-15	28-Apr-16
US20160114322	PARALLELIZED SAMPLE HANDLING	Not Available	19-Apr-13	18-Apr-14	28-Apr-16
US20160114037	COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCY	Not Available	28-Oct-14	8-Jan-15	28-Apr-16
US20160114027	RECOMBINANT HCMV AND RHCMV VECTORS AND USES THEREOF	Not Available	14-May-10	1-Oct-15	28-Apr-16
US20160114022	THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR FILOVIRUSES INCLUDING EBOLAVIRUS AND MARBURG VIRUS	Not Available	11-Oct-14	10-Oct-15	28-Apr-16
US20160113929	METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS	Not Available	11-Mar-10	2-Jun-15	28-Apr-16
US20160113920	COMPOSITIONS AND METHODS FOR INHIBITING BACTERIAL AND VIRAL PATHOGENS	Not Available	24-Oct-14	23-Oct-15	28-Apr-16
US20160113881	NOVEL NANOPARTICLE COMPOSITIONS	Not Available	3-Apr-13	3-Apr-14	28-Apr-16
US20160113870	CIRCULATION OF COMPONENTS DURING MICROFLUIDIZATION AND/OR HOMOGENIZATION OF EMULSIONS	Novartis AG	3-Dec-09	5-Sep-14	28-Apr-16
US20160108463	Biological Specimen Collection and Transport System	Longhorn Vaccines and Diagnostics, LLC	1-Oct-07	15-Dec-15	21-Apr-16
US20160108461	TARGETED WHOLE GENOME AMPLIFICATION METHOD FOR IDENTIFICATION OF PATHOGENS	Not Available	14-Sep-06	5-Oct-15	21-Apr-16
US20160108359	AVIAN CELLS FOR IMPROVED VIRUS PRODUCTION	Not Available	5-Jun-13	3-Jun-14	21-Apr-16
US20160108097	MONOMERIC GRIFFITHSIN TANDEMERS	The United States of America, as represented by the Secretary, Department of Health and Human Serv	5-Jun-13	5-Jun-14	21-Apr-16
US20160108096	FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIA	Not Available	17-Sep-14	17-Sep-15	21-Apr-16
US20160108063	BORON-CONTAINING SMALL MOLECULES	Not Available	16-Feb-05	21-Dec-15	21-Apr-16
US20160106842	LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS	Not Available	8-Mar-13	6-Mar-14	21-Apr-16
US20160102295	MODIFIED ADENOVIRUS HEXON PROTEIN AND USES THEREOF	Not Available	28-Apr-06	22-May-15	14-Apr-16
US20160102091	HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS	3-V BIOSCIENCES, INC.	8-Mar-11	5-Oct-15	14-Apr-16
US20160101145	PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOF	Not Available	24-Sep-14	24-Sep-15	14-Apr-16
US20160096899	METHODS FOR TREATING JUVENILE ARTHRITIS WITH ANTI-BILE SALT-STIMULATED LIPASE (BSSL) ANTIBODIES	Not Available	8-Apr-09	28-Sep-15	7-Apr-16
US20160096895	BINDING MEMBERS-513	Not Available	7-Nov-08	23-Oct-15	7-Apr-16
US20160095936	IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF	Not Available	5-Apr-12	2-Jul-15	7-Apr-16
US20160090589	COMPOSITIONS FOR AND METHODS OF IDENTIFYING ANTIGENS	Not Available	21-Feb-06	6-May-15	31-Mar-16

CC-BY-NC-SA Dr. David E. Martin

US20160090389	Phosphoinositide 3-Kinase Inhibitors	Respivert Ltd.	15-Mar-13	4-Dec-15	31-Mar-16
US20160084835	METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING ADSORPTION MEDIA	EXTHERA MEDICAL CORPORATION	8-Nov-13	16-Oct-15	24-Mar-16
US20160083748	TISSUE PREFERENTIAL CODON MODIFIED EXPRESSION CASSETTES, VECTORS CONTAINING SAME, AND USES THEREOF	Not Available	29-Apr-13	29-Apr-14	24-Mar-16
US20160083689	ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS	Not Available	29-Oct-04	30-Nov-15	24-Mar-16
US20160082074	COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS INFECTION	LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN	11-Mar-14	8-May-15	24-Mar-16
US20160081982	METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C	Not Available	14-Mar-13	1-Dec-15	24-Mar-16
US20160081346	ANTIMICROBIAL COMPOSITIONS AND METHODS	Not Available	23-Sep-14	22-Sep-15	24-Mar-16
US20160077094	Media Elaborated with Newly Synthesized Antibodies (MENSA) and Uses Thereof	Not Available	5-May-14	5-May-15	17-Mar-16
US20160076094	Efficient Deep Sequencing and Rapid Genomic Speciation of RNA Viruses (vRNAseq)	Not Available	8-Sep-14	1-Sep-15	17-Mar-16
US20160076053	REPLICATION DEFECTIVE ADENOVIRUS VECTOR IN VACCINATION	Not Available	24-Aug-12	15-Mar-13	17-Mar-16
US20160075704	NOVEL SUBSTITUTED SPIROCYCLES	Not Available	12-Sep-14	10-Sep-15	17-Mar-16
US20160074507	METHOD FOR PREPARING VIRAL PARTICLES WITH CYCLIC DINUCLEOTIDE AND USE OF SAID PARTICLES FOR INDUCING IMMUNE RESPONSE	Not Available	16-Sep-14	16-Sep-15	17-Mar-16
US20160074506	DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE POLYMER PARTICLES	Not Available	6-Jul-10	23-Nov-15	17-Mar-16
US20160074481	Clottable Concentrate Of Platelet Growth Factors And Preparation Method Thereof	Zheng Yang Biomedical Technology Co., LTD.	7-Jan-08	30-Nov-15	17-Mar-16
US20160068843	Compositions and Methods for "Resistance-Proof" SiRNA Therapeutics for Influenza	Sirnaomics, Inc.	8-Jul-12	7-Jul-13	10-Mar-16
US20160068587	OLIGOPEPTIDE-FREE CELL CULTURE MEDIA	Not Available	3-Jan-07	16-Nov-15	10-Mar-16
US20160068573	PEPTIDOMIMETIC MACROCYCLES	Not Available	14-Jan-09	14-Sep-15	10-Mar-16
US20160067333	GENERATING PEPTOID VACCINES	The Board of Regents of the University of Texas System	3-May-13	2-May-14	10-Mar-16
US20160060598	MEANS AND METHODS FOR INFLUENCING THE STABILITY OF ANTIBODY PRODUCING CELLS	Not Available	9-Dec-05	26-Aug-15	3-Mar-16
US20160060231	SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY	Not Available	6-Feb-13	9-Nov-15	3-Mar-16
US20160060230	SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY	Not Available	6-Feb-13	9-Nov-15	3-Mar-16
US20160060224	N-MYRISTOYL TRANSFERASE INHIBITORS	UNIVERSITY OF DUNDEE	2-Sep-08	31-Aug-15	3-Mar-16
US20160058814	PLANT EXTRACTS AND RELATED COMPOSITIONS, METHODS AND SYSTEMS	Not Available	26-Aug-14	26-Aug-14	3-Mar-16
US20160058012	WEAR RESISTANT ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE	Not Available	14-Dec-10	24-Sep-15	3-Mar-16
US20160058008	ANTIMICROBIAL COMPOSITIONS AND METHODS WITH NOVEL POLYMERIC BINDING SYSTEM	Not Available	28-Aug-14	28-Aug-15	3-Mar-16
US20160054312	CHEMICALLY DIFFERENTIATED SENSOR ARRAY	Nanomedical Diagnostics, Inc.	28-Apr-14	15-Oct-15	25-Feb-16
US20160053308	PROBE KIT FOR DETECTING A SINGLE STRAND TARGET NUCLEOTIDE SEQUENCE	Fondzione Istituto Italiano Di Tecnolgia	27-Dec-12	27-Dec-13	25-Feb-16
US20160053222	BACILLUS BASED DELIVERY SYSTEM AND METHODS OF USE	Not Available	18-Apr-11	9-Sep-15	25-Feb-16

US20160052959	RADIOLABELED CATIONIC STEROID ANTIMICROBIALS AND DIAGNOSTIC METHODS	BRIGHAM YOUNG UNIVERSITY	22-Aug-14	19-Aug-15	25-Feb-16
US20160051691	CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES	Not Available	4-Dec-07	25-Aug-15	25-Feb-16
US20160051670	METHODS FOR PREPARING SQUALENE	Not Available	12-May-10	23-Oct-15	25-Feb-16
US20160051669	COMPOSITIONS AND METHODS FOR SELECTIVELY MODULATING TREGS	Not Available	21-Aug-14	21-Aug-15	25-Feb-16
US20160046705	HETERODIMERIC IMMUNOGLOBULINS	Not Available	21-Nov-12	21-Nov-13	18-Feb-16
US20160046687	GM-CSF AND IL-4 CONJUGATES, COMPOSITIONS, AND METHODS RELATED THERETO	Not Available	23-Oct-12	23-Oct-13	18-Feb-16
US20160045547	METHOD OF PREVENTING OR TREATING SINUSITIS WITH OXIDATIVE REDUCTIVE POTENTIAL WATER SOLUTION	OCULUS INNOVATIVE SCIENCES, INC.	30-Dec-03	27-Oct-15	18-Feb-16
US20160041168	ARRAYED DETECTOR SYSTEM FOR MEASUREMENT OF INFLUENZA IMMUNE RESPONSE	Not Available	2-May-08	23-Oct-15	11-Feb-16
US20160040161	In Vivo Delivery of Oligonucleotides	OncoImmunin Inc.	12-Dec-11	12-Dec-12	11-Feb-16
US20160039867	SINGLE-CHAIN ANTIPARALLEL COILED COIL PROTEINS	Complix NV	8-Dec-08	21-Aug-15	11-Feb-16
US20160039860	ENANTIOMERS OF THE 1',6'-ISOMER OF NEPLANOCIN A	Not Available	4-Aug-14	4-Aug-15	11-Feb-16
US20160039826	2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-1 -YL)METHYL)-3-(2-(TRIFLUOROMETHYL)BENZYL) QUINAZOLIN-4(3H)-ONE DERIVATIVES AND THEIR USE AS PHOSPHOINOSITIDE 3-KINASE INHIBITORS	Not Available	15-Mar-13	14-Mar-14	11-Feb-16
US20160039812	SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY	Not Available	31-Jul-14	27-Jul-15	11-Feb-16
US20160032319	VECTORS COMPRISING STUFFER/FILLER POLYNUCLEOTIDE SEQUENCES AND METHODS OF USE	THE CHILDREN'S HOSPITAL OF PHILADELPHIA	15-Mar-13	14-Mar-14	4-Feb-16
US20160031861	SUBSTITUTED OXETANES AND THEIR USE AS INHIBITORS OF CATHEPSIN C	Not Available	1-Aug-14	31-Jul-15	4-Feb-16
US20160031831	SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY	Not Available	31-Jul-14	27-Jul-15	4-Feb-16
US20160031830	SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY	Not Available	31-Jul-14	27-Jul-15	4-Feb-16
US20160031829	SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY	Not Available	31-Jul-14	27-Jul-15	4-Feb-16
US20160031825	SUBSTITUTED DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY	Not Available	31-Jul-14	27-Jul-15	4-Feb-16
US20160030443	METHODS AND COMPOSITIONS FOR MODULATING REGULATORY T CELL FUNCTION	Not Available	14-Mar-13	14-Mar-14	4-Feb-16
US20160025675	METHOD FOR ELECTRONIC BIOLOGICAL SAMPLE ANALYSIS	Nanomedical Diagnostics, Inc.	28-Apr-14	1-Oct-15	28-Jan-16
US20160025603	AIRBORNE AGENT COLLECTORS, METHODS, SYSTEMS AND DEVICES FOR MONITORING AIRBORNE AGENTS	Not Available	22-Jul-14	21-Jul-15	28-Jan-16
US20160024525	REVERSE GENETICS USING NON-ENDOGENOUS POL I PROMOTERS	NOVARTIS AG	21-May-09	7-May-15	28-Jan-16
US20160024158	Inhibitory Polypeptides Specific to WNT Inhibitors	Not Available	15-Mar-13	14-Mar-14	28-Jan-16
US20160022801	RODENT HEPADNAVIRUS CORES WITH REDUCED CARRIER-SPECIFIC ANTIGENICITY	Not Available	15-Mar-13	14-Mar-14	28-Jan-16
US20160016999	INHIBITORY PEPTIDES OF VIRAL INFECTION	Not Available	17-Jul-14	16-Jul-15	21-Jan-16
US20160016986	STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENT	Not Available	21-Jul-14	21-Jul-15	21-Jan-16

CC-BY-NC-SA Dr. David E. Martin

US20160016916	Exo Olefin-Containing Nuclear Transport Modulators and Uses Thereof	Not Available	15-Mar-13	14-Mar-14	21-Jan-16
US20160015826	Constructs Binding to Phosphatidylserine and Their Use in Disease Treatment and Imaging	Not Available	24-Jan-05	2-Feb-15	21-Jan-16
US20160015803	IMMUNOSTIMULATORY COMBINATIONS AND USE THEREOF	Not Available	18-Jul-14	17-Jul-15	21-Jan-16
US20160011183	MULTIANALYTE ASSAY	Not Available	30-Apr-07	15-Jun-15	14-Jan-16
US20160008809	METHODS AND COMPOSITIONS FOR PAPER-BASED AND HYBRID MICROFLUIDIC DEVICES INTEGRATED WITH NUCLEIC ACID AMPLIFICATION FOR DISEASE DIAGNOSIS	University of Texas at El Paso	10-Jul-14	10-Jul-15	14-Jan-16
US20160008461	METHODS OF GENERATING ROBUST PASSIVE AND ACTIVE IMMUNE RESPONSES	Not Available	8-Jan-13	2-Aug-14	14-Jan-16
US20160008451	NANOPARTICLE-BASED COMPOSITIONS	Not Available	14-Mar-13	14-Mar-14	14-Jan-16
US20160008397	IMMUNOMODULATION BY CONTROLLING EXPRESSION LEVELS OF MICRORNAS IN DENDRITIC CELLS	Not Available	14-Jul-14	10-Jul-15	14-Jan-16
US20160008363	DRUG COMBINATION	VERONA PHARMA PLC	15-Mar-13	17-Mar-14	14-Jan-16
US20160003747	Apparatus for two-step surface-enhanced raman spectroscopy	REAL-TIME ANALYZERS, INC	16-Dec-11	11-Sep-15	7-Jan-16
US20160002608	METHODS TO PRODUCE BUNYAVIRUS REPLICON PARTICLES	Not Available	20-Sep-10	10-Jul-15	7-Jan-16
US20160000905	Nanoparticle Delivery of TLR Agonists and Antigens	Not Available	25-Feb-13	24-Feb-14	7-Jan-16
US20160000790	DRUG COMBINATION	VERONA PHARMA PLC	15-Mar-13	17-Mar-14	7-Jan-16
US20160000754	Antiviral Activity from Medicinal Mushrooms and their Active Constituents	Not Available	6-Jan-04	14-Sep-15	7-Jan-16
US20150377887	IN SITU AFFINITY MATURATION OF ANTIBODIES	Not Available	27-Feb-13	27-Feb-14	31-Dec-15
US20150376621	MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS OF USE	ARROWHEAD RESEARCH CORPORATION	28-Feb-08	14-May-15	31-Dec-15
US20150376584	METHODS OF TREATING VIRAL INFECTIONS, PARTICULARLY RABIES, MERS-COV, INFLUENZA, EBOLA, CHIKUNGUNYA, VENEZUELAN EQUINE ENCEPHALITUS, CANINE PARVOVIRUS, ADENOVIRUS, RESPIRATORY SYNCYTIAL VIRUS, RHINOVIRUS, AND POXVIRUS IN MAMMALIAN PATIENTS	TAMIR BIOTECHNOLOGY, INC.	28-Mar-14	10-Jun-15	31-Dec-15
US20150376145	STABLE SODIUM CHANNEL BLOCKERS	PARION SCIENCES, INC.	30-Jun-14	30-Jun-15	31-Dec-15
US20150376131	SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY	Not Available	23-Aug-12	2-Sep-15	31-Dec-15
US20150374723	Anti-Viral Azide Containing Compounds	Not Available	28-Jul-10	20-Aug-15	31-Dec-15
US20150374626	TREATMENT OF EVOLVING BACTERIAL RESISTANCE DISEASES INCLUDING KLEBSIELLA PNEUMONIAE WITH LIPOSOMALLY FORMULATED GLUTATHIONE	YOUR ENERGY SYSTEMS, LLC	15-Feb-13	15-Mar-13	31-Dec-15
US20150369806	DETECTION OF VIRAL DISEASES USING A BIOCHIP THAT CONTAINS GOLD NANOPARTICLES	Not Available	19-Jun-14	17-Jun-15	24-Dec-15
US20150368661	METHODS FOR PRODUCING ANTIBODIES	Not Available	11-Feb-13	11-Feb-14	24-Dec-15
US20150368294	GADD45BETA TARGETING AGENTS	Not Available	22-Oct-09	10-Feb-15	24-Dec-15
US20150366888	SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF	Not Available	24-Jun-14	22-Jun-15	24-Dec-15
US20150366796	INTRADERMAL DELIVERY OF IMMUNOLOGICAL COMPOSITIONS COMPRISING TOLL-LIKE RECEPTOR AGONISTS	Not Available	1-Feb-13	30-Jan-14	24-Dec-15

CC-BY-NC-SA Dr. David E. Martin

US20150361432	MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS OF USE	Not Available	26-Jul-02	6-Aug-15	17-Dec-15
US20150361097	HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS	Not Available	22-Jan-13	21-Jan-14	17-Dec-15
US20150361096	HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS	Not Available	22-Jan-13	21-Jan-14	17-Dec-15
US20150359871	IMMUNOGENIC COMPOSITIONS COMPRISING SILICIFIED VIRUS AND METHODS OF USE	PORTLAND STATE UNIVERSITY	31-Jan-13	31-Jan-14	17-Dec-15
US20150359746	Technology for the Preparation of Microparticles	Not Available	24-Jul-07	17-Jun-15	17-Dec-15
US20150355172	ADP-RIBOSE DETECTION REAGENTS	The Board of Regents of the University of Texas System	10-Jun-14	9-Jun-15	10-Dec-15
US20150353905	CAS9-NUCLEIC ACID COMPLEXES AND USES RELATED THERETO	Not Available	16-Jan-13	15-Jan-14	10-Dec-15
US20150353596	17-Substituted Steroid Compounds	Not Available	28-Aug-02	24-Aug-15	10-Dec-15
US20150353561	NOVEL COMPOUNDS	CHIESI FARMACEUTICI S.P.A.	9-Jun-14	5-Jun-15	10-Dec-15
US20150352218	HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM	3M INNOVATIVE PROPERTIES COMPANY	3-Jun-11	14-Aug-15	10-Dec-15
US20150344425	INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS	ACTELION PHARMACEUTICALS LTD	18-Dec-12	17-Dec-13	3-Dec-15
US20150343028	METHODS OF MODULATING IMMUNE RESPONSES BY MODIFYING AKT3 BIOACTIVITY	Not Available	17-Apr-14	17-Apr-15	3-Dec-15
US20150337369	SINGLE CELL ANALYSIS OF T CELLS USING HIGH-THROUGHPUT MULTIPLEX AMPLIFICATION AND DEEP SEQUENCING	Not Available	7-May-14	30-Apr-15	26-Nov-15
US20150337334	METHOD FOR PRODUCTION OF REPROGRAMMED CELL USING CHROMOSOMALLY UNINTEGRATED VIRUS VECTOR	Not Available	16-Jul-08	29-Jul-15	26-Nov-15
US20150337015	ANTIVIRAL RIFT VALLEY FEVER VIRUS PEPTIDES AND METHODS OF USE	The United States of America, as represented by the Secretary of the Army, on behalf of the United	6-Dec-12	4-Jun-15	26-Nov-15
US20150335733	Immunogenic Composition and Methods of Using the Compositions for Inducing Humoral and Cellular Immune Responses	Not Available	8-Apr-11	27-Apr-15	26-Nov-15
US20150335728	METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST VIRUS	Academia Sinica	27-Mar-09	18-Feb-14	26-Nov-15
US20150335657	Methods for Modulating Sirtuin Enzymes	Not Available	5-May-14	4-May-15	26-Nov-15
US20150329866	NOVEL siRNAS AND METHODS OF USE THEREOF	Not Available	25-Oct-06	8-Jan-15	19-Nov-15
US20150329834	METHODS OF PROPAGATING MONKEY ADENOVIRAL VECTORS	GenVec, Inc.	9-Nov-09	4-Aug-15	19-Nov-15
US20150328282	METHODS FOR TREATING VIRAL DISORDERS	Not Available	24-Sep-09	5-Aug-15	19-Nov-15
US20150322491	High density self-contained biological analysis	Not Available	15-Nov-06	16-Jul-15	12-Nov-15
US20150322155	ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING MOLECULE	Robert Yongxin Zhao	15-Jul-15	15-Jul-15	12-Nov-15
US20150322137	HUMAN ANTIBODY SPECIFIC TO HUMAN METAPNEUMOVIRUS, OR ANTIGEN-BINDING FRAGMENT THEREOF	Not Available	28-Jan-13	28-Jan-14	12-Nov-15
US20150322022	THERAPEUTIC CATECHOLS	RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY	12-May-14	11-May-15	12-Nov-15
US20150322008	INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONIST	ACTELION PHARMACEUTICALS LTD	12-Dec-12	11-Dec-13	12-Nov-15
US20150320842	A COMPOSITION FOR PREVENTING OR TREATING AN RNA VIRAL INFECTION COMPRISING SAMHD1 OR A NUCLEIC ACID MOLECULE ENCODING THE SAMHD1	SNU R&DB FOUNDATION	7-Jan-13	7-Jan-13	12-Nov-15
US20150320801	USE OF ASC AND ASC-CM TO TREAT ARDS, SARS, AND MERS	Not Available	6-May-14	6-May-15	12-Nov-15
US20150315612	ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR	Not Available	30-Sep-03	20-Jul-15	5-Nov-15

US20150315574	PRODUCTION OF STABLE NON-POLYADENYLATED RNAS	Massachusetts Institute of Technology	16-Oct-12	16-Oct-13	5-Nov-15
US20150314017	DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELL-BINDING MOLECULE	Dr. Robert Yongxin Zhao	15-Jul-15	15-Jul-15	5-Nov-15
US20150313960	NOVEL DEPSIPEPTIDE AND USES THEREOF	Not Available	3-Dec-12	1-Jul-15	5-Nov-15
US20150313929	USE OF TYLVALOSIN AS ANTIVIRAL AGENT	CAMBRIDGE UNIVERSITY TECHNICAL SERVICES	13-Jul-06	8-Jun-15	5-Nov-15
US20150313909	ANTIVIRAL COMPOUNDS AND METHODS	Biotron Limited	26-Jun-03	6-Feb-15	5-Nov-15
US20150309018	SYSTEM AND METHOD FOR ELECTRONIC BIOLOGICAL SAMPLE ANALYSIS	NANOMEDICAL DIAGNOSTICS, INC.	28-Apr-14	28-Apr-14	29-Oct-15
US20150307936	SYSTEM AND METHOD FOR DNA SEQUENCING AND BLOOD CHEMISTRY ANALYSIS	Nanomedical Diagnostics, Inc.	28-Apr-14	10-Apr-15	29-Oct-15
US20150307935	NON-MASS DETERMINED BASE COMPOSITIONS FOR NUCLEIC ACID DETECTION	Not Available	6-Aug-09	13-Jul-15	29-Oct-15
US20150307849	HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS	Not Available	11-Jul-03	23-Feb-15	29-Oct-15
US20150307572	BIOACTIVE PEPTIDES AND METHODS OF USING SAME	Not Available	12-Jul-07	23-Feb-15	29-Oct-15
US20150307530	NOVEL MUCOLYTIC AGENTS	PARION SCIENCES, INC.	31-Aug-12	30-Aug-13	29-Oct-15
US20150306213	HMGB1-DERIVED PEPTIDES ENHANCE IMMUNE RESPONSE TO ANTIGENS	The Regents of the University of California	27-Jul-10	9-Mar-15	29-Oct-15
US20150306212	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13	12-Jun-15	29-Oct-15
US20150306205	VACCINE COMPOSITION FOR NAIVE SUBJECTS	Not Available	17-Dec-12	17-Dec-13	29-Oct-15
US20150306137	METHODS OF TREATING OR PREVENTING INFLAMMATION AND HYPERSENSITIVITY WITH OXIDATIVE REDUCTIVE POTENTIAL WATER SOLUTION	OCULUS INNOVATIVE SCIENCES, INC.	20-Jan-06	7-Jul-15	29-Oct-15
US20150301055	CIRCULATING BIOMARKERS FOR DISEASE	Not Available	6-Apr-10	1-Jul-15	22-Oct-15
US20150299728	TC-83-DERIVED ALPHAVIRUS VECTORS, PARTICLES AND METHODS	Not Available	18-May-04	6-Jul-15	22-Oct-15
US20150299707	CONSTRUCTION OF POOL OF INTERFERING NUCLEIC ACIDS COVERING ENTIRE RNA TARGET SEQUENCE AND RELATED COMPOSITIONS	BIOMICS BIOTECHNOLOGIES CO., LTD.	7-Jul-08	2-Jul-15	22-Oct-15
US20150299667	INFLUENZA VIRUS AND TYPE 1 DIABETES	ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLE VENEZIE	10-Oct-12	10-Oct-13	22-Oct-15
US20150299271	TREATING CANCER WITH VIRAL NUCLEIC ACID	Not Available	20-Feb-07	6-Jul-15	22-Oct-15
US20150299194	4-AMINO-IMIDAZOQUINOLINE COMPOUNDS	HOFFMANN-LA ROCHE INC.	22-Apr-14	22-Apr-15	22-Oct-15
US20150299142	3,5-DIAMINO-6-CHLORO-N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2-CARBOXAMIDE COMPOUNDS	PARION SCIENCES, INC.	17-Dec-12	8-Jan-15	22-Oct-15
US20150297700	Novel Adenovirus Vectors	Not Available	10-Apr-07	27-Apr-15	22-Oct-15
US20150297677	COMPOSITIONS AND METHODS FOR INHIBITING VIRAL ENTRY	Children Medical Center Corporation	13-Dec-12	12-Dec-13	22-Oct-15
US20150297668	ANALOGS OF C5a AND METHODS OF USING SAME	BOARD PF REGENTS OF THE UNIVERSITY OF NEBRASKA	29-Jun-10	29-Jun-11	22-Oct-15
US20150291609	MERTK-SPECIFIC PYRIMIDINE COMPOUNDS	Not Available	11-Apr-14	3-Apr-15	15-Oct-15
US20150291606	MERTK-SPECIFIC PYRROLOPYRIMIDINE COMPOUNDS	Not Available	11-Apr-14	3-Apr-15	15-Oct-15
US20150291605	MERTK-SPECIFIC PYRAZOLOPYRIMIDINE COMPOUNDS	Not Available	11-Apr-14	3-Apr-15	15-Oct-15
US20150291531	THERAPEUTIC HYDROXYQUINOLONES	RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY	9-Nov-12	8-Nov-13	15-Oct-15

CC-BY-NC-SA Dr. David E. Martin

US20150290235	USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN COMBINATION WITH (DEOXY)NUCLEOSIDE OR (DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND HEMATOLOGICAL MALIGNANCIES OR VIRAL INFECTIONS	Not Available	23-Nov-12	8-Nov-13	15-Oct-15
US20150290234	TARGETED INTRACELLULAR DELIVERY OF ANTIVIRAL AGENTS	Not Available	23-Mar-07	21-Apr-15	15-Oct-15
US20150290212	THERAPEUTIC USES OF SELECTED PYRAZOLOPYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY	Not Available	11-Apr-14	3-Apr-15	15-Oct-15
US20150290197	THERAPEUTIC USES OF SELECTED PYRROLOPYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY	Not Available	11-Apr-14	3-Apr-15	15-Oct-15
US20150290194	THERAPEUTIC USES OF SELECTED PYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITY	Not Available	11-Apr-14	3-Apr-15	15-Oct-15
US20150290189	CHEMICALLY AND METABOLICALLY STABLE DIPEPTIDE POSSESSING POTENT SODIUM CHANNEL BLOCKER ACTIVITY	PARION SCIENCES, INC.	27-Jun-11	12-Jan-15	15-Oct-15
US20150290134	TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES	Not Available	24-Jan-06	21-Apr-15	15-Oct-15
US20150289573	SELF SANITIZING FACE MASKS AND METHOD OF MANUFACTURE	Not Available	1-Jun-07	26-Jun-15	15-Oct-15
US20150284475	BISPECIFIC ANTIBODY	Not Available	21-Nov-12	21-Nov-12	8-Oct-15
US20150284451	COMPOSITIONS AND METHODS FOR INHIBITING PATHOGEN INFECTION	Not Available	29-Oct-12	29-Oct-13	8-Oct-15
US20150284416	NOVEL LINKERS FOR CONJUGATION OF CELL-BINDING MOLECULES	SUZHOU M-CONJ BIOTECH CO., LTD	16-Jun-15	16-Jun-15	8-Oct-15
US20150283531	Microspotting Device	Not Available	18-Apr-12	17-Apr-13	8-Oct-15
US20150283233	Compositions and Methods for Enhancing Immune Responses	Not Available	15-Jun-12	17-Jun-13	8-Oct-15
US20150283221	ATTENUATED LISTERIA MONOCYTOGENES MUTANT AS A VACCINE VECTOR FOR THE DELIVERY OF EXOGENEOUS ANTIGENS	The Board of Trustees of the University of Illinois	7-Apr-14	7-Apr-15	8-Oct-15
US20150275183	Human Betacoronavirus Lineage C and Identification of N-Terminal Dipeptidyl Peptidase As Its Virus Receptor	Not Available	23-Sep-12	23-Sep-13	1-Oct-15
US20150274698	Hydrazide Containing Nuclear Transport Modulators And Uses Thereof	Not Available	29-Jul-11	10-Jun-15	1-Oct-15
US20150272988	INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES	Advanced Inhalation Therapies (AIT) Ltd.	7-Mar-12	7-Mar-13	1-Oct-15
US20150267245	PRESERVATION OF BIOLOGICAL MATERIALS IN NON-AQUEOUS FLUID MEDIA	GenTegra, LLC	14-Mar-13	14-Mar-14	24-Sep-15
US20150267202	ANTISENSE ANTIVIRAL COMPOUND AND METHOD FOR TREATING ss/RNA VIRAL INFECTION	Not Available	16-Sep-04	6-Nov-14	24-Sep-15
US20150267194	DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4 AND METHODS OF USE THEREOF	Quark Pharmaceutical, Inc.	12-Sep-12	12-Sep-13	24-Sep-15
US20150266929	VIRUS-LIKE PARTICLES, METHODS OF PREPARATION, AND IMMUNOGENIC COMPOSITIONS	Not Available	17-May-02	4-May-15	24-Sep-15
US20150266901	ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES	Not Available	9-Feb-05	8-Jun-15	24-Sep-15
US20150266882	PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS	Not Available	19-Oct-12	18-Oct-13	24-Sep-15
US20150265721	Compounds and Methods for Modulating an Immune Response	Not Available	23-Mar-09	23-Dec-14	24-Sep-15
US20150265697	HIGH-YIELD TRANSGENIC MAMMALIAN EXPRESSION SYSTEM FOR GENERATING VIRUS-LIKE PARTICLES	Academia Sinica	5-Sep-06	11-Feb-15	24-Sep-15
US20150265696	Compositions And Methods For Treating And Preventing Porcine Reproductive And Respiratory Syndrome	Not Available	24-Apr-12	23-Feb-15	24-Sep-15
US20150259427	GITR BINDING MOLECULES AND USES THEREFOR	Not Available	25-Mar-05	23-Mar-15	17-Sep-15

CC-BY-NC-SA Dr. David E. Martin

US20150259399	ANTIBODIES AND PROCESSES FOR PREPARING THE SAME	Not Available	16-May-08	18-Mar-15	17-Sep-15
US20150259340	NOVEL KINASE INHIBITORS	Not Available	19-Oct-12	18-Oct-13	17-Sep-15
US20150259292	HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS	Not Available	8-Mar-11	19-Mar-15	17-Sep-15
US20150258191	ARRANGING INTERACTION AND BACK PRESSURE CHAMBERS FOR MICROFLUIDIZATION	Novartis AG	3-Dec-09	13-Mar-15	17-Sep-15
US20150252439	Methods and Compositions for Prostate Cancer Metastasis	Not Available	25-Mar-11	20-May-15	10-Sep-15
US20150252080	FUSION PROTEINS FOR PROMOTING AN IMMUNE RESPONSE, NUCLEIC ACIDS ENCODING SAME, AND METHODS OF MAKING AND USE THEREOF	Not Available	7-Sep-12	9-Sep-13	10-Sep-15
US20150250896	HYDROPHILIC LINKERS AND THEIR USES FOR CONJUGATION OF DRUGS TO A CELL BINDING MOLECULES	Hangzhou DAC Biotech Co., Ltd.	24-Nov-12	24-Nov-12	10-Sep-15
US20150247190	METHODS AND SYSTEMS FOR MICROFLUIDICS IMAGING AND ANALYSIS	Not Available	5-Oct-12	4-Oct-13	3-Sep-15
US20150246110	ADJUVANTED INFLUENZA VACCINES INCLUDING CYTOKINE-INDUCING AGENTS	Novartis AG	4-Nov-05	14-May-15	3-Sep-15
US20150246091	COMPOUNDS AND METHODS FOR PREVENTING OR TREATING A VIRAL INFECTION	Not Available	2-Nov-07	15-May-15	3-Sep-15
US20150246015	Esters of Short Chains Fatty Acids for Use in the Treatment of Immunogenic Disorders	Not Available	3-Oct-12	3-Oct-13	3-Sep-15
US20150239940	COMPOSITIONS AND METHODS FOR VIRUS INHIBITION	AUTOIMMUNE TECHNOLOGIES, LLC	4-Nov-03	13-May-15	27-Aug-15
US20150239875	SUBSTITUTED PYRIDONES AND PYRAZINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY	Not Available	21-Feb-14	12-Feb-15	27-Aug-15
US20150238550	AAV Vectors Targeted to Oligodendrocytes	Not Available	28-Sep-12	27-Sep-13	27-Aug-15
US20150238489	HETEROCYCLYL CARBOXAMIDES FOR TREATING VIRAL DISEASES	Not Available	31-Aug-12	30-Aug-13	27-Aug-15
US20150232957	MODIFIED OLIGONUCLEOTIDES COMPRISING THIOL FUNCTIONS AND USE THEREOF FOR DETECTING NUCLEIC ACIDS	Not Available	4-Apr-12	4-Apr-13	20-Aug-15
US20150232881	CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS	EDITAS MEDICINE, INC.	7-Nov-13	7-Nov-14	20-Aug-15
US20150232878	Construct	Not Available	28-Mar-06	20-Oct-14	20-Aug-15
US20150232454	THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONES	RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY	11-Sep-12	11-Sep-13	20-Aug-15
US20150231232	OUTER MEMBRANE VESICLES	Not Available	18-Sep-12	18-Sep-13	20-Aug-15
US20150225432	COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS	Novartis AG	2-Sep-09	24-Apr-15	13-Aug-15
US20150218162	SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES	Not Available	18-Jun-04	13-Apr-15	6-Aug-15
US20150218109	C-REL INHIBITORS AND USES THEREOF	Not Available	21-Sep-12	19-Sep-13	6-Aug-15
US20150216973	METHOD FOR THE INDUCTION OF AN IMMUNE RESPONSE	Not Available	8-Aug-12	8-Aug-13	6-Aug-15
US20150211006	CHIRAL CONTROL	Not Available	13-Jul-12	12-Jul-13	30-Jul-15
US20150210733	NUCLEIC ACID CHEMICAL MODIFICATIONS	Not Available	2-Mar-09	22-Jan-15	30-Jul-15
US20150210655	CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORS	ASTRAZENECA AB	24-Jan-14	21-Jan-15	30-Jul-15
US20150203847	CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITION	Not Available	23-Sep-08	31-Dec-14	23-Jul-15

CC-BY-NC-SA Dr. David E. Martin

US20150203816	MEANS AND METHODS FOR INFLUENCING THE STABILITY OF CELLS	Not Available	4-Dec-09	26-Mar-15	23-Jul-15
US20150202284	METHOD OF MAKING A VACCINE	The United States of America, as represented by the Secretary, Dept. of Health & Human Services	11-Oct-08	20-Jan-15	23-Jul-15
US20150196619	EV576 FOR USE IN THE TREATMENT OF VIRAL INFECTIONS OF THE RESPIRATORY TRACT	Not Available	8-Jan-10	2-Jan-15	16-Jul-15
US20150196578	COMBINATION THERAPY TREATMENT FOR VIRAL INFECTIONS	Not Available	14-Oct-09	10-Dec-14	16-Jul-15
US20150196032	ANTIVIRAL COMPOSITIONS	Long Island University	30-May-07	19-Mar-15	16-Jul-15
US20150191704	POXVIRUS-PLASMODIUM RECOMBINANTS, COMPOSITIONS CONTAINING SUCH RECOMBINANTS, USES THEREOF, AND METHODS OF MAKING AND USING SAME	Not Available	30-Dec-13	19-Dec-14	9-Jul-15
US20150191607	Anti-fouling Paints and Coatings	REACTIVE SURFACES, LTD	3-Jul-03	4-Dec-13	9-Jul-15
US20150184231	BIOAGENT DETECTION OLIGONUCLEOTIDES	Not Available	27-Dec-11	27-Dec-12	2-Jul-15
US20150183837	IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF	Not Available	17-Dec-07	13-Feb-15	2-Jul-15
US20150182636	GENETICALLY MODIFIED HUMAN UMBILICAL CORD PERIVASCULAR CELLS FOR PROPHYLAXIS AGAINST OR TREATMENT OF BIOLOGICAL OR CHEMICAL AGENTS	Not Available	21-Apr-08	13-Mar-15	2-Jul-15
US20150182588	SYNTHETIC MEMBRANE-RECEIVER COMPLEXES	Not Available	18-Nov-13	23-Dec-14	2-Jul-15
US20150176027	ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR	Not Available	17-Dec-01	16-Jan-15	25-Jun-15
US20150175656	CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS	Not Available	20-Mar-09	5-Mar-15	25-Jun-15
US20150174257	METHODS AND REAGENTS FOR EFFICIENT AND TARGETED GENE TRANSFER TO MONOCYTES AND MACROPHAGES	Not Available	29-Apr-09	3-Mar-15	25-Jun-15
US20150174206	USES OF INTERFERONS WITH ALTERED SPATIAL STRUCTURE	Not Available	28-Aug-03	28-Jan-15	25-Jun-15
US20150174198	GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA VIRUS SPIKE PROTEIN	Not Available	28-Oct-05	17-Nov-14	25-Jun-15
US20150174158	INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES	Not Available	7-Mar-12	7-Mar-13	25-Jun-15
US20150173366	PHYSICAL ANTIMICROBIAL METHOD	NMS TECHNOLOGIES CO., LTD.	1-Aug-12	16-Jul-13	25-Jun-15
US20150168405	OLIGONUCLEOTIDE BASED ANALYTE DETECTION METHOD	Not Available	16-Feb-10	24-Feb-15	18-Jun-15
US20150166989	PARTICLE-NUCLEIC ACID CONJUGATES AND THERAPEUTIC USES RELATED THERETO	Not Available	25-Jun-12	27-Feb-13	18-Jun-15
US20150166966	REVERSE GENETICS METHODS FOR VIRUS RESCUE	Not Available	20-Oct-09	1-Oct-14	18-Jun-15
US20150166548	NOVEL COMPOUNDS	CHIESI FARMACEUTICI S.p.A.	16-Dec-13	16-Dec-14	18-Jun-15
US20150166532	HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSES	Not Available	11-Apr-12	15-Mar-13	18-Jun-15
US20150166488	ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPTHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS	PARION SCIENCES, INC.	13-Dec-13	19-Dec-14	18-Jun-15
US20150166487	ARYLALKYL- AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS	Parion Sciences, Inc.	13-Dec-13	13-Dec-13	18-Jun-15
US20150165019	Saccharide Conjugate Vaccines	Not Available	24-Dec-04	5-Aug-14	18-Jun-15
US20150165009	TLR5 LIGANDS, THERAPEUTIC METHODS, AND COMPOSITIONS RELATED THERETO	Emory University	24-Sep-10	20-Sep-11	18-Jun-15

CC-BY-NC-SA Dr. David E. Martin

US20150164800	REGULATING THE INTERACTION BETWEEN TAM LIGANDS AND LIPID MEMBRANES WITH EXPOSED PHOSPHATIDYL SERINE	Salk Institute For Biological Studies	25-Jul-12	23-Jul-13	18-Jun-15
US20150159205	METHODS AND REAGENTS FOR AMPLIFYING NUCLEIC ACIDS	The United States of America, as represented by the Secretary, Department of Health and Human	6-Aug-12	6-Aug-12	11-Jun-15
US20150159173	METHOD OF INCREASING THE FUNCTION OF AN AAV VECTOR	The Trustees of the University of Pennsylvania	7-Apr-05	18-Feb-15	11-Jun-15
US20150157636	METHODS FOR TREATING VIRAL DISORDERS	Not Available	24-Sep-09	18-Feb-15	11-Jun-15
US20150152149	Peptides Having Activity of Inhibiting Infections of Respiratory Viruses and Use of the Same	Not Available	9-May-13	21-Feb-14	4-Jun-15
US20150150963	VACCINATION WITH INTERLEUKIN-4 ANTAGONISTS	THE AUSTRALIAN NATIONAL UNIVERSITY	5-Jun-12	5-Jun-13	4-Jun-15
US20150150893	ANDROGRAPHOLIDE ANALOGS AND THEIR USE FOR MEDICATION	Not Available	18-Jun-12	31-May-13	4-Jun-15
US20150150878	Methods For Inhibiting Viruses By Targeting Cathepsin-L Cleavage Sites In The Viruses' Glycoproteins	Not Available	4-Apr-12	4-Apr-13	4-Jun-15
US20150148402	MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS OF USE	NOVARTIS AG	1-Oct-04	9-May-14	28-May-15
US20150147346	REPLIKIN SEQUENCES AND THEIR ANTIBODIES FOR DIAGNOSTICS, THERAPEUTICS, AND VACCINES AGAINST PRION AND NEURODEGENERATIVE DISORDERS INCLUDING ALZHEIMER'S DISEASE	Not Available	2-May-12	1-May-13	28-May-15
US20150141625	IMMUNE RESPONSE MODIFIER CONJUGATES	Not Available	22-Feb-06	20-Jan-15	21-May-15
US20150141387	PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT	Not Available	18-Dec-08	14-Jan-15	21-May-15
US20150140121	Compositions and Methods for Tight Junction Modulation	Not Available	8-Jun-12	10-Jun-13	21-May-15
US20150139949	ANTI-VIRAL COMBINATION THERAPY	Not Available	6-Apr-11	19-May-14	21-May-15
US20150133633	MODIFICATION OF PEPTIDES USING A BIS(THIOETHER)ARYLBRIDGE APPROACH	Not Available	18-May-12	17-May-13	14-May-15
US20150133402	BORON-CONTAINING SMALL MOLECULES	Not Available	20-Jun-07	7-Nov-14	14-May-15
US20150133391	CELL-FREE NUCLEIC ACIDS FOR THE ANALYSIS OF THE HUMAN MICROBIOME AND COMPONENTS THEREOF	Not Available	7-Nov-13	7-Nov-14	14-May-15
US20150132339	ADJUVANTED FORMULATIONS OF STREPTOCOCCUS PNEUMONIAE ANTIGENS	Not Available	7-Mar-12	7-Mar-13	14-May-15
US20150132337	COMBINATION GAS VACCINES AND THERAPEUTICS	Not Available	17-Sep-08	13-Nov-14	14-May-15
US20150132220	Compositions and Imaging Methods Comprising Detectably Labeled Phosphatidylethanolamine-Binding Peptides	Not Available	15-Jul-02	8-Jan-15	14-May-15
US20150126722	OLIGONUCLEOTIDE COMPOUND AND METHOD FOR TREATING NIDOVIRUS INFECTIONS	Not Available	24-Dec-03	4-Jun-14	7-May-15
US20150125540	RELEASE OF AGENTS FROM CELLS	Not Available	15-Oct-09	5-Jan-15	7-May-15
US20150125502	DISINFECTING COMPOSITION AND WIPES WITH REDUCED CONTACT TIME	Not Available	6-Nov-13	4-Nov-14	7-May-15
US20150125483	FUSION PROTEINS OF CILIATE GRANULE LATTICE PROTEINS, GRANULAR PROTEIN PARTICLES THEREOF, AND USES THEREFOR	Tetragenetics, Inc.	27-May-11	29-May-12	7-May-15
US20150125475	IMMUNOLOGICALLY USEFUL ARGININE SALTS	Not Available	7-Mar-12	7-Mar-13	7-May-15
US20150125384	MODULAR NANODEVICES FOR SMART ADAPTABLE VACCINES	Not Available	15-Feb-07	10-Nov-14	7-May-15
US20150119445	Carbohydrate Conjugates as Delivery Agents for Oligonucleotides	Not Available	4-Dec-07	22-Jul-14	30-Apr-15
US20150119444	Carbohydrate Conjugates as Delivery Agents for Oligonucleotides	Not Available	4-Dec-07	11-Jul-14	30-Apr-15

US20150119426	MODULATORS OF THE RELAXIN RECEPTOR 1	Not Available	4-May-12	15-Mar-13	30-Apr-15
US20150119364	BORON-CONTAINING SMALL MOLECULES	Not Available	16-Feb-05	10-Nov-14	30-Apr-15
US20150119318	PEPTIDE COMPOSITIONS AND METHODS FOR INHIBITING HERPESVIRUS INFECTION	THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND	30-Oct-09	9-Jul-14	30-Apr-15
US20150118746	INFLUENZA VIRUS REASSORTMENT METHOD	Not Available	21-May-10	24-Oct-14	30-Apr-15
US20150118319	PROTEOLYSIS-RESISTANT CAPSID OF CHIMERIC HEPATITIS E VIRUS AS AN ORAL DELIVERY VECTOR	Not Available	27-Feb-09	5-Nov-14	30-Apr-15
US20150118265	MODIFIED ERYTHROCYTE PRECURSOR CELLS AND USES THEREOF	Anthrogenesis Corporation	13-Mar-12	12-Mar-13	30-Apr-15
US20150118264	PHARMACEUTICAL COMPOSITION COMPRISING A POLYMERIC CARRIER CARGO COMPLEX AND AT LEAST ONE PROTEIN OR PEPTIDE ANTIGEN	CureVac GMBH	31-Jan-12	31-Jan-13	30-Apr-15
US20150118222	TREATMENT USING BRUTON'S TYROSINE KINASE INHIBITORS AND IMMUNOTHERAPY	Not Available	25-Oct-13	24-Oct-14	30-Apr-15
US20150118201	Directed Evolution and In Vitro Panning of Virus Vectors	Not Available	30-Apr-08	22-Oct-14	30-Apr-15
US20150118183	NEGATIVELY CHARGED NUCLEIC ACID COMPRISING COMPLEXES FOR IMMUNOSTIMULATION	CUREVAC GMBH	31-Jan-12	31-Jan-13	30-Apr-15
US20150111955	AAV VECTOR COMPOSITIONS AND METHODS FOR GENE TRANSFER TO CELLS, ORGANS AND TISSUES	Not Available	17-Feb-12	19-Feb-13	23-Apr-15
US20150111945	COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS GENE EXPRESSION	Not Available	20-Jul-09	28-Mar-14	23-Apr-15
US20150111893	Nuclear Transport Modulators and Uses Thereof	Not Available	9-May-12	9-May-13	23-Apr-15
US20150110807	HDC-SIGN BINDING PEPTIDES	Sloan-Kettering Institute for Cancer Research	19-Dec-11	10-Dec-12	23-Apr-15
US20150105375	METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C	Not Available	14-Mar-13	18-Dec-14	16-Apr-15
US20150104867	ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS	Baxter Healthcare SA	29-Oct-04	2-May-14	16-Apr-15
US20150104500	Methods and Compositions for Preventing a Condition	Not Available	9-Aug-10	28-Aug-14	16-Apr-15
US20150099770	CARBOXYLIC ACID COMPOUNDS	Not Available	18-May-12	17-May-13	9-Apr-15
US20150099769	PYRROLO[3,2-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THERAPY	Not Available	6-Dec-04	15-Sep-14	9-Apr-15
US20150099764	DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES	PARION SCIENCES, INC.	29-May-12	9-Dec-14	9-Apr-15
US20150099656	Multiplex Immuno Screening Assay	Not Available	4-May-12	3-May-13	9-Apr-15
US20150099263	SELECTIVE DETECTION OF HUMAN RHINOVIRUS	Not Available	5-Dec-08	15-Dec-14	9-Apr-15
US20150099261	RESPIRATORY INFECTION ASSAY	Not Available	9-Dec-11	10-Dec-12	9-Apr-15
US20150093413	NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC ANTIGEN	CureVac GmbH	15-Feb-12	15-Feb-13	2-Apr-15
US20150086576	SORTASE-MODIFIED VHH DOMAINS AND USES THEREOF	Not Available	13-Apr-12	15-Apr-13	26-Mar-15
US20150080447	Sceletium Extract and Uses Thereof	H. L. Hall & Sons Limited	20-Mar-09	15-Jul-14	19-Mar-15
US20150080396	Novel Pyrimidine Derivatives and Their Use in the Treatment of Cancer and Further Diseases	ASTRAZENECA AB	21-May-09	26-Aug-14	19-Mar-15

CC-BY-NC-SA Dr. David E. Martin

US20150080344	PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONS	Not Available	14-Apr-10	29-Sep-14	19-Mar-15
US20150080319	Inhibition Of Tace Activity With Cyclic Peptides	Not Available	2-Jun-11	19-Sep-14	19-Mar-15
US20150079155	Cationic Liposomal Drug Delivery System for Specific Targeting of Human CD14+ Monocytes in Whole Blood	Not Available	14-Mar-12	14-Mar-13	19-Mar-15
US20150079121	Human Respiratory Syncytial Virus Consensus Antigens, Nucleic Acid Constructs And Vaccines Made Therefrom, And Methods Of Using Same	Not Available	10-Apr-12	10-Apr-13	19-Mar-15
US20150073136	PYRAZINONE DERIVATIVES	Not Available	27-Jun-07	17-Nov-14	12-Mar-15
US20150072973	NOVEL SELECTIVE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 7, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS	Not Available	13-Aug-10	17-Sep-14	12-Mar-15
US20150072023	INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES	Not Available	11-Sep-13	11-Sep-14	12-Mar-15
US20150065459	BORON-CONTAINING SMALL MOLECULES	Not Available	16-Feb-05	10-Nov-14	5-Mar-15
US20150065458	Composition for Inactivating an Enveloped Virus	Not Available	19-May-06	17-Nov-14	5-Mar-15
US20150064137	USE OF ENGINEERED VIRUSES TO SPECIFICALLY KILL SENESCENT CELLS	Kythera Biopharmaceuticals, Inc.	17-Apr-12	16-Apr-13	5-Mar-15
US20150056636	Transgenic Immunodeficient Mouse Expressing Human SIRP-alpha	Not Available	26-Mar-12	26-Mar-13	26-Feb-15
US20150056305	DITHIOL MUCOLYTIC AGENTS	PARION SCIENCES, INC.	23-Aug-13	13-Aug-14	26-Feb-15
US20150051206	COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS	IRM LLC	1-Sep-11	29-Aug-12	19-Feb-15
US20150050713	Technology for the Preparation of Microparticles	Not Available	24-Jul-07	25-Jul-14	19-Feb-15
US20150050308	CORONAVIRUS, NUCLEIC ACID, PROTEIN, AND METHODS FOR THE GENERATION OF VACCINE, MEDICAMENTS AND DIAGNOSTICS	Not Available	18-Aug-03	13-Aug-14	19-Feb-15
US20150050278	SOLUBLE ENGINEERED MONOMERIC FC	Not Available	16-Mar-12	14-Mar-13	19-Feb-15
US20150045412	USE OF THE CHROMOSOME 19 MICRORNA CLUSTER (C19MC) FOR TREATING MICROBIAL DISEASE AND PROMOTING AUTHOPHAGY	Not Available	7-Mar-12	6-Mar-13	12-Feb-15
US20150044768	METHODS AND COMPOSITIONS FOR PRODUCTION OF RECOMBINANT PROTEIN IN HBX-EXPRESSING MAMMALIAN CELLS	Not Available	28-May-08	24-Oct-14	12-Feb-15
US20150044305	INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES	Not Available	7-Mar-12	7-Mar-13	12-Feb-15
US20150044279	METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSE	Not Available	10-Apr-03	6-Oct-14	12-Feb-15
US20150037288	METHODS FOR INCREASING THE INFECTIVITY OF VIRUSES	Not Available	26-Jan-12	25-Jan-13	5-Feb-15
US20150037281	VARIANTS OF PROTHYMOSIN ALPHA AND METHODS OF USING SAME	Icahn School of Medicine at Mount Sinai	2-Mar-12	1-Mar-13	5-Feb-15
US20150034084	INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASES	Advanced Inhalation Therapies (AIT) Ltd.	7-Mar-12	7-Mar-13	5-Feb-15
US20150031038	SAMPLE PREPARATION METHODS	Not Available	6-Sep-11	6-Sep-12	29-Jan-15
US20150031016	Mixed Cell Diagnostic Systems For Detection Of Respiratory, Herpes and Enteric Viruses	Diagnostic Hybrids Inc.	24-Apr-98	4-Aug-14	29-Jan-15
US20150031014	DETECTING ANALYTES WITH A PH METER	The Board of Trustees of the University of Illinois	25-Jul-13	25-Jul-14	29-Jan-15
US20150030627	Trans-complementing, replication deficient lentiviral vectors and methods for making and using them	VIRxSYS.CON390	17-Aug-06	8-Oct-14	29-Jan-15
US20150030626	IMMUNOMODULATORY CONJUGATES	Ascend Biopharamaceuticals Ltd	9-Nov-11	9-Nov-12	29-Jan-15

CC-BY-NC-SA Dr. David E. Martin

US20150030625	GAS57 MUTANT ANTIGENS AND GAS57 ANTIBODIES	Not Available	12-Sep-07	13-Oct-14	29-Jan-15
US20150030607	INFLUENZA HEMAGGLUTININ-SPECIFIC MONOCLONAL ANTIBODIES FOR PREVENTING AND TREATING INFLUENZA VIRUS INFECTION	Not Available	20-Oct-10	9-Oct-14	29-Jan-15
US20150025075	HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS	ACTELION PHARMACEUTICALS LTD.	20-Jan-12	18-Jan-13	22-Jan-15
US20150024415	DETECTION AND QUANTIFICATION OF ANALYTES BASED ON SIGNAL INDUCED BY ALKALINE PHOSPHATE	The Board of Trustees of the University of Illinois	16-Feb-12	19-Feb-13	22-Jan-15
US20150024405	ENHANCED DEPOSITION OF CHROMOGENS UTILIZING PYRIMIDINE ANALOGS	Ventana Medical Systems, Inc.	30-Dec-10	6-Oct-14	22-Jan-15
US20150024002	ALPHAVIRUS VECTORS FOR RESPIRATORY PATHOGEN VACCINES	Not Available	21-May-04	20-Aug-14	22-Jan-15
US20150023990	ALKOXY SUBSTITUTED IMIDAZOQUINOLINES	3M INNOVATIVE PROPERTIES COMPANY	3-Oct-03	30-Sep-14	22-Jan-15
US20150023924	VARIANT AAV AND COMPOSITIONS, METHODS AND USES FOR GENE TRANSFER TO CELLS, ORGANS AND TISSUES	Not Available	22-Jul-13	22-Jul-14	22-Jan-15
US20150023921	HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS	BIOTRON LIMITED	3-Aug-07	3-Apr-14	22-Jan-15
US20150023879	DIAGNOSTIC CHEWING GUM FOR PATHOGENS	Julius-Maximilians-Universitaet Wuerzburg	8-Mar-12	8-Mar-13	22-Jan-15
US20150021204	AMPEROMETRIC GAS SENSOR	Not Available	25-Jun-12	30-Sep-14	22-Jan-15
US20150021203	AMPEROMETRIC GAS SENSOR	Not Available	25-Jun-12	30-Sep-14	22-Jan-15
US20150018396	PREVENTION AND TREATMENT OF RESPIRATORY INFECTION WITH PEROXISOME PROLIFERATOR ACTIVATOR RECEPTOR DELTA AGONIST	Not Available	8-Mar-12	3-Mar-13	15-Jan-15
US20150018332	Nuclear Transport Modulators and Uses Thereof	KARYOPHARM THERAPEUTICS INC.	29-Jul-11	26-Jul-12	15-Jan-15
US20150017251	MICROPARTICLES FOR USE IN IMMUNOGENIC COMPOSITIONS	NOVARTIS AG	6-Aug-08	18-Jul-14	15-Jan-15
US20150011615	Carbohydrate Conjugates as Delivery Agents for Oligonucleotides	Not Available	4-Dec-07	11-Jul-14	8-Jan-15
US20150011508	COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS	IRM LLC	1-Sep-11	28-Aug-12	8-Jan-15
US20150010983	COMPOSITIONS, METHODS AND USES FOR INDUCING VIRAL GROWTH	Not Available	5-Dec-08	19-Sep-14	8-Jan-15
US20150005227	METHOD OF TREATING AN ISCHEMIA-REPERFUSION INJURY-RELATED DISORDER BY ADMINISTERING GPCR LIGANDS	Not Available	18-Sep-06	7-Sep-14	1-Jan-15
US20150004188	COMPOSITIONS, COMPRISING IMPROVED IL-12 GENETIC CONSTRUCTS AND VACCINES, IMMUNOTHERAPEUTICS AND METHODS OF USING THE SAME	Not Available	12-Dec-11	11-Dec-12	1-Jan-15
US20140364492	PHORBOL TYPE DITERPENE COMPOUND, PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF VIRAL INFECTIOUS DISEASES INCLUDING SAME	KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY	26-Oct-11	28-Sep-12	11-Dec-14
US20140364408	Hydrazide Containing Nuclear Transport Modulators And Uses Thereof	KARYOPHARM THERAPEUTICS INC.	29-Jul-11	29-Jul-12	11-Dec-14
US20140364358	Method for Preventing and Treating Hyperpermeability	Apeptico Forschung UND Entwicklung GMBH	5-Mar-09	7-Mar-14	11-Dec-14
US20140363465	MYCOBACTERIAL VACCINE VECTORS AND METHODS OF USING THE SAME	Beth Israel Deaconess Medical Center, Inc.	4-Apr-11	4-Apr-12	11-Dec-14
US20140363422	METHOD OF PROVIDING MONOCLONAL AUTO-ANTIBODIES WITH DESIRED SPECIFICITY	Not Available	28-Dec-11	2-Jan-13	11-Dec-14
US20140357673	Deubiquitinase Inhibitors and Methods for Use of the Same	Not Available	24-Sep-10	31-Jul-14	4-Dec-14
US20140356390	MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF SYNONYMOUS CODONS	The Government of the United States of America as represented by the Secretary of the Department of	8-Oct-04	20-Aug-14	4-Dec-14
US20140349375	METHYLSULFONYLMETHANE (MSM) TO MODULATE MICROBIAL ACTIVITY	Biogentic Innovations, LLC	30-Oct-09	12-Aug-14	27-Nov-14

US20140349295	METHOD FOR DETECTING TARGET NUCLEIC ACID	Not Available	31-Oct-11	25-Oct-12	27-Nov-14
US20140349276	SIGNAL PROPAGATION BIOMOLECULES, DEVICES AND METHODS	STC.UNM	21-May-13	21-May-14	27-Nov-14
US20140348906	IMMUNOSTIMULATORY COMPOSITIONS COMPRISING LIPOSOME-ENCAPSULATED OLIGONUCLEOTIDES AND EPITOPES	Not Available	17-Jul-09	13-Aug-14	27-Nov-14
US20140348791	MODIFIED ADENOVIRAL VECTORS AND METHODS OF TREATMENT USING SAME	Beth Israel Deaconess Medical Center, Inc.	9-Sep-11	7-Sep-12	27-Nov-14
US20140348785	NEUTRALIZING GP41 ANTIBODIES AND THEIR USE	Not Available	7-Nov-11	7-Nov-12	27-Nov-14
US20140348781	CONJUGATES OF GM-CSF AND IL-9, COMPOSITIONS AND METHODS RELATED THERETO	CHILDREN'S HEALTHCARE OF ATLANTA, INC	22-May-13	20-May-14	27-Nov-14
US20140342941	METHOD FOR USING PERMUTED NUCLEIC ACID PROBES	Ventana Medical Systems, Inc.	1-Sep-06	5-Aug-14	20-Nov-14
US20140342407	NEUTRALIZING GP41 ANTIBODIES AND THEIR USE	The United States of America, as represented by the Secretary, Department of Health and Human Serv	7-Nov-11	4-Aug-14	20-Nov-14
US20140336245	VIRUS VECTORS FOR HIGHLY EFFICIENT TRANSGENE DELIVERY	Not Available	22-Nov-11	21-Nov-12	13-Nov-14
US20140335618	TAL EFFECTOR-MEDIATED DNA MODIFICATION	Iowa State University Research Foundation, Inc.	10-Dec-09	14-Apr-14	13-Nov-14
US20140335592	TAL EFFECTOR-MEDIATED DNA MODIFICATION	Iowa State University Research Foundation, Inc.	10-Dec-09	24-Feb-14	13-Nov-14
US20140335117	Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses	Not Available	7-Oct-11	5-Oct-12	13-Nov-14
US20140335111	VACCINES AND IMMUNOTHERAPEUTICS USING IL-28 AND COMPOSITIONS AND METHODS OF USING THE SAME	The Trustees of the University of Pennsylvania	4-Apr-08	28-Apr-14	13-Nov-14
US20140335104	Methods of Detecting Cells with a Disrupted Cell Membrane, Cells Infected with A Pathogen, Dying Cells or Dead Cells	Not Available	13-May-08	14-Apr-14	13-Nov-14
US20140329889	CYCLIC DI-NUCLEOTIDE INDUCTION OF TYPE I INTERFERON	Not Available	3-May-13	2-May-14	6-Nov-14
US20140329878	OLIGONUCLEOTIDE MODULATORS OF THE TOLL-LIKE RECEPTOR PATHWAY	Not Available	3-Mar-11	1-Mar-12	6-Nov-14
US20140329817	MYXOVIRUS THERAPEUTICS, COMPOUNDS, AND USES RELATED THERETO	CHILDREN'S HEATLHCARE OF ATLANTA, INC.	24-Oct-11	24-Oct-12	6-Nov-14
US20140328946	ANTIMICROBIAL SOLUTIONS CONTAINING DICHLORIDE MONOXIDE AND METHODS OF MAKING AND USING THE SAME	Not Available	13-Mar-07	21-Jul-14	6-Nov-14
US20140328874	SAMPLE QUANTIFICATION BY DISC CENTRIFUGATION	Not Available	19-Oct-11	19-Oct-12	6-Nov-14
US20140323556	SCALABLE MANUFACTURING PROCESS TO PRODUCE RECOMBINANT LENTIVIRAL VECTORS IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM	Not Available	15-Mar-13	17-Mar-14	30-Oct-14
US20140323392	METHODS AND COMPOSITIONS RELATED TO INHIBITION OF VIRAL ENTRY	UNIVERSITY OF UTAH RESEARCH FOUNDATION	28-Mar-11	28-Mar-12	30-Oct-14
US20140323390	COMPOUNDS AND COMPOSITIONS AS TLR2 AGONISTS	IRM LLC	23-Mar-10	9-Jul-14	30-Oct-14
US20140322355	HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS	3-V BIOSCIENCES, INC.	8-Mar-11	25-Jun-14	30-Oct-14
US20140317766	ANTIBODY PRODUCING NON-HUMAN MAMMALS	Not Available	27-Jun-08	29-Apr-14	23-Oct-14
US20140315982	DOUBLE-STRANDED NUCLEIC ACID MOLECULE FOR GENE EXPRESSION CONTROL	Osaka City University	2-Nov-11	1-Nov-12	23-Oct-14
US20140315215	THERMOSTABLE ASSAY REAGENTS	The Secretary of State for Health	14-Sep-11	14-Sep-12	23-Oct-14
US20140314858	IPNV-ISAV BIVALENT VACCINE USING A VIRUS-LIKE PARTICLE-BASED PLATFORM AND METHODS OF USING THE SAME	Advanced BioNutrition Corporation	9-Sep-11	7-Sep-12	23-Oct-14
US20140314839	CONTROLLED-RELEASE PEPTIDE COMPOSITIONS AND USES THEREOF	Not Available	2-Dec-11	30-Nov-12	23-Oct-14
US20140314809	MALARIA ANTIGEN SCREENING METHOD	Not Available	19-Apr-13	19-Apr-13	23-Oct-14

CC-BY-NC-SA Dr. David E. Martin

US20140314797	YEAST STRAIN FOR THE PRODUCTION OF PROTEINS WITH TERMINAL ALPHA-1,3-LINKED GALACTOSE	Not Available	30-May-08	2-Jul-14	23-Oct-14
US20140314755	ANTIBODY PRODUCING NON-HUMAN MAMMALS	Not Available	27-Jun-08	30-Apr-14	23-Oct-14
US20140314739	Vaccine adjuvant composition comprising inulin particles	Vaxine Pty Ltd.	18-Jun-11	19-Jun-12	23-Oct-14
US20140309189	HIGHLY ACTIVE NUCLEOSIDE DERIVATIVE FOR THE TREATMENT OF HCV	Achillion Pharmaceuticals, Inc.	12-Apr-13	14-Apr-14	16-Oct-14
US20140309164	DEUTERATED NUCLEOSIDE PRODRUGS USEFUL FOR TREATING HCV	Achillion Pharmaceuticals, Inc.	12-Apr-13	14-Apr-14	16-Oct-14
US20140308379	USE OF FLAXSEED AND FLAXSEED DERIVATIVES FOR TREATMENT OF NEUROLOGICAL DISORDERS AND VIRAL DISEASES	The Trustees of the University of Pennsylvania	20-Nov-12	19-Nov-13	16-Oct-14
US20140308313	COMPOSITIONS AND METHODS FOR IMMUNISATION USING CD1D LIGANDS	Not Available	15-Mar-06	26-Jun-14	16-Oct-14
US20140308211	MUTANT PROTEASE BIOSENSORS WITH ENHANCED DETECTION CHARACTERISTICS	Not Available	11-May-10	5-May-14	16-Oct-14
US20140303232	LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS	NOVARTIS AG	8-Mar-13	7-Mar-14	9-Oct-14
US20140303071	CYCLIC ANTIMICROBIAL PEPTIDES	Not Available	22-Dec-05	20-Jun-14	9-Oct-14
US20140302124	Cytotoxic T Lymphocyte Inducing Immunogens For Prevention Treatment and Diagnosis of INFLUENZA VIRUS INFECTION	Immunotape, Inc.	19-Oct-11	18-Oct-12	9-Oct-14
US20140302120	CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR	Not Available	7-Feb-07	19-Jun-14	9-Oct-14
US20140302091	METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES	Not Available	6-Apr-07	18-Nov-11	9-Oct-14
US20140302077	LIVE ATTENUATED INFLUENZA VIRUS	Westfaelische Wilhelms-Universitaet Munester	2-Sep-11	28-Aug-12	9-Oct-14
US20140298500	MUTANT PROTEASE BIOSENSORS WITH ENHANCED DETECTION CHARACTERISTICS	Not Available	11-May-10	5-May-14	2-Oct-14
US20140296179	NUTRITIONAL COMPOSITION COMPRISING IMMUNOGLOBULINS AND OLIGOSACCHARIDES	N.V. NUTRICIA	24-Aug-04	5-Mar-14	2-Oct-14
US20140295404	SAMPLE FIXATION AND STABILISATION	Not Available	1-Mar-13	28-Feb-14	2-Oct-14
US20140294828	ALPHABODIES SPECIFICALLY BINDING TO VIRAL PROTEINS AND METHODS FOR PRODUCING THE SAME	COMPLIX SA	6-Jan-11	6-Jan-11	2-Oct-14
US20140294765	LSR ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER	COMPUGEN LTD.	21-Jun-12	19-Jun-13	2-Oct-14
US20140294727	PEPTIDES FOR ASSISTING DELIVERY ACROSS THE BLOOD BRAIN BARRIER	Children's Medical Center Corporation	22-May-06	30-Apr-14	2-Oct-14
US20140294670	TRANSPORTABLE VACUUM ASSISTED DECONTAMINATION UNIT AND DECONTAMINATION PROCESS	STERIS Inc.	1-Apr-13	31-Mar-14	2-Oct-14
US20140287987	METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES	CITY OF HOPE	26-Jan-07	9-Jun-14	25-Sep-14
US20140286988	HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROM	3M Innovative Properties Company	3-Jun-11	1-Jun-12	25-Sep-14
US20140283945	LOADING VIALS	BioFire Diagnostics, LLC	10-Nov-11	9-Nov-12	25-Sep-14
US20140275237	BERAPROST ISOMER AS AN AGENT FOR THE TREATMENT OF VIRAL INFECTION	Gemmus Pharma Inc.	15-Mar-13	12-Mar-14	18-Sep-14
US20140275159	SUBSTITUTED 2-AZA-BICYCLO[2.2.2]OCTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C	BOEHRINGER INGELHEIM INTERNATIONAL GMBH	14-Mar-13	12-Mar-14	18-Sep-14
US20140275155	SUBSTITUTED BICYCLIC 1-CARBOXYLIC-ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C	BOEHRINGER INGELHEIM INTERNATIONAL GMBH	14-Mar-13	12-Mar-14	18-Sep-14
US20140275114	SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C	BOEHRINGER INGELHEIM INTERNATIONAL GMBH	14-Mar-13	12-Mar-14	18-Sep-14

CC-BY-NC-SA Dr. David E. Martin

US20140275037	SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENAVIRUSES	Siga Technologies, Inc.	6-Dec-04	19-Dec-13	18-Sep-14
US20140275025	SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C	BOEHRINGER INGELHEIM INTERNATIONAL GMBH	14-Mar-13	12-Mar-14	18-Sep-14
US20140274980	COMPOUND	RESPIVERT LTD.	15-Mar-13	14-Mar-14	18-Sep-14
US20140273228	METHOD FOR PROPAGATING ADENOVIRAL VECTORS ENCODING INHIBITORY GENE PRODUCTS	GenVec, Inc.	10-Nov-05	28-May-14	18-Sep-14
US20140273156	LUCIFERASE BIOSENSOR	PROMEGA CORPORATION	10-Oct-03	14-Feb-14	18-Sep-14
US20140271829	RECOMBINANT SELF-REPLICATING POLYCISTRONIC RNA MOLECULES	Not Available	11-Oct-11	11-Oct-12	18-Sep-14
US20140271700	COMPOSITIONS AND METHODS FOR TREATING CLOSTRIDIUM DIFFICILE-ASSOCIATED DISEASES	National Health Research Institutes	14-Mar-13	13-Mar-14	18-Sep-14
US20140271580	IMMUNOPROTECTIVE PRIMARY MESENCHYMAL STEM CELLS AND METHODS	THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND	14-Mar-13	14-Mar-13	18-Sep-14
US20140271550	Constructs and Methods for Delivering Molecules via Viral Vectors with Blunted Innate Immune Responses	The Trustees of the University of Pennsylvania	14-Mar-13	14-Mar-14	18-Sep-14
US20140270457	STAIN-FREE HISTOPATHOLOGY BY CHEMICAL IMAGING	The Board of Trustees of the University of Illinois	15-Mar-13	14-Mar-14	18-Sep-14
US20140255472	PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING RNA	Not Available	31-Aug-11	31-Aug-12	11-Sep-14
US20140255439	VIRUS-LIKE PARTICLES AND PROCESS FOR PREPARING SAME	FOLIA BIOTECH INC.	13-May-11	1-May-12	11-Sep-14
US20140255426	WNT PATHWAY INHIBITORS FOR TREATING VIRAL INFECTIONS	Children's Healthcare of Atlanta, Inc.	11-Mar-13	10-Mar-14	11-Sep-14
US20140255349	PEPTIDES WITH VIRAL INFECTION ENHANCING PROPERTIES AND THEIR USE	Centre National de la Recherche Scientique	30-Jun-11	28-Jun-12	11-Sep-14
US20140249296	USING SORTASES TO INSTALL CLICK CHEMISTRY HANDLES FOR PROTEIN LIGATION	Whitehead Institute for Biomedical Research	28-Jun-11	28-Jun-12	4-Sep-14
US20140249129	Substituted Bicyclic Dihydropyrimidinones And Their Use As Inhibitors Of Neutrophil Elastase Activity	Boehringer Ingelheim International GmbH	4-Mar-13	20-Feb-14	4-Sep-14
US20140248620	Methods and Compositions for Prostate Cancer Metastasis	Florida Agricultural and Mechanical University (FAMU)	25-Mar-11	23-Mar-12	4-Sep-14
US20140248357	Respiratory Disease Treatment	PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED	7-Aug-08	7-Apr-14	4-Sep-14
US20140248320	ADJUVANTED INFLUENZA B VIRUS VACCINES FOR PEDIATRIC PRIMING	Not Available	20-Oct-11	19-Oct-12	4-Sep-14
US20140248313	COMBINATION ADJUVANT FORMULATION	Dalhousie University	16-Oct-08	15-Feb-13	4-Sep-14
US20140248312	INFLUENZA VACCINES INCLUDING COMBINATIONS OF PARTICULATE ADJUVANTS AND IMMUNOPOTENTIATORS	NOVARTIS VACCINES AND DIAGNOSTICS SRL	4-Nov-05	28-Feb-14	4-Sep-14
US20140243505	BISPECIFIC ANTIBODY	WUHAN YZY BIOPHARMA CO., LTD.	21-Nov-12	13-Mar-14	28-Aug-14
US20140243341	BROAD-SPECTRUM ANTIVIRALS AGAINST 3C OR 3C-LIKE PROTEASES OF PICORNAVIRUS-LIKE SUPERCLUSTER: PICORNAVIRUSES, CALICIVIRUSES AND CORONAVIRUSES	Not Available	27-Sep-11	27-Sep-12	28-Aug-14
US20140242692	MAMMALIAN GENES INVOLVED IN TOXICITY AND INFECTION	Not Available	10-Dec-10	11-Dec-11	28-Aug-14
US20140242152	IMMUNOGENIC COMPOSITIONS AND USES THEREOF	Not Available	6-Jul-11	6-Jul-12	28-Aug-14
US20140242108	Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists	CAYLA	22-Feb-13	22-Feb-13	28-Aug-14
US20140235844	Short Interfering RNA (siRNA) Analogues	Santaris Pharma A/S	21-Mar-03	11-Feb-14	21-Aug-14

CC-BY-NC-SA Dr. David E. Martin

US20140235653	HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Karyopharm Therapeutics, Inc.	29-Jul-11	19-Mar-14	21-Aug-14
US20140235460	QUANTITATIVE NUCLEASE PROTECTION ASSAY (QNPA) AND SEQUENCING (QNPS) IMPROVEMENTS	HTG Molecular Diagnostics, Inc.	4-May-11	1-May-14	21-Aug-14
US20140234845	ORGANISM IDENTIFICATION PANEL	Not Available	2-Apr-07	1-Apr-08	21-Aug-14
US20140234374	COMPOSITIONS AND METHODS FOR ACTIVATING INNATE AND ALLERGIC IMMUNITY	ID BIOMEDICAL CORPORATION OF QUEBEC	26-Apr-12	28-Apr-14	21-Aug-14
US20140234372	NOVEL VLPS DERIVED FROM CELLS THAT DO NOT EXPRESS A VIRAL MATRIX OR CORE PROTEIN	Not Available	25-May-07	14-Apr-14	21-Aug-14
US20140234274	Directed Evolution and In Vitro Panning of Virus Vectors	University of North Carolina at Chapel Hill	30-Apr-08	17-Jan-14	21-Aug-14
US20140228347	COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS	IRM LLC	1-Sep-11	22-Apr-14	14-Aug-14
US20140227704	METHODS FOR RAPID IDENTIFICATION AND QUANTITATION OF NUCLEIC ACID VARIANTS	IBIS BIOSCIENCES, INC.	11-Nov-09	7-Oct-13	14-Aug-14
US20140227346	IMMUNOGENIC COMBINATION COMPOSITIONS AND USES THEREOF	Not Available	6-Jul-11	6-Jul-12	14-Aug-14
US20140227317	HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM	3M INNOVATIVE PROPERTIES COMPANY	3-Jun-11	1-Jun-12	14-Aug-14
US20140227262	PD-1 Antagonists and Methods for Treating Infectious Disease	AMPLIMMUNE, INC.	25-Aug-08	1-Nov-13	14-Aug-14
US20140221631	BORON-CONTAINING SMALL MOLECULES	Anacor Pharmaceuticals, Inc.	16-Feb-06	7-Mar-14	7-Aug-14
US20140221394	HYDROBENZAMIDE DERIVATIVES AS INHIBITORS OF HSP90	Astex Therapeutic Ltd.	12-Oct-06	7-Jan-14	7-Aug-14
US20140221335	SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY	BOEHRINGER INGELHEIM INTERNATIONAL GMBH	6-Feb-13	28-Jan-14	7-Aug-14
US20140220690	MAMMALIAN GENES INVOLVED IN INFECTION	VANDERBILT UNIVERSITY	11-Nov-09	28-Oct-10	7-Aug-14
US20140220573	EMBODIMENTS OF A PROBE AND METHOD FOR TARGETING NUCLEIC ACIDS	University Of Idaho	19-Jul-11	19-Jul-12	7-Aug-14
US20140220086	Antimicrobial Compositions and Methods of Use Thereof	Not Available	21-Sep-11	21-Sep-12	7-Aug-14
US20140220083	CATIONIC OIL-IN-WATER EMULSIONS	Not Available	6-Jul-11	6-Jul-12	7-Aug-14
US20140220063	VACCINE COMPOSITION	Not Available	5-Feb-13	29-Jan-14	7-Aug-14
US20140212498	OIL-IN-WATER EMULSIONS THAT CONTAIN NUCLEIC ACIDS	Not Available	6-Jul-11	6-Jul-12	31-Jul-14
US20140212429	BINDING MEMBERS-513	MEDIMMUNE LIMITED	7-Nov-08	16-Apr-14	31-Jul-14
US20140206682	COMPOUNDS AND COMPOSITIONS AS PDGFR KINASE INHIBITORS	IRM LLC	1-Sep-11	31-Aug-12	24-Jul-14
US20140206556	Systems and Methods for Identifying Replikin Scaffolds and Uses of Said Replikin Scaffolds	Not Available	6-Jun-03	19-Jun-13	24-Jul-14
US20140205629	TC-83-DERIVED ALPHAVIRUS VECTORS, PARTICLES AND METHODS	AlphaVax, Inc.	18-May-04	28-Mar-14	24-Jul-14
US20140203192	SYSTEMS AND METHODS FOR DISTINGUISHING OPTICAL SIGNALS OF DIFFERENT MODULATION FREQUENCIES IN AN OPTICAL SIGNAL DETECTOR	Gen-Probe Incorporated	24-Feb-11	21-Mar-14	24-Jul-14
US20140203189	SYSTEMS AND METHODS FOR DISTINGUISHING OPTICAL SIGNALS OF DIFFERENT MODULATION FREQUENCIES IN AN OPTICAL SIGNAL DETECTOR	GEN-PROBE INCORPORATED	24-Feb-11	21-Mar-14	24-Jul-14
US20140200149	Methods and compositions for identification of source of microbial contamination in a sample	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	6-Mar-12	6-Mar-13	17-Jul-14
US20140199379	COMPOSITIONS HAVING MEANS FOR TARGETING AT LEAST ONE ANTIGEN TO DENDRITIC CELLS	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS	22-Jul-11	23-Jul-12	17-Jul-14

CC-BY-NC-SA Dr. David E. Martin

US20140199347	ADJUVANT COMPOSITIONS WITH 4-1BBL	UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.	10-Feb-11	7-Feb-12	17-Jul-14
US20140199281	SYNERGISTIC BACTERIAL COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOF	Seres Health, Inc.	23-Nov-12	20-Mar-14	17-Jul-14
US20140194628	SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODS	3M INNOVATIVE PROPERTIES COMPANY	25-Nov-03	11-Mar-14	10-Jul-14
US20140194500	Methods For Treating of SARS	Not Available	8-Jan-13	8-Jan-13	10-Jul-14
US20140194345	NOVEL DEPSIPEPTIDE AND USES THEREOF	Not Available	3-Dec-12	3-Dec-13	10-Jul-14
US20140193804	Biological Specimen Collection and Transport System and Method of Use	Longhorn Vaccines and Diagnostics, LLC	1-Oct-07	7-Jan-14	10-Jul-14
US20140193439	VACCINES AND IMMUNOTHERAPEUTICS COMPRISING IL-15 RECEPTOR ALPHA AND/OR NUCLEIC ACID MOLECULES ENCODING THE SAME, AND METHODS FOR USING THE SAME	Not Available	14-Sep-09	6-Jan-14	10-Jul-14
US20140186396	METHODS FOR STABILIZING INFLUENZA ANTIGEN ENVELOPED VIRUS-BASED VIRUS-LIKE PARTICLE SOLUTIONS	TAKEDA VACCINES, INC.	28-Dec-09	6-Mar-14	3-Jul-14
US20140186292	DEFECTIVE RIBOSOMAL PRODUCTS IN BLEBS (DRIBBLES) AND METHODS OF USE TO STIMULATE AN IMMUNE RESPONSE	Providence Health & Services - Oregon	29-Jul-05	10-Feb-14	3-Jul-14
US20140179761	TARGETING LIPIDS	Tekmira Pharmaceuticals Corporation	4-Dec-08	22-Oct-13	26-Jun-14
US20140179714	NOVEL COMPOUNDS	Chiesi Farmaceutici S.p.A.	14-Sep-11	11-Feb-14	26-Jun-14
US20140178977	SYSTEMS AND METHODS FOR DETECTING MULTIPLE OPTICAL SIGNALS	Gen-Probe Incorporated	10-Mar-05	3-Mar-14	26-Jun-14
US20140178429	Vaccines Including Antigen From Four Strains of Influenza Virus	NOVARTIS AG	6-Dec-06	24-Sep-13	26-Jun-14
US20140178428	QUALITY CONTROL METHODS FOR OIL-IN-WATER EMULSIONS CONTAINING SQUALENE	Novartis AG	8-Nov-06	27-Aug-13	26-Jun-14
US20140178422	PRIMARY MESENCHYMAL STEM CELLS AS A VACCINE PLATFORM	The Administrators of the Tulane Educational Fund	21-Dec-12	15-Nov-13	26-Jun-14
US20140171447	CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY	Parion Sciences, Inc.	17-Dec-12	13-Dec-13	19-Jun-14
US20140171414	NOVEL COMPOUNDS	CHIESI FARMACEUTICI S.p.A.	18-Dec-12	17-Dec-13	19-Jun-14
US20140170709	VECTOR FOR GENE THERAPY	TAKARA BIO INC.	20-Apr-07	31-Jan-14	19-Jun-14
US20140170244	3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS	Parion Sciences, Inc.	17-Dec-12	13-Dec-13	19-Jun-14
US20140170183	D-Amino Acid Derivative-Modified Peptidoglycan and Methods of Use Thereof	The Regents of the University of California	30-Nov-12	27-Nov-13	19-Jun-14
US20140170174	POLYCHLORINATED BIPHENYLS AND SQUALENE-CONTAINING ADJUVANTS	Novartis AG	28-Dec-07	10-Dec-13	19-Jun-14
US20140170156	HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)	GENMAB A/S	16-Dec-02	7-Nov-13	19-Jun-14
US20140170141	POLYPEPTIDES AND USES THEREOF FOR TREATMENT OF AUTOIMMUNE DISORDERS AND INFECTION	COMPUGEN LTD.	30-Jun-11	1-Jul-12	19-Jun-14
US20140163213	CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity	COLEY PHARMACEUTICAL GMBH	27-Sep-06	4-Oct-13	12-Jun-14
US20140163035	HETEROCYCLIC AMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS	ACTELION PHARMACEUTICALS LTD.	22-Jul-11	20-Jul-12	12-Jun-14
US20140162941	PROCESS FOR PREPARING BIOLOGICAL SAMPLES	BAYLOR COLLEGE OF MEDICINE	27-Jul-11	26-Jul-12	12-Jun-14
US20140162888	CIRCULATING BIOMARKERS FOR DISEASE	Not Available	6-Apr-10	6-Apr-11	12-Jun-14
US20140162357	METHODS FOR GENERATION OF ANTIBODIES	NATIONAL JEWISH HEALTH	13-Mar-07	4-Sep-13	12-Jun-14

CC-BY-NC-SA Dr. David E. Martin

US20140162285	Methods of Modulating Vesicular Trafficking	The General Hospital Corporation	21-May-09	2-Dec-13	12-Jun-14
US20140161906	USE OF ANGIOGENESIS ANTAGONISTS IN CONDITIONS OF ABNORMAL VENOUS PROLIFERATION	UNIVERSITY OF UTAH RESEARCH FOUNDATION	8-Nov-07	12-Jun-13	12-Jun-14
US20140161724	Compositions and Imaging Methods Comprising Detectably Labeled Phosphatidylethanolamine-Binding Peptides	Board of Regents, The University of Texas System	15-Jul-02	16-Dec-13	12-Jun-14
US20140155370	NUCLEAR TRANSPORT MODULATORS AND USES THEREOF	Not Available	5-Mar-10	28-Jun-13	5-Jun-14
US20140154288	PAPAYA MOSAIC VIRUS COMPOSITIONS AND USES THEREOF FOR STIMULATION OF THE INNATE IMMUNE RESPONSE	FOLIA BIOTECH INC.	13-May-11	1-May-12	5-Jun-14
US20140154282	CONJUGATES UTILIZING PLATFORM TECHNOLOGY FOR STIMULATING IMMUNE RESPONSE	Not Available	26-Jan-11	26-Jan-12	5-Jun-14
US20140154254	HETERODIMERIC IMMUNOGLOBULINS	AMGEN INC.	21-Nov-12	21-Nov-13	5-Jun-14
US20140148350	CIRCULATING BIOMARKERS FOR DISEASE	Not Available	18-Aug-10	18-Aug-11	29-May-14
US20140142118	CHEMICALLY AND METABOLICALLY STABLE DIPEPTIDE POSSESSING POTENT SODIUM CHANNEL BLOCKER ACTIVITY	PARION SCIENCES, INC.	27-Jun-11	27-Jun-12	22-May-14
US20140142064	BORON-CONTAINING SMALL MOLECULES	ANACOR PHARMACEUTICALS, INC.	16-Feb-05	27-Jan-14	22-May-14
US20140141986	CIRCULATING BIOMARKERS	Not Available	22-Feb-11	17-Feb-12	22-May-14
US20140141502	Methods For Concurrent Identification And Quantification Of An Unknown Bioagent	IBIS BIOSCIENCES, INC.	18-Feb-04	27-Jan-14	22-May-14
US20140141452	Method of Determining, Identifying or Isolating Cell-Penetrating Peptides	Phylogica Limited	23-May-11	23-May-12	22-May-14
US20140141070	LIPOSOMES HAVING USEFUL N:P RATIO FOR DELIVERY OF RNA MOLECULES	Not Available	6-Jul-11	6-Jul-12	22-May-14
US20140141033	CONJUGATED TLR7 AND/OR TLR8 AND TLR2 AGONISTS	CAYLA	19-Nov-12	15-Mar-13	22-May-14
US20140135230	Lipoparticles Comprising Proteins, Methods Of Making, And Using The Same	Integral Molecular, Inc.	30-Jul-03	1-Nov-13	15-May-14
US20140134699	NOVEL STABILISATION METHOD FOR VIRUSES OR BACTERIA	Leukocare AG	28-Jun-11	28-Jun-12	15-May-14
US20140134606	EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASES	MOREHOUSE SCHOOL OF MEDICINE	6-Oct-08	21-Jan-14	15-May-14
US20140134206	INFLAMMATION AND IMMUNITY TREATMENTS	OCEAN SPRAY CRANBERRIES, INC.	1-Apr-11	30-Mar-12	15-May-14
US20140134150	TECHNOLOGY FOR PREPARATION OF MACROMOLECULAR MICROSPHERES	Ansun Biopharma, Inc.	24-Jan-06	6-Jan-14	15-May-14
US20140128324	METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES	CITY OF HOPE	26-Jan-07	14-Jan-14	8-May-14
US20140127321	ANTIVIRAL RESIN MEMBER	NBC MESHTEC, INC.	6-Jul-11	6-Jul-12	8-May-14
US20140127310	TREATMENT OF DISEASE WITH POLY-N-ACETYLGLUCOSAMINE NANOFIBERS	Marine Polymer Technologies, Inc.	15-Apr-11	16-Apr-12	8-May-14
US20140127216	NOVEL EXPRESSION CASSETTE FOR EFFICIENT SURFACE DISPLAY OF ANTIGENIC PROTEINS	Temasek Life Sciences Laboratory Limited	8-Feb-11	8-Feb-12	8-May-14
US20140120139	METHODS FOR INDUCING AN IMMUNE RESPONSE VIA BUCCAL AND/OR SUBLINGUAL ADMINISTRATION OF A VACCINE	Board of Regents, The University of Texas System	26-Jul-10	25-Jan-13	1-May-14
US20140116887	ELECTROCHEMISTRY AND ELECTROGENERATED CHEMILUMINESCENCE WITH A SINGLE FARADAIC ELECTRODE	Board of Regents of the University of Texas System	3-Jun-05	28-Oct-13	1-May-14
US20140113855	Modified Release Formulations for Oprozomib	Not Available	24-Oct-12	24-Oct-13	24-Apr-14
US20140107133	3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6-PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL)CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE	Parion Sciences, Inc.	27-Jun-11	18-Dec-13	17-Apr-14

US20140106335	OLIGONUCLEOTIDE PROBE FOR THE DETECTION OF ADENOVIRUS	Qiagen Hamburg GMBH	28-Dec-10	28-Dec-10	17-Apr-14
US20140105928	Antiviral and antibacterial activity from medicinal mushrooms	Not Available	6-Jan-04	20-Dec-13	17-Apr-14
US20140105912	VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER	THE TRUSTEES OF DARTMOUTH COLLEGE	7-Sep-12	9-Sep-13	17-Apr-14
US20140099696	Technology for the Preparation of Microparticles	Ansun Biopharma, Inc.	24-Jul-07	30-Apr-13	10-Apr-14
US20140099323	METHODS FOR TREATMENT OF INFLAMMATORY DISEASES	Not Available	8-Apr-09	30-Oct-13	10-Apr-14
US20140094404	METHODS AND REAGENTS FOR EFFICIENT AND TARGETED DELIVERY OF THERAPEUTIC MOLECULES TO CXCR4 CELLS	Not Available	13-Jan-11	13-Jan-12	3-Apr-14
US20140093532	Immunogenic Compositions In Particulate Form And Methods For Producing The Same	MUCOSIS B.V.	22-Mar-11	22-Mar-12	3-Apr-14
US20140087954	QUANTITATIVE NUCLEASE PROTECTION ASSAY (QNPA) AND SEQUENCING (QNPS) IMPROVEMENTS	HTG Molecular Diagnostics, Inc.	4-May-11	26-Apr-12	27-Mar-14
US20140087363	METHOD FOR GENERATING, STORING, TRANSPORTING, ELUTING AND DETECTING CLINICAL RELEVANT INFORMATION IN PLASMA USING FILTER PAPER	HVIDOVRE HOSPITAL	9-Dec-10	9-Dec-11	27-Mar-14
US20140086928	Antigenic GM-CSF Peptides and Antibodies to GM-CSF	MORPHOTEK, INC.	8-Feb-06	26-Nov-13	27-Mar-14
US20140082769	MOLECULES AND METHODS FOR INHIBITION AND DETECTION OF PROTEINS	Not Available	11-Mar-11	12-Mar-12	20-Mar-14
US20140080828	IMIDAZOLYL AMIDE COMPOUNDS AND USES RELATED THERETO	CHILDREN'S HEATLHCARE OF ATLANTA, INC.	31-Mar-11	28-Mar-12	20-Mar-14
US20140080171	OPTICAL CYTOMETRY	The Regents of the University of California	6-May-09	25-Nov-13	20-Mar-14
US20140080121	PRIMATE T-LYMPHOTROPIC VIRUSES	Johns Hopkins University	21-Feb-05	20-Sep-13	20-Mar-14
US20140079667	TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASE	Infinity Pharmaceuticals, Inc.	5-May-10	23-Aug-13	20-Mar-14
US20140073683	MODIFIED SMALL INTERFERING RNA MOLECULES AND METHODS OF USE	Not Available	26-Jul-02	12-Mar-13	13-Mar-14
US20140073651	BENZAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS	Actelion Pharmaceuticals Ltd.	22-Feb-11	21-Feb-12	13-Mar-14
US20140072956	COMPOSITION, DEVICE AND ASSOCIATED METHOD	General Electric Company	15-Dec-05	28-Feb-07	13-Mar-14
US20140072575	RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM	MedImmune Limited	1-Jun-07	13-Sep-13	13-Mar-14
US20140066592	METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES	City of Hope	26-Jan-07	11-Oct-13	6-Mar-14
US20140057926	SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY	BOEHRINGER INGELHEIM INTERNATIONAL GMBH	23-Aug-12	20-Aug-13	27-Feb-14
US20140057920	SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY	BOEHRINGER INGELHEIM INTERNATIONAL GMBH	23-Aug-12	20-Aug-13	27-Feb-14
US20140057916	SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY	BOEHRINGER INGELHEIM INTERNATIONAL GMBH	23-Aug-12	20-Aug-13	27-Feb-14
US20140057315	ANTIGEN PRESENTING CELL ASSAY	University of Pittsburgh - Of the Commonwealth System of Higher Education	8-Apr-10	11-Oct-13	27-Feb-14
US20140056929	IMMUNOMODULATION BY CONTROLLING INTERFERON-GAMMA LEVELS WITH THE LONG NON-CODING RNA NeST	The Board of Trustees of the Leland Stanford Junior University	23-Aug-12	23-Aug-13	27-Feb-14
US20140051148	Cells and Methodology to Generate Non-Segmented Negative-Strand RNA Viruses	Centre National De La Recherche Scientifique	22-Dec-06	15-Oct-13	20-Feb-14
US20140050778	NUCLEIC ACID BINDING COMPOUNDS, METHODS OF MAKING, AND USE THEREOF	UNIVERSITY OF ROCHESTER	28-Dec-10	28-Dec-11	20-Feb-14
US20140050763	MODIFIED VIRAL PARTICLES WITH IMMUNOGENIC PROPERTIES AND REDUCED LIPID CONTENT USEFUL FOR TREATING AND PREVENTING INFECTIOUS DISEASES	ELI LILLY & COMPANY	29-Jun-00	30-Oct-13	20-Feb-14

CC-BY-NC-SA Dr. David E. Martin

US20140050753	POLYIONIC PAPILLOMA VIRUS-LIKE PARTICLE (VLP) VACCINES	THE JOHNS HOPKINS UNIVERSITY	8-Sep-10	8-Sep-11	20-Feb-14
US20140050698	RECOMBINANT SUPER-COMPOUND INTERFERON AND USES THEREOF	Superlab Far East Limited	28-Feb-01	5-Sep-13	20-Feb-14
US20140045919	Folate Conjugates	Alnylam Pharmaceuticals, Inc.	4-Dec-07	8-Jul-13	13-Feb-14
US20140045837	9-Substituted 8-Oxoadenine Compound	AstraZeneca Aktiebolag	26-Mar-04	21-Oct-13	13-Feb-14
US20140045774	METHODS FOR TREATING VIRAL DISORDERS	TRUSTEES OF BOSTON UNIVERSITY	24-Sep-09	11-Jun-13	13-Feb-14
US20140045743	COMPOSITIONS AND METHODS FOR CORONAVIRUS INHIBITION	Autoimmune Technologies, LLC	4-Nov-03	8-Aug-13	13-Feb-14
US20140044641	POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR TREATMENT OF IMMUNE RELATED DISORDERS AND CANCER	COMPUGEN LTD.	15-Apr-11	16-Apr-12	13-Feb-14
US20140038978	HETEROCYCLIC COMPOUNDS AS CCR2B ANTAGONISTS	AstraZeneca AB	24-Dec-04	13-Sep-13	6-Feb-14
US20140038174	Compositions and Methods for Detecting and Identifying Nucleic Acid Sequences in Biological Samples	LONGHORN VACCINES AND DIAGNOSTICS, LLC	26-Apr-11	8-Oct-13	6-Feb-14
US20140038170	APPARATUS, SYSTEMS, AND METHODS FOR PERFORMING THERMAL MELT ANALYSES AND AMPLIFICATIONS	Not Available	31-Jul-12	31-Jul-13	6-Feb-14
US20140037700	Composition and Method for Enhancing an Immune Response	MICO BIO, INC.	20-Apr-11	19-Apr-12	6-Feb-14
US20140031418	Regimens and Compositions for AAV-Mediated Passive Immunization of Airborne Pathogens	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	20-Apr-11	20-Apr-12	30-Jan-14
US20140031371	POLY AROMATIC SODIUM CHANNEL BLOCKERS	PARION SCIENCES, Inc.	26-Feb-08	1-Oct-13	30-Jan-14
US20140031333	COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS	IRM LLC	1-Sep-11	19-Sep-13	30-Jan-14
US20140031276	COMPOUNDS AND METHODS FOR PREVENTING OR TREATING A VIRAL INFECTION	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)	2-Nov-07	19-Jun-13	30-Jan-14
US20140030740	Rapid Bioluminescence Detection System	The Secretary of State for Health	7-Jan-09	2-Aug-13	30-Jan-14
US20140030725	MUTANT PROTEASE BIOSENSORS WITH ENHANCED DETECTION CHARACTERISTICS	PROMEGA CORPORATION	11-May-10	12-Nov-12	30-Jan-14
US20140030703	Compositions and Methods for Detecting and Identifying Nucleic Acid Sequences in Biological Samples	LONGHORN VACCINES AND DIAGNOSTICS, LLC	12-Sep-06	8-Oct-13	30-Jan-14
US20140030364	ANTIVIRAL COMPOSITIONS COMPRISING ETHANOL EXTRACT OF TETRACERA SCANDENS AND USE THEREOF	Not Available	24-Jul-12	28-Mar-13	30-Jan-14
US20140030295	Use of Sirt1 Activators or Inhibitors to Modulate an Immune Response	THE J. DAVID GLADSTONE INSTITUTES	7-Feb-08	17-Dec-12	30-Jan-14
US20140024804	Crystalline Tripeptide Epoxy Ketone Protease Inhibitors	Onyx Therapeutics, Inc.	20-Mar-09	24-Sep-13	23-Jan-14
US20140024583	ORGANIC COMPOUNDS	Not Available	5-Jun-06	15-Jul-13	23-Jan-14
US20140023645	ENGINEERED ANTIBODY CONSTANT DOMAIN MOLECULES	The United States of America, as represented by the Secretary, Dept. of Health & Human Services	31-Jan-08	1-Oct-13	23-Jan-14
US20140023592	SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS	Fraunhofer-Gesellschaft zur Forderung der Angewandten Forschung e.V.	25-Jul-07	30-Sep-13	23-Jan-14
US20140017727	Cna-B DOMAIN ANTIGENS IN VACCINES AGAINST GRAM POSITIVE BACTERIA	Not Available	12-Jan-09	7-Jun-13	16-Jan-14
US20140017285	ADJUVANT NANOEMULSIONS WITH PHOSPHOLIPIDS	NOVARTIS AG	24-Mar-11	23-Mar-12	16-Jan-14
US20140017279	ADJUVANT NANOEMULSIONS WITH CRYSTALLISATION INHIBITORS	Novartis AG	27-Jan-11	27-Jan-12	16-Jan-14
US20140011982	Antibodies Against Influenza Virus and Methods of Use Thereof	BURNHAM INSTITUTE FOR MEDICAL RESEARCH	6-Dec-07	12-Aug-13	9-Jan-14
US20140011812	Methods of Treating Inflammation	Massachusetts Institute of Technology	8-Oct-10	7-Oct-11	9-Jan-14
US20140011777	SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES	3M INNOVATIVE PROPERTIES COMPANY	18-Jun-04	9-Sep-13	9-Jan-14

US20140011187	Biological Specimen Collection and Transport System and Method of Use	Longhorn Vaccines and Diagnostics, LLC	1-Oct-07	19-Mar-13	9-Jan-14
US20140010837	Methods and Compositions for Preventing a Condition	Cyvax, Inc.	9-Aug-10	11-Sep-13	9-Jan-14
US20140005241	Suppression of Sars Replication by Sars Helicase Inhibitors	The Curators of the University of Missouri	15-Jun-12	17-Jun-13	2-Jan-14
US20140005102	Oligoadenylate Synthetase (OAS)	Kineta Two LLC	23-Nov-05	1-Jul-13	2-Jan-14
US20140005101	Oligoadenylate Synthetase (OAS)	Kineta Two LLC	23-Nov-05	14-Jun-13	2-Jan-14
US20140005097	BIOACTIVE PEPTIDES AND METHODS OF USING SAME	Compugen Ltd.	12-Jul-07	21-Jun-13	2-Jan-14
US20140004193	COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME	Not Available	24-Apr-12	24-Apr-13	2-Jan-14
US20140004146	METHOD FOR PRODUCING VIRUS-LIKE PARTICLE BY USING DROSOPHILA CELL AND APPLICATIONS THEREOF	INSTITUT PASTEUR OF SHANGHAI, CHINESE ACADEMY OF SCIENCES	17-Mar-11	19-Mar-12	2-Jan-14
US20140004143	ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	17-Dec-01	13-Sep-13	2-Jan-14
US20140004128	ANTI-IL-18 ANTIBODIES AND THEIR USES	Medimmune Limited	20-Dec-10	20-Dec-11	2-Jan-14
US20140004123	MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION OF B CELLS	Institute For Research in Biomedicine	26-Feb-03	25-Apr-13	2-Jan-14
US20130345414	TREATING CANCER WITH VIRAL NUCLEIC ACID	Not Available	20-Feb-07	26-Jul-13	26-Dec-13
US20130345284	siRNA Compositions and Methods for Treatment of HPV and Other Infections	Not Available	29-Jul-10	29-Jan-13	26-Dec-13
US20130345270	METHODS OF TREATING CANCER AND OTHER DISORDERS	Waake Forest University Health Sciences	12-Nov-10	7-Nov-11	26-Dec-13
US20130344613	USE OF A FLUORESCENT MATERIAL TO DETECT FAILURE OR DETERIORATED PERFORMANCE OF A FLUOROMETER	GEN-PROBE INCORPORATED	14-Jun-12	7-Jun-13	26-Dec-13
US20130344100	VIRUS LIKE PARTICLE PRODUCTION IN PLANTS	MEDICAGO INC.	22-Dec-10	22-Dec-11	26-Dec-13
US20130341206	AMPEROMETRIC GAS SENSOR	STERIS CORPORATION	25-Jun-12	26-Feb-13	26-Dec-13
US20130338224	DECONTAMINATING COMPOSITION HAVING SIMULTANEOUSLY BACTERICIDAL, FUNGICIDAL AND VIROCIDAL PROPERTIES, METHODS FOR OBTAINING AND USING SAID COMPOSITION	HIGHTECH BIO-ACTIVITIES HOLDING GMBH	29-Mar-04	7-Aug-13	19-Dec-13
US20130338174	PURINE DERIVATIVES	ABBOTT PHILLIP	17-Dec-10	14-Dec-11	19-Dec-13
US20130338130	METHYLSULFONYLMETHANE (MSM) FOR TREATMENT OF DRUG RESISTANT MICROORGANISMS	Biogenic Innovations, LLC	30-Oct-09	19-Aug-13	19-Dec-13
US20130336996	NOVEL COMPOSITIONS OF TLR7 AND/OR TLR8 AGONISTS CONJUGATED TO LIPIDS	CAYLA	15-Jun-12	15-Mar-13	19-Dec-13
US20130336929	METHODS AND CELLS FOR IDENTIFYING RIG-I PATHWAY REGULATORS	KINETA, INC.	25-Feb-11	23-Feb-12	19-Dec-13
US20130336923	Carbonic Anhydrase IX (G250) Antibodies and Methods of Use Thereof	DANA-FARBER CANCER INSTITUTE, INC.	2-Dec-05	8-May-13	19-Dec-13
US20130331313	METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY-INDUCED CONDITIONS	HEMAQUEST PHARMACEUTICALS INC	11-Mar-10	7-Jun-13	12-Dec-13
US20130330840	FLOW CYTOMETRY ANALYSIS OF MATERIALS ADSORBED TO METAL SALTS	NOVARTIS AG	14-Dec-10	14-Dec-11	12-Dec-13
US20130330335	BIOINFORMATIC PROCESSES FOR DETERMINATION OF PEPTIDE BINDING	IOGENETICS, LLC	23-Mar-10	21-Mar-11	12-Dec-13
US20130324559	DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER MUCOSAL DISEASES	PARION SCIENCES, INC.	29-May-12	29-May-13	5-Dec-13

CC-BY-NC-SA Dr. David E. Martin

US20130323835	Mammalian Genes Involved in Infection	Zirus, Inc.	15-Jul-09	15-Jul-10	5-Dec-13
US20130323819	EXPRESSION OF ANTIBODY OR A FRAGMENT THEREOF IN LACTOBACILLUS	ALVAREZ MIGUEL ANGEL	5-Aug-10	4-Aug-11	5-Dec-13
US20130317080	MODIFIED iRNA AGENTS	ALNYLAM PHARMACEUTICALS, INC.	15-Sep-10	14-Sep-11	28-Nov-13
US20130317031	Nuclear Transport Modulators And Uses Thereof	Karyopharm Therapeutics Inc.	9-May-12	9-May-13	28-Nov-13
US20130315952	ADMINISTRATION OF INTERFERON FOR PROPHYLAXIS AGAINST OR TREATMENT OF PATHOGENIC INFECTION	Defyrus, Inc.	9-Jun-09	13-Nov-12	28-Nov-13
US20130302351	ANTAGONISM OF THE VIP SIGNALING PATHWAY	EMORY UNIVERSITY	2-Feb-11	31-Jan-12	14-Nov-13
US20130302278	USE OF TLR AGONISTS AND/OR TYPE 1 INTERFERONS TO ALLEVIATE TOXICITY OF TNF-R AGONIST THERAPEUTIC REGIMENS	IMMURX INC	15-Jun-07	16-Apr-13	14-Nov-13
US20130295129	IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOF	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	5-Apr-12	15-Mar-13	7-Nov-13
US20130291134	HUMANIZED TRANSGENIC MOUSE MODEL	BRUMEANU TEPDPR D	24-Sep-10	22-Aug-12	31-Oct-13
US20130289043	(4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-CARBOXAMIDE DERIVATIVES	AstraZeneca AB	15-Dec-08	27-Jun-13	31-Oct-13
US20130288922	ARRAYED DETECTOR SYSTEM FOR MEASUREMENT OF INFLUENZA IMMUNE RESPONSE	UNIV ROCHESTER	2-May-08	11-Jul-13	31-Oct-13
US20130288917	Rapid High Resolution, High Throughput RNA Structure, RNA-Macromolecular Interaction, and RNA-Small Molecule Interaction Mapping	The Board of Trustees of the Leland Stanford Junior University	21-Oct-10	21-Oct-11	31-Oct-13
US20130287832	SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINES	Novartis AG	20-Aug-10	19-Aug-11	31-Oct-13
US20130287811	Method for Producing Viral Vaccines	BAXTER HEALTHCARE SA	28-Aug-07	26-Jun-13	31-Oct-13
US20130287772	BIOMARKERS FOR THERANOSTICS	Caris Life Sciences Luxembourg Holdings	1-Mar-10	1-Mar-11	31-Oct-13
US20130281324	BI-FUNCTINAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES	Nuevolution A/S	16-Apr-10	16-Apr-11	24-Oct-13
US20130280806	MAMMALIAN GENES INVOLVED IN INFECTION	HODGE THOMAS	17-May-10	17-May-11	24-Oct-13
US20130280298	Immunogenic Affinity-Conjugated Antigen Systems Based on Papaya Mosaic Virus and Uses Thereof	LECLERC DENIS	15-Nov-06	15-Mar-13	24-Oct-13
US20130274465	ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTS	IRM LLC	1-Sep-10	1-Sep-11	17-Oct-13
US20130274129	TAL-EFFECTOR ASSEMBLY PLATFORM, CUSTOMIZED SERVICES, KITS AND ASSAYS	ARNOLD MATTHIAS	4-Apr-12	4-Apr-13	17-Oct-13
US20130273540	METHOD FOR CHROMOGENIC DETECTION OF TWO OR MORE TARGET MOLECULES IN A SINGLE SAMPLE	BIENIARZ CHRISTOPHER A	22-Aug-08	7-Jun-13	17-Oct-13
US20130273277	POWDERED POUCH AND METHOD OF MAKING SAME	Monosol, LLC.	16-Apr-12	14-Mar-13	17-Oct-13
US20130273150	Dendritic Cell Marker and Uses Thereof	CAMINSCHI IRINA	30-Aug-07	21-Mar-13	17-Oct-13
US20130273120	METHODS AND COMPOSITIONS FOR INTRANASAL DELIVERY	HARUTA SHUNJI	15-Apr-10	14-Mar-13	17-Oct-13
US20130273113	IMMUNOGENIC APOPTOSIS INDUCING COMPOSITIONS AND METHODS OF USE THEREOF	The Regents of the University of Michigan	12-Apr-12	15-Mar-13	17-Oct-13
US20130273104	Adjuvanted Influenza Vaccines for Pediatric Use	GROTH NICOLA	22-Feb-08	21-Jun-13	17-Oct-13
US20130273080	SIALOADHESIN-RELATED COMPOSITIONS AND METHODS	DELPUTTE PETER	11-May-06	15-Mar-13	17-Oct-13
US20130267578	COMPOSITIONS AND METHODS FOR INHIBITING NADPH OXIDASE EXPRESSION	QUARK PHARMACEUTICALS, INC.	15-Jun-07	6-Jun-13	10-Oct-13
US20130267532	CYCLIC AMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE	HORI SEIJI	19-Nov-10	18-Nov-11	10-Oct-13

US20130267436	LUMINOPHORE-LABELED MOLECULES COUPLED WITH PARTICLES FOR MICROARRAY-BASED ASSAYS	CapitaBio Corporation	27-Oct-10	27-Oct-10	10-Oct-13
US20130267429	BIOLOGICAL SAMPLE TARGET CLASSIFICATION, DETECTION AND SELECTION METHODS, AND RELATED ARRAYS AND OLIGONUCLEOTIDE PROBES	GARDNER SHEA	21-Dec-09	2-May-13	10-Oct-13
US20130266645	DERIVATIVES OF STEROID BENZYLAMINES, HAVING AN ANTIPARASITIC ANTIBACTERIAL, ANTIMYCOTIC AND/OR ANTIVIRAL ACTION	Justus-Liebig-Universitat Giessen	6-Oct-10	6-Oct-11	10-Oct-13
US20130266612	VACCINE COMPOSITION	NITTO DENKO CORPORATION	4-Apr-12	3-Apr-13	10-Oct-13
US20130261196	Nucleic Acids For Multiplex Organism Detection and Methods Of Use And Making The Same	DIAMOND LISA	11-Jun-10	10-Jun-11	3-Oct-13
US20130261087	SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND UREAS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS ASSOCIATED WITH ARENA VIRUSES	SIGA TECHNOLOGIES INC.	6-Dec-04	6-Jul-11	3-Oct-13
US20130261049	ALPHABODIES SPECIFICALLY BINDING TO CLASS-I VIRAL FUSION PROTEINS AND METHODS FOR PRODUCING THE SAME	COMPLIX SA	6-Jan-11	2-Dec-11	3-Oct-13
US20130259887	REOVIRUS VACCINES AND METHODS OF USE THEREFOR	BOEHME KARL W	7-Apr-10	4-Apr-11	3-Oct-13
US20130259871	Human Monoclonal Antibody with Specificity for Dengue Virus Serotype 1 E Protein and Uses Thereof	DSO NATIONAL LABORATORIES	14-Dec-10	14-Dec-11	3-Oct-13
US20130259829	CLIP INHIBITORS AND METHODS OF MODULATING IMMUNE FUNCTION	Viral Genetics, Inc.	25-Jul-08	6-Jun-13	3-Oct-13
US20130253002	COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS	CORTEZ ALEX	3-Mar-08	22-Apr-13	26-Sep-13
US20130251746	Methods and Compositions for Poxvirus A35R Protein	East Carolina University	1-Dec-08	20-Dec-12	26-Sep-13
US20130251734	USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIALS	The Salk Institute for Biological Studies	9-Nov-07	8-Mar-13	26-Sep-13
US20130251590	Peracid/Peroxide Composition, Process for Accurately Making the Same, and Method for Use as an Evaporating Film Anti-Microbial Solution and as a Photosensitizer	BioMed Protect ,LLC	11-Jan-05	21-Sep-09	26-Sep-13
US20130244980	BORON-CONTAINING SMALL MOLECULES	ANACOR PHARMACEUTICALS, INC.	16-Feb-05	30-Apr-13	19-Sep-13
US20130244920	WATER SOLUBLE COMPOSITIONS INCORPORATING ENZYMES, AND METHOD OF MAKING SAME	LEE DAVID M	16-Mar-12	16-Mar-12	19-Sep-13
US20130243841	CONCENTRATION OF VACCINE ANTIGENS WITH LYOPHILIZATION	Novartis AG	1-Jun-10	1-Jun-11	19-Sep-13
US20130243756	Methods for Treating Diseases and HSV Using Antibodies to Aminophospholipids	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM	15-Jul-02	19-Feb-13	19-Sep-13
US20130243727	TRIAZOLES AS INHIBITORS OF FATTY ACID SYNTHASE	INFINITY PHARMACEUTICALS, INC.	5-May-10	29-Apr-13	19-Sep-13
US20130237507	Novel Amide Compounds	BURKAMP FRANK	3-Apr-09	17-Apr-13	12-Sep-13
US20130236884	COMPOSITIONS FOR USE IN IDENTIFICATION OF ORTHOPOXVIRUSES	IBIS BIOSCIENCES, INC.	5-Dec-03	7-May-13	12-Sep-13
US20130236493	METHODS TO PRODUCE BUNYAVIRUS REPLICON PARTICLES	STICHTING DIENST LANDBOUWKUNDIG ONDERZOEK	20-Sep-10	20-Sep-11	12-Sep-13
US20130236396	NANOPARTICLES PRODUCED FROM RECOMBINANT POLYMERS AND METHODS OF MAKING AND USING THE SAME	UNIVERSITY OF UTAH RESEARCH FOUNDATION	3-May-10	3-May-11	12-Sep-13
US20130231302	ANTIMICROBIAL SOLUTIONS	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM	10-Sep-10	9-Sep-11	5-Sep-13
US20130230919	ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS	Baxter Healthcare S.A.	29-Oct-04	16-Apr-13	5-Sep-13
US20130230856	CAPTURE OF TARGET DNA AND RNA BY PROBES COMPRISING INTERCALATOR MOLECULES	QUANTIBACT A/S	27-Oct-10	27-Oct-11	5-Sep-13

US20130230851	Nanoreporters And Methods Of Manufacturing And Use Thereof	NANOSTRING TECHNOLOGIES, INC.	23-Dec-05	11-Mar-13	5-Sep-13
US20130230578	LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS	3M INNOVATIVE PROPERTIES COMPANY	17-Aug-10	16-Aug-11	5-Sep-13
US20130230529	NOVEL PARAMYXOVIRUS AND USES THEREOF	The University of Hong Kong	20-Jan-12	22-Jan-13	5-Sep-13
US20130225655	Combinations of TGFBeta and COX-2 Inhibitors and Methods for Their Therapeutic Application	EVANS DAVID	4-May-10	4-May-11	29-Aug-13
US20130225651	siRNA Compositions and Methods for Potently Inhibiting Viral Infection	The University of Hong Kong	11-Dec-08	12-Dec-11	29-Aug-13
US20130225637	ISATIN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE THEREOF	HORNE DAVID A	24-Feb-12	25-Feb-13	29-Aug-13
US20130225555	Imidazoquinolines with Immuno-Modulating Properties	AstraZeneca AB	8-May-07	14-Mar-13	29-Aug-13
US20130224245	CONCENTRATION OF VACCINE ANTIGENS WITHOUT LYOPHILIZATION	Novartis AG	1-Jun-10	1-Jun-11	29-Aug-13
US20130224144	SEQUENTIAL ADMINISTRATION OF A REPLICATION DEFECTIVE ADENOVIRUS VECTOR IN VACCINATION PROTOCOLS	Etubics Corporation	2-Jul-07	18-Sep-12	29-Aug-13
US20130217584	MICROARRAY-BASED ASSAY INTEGRATED WITH PARTICLES FOR ANALYZING MOLECULAR INTERACTIONS	CapitalBio Corporation	6-Aug-10	6-Aug-10	22-Aug-13
US20130217071	METHODS AND COMPOSITIONS FOR PERFORMING NUCLEIC ACID AMPLIFICATION REACTIONS	MONTESCLAROS LUZ	30-Dec-11	21-Dec-12	22-Aug-13
US20130217012	C-CBL MUTATIONS AND USES THEREOF	The University of Chicago	4-Jun-10	3-Jun-11	22-Aug-13
US20130216612	TARGETED INTRACELLULAR DELIVERY OF ANTIVIRAL AGENTS	BBB HOLDING B V	23-Mar-07	2-May-13	22-Aug-13
US20130216581	Carbon Nanotube Compositions and Methods of Use Thereof	UNIV YALE	19-Mar-08	15-Mar-13	22-Aug-13
US20130216573	INFLUENZA VIRUS REASSORTMENT	NOVARTIS AG	21-May-10	20-May-11	22-Aug-13
US20130216566	Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using	ADAMS DANIEL	20-Jun-03	21-Jun-04	22-Aug-13
US20130210894	APPLICATION OF HIGHLY CONSERVED DOMAIN SEQUENCES FROM VIRAL GENOME AS TEMPLATE TO DESIGN THERAPEUTIC SLIRNAS	CHEN LI	20-Sep-10	19-Sep-11	15-Aug-13
US20130210820	Pharmaceutical Compounds	ASTEX THERAPEUTICS LIMITED	11-Apr-08	30-Jan-13	15-Aug-13
US20130210770	PHARMACEUTICAL FORMULATIONS	Anacor Pharmaceuticals, Inc.	16-Feb-05	12-Apr-13	15-Aug-13
US20130209550	Anti-Viral Azide Containing Compounds	LIFE TECHNOLOGIES CORPORATION	28-Jul-10	28-Jul-11	15-Aug-13
US20130209510	METHODS FOR PREPARING SQUALENE	Novartis AG	12-May-10	12-May-11	15-Aug-13
US20130209502	ALUMINA NANOPARTICLE BIOCONJUGATES AND METHODS OF STIMULATING AN IMMUNE RESPONSE USING SAID BIOCONJUGATES	HU HONG-MING	27-Aug-10	26-Aug-11	15-Aug-13
US20130209406	RECOMBINANT RNA VIRUSES AND USES THEREOF	TENOEVER BENJAMIN R	6-Jun-10	6-Jun-11	15-Aug-13
US20130209364	Anti-Viral Azide Containing Compounds	LIFE TECHNOLOGIES CORPORATION	28-Jul-10	28-Jul-11	15-Aug-13
US20130203836	2' AND 5' MODIFIED MONOMERS AND OLIGONUCLEOTIDES	ALNYLAM PHARMACEUTICALS, INC.	1-Apr-10	31-Mar-11	8-Aug-13
US20130203655	METHODS FOR PREVENTING OR TREATING VIRAL INFECTION	KIELIAN MARGARET	12-Feb-10	9-Feb-11	8-Aug-13
US20130203151	PRODUCTION OF ALPHAVIRUS REPLICON PARTICLES IN PACKAGING CELLS	BALSITIS SCOTT	26-Apr-10	26-Apr-11	8-Aug-13
US20130202684	PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN ENCODING RNA	Lichtstrasse	31-Aug-10	31-Aug-11	8-Aug-13
US20130202609	GAS57 MUTANT ANTIGENS AND GAS57 ANTIBODIES	GRANDI GUIDO	12-Sep-07	14-Mar-13	8-Aug-13

CC-BY-NC-SA Dr. David E. Martin

US20130202598	ACTIVATABLE TOXIN COMPLEXES COMPRISING A CLEAVABLE INHIBITORY PEPTIDE	RAMOT AT TEL-AVIV UNIVERSITY LTD.	20-Sep-10	22-Aug-11	8-Aug-13
US20130202593	INTRACELLULAR IMMUNITY	MEDICAL RESEARCH COUNCIL	23-Jul-10	23-Jan-13	8-Aug-13
US20130197296	Removing Cells from an Organism	DAPPRICH JOHANNES	13-Jan-12	14-Jan-13	1-Aug-13
US20130196903	Multimeric Inhibitors of Viral Fusion and Uses Thereof	JV BIO SRL	11-Aug-10	11-Aug-11	1-Aug-13
US20130196380	IN VITRO PROCESS FOR THE PREPARATION OF ANTIBODIES OF THE IGG TYPE	JANSEN GABRIELE	5-Feb-10	4-Feb-11	1-Aug-13
US20130195969	SMALL LIPOSOMES FOR DELIVERY OF IMMUNOGEN ENCODING RNA	NOVARTIS AG	31-Aug-10	31-Aug-11	1-Aug-13
US20130195968	VIRION-LIKE DELIVERY PARTICLES FOR SELF-REPLICATING RNA MOLECULES	Novartis AG	6-Jul-10	6-Jul-11	1-Aug-13
US20130195932	ARCHAEAL POLAR LIPID AGGREGATES FOR ADMINISTRATION TO ANIMALS	NATIONAL RESEARCH COUNCIL OF CANADA	15-Dec-06	23-Jan-13	1-Aug-13
US20130195930	Inulin and Inulin Acetate Formulations	SOUTH DAKOTA SATE UNIVERSITY	20-Jan-12	22-Jan-13	1-Aug-13
US20130195914	Expression Of Positive Sense Single Stranded RNA Virus And Uses Thereof	Viracine Therapeutics Corporation	12-Apr-10	8-Apr-11	1-Aug-13
US20130195893	USE OF A PNEUMOCOCCAL P4 PEPTIDE FOR ENHANCING OPSONOPHAGOCYTOSIS IN RESPONSE TO A PATHOGEN	The Government of the United States of America as represented by the Secretary of the department of	31-Jul-08	27-Mar-13	1-Aug-13
US20130195792	METHOD OF TREATING INFLAMMATION	CYTOSORBENTS CORPORATION	1-Apr-10	1-Apr-11	1-Aug-13
US20130190494	PURINE ANALOGS	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	31-May-06	8-Mar-13	25-Jul-13
US20130190381	INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID METABOLISM AS BROAD SPECTRUM ANTI-VIRALS	THE TRUSTEES OF PRINCETON UNIVERSITY	18-Feb-10	18-Feb-11	25-Jul-13
US20130190206	Direct Clone Analysis and Selection Technology	Dublin City University	13-Jul-10	13-Jul-11	25-Jul-13
US20130189680	POLYMER STABILIZATION OF CHROMOGEN SOLUTIONS	VENTANA MEDICAL SYSTEMS, INC.	23-Jan-12	18-Jan-13	25-Jul-13
US20130189351	LIPIDS SUITABLE FOR LIPOSOMAL DELIVERY OF PROTEIN CODING RNA	NOVARTIS AG	31-Aug-10	31-Aug-11	25-Jul-13
US20130189311	ARRANGING INTERACTION AND BACK PRESSURE CHAMBERS FOR MICROFLUIDIZATION	Novartis AG	3-Dec-09	3-Dec-10	25-Jul-13
US20130189247	Multimeric Proteins Comprising Immunoglobulin Constant Domains	RESEARCH CORPORATION TECHNOLOGIES, INC.	12-Feb-10	11-Feb-11	25-Jul-13
US20130184170	OLIGONUCLEOTIDE AMPLIFICATION PRIMERS FOR TARGETING ONCOGENIC HPV	GENERA BIOSYSTEMS LIMITED	5-Apr-07	4-Jun-12	18-Jul-13
US20130183670	METHOD FOR PRODUCING NUCLEIC ACID PROBES	Ventana Medical Systems, Inc.	1-Sep-06	11-Mar-13	18-Jul-13
US20130183355	DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE POLYMER PARTICLES	NOVARTIS AG	6-Jul-10	7-Jun-11	18-Jul-13
US20130183341	INFLUENZA VIRUS-LIKE PARTICLES (VLPS) COMPRISING HEMAGGLUTININ PRODUCED WITHIN A PLANT	MEDICAGO INC.	13-Jul-07	4-Jan-13	18-Jul-13
US20130183321	GITR BINDING MOLECULES AND USES THEREFOR	GITR, INC.	25-Mar-05	1-Mar-13	18-Jul-13
US20130178512	CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES	ALNYLAM PHARMACEUTICALS, INC	4-Dec-07	4-Dec-12	11-Jul-13
US20130178482	3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6-PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL) CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE	Parion Sciences, Inc.	27-Jun-11	26-Jun-12	11-Jul-13
US20130178466	Treatment of Microbial Infections	BIOCOPEA LIMITED	11-Nov-09	9-Nov-10	11-Jul-13
US20130178448	Treatment of Respiratory Disorders	BANNISTER ROBIN MARK	5-Feb-10	4-Feb-11	11-Jul-13

CC-BY-NC-SA Dr. David E. Martin

US20130178383	VESICLE ISOLATION METHODS	KLASS MICHAEL	12-Nov-08	29-Aug-12	11-Jul-13
US20130178372	Methods And Computer Systems For Identifying Target-Specific Sequences For Use In Nanoreporters	NANOSTRING TECHNOLOGIES, INC.	10-Apr-07	7-Mar-13	11-Jul-13
US20130177640	DELIVERY OF RNA TO DIFFERENT CELL TYPES	NOVARTIS AG	6-Jul-10	7-Jun-11	11-Jul-13
US20130177639	DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYS	NOVARTIS AG	6-Jul-10	6-Jul-11	11-Jul-13
US20130177477	DECONTAMINANT DISPENSER SUITABLE FOR USE AS A PROJECTILE	STERIS INC.	6-Mar-07	28-Feb-13	11-Jul-13
US20130172327	SUBSTITUTED N- [1-CYANO-2- (PHENYL) ETHYL] -2-AZABICYCLO [2.2.1] HEPTANE-3-CARBOXAMIDE INHIBITORS OF CATHEPSIN C	BOEHRINGER INGELHEIM INTERNATIONAL GMBH	19-Sep-11	14-Sep-12	4-Jul-13
US20130171241	LIPOSOMES WITH LIPIDS HAVING AN ADVANTAGEOUS PKA-VALUE FOR RNA DELIVERY	NOVARTIS AG	6-Jul-10	6-Jul-11	4-Jul-13
US20130171129	CONSTRAINED IMMUNOGENIC COMPOSITIONS AND USES THEREFOR	COULIBALY FASSELI JOSEPH	23-Jun-10	23-Jun-11	4-Jul-13
US20130165455	TLR AGONISTS	The Regents of The University of California	22-Aug-05	20-Nov-12	27-Jun-13
US20130165417	METHODS AND COMPOSITIONS FOR TREATING ACE2-RELATED DISORDERS	UNIVERSITY OF FLORIDA RESEARCH FOUNDATION	23-Apr-10	23-Apr-11	27-Jun-13
US20130157964	Blockade Of Inflammatory Proteases With Cyclic Peptides	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	2-Jun-11	1-Jun-12	20-Jun-13
US20130157876	Systems and Methods for Detecting Antibiotic Resistance	TESSARAE, LLC	21-Aug-10	21-Feb-13	20-Jun-13
US20130157283	RAPID PATHOGEN DIAGNOSTIC DEVICE AND METHOD	PRESIDENT AND FELLOWS OF HARVARD COLLEGE	19-Jan-10	19-Jan-11	20-Jun-13
US20130157254	Method and apparatus for two-step surface-enhanced raman spectroscopy	Real-Time Analyzers, Inc.	16-Dec-11	16-Dec-11	20-Jun-13
US20130156807	CONJUGATES OF SYNTHETIC TLR AGONISTS AND USES THEREFOR	The Regents of The University of California	7-Feb-07	8-Jan-13	20-Jun-13
US20130149375	IMMUNISATION OF LARGE MAMMALS WITH LOW DOSES OF RNA	GEALL ANDREW	6-Jul-10	6-Jul-11	13-Jun-13
US20130149194	ORGANIC PEROXIDE COMPOUNDS FOR MICROORGANISM INACTIVATION	GREGERSEN JENS PETER	6-May-10	6-May-11	13-Jun-13
US20130145484	ANTIBODY PRODUCING NON-HUMAN MAMMALS	MERUS B.V.	27-Jun-08	25-Jan-13	6-Jun-13
US20130143810	Virally-Inactivated Growth Factors-Containing Platelet Lysate Depleted of PDGF and VEGF and Preparation Method Thereof	BURNOUF THIERRY	25-May-10	26-Nov-12	6-Jun-13
US20130143203	COMPOSITIONS FOR USE IN IDENTIFICATION OF ADVENTITIOUS VIRUSES	IBIS BIOSCIENCES, INC.	3-Mar-05	21-May-12	6-Jun-13
US20130142833	CIRCULATION OF COMPONENTS DURING HOMOGENIZATION OF EMULSIONS	Novartis AG	3-Dec-09	3-Dec-10	6-Jun-13
US20130142826	RECOMBINANT INFLUENZA VIRUS-LIKE PARTICLES (VLPS) PRODUCED IN TRANSGENIC PLANTS EXPRESSING HEMAGGLUTININ	MEDICAGO, INC.	21-Jan-08	23-Jan-13	6-Jun-13
US20130142773	Mutations in OAS1 Genes	KINETA TWO, LLC	4-May-05	14-Nov-12	6-Jun-13
US20130137678	Antiviral Compounds and Uses Thereof	MOUNT SINAI SCHOOL OF MEDICINE	28-May-10	31-May-11	30-May-13
US20130137172	HIGH DENSITY SELF-CONTAINED BIOLOGICAL ANALYSIS	BioFire Diagnostics, Inc. f/k/a Idaho Technology, Inc.	15-May-09	28-Jan-13	30-May-13
US20130137140	INCREASED PROTEIN EXPRESSION THROUGH INCREASED MEMBRANE FORMATION	UNIVERSITEIT GENT	17-Jun-10	15-Jun-11	30-May-13
US20130136768	Recombinant HCMV and RHCMV vectors and uses thereof	Oregon Health & Science University	14-May-10	14-Nov-12	30-May-13
US20130130262	SAMPLE-TO-ANSWER MICROFLUIDIC CARTRIDGE	BATTRELL C FREDERICK	29-Jan-10	28-Jan-11	23-May-13

CC-BY-NC-SA Dr. David E. Martin

US20130129805	COMPOSITION WITH STERILIZING ACTIVITY AGAINST BACTERIA, FUNGUS AND VIRUSES, APPLICATION THEREOF AND METHOD FOR PREPARATION THEREOF	GP&E	18-Nov-11	18-Nov-11	23-May-13
US20130129786	HYDROPHILIC FILTRATION DURING MANUFACTURE OF VACCINE ADJUVANTS	Novartis AG	3-Dec-09	3-Dec-10	23-May-13
US20130129782	DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES	NOVARTIS AG	9-Sep-04	11-Jan-13	23-May-13
US20130129781	METHODS AND COMPOSITIONS FOR INTRANASAL DELIVERY	HARUTA SHUNJI	15-Apr-10	15-Apr-11	23-May-13
US20130129702	MATERIALS AND METHODS FOR PREVENTION AND TREATMENT OF RNA VIRAL DISEASES	UNIVERSITY OF SOUTH FLORIDA	30-Apr-02	17-Sep-12	23-May-13
US20130122581	TAL EFFECTOR-MEDIATED DNA MODIFICATION	IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC.	10-Dec-09	10-Jan-13	16-May-13
US20130122516	DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRY	BIENIARZ CHRISTOPHER	2-Jul-10	1-Jul-11	16-May-13
US20130122487	DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES	Novartis AG	9-Sep-04	10-Jan-13	16-May-13
US20130122043	MODIFIED POLYPEPTIDES AND PROTEINS AND USES THEREOF	WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH	20-Apr-10	20-Apr-11	16-May-13
US20130122038	HETEROLOGOUS PRIME-BOOST IMMUNIZATION USING MEASLES VIRUS-BASED VACCINES	Crucell Holland B.V.	14-Nov-11	13-Nov-12	16-May-13
US20130122031	HMGB1-DERIVED PEPTIDES ENHANCE IMMUNE RESPONSE TO ANTIGENS	MESSMER DAVORKA	27-Jul-10	27-Jul-11	16-May-13
US20130115593	SUBSTRATES FOR CHROMOGENIC DETECTION AND METHODS OF USE IN DETECTION ASSAYS AND KITS	Ventana Medical Systems, Inc.	16-Aug-10	12-Aug-11	9-May-13
US20130115244	Immunogenic Substances Comprising a Polyinosinic Acid - Polycytidilic Acid Based Adjuvant	Yisheng Biopharma (Singapore) PTE. LTD.	13-Jan-06	1-Oct-12	9-May-13
US20130115228	IMMUNOSTIMULATORY COMBINATIONS	TRUSTEES OF DARTMOUTH COLLEGE	30-Dec-02	22-Oct-12	9-May-13
US20130115215	DOMAIN INSERTION IMMUNOGLOBULIN	ZHOU HONGXING	14-Jul-10	14-Jul-11	9-May-13
US20130102652	METHODS AND COMPOSITIONS RELATED TO MODIFIED ADENOSINES FOR CONTROLLING OFF-TARGET EFFECTS IN RNA INTERFERENCE	UNIVERSITY OF UTAH RESEARCH FOUNDATION	23-Mar-10	23-Mar-11	25-Apr-13
US20130102560	NUTRITIONAL COMPOSITION COMPRISING IMMUNOGLOBULINS AND OLIGOSACCHARIDES	N.V. NUTRICIA	24-Aug-04	14-Sep-12	25-Apr-13
US20130102524	Compounds And Their Use	Novabiotics Limited	31-Mar-10	30-Mar-11	25-Apr-13
US20130101629	HOMOGENOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOF	NOVARTIS AG	15-Dec-09	15-Dec-10	25-Apr-13
US20130101622	IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS	Novartis AG	23-Mar-06	7-May-12	25-Apr-13
US20130101609	IRRADIATED BIODEGRADABLE POLYMER MICROPARTICLES	NOVARTIS AG	24-Jan-10	24-Jan-11	25-Apr-13
US20130096103	IMIDAZOQUINOLINE COMPOUNDS	NOVARTIS VACCINES & DIAGNOSTICS, INC.	14-Sep-04	19-Jun-12	18-Apr-13
US20130096073	Casein Derived Peptides And Uses Thereof	SIDELMAN ZVI	1-Mar-00	5-Sep-12	18-Apr-13
US20130096056	AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS	XENON PHARMACEUTICALS INC.	3-Jun-05	14-Sep-12	18-Apr-13
US20130096020	GENERATION OF BINDING MOLECULES	MERUS BIOPHARMACEUTICALS B.V.	26-Sep-11	26-Sep-12	18-Apr-13
US20130095552	NOROVIRUS AND SAPOVIRUS ANTIGENS	Novartis Vaccines and Diagnostics, Inc.	22-Nov-05	27-Nov-12	18-Apr-13
US20130095135	PROCESS FOR REMOVING ADVENTITIOUS AGENTS DURING THE PRODUCTION OF A VIRUS IN CELL CULTURE	GlaxoSmithKline Biologicals S.A.	8-Jul-10	6-Jul-11	18-Apr-13
US20130091611	Anti-viral Formulations Nanomaterials and Nanoparticles	LAMBKIN-WILLIAMS ROBERT	16-Feb-06	30-Nov-12	18-Apr-13

US20130087700	DIRECT IMPACT IONIZATION (DII) MASS SPECTROMETRY	Services, National Institutes of Health	11-Oct-11	11-Oct-11	11-Apr-13
US20130085095	PROTEIN COMPLEMENTATION REGULATORS	Trustees of Boston University	29-Sep-11	28-Sep-12	4-Apr-13
US20130084303	PEPTIDES SHARED AMONG LETHAL CANCERS AND THERAPEUTIC COMPOSITIONS COMPRISING SAID PEPTIDES	BOGOCH ELENORE S	7-Aug-09	19-Jul-12	4-Apr-13
US20130071428	PEPTIDES, CONJUGATES AND METHOD FOR INCREASING IMMUNOGENICITY OF A VACCINE	ACADEMISCH ZIEKENHUIS LEIDEN H.O.D.N. LUMC	15-Mar-10	15-Mar-11	21-Mar-13
US20130059846	COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS	IRM LLC	1-Sep-11	27-Aug-12	7-Mar-13
US20130059832	COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS	IRM LLC	1-Sep-11	29-Aug-12	7-Mar-13
US20130059803	BORON-CONTAINING SMALL MOLECULES	Anacor Pharmaceuticals, Inc.	16-Feb-05	7-Sep-12	7-Mar-13
US20130059802	BORON-CONTAINING SMALL MOLECULES	Anacor Pharmaceuticals, Inc.	16-Feb-05	7-Sep-12	7-Mar-13
US20130059776	Antiviral Cell-Penetrating Peptides	CURRELI FRANCESCA	6-May-08	31-Oct-12	7-Mar-13
US20130058945	Antigenic GM-CSF Peptides and Antibodies to GM-CSF	CHAO QIMIN	8-Feb-06	24-Oct-12	7-Mar-13
US20110070575	Immunomodulatory Compositions, Combinations and Methods	Coley Pharmaceutical Group, Inc.	8-Dec-04	8-Dec-05	24-Mar-11
US20110067121	Transgenic mice having a human major histocompatibility complex (MHC) phenotype, experimental uses and applications	INSTITUT PASTEUR	30-Jul-03	22-Dec-09	17-Mar-11
US20110065111	Compositions For Use In Genotyping Of Klebsiella Pneumoniae	Ibis Biosciences, Inc.	31-Aug-09	27-Aug-10	17-Mar-11
US20110065091	Coronavirus, Nucleic Acid, Protein, and Methods for the Generation of Vaccine, Medicaments and Diagnostics	VAN DER HOEK CORNELIA MARIA	18-Aug-03	26-Jul-10	17-Mar-11
US20110065089	NOVEL STRAIN OF SARS-ASSOCIATED CORONAVIRUS AND APPLICATIONS THEREOF	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE	2-Dec-03	6-Apr-10	17-Mar-11
US20110064772	VIRAL ADJUVANTS	University of North Carolina at Chapel Hill	9-Jul-04	24-Nov-10	17-Mar-11
US20110053986	RESPIRATORY DISEASE TREATMENT	FINCH HARRY	7-Aug-08	4-Aug-10	3-Mar-11
US20110053909	Compounds - 801	ALCARAZ LILIAN	31-Jul-09	30-Jul-10	3-Mar-11
US20110053894	Broad Spectrum Antiviral and Methods of Use	LOVELACE RESPIRATORY RESEARCH INSTITUTE	17-Apr-06	17-Apr-07	3-Mar-11
US20110053893	COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS	IRM LLC	2-Sep-09	1-Sep-10	3-Mar-11
US20110053831	COMPOSITIONS AND USES THEREOF FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) AND CLINICAL DISORDERS ASSOCIATED WITH THEREWITH	Phylogica Limited	20-Jun-07	20-Jun-08	3-Mar-11
US20110053169	METHOD FOR CONTINUOUS MODE PROCESSING OF THE CONTENTS OF MULTIPLE REACTION RECEPTACLES IN A REAL-TIME AMPLIFICATION ASSAY	GEN-PROBE INCORPORATED	10-Mar-05	4-Nov-10	3-Mar-11
US20110052716	Adjuvant Comprising Aluminum, Oligonucleotide and Polycation	O'HAGAN DEREK	27-Aug-09	27-Aug-10	3-Mar-11
US20110052558	MATERIALS AND METHODS FOR PREVENTION AND TREATMENT OF RNA VIRAL DISEASES	UNIVERSITY OF SOUTH FLORIDA	30-Apr-02	15-Dec-09	3-Mar-11
US20110046155	HYDROBENZAMIDE DERIVATIVES AS INHIBITORS OF HSP90	FREDERICKSON MARTYN	12-Oct-06	12-Oct-07	24-Feb-11
US20110046134	NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE	BISCHOFF ALEXANDER	21-Jun-07	29-Oct-10	24-Feb-11
US20110046001	Multiplex Assay for Respiratory Viruses	AUTOGENOMICS, INC.	20-Nov-07	20-Nov-08	24-Feb-11
US20110045456	COMPOSITIONS FOR USE IN IDENTIFICATION OF ADVENTITIOUS CONTAMINANT VIRUSES	IBIS BIOSCIENCES, INC.	14-Jun-07	12-Jun-08	24-Feb-11

US20110045024	RNA VIRUS VACCINES AND METHODS	DITTMER DIRK P	14-Dec-05	2-Aug-10	24-Feb-11
US20110045022	VACCINES INCLUDING ANTIGEN FROM FOUR STRAINS OF INFLUENZA VIRUS	TSAI THEODORE	6-Dec-06	5-Dec-07	24-Feb-11
US20110039884	Imidazopyridinones	Pfizer Limited	3-Aug-07	28-Oct-10	17-Feb-11
US20110038935	ANTIBODIES AGAINST INFLUENZA VIRUS AND METHODS OF USE THEREOF	LIDDINGTON ROBERT C	6-Dec-07	8-Dec-08	17-Feb-11
US20110038900	NANOPARTICLES FOR USE IN PHARMACEUTICAL COMPOSITIONS	NOVARTIS AG	28-Apr-08	28-Apr-09	17-Feb-11
US20110038884	IMMUNOPOTENTIATING AGENT COMPRISING EP1 AGONIST	NATIONAL UNIVERSITY CO., HAMAMATSU UNIVER. SCHOOL OF MEDICINE	28-Apr-08	27-Apr-09	17-Feb-11
US20110038879	IMMUNOGENIC AND THERAPEUTIC COMPOSITIONS FOR STREPTOCOCCUS PYOGENES	NOVARTIS AG	30-Oct-06	30-Oct-07	17-Feb-11
US20110038852	ANTIVIRALS THAT TARGET TRANSPORTERS, CARRIERS, AND ION CHANNELS	3-V BIOSCIENCES, INC.	10-Jun-09	9-Jun-10	17-Feb-11
US20110038849	INHIBITORY POLYNUCLEOTIDE COMPOSITIONS AND METHODS FOR TREATING CANCER	Intradigm Corporation	21-Dec-06	21-Dec-06	17-Feb-11
US20110034438	STRUCTURAL MIMETICS OF PROLINE-RICH PEPTIDES AND THE PHARMACEUTICAL USE THEREOF	FORSCHUNGSVERBUND BERLIN E.V.	25-Sep-06	25-Sep-07	10-Feb-11
US20110033498	METHODS OF PREVENTING AND TREATING VIRAL INFECTIONS BY INHIBITING THE DelSGYLATION ACTIVITY OF OTU DOMAIN-CONTAINING VIRAL PROTEINS	FRIAS-STAHELI NATALIA	5-Apr-07	7-Apr-08	10-Feb-11
US20110033485	ANALOGUES OF GLYCOLIPIDS USEFUL AS IMMUNOADJUVANTS	PANZA LUIGI	12-Oct-07	10-Oct-08	10-Feb-11
US20110033454	Methods For Treating Diseases Using Antibodies to Aminophospolipids	Board of Regents, The University of Texas System	15-Jul-02	26-Aug-10	10-Feb-11
US20110028945	Device including altered microorganisms, and methods and systems of use	Searete LLC,	14-Dec-05	28-May-10	3-Feb-11
US20110028715	NOVEL ADENINE COMPOUND	AstraZeneca Aktiebolag	20-Mar-07	14-Oct-10	3-Feb-11
US20110028531	NOVEL SIRNA COMPOUNDS FOR INHIBITING RTP801	FEINSTEIN ELENA	20-Mar-08	17-Mar-09	3-Feb-11
US20110028334	CAPTURE PRIMERS AND CAPTURE SEQUENCE LINKED SOLID SUPPORTS FOR MOLECULAR DIAGNOSTIC TESTS	IBIS BIOSCIENCES, INC.	31-Jul-09	30-Jul-10	3-Feb-11
US20110027315	PROTEIN CAGES AND THEIR USES	DOUGLAS TREVOR	7-Sep-07	5-Sep-08	3-Feb-11
US20110027314	Influenza Vaccines Containing Hemagglutinin and Matrix Proteins	NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO. KG	27-Jan-06	26-Jan-07	3-Feb-11
US20110027306	TC-83-Derived Alphavirus Vectors, Particles and Methods	AlphaVax, Inc.	18-May-04	6-Jul-10	3-Feb-11
US20110027267	Fusion Proteins of Mannose Binding Lectins for Treatment of Disease	ANAPHORE, INC.	9-Nov-07	10-Nov-08	3-Feb-11
US20110027257	CLOTTABLE CONCENTRATE OF PLATELET GROWTH FACTORS AND PREPARATION METHOD THEREOF	GWO REI BIOMEDICAL TECHNOLOGY CORPORATION	7-Jan-08	7-Jan-09	3-Feb-11
US20110027228	USES OF INTERFERONS WITH ALTERED SPATIAL STRUCTURE	WEI GUANGWEN	28-Aug-03	15-Oct-10	3-Feb-11
US20110027181	Device including altered microorganisms, and methods and systems of use	Searete LLC	14-Dec-05	28-May-10	3-Feb-11
US20110021861	HAZARDOUS SUBSTANCE-REMOVING MATERIAL	KOSUGI TAKUJI	25-Mar-08	23-Mar-09	27-Jan-11
US20110021606	RNAi Modulation of RSV, PIV and Other Respiratory Viruses and Uses Thereof	SOUTH ALABAMA MEDICAL SCIENCE FOUNDATION	22-Oct-04	23-Jul-10	27-Jan-11
US20110021554	IMMUNE RESPONSE MODIFIER FORMULATIONS AND METHODS	GUY CYNTHIA A	30-Dec-04	29-Sep-10	27-Jan-11
US20110021415	ANTIMICROBIAL PEPTIDES	NOVABIOTICS LIMITED	18-Aug-04	29-Sep-10	27-Jan-11
US20110020897	RNA-DEPENDENT DNA POLYMERASE FROM GEOBACILLUS STEAROTHERMOPHILUS	LAMPSON BERT C	10-Mar-04	1-Mar-10	27-Jan-11

CC-BY-NC-SA Dr. David E. Martin

US20110020315	TREATMENT OF INFLAMMATORY ILLNESSES WITH ACE2	LOIBNER HANS	18-Dec-07	18-Dec-08	27-Jan-11
US20110009414	HETEROCYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS	Xenon Pharmaceuticals Inc.	20-Sep-04	6-May-09	13-Jan-11
US20110008905	SYSTEM FOR DETECTING POLYNUCLEOTIDES	INVESTIGEN	20-May-03	9-Jun-10	13-Jan-11
US20110008838	CHIMERIC VARICELLA ZOSTER VIRUS VIRUS-LIKE PARTICLES	PUSHKO PETER	19-Jul-07	21-Jul-08	13-Jan-11
US20110008395	MIXED MICELLES INCLUDING AMPHIPATHIC CONJUGATES OF RNA AGENTS, AND USES THEREOF	LEVCHENKO TATYANA S	6-Jul-07	7-Jul-08	13-Jan-11
US20110008384	Antiviral activity from medicinal mushrooms	STAMETS PAUL EDWARD	6-Jan-04	27-Mar-07	13-Jan-11
US20110008283	INTERFERON FUSION PROTEINS	ARTYMIUK PETER	8-Aug-07	5-Aug-08	13-Jan-11
US20110008280	METHODS FOR TREATING VIRAL INFECTION USING IL-28 AND IL-29 CYSTEINE MUTANTS	ZymoGenetics, Inc.	2-Apr-04	20-May-10	13-Jan-11
US20110003890	USE OF ANGIOGENESIS ANTAGONISTS IN CONDITIONS OF ABNORMAL VENOUS PROLIFERATION	KENNEDY THOMAS P	8-Nov-07	10-Nov-08	6-Jan-11
US20110003315	CHIMERIC PCSK9 PROTEINS, CELLS COMPRISING SAME, AND ASSAYS USING SAME	INSTITUT DE RECHERCHES CLINIQUES DE MONTREAL	8-May-06	8-May-07	6-Jan-11
US20110002958	Alphavirus Vectors for Respiratory Pathogen Vaccines	NOVARTIS VACCINES AND DIAGNOSTICS, INC.	21-May-04	1-Jun-10	6-Jan-11
US20110002946	Immunostimulatory Combinations	AHONEN CORY L	30-Dec-02	29-Jul-10	6-Jan-11
US20110002888	Albumin Fusion Proteins	Human Gemone Sciences, Inc.	21-Dec-01	3-Jun-10	6-Jan-11
US20110000480	ADMINISTRATION OF INTERFERON FOR PROPHYLAXIS AGAINST OR TREATMENT OF PATHOGENIC INFECTION	ENNIS JANE E	9-Jun-09	9-Jun-10	6-Jan-11
US20100330592	METHOD FOR DETECTING TRUNCATED MOLECULES	KEY MARC E	29-Jan-08	29-Jan-09	30-Dec-10
US20100330190	IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF	BOZIA JADRANKA	17-Dec-07	17-Dec-08	30-Dec-10
US20100330141	PRODUCT FOR ABSORPTION PURPOSES	HJERTEN MARIE-CHRISTINE	13-Jun-03	13-Sep-10	30-Dec-10
US20100330140	DEVICES AND METHODS FOR DECREASING HUMAN PATHOGEN TRANSMISSION	FILLIGENT LIMITED	26-Jun-07	25-Jun-08	30-Dec-10
US20100330122	VARICELLA ZOSTER VIRUS VIRUS-LIKE PARTICLES (VLPs) AND ANTIGENS	PUSHKO PETER	19-Jul-07	21-Jul-08	30-Dec-10
US20100330114	Use of SIRT1 Activators or Inhibitors to Modulate an Immune Response	KWON HYE-SOOK	7-Feb-08	16-Jul-10	30-Dec-10
US20100330075	MONOCLONAL HUMAN TUMOR-SPECIFIC ANTIBODY	ABELA IRENE	13-Mar-07	13-Mar-08	30-Dec-10
US20100329971	NOVEL HYDROXY RADICAL GENERATION METHOD, AND ANTI-VIRAL MATERIAL UTILIZING HYDROXYL RADICAL GENERATED BY THE METHOD	MOCHIGASE CO., LTD.	8-Feb-08	9-Feb-09	30-Dec-10
US20100319074	MULTI-TARGETED RNAI THERAPEUTICS FOR SCARLESS WOUND HEALING OF SKIN	SIR NAOMICS, INC.	6-Nov-07	6-Nov-08	16-Dec-10
US20100317684	Amide and Carbamate Derivatives of N-{2-[4-Amino-2-(Ethoxymethyl)-1H-Imidazo[4,5-c] Quinolin-1-Yl]-1,1-Dimethylethyl} Methanesulfonamide and Methods	Coley Pharmaceutical Group, Inc.	9-Sep-05	8-Sep-06	16-Dec-10
US20100317601	Casein Derived Peptides And Uses Thereof	SIDELMAN ZVI	1-Mar-00	28-Jul-10	16-Dec-10
US20100317054	PORCINE DC-SIGN, ICAM-3 AND LSECtin AND USES THEREOF	VIRGINIA TECH INTELLECTUAL PROPERTIES, INC.	29-Oct-07	29-Oct-08	16-Dec-10
US20100317034	PRIMATE T-LYMPHOTROPIC VIRUSES	and Johns Hopkins University	21-Feb-05	1-Jul-10	16-Dec-10
US20100316695	CONDENSATION PRODUCTS BASED ON BICYCLIC OR POLYCYCLIC AROMATICS OR HETEROAROMATICS	BASF SE	14-Nov-07	11-Nov-08	16-Dec-10
US20100316641	ENGINEERED ANTIBODY CONSTANT DOMAIN MOLECULES	DIMITROV DIMITER S	31-Jan-08	30-Jan-09	16-Dec-10

CC-BY-NC-SA Dr. David E. Martin

US20100316624	TREATMENT OF FIBROSES AND LIVER DISORDERS	LOIBNER HANS	21-Dec-07	22-Dec-08	16-Dec-10
US20100311797	Novel Compounds	BONNERT ROGER VICTOR	26-May-06	2-Jun-10	9-Dec-10
US20100311656	TREATMENT OR PREVENTION OF RESPIRATORY VIRAL INFECTIONS WITH ALPHA THYMOSIN PEPTIDES	SciClone Pharmaceuticals, Inc.	23-Apr-03	16-Jun-10	9-Dec-10
US20100311039	NON-TARGET AMPLIFICATION METHOD FOR DETECTION OF RNA SPLICE-FORMS IN A SAMPLE	QIAGEN GAITHERSBURG INC.	1-May-09	30-Apr-10	9-Dec-10
US20100310638	LIPOSOMES COMPRISING DURAMYCIN AND ANTI-VIRAL AGENTS	Board of Regents, The University of Texas System	15-Jul-02	4-Mar-10	9-Dec-10
US20100310604	RECOMBINANT INFLUENZA VIRUS-LIKE PARTICLES (VLPS) PRODUCED IN TRANSGENIC PLANTS EXPRESSING HEMAGGLUTININ	MEDICAGO INC.	21-Jan-08	12-Jan-09	9-Dec-10
US20100310562	SYSTEM FOR DELIVERY INTO XCR1 POSITIVE CELL AND USES THEREOF	Bundesrepublik Deutschland letztvertreten durch das Robert Koch-Institut vertreten durch seinen	20-Nov-07	19-Nov-08	9-Dec-10
US20100305138	PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS	XENON PHARMACEUTICALS INC.	29-Jul-03	15-Jun-10	2-Dec-10
US20100304363	PEPTIDE COMPOUNDS FOR DETECTING OR INHIBITING SARS CORONAVIRUS AND APPLICATION THEREOF	ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE	27-May-09	26-May-10	2-Dec-10
US20100304361	METHOD AND DEVICE FOR MONITORING A THERAPEUTIC TREATMENT REGIME	DAS DEVELOPMENT PARTNERS	26-Jul-07	28-Jul-08	2-Dec-10
US20100303823	HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)	GENMAB A/S	16-Dec-02	11-Nov-09	2-Dec-10
US20100298547	METHODS FOR THE DIRECTED EXPANSION OF EPITOPES FOR USE AS ANTIBODY LIGANDS	BONNIN DUSTAN	7-May-07	7-May-08	25-Nov-10
US20100298364	SALTS 756	AstraZeneca AB	21-May-09	20-May-10	25-Nov-10
US20100298209	COMPOUNDS FOR PREVENTING OR TREATING A VIRAL INFECTION	ESTAQUIER JEROME	2-Nov-07	31-Oct-08	25-Nov-10
US20100297651	Methods of Modulating Vesicular Trafficking	THE GENERAL HOSPITAL CORPORATION	21-May-09	21-May-10	25-Nov-10
US20100297165	IMMUNOSTIMULATORY COMBINATIONS OF TLR LIGANDS AND METHODS OF USE	Office of Technology Transfer	24-Sep-07	24-Sep-08	25-Nov-10
US20100297108	METHOD OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN AMYLOIDOSES AND PROTEIN AGGREGATION DISORDERS	GRIMM JAN	31-Aug-07	1-Sep-08	25-Nov-10
US20100292504	BORON-CONTAINING SMALL MOLECULES	Anacor Pharmaceuticals, Inc.	20-Jun-07	30-Jul-10	18-Nov-10
US20100292307	Construct	ISIS INNOVATION LIMITED	28-Mar-06	28-Mar-07	18-Nov-10
US20100291544	COMPOSITIONS FOR USE IN IDENTIFICATION OF STRAINS OF HEPATITIS C VIRUS	IBIS BIOSCIENCES, INC.	25-May-07	27-May-08	18-Nov-10
US20100291145	Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES	ANTIGEN EXPRESS, INC.	14-Sep-99	26-Jul-10	18-Nov-10
US20100291129	Norovirus and sapovirus antigens	COIT DORIS	22-Nov-05	24-Mar-09	18-Nov-10
US20100291120	PEPTIDES REGULATING THE SURFACE EXPRESSION OF THE T CELL RECEPTOR	MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN	23-Jun-06	23-Jun-07	18-Nov-10
US20100291075	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Neutralizing Antibodies	Theraclone Sciences, Inc.	23-Apr-09	23-Apr-10	18-Nov-10
US20100291033	Albumin Fusion Proteins	Human Genome Sciences, Inc.	21-Dec-01	3-Jun-10	18-Nov-10
US20100286251	Mammalian Genes Involved In Viral Infection And Tumor Suppression	RUBIN DONALD H	11-Oct-06	5-Mar-10	11-Nov-10
US20100286238	SUPPRESSION OF VIRUSES INVOLVED IN RESPIRATORY INFECTION OR DISEASE	ARNDT GREGORY MARTIN	15-May-07	14-May-08	11-Nov-10
US20100286118	SUBSTITUTED 1-CYANOETHYLHETEROCYCLYLCARBOXAMIDE COMPOUNDS 750	FORD RHONAN	7-May-09	6-May-10	11-Nov-10
US20100286025	SYNTHETIC APOLIPOPROTEIN E MIMICKING POLYPEPTIDES AND METHODS OF USE	ANANTHARAMAIAH GATTADAHALLI M	28-Aug-07	27-Aug-08	11-Nov-10

US20100285457	High-Throughput Diagnostic Assay For the Human Virus Causing Severe Acute Respiratory Syndrome (SARS)	CHAN KWOK HUNG	24-Mar-03	12-Jun-09	11-Nov-10
US20100285135	Nanoparticles For Use In Immunogenic Compositions	NOVARTIS AG	2-Dec-05	1-Dec-06	11-Nov-10
US20100284968	Use of PS20/WFDC1 and Interferons to Diagnose, Monitor and Treat Viral Diseases	BAIG EHTESHAM	15-Oct-07	15-Oct-08	11-Nov-10
US20100284967	MODIFIED PHAGE FOR DISPLAYING POST-TRANSLATIONALLY MODIFIED PROTEINS AND USES THEREOF	National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS) U.S. Govt.	21-Nov-06	20-Nov-07	11-Nov-10
US20100284965	COMPOSITIONS AND METHODS FOR ADOPTIVE AND ACTIVE IMMUNOTHERAPY	Yale University	15-Jan-08	14-Jan-09	11-Nov-10
US20100284917	COMPOUNDS AND MARKERS FOR SURFACE-ENHANCED RAMAN SCATTERING	JULIUS-MAXIMILIANS- UNIVERSITAT	24-Sep-07	24-Sep-08	11-Nov-10
US20100284016	OPTICAL CYTOMETRY	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	6-May-09	6-May-09	11-Nov-10
US20100280102	DOUBLE-STRANDED RIBONUCLEIC ACID WITH INCREASED EFFECTIVENESS IN AN ORGANISM	Alnylam Pharmaceuticals	13-Jun-03	16-Jun-10	4-Nov-10
US20100280067	INHIBITORS OF ACETYL-COA CARBOXYLASE	ACHARYA VINOD PARAMESHWARAN	30-Apr-09	30-Apr-10	4-Nov-10
US20100280048	Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase	ASTRAZENECA R&D	6-Nov-07	5-Nov-08	4-Nov-10
US20100280001	IMIDAZOQUINOLINES WITH IMMUNO-MODULATING PROPERTIES	BONNERT ROGER VICTOR	8-May-07	6-May-08	4-Nov-10
US20100279906	FORMULATIONS COMPRISING AN ANTI-MICROBIAL COMPOSITION	BYOTROL PLC	17-Sep-07	17-Sep-08	4-Nov-10
US20100279888	COMPOSITIONS AND METHODS OF DETECTION	GENERA BIOSYSTEMS LIMITED	5-Apr-07	4-Apr-08	4-Nov-10
US20100279351	Method for Generation of Antibodies	NATIONAL JEWISH MEDICAL AND RESEARCH CENTER	13-Mar-07	13-Mar-08	4-Nov-10
US20100279279	Compositions and methods for analysis of target analytes	DANIELZADEH ROBERT	17-Sep-03	30-Nov-07	4-Nov-10
US20100279276	METHODS FOR DETERMINING THE PRESENCE OF SARS CORONAVIRUS IN A SAMPLE	GEN-PROBE INCORPORATED	17-Apr-03	6-Jul-10	4-Nov-10
US20100279273	NUCLEIC ACID SEQUENCES FOR THE AMPLIFICATION AND DETECTION OF RESPIRATORY VIRUSES	UNIVERSITE LAVAL	17-Jul-07	17-Jul-08	4-Nov-10
US20100278861	METHODS AND COMPOSITIONS FOR PREDICTING EMERGENCE AND EXPANSION OF DRUG RESISTANT STRAINS OF INFLUENZA VIRUS	NIMAN HENRY L	29-Jan-09	29-Jan-10	4-Nov-10
US20100278846	NASAL-ADMINISTERED VACCINES USING MULTI-SCREENED NALT-TARGETING AND PHAGOCYTIC POLYPEPTIDE TRANSPORT SEQUENCES	FERGUSON IAN A	23-Jun-04	11-Dec-09	4-Nov-10
US20100278829	DUAL INHIBITION OF IMMUNOPHILIN/CYCLOPHILIN FAMILY MEMBERS AND EMMPRIN IMMUNOGLOBULIN RECEPTOR SUPERFAMILY MEMBERS	EDWARDS III CARL KEITH	6-Feb-09	6-Feb-10	4-Nov-10
US20100273997	Ribozyme to cleave coronavirus gene	FUKUDA NOBORU	9-Aug-05	9-Aug-06	28-Oct-10
US20100273854	COMPOSITIONS AND METHODS FOR INHIBITING NADPH OXIDASE EXPRESSION	FEINSTEIN ELENA	15-Jun-07	12-Jun-08	28-Oct-10
US20100273740	Phospholipids for the Treatment of Infection by Togaviruses, Herpes Viruses and Coronaviruses	FLEMING RONALD A	20-Feb-04	23-Nov-09	28-Oct-10
US20100273670	DETECTION OF ANTIVIRAL RESISTANCE IN INFLUENZA A USING DNA MICROARRAY	DAWSON ERICA	21-Aug-06	21-Aug-07	28-Oct-10
US20100272785	RNA SEQUENCE MOTIFS IN THE CONTEXT OF DEFINED INTERNUCLEOTIDE LINKAGES INDUCING SPECIFIC IMMUNE MODULATORY PROFILES	COLEY PHARMACEUTICAL GMBH	13-Aug-07	8-Aug-08	28-Oct-10
US20100272776	Device including bone cage and method for treatment of disease in a subject	Searete LLC, a limited liability corporation of the State of Delaware	23-Apr-09	28-Jul-09	28-Oct-10
US20100272771	Device including bone cage and method for treatment of disease in a subject	HARLOW ED	23-Apr-09	23-Apr-09	28-Oct-10
US20100272730	Antigenic GM-CSF Peptides And Antibodies To GM-CSF	MORPHOTEK, INC.	8-Feb-06	16-Apr-10	28-Oct-10

CC-BY-NC-SA Dr. David E. Martin

US20100272706	ANTIVIRALS	GREBER URS	22-Jun-07	20-Jun-08	28-Oct-10
US20100272668	ANTIVIRAL SUBSTANCE, ANTIVIRAL FIBER, AND ANTIVIRAL FIBER STRUCTURE	Daiwabo Holdings Co., Ltd.	20-Feb-08	20-Feb-09	28-Oct-10
US20100267981	BORON-CONTAINING SMALL MOLECULES	Anacor Pharmaceuticals, Inc.	16-Feb-05	2-Dec-09	21-Oct-10
US20100267805	TARGETING OPPOSITE STRAND REPLICATION INTERMEDIATES OF SINGLE-STRANDED VIRUSES BY RNAI	ALNYLAM PHARMACEUTICALS, INC.	24-Sep-04	1-Mar-10	21-Oct-10
US20100266677	NUCLEIC ACID BINDING COMPOUNDS AND METHODS OF USE	UNIVERSITY OF ROCHESTER	26-Jul-07	28-Jul-08	21-Oct-10
US20100266634	ADJUVANCY AND IMMUNE POTENTIATING PROPERTIES OF NATURAL PRODUCTS OF ONCHOCERCA VOLVULUS	NEW YORK BLOOD CENTER, INC.	15-Jun-04	18-Feb-10	21-Oct-10
US20100266620	Immunoconjugates for treatment of infectious diseases	SUN LE	20-Jan-06	19-Jan-07	21-Oct-10
US20100266604	USE OF TAM RECEPTOR INHIBITORS AS IMMUNOENHANCERS AND TAM ACTIVATORS AS IMMUNOSUPPRESSORS	The Salk Institute for Biological Studies	9-Nov-07	7-Nov-08	21-Oct-10
US20100266598	PEPTIDE THAT ELICITS NEUTRALIZING ANTIBODIES TARGETING THE HIV CO-RECEPTOR, CCR5	Government of the US, as Represented by the Secretary, Department of Health and Human Services	9-Apr-04	28-Dec-09	21-Oct-10
US20100262374	Systems and methods for analyzing nanoreporters	HWANG JENQ-NENG	22-May-06	21-May-07	14-Oct-10
US20100261779	Phosphate-Modified Oligonucleotide Analogs with Enhanced Immunostimulatory Activity	JURK MARION	15-May-08	15-May-08	14-Oct-10
US20100261690	NOVEL COMBINATIONS	ASTRAZENECA R&D	3-Apr-09	30-Mar-10	14-Oct-10
US20100261026	Compositions comprising oriented, immobilized macromolecules and methods for their preparation	NanoString Technologies, Inc.	23-Dec-05	22-Dec-06	14-Oct-10
US20100256348	Oligoadenylate Synthetase (OAS)	ILLUMIGEN BIOSCIENCES, INC.	23-Nov-05	30-Mar-10	7-Oct-10
US20100256105	NOVEL COMPOUNDS	AstraZeneca R&D	3-Apr-09	30-Mar-10	7-Oct-10
US20100256104	NOVEL AMIDE COMPOUNDS	ASTRAZENECA R&D	3-Apr-09	30-Mar-10	7-Oct-10
US20100256103	NOVEL COMPOUNDS	ASTRAZENECA R&D	3-Apr-09	30-Mar-10	7-Oct-10
US20100256096	Sulfonyl semicarbazides, carbonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenaviruses	BAILEY THOMAS R	6-Dec-04	17-Jan-07	7-Oct-10
US20100256070	RECOMBINANT VIBRIO CHOLERAE EXOTOXINS	SEED BRIAN	20-Jul-07	18-Jul-08	7-Oct-10
US20100254985	Protein Formulations	MEDIMMUNE, LLC	3-Feb-06	6-May-10	7-Oct-10
US20100254944	Albumin Fusion Proteins	STUMP DAVID CARTER	14-Sep-06	13-Sep-07	7-Oct-10
US20100254942	HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODS	BIOTRON LIMITED	3-Aug-07	4-Aug-08	7-Oct-10
US20100249200	Novel Compounds 569	CONNOLLY STEPHEN	20-Dec-06	30-Mar-10	30-Sep-10
US20100249021	METHOD AND MEDICAMENT FOR INHIBITING THE INFECTION OF INFLUENZA VIRUS	INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCES	14-Nov-07	18-Dec-07	30-Sep-10
US20100248219	Compositions for use in identification of influenza viruses	ESHOO MARK W	17-Oct-05	17-Oct-06	30-Sep-10
US20100247574	CHIMERIC NEWCASTLE DISEASE VIRUS VLPs	MAHMOOD KUTUB	21-Feb-07	21-Feb-08	30-Sep-10
US20100247571	METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST VIRUS	ACADEMIA SINICA	27-Mar-09	26-Mar-10	30-Sep-10
US20100247560	MUTANT BOTULINUM NEUROTOXIN SEROTYPE A POLYPEPTIDE AND USES THEREOF	THOMAS JEFFERSON UNIVERSITY	25-Sep-07	25-Sep-08	30-Sep-10
US20100247554	USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIALS	BHATTACHARYYA SUCHITA	9-Nov-07	7-Nov-08	30-Sep-10

CC-BY-NC-SA Dr. David E. Martin

US20100247550	SYSTEMS AND METHODS FOR IDENTIFYING REPLIKIN SCAFFOLDS AND USES OF SAID REPLIKIN SCAFFOLDS	BOGOCH ELENORE S	28-Apr-04	3-Feb-10	30-Sep-10
US20100240903	CRYSTALLINE TRIPEPTIDE EPOXY KETONE PROTEASE INHIBITORS	Onyx Therapeutics, Inc.	20-Mar-09	22-Mar-10	23-Sep-10
US20100240746	STEREOISOMERS OF TRICYCLODECAN-9-YL-XANTHOGENATE	LUMAVITA AG	3-Jul-07	3-Jul-08	23-Sep-10
US20100240693	Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring Compounds and Methods	Coley Pharmaceutical Group, Inc	9-Feb-05	8-Feb-06	23-Sep-10
US20100240623	8-OXOADENINE DERIVATIVES ACTING AS MODULATORS OF TLR7	COOK ANTHONY	5-Jul-06	3-Jul-07	23-Sep-10
US20100240063	SYSTEMS AND METHODS FOR DETECTING MULTIPLE OPTICAL SIGNALS	GEN-PROBE INCORPORATED	10-Mar-05	1-Jun-10	23-Sep-10
US20100239611	Combination adjuvant formulation	BABIUK LORNE	16-Oct-08	15-Oct-09	23-Sep-10
US20100239610	INFLUENZA VIRUS-LIKE PARTICLES (VLPS) COMPRISING HEMAGGLUTININ PRODUCED WITHIN A PLANT	MEDICAGO INC.	13-Jul-07	11-Jul-08	23-Sep-10
US20100239593	RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEM	MedImmune Limited	1-Jun-07	30-May-08	23-Sep-10
US20100239520	ORGANIC COMPOUNDS	DALES NATALIE	24-Aug-06	22-Aug-07	23-Sep-10
US20100234355	ISOQUINOLINE DERIVATIVES AND THEIR USE AS INHIBITORS OF CYTOKINE MEDIATED DISEASES	MARTIN BARRIE	19-Jun-06	18-Jun-07	16-Sep-10
US20100233250	VACCINE	BARAS BENOIT	19-Jun-07	20-Jun-08	16-Sep-10
US20100233146	Coatings and Surface Treatments Having Active Enzymes and Peptides	REACTIVE SURFACES, LTD.	9-Sep-02	29-May-09	16-Sep-10
US20100233116	ORGANIC COMPOUNDS	DALES NATALIE	15-Aug-06	13-Aug-07	16-Sep-10
US20100233084	Method for Delivery Across the Blood Brain Barrier	IMMUNE DISEASE INSTITUTE, INC.	22-May-06	22-May-07	16-Sep-10
US20100233031	Method and Apparatus for Analyzing Bioprocess Fluids	BioScale, Inc.	2-May-05	25-May-10	16-Sep-10
US20100227767	STOCHASTIC CONFINEMENT TO DETECT, MANIPULATE, AND UTILIZE MOLECULES AND ORGANISMS	BOEDICKER JAMES Q	26-Jul-07	28-Jul-08	9-Sep-10
US20100226931	Compounds for immunopotentiation	SILVER JOEL B	24-Jun-04	24-Jun-05	9-Sep-10
US20100222409	COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PRO-APOPTOTIC GENES	FEINSTEIN ELENA	27-Jun-07	26-Jun-08	2-Sep-10
US20100222234	Malaria antigen screening method	AGUAIR JOAO CARLOS	31-Aug-05	25-Aug-06	2-Sep-10
US20100221755	USE OF ANTIBODY SECRETING CELL ELISPOT TO ASSESS ANTIBODY RESPONSES FOLLOWING ANTIGEN EXPOSURE	University of Rochester	15-Jun-07	16-Jun-08	2-Sep-10
US20100221349	NUCLEIC ACID CONSTRUCTS	Powderject Vaccines, Inc.	1-Feb-05	1-Feb-06	2-Sep-10
US20100221307	ANTIVIRAL AGENTS, ANTIVIRAL FIBERS AND ANTIVIRAL FIBER STRUCTURES	DAIWABO HOLDINGS CO., LTD.	20-Feb-08	20-Feb-09	2-Sep-10
US20100221257	BINDING MEMBERS-513	MEDIMMUNE LIMITED	7-Nov-08	5-Nov-09	2-Sep-10
US20100221242	ANTI-VIRAL GRIFFITHSIN COMPOUNDS, COMPOSITIONS AND METHODS OF USE	MCMAHON JAMES B	1-Dec-05	1-Dec-06	2-Sep-10
US20100216843	NOVEL SALT 628	ASTRAZENECA R&D	20-Feb-09	16-Feb-10	26-Aug-10
US20100216773	PHENANTHROINDOLIZIDINE ANALOGUES	National Health Research Institutes	24-Feb-09	11-Feb-10	26-Aug-10
US20100216689	CYTOTOXIC T CELL ACTIVATOR COMPRISING EP4 AGONIST	National University Corporation, Hamamatsu University School of Medicine	8-May-07	7-May-08	26-Aug-10
US20100215683	PROTECTIVE ANTIGENS FOR GROUP B STREPTOCOCCUS HYPERVIRULENT STRAINS	NOVARTIS AG	20-Feb-09	16-Feb-10	26-Aug-10

US20100215675	REPLIKIN-BASED COMPOUNDS FOR PREVENTION AND TREATMENT OF INFLUENZA AND METHODS OF DIFFERENTIATING INFECTIVITY AND LETHALITY IN INFLUENZA	BOGOCH ELENORE S	9-Jan-09	16-Oct-09	26-Aug-10
US20100210745	Molecular Healing of Polymeric Materials, Coatings, Plastics, Elastomers, Composites, Laminates, Adhesives, and Sealants by Active Enzymes	REACTIVE SURFACES, LTD.	9-Sep-02	29-Jan-10	19-Aug-10
US20100210688	Novel Benzothiazolone Derivatives	BONNERT ROGER	9-Aug-05	27-Apr-10	19-Aug-10
US20100209454	ATTENUATED VIRUSES USEFUL FOR VACCINES	CELLO JERONIMO	30-Mar-07	31-Mar-08	19-Aug-10
US20100209451	Compositions and Methods Related to Adenovirus Based Delivery of Antigens	INTROGEN THERAPEUTICS, INC.	16-Jun-06	18-Jun-07	19-Aug-10
US20100209440	Targeted Delivery of siRNA	Immune Disease Institute, Inc.	26-Jan-07	25-Jan-08	19-Aug-10
US20100204286	METHOD FOR REDUCING GASTROINTESTINAL ADVERSE EFFECTS OF CYTOTOXIC AGENTS	BYRNES JOHN J	12-Feb-09	11-Feb-10	12-Aug-10
US20100204266	COMPOSITIONS FOR USE IN IDENTIFICATION OF MIXED POPULATIONS OF BIOAGENTS	Ibis Biosciences, INC	23-Mar-07	21-Mar-08	12-Aug-10
US20100204203	Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors	BONNERT ROGER VICTOR	11-Jan-07	10-Jan-08	12-Aug-10
US20100203582	Protein Expression System Involving Mutated Severe Respiratory Syndrome-Associated Coronavirus 3C-Like Protease	Academia Sinica	12-Feb-09	12-Feb-09	12-Aug-10
US20100197748	ANTI-MICROBIAL COMPOSITION	BYOTROL PLC	17-Jul-07	17-Jul-08	5-Aug-10
US20100197708	INDOLE COMPOUNDS	BARDEN TIMOTHY	7-Aug-06	7-Aug-07	5-Aug-10
US20100196285	Use of Deuterium Oxide to Treat Virus-Based Diseases of the Respiratory Tract	BAYERL THOMAS	7-Jan-09	6-Jan-10	5-Aug-10
US20100196222	AIR CLEANING APPARATUS	FUJIFILM CORPORATION	20-Sep-07	19-Sep-08	5-Aug-10
US20100190748	BORON-CONTAINING SMALL MOLECULES	Anacor Pharmaceuticals, Inc.	16-Feb-05	21-Jul-09	29-Jul-10
US20100189772	Compositions of TLR ligands and antivirals	COLEY PHARMACEUTICAL GMBH	27-Sep-06	27-Sep-07	29-Jul-10
US20100186680	LIVESTOCK STERILIZING METHOD, LIVESTOCK STERILIZING APPARATUS, AND LIVESTOCK OR LIVESTOCK MEAT	HAGIWARA NOBUKO	21-Feb-05	21-Feb-06	29-Jul-10
US20100184663	Methods and Compositions Related to Inhibition of Viral Entry	University of Utah Research Foundation	8-Feb-07	8-Feb-08	22-Jul-10
US20100184613	Proteome Epitope Tags and Methods of Use Thereof in Protein Modification Analysis	Millipore Corporation	10-May-02	9-Oct-09	22-Jul-10
US20100184192	AVIAN INFLUENZA CHIMERIC VLPS	PUSHKO PETER	11-Jul-03	19-Jan-10	22-Jul-10
US20100184190	Influencing viral lipid constituents	MedImmune, LLC	17-Oct-06	9-Oct-07	22-Jul-10
US20100184019	Novel Human Virus Causing Severe Acute Respiratory Syndrome (SARS) and Uses Thereof	CHAN KWOK HUNG	24-Mar-03	10-Feb-10	22-Jul-10
US20100183673	METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONS	ETUBICS CORPORATION	2-Jul-07	4-Jan-10	22-Jul-10
US20100183671	LOW-ADDITIVE INFLUENZA VACCINES	Novartis Vaccines & Diagnostics GmbH & Co., KG	27-Jun-07	27-Jun-08	22-Jul-10
US20100183634	MULTIFUNCTIONAL NUCLEIC ACID NANO-STRUCTURES	Cornell University, a New York Corporation	1-Jan-09	31-Dec-09	22-Jul-10
US20100183516	SELF COUPLING RECOMBINANT ANTIBODY FUSION PROTEINS	BARTH STEFAN	25-Jul-07	25-Jul-08	22-Jul-10
US20100179145	PHARMACEUTICAL COMBINATIONS	GALLAGHER NEIL JAMES	12-Oct-06	12-Oct-07	15-Jul-10
US20100178299	METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES	Northeastern University	13-Feb-07	13-Feb-08	15-Jul-10

CC-BY-NC-SA Dr. David E. Martin

US20100175006	SYSTEM AND METHOD FOR DETECTING, COLLECTING, ANALYZING, AND COMMUNICATING EVENT-RELATED INFORMATION	Georgetown University	28-Aug-08	2-Dec-09	8-Jul-10
US20100173980	ANTIVIRAL OLIGONUCLEOTIDES TARGETING RSV	JUTEAU JEAN-MARC	13-Sep-02	21-Dec-09	8-Jul-10
US20100173906	Substituted 3,4,6,7-Tetrahydro-5H-1,2a,4a,8-Tetraazacyclopenta[cd]Phenalenes and Methods	GRIESGRABER GEORGE W	6-Sep-06	6-Sep-07	8-Jul-10
US20100173325	Composition and Method for Analysis of Target Analytes	Millipore Corporation	17-Sep-03	4-Jul-09	8-Jul-10
US20100173280	Systems for Detection and Production of Respiratory, Herpes and Enteric Viruses	Diagnostic Hybrids, Inc	20-Sep-05	19-Sep-06	8-Jul-10
US20100172965	ANTIVIRAL OLIGONUCLEOTIDES TARGETING VIRAL FAMILIES	JUTEAU JEAN-MARC	13-Sep-02	21-Dec-09	8-Jul-10
US20100172917	Binding molecules against SARS-coronavirus and uses thereof	Crucell Holland B.V.	22-Jul-03	16-Nov-09	8-Jul-10
US20100166874	Technology for Preparation of Macromolecular Microspheres	FANG FANG	24-Jan-06	8-Dec-09	1-Jul-10
US20100166782	CLIP INHIBITORS AND METHODS OF MODULATING IMMUNE FUNCTION	AGADJANYAN MICHAEL	25-Jul-08	23-Jul-09	1-Jul-10
US20100166780	CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory Activity	Pfizer Inc	27-Sep-06	27-Sep-07	1-Jul-10
US20100166769	High-yield Transgenic Mammalian Expression System for Generating Virus-like Particles	Academia Sinica	5-Sep-06	12-Feb-10	1-Jul-10
US20100166661	siRNA COMPOSITIONS AND METHODS FOR POTENTLY INHIBITING VIRAL INFECTION	LIN YONGPING	11-Dec-08	11-Dec-09	1-Jul-10
US20100160486	POLYOLEFIN ANTIMICROBIAL COMPOSITIONS AND MELT-PROCESSING METHODS	BISHOP KEVIN L	19-Dec-08	19-Dec-08	24-Jun-10
US20100160323	NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE	BISCHOFF ALEXANDER	23-Dec-08	22-Dec-09	24-Jun-10
US20100160285	Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease	BIRKINSHAW TIMOTHY NICHOLAS	24-Aug-04	18-Dec-09	24-Jun-10
US20100160245	Quercetin-Containing Compositions	Quercegen Pharma LLC	17-Jul-06	16-Dec-09	24-Jun-10
US20100158943	ADMINISTRATION ROUTES FOR PRIMING/BOOSTING WITH INFLUENZA VACCINES	NOVARTIS VACCINES AND DIAGNOSTICS SRL	4-Nov-05	6-Nov-06	24-Jun-10
US20100158935	MUTANT FORMS OF STREPTOLYSIN O	NOVARTIS AG	21-Dec-07	24-Feb-10	24-Jun-10
US20100158928	IMMUNE RESPONSE MODIFIER COMPOSITIONS AND METHODS	GRIESGRABER GEORGE W	25-Dec-06	20-Dec-07	24-Jun-10
US20100152230	HYDROXY SUBSTITUTED 1H-IMIDAZOPYRIDINES AND METHODS	Pfizer Inc.	2-Sep-05	1-Sep-06	17-Jun-10
US20100152197	(4-TERT-BUTYLPIPERAZIN-2-YL)(PIPERAZIN-1-YL)METHANONE-N-CARBOXAMIDE DERIVATIVES	ASTRAZENECA AB	15-Dec-08	10-Dec-09	17-Jun-10
US20100152187	AMINOTHIAZOLE DERIVATIVES AS HUMAN STEAROYL-COA DESATURASE INHIBITORS	XENON PHARMACEUTICALS INC.	3-Jun-05	5-Jun-06	17-Jun-10
US20100152184	PHARMACEUTICAL COMPOUNDS	ASTEX THERAPEUTICS LIMITED	16-Nov-06	12-Oct-07	17-Jun-10
US20100151490	Antigenic Protein Conjugates and Process for Preparing Same	ABBOTT LABORATORIES	1-Sep-06	25-Feb-10	17-Jun-10
US20100150960	COMPOSITIONS AND METHODS FOR CHITOSAN ENHANCED IMMUNE RESPONSE	The United States of America, as represented by the Secretary,Department of Health and Human Servi	22-Sep-06	21-Sep-07	17-Jun-10
US20100150943	IMMUNOGENIC COMPOSITIONS FOR GRAM POSITIVE BACTERIA	NOVARTIS AG	26-Jul-06	26-Jul-07	17-Jun-10
US20100150923	FUSION PROTEINS OF RECOMBINANT SARS CORONAVIRUS STRUCTURAL PROTEINS, THEIR PRODUCTION AND USES	Chinese Academy of Medical Sciences, Institute of Basic Medical Sciences	20-Jun-05	13-Jun-06	17-Jun-10
US20100146647	Antibody producing non-human mammals	Merus B. V.	27-Jun-08	19-Oct-09	10-Jun-10
US20100144846	Oligoribonucleotides and uses thereof	COLEY PHARMACEUTICAL GMBH	26-Oct-06	26-Oct-07	10-Jun-10

CC-BY-NC-SA Dr. David E. Martin

US20100144833	RNAi Modulation Of RSV, PIV And Other Respiratory Viruses And Uses Thereof	BARIK SAILEN	22-Oct-04	25-Jun-09	10-Jun-10
US20100144828	CAFFEOYLQUINIC ACID DERIVATIVES CONTAINING NITROGEN, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USAGE THEREOF	ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICA	23-Mar-07	21-Mar-08	10-Jun-10
US20100144759	NOVEL N-(FLUORO-PYRAZINYL)-PHENYLSULFONAMIDES AS MODULATORS OF CHEMOKINE RECEPTOR CCR4	AstraZeneca AB	12-Dec-05	8-Dec-09	10-Jun-10
US20100144606	COMBINATION 408	AstraZeneca AB	20-Jun-08	19-Jun-09	10-Jun-10
US20100144589	METHODS OF PREDICTING CANCER LETHALITY USING REPLIKIN COUNTS	BOGOCH ELENORE S	23-Apr-08	7-Aug-09	10-Jun-10
US20100144040	CELLS AND METHODOLOGY TO GENERATE NON-SEGMENTED NEGATIVE-STRAND RNA VIRUSES	CHARNEAU PIERRE	22-Dec-06	21-Dec-07	10-Jun-10
US20100144015	COMPOSITIONS, METHODS AND USES FOR INDUCING VIRAL GROWTH	KINNEY RICHARD	5-Dec-08	4-Dec-09	10-Jun-10
US20100143888	ENZYMATIC DIAGNOSTIC TEST FOR SARS AND OTHER VIRAL DISEASES	MND Diagnostic Ltd.	23-Jun-03	25-Nov-09	10-Jun-10
US20100143881	Selective detection of human rhinovirus	and Human Services	5-Dec-08	5-Dec-08	10-Jun-10
US20100143411	METHOD FOR IDENTIFICATION OF T-LYMPHOCYTE ANTIGENS	The Government of the U.S.A. as represented by the Secretary, Dept. of Health and Human Service	27-May-08	27-May-09	10-Jun-10
US20100143406	METHODS OF ENHANCING PROTEIN INCORPORATION INTO VIRUS LIKE PARTICLES	PUSHKO PETER	30-Jun-06	27-Jun-07	10-Jun-10
US20100143302	Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof	Beth Israel Deaconess Medical Center, Inc	16-Mar-06	15-Mar-07	10-Jun-10
US20100130503	NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90	SANOFI-AVENTIS	24-Oct-06	24-Nov-09	27-May-10
US20100130491	9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7) MODULATORS	BONNERT ROGER VICTOR	19-Mar-07	19-Mar-08	27-May-10
US20100130430	STABILIZED THERAPEUTIC SMALL HELICAL ANTIVIRAL PEPTIDES	New York Blood Center, Inc	5-Oct-06	2-Oct-07	27-May-10
US20100129811	COMPOSITIONS FOR USE IN IDENTIFICATION OF PSEUDOMONAS AERUGINOSA	Ibis Biosciences, Inc.	11-Sep-03	2-Oct-09	27-May-10
US20100129437	TARGETED INTRACELLULAR DELIVERY OF ANTIVIRAL AGENTS	BBB Holding B.V.	23-Mar-07	21-Mar-08	27-May-10
US20100129400	ATTENUATED VIRUSES, VACCINES AND METHODS OF USE THEREOF	THE PENN STATE RESEARCH FOUNDATION	22-Dec-06	12-Jan-10	27-May-10
US20100129386	Composotions And Methods For The Identification And Treatment Of Immune-Mediated Inflammatory Diseases	CONG YINGZI	24-Jan-06	24-Jan-07	27-May-10
US20100129321	DIARYL UREA FOR TREATING VIRUS INFECTIONS	BAYER HEALTHCARE LLC	15-Dec-05	6-Dec-06	27-May-10
US20100119550	RECOMBINANT MULTIVALENT VACCINE	GOMI YASUYUKI	24-Nov-05	24-Nov-05	13-May-10
US20100113745	Means and Methods for Influencing the Stability of Antibody Producing Cells	Meibergdreef 9	9-Dec-05	8-Dec-06	6-May-10
US20100113565	IMMUNOSTIMULATORY COMBINATIONS AND METHODS	Not Available	8-Dec-04	8-Dec-05	6-May-10
US20100113510	QUINUCLIDINOL DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS	FORD RHONAN	19-Dec-06	17-Dec-07	6-May-10
US20100112710	METHODS AND COMPUTER SYSTEMS FOR IDENTIFYING TARGET-SPECIFIC SEQUENCES FOR USE IN NANOREPORTERS	NANOSTRING TECHNOLOGIES, INC.	10-Apr-07	10-Apr-08	6-May-10
US20100112643	METHOD FOR DIRECT CAPTURE OF RIBONUCLEIC ACID	The Government of the United States of America, as represented by the Secretary of the Navy	4-Nov-08	4-Nov-08	6-May-10
US20100112092	ANTIMICROBIAL SOLUTIONS CONTAINING DICHLORINE MONOXIDE AND METHODS OF MAKING AND USING THE SAME	Oculus Innovative Sciences, Inc.	13-Mar-07	13-Mar-08	6-May-10
US20100111873	TREATING CANCER WITH VIRAL NUCLEIC ACID	HADAC ELIZABETH M	20-Feb-07	20-Feb-08	6-May-10

CC-BY-NC-SA Dr. David E. Martin

US20100105873	INTEGRATED APPROACH FOR GENERATING MULTIDOMAIN PROTEIN THERAPEUTICS	MEDIMMUNE, INC.	1-Jul-05	30-Jun-06	29-Apr-10
US20100105642	NOVEL COMPOUNDS 409	ASTRAZENECA AB	18-Jun-08	18-Jun-09	29-Apr-10
US20100105025	DEVICES FOR GENERATING DETECTABLE POLYMERS	Not Available	12-Oct-06	12-Oct-07	29-Apr-10
US20100105024	RAPID TEST INCLUDING GENETIC SEQUENCE PROBE	Transgenex Nanobiotech, Inc.	14-Jan-08	16-Apr-09	29-Apr-10
US20100104503	MODULAR NANOPARTICLES FOR ADAPTABLE VACCINES	CAPLAN MICHAEL J	15-Feb-07	15-Feb-08	29-Apr-10
US20100099870	NOVEL ADENINE COMPOUND	AstraZeneca Aktiebolag	20-Mar-07	19-Mar-08	22-Apr-10
US20100099745	ENHANCING DISEASE RESISTANCE AGAINST RNA VIRAL INFECTIONS WITH INTRACYTOPLASMIC PATHOGEN SENSORS	GUO ZHA	18-Oct-06	16-Oct-07	22-Apr-10
US20100099672	METHODS FOR TREATING HEPATITIS C	PTC THERAPEUTICS, INC.	22-Jul-04	23-Dec-09	22-Apr-10
US20100099665	ISOQUINOLINONE DERIVATIVES	AstraZeneca AB	1-Oct-08	1-Oct-09	22-Apr-10
US20100099149	STABILIZING COMPOSITIONS AND METHODS FOR EXTRACTION OF RIBONUCLEIC ACID	DNA GENOTEK INC.	6-Oct-06	5-Oct-07	22-Apr-10
US20100099079	Non-dividing cell-based assay for high throughput antiviral compound screening	SAINZ JR BRUNO	26-Sep-08	24-Sep-09	22-Apr-10
US20100093998	NOVEL ADENINE COMPOUND	AstraZeneca Aktiebolag	20-Mar-07	19-Mar-08	15-Apr-10
US20100093862	POTENTIATION OF CELLULAR IMMUNITY USING HISTONE DEACETYLASE (HDAC) INHIBITORS.	Sapporo Medical Univeristy and Japan Science and Technology Agency	6-Dec-06	6-Dec-07	15-Apr-10
US20100093851	SILVER POLYAMIDE COMPOSITE	BISHOP KEVIN L	14-Oct-08	14-Oct-08	15-Apr-10
US20100093816	SALT	ARGENTA DISCOVERY LTD.	7-Feb-07	6-Feb-08	15-Apr-10
US20100093813	Salts 668	ASTRAZENECA AB	8-Feb-07	6-Feb-08	15-Apr-10
US20100093627	ALBUMIN FUSION PROTEINS	Human Genome Sciences. Inc.	9-Feb-04	3-Aug-09	15-Apr-10
US20100093038	Means and Methods for Influencing the Stability of Cells	Academisch Medisch Centrum bij de Universiteit van Amsterdam	9-Dec-05	9-Dec-05	15-Apr-10
US20100092474	PHARMACEUTICAL COMBINATIONS	GALLAGHER NEIL JAMES	12-Oct-06	12-Oct-07	15-Apr-10
US20100092470	ANTIBODIES, ANALOGS AND USES THEREOF	ICB International, Inc.	22-Sep-08	21-Sep-09	15-Apr-10
US20100092401	IMMUNE RESPONSE MODIFIER FORMULATIONS	Graceway Pharmaceuticals, LLC	18-Jul-06	12-Jul-07	15-Apr-10
US20100092399	METHODS OF TREATING OR PREVENTING INFLAMMATION AND HYPERSENSITIVITY WITH OXIDATIVE REDUCTIVE POTENTIAL WATER SOLUTION	Oculus Innovative Sciences, Inc.	20-Jan-06	21-Dec-09	15-Apr-10
US20100087443	9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7) MODULATORS	Not Available	19-Mar-07	19-Mar-08	8-Apr-10
US20100087388	ODCASE INHIBITORS AS ANTI-VIRALS AND ANTIBIOTICS	Not Available	3-Oct-05	3-Oct-06	8-Apr-10
US20100086950	IP-10 BASED IMMUNOLOGICAL MONITORING	Hvidovre Hospital	5-Sep-06	5-Sep-07	8-Apr-10
US20100086942	COMPOUNDS	AstraZeneca AB	21-Feb-07	4-Dec-09	8-Apr-10
US20100086571	METHODS TO DECREASE THE RISK OF METABOLIC SYNDROME POST IMMUNIZATION	CLASSEN JOHN BARTHELOW	5-Oct-06	5-Oct-07	8-Apr-10
US20100075298	Method for rapid identification and quantification of microorganisms	The Regents of the University of California	23-Sep-08	23-Sep-08	25-Mar-10
US20100070195	COMPUTER-IMPLEMENTED BIOLOGICAL SEQUENCE IDENTIFIER SYSTEM AND METHOD	The Government of the United States of America, as represented by the Secretary of the Navy	2-Jul-04	12-Nov-09	18-Mar-10

US20100070194	METHODS FOR RAPID IDENTIFICATION AND QUANTITATION OF NUCLEIC ACID VARIANTS	ECKER DAVID J	21-Jul-05	11-Nov-09	18-Mar-10
US20100069614	Antibody producing non-human mammals	Merus B.V.	27-Jun-08	29-Jun-09	18-Mar-10
US20100069427	Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring Compounds and Methods	COLEY PHARMACEUTICAL GROUP, INC.	11-Feb-05	10-Feb-06	18-Mar-10
US20100068223	Storage of Influenza Vaccines Without Refrigeration	SCHEFFCZIK HANNO	24-Mar-06	23-Mar-07	18-Mar-10
US20100063126	Carbazole-Derived Pharmaceutical Compositions	JadoLabs GmbH	29-Jun-04	29-Jun-05	11-Mar-10
US20100062441	C-MET MUTATIONS AND USES THEREOF	SALGIA RAVI	15-Mar-07	14-Mar-08	11-Mar-10
US20100061995	Immunotherapy To Treat Or Prevent Viral Infection	CARRAGHER DAMIAN MICHAEL	8-Sep-08	8-Sep-08	11-Mar-10
US20100061961	RECOMBINANT SUPER-COMPOUND INTERFERON	WEI GUANGWEN	28-Aug-03	4-Sep-09	11-Mar-10
US20100056508	AMINE DERIVATIVES AND THEIR USE IN BETA-2-ADRENORECEPTOR MEDIATED DISEASES	ASTRAZENECA AB	20-Dec-06	19-Dec-07	4-Mar-10
US20100056383	HIGH DENSITY SELF-CONTAINED BIOLOGICAL ANALYSIS	JONES DAVID E	15-Nov-06	14-Nov-07	4-Mar-10
US20100055761	METHODS, COMPOSITIONS, AND KITS FOR THE SELECTIVE ACTIVATION OF PROTOXINS THROUGH COMBINATORAL TARGETING	THE GENERAL HOSPITAL CORPORATION	20-Jul-06	20-Jul-07	4-Mar-10
US20100055116	Methods and Compositions for Targeting c-Rel	CHENG SHUHUA	13-Apr-06	13-Apr-07	4-Mar-10
US20100048584	PYRIDYL DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS	XENON PHARMACEUTICALS INC.	30-Jul-03	2-Sep-09	25-Feb-10
US20100048575	NOVEL TETRACYCLIC INHIBITORS OF CYSTEINE PROTEASES, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS	COLLAND FREDERIC	30-Oct-06	25-Oct-07	25-Feb-10
US20100048472	Albumin Fusion Proteins	Human Genome Sciences, Inc.	22-Jan-03	20-Apr-09	25-Feb-10
US20100047282	METHOD OF ACCELERATED VACCINATION AGAINST EBOLA VIRUSES	The Government of the USA as represented by the Secretary of Health and Human Services, NIH	2-Aug-04	5-Nov-09	25-Feb-10
US20100047277	VIROSOMES, METHODS OF PREPARATION, AND IMMUNOGENIC COMPOSITIONS	COMPANS RICHARD W	13-Jul-06	12-Jul-07	25-Feb-10
US20100047264	Immunogenic Affinity-Conjugated Antigen Systems Based on Papaya Mosaic Virus and Uses Thereof	FOLIA BIOTECH INC.	15-Nov-06	25-Oct-07	25-Feb-10
US20100047179	TARGETED SPLIT BIOMOLECULAR CONJUGATES FOR THE TREATMENT OF DISEASES, MALIGNANCIES AND DISORDERS, AND METHODS OF THEIR PRODUCTION	ST. JUDE CHILDREN'S RESEARCH HOSPITAL	27-Oct-06	26-Oct-07	25-Feb-10
US20100042394	System and Method to Predict the Global Spread of Infectious Agents Via Commercial Air Travel	KHAN KAMRAN	2-Apr-07	2-Apr-08	18-Feb-10
US20100041638	Chemical Compounds 293	ANDREWS GLEN	27-May-08	26-May-09	18-Feb-10
US20100041617	Modulating mxa expression	CHUNG EUN J	27-Sep-04	27-Sep-05	18-Feb-10
US20100041013	ASSAY FOR A HEALTH STATE	HUMAN GENETIC SIGNATURES PTY LTD.	14-Sep-05	14-Sep-06	18-Feb-10
US20100040703	USE OF NITRIC OXIDE	MILLER CHRIS	13-Aug-08	12-Aug-09	18-Feb-10
US20100040676	POLYCISTRONIC HIV VECTOR CONSTRUCTS	Novartis Vaccines and Diagnostics, Inc.	5-May-04	22-Oct-09	18-Feb-10
US20100040655	Anti-viral Formulations Nanomaterials And Nanoparticles	INTRINSIQ MATERIALS LIMITED	16-Feb-06	16-Feb-07	18-Feb-10
US20100040635	NEUTRALIZING ANTIBODIES TO INFLUENZA VIRUSES	Sea Lane Biotechnologies	28-Mar-08	27-Mar-09	18-Feb-10
US20100035973	DISRUPTION OF PROGRAMMED DEATH 1 (PD-1) LIGAND TO ADJUVANT ADENO-ASSOCIATED VIRUS VECTOR VACCINES	Nationwide Children's Hospital, Inc.	17-Jul-06	13-Jul-07	11-Feb-10

US20100035848	THERAPY FOR DISORDERS OF THE PROXIMAL DIGESTIVE TRACT	BARNES THOMAS MICHAEL	10-Mar-08	10-Mar-09	11-Feb-10
US20100035836	BICYCLIC NUCLEOSIDES AND NUCLEOTIDES AS THERAPEUTIC AGENTS	BETHELL RICHARD	3-Jul-08	1-Jul-09	11-Feb-10
US20100035761	High-throughput rna structure analysis	GIDDINGS MORGAN C	5-Jun-06	5-Jun-07	11-Feb-10
US20100035239	Compositions for use in identification of bacteria	ISIS Pharmaceuticals, Inc.	11-Sep-03	17-Feb-05	11-Feb-10
US20100035234	VACCINE ASSAYS	Novartis AG	19-May-08	19-May-09	11-Feb-10
US20100035232	TARGETED WHOLE GENOME AMPLIFICATION METHOD FOR IDENTIFICATION OF PATHOGENS	ECKER DAVID J	14-Sep-06	14-Sep-07	11-Feb-10
US20100035227	Compositions for use in identification of alphaviruses	ISIS Pharmaceuticals, Inc.	3-Mar-04	2-Mar-05	11-Feb-10
US20100034852	METHODS AND COMPOSITIONS FOR PREDICTING AND TREATING DRUG RESISTANT STRAINS OF INFLUENZA VIRUS	NIMAN HENRY L	25-Jan-07	24-Jan-08	11-Feb-10
US20100029732	Combinations of Beta-2-Adrenoceptor Agonistic Benzothiazolone	ASTRAZENECA AB	8-Feb-07	6-Feb-08	4-Feb-10
US20100029722	ORGANIC COMPOUNDS	DALES NATALIE	20-Dec-06	19-Dec-07	4-Feb-10
US20100029718	ORGANIC COMPOUNDS	Novartis AG	22-Sep-06	19-Sep-07	4-Feb-10
US20100029713	QUINICLIDINE DERIVATIVES OF (HETERO) ARYLCYCLOHEPTANECARBOXYLIC ACID AS MUSCARINIC RECEPTOR ANTAGONISTS	ASTRAZENECA AB	14-Nov-06	13-Nov-07	4-Feb-10
US20100029585	TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE	DIETSCH GREGORY	1-Aug-08	31-Jul-09	4-Feb-10
US20100029557	ALPHA-LACTALBUMIN COMPOSITION	GULDMANN MARIANNE	17-Nov-06	15-Nov-07	4-Feb-10
US20100029552	Peptide inhibitors of c-jun dimerization and uses thereof	Phylogica Limited	20-Aug-04	22-Aug-05	4-Feb-10
US20100028853	OPTICAL DETERMINATION OF LIVING VS. NON LIVING CELLS	Not Available	25-Oct-05	2-Nov-06	4-Feb-10
US20100028381	FORMULATION FOR DELIVERY OF IMMUNE RESPONSE MODIFIERS	3M INNOVATIVE PROPERTIES COMPANY	19-Jun-06	18-Jun-07	4-Feb-10
US20100028369	Hazardous substance removing material and method for removing hazardous substance	FUJIFILM Corporation	29-Jul-08	28-Jul-09	4-Feb-10
US20100022491	4-HYDROXY-2-OXO-2,3-DIHYDRO-1,3-BENZOTHIAZOL-7YL COMPOUNDS FOR MODULATION OF B2-ADRENORECEPTOR ACTIVITY	ASTRAZENECA AB	20-Dec-06	19-Dec-07	28-Jan-10
US20100021987	Compositions, Methods, and Kits for Enhancing Protein Expression	LIFESENSORS, INC.	30-Dec-04	30-Dec-05	28-Jan-10
US20100021907	METHOD OF DETECTING A PLURALITY OF NUCLEIC ACIDS	KABUSHIKI KAISHA TOSHIBA	3-Jul-08	12-Jun-09	28-Jan-10
US20100021895	Vectors for Inducing Homozygous Mutations and Methods of Using Same	RULEY H EARL	12-Jul-06	12-Jul-07	28-Jan-10
US20100021470	MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION OF B CELLS	INSTITUTE FOR RESEARCH IN BIOMEDICINE	26-Feb-03	26-Feb-04	28-Jan-10
US20100016388	Salts of a Selective Beta-2 Andrenoceptor Agonist	Not Available	1-Mar-07	29-Feb-08	21-Jan-10
US20100016359	METHODS FOR CONTROLLING SR PROTEIN PHOSPHORYLATION, AND ANTIVIRAL AGENTS WHOSE ACTIVE INGREDIENTS COMPRISE AGENTS THAT CONTROL SR PROTEIN ACTIVITY	Masatoshi Hagiwara	26-Dec-03	29-Jun-09	21-Jan-10
US20100015633	METHODS AND KIT FOR ANALYTE DETECTION	GENERAL ELECTRIC COMPANY	18-Jul-08	18-Jul-08	21-Jan-10
US20100015607	NANOREPORTERS AND METHODS OF MANUFACTURING AND USE THEREOF	INSTITUTE FOR SYSTEMS BIOLOGY	23-Dec-05	22-Dec-06	21-Jan-10
US20100015594	HUMAN PAPILLOMA VIRUS (HPV) DETECTION USING NUCLEIC ACID PROBES, MICROBEADS AND FLUORESCENT-ACTIVATED CELL SORTER (FACS)	GOULD TOBY	10-Dec-04	9-Dec-05	21-Jan-10

CC-BY-NC-SA Dr. David E. Martin

US20100015283	Method of Preparing Powder Kimchi and Kimchi Composition Using the Same	Not Available	26-Jun-06	26-Jun-07	21-Jan-10
US20100015211	Combination Approaches For Generating Immune Responses	BARNETT SUSAN W	1-Nov-04	1-Nov-05	21-Jan-10
US20100015173	COILED-COIL LIPOPEPTIDE HELICAL BUNDLES AND SYNTHETIC VIRUS-LIKE PARTICLES	UNIVERSITÃƒÂ„T ZÃƒÂ¼RICH PROREKTORAT FORSCHUNG	9-Dec-06	6-Dec-07	21-Jan-10
US20100010217	METHODS FOR THE PREPARATION OF IMIDAZOLE-CONTAINING COMPOUNDS	LAN JIONG	23-Mar-06	23-Mar-07	14-Jan-10
US20100010199	MAKING INFLUENZA VIRUS VACCINES WITHOUT USING EGGS	NOVARTIS AG	11-Sep-06	11-Sep-07	14-Jan-10
US20100010080	USE OF TYLVALOSIN AS ANTIVIRAL AGENT	CAMBRIDGE UNIVERSITY TECHNICAL SERVICES	13-Jul-06	13-Jul-07	14-Jan-10
US20100009343	COMPOSITIONS AND METHOD FOR RAPID, REAL-TIME DETECTION OF INFLUENZA A VIRUS (H1N1) SWINE 2009	Longhorn Vaccines & Diagnostics, LLC	12-Sep-06	28-Jul-09	14-Jan-10
US20100004304	METHODS AND COMPOSITIONS FOR THE TREATMENT OF MALIGNANT MELANOMA, BREAST, PROSTATE, COLON, PAPILLARY THYROID AND PANCREATIC CANCER	GIULLANT CESIDIO	16-Mar-04	1-Oct-08	7-Jan-10
US20100003723	RNA-DEPENDENT DNA POLYMERASE FROM GEOBACILLUS STEAROTHERMOPHILUS	LAMPSON BERT C	10-Mar-04	10-Mar-04	7-Jan-10
US20100003277	VACCINES AND IMMUNOTHERAPEUTICS USING CODON OPTIMIZED IL-15 AND METHODS FOR USING THE SAME	KUTZLER MICHELE	13-Jan-06	12-Jan-07	7-Jan-10
US20100003269	METHODS AND USES OF CAULIFLOWER AND COLLARD FOR RECOMBINANT PROTEIN PRODUCTION	THOMAS JEFFERSON UNIVERSITY	11-Jul-06	28-Jun-07	7-Jan-10
US20090318435	PYRAZOLOPYRIDINES AND ANALOGS THEREOF	BONK JASON D	3-Oct-03	8-Jun-09	24-Dec-09
US20090318337	Compositions and methods for activating innate and allergic immunity	ID Biomedical Corporation of Quebec	22-Oct-03	22-Oct-04	24-Dec-09
US20090317421	COMPOSITIONS AND METHODS RELATED TO STAPHYLOCOCCAL BACTERIUM PROTEINS	BURTS MONICA	18-Jan-06	18-Jan-07	24-Dec-09
US20090317417	Modified AAV Vectors Having Reduced Capsid Immunogenicity and Use Thereof	The Trustees of the University of Pennsylvania	28-Apr-06	27-Apr-07	24-Dec-09
US20090312285	BIOLOGICAL SPECIMEN COLLECTION AND TRANSPORT SYSTEM AND METHODS OF USE	Longhorn Vaccines & Diagnostics, LLC	1-Oct-07	1-Oct-08	17-Dec-09
US20090311683	COMPOSITIONS FOR THE USE IN IDENTIFICATION OF FUNGI	IBIS BIOSCIENCES, INC.	6-Apr-06	6-Apr-07	17-Dec-09
US20090311334	MUCOSAL IMMUNOGENIC SUBSTANCES COMPRISING A POLYINOSINIC ACID - POLYCYTIDILIC ACID BASED ADJUVANT	LI LIE TAO VICTOR	13-Jan-06	27-Jun-06	17-Dec-09
US20090311288	IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS	Novartis AG	23-Mar-06	23-Mar-07	17-Dec-09
US20090306347	ANTIBODY PRODUCED USING OSTRICH AND METHOD FOR PRODUCTION THEREOF	JAPAN SCIENCE AND TECHNOLOGY AGENCY	29-Aug-05	29-Aug-06	10-Dec-09
US20090306090	HETEROCYCLIC DERIVATIVES AND THEIR USE AS STEAROYL-COA DESATURASE INHIBITORS	Xenon Pharmaceuticals Inc.	20-Sep-04	13-Aug-09	10-Dec-09
US20090306042	Novel Compounds 010	CAGE PETER ALAN	12-Dec-07	10-Dec-08	10-Dec-09
US20090305282	NOVEL HUMAN VIRUS CAUSING RESPIRATORY TRACT INFECTION AND USES THEREOF	CHAN KWOK HUNG	21-Jul-04	1-Jun-09	10-Dec-09
US20090304743	Composition and Methods for Immunisation Using CD1D Ligands	GALLI GRAZIA	15-Mar-06	15-Mar-07	10-Dec-09
US20090304742	INFLUENZA VACCINES WITH REDUCED AMOUNT OF EMULSION ADJUVANT	Novartis Vaccines and Diagnostics SRL	4-Nov-05	6-Nov-06	10-Dec-09
US20090304739	INFLUENZA VACCINES INCLUDING COMBINATIONS OF PARTICULATE ADJUVANTS AND IMMUNOPOTENTIATORS	NOVARTIS VACCINES AND DIAGNOSTICS SRL	4-Nov-05	6-Nov-06	10-Dec-09
US20090304729	CELL-DERIVED VIRAL VACCINES WITH LOW LEVELS OF RESIDUAL CELL DNA	NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO KG	1-Nov-05	1-Nov-06	10-Dec-09
US20090304683	Soluble Fragments of The Sars-Cov Spike Glycoprotein	DIMITROV DIMITER S	19-Jan-07	19-Jan-07	10-Dec-09
US20090304681	Methods for the treatment and prevention of infection using anti-selectin agents	Not Available	29-Jul-04	27-Jul-05	10-Dec-09

US20090304630	Treating severe and acute viral infections	HEMISPHERx BIOPHARMA	16-May-03	2-Aug-07	10-Dec-09
US20090300778	Neutral Sphingomyelinase-E and Its Use	HOPPE UTA	8-Feb-06	8-Feb-07	3-Dec-09
US20090299250	ANTIVIRAL FILTER AND ITS USE IN AN AIR PURIFIER, AIR CONDITIONER OR AIR HUMIDIFIER	Universite De Rouen	19-Jul-06	19-Jul-07	3-Dec-09
US20090298914	RNA Interference Mediated Inhibition of Severe Acute Respiratory Syndrome (SARS) Virus Gene Expression Using Short Interfering Nucleic Acid (siNA)	Sirna Therapeutics, Inc.	15-Apr-03	17-Nov-08	3-Dec-09
US20090298821	HYDROXY AND ALKOXY SUBSTITUTED IH-IMIDAZONAPHTHYRIDINES AND METHODS	Pfizer Inc.	15-Mar-06	14-Mar-07	3-Dec-09
US20090298807	Compounds	ALCARAZ LILIAN	6-Feb-08	4-Feb-09	3-Dec-09
US20090297555	RECOMBINANT HUMAN CYTOMEGALOVIRUS AND VACCINES COMPRISING HETEROLOGOUS ANTIGENS	MEDIMMUNE, LLC	25-Jun-04	30-Jun-09	3-Dec-09
US20090286835	NOVEL COMPOUNDS	AstraZeneca AB	4-Oct-07	3-Oct-08	19-Nov-09
US20090286813	Thioxanthine Derivatives and Their Use as Inhibitors of MPO	ASTRAZENECA AB	13-Apr-06	12-Apr-07	19-Nov-09
US20090286726	USE OF THE LONG PENTRAXIN PTX3 FOR THE PREVENTION OR TREATMENT OF VIRAL DISEASES	TECNOGEN S.P.A.	10-Mar-06	28-Feb-07	19-Nov-09
US20090286222	Mixed Cell Diagnostic Systems For Detection Of Respiratory, Herpes And Enteric Viruses	GOODRUM PATRICIA GAIL RAY	24-Apr-98	16-Oct-08	19-Nov-09
US20090285921	PLANT EXTRACT AND ITS THERAPEUTIC USE	Veritron Limited	16-May-08	1-Dec-08	19-Nov-09
US20090285901	Polyamino acid for use as adjuvant	AKASHI MITSURU	20-Apr-05	27-Jul-09	19-Nov-09
US20090285854	FROZEN STOCKPILING OF INFLUENZA VACCINES	Novartis AG	20-Jul-06	20-Jul-07	19-Nov-09
US20090281042	COMPOSITIONS AND METHODS USING SAME FOR THE DETECTION OF VIRUSES	ARAD DORIT	8-Sep-05	10-Sep-06	12-Nov-09
US20090281041	ANTIVIRAL CELL-PENETRATING PEPTIDES	CURRELI FRANCESCA	6-May-08	5-May-09	12-Nov-09
US20090280507	METHOD FOR MEASUREMENT OF SARS VIRUS NUCLEOCAPSID PROTEIN, REAGENT KIT FOR THE MEASUREMENT, TEST DEVICE, MONOCLONAL ANTIBODY DIRECTED AGAINST SARS VIRUS NUCLEOCAPSID PROTEIN, AND HYBRIDOMA CAPABLE OF PRODUCING THE MONOCLONAL ANTIBODY	SYSMEX CORPORATION	11-Oct-05	11-Oct-06	12-Nov-09
US20090275666	CONDENSATION PRODUCTS, METHOD FOR THEIR PRODUCTION AND USE THEREOF IN MEDICAMENTS, AS DISINFECTANTS OR AS A TANNIN	BASF SE	17-May-06	28-Feb-07	5-Nov-09
US20090275583	ANTIVIRAL COMPOUNDS AND USE THEREOF	Myriad Genetics, Incorporated	13-Oct-06	13-Apr-09	5-Nov-09
US20090275508	USE OF THYMOSIN ALPHA 1, ALONE OR IN COMBINATION WITH PTX3 OR GANCICLOVIR, FOR THE TREATMENT OF CYTOMEGALOVIRUS INFECTION	SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.	2-May-06	12-Apr-07	5-Nov-09
US20090275016	ARRAYED DETECTOR SYSTEM FOR MEASUREMENT OF INFLUENZA IMMUNE RESPONSE	UNIVERSITY OF ROCHESTER	2-May-08	1-May-09	5-Nov-09
US20090270443	1-AMINO IMIDAZO-CONTAINING COMPOUNDS AND METHODS	Not Available	2-Sep-04	2-Sep-05	29-Oct-09
US20090270431	Cyclopentenol Nucleoside Compounds Intermediates for their Synthesis and Methods of Treating Viral Infections	THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION	19-Oct-05	19-Oct-06	29-Oct-09
US20090269367	METHODS AND COMPOUNDS FOR MITIGATING PATHOGENIC OUTBREAKS USING REPLIKIN COUNT CYCLES	BOGOCH ELENORE S	23-Apr-08	23-Apr-09	29-Oct-09
US20090264653	USEFUL INDOLE COMPOUNDS	BARDEN TIMOTHY	16-Dec-05	18-Dec-06	22-Oct-09
US20090264509	Adenoviral vector-based foot-and-mouth disease vaccine	GENVEC, INC.	10-Nov-05	8-May-08	22-Oct-09
US20090264444	Organic compounds	CHOWDHURY SULTAN	20-Feb-08	20-Feb-09	22-Oct-09

CC-BY-NC-SA Dr. David E. Martin

US20090264362	Influenza virus inhibiting peptides	The Administrators of the Tulane Educational Fund	4-Nov-03	17-Feb-09	22-Oct-09
US20090264307	ARRAY-BASED POLYMORPHISM MAPPING AT SINGLE NUCLEOTIDE RESOLUTION	The Trustees of Princeton University	13-Jan-06	12-Jan-07	22-Oct-09
US20090264300	ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES	Nuevolution A/S	1-Dec-05	1-Dec-06	22-Oct-09
US20090263352	METHODS FOR TREATING VIRAL INFECTION USING IL-28 AND IL-29 CYSTEINE MUTANTS	ZymoGenetics, LLC	2-Apr-04	21-May-09	22-Oct-09
US20090258440	SURFACE FOR LABEL INDEPENDENT DETECTION AND METHOD THEREOF	BUNCH THOMAS A	10-Apr-08	3-Apr-09	15-Oct-09
US20090258340	Assay for SARS coronavirus by amplification and detection of the replicase sequence	Becton, Dickinson and Company	12-Sep-03	3-Feb-09	15-Oct-09
US20090258074	MIXTURES OF TANNINS, THEIR PRODUCTION AND USE IN MEDICAMENTS OR AS DISINFECTANTS	BASF SE	17-May-06	28-Feb-07	15-Oct-09
US20090258011	Antibodies against west nile virus and therapeutic and prophylactic uses thereof	Washington University	21-Jun-04	6-Apr-09	15-Oct-09
US20090257950	Membrane Scaffold Proteins	THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS	20-Nov-00	10-Oct-07	15-Oct-09
US20090253714	Methods of reducing risk of infection from pathogens	Not Available	20-Aug-03	18-Aug-04	8-Oct-09
US20090253695	Hydroxyalkyl Substituted Imidazonaphthyridines	Coley Pharmaceutical Group, Inc,	23-Feb-05	22-Feb-06	8-Oct-09
US20090252775	VIRUCIDAL DISINFECTANT	B. BRAUN MEDICAL AG	28-Jan-05	28-May-09	8-Oct-09
US20090252646	STERILIZATION METHODS AND SYSTEMS FOR GAMING EQUIPMENT	Invention Factory, LLC	8-Jan-07	28-May-09	8-Oct-09
US20090247614	Folate Conjugates	ALNYLAM PHARMACEUTICALS, INC.	4-Dec-07	4-Dec-08	1-Oct-09
US20090247608	Targeting Lipids	ALNYLAM PHARMACEUTICALS, INC.	4-Dec-07	4-Dec-08	1-Oct-09
US20090239848	NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE	FOREST LABORATORIES HOLDINGS LIMITED	20-Mar-08	20-Mar-09	24-Sep-09
US20090239830	Treatment of viral infections by modulation of host cell metabolic pathways	BENNETT BRYSON	1-Jun-07	2-Jun-08	24-Sep-09
US20090239824	HYDROLYTICALLY-RESISTANT BORON-CONTAINING THERAPEUTICS AND METHODS OF USE	Anacor Pharmaceuticals, Inc.	16-Jun-03	13-Nov-08	24-Sep-09
US20090239814	Carbohydrate Conjugates as Delivery Agents for Oligonucleotides	ALNYLAM PHARMACEUTICALS, INC.	4-Dec-07	4-Dec-08	24-Sep-09
US20090239810	NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE	Forest Laboratories Holdings Limited	20-Mar-08	20-Mar-09	24-Sep-09
US20090235625	FILTER AND ASSOCIATED METHOD	GENERAL ELECTRIC COMPANY	28-Sep-07	28-Sep-07	24-Sep-09
US20090233965	Alkyl Esters Of Cyclic Amino Alcohols With Muscarinic M3 Receptor Antagonist Activity, Useful For Treating E.G. Chronic Bronchial Obstruction, Asthma And Overactive Bladder	ASTRAZENECA AB	24-Apr-06	23-Apr-07	17-Sep-09
US20090233907	Pyridopyrimidine Derivatives and Their Use as PDE4 Inhibitors	ASTRAZENECA AB	22-Mar-06	20-Mar-07	17-Sep-09
US20090233309	BIOLOGICAL SPECIMEN COLLECTION/TRANSPORT COMPOSITIONS AND METHODS	LONGHORN VACCINES & DIAGNOSTICS, LLC	1-Oct-07	20-Apr-09	17-Sep-09
US20090232844	IMMUNOPOTENTIATING COMPOUNDS	SUTTON JAMES	23-Mar-06	23-Mar-07	17-Sep-09
US20090232843	Identifying and predicting influenza variants and uses thereof	NIMAN HENRY L	8-Jul-05	4-Jan-08	17-Sep-09
US20090232808	MOLECULES AND CHIMERIC MOLECULES THEREOF	APOLLO LIFE SCIENCES LIMITED	28-Jan-05	27-Jan-06	17-Sep-09
US20090232748	Virucidal activities of cetylpyridinium chloride	ViraTox, L.L.C.	7-Nov-03	18-Mar-09	17-Sep-09
US20090227637	DIARYL UREAS FOR TREATING VIRUS INFECTIONS	RIEDL BERND	15-Dec-05	6-Dec-06	10-Sep-09

CC-BY-NC-SA Dr. David E. Martin

US20090227541	BORON-CONTAINING SMALL MOLECULES	Anacor Pharmaceuticals, Inc.	20-Jun-07	19-Jun-08	10-Sep-09
US20090227030	Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor	The Trustees of the University of Pennsylvania	17-Dec-01	31-Oct-07	10-Sep-09
US20090227005	Methods for pathogen detection	Searete LLC, a limited liability corporation of the State of Delaware	27-Mar-07	28-Sep-07	10-Sep-09
US20090226885	Nucleic Acid Sequences That Can Be Used As Primers And Probes In The Amplification And Detection Of Sars Coronavirus	OVERDIJK MARLIEKE	10-Jun-03	8-Mar-04	10-Sep-09
US20090222936	Recombinant Expression of Multiprotein Complexes Using Polygenes	BERGER IMRE	8-Nov-05	6-Nov-06	3-Sep-09
US20090221653	7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-derivatives as beta2 adrenoreceptor agonists	AstraZeneca AB	29-Aug-05	28-Aug-06	3-Sep-09
US20090221640	Novel Crystal Modifications	ASTRAZENECA AB	16-Mar-06	15-Mar-07	3-Sep-09
US20090221631	IMIDAZOPYRIDINONES	Not Available	3-Aug-07	15-May-09	3-Sep-09
US20090221624	4-AMINOQUINOLINE COMPOUNDS FOR TREATING VIRUS-RELATED CONDITIONS	BUSCHER BENJAMIN A	6-May-05	4-May-06	3-Sep-09
US20090221583	NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE	AURIGENE DISCOVERY TECHNOLOGIES LIMITED	21-Jun-07	23-Jun-08	3-Sep-09
US20090221556	HYDROXY AND ALKOXY SUBSTITUTED 1H-IMIDAZOQUINOLINES AND METHODS	Pfizer Inc.	4-Nov-05	3-Nov-06	3-Sep-09
US20090221551	SUBSTITUTED FUSED[1,2] IMIDAZO[4,5C] RING COMPOUNDS AND METHODS	Pfizer Inc.	15-Mar-06	14-Mar-07	3-Sep-09
US20090221487	POLYETHLENE GLYCOL MODIFICATIONS OF THYMOSIN ALPHA-1	Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China	10-Nov-05	11-Nov-06	3-Sep-09
US20090220941	COMPOSITIONS FOR- DETECTING OF INFLUENZA VIRUSES AND KITS AND METHODS USING SAME	MND DIAGNOSTIC LTD	25-Oct-05	25-Oct-06	3-Sep-09
US20090220937	Compositions for Use in Identification of Adventitious Viruses	IBIS BIOSCIENCES, INC.	3-Mar-05	3-Mar-06	3-Sep-09
US20090220547	Reducing interference between oil-containing adjuvants and surfactant-containing antigens	NOVARTIS VACCINES AND DIAGNOSTICS SRL	2-Aug-05	2-Aug-06	3-Sep-09
US20090220546	Adjuvanted influenza vaccines for pediatric use	GROTH NICOLA	22-Feb-08	20-Feb-09	3-Sep-09
US20090220545	Adjuvant-Sparing Multi-Dose Influenza Vaccination Regimen	NOVARTIS AG	15-Jun-06	15-Jun-07	3-Sep-09
US20090220544	ADJUVANTED VACCINES WITH NON-VIRION ANTIGENS PREPARED FROM INFLUENZA VIRUSES GROWN IN CELL CULTURE	NOVARTIS VACCINES AND DIAGNOSTICS SRL	4-Nov-05	6-Nov-06	3-Sep-09
US20090220541	EMULSIONS WITH FREE AQUEOUS-PHASE SURFACTANT FOR ADJUVANTING SPLIT INFLUENZA VACCINES	NOVARTIS VACCINES AND DIAGNOSTICS SRL	4-Nov-05	6-Nov-06	3-Sep-09
US20090220530	DEFECTIVE RIBOSOMAL PRODUCTS IN BLEBS (DRIBBLES) AND METHODS OF USE TO STIMULATE AN IMMUNE RESPONSE	HU HONG-MING	29-Jul-05	27-Jul-06	3-Sep-09
US20090220514	ADAM10 and its Uses Related to Infection	HODGE THOMAS	13-Jan-06	16-Jan-07	3-Sep-09
US20090220456	USES OF INTERFERONS WITH ALTERED SPATIAL STRUCTURE	Not Available	28-Aug-03	11-Feb-09	3-Sep-09
US20090216860	SYSTEM AND METHOD FOR DETECTING, COLLECTING, ANALYZING, AND COMMUNICATING EVENT RELATED INFORMATION	Georgetown University	25-Feb-08	19-Nov-08	27-Aug-09
US20090216747	System and method for detecting, collecting, analyzing, and communicating event-related information	Georgetown University- OTC	25-Feb-08	28-Aug-08	27-Aug-09
US20090215786	NOVEL CYSTEINE PROTEASE INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS	BOISSY GUILLAUME	5-Aug-05	26-Jul-06	27-Aug-09
US20090214663	Virus coated nanoparticles and uses thereof	ALBRECHT THOMAS B	26-Sep-06	26-Mar-09	27-Aug-09
US20090214590	Virus Vaccines Comprising Envelope-Bound Immunomodulatory Proteins and Methods of Use Thereof	Wayne State University	8-Jul-05	10-Jul-06	27-Aug-09

CC-BY-NC-SA Dr. David E. Martin

US20090214587	Recombinant virus and use thereof	Post Genome Institute Co., Ltd.	8-Oct-04	11-Oct-05	27-Aug-09
US20090214537	Serum Resistance Factors of Gram Positive Bacteria	NOVARTIS VACCINES AND DIAGNOSTICS, INC.	13-May-05	12-May-06	27-Aug-09
US20090214533	METHODS FOR CONVERTING OR INDUCING PROTECTIVE IMMUNITY	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	17-Aug-06	17-Feb-09	27-Aug-09
US20090214510	Broad Spectrum Antiviral Compositions	Government of the US as represented by the Secretary, Department of Health and Human Services	21-Feb-06	21-Feb-07	27-Aug-09
US20090214444	POLY AROMATIC SODIUM CHANNEL BLOCKERS	PARION SCIENCES, Inc.	26-Feb-08	26-Feb-09	27-Aug-09
US20090209640	Prevention of and countermeasures against viral infection	CHOKO CO., LTD.	20-Nov-03	15-Apr-09	20-Aug-09
US20090209555	2-PYRAZINONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL	HANSEN PETER	8-May-06	7-May-07	20-Aug-09
US20090209524	Novel Compounds	AstraZeneca AB	22-Nov-07	20-Nov-08	20-Aug-09
US20090209505	PRODRUGS OF HETEROARYL COMPOUNDS	Koronis Pharmaceuticals, Incorporated	20-Jun-03	7-Apr-09	20-Aug-09
US20090209458	Cell-penetrating socs polypeptides that inhibit cytokine-induced signaling	VANDERBILT UNIVERSITY	4-Mar-04	4-Mar-05	20-Aug-09
US20090208531	ANTIVIRAL AGENTS AND VACCINES AGAINST INFLUENZA	National Institutes of Health Office of Technology	16-Feb-06	16-Feb-07	20-Aug-09
US20090205116	ARTICLE, LAMINATE AND ASSOCIATED METHODS	GENERAL ELECTRIC COMPANY	30-Sep-05	5-Dec-08	20-Aug-09
US20090203753	7-(2-amino-1-hydroxy-ethyl)-4-hydroxybenzothiazol-2(3H)-one-derivatives as beta2 adrenoreceptor agonists	AstraZeneca AB	29-Aug-05	28-Aug-06	13-Aug-09
US20090203675	Sulfonyl Semicarbazides, Semicarbazides and Ureas, Pharmaceutical Compositions Thereof, and Methods for Treating Hemorrhagic Fever Viruses, Including Infections Associated with Arena Viruses	SIGA TECHNOLOGIES, INC.	6-Dec-04	6-Dec-05	13-Aug-09
US20090203112	VERO CELL LINE WHICH IS ADAPTED TO GROW IN SUSPENSION	Ricardo Kratje	4-Oct-05	3-Oct-06	13-Aug-09
US20090202995	MOLECULAR CARDIOTOXICOLOGY MODELING	JOHNSON KORY R	26-Aug-05	28-Aug-06	13-Aug-09
US20090202590	INFLUENZA VACCINES EXTEMPORANEOUSLY ADSORBED TO ALUMINIUM ADJUVANTS	NOVARTIS VACCINES AND DIGNOSTICS SRL	4-Nov-05	6-Nov-06	13-Aug-09
US20090197914	Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them	CAGE PETER	7-Mar-06	6-Mar-07	6-Aug-09
US20090197894	NICOTINAMIDE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS	XENON PHARMACEUTICALS INC.	21-Dec-01	14-Apr-09	6-Aug-09
US20090197890	PYRIDAZINE DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS	XENON PHARMACEUTICALS INC.	30-Jul-03	20-Feb-09	6-Aug-09
US20090197338	Method of Increasing the Function of an AAV Vector	The Trustees of teh University of Pennsylvania	7-Apr-05	7-Apr-06	6-Aug-09
US20090196921	Compositions Methods and Kits For Enhancing Immune Response To A Respiratory Condition	The Procter & Gamble Company	6-Feb-08	6-Feb-09	6-Aug-09
US20090192505	Method for cryospray ablation	Reset Medical, Inc.	5-Dec-07	5-Dec-08	30-Jul-09
US20090192163	Novel Compounds	ASTRAZENECA AB	6-Oct-05	5-Oct-06	30-Jul-09
US20090192153	NOVEL ADENINE COMPOUND	AstraZeneca Aktiebolag A corporation of Sweden	22-Sep-05	21-Sep-06	30-Jul-09
US20090192099	PRODRUGS OF HETEROARYL COMPOUNDS	Koronis Pharmaceuticals, Incorporated	20-Jun-03	30-Mar-09	30-Jul-09
US20090192090	PEPTIDES AND PEPTIDOMIMETICS HAVING IMMUNE-MODULATING, ANTI-INFLAMMATORY, AND ANTI-VIRAL ACTIVITY	TAKEDA PHARMACEUTICAL COMPANY LIMITED	25-Jun-03	31-Dec-08	30-Jul-09
US20090192081	Casein derived peptides and uses thereof	SIDELMAN ZVI	1-Mar-00	31-Oct-07	30-Jul-09

CC-BY-NC-SA Dr. David E. Martin

US20090191229	ADJUVANCY AND IMMUNE POTENTIATING PROPERTIES OF NATURAL PRODUCTS OF ONCHOCERCA VOLVULUS	NEW YORK BLOOD CENTER	15-Jun-04	23-Mar-09	30-Jul-09
US20090186056	COMPOSITIONS AND METHODS FOR PREVENTING INFECTION	LA JOLLA BIOSCIENCES LLC	8-Aug-02	19-Mar-09	23-Jul-09
US20090186041	ANTI-TSG101 ANTIBODIES AND THEIR USES FOR TREATMENT OF VIRAL INFECTIONS	Functional Genetics, Inc.	15-Nov-06	18-Apr-08	23-Jul-09
US20090186025	Fusion Protein Comprising an Fc Receptor Binding Polypeptide and an Antigenic Polypeptide for Mediating an Immune Response	ImmunoBiology Limited	22-Mar-06	22-Mar-07	23-Jul-09
US20090186014	METHOD FOR TREATMENT OF PANCREATITIS	Ore Pharmaceuticals Inc.	10-Oct-07	9-Oct-08	23-Jul-09
US20090182133	BENZOPYRANONE DERIVATIVES AND THEIR USE AS ANTI-VIRAL AGENTS	Shanghai Institute of Materia Medica Chinese Academy of Sciences	29-Dec-05	15-Dec-06	16-Jul-09
US20090181972	Novel Inhibitors of Cysteine Proteases, the Pharmaceutical Compositions Thereof and their Therapeutic Applications	BOISSY GUILLAUNE	8-Dec-05	5-Dec-06	16-Jul-09
US20090181361	Rapid test for detecting infection	KUMAR ARUN	14-Jan-08	14-Jan-08	16-Jul-09
US20090176821	Amide and Carbamate Derivatives of Alkyl Substituted N-[4-(4-Amino-1H-Imidazo[4,5-C] Quinolin-1-YL)Butyl]Methanesulfonamides and Methods	COLEY PHARMACEUTICAL GROUP, INC.	9-Sep-05	8-Sep-06	9-Jul-09
US20090176815	Novel Tricyclic Spiropiperidine Compounds, Their Synthesis and Their Uses as Modulators of Chemokine Receptor Activity	ERIKSSON TOMAS	19-Jul-06	16-Jan-09	9-Jul-09
US20090176699	Inhibitors Based on Fusion, Hr1 and Hr2 Sequences in Bacterial Adhesin	CHIRON SRL	6-Jul-04	6-Jul-05	9-Jul-09
US20090175948	AEROSOL METHOD FOR NANO SILVER-SILICA COMPOSITE ANTI-MICROBIAL AGENT	BRINKER C JEFFREY	30-Nov-07	26-Nov-08	9-Jul-09
US20090175902	Immunogenic Substances Comprising A Polyinosinic Acid-Polycytidilic Acid Based Adjuvant	Not Available	13-Jan-06	27-Jun-06	9-Jul-09
US20090170717	RE-SEQUENCING PATHOGEN MICROARRAY	The Government of the United States of America, as represented by the Secretary of the Air Force	2-Jul-04	10-Apr-08	2-Jul-09
US20090169636	Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions	Not Available	24-Feb-06	24-Feb-07	2-Jul-09
US20090163533	1-Substituted Pyrazolo (3,4-C) Ring Compounds as Modulators of Cytokine Biosynthesis for the Treatment of Viral Infections and Neoplastic Diseases	COLEY PHARMACEUTICAL GROUP, INC.	1-Apr-05	31-Mar-06	25-Jun-09
US20090163518	Novel Compounds	BONNERT ROGER	27-May-03	4-Mar-09	25-Jun-09
US20090162831	HUMAN PARVOVIRUS	DELWART ERIC L	24-May-04	24-May-05	25-Jun-09
US20090162392	MUTANT FORMS OF STREPTOLYSIN O	NOVARTIS AG	21-Dec-07	19-Dec-08	25-Jun-09
US20090162365	Novel siRNAS and methods of use thereof	FEINSTEIN ELENA	25-Oct-06	25-Oct-07	25-Jun-09
US20090162320	GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA VIRUS SPIKE PROTEIN	DNAVEC Corporation	28-Oct-05	27-Oct-06	25-Jun-09
US20090155564	ARTICLE AND ASSOCIATED METHOD	GENERAL ELECTRIC COMPANY	28-Sep-07	28-Sep-07	18-Jun-09
US20090149475	Thioxanthine Derivatives and Their Use as Inhibitors of MPO	ASTRAZENECA AB	13-Apr-06	12-Apr-07	11-Jun-09
US20090149448	Phenoxyacetic Acid Derivatives Useful for Treating Respiratory Diseases	ASTRAZENECA AB	23-Nov-04	22-Nov-05	11-Jun-09
US20090149429	ANTIVIRAL COMPOUNDS	Myriad Genetics, Incorporated	22-Jun-05	22-Jun-06	11-Jun-09
US20090131486	2-PYRIDONE DERIVATIVES FOR THE TREATMENT OF DISEASE OR CONDITION IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL	HANSEN PETER	8-May-06	7-May-07	21-May-09
US20090131459	2-Thioxanthine Derivatives Acting as MPO-Inhibitors	ASTRAZENECA AB	5-Jun-06	4-Jun-07	21-May-09

US20090131328	FURIN INHIBITORS	SMITH JUDITH	23-Jul-04	22-Jul-05	21-May-09
US20090130146	COMBINATION VACCINE	CHIRON BEHRING GMBH & CO. KG	8-Oct-04	7-Oct-05	21-May-09
US20090130138	Antiviral and antibacterial activity from medicinal mushrooms	STAMETS PAUL EDWARD	6-Jan-04	24-Sep-08	21-May-09
US20090126514	Devices for collection and preparation of biological agents	BELGRADER PHIL	5-Sep-07	5-Sep-07	21-May-09
US20090124843	HAZARDOUS SUBSTANCE REMOVING METHOD, HAZARDOUS SUBSTANCE REMOVING MATERIAL USED THEREIN SUCH AS AIR FILTER, MASK, WIPE SHEET, AND THE LIKE, AND STORAGE METHOD THEREOF	Not Available	28-Mar-03	21-Nov-08	14-May-09
US20090124652	Polymorphs of 1-(2-Methylpropyl)-1H-Imidazo[4,5-C][1,5]Naphthyridin-4-Amine Ethane-Sulfonate	Takeda Pharmaceutical Company Limited	30-Dec-04	28-Dec-05	14-May-09
US20090124640	Pyrrolo[3,2-D]Pyrimidin-4-One Derivative as Myeloperoxidase Inhibitor	ASTRAZENECA AB	5-Jun-06	4-Jun-07	14-May-09
US20090124611	Pyrazolopyridine-1,4-Diamines and Analogs Thereof	Coley Pharmaceutical Group, Inc.	1-Apr-05	31-Mar-06	14-May-09
US20090124596	Chemical Compounds 637	BONNERT ROGER VICTOR	11-Jan-07	10-Jan-08	14-May-09
US20090124512	DNA ARRAY ANALYSIS AS A DIAGNOSTIC FOR CURRENT AND EMERGING STRAINS OF INFLUENZA	REGENTS OF THE UNIVERSITY OF COLORADO	18-Jan-06	18-Jan-07	14-May-09
US20090123494	MOMLV-BASED PSEUDOVIRION PACKAGING CELL LINE	FLICK RAMON	31-Jul-07	31-Jul-08	14-May-09
US20090123460	IMMUNOSTIMULATORY COMBINATIONS	3M Innovative Properties Company	30-Dec-02	17-Mar-08	14-May-09
US20090123417	RECOMBINANT SUPER-COMPOUND INTERFERON AND USES THEREOF	WEI GUANGWEN	28-Feb-01	6-Oct-08	14-May-09
US20090118503	FAAH INHIBITORS	Not Available	20-Jun-07	20-Jun-08	7-May-09
US20090118288	N-Benzyl-Morpholine Derivatives as Modulators of the Chemokine Receptor	ASTRAZENECA AB	21-Jul-05	19-Jul-06	7-May-09
US20090118263	Novel Adenine Compound	ASTRAZENECA AKTIEBOLAG	22-Sep-05	20-Sep-06	7-May-09
US20090117537	METHOD FOR DETECTING SARS CORONAVIRUS	EIKEN KAGAKU KABUSHIKI KAISHA	27-Jun-03	10-Jun-08	7-May-09
US20090117367	ARTICLE AND ASSOCIATED METHOD	GENERAL ELECTRIC COMPANY	28-Sep-07	28-Sep-07	7-May-09
US20090117123	IMMUNOPEPTIDES OF HPV E6 AND E7 PROTEINS	National Health Research Institutes	2-Nov-07	23-Sep-08	7-May-09
US20090117115	Binary epitope antibodies and B cell superantigen immune stimulants	NISHIYAMA YASUHIRO	9-Nov-06	9-Nov-07	7-May-09
US20090117113	Immunogenic And Therapeutic Compositions For Streptococcus Pyogenes	Chiron Corporation	8-Oct-04	11-Oct-05	7-May-09
US20090111828	L-ALANINE DERIVATIVES	ASTRAZENECA AB	23-Nov-05	22-Nov-06	30-Apr-09
US20090111091	SPECIMEN PRETREATMENT LIQUID, KIT FOR MEASURING VIRUS, AND METHOD FOR DETECTING VIRUS	SYSMEX CORPORATION	31-Oct-07	31-Oct-08	30-Apr-09
US20090105295	HYDROXYLAMINE SUBSTITUTED IMIDAZOQUINOLINES	Coley Pharmaceutical Group, Inc.	14-Nov-03	12-Nov-04	23-Apr-09
US20090105212	NOVEL ADENINE COMPOUND	AstraZeneca Aktiebolag a corporation of Sweden	22-Sep-05	22-Sep-06	23-Apr-09
US20090105203	COMPOUNDS FOR TREATING VIRAL INFECTIONS	Myriad Genetics, Incorporated	16-Oct-06	16-Oct-07	23-Apr-09
US20090105151	AMPHIPATHIC ALPHA-HELICAL PEPTIDE COMPOSITIONS AS ANTIVIRAL AGENTS	CHEONG KWANG HO	19-Jul-07	14-Jul-08	23-Apr-09
US20090105092	VIRAL DATABASE METHODS	THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK	28-Nov-06	27-Nov-07	23-Apr-09
US20090104226	Alphavirus Vectors for Respiratory Pathogen Vaccines	NOVARTIS VACCINES AND DIAGNOSTICS INC.	21-May-04	20-May-05	23-Apr-09

CC-BY-NC-SA Dr. David E. Martin

US20090104209	METHODS OF REDUCING A VIRAL INFECTION AND KITS THEREFORE	LABONTE PATRICK	21-Sep-07	19-Sep-08	23-Apr-09
US20090104147	Sialoadhesin-Related Compositions and Methods	DELPUTTE PETER	11-May-06	11-May-07	23-Apr-09
US20090099216	NOVEL ADENINE COMPOUND	AstraZeneca Aktiebolag A corporation of Sweden	22-Sep-05	22-Sep-06	16-Apr-09
US20090099161	Substituted Imidazoquinolines and Imidazonaphthyridines	Coley Pharmaceutial Group, Inc.	11-Feb-05	10-Feb-06	16-Apr-09
US20090099156	Heterocyclic Compounds as Ccr2b antagonists	BOWER JUSTIN FAIRFIELD	24-Dec-04	19-Dec-05	16-Apr-09
US20090099110	Antiviral oligonucleotides	JUTEAU JEAN-MARC	13-Sep-02	28-Feb-08	16-Apr-09
US20090099043	Construction of pool of interfering nucleic acids covering entire RNA target sequence and related compositions	ZHU YORK YUAN YUAN	23-Jul-07	21-Nov-08	16-Apr-09
US20090098530	Cell Line For Producing Coronaviruses	CRUCELL HOLLAND B.V.	22-Jul-05	21-Jul-06	16-Apr-09
US20090098207	Technology for the Preparation of Microparticles	NexBio, Inc.	24-Jul-07	24-Jul-08	16-Apr-09
US20090092962	METHOD FOR DETECTING SARS CORONAVIRUS	EIKEN KAGAKU KABUSHIKI KAISHA	27-Jun-03	10-Jun-08	9-Apr-09
US20090092633	Polyamino acid for use as adjuvant	AKASHI MITSURU	20-Apr-05	19-Apr-06	9-Apr-09
US20090092581	Interferons of rhesus and cynomolgus origin and uses thereof	CLARK WILLIAM A	11-Apr-07	11-Apr-08	9-Apr-09
US20090083865	Transgenic Mouse Lines Expressing Human Ace2 and Uses Thereof	CHAN TEH-SHENG	11-Jan-06	11-Jan-07	26-Mar-09
US20090082547	COMPOSITIONS FOR ENHANCING TRANSPORT OF MOLECULES INTO CELLS	IVERSEN PATRICK L	29-Apr-03	5-Nov-08	26-Mar-09
US20090082332	PURINE DERIVATIVES FOR THE TREATMENT OF VIRAL OR ALLERGIC DISEASES AND CANCERS	ABBOT PHILIP	22-Sep-05	20-Sep-06	26-Mar-09
US20090082287	METHODS OF ENHANCING MUCOSAL HYDRATION AND MUCOSAL CLEARANCE BY TREATMENT WITH SODIUM CHANNEL BLOCKERS AND OSMOLYTES	PARION SCIENCES, INC.	7-Sep-06	7-Sep-07	26-Mar-09
US20090081675	METHODS, COMPOUNDS AND SYSTEMS FOR DETECTING A MICROORGANISM IN A SAMPLE	COLSTON JR BILL W	24-Aug-07	21-Aug-08	26-Mar-09
US20090081252	DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINES	CHIRON BEHRING GMBH & CO.	9-Sep-04	9-Sep-05	26-Mar-09
US20090081157	Immunostimulatory Combinations for Vaccine Adjuvants	Not Available	9-Jan-06	9-Jan-07	26-Mar-09
US20090078263	Hazardous substance removing method, hazardous substance removing material used therein such as air filter, mask, wipe sheet, and the like, and storage method thereof	ARAJ JUN-ICHIRO	28-Mar-03	21-Nov-08	26-Mar-09
US20090076076	INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF	Baylor University	13-Jun-07	13-Jun-08	19-Mar-09
US20090075980	Pyrazolopyridines and Analogs Thereof	Coley Pharmaceutical Group, Inc.	3-Oct-03	31-Mar-06	19-Mar-09
US20090074810	Modified Adenovirus Hexon Protein and Uses Thereof	The Trustees of the University of Pennsylvania	28-Apr-06	27-Apr-07	19-Mar-09
US20090069314	Hydroxyalkyl Substituted Imidazoquinoline Compounds and Methods	Coley Pharmaceutical Group, Inc.	23-Feb-05	22-Feb-06	12-Mar-09
US20090068759	REUSABLE DETECTION SURFACES AND METHODS OF USING SAME	BioScale, Inc.	6-Sep-07	5-Sep-08	12-Mar-09
US20090068665	METHODS AND KITS FOR IDENTIFYING TARGET NUCLEOTIDES IN MIXED POPULATIONS	APPLIED BIOSYSTEMS INC.	30-Apr-04	31-Jul-08	12-Mar-09
US20090068636	VIRAL PROTEIN	CHANG MING-FU	2-Mar-04	19-Sep-07	12-Mar-09
US20090068142	COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS INFECTION AND SARS	Three Rivers Pharmaceuticals LLC	1-Apr-03	29-Jul-08	12-Mar-09
US20090068095	CARBONIC ANHYDRASE IX (G250) ANITBODIES AND METHODS OF USE THEREOF	LO AGNES	2-Dec-05	4-Dec-06	12-Mar-09

CC-BY-NC-SA Dr. David E. Martin

US20090062328	Oxime and Hydroxylamine Substituted Imidazo[4,5-c] Ring Compounds and Methods	COLEY PHARMACEUTICAL GROUP, INC.	11-Feb-05	10-Feb-06	5-Mar-09
US20090062272	IMIDAZOQUINOLINYL SULFONAMIDES	BONK JASON D	30-Dec-03	23-Dec-04	5-Mar-09
US20090062259	Bezothiazol Derivatives as Beta2 Adrenoreceptor Agonists	ASTRAZENECA AB	14-Mar-06	12-Mar-07	5-Mar-09
US20090062229	METHOD AND COMPOSITION FOR REDUCING THE EXPRESSION OF ROCK-II	Myriad Genetics, Incorporated	20-Aug-03	6-May-08	5-Mar-09
US20090061027	Composition For The Prevention and Treatment Of Common Cold Diseases	PANDALIS GEORGIOS	24-Mar-06	2-Mar-07	5-Mar-09
US20090061017	SHELF STABLE, REDUCED CORROSION, READY TO USE PEROXYCARBOXYLIC ACID ANTIMICROBIAL COMPOSITIONS	BESSE MICHAEL	30-Aug-07	30-Aug-07	5-Mar-09
US20090060950	Method for Producing Viral Vaccines	BAXTER HEALTHCARE	28-Aug-07	28-Aug-08	5-Mar-09
US20090054413	Novel 5,6-Dihydropyrazolo[3,4-E] [L,4]Diazepin-4 (IH) -One Derivatives for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease	AstraZeneca AB	3-Oct-05	2-Oct-06	26-Feb-09
US20090054342	Bioactive peptides and method of using same	AYALON-SOFFER MICHAL	18-Sep-06	18-Sep-07	26-Feb-09
US20090053708	Method and/or Apparatus of Oligonucleotide Design and/or Nucleic Acid Detection	LEE CHARLIE	12-Aug-05	8-Aug-06	26-Feb-09
US20090053299	Methods for generating immune response using cationic-liposome-mediated nucleic acid delivery	Georgetown University	9-Jul-07	9-Jul-08	26-Feb-09
US20090053257	REPLIKIN PEPTIDES AND USES THEREOF	BOGOCH ELENORE S	6-Jun-03	10-Jul-08	26-Feb-09
US20090053248	Compositions and methods for transepithelial molecular transport	Thomas Jefferson University	31-May-02	25-Mar-08	26-Feb-09
US20090047665	COMPOSITIONS FOR USE IN IDENTIFICATION OF ADENOVIRUSES	IBIS BIOSCIENCES, INC.	11-Sep-03	16-Sep-08	19-Feb-09
US20090047353	CHANGING TH1/TH2 BALANCE IN SPLIT INFLUENZA VACCINES WITH ADJUVANTS	NOVARTIS VACCINES AND DIAGNOSTICS SRL	4-Nov-05	6-Nov-06	19-Feb-09
US20090047306	ADJUVANT COMPOSITIONS	M N L PHARMA LIMITED	21-Jan-04	21-Jan-05	19-Feb-09
US20090047272	Compositions with Modified Nucleases Targeted to Viral Nucleic Acids and Methods of Use for Prevention and Treatment of Viral Diseases	APPELBAUM JACOB G	14-Apr-04	14-Apr-05	19-Feb-09
US20090042942	Muscarinic Receptor Antagonists	ASTRAZENECA AB	20-Apr-05	18-Apr-06	12-Feb-09
US20090042925	OXIME SUBSTITUTED IMIDAZOQUINOLINES	Coley pharmaceutical Group, Inc.	14-Nov-03	12-Nov-04	12-Feb-09
US20090042858	LACTAM CONTAINING HCV INHIBITORS	BARSANTI PAUL	16-Jun-05	16-Jun-06	12-Feb-09
US20090042827	ANTIVIRAL OLIGONUCLEOTIDES TARGETING HBV	JUTEAU JEAN-MARC	13-Sep-02	10-Jul-08	12-Feb-09
US20090042292	B7-DC Variants	The Johns Hopkins University	13-Jul-07	11-Jul-08	12-Feb-09
US20090042274	Method of Purifying Virus Envelope	GENOMIDEA INC.	27-Jul-04	22-Jul-05	12-Feb-09
US20090042252	INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES	Maxygen, Inc.	18-Nov-02	30-Oct-06	12-Feb-09
US20090041818	ANTIVIRAL AGENT, AND FABRIC AND ANTIVIRAL MEMBER SUPPORTING ANTIVIRAL AGENT	ITO HIROSHI	12-Aug-03	10-Aug-04	12-Feb-09
US20090041803	Dioscorea Extracts	Academia Sinica	1-Dec-03	2-Sep-08	12-Feb-09
US20090041781	METHODS FOR DETECTING PARVOVIRUS INFECTIONS	The Research Foundation of State University of New York	5-May-03	16-Oct-08	12-Feb-09
US20090036653	Methods for the directed expansion of epitopes for use as antibody ligands	Peptimmune, Inc.	13-Apr-06	7-May-08	5-Feb-09
US20090036535	Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease	ASTRAZENECA AB	6-Oct-05	5-Oct-06	5-Feb-09

CC-BY-NC-SA Dr. David E. Martin

US20090035861	RNAi Medicine Having No Adverse Effects	GONDAI TAKUMA	28-Jan-05	27-Jan-06	5-Feb-09
US20090035323	IMMUNE RESPONSE MODIFIER CONJUGATES	Not Available	22-Feb-06	21-Feb-07	5-Feb-09
US20090012280	OLIGONUCLEOTIDE COMPOUND AND METHOD FOR TREATING NIDOVIRUS INFECTIONS	BESTWICK RICHARD K	24-Dec-03	25-Apr-08	8-Jan-09
US20090012151	Novel Compounds 951	BONNERT ROGER VICTOR	5-Jul-07	3-Jul-08	8-Jan-09
US20090012125	Piperidine Derivatives, Their Process for Preparation, Their Use as Therapeutic Agents and Pharmaceutical Compositions Containing Them	CAGE PETER	7-Mar-06	6-Mar-07	8-Jan-09
US20090011465	INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES	MAXYGEN, INC.	18-Nov-02	30-Oct-06	8-Jan-09
US20090011403	MICROPOROUS MATERIALS, METHODS OF MAKING, USING, AND ARTICLES THEREOF	UNIVERSITY OF UTAH RESEARCH FOUNDATION	26-May-04	17-May-05	8-Jan-09
US20090005376	1-Alkoxy 1H-Imidazo Ring Systems and Methods	3M Innovative Properties Company	2-Sep-04	1-Sep-05	1-Jan-09
US20090005371	Substituted Fused [1,2]Imidazo[4,5-C] Ring Compounds and Methods	HEPPNER PHILIP D	11-Feb-05	10-Feb-06	1-Jan-09
US20090004643	METHODS FOR CONCURRENT IDENTIFICATION AND QUANTIFICATION OF AN UNKNOWN BIOAGENT	ISIS Pharmaceuticals, Inc.	18-Feb-04	17-Feb-05	1-Jan-09
US20080319170	Methods and Uses of Antibodies in the Purification of Interferon	ViraNative AB	12-Feb-05	13-Feb-06	25-Dec-08
US20080318998	Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines	COLEY PHARMACEUTICAL GROUP, INC.	9-Feb-05	8-Feb-06	25-Dec-08
US20080317702	METHOD FOR TREATING MICROORGANISMS AND/OR INFECTIOUS AGENTS	EDGINGTON GARRY	19-Jun-07	19-Jun-08	25-Dec-08
US20080311138	Adjuvant Activity of Gastrointestinal Peptides	Not Available	13-Dec-04	13-Dec-05	18-Dec-08
US20080311125	Scytovirin Domain 1 Related Polypeptides	Office of Technology Transfer	25-May-05	24-May-06	18-Dec-08
US20080311042	Loop-Variant Pdz Domains as Biotherapeutics, Diagnostics and Research Reagents	DELAGRAVE SIMON	5-Dec-05	4-Dec-06	18-Dec-08
US20080310992	APPARATUS AND METHOD FOR USING OZONE AS A DISINFECTANT	VIROFORCE SYSTEMS INC.	29-Nov-06	17-Jun-08	18-Dec-08
US20080305120	Immunogenic Compositions Comprising Hmgb 1 Polypeptides	MEDIMMUNE, INC.	17-Jun-04	16-Jun-05	11-Dec-08
US20080305119	Modified Bacteriophage Vectors and Uses Thereof	UNIVERSITY OF ROCHESTER	29-Oct-04	5-Oct-05	11-Dec-08
US20080300275	Novel Benzothiazolone Derivatives	ASTRAZENECA AB	9-Aug-05	3-Aug-06	4-Dec-08
US20080300244	NOVEL COMPOUNDS	AstraZeneca AB	14-Dec-06	13-Dec-07	4-Dec-08
US20080300191	PROTEASE INHIBITORS FOR CORONAVIRUSES AND SARS-COV AND THE USE THEREOF	CAI SUI XIONG	6-May-03	6-May-04	4-Dec-08
US20080299545	CHROMATOGRAPHIC METHODS FOR ASSESSING ADENOVIRUS PURITY	CLARKE PETER	6-Mar-07	6-Mar-08	4-Dec-08
US20080299182	METHODS AND FORMULATIONS FOR TOPICAL GENE THERAPY	ONISHI ERIC	1-Mar-07	29-Feb-08	4-Dec-08
US20080299070	Antiviral Compounds	ENGEL ROBERT	30-May-07	30-May-08	4-Dec-08
US20080295843	SELF SANITIZING FACE MASKS AND METHOD OF MANUFACTURE	HAAS MARCI B	1-Jun-07	1-Jun-07	4-Dec-08
US20080293775	Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease	ASTRAZENECA AB	15-Dec-05	12-Dec-06	27-Nov-08
US20080293742	Novel N-(Fluoro-Pyrazinyl)-Phenylsulfonamides as Modulators of Chemokine Receptor Ccr4	CHESHIRE DAVID	12-Dec-05	11-Dec-06	27-Nov-08
US20080292657	PRIMATE T-LYMPHOTROPIC VIRUSES	Centers for Disease Control and Prevention	21-Feb-05	24-Feb-07	27-Nov-08
US20080292641	Antigenic GM-CSF peptides and antibodies to GM-CSF	Morphotek, Inc.	8-Feb-06	8-Feb-07	27-Nov-08

US20080287453	Piperazine Compounds Useful as Antagonists of C-C Chemokines (Ccr2b and Ccr5) for the Treatment of Inflammatory Diseases	BOWER JUSTIN FAIRFIELD	21-Dec-05	18-Dec-06	20-Nov-08
US20080286756	COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING SEVERE ACUTE RESPIRATORY SYNDROME (SARS)	THE CHINESE UNIVERSITY OF HONG KONG	29-Jul-03	3-Apr-08	20-Nov-08
US20080280951	Salt II	ASTRAZENECA AB	2-Aug-05	31-Jul-06	13-Nov-08
US20080279920	Compositions For Treating Respiratory Viral Infections and Their Use	Intradigm Corporation	5-Nov-04	4-Nov-05	13-Nov-08
US20080279891	Viral Adjuvants	JOHNSTON ROBERT E	9-Jul-04	8-Jul-05	13-Nov-08
US20080279812	Disease Prevention and Vaccination Prior to Thymic Reactivation	Monash University	5-Dec-03	19-Apr-04	13-Nov-08
US20080279722	TRANSPORTABLE DECONTAMINATION UNIT AND DECONTAMINATION PROCESS	BACIK MICHAEL A	6-Mar-07	20-Feb-08	13-Nov-08
US20080279721	DECONTAMINATION UNIT AND PROCESS	CENTANNI MICHAEL A	6-Mar-07	20-Feb-08	13-Nov-08
US20080279720	DECONTAMINATION UNIT WITH COLLAPSIBLE DECONTAMINATION ENCLOSURE AND DECONTAMINATION PROCESS	CENTANNI MICHAEL A	6-Mar-07	20-Feb-08	13-Nov-08
US20080275084	Piperidines for the Treatment of Chemokine Mediated Diseases	ASTRAZENECA AB	27-May-05	24-May-06	6-Nov-08
US20080274140	Vaccines and Methods for Using the Same	KUTZLER MICHELE	19-Nov-04	18-Nov-05	6-Nov-08
US20080269240	Novel Adenine Compound	AstraZeneca Aktiebolag A Corporation of Sweden	22-Sep-05	21-Sep-06	30-Oct-08
US20080269192	Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds	Coley Pharmaceutical Group, Inc.	30-Dec-04	29-Dec-05	30-Oct-08
US20080269156	Inhibitors of RTP801 and their use in disease treament	FEINSTEIN ELENA	26-Feb-07	26-Feb-08	30-Oct-08
US20080269148	Modified Small Interfering Rna Molecules and Methods of Use	HAN JANG	1-Oct-04	30-Sep-05	30-Oct-08
US20080269115	Immunogenic Sars Domain	BEADENKOPF ROBERT J	17-Jun-04	16-Jun-05	30-Oct-08
US20080267997	Modified Viral Particles with Immunogenic Properties and Reduced Lipid Content Useful for Treating and Preventing Infectious Diseases	Lipid Sciences, Inc.	29-Jun-00	9-May-08	30-Oct-08
US20080267992	Sars Virus Vaccine with Adenovirus Carrier and Preparation Method Thereof, and Use of Sars Virus S Gene for Preparation of Vaccine	Cancer Center, Sun Yat-Sun University	4-Jun-04	4-Jun-04	30-Oct-08
US20080267819	TRANSPORTABLE DECONTAMINATION UNIT AND DECONTAMINATION PROCESS	BACIK MICHAEL A	6-Mar-07	20-Feb-08	30-Oct-08
US20080261258	Immune Cell Biosensors and Methods of Using Same	Amaox, Inc.	9-Jul-04	11-Jul-05	23-Oct-08
US20080261257	Fluorescent Proteins and Related Methods and Compounds	UNIVERSITY OF MASSACHUSETTS	20-Sep-04	20-Sep-05	23-Oct-08
US20080260775	New Live Virus Vaccines	JOHNSON PHILIP R	15-Feb-05	15-Feb-06	23-Oct-08
US20080260773	Saccharide Conjugate Vaccines	Not Available	24-Dec-04	23-Dec-05	23-Oct-08
US20080260769	Polypeptides for Oligomeric Assembly of Antigens	CAPECCHI BARBARA	23-Jul-04	22-Jul-05	23-Oct-08
US20080260764	REPLIKIN PEPTIDES AND USES THEREOF	BOGOCH ELENORE S	30-May-06	30-May-07	23-Oct-08
US20080255150	Novel Compounds	ASTRAZENECA AB	5-Nov-05	1-Nov-06	16-Oct-08
US20080255076	Steroid-Derived Pharmaceutical Compositions	JadoLabs GmbH	29-Jun-04	29-Jun-05	16-Oct-08
US20080254440	Anti-Sars Virus Antibody, Hybridoma Producing the Antibody and Immunoassay Reagent Using the Antibody	FUJII NOBUYUKI	31-Oct-03	29-Oct-04	16-Oct-08

US20080249145	Salts 668	WHITTOCK ROBERT	8-Feb-07	7-Feb-08	9-Oct-08
US20080249110	Novel Substituted 3-Sulfur Indoles	BONNERT ROGER	27-May-03	25-May-04	9-Oct-08
US20080249097	PRODRUGS OF HETEROARYL COMPOUNDS	Koronis Pharmaceuticals, Incorporation	20-Jun-03	27-Dec-06	9-Oct-08
US20080249039	Modified Short Interfering Rna (Modified Sirna)	SANTARIS PHARMA A/S	30-Jan-04	28-Jan-05	9-Oct-08
US20080248551	METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSES	OSORIO JORGE E	6-Apr-07	4-Apr-08	9-Oct-08
US20080248043	Antibodies to SARS coronavirus	Amgen Inc.	19-May-06	21-May-07	9-Oct-08
US20080242851	MODIFIED POLYNUCLEOTIDES FOR REDUCING OFF-TARGET EFFECTS IN RNA INTERFERENCE	DHARMACON, INC.	2-Apr-03	19-Sep-07	2-Oct-08
US20080242794	COLOR STABILIZED ANTIMICROBIAL POLYMER COMPOSITES	BLANTON THOMAS N	30-Mar-07	30-Mar-07	2-Oct-08
US20080242649	New Combination 665	CADOGAN ELAINE BRIDGET	8-Feb-07	7-Feb-08	2-Oct-08
US20080241935	Methods for pathogen detection	Searete LLC, a limited liability corporation of the State of Delaware	27-Mar-07	27-Mar-07	2-Oct-08
US20080241910	Devices for pathogen detection	Searete LLC, a limited liability corporation of the State of Delaware	27-Mar-07	27-Mar-07	2-Oct-08
US20080241909	Microfluidic chips for pathogen detection	Searete LLC, a limited liability corporation of the State of Delaware	27-Mar-07	27-Mar-07	2-Oct-08
US20080241511	PRODUCTION OF SILVER SULFATE GRAINS USING INORGANIC ADDITIVES	BLANTON THOMAS N	30-Mar-07	30-Mar-07	2-Oct-08
US20080241189	Sequential Delivery Of Immunogenic Molecules Via Adenovirus And Adeno-Associated Virus-Mediated Administrations	The Trustees of the University of Pennsylvania	28-Apr-04	27-Apr-05	2-Oct-08
US20080241000	Systems for pathogen detection	Searete LLC, a limited liability corporation of the State of Delaware	27-Mar-07	27-Mar-07	2-Oct-08
US20080234345	METHOD FOR REDUCING OR ALLEVIATING INFLAMMATION IN THE DIGESTIVE TRACT	Gene Logic Inc.	8-Sep-06	7-Sep-07	25-Sep-08
US20080234319	Novel Compounds 679	EBDEN MARK	22-Mar-07	21-Mar-08	25-Sep-08
US20080233650	Method for propagating adenoviral vectors encoding inhibitory gene products	GENVEC, INC.	10-Nov-05	9-May-08	25-Sep-08
US20080233570	METHODS FOR IDENTIFICATION OF SEPSIS-CAUSING BACTERIA	HALL THOMAS A	11-Sep-03	25-May-07	25-Sep-08
US20080233558	Inhibitors of viral entry screening method	Medical Research Council	1-Feb-05	1-Aug-07	25-Sep-08
US20080233150	RESPIRATORY SYNCYTIAL VIRUS-VIRUS LIKE PARTICLE (VLPS)	MAHMOOD KUTUB	16-Nov-06	16-Nov-07	25-Sep-08
US20080233128	Treatment of Viral Infections	KRAUSE WERNER	2-Nov-06	1-Nov-07	25-Sep-08
US20080227817	New Salt I	ASTRAZENECA AB	2-Aug-05	31-Jul-06	18-Sep-08
US20080227797	Pyridopyrimidine Derivatives as Pde4 Inhibitors for the Treatment of Inflammatory and Immune Diseases	ASTRAZENECA AB	4-Jul-05	3-Jul-06	18-Sep-08
US20080227219	Electrochemiluminescent assay	Not Available	17-Nov-04	16-Nov-05	18-Sep-08
US20080227149	Interferon-Alpha Polypeptides and Conjugates	MAXYGEN, INC.	18-Nov-02	25-Oct-07	18-Sep-08
US20080226681	Highly Active Glycoproteins-Process Conditions and an Efficient Method for their Production	Glycotope GmbH	13-Feb-04	14-Feb-05	18-Sep-08
US20080226597	EVOLVED INTERFERON-ALPHA POLYPEPTIDES	MAXYGEN, INC.	18-May-05	17-May-06	18-Sep-08
US20080213891	RNAi Agents Comprising Universal Nucleobases	Alnylam Pharmaceuticals, Inc.	21-Jul-04	6-Aug-07	4-Sep-08
US20080213308	Imidazoquinoline Compounds	CHU DANIEL	14-Sep-04	14-Sep-05	4-Sep-08

CC-BY-NC-SA Dr. David E. Martin

US20080213284	RECEPTOR BINDING POLYPEPTIDES	National Health Research Institutes, a Taiwanese corporation	9-Jan-04	10-Jan-05	4-Sep-08
US20080213125	Apparatus and Method for Using Ozone as a Disinfectant	Huawei Technologies Co. LTD.	18-Mar-04	18-Mar-05	4-Sep-08
US20080210748	Systems and methods for receiving pathogen related information and responding	Searete LLC, a limited liability corporation of the State of Delaware,	30-Nov-05	11-Sep-07	4-Sep-08
US20080207698	Novel Compounds 569	CONNOLLY STEPHEN	20-Dec-06	19-Dec-07	28-Aug-08
US20080207688	Novel Piperidine Derivatives	ASTRAZENECA AB	21-Jul-05	19-Jul-06	28-Aug-08
US20080207674	Immune Response Modifier Formulations And Methods	Coley Pharmaceutical Group, Inc.	30-Dec-04	28-Dec-05	28-Aug-08
US20080207650	Chemical Compounds 636	BONNERT ROGER VICTOR	11-Jan-07	10-Jan-08	28-Aug-08
US20080207597	HOMOPIPERAZINE COMPOUNDS THAT INHIBIT RIBOSOMAL FRAMESHIFTING BY BINDING TO RNA PSEUDOKNOT STRUCTURE OF SARS CORONAVIRUS	SUNGKYUNKWAN UNIVERSITY FOUNDATION FOR CORPORATE COLLABORATION	22-Dec-06	20-Dec-07	28-Aug-08
US20080207596	Novel compounds 329	MARTIN BARRIE	19-Jun-06	19-Jun-07	28-Aug-08
US20080207587	Pyridazine Derivatives for Inhibiting Human Stearoyl-Coa-Desaturase	XENON PHARMACEUTICALS INC.	20-Sep-04	20-Sep-05	28-Aug-08
US20080207573	COMPOUNDS FOR TREATING VIRAL INFECTIONS	Myriad Genetics, Incorporated	16-Oct-06	7-May-08	28-Aug-08
US20080206283	Vaccine Against Sars	DONG JOHN Y	17-Jun-03	17-Jun-04	28-Aug-08
US20080206235	COMPOSITIONS AND METHODS FOR STIMULATING AN IMMUNE RESPONSE	Johns Hopkins University	27-Dec-06	27-Dec-07	28-Aug-08
US20080200505	Piperidines for the Treatment of Chemokine Mediated Diseases	ASTRAZENECA AB	27-May-05	24-May-06	21-Aug-08
US20080199915	Methods and Kits For Mass Production Of Dsrna	RNA-Line Oy	2-May-03	2-May-03	21-Aug-08
US20080199495	Stimulation of thymus for vaccination development	Monash University	15-Apr-99	24-May-07	21-Aug-08
US20080199491	Sustained Release Vaccine Composition	BRANDON MALCOLM	16-Jun-04	16-Jun-05	21-Aug-08
US20080199481	COMPOUNDS	ASTRAZENECA AB	21-Feb-07	19-Feb-08	21-Aug-08
US20080194922	POTENTIATION FOR MEDICAL THERAPIES	HOLDEN JAMES F	7-Sep-05	28-Sep-07	14-Aug-08
US20080194689	Disinfectant and Germicidal Agent	REICHWAGEN SVEN	25-May-05	26-May-06	14-Aug-08
US20080194632	Novel Piperidine Derivatives as Chemokine Receptor Modulators Useful for the Treatment of Respiratory Diseases	ASTRAZENECA AB	1-Aug-05	31-Jul-06	14-Aug-08
US20080194481	Albumin Fusion Proteins	Human Genome Sciences, Inc.	21-Dec-01	31-Oct-07	14-Aug-08
US20080194422	PCR PRIMER SET DETECTING SEVERE ACUTE RESPIRATORY SYNDROME (SARS)-CORONAVIRUS, METHOD AND KIT FOR DETECTING SARS-CORONAVIRUS USING THE SAME	SAMSUNG ELECTRONICS CO., LTD.	12-Dec-03	21-Apr-08	14-Aug-08
US20080193919	Systems and methods for receiving pathogen related information and responding	Searete LLC, a limited liability corporation of the State of Delaware	30-Nov-05	22-Jan-08	14-Aug-08
US20080193474	Immunostimulatory Compositions	GRAM CHRISTOPHER D	25-Apr-05	25-Apr-06	14-Aug-08
US20080188513	1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Ethanesulfonate and 1-(2-Methylpropyl)-1H-Imidazo[4,5-C](1,5]Naphthyridin-4-Amine Methanesulfonate	taked Pharmaceutical Company Limited	30-Dec-04	28-Dec-05	7-Aug-08
US20080188488	Heterocyclic Derivatives and Their Use as Stearoyl-Coa Desaturase Inhibitors	XENON PHARMACEUTICALS INC.	20-Sep-04	20-Sep-05	7-Aug-08
US20080187609	Methods and apparatus to prevent, treat, and cure the symptoms of nausea caused by chemotherapy treatments of human cancers	VAIL MARILYN L	3-Apr-00	18-Mar-08	7-Aug-08

CC-BY-NC-SA Dr. David E. Martin

US20080187528	ANTI-TSG101 ANTIBODIES AND THEIR USES FOR TREATMENT OF VIRAL INFECTIONS	Functional Genetics, Inc.	15-Nov-06	15-Nov-07	7-Aug-08
US20080183396	Systems and methods for transmitting pathogen related information and responding	Searete LLC, a limited libility corporation of the State of Delaware	30-Nov-05	11-Sep-07	31-Jul-08
US20080182900	Method of treatment of virus infections using shikonin compounds	WANG FEIXIN	21-Feb-03	26-Sep-07	31-Jul-08
US20080182874	Novel Compounds	ASTRAZENECA AB	30-Nov-04	28-Nov-05	31-Jul-08
US20080181969	POLYMER COMPOSITE	BARNES CRAIG L	31-Jan-07	31-Jan-07	31-Jul-08
US20080176902	Salt III	ASTRAZENECA AB	2-Aug-05	31-Jul-06	24-Jul-08
US20080176841	EPOXIDE INHIBITORS OF CYSTEINE PROTEASES	THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY	13-Jun-06	13-Jun-07	24-Jul-08
US20080176217	METHOD OF PREDICTING INFLUENZA OUTBREAKS BY CORRELATING AN INCREASE IN REPLIKIN COUNT IN SHRIMP WHITE SPOT SYNDROME VIRUS AND/OR TAURA SYNDROME VIRUS	BOGOCH ELENORE S	24-Oct-06	24-Oct-07	24-Jul-08
US20080175861	MODIFIED POLYMERASES AND ATTENUATED VIRUSES AND METHODS OF USE THEREOF	THE PENN STATE RESEARCH FOUNDATION	22-Dec-06	24-Dec-07	24-Jul-08
US20080175832	Materials and Methods for Prevention and Treatment of RNA Viral Diseases	BEHERA ARUNA K	30-Apr-02	17-Jan-08	24-Jul-08
US20080172247	Method to Decrease the Risk of a Vaccine-Induced Chronic Immune Mediated Disorder in Humans With a Family History of the Disorder	CLASSEN IMMUNOTHERAPIES	6-Apr-04	6-Apr-05	17-Jul-08
US20080171363	INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES	MAXYGEN, INC.	19-May-04	14-Aug-07	17-Jul-08
US20080171066	Listeriolysin-Containing Bacillus Spores as Antigen Delivery Agents	CUTTING SIMON	19-Feb-05	20-Feb-06	17-Jul-08
US20080171057	Reagents, Devices, and Methods For Proteomic Analysis With Applications Including Diagnostics, Vaccines, Quality Control and Research	NETWORK IMMUNOLOGY INC.	21-Apr-04	19-Apr-05	17-Jul-08
US20080170996	Compositions and Methods for Stimulation of Lung Innate Immunity	The Board of Regents of the University of Texas System	28-Jul-06	30-Jul-07	17-Jul-08
US20080167332	Novel Compounds 243	ELKINS BARRY	19-Jul-06	18-Jul-07	10-Jul-08
US20080167321	Pyridine Derivatives For Inhibiting Human Stearoyl-Coa-Desaturase	XENON PHARMACEUTICALS INC.	20-Sep-04	20-Sep-05	10-Jul-08
US20080167198	Filter based detection system	COONEY CHRISTOPHER GERARD	4-Jan-07	4-Jan-07	10-Jul-08
US20080166793	Sorting, amplification, detection, and identification of nucleic acid subsequences in a complex mixture	The Regents of the University of California	4-Jan-07	4-Jan-07	10-Jul-08
US20080166701	Immunoassay Method and Immunoassay Kit to Be Used Therein	ARKRAY, Inc.	25-Jul-05	24-Jul-06	10-Jul-08
US20080166370	Immunogenic Compositions Comprising Multiple Gonococcal Antigens	CHIRON SRL	26-Jun-03	25-Jun-04	10-Jul-08
US20080160010	Peptide That Elicits Neutralizing Antibodies Targeting the Hiv Co-Receptor	The Government of the United States of America as	9-Apr-04	11-Apr-05	3-Jul-08
US20080159962	Use of Inhibitors of the Renin-Angiotensin System for the Treatment of Lung Injuries	IMBA-INSTITUTE FUR MOLEKULARE BIOTECHNOLOGIE GMBH	19-May-05	19-May-06	3-Jul-08
US20080156743	HAZARDOUS SUBSTANCE REMOVING MATERIAL, METHOD FOR REMOVING HAZARDOUS SUBSTANCES, AND NONWOVEN FABRIC	FUJIFILM Corporation	27-Dec-06	27-Dec-07	3-Jul-08
US20080154210	Mixture for Transdermal Delivery of Low and High Molecular Weight Compounds	ORYXE	28-May-04	25-May-05	26-Jun-08
US20080153850	Adamantyl Derivates as P2x7 Receptor Antagonists	AstraZeneca AB	30-Aug-04	29-Aug-05	26-Jun-08
US20080153837	Novel Fluorene Derivatives, Composition Containing Said Derivatives and the Use Thereof	AVENTIS PHARMA S.A.	19-May-05	14-Nov-07	26-Jun-08
US20080152728	Noble gas-chlorine mixture effective against micro organisms	GLOBUS ALFRED R	7-Jul-03	25-Apr-07	26-Jun-08

US20080152544	Building decontamination with vaporous hydrogen peroxide	STERIS INC.	29-Jan-04	3-Mar-08	26-Jun-08
US20080149100	Antiviral Heat Treatment	DE HAAN PETRUS THEODORUS	20-Dec-06	20-Dec-06	26-Jun-08
US20080146612	Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor	ASTRAZENECA AB	27-Jan-05	25-Jan-06	19-Jun-08
US20080146455	METHODS FOR IDENTIFICATION OF SEPSIS-CAUSING BACTERIA	HALL THOMAS A	11-Sep-03	25-May-07	19-Jun-08
US20080145847	METHODS FOR IDENTIFICATION OF SEPSIS-CAUSING BACTERIA	HALL THOMAS A	11-Sep-03	25-May-07	19-Jun-08
US20080138808	METHODS FOR IDENTIFICATION OF SEPSIS-CAUSING BACTERIA	HALL THOMAS A	11-Sep-03	25-May-07	12-Jun-08
US20080132502	5-Heteroaryl Thiazoles And Their Use As PI3K Inhibitors	ARNOULD JEAN-CLAUDE	9-Nov-04	7-Nov-05	5-Jun-08
US20080132480	Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease	AstraZeneca AB	24-Aug-04	22-Aug-05	5-Jun-08
US20080131465	Group a Streptococcus Crge Protein	MANETTI ANDREA	27-Sep-04	27-Sep-05	5-Jun-08
US20080131446	Vaccine Composition	SANOFI PASTEUR SA	17-Nov-03	9-Jan-08	5-Jun-08
US20080125434	Heterocyclic Derivatives and Their Use as Strearoyl-Coa Desaturase Inhibitors	XENON PHARMACEUTICALS INC.	20-Sep-04	20-Sep-05	29-May-08
US20080124323	Nutritional Composition Comprising Indigestible Oligosaccharides	N.V. Nutricia	24-Aug-04	24-Aug-05	29-May-08
US20080124311	Novel pharmaceutical compositions for the treatment of virus infection and cancer	Illumigen Biosciences, Inc.	23-Nov-05	17-Nov-06	29-May-08
US20080124303	Methods and compositions for treatment of viral infections	Cavit Sciences, Inc	12-Dec-05	12-Jul-07	29-May-08
US20080124302	Uses of Recombinant Super-Compound Interferons	WEI GUANGWEN	9-Mar-05	9-Mar-06	29-May-08
US20080118530	Modulation of Replicative Fitness By Deoptimization of Synonymous Codons	BURNS CARA C	8-Oct-04	7-Oct-05	22-May-08
US20080118517	Human monoclonal antibodies against interleukin 8 (IL-8)	GENMAB A/S	16-Dec-02	27-Jun-07	22-May-08
US20080118495	Mammalian Genes Involved in Infection	RUBIN DONALD H	27-Oct-04	27-Oct-05	22-May-08
US20080118473	Methods of treating a respiratory condition comprising probiotic treatment	Alimentary Health Ltd.	1-Nov-06	31-Oct-07	22-May-08
US20080114019	Hydroxylamine Substituted Imidazoquinolines	Coley Pharmaceutical Group, Inc.	12-Aug-03	12-Aug-04	15-May-08
US20080114002	Substituted Acids for the Treatment of Respiratory Diseases	ASTRAZENECA AB	8-Jul-04	6-Jul-05	15-May-08
US20080113409	Transient protein expression methods	HATEBOER GUUS	15-Apr-99	1-Jun-07	15-May-08
US20080113337	Method of Examining/Judging Presence of Virus Infection such as HIV or Presence of Prion Infection by Near-Infrared Spectroscopy and Device Used in Same	OSAKA UNIVERSITY	12-Nov-04	10-Nov-05	15-May-08
US20080108629	Heterocyclic Derivatives for the Treatment of Diseases Mediated by Stearoyl-Coa Desaturase Enzymes	XENON PHARMACEUTICALS INC.	20-Sep-04	20-Sep-05	8-May-08
US20080107650	METHOD FOR TREATING INFLAMMATORY DISEASES OF THE DIGESTIVE TRACT	Gene Logic Inc.	8-Sep-06	7-Sep-07	8-May-08
US20080103746	Systems and methods for pathogen detection and response	Searete LLC, a limited liability corporation	30-Nov-05	11-Sep-07	1-May-08
US20080103149	NOVEL TETRACYCLIC INHIBITORS OF CYSTEINE PROTEASES, THE PHARMACEUTICAL COMPOSITIONS THEREOF AND THEIR THERAPEUTIC APPLICATIONS	COLLAND FREDERIC	30-Oct-06	30-Oct-06	1-May-08
US20080102444	METHODS AND COMPOSITIONS FOR DETECTING RHINOVIRUSES	Focus Technologies, Inc.	6-Jul-04	15-Oct-07	1-May-08
US20080096959	Durable Biocides and Disinfectants	MITSUI NORIN CO., LTD.	7-Jul-04	5-Jul-05	24-Apr-08

CC-BY-NC-SA Dr. David E. Martin

US20080096928	Methods for treating Hepatitis C	AREFOLOV ALEXANDER	14-Jul-04	14-Jul-05	24-Apr-08
US20080096895	Heterocyclic Derivatives and Their Use as Stearoyl-Coa Desaturase Inhibitors	XENON PHARMACEUTICALS INC.	20-Sep-04	20-Sep-05	24-Apr-08
US20080096186	PCR PRIMER SET FOR DETECTING SEVERE ACUTE RESPIRATORY SYNDROME (SARS)-CORONAVIRUS, METHOD AND KIT FOR DETECTING SARS-CORONAVIRUS USING THE SAME	HWANG JUNG-JOO	12-Dec-03	24-Nov-04	24-Apr-08
US20080090913	Sphingolipid-Derived Phamaceutical Compositions	BRAXMEIER TOBIAS	29-Jun-04	29-Jun-05	17-Apr-08
US20080090841	METHODS OF ENHANCING MUCOSAL HYDRATION AND MUCOSAL CLEARANCE BY TREATMENT WITH SODIUM CHANNEL BLOCKERS AND OSMOLYTES	PARION SCIENCES, Inc.	7-Sep-06	7-Sep-07	17-Apr-08
US20080090791	Cystic fibrosis treatment methods	Hollis-Eden Pharmaceuticals, Inc.	13-Oct-06	13-Oct-06	17-Apr-08
US20080090229	Devices for generating detectable polymers	ENGELHARD ERIC K	12-Oct-06	12-Oct-06	17-Apr-08
US20080090224	Nucleic acid detection	HAI KANG LIFE CORPORATION LIMITED	2-May-03	30-Apr-04	17-Apr-08
US20080085895	Substituted Chiral Fused [1,2]Imidazo[4,5-C] Ring Compounds	DANIELSON MICHAEL M	30-Dec-04	29-Dec-05	10-Apr-08
US20080085873	Disease treatment methods	Hollis-Eden Pharmaceuticals, Inc.	28-Aug-02	13-Oct-06	10-Apr-08
US20080081047	Anti-Sars Monoclonal Antibodies	ANDONOV ANTON	5-Dec-03	6-Dec-04	3-Apr-08
US20080076710	INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES	MAXYGEN, INC.	19-May-04	4-May-07	27-Mar-08
US20080076115	Compositions and Methods for Detecting Severe Acute Respiratory Syndrome Coronavirus	GILLIM-ROSS LAURA	3-Nov-03	3-Nov-04	27-Mar-08
US20080075740	Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor	The Trustees of the University of Pennsylvania	17-Dec-01	31-Oct-07	27-Mar-08
US20080075737	Adeno-Associated Virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor	The Trustees of the University of Pennsylvania	17-Dec-01	6-Sep-07	27-Mar-08
US20080075693	METHODS FOR TREATING VIRAL INFECTION USING IL-28 AND IL-29 CYSTEINE MUTANTS	ZymoGenetics, Inc.	2-Apr-04	20-Sep-07	27-Mar-08
US20080071063	Protein Formulations	MedImmune, Inc.	3-Feb-06	2-Feb-07	20-Mar-08
US20080070907	Substituted chiral fused [1,2] imidazo [4,5-C] ring compounds and methods	Coley Pharmaceutical Group, Inc.	12-Jul-06	12-Jul-07	20-Mar-08
US20080069839	ISOLATION AND CHARACTERIZATION OF THE PRECURSOR VIRUS OF HUMAN SARS VIRUS: SARS-ASSOCIATED CORONA VIRUS-LIKE VIRUS	GUAN YI	22-May-03	24-May-04	20-Mar-08
US20080069838	NOVEL HUMAN VIRUS CAUSING SEVERE ACUTE RESPIRATORY SYNDROME (SARS) AND USES THEREOF	CHAN KWOK HUNG	24-Mar-04	24-Mar-04	20-Mar-08
US20080069836	METHOD OF USING ADENOVIRAL VECTORS WITH INCREASED IMMUNOGENICITY IN VIVO	and Human Services	1-Sep-04	26-Feb-07	20-Mar-08
US20080069830	Dna Sequences, Peptides, Antibodies and Vaccines for Prevention and Treatment of Sars	HOFFMAN STEPHEN L	24-Jun-03	24-Jun-04	20-Mar-08
US20080069804	Alphavirus Replicon Packaging Constructs	PERRI SILVIA	25-May-04	20-May-05	20-Mar-08
US20080064105	Animal protein-free media for cultivation of cells	Baxter Healthcare Corporation	29-Oct-04	30-Oct-07	13-Mar-08
US20080064080	Animal protein-free media for cultivation of cells	Baxter Healthcare Corporation	29-Oct-04	30-Oct-07	13-Mar-08
US20080063664	High-yield transgenic mammalian expression system for generating virus-like particles	Academia Sinica	5-Sep-06	5-Sep-06	13-Mar-08
US20080058309	Novel Compounds 171	ASTRAZENECA AB	27-Jul-06	26-Jul-07	6-Mar-08
US20080057513	METHOD FOR PRODUCING NUCLEIC ACID PROBES	Ventana Medical Systems, Inc.	1-Sep-06	31-Aug-07	6-Mar-08

US20080051297	Method for determining antigen-specific T cell response in high throughput format	Centro di Biotecnologie Avanzate and istituto Giannina Gaslini	12-Jun-06	11-Jun-07	28-Feb-08
US20080050718	Methods, Articles, and Compositions for Identifying Oligonucleotides	ATKINS JOHN F	14-Nov-03	15-Nov-04	28-Feb-08
US20080044816	Assay for Sars Coronavirus by Amplification and Detection of the Replicase Sequence	BECTON, DICKINSON AND COMPANY	12-Sep-03	13-Sep-04	21-Feb-08
US20080044814	Reagents and Methods for Detecting Severe Acute Respiratory Syndrome Coronavirus	HIBBERD MARTIN L	21-Apr-03	21-Apr-04	21-Feb-08
US20080044438	Yeast Cell Particles As Oral Delivery Vehicles For Antigens	OSTROFF GARY R	17-Mar-06	16-Mar-07	21-Feb-08
US20080044437	Encapsidation System for Production of Recombinant Virus-Like Particles	CHEN QUN	2-Sep-04	1-Sep-05	21-Feb-08
US20080044426	Novel Atypical Pneumonia-Causing Virus	BESTEBROER THEODORUS MARINUS	18-Nov-03	18-Nov-04	21-Feb-08
US20080044423	COMPOUNDS	COCHRANE DUNCAN	23-Jun-06	22-Jun-07	21-Feb-08
US20080044384	Recombinant Human Cytomegalovirus And Vaccines Comprising Heterologous Antigens	MedImmune Vaccines, Inc.	25-Jun-04	24-Jun-05	21-Feb-08
US20080044378	Methods and Compositions for Protein Production Using Adenoviral Vectors	INTROGEN THERAPEUTICS, INC.	15-May-06	15-May-07	21-Feb-08
US20080033172	Mutagenic Heterocycles	Koronis Pharmaceuticals, Incorporated	19-Dec-03	10-Dec-04	7-Feb-08
US20080031979	USE OF EXTRACTS FOR THE TREATMENT OF VIRAL DISORDERS	BODDUPALLI SEKHAR	4-Aug-06	4-Aug-06	7-Feb-08
US20080031877	Purification of bacterial antigens	COVACCI ANTONELLO	17-Feb-06	16-Feb-07	7-Feb-08
US20080031868	HUMAN LYSOZYME MEDICINE, ITS MANUFACTURING METHOD AND APPLICATION THEREOF	AN MI	9-Jun-05	9-Jun-05	7-Feb-08
US20080031853	INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES	ROCHE PALO ALTO LLC	19-May-04	15-Aug-07	7-Feb-08
US20080031770	Apparatus and method for using ozone as a disinfectant	BOAST NIGEL	2-Aug-06	29-Nov-06	7-Feb-08
US20080027092	1-Acetic Acid-Indole, -Indazole and -Benzimidazole Derivatives Useful for the Treatment of Respiratory Disorders	BONNERT ROGER VICTOR	26-Nov-03	24-Nov-04	31-Jan-08
US20080027006	Compositions And Methods For Modification And Prevention Of Sars Coronavirus Infectivity	The Regents of the University of Colorado	12-Feb-04	14-Feb-05	31-Jan-08
US20080021038	Novel Piperidine/8-Azabicyclo [3.2.1.] Octan Derivatives As Modulators Of Chemokine Receptor Ccr5	FAULL ALAN	24-Jun-04	20-Jun-05	24-Jan-08
US20080020379	Diagnosis and prognosis of infectious diseases clinical phenotypes and other physiologic states using host gene expression biomarkers in blood	AGAN BRIAN K	5-Nov-04	7-Nov-05	24-Jan-08
US20080015247	QUERCETIN-CONTAINING COMPOSITIONS	LINES THOMAS C	17-Jul-06	16-Jul-07	17-Jan-08
US20080015230	HETEROCYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS	XENON PHARMACEUTICALS INC.	20-Sep-04	20-Sep-05	17-Jan-08
US20080015194	METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT	Joseph Errico	23-Jan-06	23-Jan-07	17-Jan-08
US20080015184	Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines	3M INNOVATIVE PROPERTIES COMPANY	14-Jun-04	14-Jun-05	17-Jan-08
US20080014204	Compositions Against Sars-Coronavirus and Uses Thereof	DE KRUIF CORNELIS A	11-Nov-04	10-Nov-05	17-Jan-08
US20080014183	Anticancer Agent Containing Dendritic Cell Having Rna Virus Transferred Thereinto	DNAVEC RESEARCH INC.	24-Jun-04	28-Apr-05	17-Jan-08
US20080009496	MUTAGENIC HETEROCYCLES	Koronis Pharmaceuticals, Inc.	19-Dec-03	27-Dec-06	10-Jan-08
US20080009040	ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS	Baxter Healthcare Corporation	29-Oct-04	20-Sep-07	10-Jan-08
US20080004236	High Dose, Short Interval Use of Sulfated Polysaccharides for Treatment of Infections	COMPER WAYNE D	6-Feb-04	7-Feb-05	3-Jan-08
US20080004228	New Expression Tools for Multiprotein Applications	BERGER IMRE	9-Mar-04	25-Nov-04	3-Jan-08

US20080004206	Albumin fusion proteins	BELL ADAM	21-Dec-01	31-Jul-06	3-Jan-08
US20080003236	ADENOVIRUS FIBER SHAFT COMPOSITION AND METHODS OF USE	GenVec, Inc.	18-Oct-04	13-Apr-07	3-Jan-08
US20070299081	Heterocyclic Derivatives and Their Use as Mediators of Stearoyl-Coa Desaturase	XENON PHARMACEUTICALS INC.	20-Sep-04	20-Sep-05	27-Dec-07
US20070298415	Method of Amplifying Nucleic Acid	Takara Bio Inc.	10-Dec-03	6-Dec-04	27-Dec-07
US20070292453	RNA virus vaccines and methods	DITTMER DIRK P	14-Dec-05	14-Dec-06	20-Dec-07
US20070287725	Isoxazole, Dihydroisoxazole, And Oxadiazole Substituted Imidazo Ring Compounds And Method	3M INNOVATIVE PROPERTIES COMPANY	18-Jun-04	17-Jun-05	13-Dec-07
US20070287724	Substituted Imidazoquinolines, Imidazopyridines, and Imidazonaphthyridines	3M INNOVATIVE PROPERTIES COMPANY	18-Jun-04	17-Jun-05	13-Dec-07
US20070286872	Live Attenuated Nidovirus Vaccines	Vanderbilt University	22-Apr-03	22-Apr-04	13-Dec-07
US20070286822	Compounds for the Treatment of Periodontal Disease	ANACOR PHARMACEUTICALS INC.	12-Jun-06	12-Jun-07	13-Dec-07
US20070281325	COMPOSITIONS AND METHODS FOR ANALYSIS OF TARGET ANALYTES	DANIELZADEH ROBERT	17-Sep-03	20-Jul-06	6-Dec-07
US20070276009	Compositions and Methods for Viral Inhibition	CHANG BRYAN	15-Oct-03	15-Oct-04	29-Nov-07
US20070275938	Therapeutic Treatment Methods	AHLEM CLARENCE N	28-Aug-02	12-Feb-07	29-Nov-07
US20070275937	Therapeutic Treatment Methods	AHLEM CLARENCE N	28-Aug-02	12-Feb-07	29-Nov-07
US20070275883	2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections	GOSSELIN GILLES	28-Jun-02	6-Sep-06	29-Nov-07
US20070275879	Use of Ulinastatin and Its Pharmaceutical Composition for Treating Severe Acute Respiratory Syndrome	GUANGDONG TECHPOOL BIOCHEM PHA	26-May-03	25-May-04	29-Nov-07
US20070275465	Double-Stranded Ribonucleic Acid with Increased Effectiveness in an Organism	Alnylam Pharmaceuticals	13-Jun-03	14-Jun-04	29-Nov-07
US20070275091	Compositions And Methods For Improved Mucus Function	KING MALCOLM	30-Mar-04	30-Mar-05	29-Nov-07
US20070275002	Use Of Proteins And Peptides Encoded By The Genome Of A Novel Sars-Associated Coronavirus Strain	AZEBI SALIHA	2-Dec-03	2-Dec-04	29-Nov-07
US20070274994	Virulence-Associated Adhesins	Novartis Vaccines and Diagnostics, Inc.	26-Jun-03	25-Jun-04	29-Nov-07
US20070274983	Nutritional Composition Comprising Immunoglobulins and Oligosaccharides	NUTRICIA NV	24-Aug-04	24-Aug-05	29-Nov-07
US20070274950	INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES	MAXYGEN INC	18-Nov-02	19-May-04	29-Nov-07
US20070274922	Water Soluble Boronic Acid Fluorescent Reporter Compounds and Methods of Use Thereof	FANG HAO	5-Sep-03	7-Sep-04	29-Nov-07
US20070270361	Sars Nucleic Acids, Proteins, Vaccines, and Uses Thereof	CHOU TE-HUI W	4-Aug-03	4-Aug-04	22-Nov-07
US20070270360	Rna Interference Mediated Inhibition of Severe Acute Respiratory Syndrome (Sars) Gene Expression Using Short Interfering Nucleic Acid	SIRNA THERAPEUTICS, INC.	15-Apr-03	13-Apr-04	22-Nov-07
US20070266957	Antipathogenic Domestic Livestock House, Disinfectants for Domestic Livestock House, Disinfectants for Living Organisms, Feedstuffs and Drinking Water for Animals	TAKAHASHI KAZUO	28-Sep-04	25-Aug-05	22-Nov-07
US20070265236	Asthma Treatment Methods	AHLEM CLARENCE N	28-Aug-02	16-Oct-06	15-Nov-07
US20070265226	Hydrolytically-Resistant Boron-Containing Therapeutics And Methods Of Use	Anacor Pharmaceuticals	2-May-06	2-May-07	15-Nov-07
US20070259914	Novel Piperidine Derivates as Modulators of Chemokine Receptor Ccr5.	TUCKER HOWARD	24-Jun-04	20-Jun-05	8-Nov-07
US20070259907	ARYL AND ARYLALKYLENYL SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES	PRINCE RYAN B	18-Jun-04	17-Jun-05	8-Nov-07

CC-BY-NC-SA Dr. David E. Martin

US20070259881	Substituted Imidazo Ring Systems and Methods	CELEBI AZIM A	18-Jun-04	17-Jun-05	8-Nov-07
US20070258999	Sars Virus Nucleotide and Amino Acid Sequences and Uses Thereof	THE PUBLIC HEALTH AGENCY OF CANADA	28-Apr-03	28-Apr-04	8-Nov-07
US20070254906	Method of Administration of Dopamine Receptor Agonists	DarPharma, Inc.	21-Jul-04	21-Jul-05	1-Nov-07
US20070254329	Mammalian Genes Involved in Viral Infection and Tumor Suppression	RUBIN DONALD H	2-May-02	2-May-03	1-Nov-07
US20070253978	Copy choice recombination and uses thereof	NIMAN HENRY L	2-Jul-04	29-Dec-06	1-Nov-07
US20070253860	Process and device for sterilising ambient air	SCHRODER WERNER	18-Oct-04	18-Apr-07	1-Nov-07
US20070249686	Modulators of Crth-2 Receptor Activity for the Treatment of Prostaglandin D2 Mediated Diseases	ASTRAZENECA AB	5-Oct-04	3-Oct-05	25-Oct-07
US20070248969	COMPOSITIONS FOR USE IN IDENTIFICATION OF BACTERIA	BLYN LAWRENCE	11-Sep-03	13-Mar-07	25-Oct-07
US20070248949	Sensitive and Specific Test to Detect Sars Coronavirus	AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH	17-Dec-03	17-Dec-04	25-Oct-07
US20070244133	Thienopyrimidines and Thiazolopyrimidines for Use in Medicine	BOWER JUSTIN F	4-Jun-04	31-May-05	18-Oct-07
US20070244044	Antimicrobial Peptides	NOVABIOTICS LIMITED	18-Aug-04	18-Aug-05	18-Oct-07
US20070243600	System for performing multi-formatted assays	GEN-PROBE INCORPORATED	10-Mar-05	10-Mar-06	18-Oct-07
US20070243544	COMPOSITIONS FOR USE IN IDENTIFICATION OF BACTERIA	BLYN LAWRENCE	11-Sep-03	13-Mar-07	18-Oct-07
US20070243263	Antiviral Methods	AgION Technologies, Inc.	14-Apr-06	21-Mar-07	18-Oct-07
US20070238681	MODULATION OF ACE2 EXPRESSION	BENNETT C F	7-Nov-06	7-Dec-06	11-Oct-07
US20070238116	COMPOSITIONS FOR USE IN IDENTIFICATION OF BACTERIA	BLYN LAWRENCE	11-Sep-03	13-Mar-07	11-Oct-07
US20070231347	Immunization Regimen with E4-Deleted Adenovirus Prime and E1-Deleted Adenovirus Boost	The Trustees of the University of Pennslyvania	28-Apr-04	27-Apr-05	4-Oct-07
US20070231344	Conjugate vaccines for non-proteinaceous antigens	The Brigham and Women's Hospital, Inc.	28-Oct-05	30-Oct-06	4-Oct-07
US20070231303	METHODS OF GENERATING CHIMERIC ADENOVIRUSES AND USES FOR SUCH CHIMERIC ADENOVIRUSES	The Trustees of the University of Pennsylvania	20-Jun-03	20-Jun-03	4-Oct-07
US20070231295	Antimicrobial Silicon Oxide Flakes	BUJARD PATRICE	12-May-04	2-May-05	4-Oct-07
US20070225303	8-Oxoadenine Compound	HASHIMOTO KAZUKI	26-Mar-04	25-Mar-05	27-Sep-07
US20070225205	INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES	MAXYGEN, INC.	19-May-04	14-Sep-06	27-Sep-07
US20070225204	INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES	MAXYGEN, INC.	19-May-04	14-Sep-06	27-Sep-07
US20070224700	Method and apparatus for analyzing bioprocess fluids	BioScale, Inc.	2-May-05	19-Dec-06	27-Sep-07
US20070224614	COMPOSITIONS FOR USE IN IDENTIFICATION OF BACTERIA	BLYN LAWRENCE	11-Sep-03	7-Mar-07	27-Sep-07
US20070219228	Aryl substituted imidazonaphthyridines	AMOS DAVID T	18-Jun-04	17-Jun-05	20-Sep-07
US20070219211	Bicyclic Heterocyclic Derivatives and Their Use as Inhibitors of Stearoyl-Coadesaturase (Scd)	XENON PHARMACEUTICALS INC.	20-Sep-04	20-Sep-05	20-Sep-07
US20070219200	PRODRUGS OF HETEROARYL COMPOUNDS	Koronos Pharmaceuticals, Incorporated	20-Jun-03	15-May-07	20-Sep-07
US20070219196	AMIDE SUBSTITUTED IMIDAZOPYRIDINES, IMIDAZOQUINOLINES, AND IMIDAZONAPHTHYRIDINES	AMOS DAVID T	24-Mar-04	24-Mar-05	20-Sep-07
US20070219149	Novel Vaccine Containing Adjuvant Capable Of Inducing Mucosal Immunity	Japan as Represented by the Director-General of National Institute of Infectious Diseases	11-Aug-03	10-Aug-04	20-Sep-07

US20070218536	Polyvalent Viral Vectors and a System for Production Thereof	GAO GUANGPING	28-Apr-04	27-Apr-05	20-Sep-07
US20070218489	COMPOSITIONS FOR USE IN IDENTIFICATION OF BACTERIA	BLYN LAWRENCE	11-Sep-03	13-Mar-07	20-Sep-07
US20070218467	Methods for rapid identification and quantitation of nucleic acid variants	ECKER DAVID J	21-Jul-05	21-Jul-06	20-Sep-07
US20070218001	Biotherapeutics, Diagnostics and Research Reagents	BIOTECH STUDIO, LLC	5-Jan-04	4-Jan-05	20-Sep-07
US20070213356	Nitrogen-Containing Heterocyclyl Substituted Imidazoquinolines and Imidazonaphthyridines	HARALDSON CHAD A	15-Jun-04	15-Jun-05	13-Sep-07
US20070213309	Sepsis Treatment Methods	AHLEM CLARENCE N	28-Aug-02	16-Oct-06	13-Sep-07
US20070212770	Oligopeptide-free cell culture media	Baxter Healthcare, S.A.	4-Jan-06	3-Jan-07	13-Sep-07
US20070212677	Identifying off-target effects and hidden phenotypes of drugs in human cells	Odyssey Thera, Inc.	22-Nov-04	31-Aug-06	13-Sep-07
US20070208052	Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines	HEPPNER PHILIP D	18-Jun-04	17-Jun-05	6-Sep-07
US20070207526	Norovirus and sapovirus antigens	COIT DORIS	22-Nov-05	22-Nov-06	6-Sep-07
US20070203209	Useful indole compounds	BARTOLINI WILMIN	18-Aug-05	18-Aug-06	30-Aug-07
US20070203107	Pharmaceutical compositions	Hollis-Eden Pharmaceuticals, Inc.	28-Aug-02	13-Oct-06	30-Aug-07
US20070203082	RNAI Agents For Anti-SARS Coronavirus Therapy	Intradigm Corporation	25-Apr-03	26-Apr-04	30-Aug-07
US20070203073	SARS and Ebola inhibitors and use thereof, and methods for their discovery	BATES PAUL	22-Jun-05	21-Jun-06	30-Aug-07
US20070203060	Casein Derived Peptides And Therapeutic Uses Thereof	SIDELMAN ZVI	1-Mar-04	1-Sep-06	30-Aug-07
US20070202492	Viral Assay	University Of Warwick	15-Apr-04	14-Apr-05	30-Aug-07
US20070197646	SUBSTITUTED TARAXASTANES USEFUL FOR TREATING VIRAL INFECTIONS	ACHILLION PHARMACEUTICALS, INC.	21-Feb-06	20-Feb-07	23-Aug-07
US20070197478	NOVEL PHARMACEUTICALS	PFIZER LTD	17-Feb-06	16-Feb-07	23-Aug-07
US20070196818	Using Nucleic Acids for Clinical Microbiology Testing	O'HARA STEPHEN	22-Oct-03	22-Oct-04	23-Aug-07
US20070196434	Methods of preventing or treating sinusitis with oxidative reductive potential water solution	Oculus Innovative Sciences, Inc.	20-Jan-06	22-Jan-07	23-Aug-07
US20070196357	Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solution	Oculus Innovative Sciences, Inc.	20-Jan-06	22-Jan-07	23-Aug-07
US20070196333	Composition comprising mixtures of IFN-alpha subtypes	HUANG SHIR-LY	23-Feb-06	23-Feb-06	23-Aug-07
US20070196274	Immunoconjugates with improved efficacy for the treatment of diseases	SUN LE	20-Jan-06	19-Jan-07	23-Aug-07
US20070192906	Rice plant having vaccine gene transferred thereinto	EBINUMA HIROYASU	9-Apr-04	8-Apr-05	16-Aug-07
US20070192905	Edible vaccines expressed in soybeans	The University of North Carolina	12-Oct-04	12-Oct-05	16-Aug-07
US20070191294	Short interfering rna (sirna) analogues	SANTARIS PHARMA AS	21-Mar-03	22-Mar-04	16-Aug-07
US20070190163	Technology for preparation of macromolecular microspheres	FANG FANG	24-Jan-06	24-Jan-07	16-Aug-07
US20070190071	9-Substituted 8-oxoadenine compound	AstraZeneca Aktiebolag	26-Mar-04	24-Mar-05	16-Aug-07
US20070190065	Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with SARS corona virus spike protein	ALTMEYER RALF	3-Jun-05	4-Dec-06	16-Aug-07

CC-BY-NC-SA Dr. David E. Martin

US20070190031	Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to hiv	EGAN MICHAEL	17-Jun-04	15-Jun-05	16-Aug-07
US20070185044	Modulation of ace2 expression	BENNETT C F	8-Mar-05	8-Mar-05	9-Aug-07
US20070185027	ANTIVIRAL AGENTS FOR THE TREATMENT, CONTROL AND PREVENTION OF INFECTIONS BY CORONAVIRUSES	SEQUOIA PHARMACEUTICALS, INC.	28-Apr-03	9-Nov-06	9-Aug-07
US20070184434	Compositions for use in identification of influenza viruses	ESHOO MARK W	17-Oct-05	17-Oct-06	9-Aug-07
US20070178533	Method and diagnostic tests based on flow cytometric analysis of antigen-specific t lymphocytes	AGRATI CHIARA	5-Aug-03	5-Aug-04	2-Aug-07
US20070178505	Promoter engineering and genetic control	ALPER HAL S	3-Jan-06	3-Jan-07	2-Aug-07
US20070178048	Antiviral composition comprising p-menthane-3,8-diol	CLARKE PAUL D	12-Mar-04	2-Mar-05	2-Aug-07
US20070173755	Methods of treating or preventing peritonitis with oxidative reductive potential water solution	Oculus Innovative Sciences, Inc.	20-Jan-06	22-Jan-07	26-Jul-07
US20070173481	Compositions and methods for preventing infection	JOLLA BIOSCIENCES LLC	20-Sep-02	11-Dec-06	26-Jul-07
US20070172817	Methods of Producing Antibodies for Diagnostics and Therapeutics	CHANG XIAO-JIA	8-Jul-03	22-Nov-06	26-Jul-07
US20070172448	Method for detecting the specificity of activated lymphocyte	HU JUN	8-Dec-03	7-Dec-04	26-Jul-07
US20070167476	Piperazine, [1,4]Diazepane, [1,4]Diazocane, and [1,5]Diazocane fused imidazo ring compounds	CELEBI AZIM A	29-Dec-03	22-Dec-04	19-Jul-07
US20070167408	NOVEL ALKYL PHOSPHOLIPID DERIVATIVES WITH REDUCED CYTOTOXICITY AND USES THEREOF	ZENTARIS GmbH	19-Dec-05	19-Dec-06	19-Jul-07
US20070166823	Methods for detecting parvovirous infections	BLUTH MARTIN H	5-May-03	5-May-04	19-Jul-07
US20070166784	Combination approaches for generating immune responses	BARNETT SUSAN W	15-Sep-03	15-Sep-04	19-Jul-07
US20070166384	Methods , composition and preparations for delivery of immune response modifiers	ZARRAGA ISIDRO ANGELO E	9-Apr-04	8-Apr-05	19-Jul-07
US20070166281	Chloroquine coupled antibodies and other proteins with methods for their synthesis	KOSAK KENNETH M	21-Aug-04	22-Feb-07	19-Jul-07
US20070160981	VIRAL PROTEASE	CHEN XIN	24-Oct-05	23-Oct-06	12-Jul-07
US20070155767	Sulfone substituted imidazo ring ethers	DELLARIA JOSEPH F JR	4-Dec-03	3-Dec-04	5-Jul-07
US20070155699	Boron-containing small molecules	Anacor Pharmaceuticals	30-Dec-05	16-Aug-06	5-Jul-07
US20070155683	Artificial cpg single-stranded oligodeoxynucleotide and antiviral use thereof	WANG LIYING	25-Jul-03	26-Jul-04	5-Jul-07
US20070154348	Supports for assaying analytes and methods of making and using thereof	FRUTOS ANTHONY G	29-Dec-05	7-Jun-06	5-Jul-07
US20070149487	Antiviral Compositions and Methods	MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH	8-Nov-05	7-Nov-06	28-Jun-07
US20070148670	Methods for detecting conformational changes in bioentities	O'MALLEY SHAWN M	28-Dec-05	25-Oct-06	28-Jun-07
US20070141597	Biomimetic Biodetector of Toxins, Viruses, Bacteria, and Biological Factors	HARMON H J	25-Oct-05	25-Oct-06	21-Jun-07
US20070141080	Treating severe acute respiratory syndrome	HEMISPHERx BIOPHARMA	16-May-03	26-Jan-07	21-Jun-07
US20070141053	Treatment of inflammatory respiratory diseases	Schering Aktiengesellschaft	9-May-03	7-May-04	21-Jun-07
US20070136890	Expression of a recombinant transgene	Board of Trustees Operating Michigan State University	3-Jul-03	2-Jul-04	14-Jun-07
US20070135439	Novel inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications	BOISSY GUILLAUME	8-Dec-05	8-Dec-05	14-Jun-07

CC-BY-NC-SA Dr. David E. Martin

US20070135367	Method for controlling sr protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control sr protein activity	FUKUHARA TAKESHI	26-Dec-03	24-Dec-04	14-Jun-07
US20070134695	Dengue virus detection measured by immunocytometry in a dendritic cell surrogate	BURGESS TIMOTHY	27-Oct-05	26-Oct-06	14-Jun-07
US20070134694	Method for the measurement of dengue virus binding inhibition	BURGESS TIMOTHY	27-Oct-05	26-Oct-06	14-Jun-07
US20070134255	Hmpv treatment with ribavirin and anti-hmpv antibody	ViroNovative B.V.	2-May-03	3-May-04	14-Jun-07
US20070134214	Inactivated host cell delivery of polynucleotides encoding immunogens	XU FENG	13-Aug-03	12-Aug-04	14-Jun-07
US20070123566	Isoflavone derivatives of tectoridin, the preparation thereof and the anti-virus medicines containing the same as an effective constituents	CHENGDU DIKANG PHARMACEUTICAL INSTITUTE	15-May-03	14-May-04	31-May-07
US20070116785	Nitric oxide as an anti-viral agent, vaccine and vaccine adjuvant	MILLER CHRISTOPHER C	18-Nov-05	20-Nov-06	24-May-07
US20070116716	Sars coronavirus s proteins and uses thereof	FIELDING BURTRAM C	10-Dec-03	10-Dec-04	24-May-07
US20070116600	Detection device and methods associated therewith	COOK RICHARD A	23-Jun-05	23-Jun-06	24-May-07
US20070111309	Vero cell line adapted to grow in suspension	DAELLI MARCELO G	4-Oct-05	29-Sep-06	17-May-07
US20070111296	Methods and Devices for Quantitative Viral Assays	SHU YING	16-Nov-05	16-Nov-06	17-May-07
US20070111231	Detection of mutations in a gene associated with resistance to viral infection, OAS2 and OAS3	Illumigen Biosciences, Inc.	23-Aug-05	23-Aug-06	17-May-07
US20070105193	Severe acute respiratory syndrome DNA vaccine compositions and methods of use	Vical Incorporated	16-May-03	12-May-04	10-May-07
US20070104808	COMPOSITIONS AND METHODS FOR TREATMENT OF RHINOVIRUS	THE QUIGLEY CORPORATION	6-Aug-01	27-Oct-06	10-May-07
US20070104686	Vaccines, immunotherapeutics and methods for using the same	CHATTERGOON MICHAEL A	13-Jun-03	14-Jun-04	10-May-07
US20070099968	Antiviral compounds and methods	Biotron Limited	24-Jun-04	24-Jun-04	3-May-07
US20070099901	Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines	3M INNOVATIVE PROPERTIES COMPANY	25-Nov-03	24-Nov-04	3-May-07
US20070099855	Glycyrrhizin or derivatives thereof for for treating or preventing severe acute respiratory syndrome (sars)	Johann Wolfgang Goethe University	6-Jun-03	7-Jun-04	3-May-07
US20070099178	Method for detecting sars coronavirus	EIKEN KAGAKU KABUSHIKI KAISHA	27-Jun-03	15-Jun-04	3-May-07
US20070098735	Methods for the Elimination of Pathogens and Other Particulate Agents	CHANDAWARKAR RAJIV Y	29-Oct-05	30-Oct-06	3-May-07
US20070098719	GITR binding molecules and uses therefor	TolerRx, Inc.	25-Mar-05	27-Mar-06	3-May-07
US20070093969	Molecular nephrotoxicology modeling	CASTLE ARTHUR	22-Nov-02	24-Nov-03	26-Apr-07
US20070092938	Diagnostics for sars virus	Temasek Life Sciences Laboratory	15-Jul-03	4-Feb-04	26-Apr-07
US20070092936	Severe acute respiratory syndrome	HAYNES BARTON F	8-May-03	10-May-04	26-Apr-07
US20070092871	Microarray for pathogen identification	COMBIMATRIX CORP	20-Oct-05	20-Oct-06	26-Apr-07
US20070087974	TREATMENT OR PREVENTION OF RESPIRATORY VIRAL INFECTIONS WITH IMMUNOMODULATOR COMPOUNDS	SCICLONE PHARMACEUTICALS, INC.	14-May-04	9-Nov-06	19-Apr-07
US20070087341	Compositions for use in identification of influenza viruses	ESHOO MARK W	17-Oct-05	17-Oct-06	19-Apr-07
US20070087340	Compositions for use in identification of influenza viruses	ESHOO MARK W	17-Oct-05	17-Oct-06	19-Apr-07
US20070087339	Compositions for use in identification of influenza viruses	ESHOO MARK W	17-Oct-05	17-Oct-06	19-Apr-07

US20070087338	Compositions for use in identification of influenza viruses	ESHOO MARK W	17-Oct-05	17-Oct-06	19-Apr-07
US20070087337	Compositions for use in identification of influenza viruses	ESHOO MARK W	17-Oct-05	17-Oct-06	19-Apr-07
US20070087336	Compositions for use in identification of influenza viruses	ESHOO MARK W	17-Oct-05	17-Oct-06	19-Apr-07
US20070087332	Pulmonary stem cells, related methods and kits of parts	LING THAI-YEN	17-Oct-05	17-Oct-05	19-Apr-07
US20070087008	Rab9a, rab11a, and modulators thereof related to infectious disease	UNIV VANDERBILT	24-Feb-04	24-Feb-05	19-Apr-07
US20070082971	Use of a plastic composition and a product obtained thereby	POLYGIENE AB	23-Feb-04	27-Jan-05	12-Apr-07
US20070077201	Stem cell expansion and uses	DOWDING CHARLES	29-Sep-04	25-Mar-06	5-Apr-07
US20070072893	Substituted imidazo ring systems and methods	AMOS DAVID T	25-Nov-03	24-Nov-04	29-Mar-07
US20070072202	Use of chimeric receptors in a screening assay for identifying agonists and antagonists of cell receptors	BATES ELIZABETH E M	24-Mar-05	24-Mar-06	29-Mar-07
US20070066649	METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF BRAIN INFLAMMATION AND SEPSIS	Not Available	29-Nov-02	1-Nov-06	22-Mar-07
US20070066648	METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF BRAIN INFLAMMATION AND SEPSIS	NOZAKI MASAKO	29-Nov-02	1-Nov-06	22-Mar-07
US20070066639	Oxime substituted imidazoquinolines	AMOS DAVID T	12-Aug-04	12-Aug-04	22-Mar-07
US20070066552	Topical administration permitting prolonged exposure of target cells to therapeutic and prophylactic nucleic acids	INTROGEN THERAPEUTICS INC	21-Jan-05	20-Jan-06	22-Mar-07
US20070065939	Systems for detection and production of respiratory, herpes and enteric viruses	Diagnostic Hybrids, Inc.	20-Sep-05	28-Apr-06	22-Mar-07
US20070065407	Interferon-Alpha Polypeptides and Conjugates	MAXYGEN INC	18-Nov-02	30-Oct-06	22-Mar-07
US20070060754	Alkoxy substituted imidazoquinolines	HARALDSON CHAD A	3-Oct-03	1-Oct-04	15-Mar-07
US20070060611	METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF BRAIN INFLAMMATION AND SEPSIS	Not Available	29-Nov-02	1-Nov-06	15-Mar-07
US20070060535	Targeted delivery of antiviral compounds through hemoglobin bioconjugates	ADAMSON J G	30-Apr-98	13-Nov-06	15-Mar-07
US20070060499	Chloroquine combination drugs and methods for their synthesis	KOSAK KENNETH M	15-Sep-05	22-Feb-06	15-Mar-07
US20070059728	COMPUTER-IMPLEMENTED BIOLOGICAL SEQUENCE IDENTIFIER SYSTEM AND METHOD	The Government of the US, as represented by the Secretary of the Navy	2-Jul-04	6-Jun-06	15-Mar-07
US20070059686	Materials and methods for the detection of severe acute respiratory syndrome virus (SARS)	ERAGEN BIOSCIENCES INC	31-Jan-04	28-Jul-06	15-Mar-07
US20070059243	METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF BRAIN INFLAMMATION AND SEPSIS	Not Available	29-Nov-02	1-Nov-06	15-Mar-07
US20070054937	METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF BRAIN INFLAMMATION AND SEPSIS	Not Available	29-Nov-02	1-Nov-06	8-Mar-07
US20070054834	Quaternary ammonium halides for treatment of infectious conditions	NANOBIO CORP	11-Apr-05	10-Apr-06	8-Mar-07
US20070053933	IL28 and IL29 TRUNCATED CYSTEINE MUTANTS AND ANTIVIRAL METHODS OF USING SAME	SHEPPARD PAUL O	20-Jul-05	20-Jul-06	8-Mar-07
US20070053920	Nematode polypeptide adjuvant	Not Available	22-Jan-03	21-Jan-04	8-Mar-07
US20070053878	Sars	FOUCHIER RONALDUS A M	8-Apr-03	8-Apr-04	8-Mar-07
US20070048759	DETECTION OF TARGET MOLECULES WITH LABELED NUCLEIC ACID DETECTION MOLECULES	LI YOUGEN	10-Jun-05	12-Jun-06	1-Mar-07
US20070048747	Methods for assaying analytes	LESLIE THOMAS M	1-Sep-05	1-Sep-05	1-Mar-07
US20070048282	Albumin fusion proteins	Human Genome Sciences, Inc.	9-Feb-04	8-Aug-06	1-Mar-07

CC-BY-NC-SA Dr. David E. Martin

US20070042441	Method and apparatus for detecting estradiol and metabolites thereof using an acoustic device	BioScale, Inc.	2-May-05	2-May-06	22-Feb-07
US20070042388	Method of probe design and/or of nucleic acids detection	LEE CHARLIE	12-Aug-05	12-Aug-05	22-Feb-07
US20070042381	BIOINFORMATICALLY DETECTABLE GROUP OF NOVEL REGULATORY VIRAL AND VIRAL ASSOCIATED OLIGONUCLEOTIDES AND USES THEREOF	Rosetta Genomics	16-Jan-03	26-May-04	22-Feb-07
US20070042351	Multi-allelic molecular detection of sars-associated coronavirus	KOSTRIKIS LEONDIOS G	22-Aug-03	13-Aug-04	22-Feb-07
US20070042350	Methods and compositions for detecting sars virus and other infectious agents	CHENG JING	14-Jul-03	14-Jul-03	22-Feb-07
US20070041941	Nucleic acid sequences encoding and compositions comrpising ige signal peptide and/or il-15 and methods for using the same	BOYER JEAN D	13-Jun-03	14-Jun-04	22-Feb-07
US20070037763	Oligonucleotide compound and method for treating nidovirus infections	AVI BIOPHARMA INC	24-Dec-03	10-May-06	15-Feb-07
US20070037231	Methods and apparatus for detecting bacteria using an acoustic device	BioScale, Inc.	2-May-05	2-May-06	15-Feb-07
US20070037142	Methods and apparatus for detecting viruses using an acoustic device	BioScale, Inc.	2-May-05	2-May-06	15-Feb-07
US20070037140	Methods and compositions for detecting sars virus	CAPITAL BIOCHIP COMPANY, LTD.	9-May-03	9-May-03	15-Feb-07
US20070036760	Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor	The Trutees of the University of Pennsylvania	30-Sep-03	30-Sep-04	15-Feb-07
US20070036744	Treatment or prevention of respiratory viral infections with alpha thymosin peptides	SciClone Pharmaceuticals, Inc.	23-Apr-03	23-Apr-04	15-Feb-07
US20070034529	Electrochemistry and electrogenerated chemiluminescence with a single faradaic electrode	BARD ALLEN J	3-Jun-05	2-Jun-06	15-Feb-07
US20070032499	Novel cysteine protease inhibitors and their therapeutic applications	BOISSY GUILLAUME	5-Aug-05	5-Aug-05	8-Feb-07
US20070031923	Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases	CHAM BILL E	29-Jun-00	10-Apr-06	8-Feb-07
US20070031832	Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom	Phylogica Limited	5-May-99	20-Feb-04	8-Feb-07
US20070031283	Assay cartridges and methods for point of care instruments	BLANKFARD MARTIN	23-Jun-05	23-Jun-06	8-Feb-07
US20070027306	Albumin fusion proteins	HASELTINE WILLIAM A	9-Feb-04	8-Aug-06	1-Feb-07
US20070026391	Methods and compositions for identifying chemical or biological agents using multiplexed labeling and colocalization detection	GHC TECHNOLOGIES INC	11-Apr-05	6-Apr-06	1-Feb-07
US20070026087	Anti-coronavirus agent	Toagosei Co., Ltd.	16-Oct-03	31-Oct-03	1-Feb-07
US20070026014	Interferon beta in severe acute respiratory syndrome (sars)	ARES TRADING S.A.	17-Apr-03	6-Apr-04	1-Feb-07
US20070026009	Systems and methods for identifying replikin scaffolds and uses of said replikin scaffolds	BOGOCH ELENORE S	27-Mar-01	16-Feb-06	1-Feb-07
US20070025966	INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES	MAXYGEN, INC.	19-May-04	13-Sep-06	1-Feb-07
US20070021439	Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers	PARION SCIENCES INC	25-Jul-05	25-Jul-05	25-Jan-07
US20070021326	Composition and its Therapeutic Use	INSIGNION HOLDINGS LTD AND VER	9-Aug-02	25-Sep-06	25-Jan-07
US20070020734	INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES	MAXYGEN, INC.	19-May-04	13-Sep-06	25-Jan-07
US20070020235	INTERFERON-ALPHA POLYPEPTIDES AND CONJUGATES	MAXYGEN, INC.	19-May-04	13-Sep-06	25-Jan-07
US20070015181	System and methods for nucleic acid and polypeptide selection	WILLIAMS RICHARD B	19-May-00	2-May-06	18-Jan-07

US20070015172	Expression profiles for microbial infection	Z-BioMed, Inc.	1-Jun-05	30-Nov-05	18-Jan-07
US20070014778	Endoribonuclease and uses thereof	LEE CHOW	6-Jun-05	5-Jun-06	18-Jan-07
US20070014719	Steroid analogs and characterization and treatment methods	DOWDING CHARLES	29-Sep-04	29-Sep-05	18-Jan-07
US20070009932	Promoter engineering and genetic control	ALPER HAL S	27-Apr-05	26-Apr-06	11-Jan-07
US20070009884	Methods and apparatuses for detecting chemical or biological agents	GHC TECHNOLOGIES INC	11-Apr-05	6-Apr-06	11-Jan-07
US20070004028	Signal measuring system for conducting real-time amplification assays	GEN-PROBE INCORPORATED	10-Mar-05	10-Mar-06	4-Jan-07
US20070003577	Purified trimeric S protein as vaccine against severe acute respiratory syndrome virus infections	CHU KID	28-Jun-05	27-Jun-06	4-Jan-07
US20070003565	Use of hab18g/cd147 molecule as target for antiviral antagonists and thus obtained antiviral antagonist	CHEN ZHINAN	9-Jun-03	9-Jun-03	4-Jan-07
US20060293352	Phenoxiacetic acid derivatives	BONNERT ROGER V	21-Aug-03	18-Aug-04	28-Dec-06
US20060293308	Pyridyl derivatives and their use as therapeutic agents	Xenon Pharmaceuticals Inc.	29-Jul-03	29-Jul-04	28-Dec-06
US20060293267	Dual functional oligonucleotides for use as anti-viral agents	UNIVERSITY OF MASSACHUSETTS	13-Apr-05	13-Apr-06	28-Dec-06
US20060292178	Proteins encoded by the severe acute respiratory syndrome (SARS) coronavirus and a role in apoptosis	Agency for Science, Technology and Research	4-Aug-04	4-Aug-05	28-Dec-06
US20060292162	Plasma or serum fraction for the treatment or prevention of bacterial infections	BUCKHEIT ROBERT W JR	22-Apr-05	24-Apr-06	28-Dec-06
US20060292151	L-SIGN polymorphisms and methods involving use of same	GARDNER JASON P	26-Mar-04	28-Mar-05	28-Dec-06
US20060287263	Methods and compositions for inducing antigen-specific immune responses	COLEY PHARMACEUTICAL GROUP LTD	18-Jul-04	18-Jul-05	21-Dec-06
US20060286667	Methods for detection and production of influenza viruses	Diagnostic Hybrids, Inc.	24-Apr-98	28-Apr-06	21-Dec-06
US20060286124	Vaccine compositions and methods of treating coronavirus infection	ID Biomedical Corporation of Quebec	30-Jun-04	30-Jun-05	21-Dec-06
US20060286121	Adenoviral vector-based vaccines	BROUGH DOUGLAS E	25-Jul-03	23-Jan-06	21-Dec-06
US20060286119	Compositions and methods for treatment of chronic and infectious diseases	Biokit S.A.	23-Dec-03	6-Apr-06	21-Dec-06
US20060281128	Compositions and methods using lentivirus-based vectors for generating immune responses	VIRXSYS CORPORATION	9-Sep-03	17-Aug-06	14-Dec-06
US20060281072	Agonistic Binding Molecules to the Human OX40 Receptor	BAKKER ALEXANDER BERTHOLD H	13-Jun-02	13-Jun-03	14-Dec-06
US20060280754	Method of preventing virus: cell fusion by inhibiting the function of the fusion initiation region in rna viruses having class i membrane fusogenic envelope proteins	GARRY ROBERT F	4-Nov-03	3-Nov-04	14-Dec-06
US20060280748	Plasma or serum fraction for treatment or prevention of abnormal cell proliferation	BUCKHEIT ROBERT W JR	22-Apr-05	24-Apr-06	14-Dec-06
US20060280723	Interferon for treating or preventing a coronaviral infection	Viragen, Inc	19-May-03	19-May-04	14-Dec-06
US20060280679	Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells	BOWDISH KATHERINE S	4-Mar-03	17-Dec-04	14-Dec-06
US20060276972	Method for determining the amount of an analyte in a sample	Gen-Probe Incorporated	10-Mar-05	10-Mar-06	7-Dec-06
US20060275841	Assay method and apparatus with reduced sample matrix effects	BLANKFARD MARTIN	20-Dec-04	19-Dec-05	7-Dec-06
US20060275802	Mutations in OAS1 genes	FELLIN P C	4-May-05	3-May-06	7-Dec-06
US20060275749	Compositions for use in identification of orthopoxviruses	ISIS Pharmaceuticals, Inc.	5-Dec-03	24-Aug-05	7-Dec-06
US20060275515	Antiviral preparations obtained from a natural cinnamon extract	OVADIA MICHAEL	24-Dec-03	22-Jun-06	7-Dec-06

CC-BY-NC-SA Dr. David E. Martin

US20060275317	Vaccine compositions for prevention of chronic and infectious diseases	Biokit S.A.	23-Dec-03	6-Apr-06	7-Dec-06
US20060270835	Diagnosis and treatment of Alzheimer disease	Biokit S.A.	23-Dec-03	6-Apr-06	30-Nov-06
US20060270614	Use of chalcones for the treatment of viral disorders	BODDUPALLI SEKHAR	24-May-05	24-May-05	30-Nov-06
US20060270041	Cell lines for production of replication-defective adenovirus	HOWE JOHN A	13-Dec-04	12-Dec-05	30-Nov-06
US20060270017	Inactivation of a pathogen in a sample by a treatment with formalin and UV light	BARRETT NOEL	26-May-05	26-May-05	30-Nov-06
US20060269976	METHOD FOR REDUCING LYSOZYME ENZYMATIC ACTIVITY	Biokit S.A.	23-Dec-03	5-Apr-06	30-Nov-06
US20060269936	Screening assay for TLR7, TLR8 and TLR9 agonists and antagonists	DOLLET SANDRA	24-Mar-05	23-Mar-06	30-Nov-06
US20060269911	Antisense antiviral compound and method for treating ssRNA viral infection	AVI BIOPHARMA INC	16-Sep-04	10-May-06	30-Nov-06
US20060269572	Accelerated vaccination	GEISBERT THOMAS W	1-Aug-03	17-Jan-06	30-Nov-06
US20060269538	Serine proteases with altered sensitivity to activity-modulating substances	COCO WAYNE M	27-May-05	26-May-06	30-Nov-06
US20060264448	Purine derivatives	PFIZER LTD	4-May-05	3-May-06	23-Nov-06
US20060264444	Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseases	BONNERT ROGER V	18-Aug-03	16-Aug-04	23-Nov-06
US20060264435	Novel compounds	BONNERT ROGER	7-Apr-03	6-Apr-04	23-Nov-06
US20060263847	Compositions and methods for treatment of sever acute respiratory syndrome (sars)	SIBER GEORGE R	20-May-03	20-May-04	23-Nov-06
US20060263765	Peptides and mixtures thereof for use in the detection of severe acute respiratory syndrome-associated coronavirus (sars)	HOUDE MICHEL	9-May-03	5-May-04	23-Nov-06
US20060259249	Rapid identification of microbial agents	ECKER DAVID J	3-Mar-04	3-Mar-05	16-Nov-06
US20060258611	Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference	UNIV HONG KONG	19-May-03	14-Jun-06	16-Nov-06
US20060258577	ANTIVIRAL AGENTS FOR THE TREATMENT, CONTROL AND PREVENTION OF INFECTIONS BY CORONAVIRUSES	ERICKSON JOHN W	28-Apr-03	28-Apr-04	16-Nov-06
US20060257993	Integration of fluids and reagents into self-contained cartridges containing sensor elements	ANSLYN ERIC	27-Feb-04	22-Dec-04	16-Nov-06
US20060257992	Integration of fluids and reagents into self-contained cartridges containing sensor elements and reagent delivery systems	ANSLYN ERIC	27-Feb-04	22-Dec-04	16-Nov-06
US20060257991	Integration of fluids and reagents into self-contained cartridges containing particle-based sensor elements and membrane-based sensor elements	ANSLYN ERIC	27-Feb-04	22-Dec-04	16-Nov-06
US20060257976	Methods and kits for propagating and evolving nucleic acids and proteins	RNA LINE OY	6-Jun-03	7-Jun-04	16-Nov-06
US20060257945	Methods and apparatus for detecting cardiac injury markers using an acoustic device	BioScale, Inc.	2-May-05	2-May-06	16-Nov-06
US20060257941	Integration of fluids and reagents into self-contained cartridges containing particle and membrane sensor elements	ANSLYN ERIC	27-Feb-04	22-Dec-04	16-Nov-06
US20060257925	Method for isolating intracellular antibodies able to neutralize protein interactions	LINE GENOMICS S.P.A.	21-Nov-02	21-Nov-03	16-Nov-06
US20060257866	Methods for identifying small molecules that modulate premature translation termination and nonsense mediated mrna decay	ALMSTEAD NEIL G	24-Jul-02	24-Jul-03	16-Nov-06
US20060257861	Screening assay for inhibitors of severe acute respiratory syndrome (SARS) using SELDI-TOF Mass Spectrometry	Wright State University	12-May-05	12-May-06	16-Nov-06
US20060257854	Membrane assay system including preloaded particles	BALLARD KARRI L	27-Feb-04	22-Dec-04	16-Nov-06
US20060257852	Severe acute respiratory syndrome coronavirus	Chiron Corporation	10-Apr-03	9-Apr-04	16-Nov-06

CC-BY-NC-SA Dr. David E. Martin

US20060253060	Method of using oxidative reductive potential water solution in dental applications	Oculus Innovative Sciences, Inc.	2-May-05	2-May-06	9-Nov-06
US20060252767	Piperazine derivatives and their use as therapeutic agents	XENON PHARMACEUTICALS INC.	30-Jul-03	29-Jul-04	9-Nov-06
US20060246081	Methods and compositions for polytopic vaccination	DEEM MICHAEL W	29-Apr-05	29-Apr-05	2-Nov-06
US20060241546	Method of treating second and third degree burns using oxidative reductive potential water solution	Oculus Innovative Sciences, Inc.	23-Mar-05	23-Mar-06	26-Oct-06
US20060240551	Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus	HE YUXIAN	2-Jun-04	8-Feb-06	26-Oct-06
US20060240530	Methods and compositions for infectious cDNA of SARS coronavirus	UNIV NORTH CAROLINA	21-Jul-03	19-Jan-06	26-Oct-06
US20060240515	Soluble fragments of the SARS-CoV spike glycoprotein	DIMITROV DIMITER S	21-Jul-03	19-Jan-06	26-Oct-06
US20060240412	Compositions for use in identification of adenoviruses	BLYN LAWRENCE	11-Sep-03	12-Apr-06	26-Oct-06
US20060235350	Method of treating skin ulcers using oxidative reductive potential water solution	Oculus Innovative Sciences, Inc.	23-Mar-05	23-Mar-06	19-Oct-06
US20060234981	Boron-containing small molecules	Anacor Pharmaceuticals	16-Feb-05	16-Feb-06	19-Oct-06
US20060234263	Method for reducing the presence of amplification inhibitors in a reaction receptacle	Gen-Probe Incorporated	10-Mar-05	10-Mar-06	19-Oct-06
US20060229356	Use of indomethacin and derivatives as broad-spectrum antiviral drugs and corresponding pharmaceutical compositions	Universita' Degli Studi Di Roma "Tor Vergata"	12-Aug-03	11-Aug-04	12-Oct-06
US20060228299	Constructs binding to phosphatidylserine and their use in disease treatment	PEREGRINE PHARMACEUTICALS INC	24-Jan-05	24-Jan-06	12-Oct-06
US20060223863	Methods for treating Hepatitis C	AREFOLOV ALEXANDER	14-Jul-04	14-Jul-05	5-Oct-06
US20060223847	Anti-coronavirus drug	Arigen, Inc.	15-Jul-03	14-Jul-04	5-Oct-06
US20060223184	Supports useful in incorporating biomolecules into cells and methods of using thereof	FRUTOS ANTHONY G	5-Apr-05	5-Apr-05	5-Oct-06
US20060223074	Spotting compositions and methods of use thereof	BUNCH THOMAS A	5-Apr-05	5-Apr-05	5-Oct-06
US20060216702	Virus-like particles, methods of preparation, and immunogenic compositions	COMPANS RICHARD W	17-May-02	4-Apr-06	28-Sep-06
US20060211765	Novel compounds	ASTRAZENECA AB	7-Apr-03	6-Apr-04	21-Sep-06
US20060211752	Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression	BENAVIDES-PERALTA URUGUAYSITO	16-Mar-04	17-May-05	21-Sep-06
US20060211130	Method for continuous mode processing of multiple reaction receptacles in a real-time amplification assay	Gen-Probe Incorporated	10-Mar-05	10-Mar-06	21-Sep-06
US20060211115	Methods of generating chimeric adenoviruses and uses for such chimeric aden oviruses	The Trustees of the University of Pennsylvania	20-Jun-03	15-Jun-04	21-Sep-06
US20060210967	Re-sequencing pathogen microarray	AGAN BRIAN K	2-Jul-04	2-Jul-05	21-Sep-06
US20060210433	Signal measuring system having a movable signal measuring device	GEN-PROBE INCORPORATED	10-Mar-05	10-Mar-06	21-Sep-06
US20060205713	Pyridazine derivatives and their use as therapeutic agents	Xenon Pharmaceuticals Inc.	29-Jul-04	29-Jul-04	14-Sep-06
US20060205040	Compositions for use in identification of adventitious viruses	SAMPATH RANGARAJAN	3-Mar-05	3-Mar-06	14-Sep-06
US20060204997	Method for performing multi-formatted assays	Gen-Probe Incorporated	10-Mar-05	10-Mar-06	14-Sep-06
US20060199802	Pyridyl derivatives and their use as therapeutic agents	ABREO MELWYN	30-Jul-03	29-Jul-04	7-Sep-06

CC-BY-NC-SA Dr. David E. Martin

US20060199176	Coronavirus S peptides	CHONG PELE C S	15-Jul-04	14-Jul-05	7-Sep-06
US20060195067	Delivery of immune response modifier compounds	KEDL ROSS M	25-Aug-03	25-Aug-04	31-Aug-06
US20060193745	Virucidal disinfectant	ARNDT ANDREAS	28-Jan-05	27-Jan-06	31-Aug-06
US20060190189	Reagents, devices and methods for proteomic analysis with applications including diagnostics, vaccines, quality control and research	HOFFMANN GEOFFREY W	21-Apr-04	16-Mar-06	24-Aug-06
US20060189644	Lipid-modified immune response modifiers	WIGHTMAN PAUL D	14-Aug-03	12-Aug-04	24-Aug-06
US20060189571	Use of lipid conjugates in the treatment of infection	YEDGAR SAUL	10-Jan-00	8-Sep-05	24-Aug-06
US20060189570	Use of lipid conjugates in the treatment of infection	YEDGAR SAUL	10-Jan-00	8-Sep-05	24-Aug-06
US20060189569	Use of lipid conjugates in the treatment of infection	OJCIUS DAVID	10-Jan-00	8-Sep-05	24-Aug-06
US20060189568	Use of lipid conjugates in the treatment of infection	YEDGAR SAUL	10-Jan-00	8-Sep-05	24-Aug-06
US20060189542	Preventive or therapeutic composition for viral infectious disease	FURUKAWA SATORU	22-Jul-03	22-Jul-04	24-Aug-06
US20060188519	Peptides, antibodies, and methods for the diagnosis of SARS	AU MUN Y D	14-Jun-04	13-Jun-05	24-Aug-06
US20060178341	Composition comprising soluble glucan oligomer from saccharomyces cerevisiae is2 inhibiting the swine influenza (SIV) and transmissible gastroenteritis coronavirus (tgev)	CHUNG BONG H	23-Jun-03	23-Jun-04	10-Aug-06
US20060177849	Nucleic acid primer set, nucleic acid probe set and method for detecting respiratory disease virus using the primer set and probe set	HUH NAM	23-Dec-04	23-Dec-05	10-Aug-06
US20060177837	Systems and methods for identifying diagnostic indicators	BOROZAN IVAN	13-Aug-04	15-Aug-05	10-Aug-06
US20060177813	Novel high-throughput screening method of drug for bioactive protein	ENDO YAETA	8-Sep-03	8-Sep-04	10-Aug-06
US20060171962	SARS vaccine	Consejo Superior de Investigaciones Cientificas	3-Sep-04	2-Sep-05	3-Aug-06
US20060171958	Antiviral activity from medicinal mushrooms	STAMETS PAUL	6-Jan-04	22-Mar-06	3-Aug-06
US20060165723	Nucleic acid sequences encoding proteins capable of associating into a virus-like particle	Fort Dodge Veterinaria S.A.	3-Sep-04	2-Sep-05	27-Jul-06
US20060165716	Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae	BAROCCHI MICHELLE	29-Jul-04	29-Jul-05	27-Jul-06
US20060163149	Product for absorption purposes	HJERTEN MARIE-CHRISTINE	13-Jun-03	11-Jun-04	27-Jul-06
US20060160109	Harnessing network biology to improve drug discovery	Odyssey Thera, Inc.	22-Nov-04	21-Nov-05	20-Jul-06
US20060154243	Antigenic peptides of SARS coronavirus and uses thereof	GOUDSMIT JAAP	21-Jul-03	20-Jan-06	13-Jul-06
US20060153803	Inhibition of sars coronavirus infection with clinically approved antiviral drugs	STANTON LAWRENCE W	9-Jun-03	9-Jun-04	13-Jul-06
US20060147958	System for detecting polynucleotides	CHOI K Y	20-May-03	21-Nov-05	6-Jul-06
US20060143719	Use of golden hamster as infectivity model of SARS	CONTAMIN HUGUES	18-Aug-04	16-Aug-05	29-Jun-06
US20060142383	3D-Structure model of SARS coronavirus 3CL protease and anti-SARS drugs	SHANGHAI LEAD DISCOVERY PHARMA	4-Jun-03	2-Dec-05	29-Jun-06
US20060142202	Compositions and methods for targeted delivery of immune response modifiers	3M INNOVATIVE PROPERTIES CO	8-Dec-00	23-Feb-06	29-Jun-06
US20060140971	Cell surface expression vector of sars virus antigen and microorganisms transformed thereby	CHOI JAE C	4-Jun-03	4-Jun-04	29-Jun-06
US20060135458	Antiviral oligonucleotides	JUTEAU JEAN-MARC	13-Sep-02	19-Oct-05	22-Jun-06

CC-BY-NC-SA Dr. David E. Martin

US20060135422	Use of angiotensin receptor blockers (ARBs) to treat diseases associated with excess ACE	MOSKOWITZ DAVID W	17-Apr-03	31-Mar-04	22-Jun-06
US20060134753	Super-antigen fusion proteins and the use thereof	Healthbanks Biotech Co., Ltd.	21-Jul-04	19-Jul-05	22-Jun-06
US20060134609	Compositions and methods for determining the presence of SARS coronavirus in a sample	GETMAN DAMON K	17-Apr-03	16-Apr-04	22-Jun-06
US20060134397	Microporous materials, methods, and articles for localizing and quantifying analytes	SMITH ROGER E	26-Nov-02	20-Nov-03	22-Jun-06
US20060128628	Human tissue antigen-binding peptides and their amino acid sequences	CHEN SHOW-LI	15-Dec-04	15-Dec-04	15-Jun-06
US20060123499	Civet animal model system for Severe Acute Respiratory Syndrome (SARS) coronavirus infection and uses thereof	CHEN JINDING	6-Dec-04	6-Dec-04	8-Jun-06
US20060122368	Antigen delivery platform	GOVERNMENT OF THE U S A AS REP	3-Dec-04	2-Dec-05	8-Jun-06
US20060121580	Binding molecules against SARS-coronavirus and uses thereof	CRUCELL	22-Jul-03	20-Jan-06	8-Jun-06
US20060121043	Use of modulators of EphA2 and EphrinA1 for the treatment and prevention of infections	MEDIMMUNE, INC.	27-Oct-04	27-Oct-05	8-Jun-06
US20060115875	Detection, characterization and treatment of viral infection and methods thereof	BROWN EARL	30-Sep-03	11-Oct-05	1-Jun-06
US20060113298	Electromagnetic wave applicator	ZAIDAN HOJIN HANDOTAI KENKYU SHINKOKAI	27-Nov-02	27-Nov-03	1-Jun-06
US20060111387	ARYL SUBSTITUTED IMIDAZOQUINOLINES	3M INNOVATIVE PROPERTIES CO	20-Dec-02	13-Jan-06	25-May-06
US20060110803	Antigenic peptides of SARS coronavirus and uses thereof	Crucell Holland B.V.	13-Jun-03	6-Dec-05	25-May-06
US20060110758	Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof	UNIV HONG KONG	22-Nov-04	28-Oct-05	25-May-06
US20060110405	Plasma or serum fraction for treatment and prevention of viral infections and related conditions	BUCKHEIT ROBERT W JR	20-Aug-04	22-Aug-05	25-May-06
US20060100232	Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereof	AGARWAL ATUL	11-Nov-04	10-Nov-05	11-May-06
US20060100229	Pyrazolopyridines and analogs thereof	BONK JASON D	3-Oct-03	1-Apr-05	11-May-06
US20060099606	Assay to detect viral uncoating	NARAYAN SHAKTI	9-Dec-03	8-Dec-04	11-May-06
US20060099573	Diagnostic assays	MIGUEZ MARIA-JOSE	24-Mar-04	24-Mar-05	11-May-06
US20060094105	Mixed cell diagnostic systems for detection of respiratory, herpes and enteric viruses	Diagnostic Hybrids, Inc.	24-Apr-98	20-Sep-05	4-May-06
US20060094104	Animal protein-free media for cultivation of cells	DORNER FRIEDRICH	29-Oct-04	29-Oct-04	4-May-06
US20060093616	Process for vaccinating eucaryotic hosts and for protecting against SARS-CoV infection	ALTMEYER RALF	29-Sep-04	28-Sep-05	4-May-06
US20060089324	RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof	BARIK SAILEN	22-Oct-04	14-Jun-05	27-Apr-06
US20060089323	RNAi modulation of RSV, PIV and other respiratory viruses and uses thereof	BARIK SAILEN	22-Oct-04	14-Jun-05	27-Apr-06
US20060088926	Method of removing hazardous substance, and hazardous substance removing material using the same such as air cleaning filter, mask and wipping sheet, and method of storing the same	DAIKIN IND LTD	28-Mar-03	26-Mar-04	27-Apr-06
US20060088909	Virus-like particles, methods of preparation, and immunogenic compositions	COMPANS RICHARD W	17-May-02	19-May-03	27-Apr-06
US20060079485	Use of lipid conjugates in the treatment of infection	OJCIUS DAVID	10-Jan-00	8-Sep-05	13-Apr-06
US20060075894	Bioagent air filtration systems	University of Wyoming Research Corporation d/b/a Western Research Institute	28-Jan-03	28-Jan-04	13-Apr-06
US20060070952	Charge-based water filtration systems	University of Wyoming Research Corporation d/b/a	28-Jan-03	28-Jan-04	6-Apr-06

CC-BY-NC-SA Dr. David E. Martin

US20060067940	Antibodies against West Nile Virus and therapeutic and prophylactic uses thereof	DIAMOND MICHAEL	21-Jun-04	21-Jun-05	30-Mar-06
US20060063150	Antisense antiviral compound and method for treating ssRNA viral infection	IVERSEN PATRICK L	16-Sep-04	14-Sep-05	23-Mar-06
US20060063149	Compositions and methods for detecting pathogen infection	BERTHET FRANCOIS X	23-Dec-03	6-Sep-05	23-Mar-06
US20060062804	SARS-CoV-specific B-cell epitope and applications thereof	National Taiwan University	21-Sep-04	21-Sep-04	23-Mar-06
US20060057605	Compositions for use in identification of viral hemorrhagic fever viruses	ISIS Pharmaceuticals, Inc.	22-Mar-04	21-Mar-05	16-Mar-06
US20060057161	Detection of coronavirus infection	CHOU CHIH-MING	16-Sep-04	16-Sep-04	16-Mar-06
US20060053516	Genetically modified plants comprising SARS-CoV viral nucleotide sequences and methods of use thereof for immunization against SARS	The University of Hong Kong	5-Dec-03	3-Dec-04	9-Mar-06
US20060051744	Feline infectious peritonitis (FIP) and systemic multi-organ coronavirus biomarkers and screening methods	AUSTIN KIMBERLY M	30-Jun-04	28-Jun-05	9-Mar-06
US20060051374	Compositions and methods for mucosal vaccination	3M Innovative Properties Company	28-Apr-04	28-Apr-05	9-Mar-06
US20060035926	Benzothiazolium compounds	LEE SHIOW-JU	13-Aug-04	15-Aug-05	16-Feb-06
US20060035859	Treating severe and acute viral infections	HEMISPHERx BIOPHARMA	16-May-03	6-Oct-05	16-Feb-06
US20060035853	Methods for tailoring the immune response to an antigen or immunogen	Biomedical Research Models, Inc.	7-Jan-04	7-Jan-05	16-Feb-06
US20060035327	Recombinant super-compound interferon and uses thereof	WEI GUANGWEN	26-Aug-04	10-Mar-05	16-Feb-06
US20060034853	Novel human virus causing respiratory tract infection and uses thereof	CHAN KWOK H	21-Jul-04	16-May-05	16-Feb-06
US20060024668	Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics	HOEK CORNELIA V D	7-Jan-04	18-Aug-04	2-Feb-06
US20060024271	Treatments for viral infections using IFN cytokines and ribavirin, alone or in combination	ALIBEK KEN	15-Jan-04	13-Jan-05	2-Feb-06
US20060019976	Methods for treating Hepatitis C	CHEN GUANGMING	22-Jul-04	14-Jul-05	26-Jan-06
US20060019967	SARS CoV main protease inhibitors	HSIEH HSING-PANG	21-Jul-04	20-Jul-05	26-Jan-06
US20060019927	Anti-viral uses of borinic acid complexes	BELLINGER-KAWAHARA CAROLYN	14-Jun-04	14-Jun-05	26-Jan-06
US20060019923	Methods and compositions for inducing innate immune responses	Coley Pharmaceutical Group, Ltd.	18-Jul-04	18-Jul-05	26-Jan-06
US20060018923	Novel human virus causing respiratory tract infection and uses thereof	CHAN KWOK H	21-Jul-04	21-Jul-04	26-Jan-06
US20060018877	Intradermal delivery of vacccines and therapeutic agents	ALARCON JASON B	29-Jun-01	29-Apr-05	26-Jan-06
US20060014254	Albumin fusion proteins	Human Genome Sciences, Inc.	22-Jan-03	7-Jul-05	19-Jan-06
US20060009459	Pyridazine derivatives and their use as therapeutic agents	ABREO MELWYN	16-Mar-04	9-Feb-05	12-Jan-06
US20060008810	Methods and compositions for detecting rhinoviruses	Focus Technologies, Inc.	6-Jul-04	6-Jul-04	12-Jan-06
US20060008379	Room decontamination with hydrogen peroxide vapor	STERIS INC.	8-Jul-04	8-Jul-04	12-Jan-06
US20060006678	Door handle cover	HERRON ROY H JR	27-May-04	26-May-05	12-Jan-06
US20060003941	Peptides and peptidomimetics having immune-modulating, anti-inflammatory, and anti-viral activity	KAWABE TAKUMI	25-Jun-03	25-Jun-04	5-Jan-06
US20060003352	Mass tag PCR for mutliplex diagnostics	BRIESE THOMAS	29-Apr-04	28-Apr-05	5-Jan-06
US20060003351	Methods and kits for identifying target nucleotides in mixed populations	Applera Corporation	30-Apr-04	29-Apr-05	5-Jan-06

CC-BY-NC-SA Dr. David E. Martin

US20060003340	Multi-allelic molecular detection of SARS-associated coronavirus	Birch Biomedical Research, LLC	22-Aug-03	13-Aug-04	5-Jan-06
US20060002947	Ii-key/antigenic epitope hybrid peptide vaccines	HUMPHREYS ROBERT	14-Sep-99	11-Jan-05	5-Jan-06
US20060002932	Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity	Duke University	4-Jun-04	3-Jun-05	5-Jan-06
US20050288866	Computational method for identifying adhesin and adhesin-like proteins of therapeutic potential	COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH	20-Jul-04	7-Feb-05	29-Dec-05
US20050287167	Polycistronic HIV vector constructs		5-May-04	5-May-05	29-Dec-05
US20050287118	Bacterial plasmid with immunological adjuvant function and uses thereof		26-Nov-03	23-Nov-04	29-Dec-05
US20050282279	Expression vector encoding coronavirus-like particle	HWU PAUL L	29-May-03	28-May-04	22-Dec-05
US20050282209	Variable length probe selection	ALBERT THOMAS	18-Jun-04	20-Jun-05	22-Dec-05
US20050282154	Angiotensin-converting enzyme-2 as a receptor for the SARS coronavirus		6-Oct-03	5-Oct-04	22-Dec-05
US20050281828	Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells	BOWDISH KATHERINE S	28-Feb-04	1-Apr-05	22-Dec-05
US20050277592	Beta-peptides	Yale University	21-Apr-04	21-Apr-05	15-Dec-05
US20050277181	Compositions and methods for detecting pathogen infection	BERTHET FRANCOIS X	23-Dec-04	27-Apr-05	15-Dec-05
US20050276818	Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP-dependent kinase and a target for SARS therapy	GODZIK ADAM	17-May-04	17-May-05	15-Dec-05
US20050276815	Antiviral activity from medicinal mushrooms	STAMETS PAUL	6-Jan-04	6-Jan-05	15-Dec-05
US20050271711	Therapeutic antimicrobial compositions and methods	The Procter & Gamble Company	26-Apr-04	25-Apr-05	8-Dec-05
US20050266550	TC-83-derived alphavirus vectors, particles and methods	Alphavax, Inc.	18-May-04	18-May-05	1-Dec-05
US20050266465	Interferon-alpha polypeptides and conjugates		19-May-04	18-May-05	1-Dec-05
US20050266425	Methods for producing and identifying multispecific antibodies	Vaccinex, Inc.	31-Dec-03	29-Dec-04	1-Dec-05
US20050266397	Methods for identification of coronaviruses	BLYN LAWRENCE B	26-Apr-03	22-Apr-04	1-Dec-05
US20050260645	Comparative genomic resequencing	ALBERT THOMAS	8-Apr-04	8-Apr-05	24-Nov-05
US20050255123	Chimeric ebola virus envelopes and uses therefor	The Trustees of the University of Pennsylvania	30-Apr-02	28-Apr-03	17-Nov-05
US20050250677	Glycopeptide antibiotic derivatives	BALZARINI JAN	1-Sep-03	1-Sep-03	10-Nov-05
US20050249742	Compositions and methods for modulating a cytotoxic T lymphocyte immune response	Dana-Farber Cancer Institute, Inc.	27-Jun-02	22-Dec-04	10-Nov-05
US20050249739	Antibodies against SARS-CoV and methods of use thereof	MARASCO WAYNE	25-Nov-03	24-Nov-04	10-Nov-05
US20050244423	Methods for treating viral infection using IL-28 and IL-29 cysteine mutants	HENDERSON KATHERINE E	2-Apr-04	4-Apr-05	3-Nov-05
US20050240353	Reagents, devices and methods for proteomic analysis with applications including diagnostics, vaccines, quality control and research		21-Apr-04	4-Feb-05	27-Oct-05
US20050239735	Enhancement of immune responses		30-Dec-03	30-Dec-04	27-Oct-05
US20050239086	Multiplex systems, methods, and kits for detecting and identifying nucleic acids	BRIESE THOMAS	27-Apr-04	27-Apr-04	27-Oct-05
US20050239047	Methods and devices for determining a cell characteristic, and applications employing the same	GIMZEWSKI JAMES K	10-Sep-02	9-Mar-05	27-Oct-05
US20050238655	Antiviral activity from medicinal mushrooms	STAMETS PAUL	6-Jan-04	4-Jan-05	27-Oct-05

CC-BY-NC-SA Dr. David E. Martin

US20050234122	Prevention of and countermeasures against viral infection	CHOKO CO., LTD.	11-Mar-04	11-Mar-04	20-Oct-05
US20050233314	Sensitive and quantitative detection of pathogens by real-time nested PCR		30-Jun-03	30-Jun-04	20-Oct-05
US20050232895	Anti-viral pharmaceutical compositions	SD Pharmaceuticals, Inc.	10-Dec-03	3-Dec-04	20-Oct-05
US20050223427	Modified polynucleotides for reducing off-target effects in RNA interference	Dharmacon, Inc.	1-Apr-04	22-Dec-04	6-Oct-05
US20050222258	Pharmaceuticals comprising shikonins as active constituent	WANG FEIXIN	21-Feb-03	14-May-05	6-Oct-05
US20050220816	Mutant viral nucleic acids and vaccine containing same		31-Mar-04	31-Mar-04	6-Oct-05
US20050215494	Baicalin and its derivatives as a treatment for SARS coronavirus infection or other related infections	CHAN KWOK H	10-Nov-03	8-Nov-04	29-Sep-05
US20050214890	Novel "Cleave-N-Read" system for protease activity assay and methods of use thereof	BAUDRY MICHEL	26-Nov-03	23-Nov-04	29-Sep-05
US20050214748	Peptide-based diagnostic reagents for SARS	CHANG TSENG Y	12-Nov-03	8-Nov-04	29-Sep-05
US20050214747	Compositions and methods for analysis of target analytes	DANIELZADEH ROBERT	16-Jan-04	17-Oct-04	29-Sep-05
US20050208066	Recombinant baculovirus and virus-like particle	CHAO YU-CHAN	25-Nov-03	24-Nov-04	22-Sep-05
US20050208060	Vaccine composition	Aventis Pasteur S.A.	22-Sep-04	15-Nov-04	22-Sep-05
US20050208020	Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines	BRICE GARY T	12-Nov-03	10-Nov-04	22-Sep-05
US20050208019	Uses of interferons with altered spatial structure	WEI GUANGWEN	28-Aug-03	26-Aug-04	22-Sep-05
US20050203038	Modulation of ACE2 expression		10-Mar-04	10-Mar-04	15-Sep-05
US20050203024	Peptides and methods for inducing cellular resistance to infection		1-Dec-03	1-Dec-04	15-Sep-05
US20050202415	Replikin peptides and uses thereof	BOGOCH ELENORE S.	23-Dec-03	4-Jun-04	15-Sep-05
US20050196382	Antiviral oligonucleotides targeting viral families		5-Dec-02	19-Oct-04	8-Sep-05
US20050196381	Lentivirus vector-based approaches for generating an immune response to HIV in humans	DROPULIC BORO	9-Sep-03	9-Sep-04	8-Sep-05
US20050191620	Particle on membrane assay system	BALLARD KARRI L.	27-Feb-04	22-Dec-04	1-Sep-05
US20050189302	Viral inactivation using ozone	KEYSER STEVEN A.	17-Mar-04	11-Oct-04	1-Sep-05
US20050187192	Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses		20-Feb-04	20-Feb-04	25-Aug-05
US20050186575	Corona-virus-like particles comprising functionally deleted genomes	BOSCH BEREND J.	17-May-02	30-Dec-03	25-Aug-05
US20050182243	Membrane scaffold proteins	BAYBURT TIMOTHY H.	18-Jun-03	11-Jan-05	18-Aug-05
US20050181357	High-throughput diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)	CHAN KWOK H.	24-Mar-03	24-Mar-04	18-Aug-05
US20050181075	Pharmacological enhancement and manufacturing method of antiviral compound	GONG JIAO	21-Nov-03	21-Nov-03	18-Aug-05
US20050176661	Antiviral oligonucleotides		5-Dec-02	12-Sep-03	11-Aug-05
US20050171044	Oligonucleotide compound and method for treating nidovirus infections	BESTWICK RICHARD K.	24-Dec-03	22-Dec-04	4-Aug-05
US20050169885	Recombinant super-compound interferon	WEI GUANGWEN	28-Aug-03	26-Aug-04	4-Aug-05
US20050164167	Method of discovery and development of broad-spectrum antiviral drugs	BUSCHER BENJAMIN A.	28-Jan-04	28-Jan-04	28-Jul-05

CC-BY-NC-SA Dr. David E. Martin

US20050163648	METHOD AND APPARATUS FOR STERILIZING AIR IN LARGE VOLUMES BY RADIATION OF ULTRAVIOLET RAYS	LIANG MICHAEL Y.	26-Jan-04	26-Jan-04	28-Jul-05
US20050158411	Methods and apparatus to prevent, treat, and cure the symptoms of nauea caused by chemotherapy treatments of human cancers	VAIL MARILYN L.	8-Dec-03	27-Nov-04	21-Jul-05
US20050158325	Immunomodulatory combinations		30-Dec-03	30-Dec-04	21-Jul-05
US20050153912	Antiviral oligonucleotides targeting viral families		5-Dec-02	12-Sep-03	14-Jul-05
US20050153310	Luciferase biosensor	BUTLER BRAEDEN	10-Oct-03	1-Oct-04	14-Jul-05
US20050148658	Method for preventing and treating severe acute respiratory syndrome	HENSLEY CHARLES	5-Jan-04	5-Jan-04	7-Jul-05
US20050147697	Compositions and methods for reducing the transmissivity of illnesses	ROSENBLOOM RICHARD A.	6-Feb-03	14-Dec-04	7-Jul-05
US20050142536	Method and kit for the detection of a novel coronoavirus associated with the severe acute respiratory syndrome (SARS)	LAUE THOMAS	30-Apr-03	30-Apr-04	30-Jun-05
US20050142157	Oxidative reductive potential water solution and methods of using the same	Oculus Innovative Sciences, Inc.	30-Dec-03	11-Aug-04	30-Jun-05
US20050139808	Oxidative reductive potential water solution and process for producing same	Oculus Innovative Sciences, Inc.	30-Dec-03	4-Jun-04	30-Jun-05
US20050123563	Lipoparticles comprising proteins, methods of making, and using the same	DORANZ BENJAMIN J.	30-Jul-03	28-Jul-04	9-Jun-05
US20050119284	ANTIVIRAL AGENTS AND METHODS OF USE	Wisconsin Alumni Research Foundation -	30-Sep-03	30-Sep-04	2-Jun-05
US20050119251	Nicotinamide derivatives and their use as therapeutic agents	FINE RICHARD M.	21-Dec-01	6-Jul-04	2-Jun-05
US20050117187	Apparatus for forming nano-grating device	CHEN YUNG-HSIN	17-Mar-04	17-Mar-04	2-Jun-05
US20050114910	Transgenic mice having a human major histocompatibility complex (MHC) phenotype, experimental uses and applications	AURIAULT CLAUDE	30-Jul-03	2-Jul-04	26-May-05
US20050113298	Receptor binding peptides derived from the SARS S protein		15-Sep-03	13-Sep-04	26-May-05
US20050112559	Compositions and methods for diagnosing and preventing severe acute respiratory syndrome (SARS)		29-Sep-03	29-Sep-04	26-May-05
US20050112558	Prognostic PCR assay for severe acute respiratory syndrome (SARS)	The Chinese University of Hong Kong	24-Sep-03	23-Sep-04	26-May-05
US20050112555	Cytidine deaminase activators, deoxycytidine deaminase activators, Vif antagonists, and methods of screening for molecules thereof	DEWHURST STEPHEN	3-Sep-03	3-Sep-04	26-May-05
US20050112554	Characterization of the earliest stages of the severe acute respiratory syndrome (SARS) virus and uses thereof	HENG XU RUI	9-Jul-04	9-Jul-04	26-May-05
US20050107324	Modulation of CEACAM1 expression	BENNETT C. F.	12-Jul-03	12-Jul-04	19-May-05
US20050106563	Epitope profiles of SARS coronavirus		8-Sep-03	8-Sep-04	19-May-05
US20050101581	Therapeutic treatment methods 2	AHLEM CLARENCE N.	28-Aug-02	5-Dec-03	12-May-05
US20050100885	Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)	BAKER BRENDA F.	28-Apr-03	26-Apr-04	12-May-05
US20050100883	Peptide-based diagnostic reagents for SARS	CHANG TSENG Y.	12-Nov-03	12-Nov-03	12-May-05
US20050100612	Virucidal activities of cetylpyridinium chloride	ViraTox, L.L.C.	7-Nov-03	10-Sep-04	12-May-05
US20050096259	Neutrophil activation by immune response modifier compounds		31-Oct-03	1-Nov-04	5-May-05
US20050095618	Compositions and methods for diagnosing and treating severe acute respiratory syndrome (SARS)	The Chinese University of Hong Kong	29-Jul-03	28-Jul-04	5-May-05
US20050095582	Compositions and methods for detecting severe acute respiratory syndrome coronavirus	Diagnostic Hybrids, Inc.	3-Nov-03	3-Nov-03	5-May-05

CC-BY-NC-SA Dr. David E. Martin

US20050090505	Methods of reducing risk of infection from pathogens	HOPKINS SAMUEL E.	20-Aug-03	18-Aug-04	28-Apr-05
US20050085529	Prenylation inhibitors reduce host cell permissiveness to viral replication		21-Oct-03	21-Oct-03	21-Apr-05
US20050080093	Methods of reducing risk of infection from pathogens	HOPKINS SAMUEL E.	18-Aug-04	18-Aug-04	14-Apr-05
US20050075307	Modulation of aminopeptidase N expression	BENNETT C. FRANK	12-Jul-03	12-Jul-04	7-Apr-05
US20050074743	Method and composition for treating a biological sample	CHAPMAN JOHN	6-Oct-03	6-Oct-03	7-Apr-05
US20050074359	Aircraft and passenger decontamination system	STERIS INC.	6-Oct-03	6-Oct-03	7-Apr-05
US20050071892	Techniques and applications of establishment of SARS-CoV primate model	GAO HONG	27-Jun-03	25-Jun-04	31-Mar-05
US20050070460	Infection prophylaxis using immune response modifier compounds	3M Innovative Properties Company	5-Aug-03	5-Aug-04	31-Mar-05
US20050069911	Proteome epitope tags and methods of use thereof in protein modification analysis	engeneOS, Inc.	10-May-02	5-Feb-04	31-Mar-05
US20050069869	SARS nucleic acids, proteins, antibodies, and uses thereof	AMBROSINO DONNA	4-Aug-03	4-Aug-04	31-Mar-05
US20050069558	Crystals and structures of SARS-CoV main protease	BONANNO JEFFREY B.	25-Jul-03	23-Jul-04	31-Mar-05
US20050069555	Thiosemicarbazones as anti-virals and immunopotentiators	BARSANTI PAUL A.	27-Dec-02	29-Dec-03	31-Mar-05
US20050065143	Pyridazine derivatives and their use as therapeutic agents	Xenon Pharmaceuticals Inc.	29-Jul-04	29-Jul-04	24-Mar-05
US20050059578	Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agents	HE JIN	15-Aug-03	15-Aug-03	17-Mar-05
US20050059576	Targeted delivery of antiviral compounds through hemoglobin bioconjugates	ADAMSON J. GORDON	30-Apr-98	17-May-04	17-Mar-05
US20050059072	Selective modulation of TLR gene expression	3M Innovative Properties Company	17-Sep-04	17-Sep-04	17-Mar-05
US20050058982	Modified small interfering RNA molecules and methods of use	Chiron Corporation	25-Jul-03	25-Jul-03	17-Mar-05
US20050054644	Hydrolytically-resistant boron-containing therapeutics and methods of use	AKAMA TSUTOMU	15-Jun-04	15-Jun-04	10-Mar-05
US20050054640	1-Amino 1H-imidazoquinolines	GRIESGRABER GEORGE W.	3-Sep-04	3-Sep-04	10-Mar-05
US20050053990	Cleavage of RNA by restriction endonucleases	ROBERTS RICHARD J.	31-Aug-04	31-Aug-04	10-Mar-05
US20050051497	Viral inactivation using ozone	KEYSER STEVEN A.	2-Aug-04	2-Aug-04	10-Mar-05
US20050048473	Enzymatic diagnostic test for SARS and other viral diseases	ARAD DORIT	23-Jun-04	23-Jun-04	3-Mar-05
US20050048465	Method of collecting nasopharyngeal cells and secretions for diagnosis of viral upper respiratory infections and screening for nasopharyngeal cancer	World Sense Technology Limited	20-Aug-04	20-Aug-04	3-Mar-05
US20050048072	Immunostimulatory combinations and treatments	3M Innovative Properties Company	25-Aug-04	25-Aug-04	3-Mar-05
US20050039220	Imageable animal model of SARS infection	XU MINGXU	27-May-04	27-May-04	17-Feb-05
US20050037338	Method and means for detection of severe acute respiratory syndrome	TSENG KUO-TANG	14-Aug-03	14-Aug-03	17-Feb-05
US20050036951	Methods of treating lung diseases	Arizeke Pharmaceuticals, Inc.	9-Jan-04	9-Jan-04	17-Feb-05
US20050032222	Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases	BELLOTTI MARC	29-Jun-00	21-Jun-04	10-Feb-05
US20050031620	Combined cancer treatment methods using selected antibodies to aminophospholipids	HUANG XIANMING	15-Aug-03	15-Aug-03	10-Feb-05
US20050031592	Methods and compositions for inducing immune responses and protective immunity by priming with alpha virus replicon vaccines	BRICE GARY L.	13-Nov-03	13-Nov-03	10-Feb-05

US20050025788	Systemic delivery of non-viral vector expressing SARS viral genomic vaccine	CHOU GEORGE CHIN-SHENG	4-Jun-04	4-Jun-04	3-Feb-05
US20050025761	Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents	Board of Regents, The University of Texas System	15-Aug-03	15-Aug-03	3-Feb-05
US20050020524	Hematopoietic stem cell gene therapy	Monash University	15-Apr-99	30-Dec-03	27-Jan-05
US20050019756	Methods and compositions for use in diagnosing and characterizing diseases involving abnormal apoptosis	DE MEIRLEIR KENNY	26-May-04	26-May-04	27-Jan-05
US20050015847	Compositions and methods for preventing infection	HILDRETH JAMES E.	8-Aug-03	8-Aug-03	27-Jan-05
US20050014830	Substances for breaking down conformation of microbes	CHU SHU FANG	17-Jul-03	4-Jun-04	20-Jan-05
US20050014752	Prodrugs of heteroaryl compounds	Koronis Pharmaceuticals, Incorporated	31-Mar-04	31-Mar-04	20-Jan-05
US20050009110	Methods of producing antibodies for diagnostics and therapeutics	CHANG XIAO-JIA	8-Jul-03	8-Jul-03	13-Jan-05
US20050009009	Diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)	CHAN KWOK HUNG	24-Mar-04	24-Mar-04	13-Jan-05
US20050008535	Noble gas-chlorine mixture effective against micro organisms	GLOBUS ALFRED R.	7-Jul-03	7-Jul-03	13-Jan-05
US20050004144	Combined use of IMPDH inhibitors with toll-like receptor agonists	REGENTS OF THE UNIVERSITY OF CALIFORNIA	14-Apr-04	14-Apr-04	6-Jan-05
US20050004071	Charged polysaccharides resistant to lysosomal degradation during kidney filtration and renal passage and their use to treat or prevent infection by coronaviruses	COMPER WAYNE D.	20-Apr-04	20-Apr-04	6-Jan-05
US20050004063	Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interference	GUAN YI	19-May-04	19-May-04	6-Jan-05
US20050003340	Assay system and methods for detecting SARS-CV	AsiaGEN Corporation	1-Jul-03	1-Jul-03	6-Jan-05
US20050002953	SARS-coronavirus virus-like particles and methods of use	HEROLD JENS	4-May-04	4-May-04	6-Jan-05
US20050002941	Combinations and kits for cancer treatment using selected antibodies to aminophospholipids	Board of Regents, The University of Texas System	15-Aug-03	15-Aug-03	6-Jan-05
US20050002913	Hematopoietic stem cell gene therapy	Monash University	15-Apr-99	18-Apr-03	6-Jan-05
US20050002901	Compositions and methods for treating coronavirus infection and SARS	BLATT LAWRENCE M.	30-Mar-04	30-Mar-04	6-Jan-05
US20040265879	Compositions for enhancing transport of molecules into cells	IVERSEN PATRICK L.	29-Apr-04	29-Apr-04	30-Dec-04
US20040265796	Methods and kits for detecting SARS-associated coronavirus	BRIESE THOMAS	23-Jan-04	23-Jan-04	30-Dec-04
US20040265367	Liposomes coated with selected antibodies that bind to aminophospholipids	HUANG XIANMING	15-Aug-03	15-Aug-03	30-Dec-04
US20040265351	Methods and compositions for enhancing immune response	KEDL ROSS M.	9-Apr-04	9-Apr-04	30-Dec-04
US20040259934	Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds	CARROLL STEVEN S.	27-Apr-04	27-Apr-04	23-Dec-04
US20040259803	Disease prevention by reactivation of the thymus	Monash University	15-Apr-99	30-Dec-03	23-Dec-04
US20040258698	Delivery of immune response modifier compounds	JING NAIYONG	9-Apr-04	9-Apr-04	23-Dec-04
US20040253624	Microporous materials, methods of making, using, and articles thereof	DURTSCHI JACOB	26-May-04	26-May-04	16-Dec-04
US20040253328	Anti-atypical pneumonia decoction	HU XIN YUAN	13-Jun-03	21-Jul-03	16-Dec-04
US20040241842	Stimulation of thymus for vaccination development	Monash University	15-Apr-99	30-Dec-03	2-Dec-04
US20040237198	Protecting shield for performing the insertion of a tube during emergency rescuing or anesthesia	YANG JUI KUANG	2-Jun-03	2-Jun-03	2-Dec-04
US20040235952	Inhibitors of severe acute respiratory syndrome (SARS) 3C-like proteinase	Agouron Pharmaceuticals, Inc.	27-Apr-04	27-Apr-04	25-Nov-04

CC-BY-NC-SA Dr. David E. Martin

US20040235946	Organosulphur prodrugs for the prevention and treatment of injectious diseases and pathologenic immune system response	OTT DAVID M.	24-May-04	24-May-04	25-Nov-04
US20040235047	Compositions and methods for treatment of Severe Acute Respiratory Syndrome (SARS)	SIBER GEORGE R.	20-May-03	20-May-03	25-Nov-04
US20040234457	Methods of preventing and treating SARS using low pH respiratory tract compositions	The Procter & Gamble Company	2-Feb-04	2-Feb-04	25-Nov-04
US20040229828	Antiviral oligonucleotides targeting RSV	Replicor, Inc.	12-Sep-03	12-Sep-03	18-Nov-04
US20040229778	Pharmaceutical compositions of antithrombin III for the treatment of retroviral diseases	ELMALEH DAVID R.	13-May-03	13-May-03	18-Nov-04
US20040229219	Method of inhibiting human metapneumovirus and human coronavirus in the prevention and treatment of severe acute respiratory syndrome (SARS)	GALLAHER WILLIAM R.	29-Apr-04	29-Apr-04	18-Nov-04
US20040229211	Sensitive diagnostic testing methodology using multiplex real time PCR with one dye (MOD) and its use as in severe acute respiratory syndrome (SARS)	YEUNG WAH HIN ALEX	22-Aug-03	22-Aug-03	18-Nov-04
US20040220139	Inhibiting viral infections	SCEUSA NICHOLAS A.	5-Nov-03	5-Nov-03	4-Nov-04
US20040219155	Selected immunoconjugates for binding to aminophospholipids	RAN SOPHIA	15-Aug-03	15-Aug-03	4-Nov-04
US20040214785	Surface sanitizing compositions with improved antimicrobial performance	Xantech Pharmaceuticals, Inc.	9-Mar-04	9-Mar-04	28-Oct-04
US20040214764	Anti-viral treatment methods using phosphatidylethanolamine-binding peptide derivatives	HE JIN	15-Aug-03	15-Aug-03	28-Oct-04
US20040213779	Methods for treating viral infections using immunoconjugates to aminophospholipids	RAN SOPHIA	15-Aug-03	15-Aug-03	28-Oct-04
US20040209844	Compositions and methods for preventing infection	HILDRETH JAMES E.	22-Sep-03	22-Sep-03	21-Oct-04
US20040208873	Human monoclonal antibodies against interleukin 8 (IL-8)	GENMAB A/S	16-Dec-03	16-Dec-03	21-Oct-04
US20040208868	Selected antibody CDRs for binding to aminophospholipids	Board of Regents, The University of Texas System	15-Aug-03	15-Aug-03	21-Oct-04
US20040204420	Compounds for modulating RNA interference	RANA TARIQ M.	5-Aug-03	5-Aug-03	14-Oct-04
US20040202720	Delivery of immune response modifier compounds using metal-containing particulate support materials	3M Innovative Properties Company	9-Apr-04	9-Apr-04	14-Oct-04
US20040191833	Selective activation of cellular activities mediated through a common toll-like receptor	3M Innovative Properties Company	24-Mar-04	24-Mar-04	30-Sep-04
US20040184950	Building decontamination with vaporous hydrogen peroxide	STERIS INC.	29-Jan-04	29-Jan-04	23-Sep-04
US20040180380	Proteome epitope tags and methods of use thereof in protein modification analysis	engeneOS, Inc.	13-Nov-03	13-Nov-03	16-Sep-04
US20040176367	1-Amino 1H-imidazoquinolines	3M Innovative Properties Company	5-Mar-04	5-Mar-04	9-Sep-04
US20040175378	Selected antibody compositions and methods for binding to aminophospholipids	Board of Regents, The University of Texas System	15-Jul-03	15-Jul-03	9-Sep-04
US20040171568	Antiviral oligonucleotides targeting HIV	Replicor, Inc.	12-Sep-03	12-Sep-03	2-Sep-04
US20040171086	Selective modulation of TLR-mediated biological activity	3M Innovative Properties Company	27-Feb-04	27-Feb-04	2-Sep-04
US20040170965	Mixed cell diagnostic systems	GOODRUM PATRICIA GAIL RAY	30-Mar-04	30-Mar-04	2-Sep-04
US20040170959	Methods for identifying antiviral oligonucleotides	Replicor, Inc.	11-Sep-03	12-Sep-03	2-Sep-04
US20040170649	Method of treating and preventing infectious diseases via creation of a modified viral particle with immunogenic properties	CHAM BILL E.	29-Jun-00	20-Jun-03	2-Sep-04
US20040170620	Selected antibody compositions for binding to aminophospholipids	RAN SOPHIA	15-Jul-03	15-Jul-03	2-Sep-04
US20040167161	Method of treating or inhibiting the development of brain inflammation and sepsis	NOZAKI MASAKO	20-May-03	26-Nov-03	26-Aug-04

CC-BY-NC-SA Dr. David E. Martin

US20040167073	Casein derived peptides and uses thereof	Chay 13 Medical Research Group N.V.	1-Mar-00	1-Mar-04	26-Aug-04
US20040162309	Methods and compositions related to IRM compounds and toll-like receptor 8	3M Innovative Properties Company	12-Feb-04	12-Feb-04	19-Aug-04
US20040162254	Antiviral oligonucleotides targeting HSV and CMV	Replicor, Inc.	12-Sep-03	12-Sep-03	19-Aug-04
US20040162253	Antiviral oligonucleotides targeting HBV	Replicor, Inc.	12-Sep-03	12-Sep-03	19-Aug-04
US20040147543	Aryl substituted imidazoquinolines	3M Innovative Properties Company	18-Dec-03	18-Dec-03	29-Jul-04
US20040147440	Compositions comprising cell-impermeant duramycin derivatives	Board of Regents, The University of Texas System	15-Aug-03	15-Aug-03	29-Jul-04
US20040142852	Composition and its therapeutic use	AL SARI AHMAD M. H.	9-May-02	29-May-03	22-Jul-04
US20040142322	Continuous non-radioactive polymerase assay	Schering Corporation	7-Oct-03	7-Oct-03	22-Jul-04
US20040141950	Immunostimulatory combinations	3M Innovative Properties Company	30-Dec-03	30-Dec-03	22-Jul-04
US20040138187	Therapeutic treatment methods	AHLEM CLARENCE N.	28-Aug-03	28-Aug-03	15-Jul-04
US20040131622	Combinations and kits for treating viral infections using immunoconjugates to aminophospholipids	Board of Regents	15-Aug-03	15-Aug-03	8-Jul-04
US20040131621	Combinations and kits for treating viral infections using antibodies to aminophospholipids	RAN SOPHIA	15-Aug-03	15-Aug-03	8-Jul-04
US20040131610	Methods for treating viral infections using antibodies to aminophospholipids	RAN SOPHIA	15-Aug-03	15-Aug-03	8-Jul-04
US20040081667	Compositions and methods for treating and preventing infection	HILDRETH JAMES E.	22-Jul-03	22-Jul-03	29-Apr-04
US20040077587	2'-C-methyl-3'-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections	LACOLLA PAOLA	27-Jun-03	27-Jun-03	22-Apr-04
US20040071757	Inhalation antiviral patch	ROLF DAVID	10-Jun-03	10-Jun-03	15-Apr-04
US20040071709	Corona-virus-like particles comprising functionally deleted genomes	BOSCH BEREND-JAN	17-May-01	14-Apr-03	15-Apr-04
US20040067920	Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof	JOHNSON KEITH A.	17-Jun-03	17-Jun-03	8-Apr-04
US20040009943	Pathogen vaccines and methods for using the same	Inex Pharmaceuticals Corporation	12-May-03	12-May-03	15-Jan-04
US20040009245	Methods and apparatus to prevent, treat and cure infections of the human respiratory system by pathogens causing severe acute respiratory syndrome (SARS)	VAIL MARILYN L.	2-May-03	2-May-03	15-Jan-04
US20040009152	Materials and methods for prevention and treatment of RNA viral diseases	BEHERA ARUNA K.	30-Apr-03	30-Apr-03	15-Jan-04
US20040005998	Method for preparation of large volume batches of poly-ICLC with increased biological potency; therapeutic, clinical and veterinary uses thereof	ONCOVIR, INC.	1-Jul-03	1-Jul-03	8-Jan-04
US20030224353	Antisense antiviral agent and method for treating ssRNA viral infection	IVERSEN PATRICK L.	24-Apr-03	24-Apr-03	4-Dec-03
US10669245	Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides dipeptidyl peptidase 1 inhibitors	ASTRAZENECA AB	24-Jan-14	19-Mar-19	2-Jun-20
US10666592	RNA targeting methods and compositions	Salk Institute for Biological Studies	22-Aug-17	31-Dec-18	26-May-20
US10662485	Bioagent detection oligonucleotides	IBIS BIOSCIENCES, INC.	27-Dec-11	13-Apr-18	26-May-20
US10662464	Methods of analyzing virus-derived therapeutics	American International Biotechnology, LLC	31-Jul-15	29-Jul-16	26-May-20
US10662423	Compositions for and methods of identifying antigens	President and Fellows of Harvard College	21-Feb-06	12-Feb-18	26-May-20

CC-BY-NC-SA Dr. David E. Martin

US10660824	Devices, system and method to control the delivery of oral medications to ensure they are efficacious , taken as prescribed, and to avoid unwanted side effects	Not Available	11-Aug-15	11-Aug-16	26-May-20
US10655108	Cell-derived viral vaccines with low levels of residual cell DNA	Seqirus UK Limited	1-Nov-05	1-Nov-06	19-May-20
US10655099	Animal protein-free media for cultivation of cells	Baxalta GmbH	29-Oct-04	29-Oct-18	19-May-20
US10654898	Recombinant human/bovine parainfluenza virus 3 (B/HPIV3) expressing a chimeric RSV/BPIV3 F protein and uses thereof	The United States of America, as represented by the Secretary, Department of Health and Human Serices	20-Jan-15	20-Jan-16	19-May-20
US10647998	Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof	The Trustees of the University of Pennsylvania	29-Apr-13	20-Jun-17	12-May-20
US10647781	Generation of binding molecules	Merus N.V.	26-Sep-11	22-Nov-17	12-May-20
US10647758	Compositions comprising AAV expressing dual antibody constructs and uses thereof	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	13-May-14	2-Jul-19	12-May-20
US10646563	Vaccines and immunotherapeutics using IL-28 and compositions and methods of using	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	4-Apr-08	11-Sep-18	12-May-20
US10646438	Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM	26-Jul-10	10-May-17	12-May-20
US10641707	Systems and methods for distinguishing optical signals of different modulation frequencies in an optical signal detector	Gen-Probe Incorporated	24-Feb-11	21-Mar-14	5-May-20
US10640788	CRISPR-related methods and compositions with governing gRNAs	Editas Medicine, Inc.	7-Nov-13	24-Jan-19	5-May-20
US10640785	Virus vectors for highly efficient transgene delivery	The Children's Hospital of Philadelphia	22-Nov-11	21-Nov-12	5-May-20
US10640776	Method for propagating adenoviral vectors encoding inhibitory gene products	GenVec, Inc.	10-Nov-05	7-Sep-17	5-May-20
US10640763	Molecular indexing of internal sequences	Cellular Research, Inc.	31-May-16	16-May-17	5-May-20
US10633447	Soluble engineered monomeric Fc	The United States of America, as represented by the Secretary, Department of Health and Human Services	16-Mar-12	9-May-17	28-Apr-20
US10632133	Anti-viral azide containing compounds	LIFE TECHNOLOGIES CORPORATION	28-Jul-10	7-Dec-17	28-Apr-20
US10626415	Method of increasing the function of an AAV vector	The Trustees of the University of Pennsylvania	7-Apr-05	27-Oct-17	21-Apr-20
US10626379	Production of viruses in cell culture	Commonwealth Scientific and Industrial Research Organisation	24-Nov-15	25-Jan-19	21-Apr-20
US10619186	Methods and compositions for library normalization	Cellular Research, Inc.	11-Sep-15	8-Sep-16	14-Apr-20
US10619153	TAL effector-mediated DNA modification	Iowa State University Research Foundation, Inc.	10-Dec-09	5-Oct-17	14-Apr-20
US10617677	Nuclear transport modulators and uses thereof	Biogen MA Inc.	9-May-12	17-Jul-18	14-Apr-20
US10614284	Descriptive measurements and quantification of staining artifacts for in situ hybridization	Ventana Medical Systems, Inc.	26-May-15	21-Nov-17	7-Apr-20
US10611827	Non-human primate-derived pan-ebola and pan-filovirus monoclonal antibodies directed against envelope glycoproteins	INTEGRATED BIOTHERAPEUTICS, INC.	28-Oct-14	27-Oct-15	7-Apr-20
US10610584	Reverse genetics systems	Seqirus UK Limited	31-Jul-09	16-Oct-17	7-Apr-20
US10610571	Cytokine conjugates for the treatment of proliferative and infectious diseases	SYNTHORX, INC.	3-Aug-17	7-Jun-19	7-Apr-20
US10605808	Antibody producing non-human animals	Merus N.V.	27-Jun-08	27-Apr-16	31-Mar-20
US10604729	Liquid loading composition, method of making and use thereof	DEVMAR PRODUCTS, LLC	8-Sep-16	21-May-18	31-Mar-20
US10604574	Oncolytic viral delivery of therapeutic polypeptides	ONCORUS, INC.	30-Jun-16	25-Oct-18	31-Mar-20
US10604561	Anti-dengue virus antibodies, polypeptides containing variant Fc regions, and methods of use	Agency for Science, Technology and Research	16-Sep-16	15-Sep-17	31-Mar-20
US10604549	Adenovirus comprising an albumin-binding moiety	FUNDACIÃ“ INSTITUT D'INVESTIGACIÃ“ BIOMÃˆDICA DE BELLVITGE (IDIBELL)	30-Apr-14	30-Apr-15	31-Mar-20

CC-BY-NC-SA Dr. David E. Martin

US10603356	Compositions and method for treatment of inflammatory bowel disease	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA	2-Jun-11	21-Apr-16	31-Mar-20
US10603299	Prevention and treatment of viral infections	Not Available	2-Jun-16	3-Jul-19	31-Mar-20
US10597736	Compositions and methods for detecting viruses in a sample	Washington University	29-Jan-16	27-Jan-17	24-Mar-20
US10596264	Peptides with viral infection enhancing properties and their use	Centre National de la Recherche Scientique	30-Jun-11	28-Jun-12	24-Mar-20
US10596197	Red blood cell membrane-derived microparticles and their use for the treatment of lung disease	University of Pittburghâ€"Of the Commonwealth System of Higher Education	7-Nov-13	1-Jun-18	24-Mar-20
US10591714	Endoscopic apparatus for thermal distribution monitoring	ELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE	7-Sep-16	31-May-17	17-Mar-20
US10590435	Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor	The Trustees of the University of Pennsylvania	17-Dec-01	26-Sep-18	17-Mar-20
US10590413	Chiral control	WAVE LIFE SCIENCES LTD.	13-Jul-12	17-Mar-17	17-Mar-20
US10590112	Dihydropyrimidinyl benzazepine carboxamide compounds	Hoffmann-La Roche Inc.	9-Jun-17	7-Dec-18	17-Mar-20
US10588966	Methods and compositions for inhibiting Akt3	Augusta University Research Institute, Inc.	15-Jan-16	6-Feb-19	17-Mar-20
US10583086	Technology for preparation of macromolecular microspheres	Ansun Biopharma, Inc.	24-Jan-06	25-Sep-17	10-Mar-20
US10577375	Derivatives of porphyrins, their process of preparation and their use for treating viral infections	CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE	30-Oct-15	28-Oct-16	3-Mar-20
US10570416	TC-83-derived alphavirus vectors, particles and methods	ALPHAVAX, INC.	18-May-04	11-Aug-16	25-Feb-20
US10570209	Methods for inducing or enhancing an immune response by administering agonistic glucocorticoid-induced TNFR-family-related receptor (GITR) antibodies	GITR, Inc.	25-Mar-05	28-Jun-18	25-Feb-20
US10564160	Antibody-secreting cell assay	MABTECH AB	28-Aug-08	28-Aug-09	18-Feb-20
US10564152	Method and device for detecting antigen-specific antibodies in a biological fluid sample by using neodymium magnets	The United States of America, as represented by the Secretary, Department of Health and Human Services	1-Sep-15	8-Aug-16	18-Feb-20
US10563224	Replication defective adenovirus vector in vaccination	Etubics Corporation	24-Aug-12	15-Feb-17	18-Feb-20
US10563154	Disinfecting aqueous foam, process for preparing same and use thereof	COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES	16-Jun-15	15-Jun-16	18-Feb-20
US10562861	Carboxylic acid compounds	Sumitomo Dainippon Pharma Co., Ltd.	18-May-12	23-Oct-18	18-Feb-20
US10561743	AAV vectors targeted to the central nervous system	The University of North Carolina at Chapel Hill	21-Nov-14	13-Jun-19	18-Feb-20
US10561722	Methods and compositions for enhancing immune responses	Bavarian Nordic A/S	3-Sep-14	3-Sep-15	18-Feb-20
US10561126	Genetically modified non-human animals and methods of use thereof	Institute for Research in Biomedicine (IRB)	13-Apr-15	16-Apr-18	18-Feb-20
US10557136	In vivo delivery of oligonucleotides	Oncolmmunin Inc.	12-Dec-11	12-Dec-12	11-Feb-20
US10557119	Erythroid cells comprising phenylalanine ammonia lyase	RUBIUS THERAPEUTICS, INC.	18-Nov-13	10-May-19	11-Feb-20
US10555993	Dimethyl fumarate and vaccination regimens	Biogen MA Inc.	14-Mar-14	23-Apr-19	11-Feb-20
US10550378	Composition comprising a gene vector that selectively depletes P16 positive senescent cells	Kythera Biopharmaceuticals, Inc.	17-Apr-12	10-Jun-19	4-Feb-20
US10550174	Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases	Ablynx N.V.	5-Jun-08	17-Oct-17	4-Feb-20
US10548971	MERS-CoV vaccine	INOVIO PHARMACEUTICALS, INC.	29-Nov-13	29-Jun-18	4-Feb-20
US10548959	Compositions and methods for modified dendrimer nanoparticle delivery	Massachusetts Institute of Technology	23-Sep-16	23-Sep-16	4-Feb-20

US10544405	Cas9-nucleic acid complexes and uses related thereto	Emory University	16-Jan-13	15-Jan-14	28-Jan-20
US10544399	Highly efficient influenza matrix (M1) proteins	Novavax, Inc.	11-Jul-03	22-Mar-18	28-Jan-20
US10544193	Compositions and methods for treating diseases by inhibiting exosome release	MOREHOUSE SCHOOL OF MEDICINE	19-Dec-16	9-Jul-18	28-Jan-20
US10544108	Hydrazide containing nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	29-Jul-11	28-Nov-18	28-Jan-20
US10544102	Benzazepine dicarboxamide compounds with secondary amide function	Hoffmann-La Roche Inc.	19-May-17	13-Nov-18	28-Jan-20
US10543485	Slip chip device and methods	University of Chicago	24-Mar-09	25-May-16	28-Jan-20
US10543269	hMPV RNA vaccines	ModernaTX, Inc.	22-Oct-15	28-Mar-19	28-Jan-20
US10539488	Sample fixation and stabilisation	RNASSIST LTD.	1-Mar-13	14-Aug-17	21-Jan-20
US10538558	Inhibition of TCR signaling with peptide variants	SIGNABLOK, INC	30-Sep-09	22-Oct-18	21-Jan-20
US10538554	Peptides and uses therefor as antiviral agents	VIRAMATIX SDN BHD	27-Nov-15	28-Nov-16	21-Jan-20
US10533021	Boron-containing small molecules	Anacor Pharmaceuticals, Inc.	20-Jun-07	28-Sep-17	14-Jan-20
US10532111	Recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies	The Board of Trustees of the Leland Stanford Junior University	16-Feb-16	18-Aug-17	14-Jan-20
US10532110	AAV vectors targeted to the central nervous system	The University of North Carolina at Chapel Hill	21-Nov-14	20-Nov-15	14-Jan-20
US10532107	Modified virus-like particles of CMV	SAIBA GMBH	22-Oct-14	20-Oct-15	14-Jan-20
US10532067	Delivery of RNA to trigger multiple immune pathways	GlaxoSmithKline Biologicals S.A.	6-Jul-10	5-Oct-17	14-Jan-20
US10527551	Method of predicting a performance characteristic of a plant or yeast hydrolysate and its use	Baxalta GmbH	30-Dec-13	18-Dec-14	7-Jan-20
US10526596	Purification of nucleic acids using metal-titanium oxides	Abbott Molecular Inc.	14-Jul-15	5-Jul-19	7-Jan-20
US10526295	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	31-Dec-15	30-Dec-16	7-Jan-20
US10526292	Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases	Parion Sciences, Inc.	29-May-12	20-Dec-17	7-Jan-20
US10526283	Prodrugs of dithiol mucolytic agents	PARION SCIENCES, INC.	30-Apr-15	2-May-16	7-Jan-20
US10525120	Methods and compositions for live attenuated viruses	TAKEDA VACCINES, INC.	6-Apr-07	22-Jul-16	7-Jan-20
US10525049	Specific Akt3 inhibitor and uses thereof	Augusta University Research Institute, Inc.	15-Jan-16	20-May-19	7-Jan-20
US10519130	Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors	FORMA Therapeutics, Inc.	5-Feb-15	2-Nov-18	31-Dec-19
US10519129	Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors	FORMA Therapeutics, Inc.	5-Feb-15	2-Nov-18	31-Dec-19
US10519128	Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors	FORMA Therapeutics, Inc.	5-Feb-15	2-Nov-18	31-Dec-19
US10519127	Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors	FORMA Therapeutics, Inc.	5-Feb-15	2-Nov-18	31-Dec-19
US10517947	Methods for preparing squalene	NOVARTIS AG	12-May-10	14-Dec-17	31-Dec-19
US10517923	Immunosuppressive agents and their use in therapy	Norwegian University of Science and Technology	6-Nov-13	6-Nov-14	31-Dec-19
US10517881	Pharmaceutical compositions and methods	POP TEST ONCOLOGY LLC	3-Aug-15	8-Jan-19	31-Dec-19
US10513508	Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors	FORMA Therapeutics, Inc.	5-Feb-15	2-Nov-18	24-Dec-19

CC-BY-NC-SA Dr. David E. Martin

US10513507	Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors	FORMA Therapeutics, Inc.	5-Feb-15	11-Dec-17	24-Dec-19
US10512684	Methods and compositions for intra-nasal immunization with recombinant MVA encoding flagellin	Bavarian Nordic A/S	26-Sep-14	25-Sep-15	24-Dec-19
US10512669	Blockade of inflammatory proteases with cyclic peptides	The Regents of the University of California	2-Jun-11	1-Jun-12	24-Dec-19
US10512665	Methods and compositions related to inhibition of viral entry	UNIVERSITY OF UTAH RESEARCH FOUNDATION	8-Feb-07	2-Jun-16	24-Dec-19
US10508098	Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors	FORMA Therapeutics, Inc.	5-Feb-15	2-Nov-18	17-Dec-19
US10507244	Anti-TIGIT antigen-binding proteins and methods of use thereof	Potenza Therapeutics, Inc.	1-Oct-15	19-Jun-17	17-Dec-19
US10503347	System and method for detecting, collecting, analyzing, and communicating event-related information	Georgetown University	25-Feb-08	27-Jul-17	10-Dec-19
US10501733	Polypeptide assemblies and methods for the production thereof	University of Utah Research Foundation	27-Feb-15	29-Feb-16	10-Dec-19
US10501527	Mast cell stabilizers for treatment of hypercytokinemia and viral infection	Emergo Therapeutics, Inc.	8-Sep-16	7-Sep-17	10-Dec-19
US10501507	Griffithsin mutants	The United States of America, as represented by the Secretary, Department of Health and Human Services	10-Feb-15	10-Feb-16	10-Dec-19
US10501412	Conjugates of cell binding molecules with cytotoxic agents	HANGZHOU DAC BIOTECH CO., LTD.	12-Jul-12	12-Jul-12	10-Dec-19
US10500272	Manufacture of surfactant-containing compositions with enhanced stability	NOVARTIS AG	2-Dec-14	12-Mar-19	10-Dec-19
US10500267	Influenza virus vectors and uses therefor	FluGen, Inc.	17-Mar-14	21-Aug-17	10-Dec-19
US10495640	Exosome-mediated diagnosis of hepatitis virus infections and diseases	MOREHOUSE SCHOOL OF MEDICINE	6-Oct-08	13-Dec-16	3-Dec-19
US10494420	Mast cell stabilizers for treatment of hypercytokinemia and viral infection	Emergo Therapeutics, Inc.	8-Sep-16	15-Nov-18	3-Dec-19
US10488353	Apparatus and system for performing thermal melt analyses and amplifications	GEN-PROBE INCORPORATED	31-Jul-12	23-Feb-17	26-Nov-19
US10487350	Methods for diagnosing infectious diseases using adsorption media	ExThera Medical Corporation	8-Nov-13	16-Oct-15	26-Nov-19
US10487332	Immunisation of large mammals with low doses of RNA	GlaxoSmithKline Biologicals SA	6-Jul-10	6-Jul-11	26-Nov-19
US10487081	Guanidine substituted imidazo[4,5-c] ring compounds	3M Innovation Properties Company	31-Aug-15	22-Oct-18	26-Nov-19
US10485883	Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor	The Trustees of the University of Pennsylvania	30-Sep-03	15-Feb-17	26-Nov-19
US10485861	Nanoparticle-based compositions	Massachusetts Institute of Technology	14-Mar-13	14-Mar-14	26-Nov-19
US10485856	Carbon nanotube compositions and methods of use thereof	Yale University	19-Mar-08	17-Mar-17	26-Nov-19
US10485761	Irradiated biodegradable polymer microparticles	GLAXOSMITHKLINE BIOLOGICALS, S.A.	24-Jan-10	16-May-18	26-Nov-19
US10479996	Antisense antiviral compound and method for treating ss/RNA viral infection	Sarepta Therapeutics, Inc.	16-Sep-04	6-Nov-14	19-Nov-19
US10479781	Peptidyl nitril compounds as dipeptidyl peptidase I inhibitors	Neuprozyme Therapeutics APS	5-Mar-15	4-Mar-16	19-Nov-19
US10476825	RNA targeting methods and compositions	Salk Institue for Biological Studies	22-Aug-17	27-Mar-18	12-Nov-19
US10472647	Primary mesenchymal stem cells as a vaccine platform	The Administrators of the Tulane Educational Fund	21-Dec-12	15-Nov-13	12-Nov-19
US10472420	Immune response modifier conjugates	3M Innovative Properties Company	22-Feb-06	20-Jan-15	12-Nov-19
US10472332	Antiviral compounds and methods	Biotron Limited	26-Jun-03	23-May-17	12-Nov-19
US10471408	Microspotting device	BioFire Diagnostics, LLC	18-Apr-12	5-Jan-17	12-Nov-19

CC-BY-NC-SA Dr. David E. Martin

US10471141	Bisphosphonate-containing vaccine pharmaceutical composition for humoral immunity	NITTO DENKO CORPORATION	3-Sep-14	2-Sep-15	12-Nov-19
US10471140	Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition	NOTTO DENKO CORPORATION	4-Aug-14	18-Apr-19	12-Nov-19
US10471063	Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonist	Verona Pharma PLC	15-Mar-13	5-Jun-17	12-Nov-19
US10466245	Covalently linked thermostable kinase for decontamination process validation	The Secretary of State for Health	20-Feb-08	8-Jul-16	5-Nov-19
US10464988	Antibody/T-cell receptor chimeric constructs and uses thereof	EUREKA THERAPEUTICS, INC.	23-Oct-15	4-Sep-18	5-Nov-19
US10464975	Stabilized anti-microbial peptides	Dana-Farber Cancer Institute, Inc.	2-Jul-15	1-Jul-16	5-Nov-19
US10464955	Charged linkers and their uses for conjugation	HANGZHOU DAC BIOTECH CO., LTD.	28-Feb-14	28-Feb-14	5-Nov-19
US10464060	Loading vials	BioFare Diagnostics, LLC	10-Nov-11	9-Nov-12	5-Nov-19
US10463723	Methods and compositions for intranasal delivery	Shin Nippon Biomedical Laboratories, Ltd.	15-Apr-10	14-Mar-13	5-Nov-19
US10463615	Circulation of components during microfluidization and/or homogenization of emulsions	NOVARTIS AG	3-Dec-09	26-Jun-17	5-Nov-19
US10457974	Methods for diagnosing infectious diseases using adsorption media	ExThera Medical Corporation	8-Nov-13	2-Nov-16	29-Oct-19
US10457901	Cleaning composition, method of making and use thereof	DevMar Products, LLC	8-Sep-16	19-Sep-18	29-Oct-19
US10456464	Liquid immunity induction-promoting composition and vaccine pharmaceutical composition that include thrombosis treatment drug	NITTO DENKO CORPORATION	4-Aug-14	4-Aug-15	29-Oct-19
US10450620	Cell-free nucleic acids for the analysis of the human microbiome and components thereof	The Board of Trustees of the Leland Stanford Junior University	7-Nov-13	7-Nov-14	22-Oct-19
US10450383	Carbonic anhydrase IX (G250) antibodies and methods of use thereof	DANA-FARBER CANCER INSTITUTE, INC.	2-Dec-05	9-May-17	22-Oct-19
US10443049	Active low molecular weight variants of angiotensin converting enzyme 2 (ACE2)	Northwestern University	24-Jan-17	24-Jan-18	15-Oct-19
US10442853	Antibodies and processes for preparing the same	TAIGA BIOTECHNOLOGIES, INC.	16-May-08	23-Aug-16	15-Oct-19
US10434158	Combination of vaccination and inhibition of the PD-1 pathway	CureVac AG	22-Feb-13	7-Feb-18	8-Oct-19
US10434116	Methods of treating coronavirus infection	United States Government as represented by the Secretary, Department of Health and Human Services	7-Apr-14	7-Apr-15	8-Oct-19
US10428128	Helix-grafted proteins as inhibitors of disease-relevant protein-protein interactions	Colorodo State University Research Foundation	7-Nov-14	9-Nov-15	1-Oct-19
US10428102	Glycolipids and pharmaceutical compositions thereof for use in therapy	THE UNIVERSITY OF NOTTINGHAM	4-Apr-14	7-Apr-15	1-Oct-19
US10428083	Heterocyclylmethyl-thienouracile as antagonists of the adenosine-A2B-receptor	BAYER PHARMA AKTIENGESELLSCHAFT	26-Mar-15	21-Mar-16	1-Oct-19
US10428027	Sulfinylphenyl or sulfonimidoylphenyl benzazepines	Hoffmann La-Roche Inc.	17-Sep-15	8-Mar-18	1-Oct-19
US10426737	Lipids and lipid compositions for the delivery of active agents	Novartis AG	19-Dec-13	17-Dec-14	1-Oct-19
US10421991	Rapid epidemiologic typing of bacteria	BioFire Diagnostics, LLC	19-May-08	11-Nov-15	24-Sep-19
US10421962	Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereof	Quark Pharmaceuticals, Inc.	12-Sep-12	15-Feb-17	24-Sep-19
US10420837	Vaccine pharmaceutical composition for transdermal administration	NITTO DENKO CORPORATION	2-Oct-14	1-Oct-15	24-Sep-19
US10420685	Mobile clinics	Baylor College of Medicine	12-Nov-14	11-Nov-15	24-Sep-19
US10416171	Influenza potency assays	Seqirus UK Limited	7-Jul-15	7-Jul-16	17-Sep-19
US10416161	Exosome-mediated diagnosis of hepatitis virus infections and diseases	MOREHOUSE SCHOOL OF MEDICINE	6-Oct-08	20-Sep-16	17-Sep-19

CC-BY-NC-SA Dr. David E. Martin

US10414800	Methods for producing a depsipeptide	NovoBiotic Pharmaceuticals, LLC	3-Dec-12	15-Jun-16	17-Sep-19
US10414779	Fused [1,2]imidazo[4,5-C] ring compounds substituted with guanidino groups	3M Innovative Properties Company	26-Aug-16	1-Aug-17	17-Sep-19
US10407492	Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases	Ablynx N.V.	5-Jun-08	17-Oct-17	10-Sep-19
US10407472	Fusion proteins, recombinant bacteria, and methods for using recombinant bacteria	Spogen Biotech Inc.	17-Sep-14	14-Dec-17	10-Sep-19
US10407431	Compounds and compositions as toll-like receptor 7 agonists	Novartis AG	1-May-14	27-Feb-18	10-Sep-19
US10407405	Nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	21-Jun-13	17-Jul-17	10-Sep-19
US10406229	Methods and compositions related to inhibition of viral entry	UNIVERSITY OF UTAH RESEARCH FOUNDATION	28-Mar-11	2-Mar-17	10-Sep-19
US10406177	Modified cells and methods of therapy	Intima Bioscience, Inc.	31-Jul-15	29-Aug-16	10-Sep-19
US10406142	Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom	3M Innovative Properties Company	3-Jun-11	6-Mar-17	10-Sep-19
US10400274	Fluorogenic probes and their use in quantitative detection of target RNA sequences	Jan Biotech, Inc.	18-Jun-16	16-Jun-17	3-Sep-19
US10400225	TAL effector-mediated DNA modification	Iowa State University Research Foundation, Inc.	10-Dec-09	21-Aug-17	3-Sep-19
US10400024	Cleavage and exchange of major histocompatibility complex ligands employing azobenzene-containing peptides	SANQUIN REAGENTS B.V.	6-Jun-14	5-Jun-15	3-Sep-19
US10399963	Substituted benzofuranyl and benzoxazolyl compounds and uses thereof	Karyopharm Therapeutics Inc.	3-Jul-13	4-Dec-17	3-Sep-19
US10399941	Conjugates of cell binding molecules with cytotoxic agents	HANGZHOU DAC BIOTECH CO., LTD.	12-Jul-12	16-Apr-14	3-Sep-19
US10398795	Decontamination device and method using ultrasonic cavitation	TOMI ENVIRONMENTAL SOLUTIONS, INC.	29-Dec-17	29-Dec-17	3-Sep-19
US10393633	Sample fixation and stabilisation	RNASSIST LTD.	1-Mar-13	30-May-17	27-Aug-19
US10392613	Purification of nucleic acids using copper-titanium oxides	ABBOTT MOLECULAR INC.	14-Jul-15	13-Jul-16	27-Aug-19
US10391188	Decontamination device and method using ultrasonic cavitation	TOMI ENVIRONMENTAL SOLUTIONS, INC.	29-Dec-17	11-Sep-18	27-Aug-19
US10391167	Mucosal vaccine composition	NITTO DENKO CORPORATION	3-Oct-13	2-Oct-14	27-Aug-19
US10391160	Dimethyl fumarate and vaccination regimens	Biogen MA Inc.	14-Mar-14	13-Mar-15	27-Aug-19
US10385320	Recombinant adeno-associated virus capsids with enhanced human skeletal muscle tropism	The Board of Trustees of the Leland Stanford Junior University	2-Dec-15	2-Dec-16	20-Aug-19
US10385119	Compositions comprising AAV expressing dual antibody constructs and uses thereof	Trustees of the University of Pennsylvania	13-May-14	15-Oct-18	20-Aug-19
US10383938	Lipidated immune response modifier compound compositions, formulations, and methods	3M Innovative Properties Company	17-Aug-10	24-Jul-18	20-Aug-19
US10383935	Methods of making and using live attenuated viruses	Regents of the University of Minnesota	23-Sep-15	31-Oct-17	20-Aug-19
US10383852	Prevention and treatment of viral infections	Not Available	2-Jun-16	27-Nov-18	20-Aug-19
US10378008	Method and apparatus for automated processing of pooled samples	GFE BLUT MBH	6-Aug-14	5-Aug-15	13-Aug-19
US10378002	Replication conditional virus that specifically kills senescent cells	Kythera Biopharmaceuticals, Inc.	17-Apr-12	6-Jul-18	13-Aug-19
US10377773	Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors	FORMA Therapeutics, Inc.	5-Feb-15	27-Feb-18	13-Aug-19
US10377767	Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors	FORMA Therapeutics, Inc.	5-Feb-15	1-Mar-18	13-Aug-19

CC-BY-NC-SA Dr. David E. Martin

US10377760	Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors	FORMA Therapeutics, Inc.	30-Dec-14	18-Jan-18	13-Aug-19
US10370625	Cleaning composition, method of making and use thereof	DEVMAR PRODUCTS, LLC	8-Sep-16	6-Sep-17	6-Aug-19
US10370455	Identification of VSIG8 as the putative VISTA receptor (V-R) and use thereof to produce VISTA/VSIG8 agonists and antagonists	IMMUNEXT, INC.	5-Dec-14	7-Dec-15	6-Aug-19
US10370338	Benzazepine dicarboxamide compounds with tertiary amide function	Hoffmann-La Roche Inc.	23-May-16	13-Nov-18	6-Aug-19
US10369219	Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition	NITTO DENKO CORPORATION	4-Aug-14	4-Aug-15	6-Aug-19
US10369216	Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant	CureVac AG	1-Apr-14	1-Apr-15	6-Aug-19
US10369205	Immunomodulatory compositions and methods of use thereof	Not Available	7-Jan-14	7-Jan-15	6-Aug-19
US10369204	Molecular vaccines for infectious disease	Dako Denmark A/S	2-Oct-08	2-Oct-09	6-Aug-19
US10363303	Microneedle compositions and methods of using same	VERNDARI, INC.	11-Jan-16	11-Jul-18	30-Jul-19
US10363282	Analogs of C5a and methods of using same	Board of Regents of The University of Nebraska	29-Jun-10	12-Jan-18	30-Jul-19
US10363247	(S,E)-3-(6-aminopyridin-3-yl)-N-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer	Karyopharm Therapeutics Inc.	18-Aug-15	18-Aug-16	30-Jul-19
US10358481	Engineered antibody constant domain molecules	The United States of America, as represented by the Secretary, Department of Health and Human Services	31-Jan-08	2-Dec-16	23-Jul-19
US10357568	Adjuvant nanoemulsions with phospholipids	GLAXOSMITHKLINE BIOLOGICALS S.A.	24-Mar-11	23-Mar-12	23-Jul-19
US10357562	Immunoprotective primary mesenchymal stem cells and methods	Autoimmune Technologies, LLC	14-Mar-13	17-Jul-15	23-Jul-19
US10357510	Metal nanoclusters and uses thereof	THE REGENTS OF THE UNIVERSITY OF MICHIGAN	7-Aug-14	7-Aug-15	23-Jul-19
US10351571	Pyrrolotriazinones and imidazotriazinones as ubiquitin-specific protease 7 inhibitors	FORMA Therapeutics, Inc.	30-Dec-14	24-May-18	16-Jul-19
US10350255	Polygonum cuspidatum extracts	PhotoDynamic Inc.	1-Oct-15	30-Sep-16	16-Jul-19
US10344320	Capacitive liquid crystal biosensors	The Johns Hopkins University	6-May-15	5-May-16	9-Jul-19
US10344263	Synthetic membrane-receiver complexes	RUBIUS THERAPEUTICS, INC.	18-Nov-13	29-Mar-17	9-Jul-19
US10344261	Immunomodulatory conjugates	ASCEND BIOPHARMACEUTICALS LTD	9-Nov-11	9-Nov-12	9-Jul-19
US10344027	Compositions and methods for inhibiting kinases	Inhibikase Therapeutics, Inc.	23-Apr-15	24-Oct-18	9-Jul-19
US10342868	Methods and compositions for inhibiting Akt3	Augusta University Research Institute, Inc.	15-Jan-16	17-Jan-17	9-Jul-19
US10342825	Solution containing hypochlorous acid and methods of using same	Sonoma Pharmaceuticals, Inc.	15-Jun-09	15-Jun-10	9-Jul-19
US10336725	Chemical compounds	AstraZeneca AB	18-Mar-14	13-Dec-17	2-Jul-19
US10335484	Methods of generating robust passive and active immune responses	HUMABS BIOMED SA	8-Jan-13	8-Jan-14	2-Jul-19
US10335393	Nuclear transport modulators and uses thereof	Biogen MA Inc.	9-May-12	4-Dec-17	2-Jul-19
US10335372	Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases	Jacob G. Appelbaum	14-Apr-04	10-Mar-17	2-Jul-19
US10329531	Synthetic membrane-receiver complexes	RUBIUS THERAPEUTICS, INC.	18-Nov-13	13-Oct-17	25-Jun-19

CC-BY-NC-SA Dr. David E. Martin

US10329329	Fusion proteins for promoting an immune response, nucleic acids encoding same, and methods of making and use thereof	UNIVERSITY OF MIAMI	7-Sep-12	28-Aug-18	25-Jun-19
US10328157	Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule	HANGZHOU DAC BIOTECH CO., LTD.	15-Jul-15	3-Feb-17	25-Jun-19
US10323074	Cryptic polypeptides and uses thereof	BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY	29-Jan-15	12-Dec-17	18-Jun-19
US10322104	Disulfur bridge linkers for conjugation of a cell-binding molecule	HANGZHOU DAC BIOTECH CO., LTD.	15-Jul-15	5-Apr-17	18-Jun-19
US10316031	Compositions and methods for inhibiting kinases	Inhibikase Therapeutics, Inc.	23-Apr-15	24-Oct-18	11-Jun-19
US10314893	Oral delivery of angiotensin converting enzyme 2 (ACE2) or angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension, cardiac dysfunction and development of autoimmune and experimental induced ocular disorders	The Trustees of the University of Pennsylvania	18-Oct-13	18-Apr-16	11-Jun-19
US10308913	Chimeric viruses presenting non-native surface proteins and uses thereof	Icahn School of Medicine at Mount Sinai	2-Dec-05	3-Mar-16	4-Jun-19
US10308705	Optimized human clotting factor VIII gene expression cassettes and their use	The University of North Carolina at Chapel Hill	6-Feb-15	5-Feb-16	4-Jun-19
US10308685	Inhibitory peptides of viral infection	UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION	17-Jul-14	25-May-17	4-Jun-19
US10307475	Methods and compositions for immunization against virus	Academia Sinica	27-Mar-09	18-Feb-14	4-Jun-19
US10307472	Combination of vaccination and OX40 agonists	CureVac AG	12-Mar-14	12-Mar-14	4-Jun-19
US10307439	Substituted nucleosides, nucleotides and analogs thereof	Alios Biopharma, Inc.	24-Jun-14	2-Feb-17	4-Jun-19
US10307434	Nucleic acid prodrugs and methods of use thereof	WAVE LIFE SCIENCES LTD.	6-Jul-09	27-May-16	4-Jun-19
US10307391	Disulfur bridge linkers for conjugation of a cell-binding molecule	HANGZHOU DAC BIOTECH CO., LTD.	15-Jul-15	5-Apr-17	4-Jun-19
US10307374	Oil-in-water emulsions that contain nucleic acids	GLAXOSMITHKLINE BIOLOGICALS S.A.	6-Jul-11	24-Apr-17	4-Jun-19
US10301650	Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor	The Trustees of the University of Pennsylvania	17-Dec-01	1-May-17	28-May-19
US10301648	Method of increasing the function of an AAV vector	The Trustees of the University of Pennsylvania	7-Apr-05	18-Feb-15	28-May-19
US10301594	Synthetic membrane-receiver complexes	RUBIUS THERAPEUTICS, INC	18-Nov-13	19-Nov-18	28-May-19
US10301593	Synthetic membrane-receiver complexes	RUBIUS THERAPEUTICS, INC.	18-Nov-13	19-Mar-18	28-May-19
US10301377	Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use	The United States of America, as Represented by the Secretary, Department of Health and Human Services	24-Feb-15	24-Feb-16	28-May-19
US10300149	Compositions for enhancing transport of molecules into cells	SAREPTA THERAPEUTICS, INC.	29-Apr-03	10-Jan-17	28-May-19
US10300145	Synthetic nanoparticles for delivery of immunomodulatory compounds	Massachusetts Institute of Technology	15-Jul-16	14-Jul-17	28-May-19
US10300127	Immune complex	The Rockefeller University	20-Mar-15	21-Mar-16	28-May-19
US10300124	Rodent hepadnavirus cores with reduced carrier-specific antigenicity	VLP BIOTECH, INC.	15-Mar-13	14-Mar-14	28-May-19
US10294534	Respiratory infection assay	THE SECRETARY OF STATE FOR HEALTH	9-Dec-11	10-Dec-12	21-May-19
US10294293	Human monoclonal antibody with specificity for dengue virus serotype 1 E protein and uses thereof	DSO National Laboratories	14-Dec-10	1-Jun-16	21-May-19
US10294280	Constrained proteins and uses therefor	Monash University	21-Jul-14	21-Jul-15	21-May-19
US10293060	Method for increasing expression of RNA-encoded proteins	CureVac AG	21-Aug-14	19-Feb-16	21-May-19
US10293055	Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule	HANGZHOU DAC BIOTECH CO., LTD.	15-Jul-15	3-Mar-17	21-May-19

US10293039	Attenuated Listeria monocytogenes mutant as a vaccine vector for the delivery of exogeneous antigens	Montana State University	7-Apr-14	7-Apr-15	21-May-19
US10292978	Specific Akt3 inhibitor and uses thereof	Augusta University Research Institute, Inc.	15-Jan-16	17-Jan-17	21-May-19
US10292961	Disulfur bridge linkers for conjugation of a cell-binding molecule	HANGZHOU DAC BIOTECH CO., LTD.	15-Jul-15	15-Jul-15	21-May-19
US10288601	Method of determining, identifying or isolating cell-penetrating peptides	Phylogica Limited	23-May-11	11-Dec-17	14-May-19
US10287576	Enzymatic encoding methods for efficient synthesis of large libraries	NUEVOLUTION A/S	1-Dec-05	12-Dec-16	14-May-19
US10287258	Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors	ASTRAZENECA AB	24-Jan-14	19-Sep-17	14-May-19
US10287253	Substituted pyrimidines containing acidic groups as TLR7 modulators	APROS THERAPEUTICS, INC.	5-Dec-16	4-Dec-17	14-May-19
US10286067	Composition for enhancing induction of humoral immunity, and vaccine pharmaceutical composition	NITTO DENKO CORPORATION	4-Aug-14	4-Aug-15	14-May-19
US10286056	Adjuvant nanoemulsions with crystallisation inhibitors	GLAXOSMITHKLINE BIOLOGICALS S.A.	27-Jan-11	27-Jan-12	14-May-19
US10280199	Coronavirus proteins and antigens	Phibro Animal Health Corporation	7-Feb-14	4-Aug-16	7-May-19
US10279029	Immunogenic compositions and uses thereof	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM	25-Mar-15	27-Feb-18	7-May-19
US10279028	Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome	Ohio State Innovation Foundation	24-Apr-12	14-Dec-17	7-May-19
US10279027	Transgenic Vero-CD4/CCR5 cell line	INTERNATIONAL AIDS VACCINE INITIATIVE	2-Oct-15	6-Apr-17	7-May-19
US10273454	Means and methods for influencing the stability of antibody producing cells	ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM	9-Dec-05	2-Jun-17	30-Apr-19
US10273290	Hydrocarbon double-stapled stabilized HIV-1 GP41 heptad repeat domain peptides	DANA-FARBER CANCER INSTITUTE, INC.	18-Jun-09	21-Sep-17	30-Apr-19
US10272150	Combination PIV3/hMPV RNA vaccines	ModernaTX, Inc.	22-Oct-15	20-Jul-18	30-Apr-19
US10272149	Modified bat influenza viruses and their uses	J. CRAIG VENTER INSTITUTE	5-Sep-14	4-Sep-15	30-Apr-19
US10266887	CRISPR effector system based diagnostics	MASSACHUSETTS INSTITUTE OF TECHNOLOGY	9-Dec-16	9-Mar-18	23-Apr-19
US10266886	CRISPR effector system based diagnostics	MASSACHUSETTS INSTITUTED OF TECHNOLOGY	9-Dec-16	9-Mar-18	23-Apr-19
US10266846	Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses therefor	The Trustees of the University of Pennsylvania	17-Dec-01	20-Oct-16	23-Apr-19
US10266545	Coumarin derivative as antiviral agent, pharmaceutical composition thereof, its preparation and use	I-NOVA MEDICINSKA ISTRAZIVANJA D.O.O.	2-Feb-16	2-Feb-16	23-Apr-19
US10265417	Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses therefor	The Trustees of the University of Pennsylvania	30-Sep-03	3-Aug-16	23-Apr-19
US10265407	Modular nanodevices for smart adaptable vaccines	Yale University	15-Feb-07	10-Nov-14	23-Apr-19
US10265395	Adjuvant compositions and related methods	Not Available	24-Mar-15	23-Mar-17	23-Apr-19
US10265371	Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells	CENTRO DE INVESTIGACION BIOMEDICA EN RED EN BIOINGENIERIA BIOMATERIALES Y NANOMEDICINA (CIBER BBN)	13-Jan-11	10-Jan-17	23-Apr-19
US10265291	Disulfur bridge linkers for conjugation of a cell-binding molecule	HANGZHOU DAC BIOTECH CO., LTD.	15-Jul-15	13-Feb-17	23-Apr-19
US10260071	CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity	COLEY PHARMACEUTICAL GMBH	27-Sep-06	26-May-16	16-Apr-19
US10259865	Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection	ADMA Biologics, Inc.	15-Mar-17	15-Mar-17	16-Apr-19
US10259848	Compositions and methods comprising hydrocarbon-stapled polypeptides	DANA-FARBER CANCER INSTITUTE, INC.	23-Jan-08	4-May-16	16-Apr-19

CC-BY-NC-SA Dr. David E. Martin

US10258655	Synergistic bacterial compositions and methods of production and use thereof	Seres Therapeutics, Inc.	25-Nov-13	25-Nov-14	16-Apr-19
US10254204	Membrane-assisted purification	Accelerate Diagnostics, Inc.	7-Mar-11	3-May-17	9-Apr-19
US10253353	Enhanced methods of ribonucleic acid hybridization	The Broad Institute, Inc.	6-Dec-13	5-Dec-14	9-Apr-19
US10253318	Methods and compositions for the treatment of cancer or other diseases	CITY OF HOPE	26-Jan-07	14-Jun-17	9-Apr-19
US10253296	Synthetic membrane-receiver complexes	RUBIUS THERAPEUTICS, INC.	18-Nov-13	28-Nov-17	9-Apr-19
US10253093	Human monoclonal antibodies against interleukin 8 (IL-8)	CORMORANT PHARMACEUTICALS AB	16-Dec-02	30-Apr-18	9-Apr-19
US10251904	Methods for treating arenaviridae and coronaviridae virus infections	GILEAD SCIENCES, INC.	16-Sep-15	16-Sep-16	9-Apr-19
US10247729	Media elaborated with newly synthesized antibodies (MENSA) and uses thereof	MICROBPLEX, INC.	5-May-14	5-May-15	2-Apr-19
US10246425	3,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compounds	Parion Sciences, Inc.	17-Dec-12	29-Jun-17	2-Apr-19
US10238739	Manufacture of surfactant-containing compositions with enhanced stability	NOVARTIS AG	2-Dec-14	2-Dec-15	26-Mar-19
US10238733	Cationic oil-in-water emulsions	GLAXOSMITHKLINE BIOLOGICALS S.A.	6-Jul-10	11-Mar-16	26-Mar-19
US10238666	Pharmaceutical compositions and methods	Pop Test Oncology LLC	3-Aug-15	29-Nov-17	26-Mar-19
US10238633	Methods for treating pulmonary emphysema using substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of Cathepsin C	Boehringer Ingelheim International GmbH	14-Mar-13	6-Jun-17	26-Mar-19
US10233429	Hand, foot, and mouth vaccines and methods of manufacture and use thereof	Takeda Vaccines, Inc.	7-Nov-14	27-Oct-17	19-Mar-19
US10233425	CD137 enrichment for efficient tumor infiltrating lymphocyte selection	The Trustees of the University of Pennsylvania	16-Sep-13	16-Sep-14	19-Mar-19
US10233237	Heterodimeric immunoglobulins	AMGEN INC.	21-Nov-12	21-Nov-13	19-Mar-19
US10233158	Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds	Parion Sciences, Inc.	13-Dec-13	4-Apr-18	19-Mar-19
US10232051	Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule	HANGZHOU DAC BIOTECH CO., LTD.	15-Jul-15	3-Mar-17	19-Mar-19
US10227376	Radiolabeled cationic steroid antimicrobials and diagnostic methods	BRIGHAM YOUNG UNIVERSITY	22-Aug-14	19-Aug-15	12-Mar-19
US10227373	Enantiomers of the 1â€²,6â€²-isomer of neplanocin A	Auburn University	4-Aug-14	17-May-17	12-Mar-19
US10226449	Heterocyclic modulators of lipid synthesis and combinations thereof	3-V Biosciences, Inc.	20-Dec-13	19-Dec-14	12-Mar-19
US10226434	Design, synthesis and methods of use of acyclic fleximer nucleoside analogues having anti-coronavirus activity	Katholieke Universiteit Leuven/Lieden University Medical Center, RC Leiden	30-Jan-15	2-Jul-18	12-Mar-19
US10222374	B-cell antigen presenting cell assay	Univeersity of Pittsburghâ€"Of the Commonwealth System of Higher Education	8-Apr-10	9-Aug-17	5-Mar-19
US10221446	Signal propagation biomolecules, devices and methods	STC.UNM	21-May-13	3-Oct-16	5-Mar-19
US10220002	Controlled-release peptide compositions and uses thereof	BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA	2-Dec-11	30-Nov-12	5-Mar-19
US10213383	Hydrophilic filtration during manufacture of vaccine adjuvants	NOVARTIS AG	3-Dec-09	3-Dec-10	26-Feb-19
US10209254	Chips, detection systems, and methods for multiplex pneumococcus serology	The UAB Research Foundation	9-Oct-13	9-Oct-14	19-Feb-19
US10209248	Multiplex immuno screening assay	Institut Pasteur	4-May-12	19-Jul-17	19-Feb-19
US10206994	RNA virus attenuation by alteration of mutational robustness and sequence space	INSTITUT PASTEUR	28-Jan-15	28-Jan-16	19-Feb-19

CC-BY-NC-SA Dr. David E. Martin

US10202640	Single cell analysis of T cells using high-throughput multiplex amplification and deep sequencing	The Board of Trustees of the Leland Stanford Junior University	7-May-14	30-Apr-15	12-Feb-19
US10202617	Expression cassette for efficient surface display of antigenic proteins	Temasek Life Sciences Laboratory Limited	8-Feb-11	8-Feb-12	12-Feb-19
US10202615	Mammalian genes involved in toxicity and infection	VANDERBILT UNIVERSITY	10-Dec-10	11-Dec-11	12-Feb-19
US10202578	Chicken cells for improved virus production	THE PIRBRIGHT INSTITUTE	5-Jun-13	3-Jun-14	12-Feb-19
US10202367	Heterocyclic compounds and methods of use thereof	The United States of America, as represented by the Secretary, Department of Health and Human Services	12-Jun-14	12-Jun-15	12-Feb-19
US10201198	Protective masks with coating comprising different electrospun fibers interweaved with each other, formulations forming the same, and method of producing thereof	Profit Royal Pharmaceutical Limited	23-Dec-14	10-Dec-15	12-Feb-19
US10190984	Systems and methods for analyzing a sample and for monitoring the performance of an optical signal detector	GEN-PROBE INCORPORATED	31-Dec-15	23-Dec-16	29-Jan-19
US10190137	CRISPR-related methods and compositions with governing gRNAS	Editas Medicine, Inc.	7-Nov-13	29-Nov-17	29-Jan-19
US10190132	Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutinin	MEDICAGO INC.	21-Jan-08	2-Sep-16	29-Jan-19
US10189822	Heterocyclic modulators of lipid synthesis	3-V Biosciences, Inc.	19-Mar-15	15-Mar-16	29-Jan-19
US10189820	Heterocyclic amides useful as protein modulators	GlaxoSmithKline Intellectual Property Development Limited	7-Apr-16	3-Jan-18	29-Jan-19
US10183074	Cationic oil-in-water emulsions	GLAXOSMITHKLINE BIOLOGICALS S.A.	6-Jul-11	23-Mar-17	22-Jan-19
US10179176	Recombinant adeno-associated virus capsids resistant to pre-existing human neutralizing antibodies	The Board of Trustees of the Leland Stanford Junior University	16-Feb-16	16-Feb-17	15-Jan-19
US10179143	Anti-viral azide containing compounds	Life Technologies Corporation	28-Jul-10	8-Aug-17	15-Jan-19
US10173987	Hydrazide containing nuclear transport modulators and uses thereof	Karyopharm Therapeutics Inc.	29-Jul-11	21-Jun-17	8-Jan-19
US10172830	Pyrazolone compounds having human neutrophil elastase inhibitory properties	Chiesi Farmaceutici S.p.A.	31-May-16	26-May-17	8-Jan-19
US10168336	Quinone methide analog signal amplification	Ventana Medical Systems, Inc.	24-Feb-14	24-Aug-16	1-Jan-19
US10167499	Luminophore-labeled molecules coupled with particles for microarray-based assays	CAPITALBIO TECHNOLOOGY CORPORATION	5-Dec-13	2-Dec-14	1-Jan-19
US10167333	Neutralizing human monoclonal antibodies against hepatitis B virus surface antigen	Not Available	16-Jan-14	15-Jan-15	1-Jan-19
US10166283	Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen	CureVac AG	15-Feb-12	21-Mar-17	1-Jan-19
US10166255	Intracellular genomic transplant and methods of therapy	INTIMA BIOSCIENCE, INC.	31-Jul-15	29-Jul-16	1-Jan-19
US10160796	Mast cell stabilizers for treatment of hypercytokinemia and viral infection	Emergo Therapeutics, Inc.	8-Sep-16	17-Nov-17	25-Dec-18
US10159731	Methods and compositions for inhibiting Akt3	Augusta University Research Institute, Inc.	15-Jan-16	20-Feb-18	25-Dec-18
US10159729	Antigen and method for production thereof	Sallpro Biotech AB	13-Sep-13	12-Sep-14	25-Dec-18
US10159672	Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity	PARION SCIENCES, INC.	27-Jun-11	15-Dec-17	25-Dec-18
US10156562	Assay for detecting Th1 and Th2 cell populations	AMGEN INC.	16-May-14	15-May-15	18-Dec-18
US10155980	Compositions and methods for detecting rare sequence variants	ACCURAGEN HOLDINGS LIMITED	15-Aug-16	1-Nov-17	18-Dec-18
US10155946	Particle-nucleic acid conjugates and therapeutic uses related thereto	Emory University	25-Jun-12	9-Oct-17	18-Dec-18
US10155932	Decreasing potential iatrogenic risks associated with influenza vaccines	Novartis AG	9-Sep-04	9-May-16	18-Dec-18

CC-BY-NC-SA Dr. David E. Martin

US10150768	Guanidine substituted imidazo[4,5-c] ring compounds	3M Innovative Properties Company	31-Aug-15	26-Aug-16	11-Dec-18
US10150743	Carboxylic acid compounds	Sumitomo Dainippon Pharma Co., Ltd.	18-May-12	11-May-16	11-Dec-18
US10149901	Influenza vaccines with reduced amounts of squalene	Seqirus UK Limited	10-Feb-09	27-Jan-16	11-Dec-18
US10149859	Nucleotide and nucleoside therapeutic compositions and uses related thereto	Emory University	11-Sep-13	10-Sep-14	11-Dec-18
US10149461	Immunocompromised ungulates	Revivicor, Inc.	27-Oct-08	23-Mar-15	11-Dec-18
US10144735	Immune response modifier compositions and methods	3M Innovative Properties Company	22-Dec-06	25-Jun-18	4-Dec-18
US10143709	Use of ASC and ASC-CM to treat ARDS, SARS, and MERS	Indiana University Research and Technology Corporation	6-May-14	6-May-15	4-Dec-18
US10143652	Methods for the preparation of liposomes	CuriRx Inc.	23-Sep-09	2-Aug-16	4-Dec-18
US10138461	Animal protein-free media for cultivation of cells	Baxalta Gmbh	29-Oct-04	22-Sep-17	27-Nov-18
US10138295	Compositions comprising AAV expressing dual antibody constructs and uses thereof	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	13-May-14	13-May-15	27-Nov-18
US10138276	Inhibition of TCR signaling with peptide variants	SIGNABLOK, Inc.	30-Sep-09	30-Sep-10	27-Nov-18
US10131709	Nucleic acid molecules encoding monoclonal antibodies specific for IL-22	ImmunoQure AG	28-Dec-11	7-Sep-16	20-Nov-18
US10131704	Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof	DANA-FARBER CANCER INSTITUTE, INC.	25-Apr-14	27-Apr-15	20-Nov-18
US10131682	Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules	HANGZHOU DAC BIOTECH CO., LTD.	24-Nov-12	24-Nov-12	20-Nov-18
US10130701	Coronavirus	THE PIRBRIGHT INSTITUTE	23-Jul-14	23-Jul-15	20-Nov-18
US10125112	Modulators of the relaxin receptor 1	THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES	4-May-12	25-Aug-16	13-Nov-18
US10125092	Lipids and lipid compositions for the delivery of active agents	Novartis AG	5-Sep-14	4-Sep-15	13-Nov-18
US10124065	Lipids and lipid compositions for the delivery of active agents	Novartis AG	8-Mar-13	6-Mar-14	13-Nov-18
US10124048	Adenovirus vectors	Oxford University Innovation Limited	10-Apr-07	27-Apr-15	13-Nov-18
US10123518	Genetically modified non-human animals and methods of use thereof	Institute For Research In Biomedicine (IRB)	13-Apr-15	12-Apr-16	13-Nov-18
US10119967	Multiplex immuno screening assay	Institut Pasteur	4-May-12	3-May-13	6-Nov-18
US10119164	Capture primers and capture sequence linked solid supports for molecular diagnostic tests	IBIS BIOSCIENCES, INC.	31-Jul-09	15-Aug-16	6-Nov-18
US10118925	Imidazo[4,5-c] ring compounds containing substituted guanidine groups	3M Innovative Properties Company	31-Aug-15	26-Aug-16	6-Nov-18
US10118923	Compositions and methods for inhibiting kinases	Inhibikase Therapeutics, Inc.	23-Apr-15	7-Nov-17	6-Nov-18
US10117920	Combination of vaccination and inhibition of the PD-1 pathway	CureVac AG	22-Feb-13	7-Feb-18	6-Nov-18
US10114011	Antigen presenting cell assay	University of Pittsburghâ€"Of the Commonwealth System of Higher Education	8-Apr-10	20-Jul-17	30-Oct-18
US10106619	Virus vaccination and treatment methods with OX40 agonist compositions	La Jolla Institute for Allergy and Immunology	4-Oct-06	4-Oct-07	23-Oct-18
US10106551	Monothiol mucolytic agents	PARION SCIENCES, INC.	30-Jan-15	29-Jan-16	23-Oct-18
US10105426	Immunostimulatory combinations	TRUSTEES OF DARTMOUTH COLLEGE	30-Dec-02	10-Sep-15	23-Oct-18
US10078083	Detecting targets using mass tags and mass spectrometry	Ventana Medical Systems, Inc.	2-Jul-10	28-Dec-15	18-Sep-18

CC-BY-NC-SA Dr. David E. Martin

US10077427	Means and methods for influencing the stability of cells	ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM	26-Mar-15	26-Mar-15	18-Sep-18
US10076491	Vaccine composition	NITTO DENKO CORPORATION	5-Feb-13	29-Jan-14	18-Sep-18
US10072309	Methods for real-time multiplex isothermal detection and identification of bacterial, viral, and protozoan nucleic acids	Not Available	8-May-15	6-May-16	11-Sep-18
US10072064	Composition comprised of antigen linked to a TNF superfamily ligand	Not Available	15-Mar-13	16-Mar-14	11-Sep-18
US10072058	Chimeric virus-like particles incorporating fusion GPI anchored GM-CSF and IL-4 conjugates	Children's Healthcare of Atlanta, Inc.	29-Apr-15	29-Apr-16	11-Sep-18
US10071976	Small molecule fatty acid synthase inhibitors	SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE	7-Mar-14	5-Mar-15	11-Sep-18
US10071970	Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity	Parion Sciences, Inc.	17-Dec-12	7-Mar-17	11-Sep-18
US10071155	Nasal mucosal vaccine composition	NITTO DENKO CORPORATION	3-Oct-13	2-Oct-14	11-Sep-18
US10071154	Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	4-Apr-08	6-Apr-09	11-Sep-18
US10071076	Methods of treating cancer and other disorders	Wake Forest University Health Sciences	12-Nov-10	27-Jun-16	11-Sep-18
US10066238	Methods for producing antibodies	UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.	11-Feb-13	11-Feb-14	4-Sep-18
US10066012	Human monoclonal antibodies against interleukin 8 (IL-8)	CORMORANT PHARMACEUTICALS AB	16-Dec-02	26-Apr-16	4-Sep-18
US10064934	Combination PIV3/hMPV RNA vaccines	ModernaTX, Inc.	22-Oct-15	11-Aug-17	4-Sep-18
US10064900	Methods of populating a gastrointestinal tract	Seres Therapeutics, Inc.	4-Feb-13	4-Feb-14	4-Sep-18
US10059769	Anti-PD-L1 antibodies and uses thereof	I-MAB	13-Jun-16	13-Jun-17	28-Aug-18
US10059741	Peptidomimetic macrocycles	Aileron Therapeutics, Inc.	1-Jul-15	1-Jul-16	28-Aug-18
US10059655	Lipids and lipid compositions for the delivery of active agents	Novartis AG	19-Dec-13	17-Dec-14	28-Aug-18
US10058624	Recombinant promoters and vectors for protein expression in liver and use thereof	Children's Healthcare of Atlanta, Inc.	16-Apr-15	15-Apr-16	28-Aug-18
US10058535	Nuclear transport modulators and uses thereof	Biogen MA Inc.	9-May-12	24-Jan-17	28-Aug-18
US10058516	Design, synthesis and methods of use of acyclic fleximer nucleoside analogues having anti-coronavirus activity	Katholieke Universiteit Leuven	30-Jan-15	28-Jan-16	28-Aug-18
US10055502	System and method for detecting, collecting, analyzing, and communicating event related information	Georgetown University	25-Feb-08	23-Sep-16	21-Aug-18
US10053728	High density self-contained biological analysis	BioFire Diagnostics, LLC	15-Nov-06	16-Jul-15	21-Aug-18
US10052398	Additive compositions for pigmented disinfection and methods thereof	Kinnos Inc.	8-Dec-14	23-May-15	21-Aug-18
US10052380	Lipidated immune response modifier compound compositions, formulations, and methods	3M Innovative Properties Company	17-Aug-10	27-Nov-17	21-Aug-18
US10047375	Artificial nucleic acid molecules	CureVac AG	30-Dec-14	28-Jun-16	14-Aug-18
US10047148	Neutralizing GP41 antibodies and their use	The United States of America, as represented by the Secretary, Department of Health and Human Services	7-Nov-11	8-Sep-17	14-Aug-18
US10047147	Neutralizing GP41 antibodies and their use	The United States of American, as represented by the Secretary, Department of Health and Human Services	7-Nov-11	4-Aug-14	14-Aug-18
US10046048	Homogenous suspension of immunopotentiating compounds and uses thereof	GLAXOSMITHKLINE BIOLOGICALS S.A.	15-Dec-09	5-Jul-16	14-Aug-18
US10040831	Compositions and methods for treating diseases by inhibiting exosome release	MOREHOUSE SCHOOL OF MEDICINE	19-Dec-16	19-Dec-16	7-Aug-18
US10040828	Human respiratory syncytial virus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same	THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA	10-Apr-12	10-Apr-13	7-Aug-18

US10040820	Method for the purification of protein complexes	Immunobiology Limited	19-Jun-09	21-Jun-10	7-Aug-18
US10039781	Pulse inhalation of nitric oxide for treating respiratory diseases	AIT THERAPEUTICS, INC.	24-Mar-15	24-Mar-16	7-Aug-18
US10039758	Compositions and methods for inhibiting bacterial and viral pathogens	Keck Graduate Institute of Applied Life Sciences	24-Oct-14	23-Oct-15	7-Aug-18
US10034931	Use of EGFR pathway inhibitors to increase immune responses to antigens	Emory University	23-Sep-13	23-Sep-14	31-Jul-18
US10034894	Method of treating inflammation	CYTOSORBENTS CORPORATION	1-Apr-10	28-Jun-17	31-Jul-18
US10031134	Antibody-nanoparticle conjugates and methods for making and using such conjugates	Ventana Medical Systems, Inc.	27-Apr-10	12-Sep-16	24-Jul-18
US10030250	Edible vaccines expressed in soybeans	Not Available	12-Oct-04	25-Jan-10	24-Jul-18
US10030074	Methods of inducing or enhancing an immune response in a subject having cancer by administering GITR antibodies	GITR, Inc.	25-Mar-05	7-Nov-16	24-Jul-18
US10030053	Immunogenic compositions and methods of use thereof	Emory University	17-Dec-07	13-Feb-15	24-Jul-18
US10029016	Immunostimulatory compositions and methods of use thereof	Massachusetts Insitute of Technology	5-Apr-12	2-Jul-15	24-Jul-18
US10028482	Disinfecting and deodorizing compositions and methods with novel polymeric binding system	OxiScience LLC	28-Aug-14	28-Aug-15	24-Jul-18
US10023845	Methods of making modified viral genomes	The Research Foundation for The State University of New York	30-Mar-07	7-Sep-16	17-Jul-18
US10023632	Antigenic GM-CSF peptides and antibodies to GM-CSF	Morphotek, Inc.	8-Feb-06	18-Jul-16	17-Jul-18
US10023558	Compounds	CHIESI FARMACEUTICI S.P.A.	31-May-16	22-Sep-17	17-Jul-18
US10022436	Microneedle compositions and methods of using same	VERNDARI, INC.	11-Jan-16	11-Jan-17	17-Jul-18
US10022435	Nucleic acid vaccines	ModernaTX, Inc.	23-Apr-14	1-Apr-16	17-Jul-18
US10022422	Peptidomimetic macrocycles	Alleron Therapeutics, Inc.	14-Jan-09	7-Apr-16	17-Jul-18
US10018369	Air curtain device	KAWANO GIKEN CO., LTD.	7-Aug-15	19-Nov-15	10-Jul-18
US10017784	Gene transfer into airway epithelial stem cell by using lentiviral vector pseudotyped with RNA virus or DNA virus spike protein	ID PHARMA CO., LTD.	28-Oct-05	17-Nov-14	10-Jul-18
US10016498	D-amino acid derivative-modified peptidoglycan and methods of use thereof	The Regents of the University of California	30-Nov-12	14-Sep-17	10-Jul-18
US10016497	MERS-CoV vaccine	INOVIO PHARMACEUTICALS, INC.	29-Nov-13	26-Nov-14	10-Jul-18
US10016455	Method of preventing or treating influenza with oxidative reductive potential water solution	Sonoma Pharmaceuticals, Inc.	30-Dec-03	9-May-17	10-Jul-18
US10013760	Stain-free histopathology by chemical imaging	BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS	15-Mar-13	2-Aug-17	3-Jul-18
US10010718	Device to kill micro-organisms inside the respiratory tract	Not Available	1-Apr-16	28-Mar-17	3-Jul-18
US10010607	Method for preparing viral particles with cyclic dinucleotide and use of said particles for inducing immune response	INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)	16-Sep-14	16-Sep-15	3-Jul-18
US10006862	Continuous process for performing multiple nucleic acid amplification assays	GEN-PROBE INCORPORATED	10-Mar-05	19-May-17	26-Jun-18
US10005833	Methods of treating inflammation associated airway diseases and viral infections	THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM	2-Jan-15	31-Dec-15	26-Jun-18
US10005772	Immune response modifier compositions and methods	3M Innovative Properties Company	22-Dec-06	20-Dec-07	26-Jun-18
US10004764	Red blood cell membrane-derived microparticles and their use for the treatment of lung disease	University of Pittsburghâ€"Of the Commonwealth System of Higher Education	7-Nov-13	6-Nov-14	26-Jun-18
US10004755	Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity	The University of North Carolina at Chapel Hill	11-Apr-14	30-Jan-17	26-Jun-18

USRE47838	Inhibitory peptides of viral infection	UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION	17-Jul-14	30-Jan-18	4-Feb-20
USRE47636	Substituted spirocycles	Boehringer Ingelheim International GmbH	12-Sep-14	30-Nov-17	8-Oct-19
USRE47493	Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelheim International GmbH	20-Feb-14	26-Mar-18	9-Jul-19
USRE46906	Methods for producing vaccine adjuvants	NOVARTIS AG	3-Dec-09	13-Oct-15	26-Jun-18
USRE46873	Multi-targeted RNAi therapeutics for scarless wound healing of skin	Sirnaomics, Inc.	6-Nov-07	26-May-16	29-May-18
USRE46630	Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity	Boehringer Ingelhelheim International GmbH	23-Aug-12	18-Sep-15	12-Dec-17
USRE46441	Circulation of components during homogenization of emulsions	NOVARTIS AG	3-Dec-09	13-Oct-15	20-Jun-17
USH2284	Vaccines for protecting against influenza	Novartis AG	27-Apr-09	27-Apr-10	3-Sep-13
USH2283	Vaccines for protecting against influenza	Novartis AG	27-Apr-09	27-Apr-10	3-Sep-13
EP2517720A1	Stabilized therapeutic small helical antiviral peptides	New York Blood Center, Inc.	2-Oct-07	31-Oct-12	31-Oct-12
EP2510946A1	Conjugates of synthetic tlr agonists and uses therefor	The Regents of The University of California	7-Feb-08	17-Oct-12	17-Oct-12
EP2471938A2	Recombinant polyvalent vaccine	National Institute of Biomedical Innovation	24-Nov-05	24-Nov-05	4-Jul-12
EP2471937A2	Recombinant polyvalent vaccine	National Institute of Biomedical Innovation	24-Nov-05	24-Nov-05	4-Jul-12
EP2471936A2	Recombinant polyvalent vaccine	National Institute of Biomedical Innovation	24-Nov-05	24-Nov-05	4-Jul-12
EP2471551A2	Decreasing potential iatrogenic risks associated with influenza vaccines	Novartis Vaccines and Diagnostics GmbH	9-Sep-05	4-Jul-12	4-Jul-12
EP2167534B1	BIOACTIVE PEPTIDES AND METHOD OF USING SAME	Compugen Ltd.	11-Jul-08	4-Jul-12	4-Jul-12
EP2121732B1	COILED-COIL LIPOPEPTIDE HELICAL BUNDLES AND SYNTHETIC VIRUS-LIKE PARTICLES	UniversitÃ¤t ZÃ¼rich Prorektorat Forschung	6-Dec-07	4-Jul-12	4-Jul-12

CC-BY-NC-SA Dr. David E. Martin

HB-1286-HD-1
Submitted on: 2/16/2021 5:06:42 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Sherilyn Wells	Individual	Support	No

Comments:

This is one small, extremely overdue step in responding to the actual science and data that has emerged in the last year. It's far from what the State could scientifically justify doing, given the low fatality rate (comparable to a flu season, according to multiple epidemiologists) and the designation of PCR tests as "useless" by the peer review of the Corman-Drosten test guidelines. The irony of the legal language - "...protect public health as supported by risk-based and scientific approaches to contagion mitigation.." - is not lost on those of us who do intensive research, because "scientific approach" is what has been sadly lacking for a very long time.. Please see my emails to all legislators dated 2/14/21 (HB 643 testimony) and 2/11/21 (. A pandemic and an emergency are two different things - related to all bills regarding masks, vaccines, huge list of "essential persons" to become "Stasi enforcers" of mask harm and loss of constitutional rights, etc., as regards Covid-19.) for an update on the actual science and statistics relevant to THIS moment. Mahalo.

HB-1286-HD-1
Submitted on: 2/16/2021 5:34:08 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Jeff Ugai	Individual	Oppose	No

Comments:

I write as a full-time Kauai resident in strong opposition to HB1286.

Although the pandemic presents no easy choices, the leadership of our Mayor and accommodations of Governor Ige protected our small island from the suffering and loss of life ravaging so many communities. One-size has never fit all across the neighbor islands, and particularly here, Kauai's unique circumstances must be taken into account when refining our response to COVID-19.

HB1286 threatens our progress and dismisses the significant sacrifices made to get us here. Science, local leadership, and common sense all support more aggressive testing. State law must do the same.

HB-1286-HD-1
Submitted on: 2/16/2021 6:34:50 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Thomas Stanton	Individual	Support	No

Comments:

Dear Legislators,

I strongly support Bill HB1286 HD1. The local citizens of Kauai are suffering tremendously because our economy continues to be restricted. These restrictions are placing an unfair burden on the portion of our population that own small buisinesses and support the tourist industry. This bill would allow Kauai citizens to be treated the same as the citizens of the other islands and help the local economy and thus the local population. It is essential we do all we can to help our local hardworking families that make Hawaii such a special place.

Mahalo for your consideration,

Thomas Stanton

HB-1286-HD-1
Submitted on: 2/16/2021 7:24:25 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Mayurachat Gulari	Individual	Support	No

Comments:

Dear Honorable Hawaii State Representatives,

I 100% support HB1286

I am a small business short-term Kauai vacation rental homeowner.

In 2019, I paid TAT+GET for a total of **$71,000**

In 2020, I paid TAT+GET for a total of **$20,000**

(mainly 80% comes from the early year; Jan-March 2020).

In 2021, so far it has been **$0**

I lost every booking in 2021 due to the new Kauai travel complication rule announced on Jan 5, 2021. Some groups booked our property and canceled within a few hours after reading the travel rule carefully. Most of the inquiries for 2021 are coming to Kauai for WFH. They all expect cheap accommodation deals on monthly rental. They also compete with locals' housing availability market. They do help the local economy very little; purchase groceries, get to enjoy restaurants take out. However, they are not heavily benefiting the Kauai tourism economy as much.

100% of visitors who come to resort bubbles required the pre-travel 1st Covid19 test and again post-travel 2nd Covid19 test. Kauai mayor claim 20% hotel occupancy, **100% of the Kauai visitors get the 2nd Covid19 tests which all are 100% Negative after 3-4 days quarantine.**

100% of the 2nd negative Covid19 test result shows that forcing the 2nd Covid19 test may not be unnecessary. **The pre-travel negative Covid19 test obtaining before boarding the plane is the most important and adequate.**

In addition, Kauai allows any FDA-approved **pre-travel antigen test!** As we know, the antigen Covid19 test is far less accurate compare to the PCR test. This shows the more complicated travel rule, the double testing, a more expensive method is effectively reducing the number of visitors. **The doubles testing and 3-4nights stay quarantine**

in the resort bubbles do not prove to provide a safer method compare to The Safe Travels Hawaii Program

Please allow the uniform travel rule across Hawaii state.

Best regards,

Mayurchat Gulari, PhD

HB-1286-HD-1
Submitted on: 2/16/2021 7:53:05 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Diane Koerner	Individual	Oppose	No

Comments:

Dear Representatives:

I moved to Kauai in 1993 and while I love this beautiful island and do not wish to live elsewhere, I have also been handicapped in having to seek specialized medical care on Oahu and even California, due to a host of illnesses over the years. We have few ICU beds on this island, and fewer doctors than needed for even a healthy population of locals. We are different than Oahu, and cannot handle the amount of tourism and the effects of Coronavirus spread that Oahu and other larger islands can.

I agree with Gary Hooser on these points:

The policy now being proposed in HB1286 is woefully inadequate if the goal is to minimize the spread of travel-related coronavirus infections in Hawai‘i. The medical community is unanimous in agreement that a single test 72 hours prior to arrival is insufficient protection if the goal is to keep COVID infection and death rates as low as possible.

A second test is especially important when taking into consideration the rise of new and more dangerous strains such as the “Kent coronavirus variant” that U.K. experts have said may be up to 70% more infectious and about 30% more lethal than other variants.

The third policy element, that of “preempting” the right of a county to have stricter health protections, is on its own sufficient reason to oppose HB1286. This is yet another example of the majority of the Legislature who live in Honolulu thinking that what’s best for Honolulu is best for everyone else, regardless of where they might live.

State laws should be a “floor, not a ceiling.” If any county wants to pass stronger laws, rules or regulations that reflect its particular circumstances, it should be allowed to do so. If the residents don’t agree, they can direct their voices to the County Council and mayor, and/or they can elect new county leaders. If visitors don’t like it and/or they are “confused,” then perhaps they would be better served by spending their vacation days in Honolulu. Or, better yet, perhaps non-essential travelers should abide by the CDC travel guidelines which are: “The CDC recommends that you do not travel at this time.”

Thank you for opposing this bill and protecting the people on Kauai.

Mahalo,
Diane Koerner

Kapaa, HI

HB-1286-HD-1
Submitted on: 2/16/2021 8:10:46 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Yulia Muzychenko	Individual	Support	No

Comments:

Kauai needs to reopen for the sake of financial recovery. Please support this bill

HB-1286-HD-1
Submitted on: 2/16/2021 8:22:17 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Tom Fuller	Individual	Support	No

Comments:

We own property as a vacation rental in Poipu, Kauai.

It is simply not fair that Kauai's mayor gets to set the law for Kauai and visitors. It is part of the state of Hawaii and the lack of consistent policies make it very hard on visitors and property owners.

We as owners are continuing to lose many many thousands of dollars because Kauai will not be a part of the Safe Travels Program. Hawaii had 35 cases Monday. 35! And the vast majority of cases are given from one resident to another, NOT from visitors.

Just today I got yet another cancelation. The message I received is typical of why this current situation is not working:

"Good afternoon, Hope you are doing well. Unfortunately, we decided to cancel our May trip. It looks like you will still have to quarantine once you arrive in Kauai. It doesn't look like the guidelines will change prior to our trip. I did see there are bubble resorts, but it would not be worth the added cost for the trip. We are disappointed, but we are looking to reschedule for September or October. If we do, we will definitely reach out to you. Thanks for everything, and take care."

Please reassert state legislative authority over tourism. Making laws is YOUR job, not the executive's.

- Very little spread of COVID-19 from tourists
- Safe Travels Programs is working - Kauai should be a part of it
- Current Kauai program DOES NOT WORK for business or tourists
- If you don't act now, half off all Kauai businesses will close PERMANENTLY
- The economic damage has begun - there are a record number of properties for sale
- There is no factual basis for Kauai opting out (low case count, has access to more hospital beds than being reported, low liklihood of transmission from travelors in Safe Travel Program)
- Inconsistent polcies hurting business and industry unfairly on Kauai
- Legislature, not executive should make laws

Thank you!

Tom and Margaret Fuller

HB-1286-HD-1
Submitted on: 2/16/2021 8:35:46 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Robert Morrice	Individual	Support	No

Comments:

It is critical that we have a consistent and clear statewide approach to the Safe Travels Program. Having each county making their own travel rules creates confusion and frustration to those traveling to the state or worse, they just don't come at all. As a business, it is very difficult to operate when the travel rules/requirements are different from one island to the next and can be changed with little to no notice.

The safety of those living in Hawaii should always be the first priority but believe it must be balanced with the needs of the residents who need to work so they don’t lose their health care coverage, access to basic services, ability to pay their bills, etc.

This Act would provide the balance needed to provide a consistent statewide approach to the Safe Travels program while ensuring the department of health to take the necessary actions to protect the public health supported by risk-based and scientific approaches to contagion mitigation.

HB-1286-HD-1
Submitted on: 2/16/2021 8:50:11 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Sean Knox	Individual	Support	No

Comments:

Aloha, I am a local, small business owner that had over 30 employees supporting various vendors at the Kauai airport. Due to the Kauais' decision to not participate with the state's safe travels program, visitor arrivals are worse than they should be. This has resulted in our 30+ employee still waiting to go back to work.

Visitors to Hawaii rarely cause the spread of the virus and the state needs to support an organized effort to bring tourism back.

Thank you,

Sean Kamahele Knox, President & CFO

HB-1286-HD-1
Submitted on: 2/16/2021 8:55:48 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Luane McGowan	Individual	Oppose	No

Comments:

Bill HB1286 is misguided and can only hurt islands such as Kauai who have, through prudent science-based management, become one of the safest places to be during the COVID-19 pandemic. Unessential travel is against all major medical institutions guidelines and should NOT be encouraged at this time. We are nearing a balance through vaccinations that will allow safe travel and economies to recover. Travelers do not seem to be “confused” as they are still arriving and accommodations on Kauai are occupied at approximately the same rate as other island open under the “Safe Travels”. This bill, HB1286, is a bad precedent that sacrifices the wellbeing of residents and carefully considered plans by taking away control based on our local needs, seemingly in favor of filling coffers on Oahu.

HB-1286-HD-1
Submitted on: 2/16/2021 9:21:43 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Jeannette Balko	Individual	Support	No

Comments:

Good day Legislators,

Please consider this testimony in SUPPORT of HB1286 scheduled to be heard by the House Committee on Judiciary and Hawaiian Affairs.

This Bill will allow Kaua'i to be reopened to tourists and inter island travelers if they test negative for Covid-19 just like all the other islands. Of course we don't want ANY testing or medical tyranny but we have to support this bill because the people's livelihoods are at stake if we do not get our economy going again.

Thank you for hearing my testimony and I am optimistic that as legislators elected by the people for the people you will consider my testimony.

Jeannette Balko

HB-1286-HD-1
Submitted on: 2/16/2021 9:24:44 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
catherine van de veer	Individual	Oppose	No

Comments:

I strongly oppose this bill on the grounds that it would endanger the health of the people of Kaua'i by forcing our County to follow less stringent guidelines for travellers, both residents and tourists. If a uniform Statewide policy is desired for the convenience of visitors, logic would demand that Kaua'i County's rules be implemented Statewide... assuming that the State's first responsibility is the health of all.

HB-1286-HD-1
Submitted on: 2/16/2021 9:30:56 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Thayne Taylor	Individual	Oppose	No

Comments:

Aloha,

Our Mayor, Derek Kawakami, has done a superb job in handleing the pandemic from the begining and shows with the lowest reported cases in the state. I do not see the value of changing a system that has worked exceptionally well for us all here on Kauai. Yes, all of our businesses, of which I own one, have been impacted, and we are all suffering economically, but what is the alternative? I'd much rather deal with having a little less money than having lingering effects of catching Covid, as I am sure most of the people on Kauai feel the same. Until we get to 60-65% "herd immunity", which is going to happen soon with the vaccine rollout, I oppose this bill that would force Kauai to open up based on what the state wants us to do.

Thank you for your time,

Thayne Taylor

HB-1286-HD-1
Submitted on: 2/16/2021 9:39:26 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Maria Walker	Individual	Oppose	No

Comments:

Aloha,

I am writing to express my and my family's strong opposition to HB1286. I believe all residents of our state can agree that each island is very different from the others, with distinct and particular needs and infrastructure. It is critically important, even as we work together as a state, to recognize when the needs of each island differ from the others, and to respect and support this. I am a resident of Kaua'i, and can attest to the enormous impact of Covid 19; we also have managed to keep the numbers of cases at a level that our tiny medical ICU system can handle when we have been allowed to decide what is best for our county. When Kaua'i was required to follow the rules imposed by the state government, we immediately experienced a proportionally strong spike in cases with arriving visitors that then spread to our community. I would have thought that the number of fatalities from Covid on Kaua'i would speak to the efficacy of establishing our additional testing requirements.

To demand a 'one size fits all' approach to required testing and quarantine for the pandemic is both potentially dangerous as well as disrespectful. Neighbor islands may have less population than O'ahu, but all the islands together contribute to the state in different ways, and their residents are all still constituents who need representation and protection from their elected officials. The county government of each island is acutely aware of the unique needs ot their particular county, something the state government may not be as well equipped to understand on a deep level. All the islands are suffering grave economic impacts, but this is not something we have a choice in; the pandemic is having its effect and we have to adapt and adjust as best we can.

I have spoken to many visitors since our state's reopening, and NONE of them felt that the reqiuirements to come to Kaua'i were confusing or unreasonable. Our tourism figures are not apprecaibly lower than any of the other islands, and I believe all the islands would benefit from additinal testing after arrival, but I understand that each island needs to decide this for themselves.

Please oppose this bill, which is unreasonably supposes that each island having their own policy with regard to testing and quarantine is somehow suppressing our tourism numbers. This is quite simply an extraordiary time in history, and it is also a questionable time to be traveling at all, which means that many people from all over the

world are traveling much less, and prudently choosing to wait until the virus is more under control and vaccination is more widespread. That is what is causing lower tourism numbers for all our islands across the state.

Thank you for hearing my testimony,

Maria Walker

1728 Hulu Rd.

Kapa'a, Hi 96746

HB-1286-HD-1
Submitted on: 2/16/2021 9:44:59 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Roxana Rosala	Individual	Oppose	No

Comments:

I oppose HB1286 because I don't think that the entire state can be covered by umbrella decisions. Every island and county has their own, different needs and will suffer shortcomings if decisions are made based on the situation on O'ahu, just because it is the most populated island. It would be more beneficial to local communities if the mayors and local politicians of each island are allowed to make their own, informed decisions based on their specific needs and situations. Thank you for your consideration.

HB-1286-HD-1
Submitted on: 2/16/2021 9:46:17 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Gini Kapali	Individual	Oppose	No

Comments:

I oppose HB 1286 as it currently stands. Please amend bill to allow each County entity to impose additional restrictions as deemed necessary to prevent the spread of COVID-19 and its associated variants.

Science has proven that additonal testing ensures the safety of our community.

We are all powering through to get back to some "normalcy"- please allow us to continue to do what we do best- taking care of our local community with the end goal of a thriving economy again. It is only a matter of time and with your humble support- we will get through this.

Respecfully submitted:

Gini Kapali

HB-1286-HD-1
Submitted on: 2/16/2021 9:49:48 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Lindsey Fritz	Individual	Oppose	No

Comments:

Aloha,

My husband and I are both born and raised on Kaua'i and are now in our 40s. We have seen the changes over the years and are all so happy with how well our Mayor has handled this challenge and been able to keep us somewhat covid-free.

Kaua'i is a special place and has always been different from the rest of the state. We are not all the same and therefore don't all fit under the same rules.

The covid vaccine only protects the person who has been vaccinated. I feel like allowing vaccinated people to come here is more dangerous because they could be carrying the virus and not even know it. All it takes is for a few people to come and introduce the virus to our community and we could easily have a situation like what happened on Lana'i and infect a large amount of our population.

We are protected now and people are feeling safe and able to enjoy their lives. We all wear masks and we're being safe because you never know. If tourist bring devastation to this island there will be strong animosity towards them going forward and you'll have a much harder time opening up in the future.

I understand tourism is an important part of our economy however if you just open up our island to tourism it doesn't mean that all the tourist related businesses will thrive. Meanwhile you'll be putting an entire island population at risk. Maybe it is time for us to think about diversifying our economy and focusing on helping these tourist related businesses find a new future. Helping all the employees who work in tourism find other options. A lot of people I know here continue to thrive in this covid world - not everyone is in the tourist industry.

It is important to think about what the people of Kaua'i want and protecting the health of people on Kaua'i. We all live here because we love it here! We love being remote and we love our small communities. The choice should be made by the people of Kaua'i and our leader/mayor. No one else should be making decisions for us.

Thank you for keeping Kaua'i safe and continuing to let us govern ourselves and do what we feel is best for our communities.

Mahalo, Lindsey & Michael Fritz (and 'ohana)

HB-1286-HD-1
Submitted on: 2/16/2021 9:57:10 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Nedi McKnight	Individual	Oppose	No

Comments:

STRONGLY OPPOSE: I am writing in with strong opposition to HB 1286.

Forcing the outer islands to relax their public health policy prior to allowing their residents the option of vaccination is outrageous. There are multiple vaccines available and the scientific data regarding the effective immunity versus sterilizing immunity is not known yet. In other words, we do not know if the person who is vaccinated can still transmit Covid19. Hawai‘i has not reached anything close to ‘herd immunity‘.

Safe Travels Program is inherently unsafe. There are a significant percentage of false negatives, based on day of infection and/or viral load. Visitors may well have a negative test within 72 hours of departure and still be able to transmit Covid19. New variants are rapidly spreading and are absolutely documented as being more contagious. In flight transmission of Covid19 has been documented. Transmission while wearing a mask has been documented. Transmission from touching contaminated objects has been documented. Covid19 spreads exponentially. All it takes is 1 or 2 transmissions into our communities to spread wildly in our multigenerational households. Most likely, our relative success in suppressing Covid19 infections compared to US continental states has more to do with outdoor activities, the ability to keep doors and windows open and our residents williness to wear masks- and less to do with the Safe Travels program.

The majority of our residents are not vaccinated yet. Many of us are still desperately waiting our turn for a vaccination. Workers on the front line of Covid19- for example, a restaurant server at a hotel, are not vaccinated yet, nor are they provided with employer issued N95 masks and goggles.

Covid19 is still evolving, with new and poorly understood variants emerging. Yet here is an incredibly flawed and socially unjust bill with a proposed end date 29 years in the future. By the way, HB1286 isn‘t just sociopathic policy, it has an error in it regarding the dates. You might want to proofread a bill as significant and consequential as this one.

Hawai‘i is surrounded by the Pacific Ocean, with one way in to our islands. Through the government checkpoint at the Airports. To many residents, it appears as if the State of Hawai‘i purposely fails to provide adequate testing and tracing to suppress community spread and clusters- in order to allow the tourist industry to continue to seed our communities with Covid19. Otherwise, the numbers would be low enough for adequate

genome sequencing to tell us the source of the infections. Covid19 was not and does not have to be endemic to this remote island chain.

The State of Hawai‘i received 1.25 billion dollars of CARES ACT money. The State of Hawai‘i had ample time and money to create visionary programs to help begin the painful but obviously necessary process of diversifying away from economic reliance on tourism. We, the residents, when confronted with policies and bills such as HB1286, are left feeling as if we have experienced nothing short of gross negligence. We have experienced risk, injury, illness and financial harm due to bungled policies, mismanaged public health policies and foolish waste (if not misappropriation) of Cares Act money. We remain isolated from ‘ohana and shut away in our homes while tourist enjoy (often unmasked) their deeply discounted vacations.

Residents pay taxes. We are your constiuents. We represent 70% of the non-tourism based economy. You force us to stay home in order to avoid coming into contact with tourists, because those tourists may unknowingly carry Covid19. As a result, we shop online instead of supporting our local stores. You force us to stay away from our favorite restaurants. In the end, HB1286 will force us to remove our aloha towards visitors.

There will not be a welcome feeling towards visitors if HB1286 takes away our ability to provide some protection to ourselves and our families. The only places tourists may feel a sense of welcome is where they spend money. If you think that tourists won‘t notice, you are underestimating them. Tourists will be very aware that hundreds of thousands of Hawaii residents do not want them here, resent their presence, and that the tourists been forced on us. Tourists are sensitive and sophisticated enough to feel when they are cultivated only for money and not for relationship.

According to HB1286, 20% of the economy depends on tourism. This bill forces 100% of the residents to absorb the risk. Many residents of Hawai‘i have spent years presenting, supporting and testifying on the need for diversifying away from tourism. We have begged for programs to create jobs and revenue through sustainable agriculture, increased revenue from land leases other visionary programs.

Healthcare, doctors, ICU beds, and residents‘ financial status are not consistent throughout the island. Therefore, we should not have a consistent policy. A minor inconvenience to a visitor can result in saving a resident‘s health and/or life. Are we to believe you would rather risk our health and lives, than risk causing a tourist a minor inconvenience while they island hop?

We are all very aware of the absolute repercussions of employer based healthcare. Hawai‘i is positioned to offer a public healthcare system similar to Medicare for All. This bill HB1286 threatens economic repercussions, stating, “When residents lose their jobs, they also lose their health care coverage”. This is a policy problem, not a public health problem. There is a very easy fix and that is to offer a Medicare for All type program in Hawai‘i. Besides, we all know that many residents of Hawai‘i work 2 or 3 part-time jobs

with low hours. Employers, including employers in the visitor industry, purposely keep workers‘ hours at 19 so as to avoid having to provide health insurance.

In closing, all of us realize US Covid19 policies have forced us all into accepting some element of risk. We are not asking Hawai‘i be shut off from the rest of the world. We are just asking for science based public health policies. Please allow outer islands to keep our very reasonable Covid19 policies in place.

Nedi McKnight

HB-1286-HD-1
Submitted on: 2/16/2021 9:59:02 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
DAVID F MOORE	Individual	Oppose	No

Comments:

Kaua`i needs to have the option to modify its participation in the "Safe Travel" program, based on its special needs as an island. We no NOT want to be forced to accept visitors with only one negative covid test, especially with the new variants that are arising. We have carefully protected our island population from covid. If you force us to be more "open", it will increase our virus burden. With vaccinations increasing, let us wait a bit longer before exposing us to more virus.

Sincerely,

David Moore, M.D.

HB-1286-HD-1
Submitted on: 2/16/2021 10:05:05 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
THOMAS P CULLEN	Individual	Oppose	No

Comments:

I highly disagree with this bill. The mayor's and the island residents should have the final say on what is acceptable concerning travel restrictions to the outer islands. I would support a two test protocol (one test prior, one test after three days quarantined on Kauai), until the numbers of Covid-19 cases on the mainland have substantially been reduced. Also if a visitor or resident has recieved a vaccination (both) prior to returning to Kauai, they should be able to aviod quarantining. We need to keep the residents of the outer island safe and the medical facilities un-overwhiled with sick locals and mainland visitor with Covid -19!

HB-1286-HD-1
Submitted on: 2/16/2021 10:10:03 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Carey Connell Sutton	Individual	Oppose	No

Comments:

This bill is very unpopular on the island of Kaua'i for any number of reasons. First of all, the timing. Why change things right now when new and more easily transmissible versions of the virus are starting to circulate widely on the mainland? Why not wait to make changes at least until the vulnerable population here an be vaccinated which sounds like it might be by the end of March?

Secondly, it's absurd to blame Kaua'i's more stringent covid rules for 'tourist confusion'. Blame confusion on the fact that Hawaii is in the unique position of being able to control outside entry to the state. Mainland visitors are not accustomed to that. And they certainly aren't accustomed to having to hunt around for covid tests, take them at the right time, etc etc. Blaming Kaua'i differing entry requirements as the reason for tourist confusion is frankly absurd.

As you know, Kaua'i opened up to the Safe Travels program for 6 weeks starting in October. Number of cases grew alarmingly and expondentially by the end of that period. If our wonderful mayor and his chief health officer hadn't opted out of the program, we were on a fast track to having our hospitals overwhelmed with cases.

And when the hospitals become overwhelmed, health care workers become overwhelmed. Meaning they won't be able to get shots in arms as quickly as they've currently been able to do.

I understand the tourist industry is hurting and a lot of people are out of work. My husband and I have donated $50,000 to local food banks here on Kaua'i to do our part to help out during this time of crisis.

I understand compromises need to be made and SHOULD be made AT SOME POINT. Just not right now.

Leave our county in peace to continue the good job that's now being done to keep covid under control here. Once 1c's have all gotten at least 1 shot,, THEN go ahead and put us back on the Safe Travels roster. To do it before then? I'm not seeing the logic.

My husband and I will be voting next election based on who supports this bill I can assure you.. And we will be donating to political campaigns based on what we see happen with this legislation..

HB-1286-HD-1
Submitted on: 2/16/2021 10:15:46 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
sandie moss	Individual	Oppose	No

Comments:

This bill forces Kauai to follow the unSafe Travels program that has already been found to cause significant problems for the islands.

Please do not approve HB 1286, a bill that seeks to impose a single set of travel rules on a county that has successfully kept its Covid rates low, and has the data to show that our brief participation in the Safe Travels pre-test out of quarantine program greatly increased our case rate.

Our Mayor has followed the rules and asked permission from the Governor for separated protocols.

Why should the Legislature insert itself into the process?

I believe the CDC is recommending a post test on day 3 to 5 after arrival.This has helped our island. I personally would like it to be 7 days.

If folks are confused about travel this is expected.This is not a normal time. Visitors know they are traveling during a global pandemic and should be flexible. Also, they should not feel entitled to put others at risk.

Our Mayor is doing a good job at keeping his community safe. He understands what Kauai has to offer for health services, which is limited.

Again, this should not be a Legislative process.

Please do not let this bill out of committee.

Sandie Moss

HB-1286-HD-1
Submitted on: 2/16/2021 10:19:50 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Mark Wigent	Individual	Oppose	No

Comments:

I am both shocked and outraged that the Hawaii State Legislature is following in the footsteps of various governors in mainland states to prevent local jurisdictions from implementing sound, science-based measures to protect public health.

The fact of the matter is that the State's Safe Travels program is not founded on sound medical and scientific principles. To this point, the CDC has updated travel guidance which directly contracts Hawaii's "Safe" Travels program. Details of the science supporting this updated CDC policy posted a pre-print version of a research paper on the topic of "Reducing travel-related SARS-CoV-2 transmission with layered mitigation measures: Symptom monitoring, quarantine, and testing" on November 23, 2020. One of the conclusions of this paper was that the pre-testing methodology employed by the Safe Travels program is largely ineffective at reducing COVID transmission risk. The contents of this paper entitled were covered in mainstream national news media at the time.

The CDC paper is available here:

https://www.medrxiv.org/content/10.1101/2020.11.23.20237412v1

Using current understanding of COVID epidemiology and mathematical modeling, the CDC research team concluded that testing 3 days prior to travel resulted reduced COVID transmission risk by only 5%-9%. If that article written by a team of 8 researchers from the CDC is not convincing enough, then compare the empirical evidence of the COVID trajectories of both Maui and Kauai to serve to validate the underlying science and mathematics in the CDC research paper.

That leadership in Hawaii's House of Representatives has introduced a bill specifically to wrest power from the County of Kauai, which has been making public health decisions which are both science-based and appropriate for Kauai's medical infrastructure, is outrageous. That the motivation for doing so is political and financial is completely unconscionable. That HR Bill 1286 is even being discussed is a sad day for Hawaii and its people.

Decisions about public health should be left in the hands of local public health authorities, not state politicians. And the decisions made by those authorities should be based on medicine and science, not wishful thinking and fantasy.

HB-1286-HD-1
Submitted on: 2/16/2021 10:51:41 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Bev Brody	Individual	Oppose	No

Comments:

My name is Bev Brody and I would like to voice my strong opposition to HB1286.

Kaua‘i was in the Safe Travels program for about seven weeks. During that time, the number of COVID-19 cases doubled the number of Kauai cases for the previous seven months!

Most all of the new cases were travel-related. Kaua‘i opted out of the Safe Travels program and numbers quickly returned to less than one new case per day.

Maui remained in the program, and went from having about 1% of the cases in the state to having about 18% of the state’s total number. They began to see 15 to 30 new cases per day, and the Big Island was not far behind.

Please consider opposing this bill and allowing the mayors to decide what is best for their counties.

Mahalo.

HB-1286-HD-1
Submitted on: 2/16/2021 10:55:51 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Michael Fritz	Individual	Oppose	No

Comments:

Aloha, I am born and raised here on Kaua'i and love our home! I strongly feel that we are a unique and special island needing our own, unique set of laws/rules that work best for us. No one that lives off of Kaua'i should have any say in how we govern ourselves or what is best for us. Only the people of Kaua'i, including our Mayor, know what is best for us and we should have the ability to govern ourselves. I strongly oppose this bill and feel like we need to keep the strict travel measures currently in place for now. Mahalo!

HB-1286-HD-1
Submitted on: 2/16/2021 11:06:28 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Joe Clarkson	Individual	Oppose	No

Comments:

I oppose the intent of HB1286. If an individual county wants to "go for zero", they should be allowed to use whatever methods they prefer to prevent Covid-19 cases from entering that county. The drawbacks to going for zero are the loss of tourism income from people who do not wish to quarantine, but the benefits are enormous. If a county is able to reduce their caseload to zero, all life within the county returns to normal, including schools, sporting events and family gatherings.

The state of Hawaii was remiss in not following the example of New Zealand and going for eradication of the virus in the spring of last year. How different our life would be if there had been no Covid cases in Hawaii for much of the last year!

PS What is with the effective date being July 1, 2050? Is this some arcane bit of legislative craftsmanship?

HB-1286-HD-1
Submitted on: 2/16/2021 11:15:59 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Judith Page	Individual	Comments	No

Comments:

I have serious reservations about this bill for many reasons which have nothing to do with COVID 19.

This is a power grab, pure and simple. It takes away the local power of mayors and moves it to the legislature.

The legislature is a body that by its very nature is deliberative and unable to act quickly. Mayors can act quickly. Who should we want in charge in an emergency, something that works like a committee and needs to reach consensus?

Why is the legislature grabbing power from the governor? It's the same argument: governors can act quickly in an emergency, the legislature cannot.

This completely changes the balance of power between the neighbor islands and Oahu, and it's already out of balance. Yes, we know where most of the population is, but does that mean that all decisions get made in Oahu with an Oahu viewpoint?

How condescending, how paternalistic, how unfair to the rest of us who live on the neighbor islands. And who gets to decide if this power grab is a good idea? Only the majority, but wait, aren't most of them on Oahu, too?

HB-1286-HD-1
Submitted on: 2/16/2021 11:20:35 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Madelynn Forgey	Individual	Oppose	No

Comments:

I strongly oppose HB1286. Kaua`i is a unique island and during this pandemic has seen strong leadership from our Mayor. It would not be in Kaua`i's best interests to have our islands protocols for Covid doctrined by the Governor or Oahu,

HB-1286-HD-1
Submitted on: 2/16/2021 11:28:43 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
trish	Individual	Oppose	No

Comments:

Please do not pass this bill. As a resident of Kauai, I feel that Derek has done a wonderful job of keeping us safe. We are only months away from the vaccine being rolled out to majority of our high risk residents. We should not change things now with the light at the end of the tunnel. Look at the numbers, Kauai's hotel occupancy is within a few percent of the other islands while keeping our covid numbers low. We have started to open up sports and other activities for the Keiki. By passing this bill and opening things up without a post test Kauai will get higher number of cases as was shown in the fall. Then we will be forced to shut these things down again. You are putting lives at stake for a 1% increase in tourists. That is a lot to risk for such little gain. Thank you for your time and consideration to not pass this bill and allow the counties to do what is best for their county regarding covid restrictions.

HB-1286-HD-1
Submitted on: 2/16/2021 11:34:50 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Jason Carnegie	Individual	Oppose	No

Comments:

The proposed HB1286 measure for aligning travel-related requirements across Hawaiian counties appears a reasonable approach, but only on the surface. Beneath that surface analysis however, the measure significantly fails to carefully consider the unique differences between counties, and specifically disregards the value of the collective will of the people of Kauai county to remain as safe as possible as demonstrated by over 10 months of their extreme vigilance.

The residents of Kauai have implemented and practiced significant measures to combat the spread of the novel coronavirus from the beginning stages of the pandemic, with conscious consideration and recognition of the extreme economic, personal, and social sacrifices which have been necessary to do so.

As a result of this deliberate and extraordinary degree of behavior change, Kauai residents deserve that their sacrifices be respected and indeed honored by state and federal authorities. The county should be allowed to persevere in ways that seek to keep us as safe as possible in the face of the prevailing pandemic.

We are infinitely closer to the waning days of the pandemic due to the rollout of the vaccination initiative on island. By allowing our local county travel restrictions to remain distinctively different from statewide regulations, 10 months-worth of arduous sacrifice will not be for naught. To act otherwise and to mandate alignment with more relaxed regulations would not be reasonable, and certainly would not align with the values of Aloha.

We remain one of, if not the leading county in the entire nation with respect to low numbers of COVID-19 cases, hospitalizations and deaths. This is an immense source of county pride and confidence, and serves as evidence that local safety is within our collective control.

These exemplary statistics are a beacon that should be allowed to continue to shine to the nation and the World as a demonstration of what is possible. As an example of the degree to which we can succeed together, rather than fail due to bureaucratic ease.

The United States has a global responsibility to lead by example. Let us not relinquish one of the very few opportunities remaining to do so on the pandemic. Let us rather embrace, celebrate and indeed support this success through allowing local travel restrictions to remain in effect until it is relatively more safe to do otherwise.

Let us also recognize that through the expansion and acceleration of the vaccination effort here on Kauai, relatively few additional resources would be required. The result would support more rapid realization of herd immunity on the island and promote a safe return of normalcy and prosperity to Kauai.

With the mutual respect of all our counties in mind, the Spirit of Aloha, and recognition of the people of Kauai as determined leaders in the battle to remain safe from COVID-19, I most strongly oppose measure HB1286 and encourage our local and state officials to do the same without hesitation or reservation.

HB-1286-HD-1
Submitted on: 2/16/2021 11:48:04 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Richard Parmentier	Individual	Oppose	No

Comments:

Dear Representatives,

I strongly oppose HB1286. Non-essential travel is ill-advised during the current COVID pandemic. Kauai lacks the resources to handle a surge in cases.

Regards,

Richard Parmentier

HB-1286-HD-1
Submitted on: 2/16/2021 11:53:28 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Aaron Placourakis	Individual	Support	No

Comments:

Aloha Chair Nakashima and Committee-

Thank you for your commitments to all of our respective communities and mahalo for the opportunity to submit testimony. I strongly support HB 1286.

I own and operate 4 restaurants on Maui and currently have close to 200 employees. I have operated restaurants in our state since 1985.

We have focused on all of the guidlines from the beginning and remain diligent in keeping things safe for our employees and guests alike. This hasn't been easy, however it apears things are improving because of all of us working together.

We are ready, willing and able to accomodate more visitors from our neighbor islands and the mainland. Please support this bill!

Mahalo.....Aaron Placourakis

HB-1286-HD-1
Submitted on: 2/16/2021 12:07:59 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Ted Steinberg	Individual	Oppose	No

Comments:

Please reject HB1286.

HB-1286-HD-1
Submitted on: 2/16/2021 12:10:10 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Ana Kahoopii	Individual	Oppose	No

Comments:

I strongly oppose HB1286 HD1

The Safe Travel program is not safe. It is not right to force a less safe plan onto counties and then blame the local community for covid spread. You have no right to gamble with our lives. It is very Oahu-centric, catering to the political donor class and very oppressive towards "neighbor" islands. This plan does not have aloha. From the beginning of this global pandemic it has been made painfully obvious the local community was expendable. Opening our Islands to tourism in October 2020 was an outrageous risk when the continental US and European countries were overwhelmed with COVID infections and closing their borders. That unethical action literally invited the variant to our shores demonstrating to us taxpaying citizens that state and county officials feel they have the right to risk our lives.

What is occurring on the ground is a different world in comparison to what is being fed to the media. Over 40% of tourists don't bother to get tested, are (wink, wink,) "promising to quarantine." An overwhelming amount of tourist refuses to mask, or observe social distancing protocols. We are spending $100,000 a day on testing tourists while our own citizens lack the same access. Millions of dollars have been spent building enclosures at the airport that sits empty, temperature screening systems that the state knew from the beginning would be an inadequate way to screen for covid and now you are introducing another literally ass-backward protocol that will increase the risk at a time when we need to tighten screening to protect our citizens from the next wave of multiple variants.

One plan that is widely supported as a better protocol by many renowned experts in Hawaii is the "Safer Travel" plan. It can be found here: https://halehawaii.cc/safertravels.

In closing, do what is pono adopt the "Safer Travel" plan.

HB-1286-HD-1
Submitted on: 2/16/2021 12:12:18 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Kris Warren	Individual	Support	No

Comments:

I would like to voice my strong support of House Bill 1286. It is time for us to stand together, as a State, to communicate consistency rather than confusion, and welcome tourism back in a healthy and effective way.

HB-1286-HD-1
Submitted on: 2/16/2021 12:12:27 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Taryn Rodighiero	Individual	Support	No

Comments:

We need to be on the same travel plan as the rest of the state because our Mayor is not providing any metric or plan for re-opening the island. We've poured our lives into our businesses are holding on as long as we can to stay open, but with no metric or plan, we are unable to gauge how long to hold on, or if we should shut our doors and save what we can.

If this bill passes, it will help small business owners make an informed decision about their future. Without it, we are left to shoot in the dark. It's not sustainable, and it's not fair. We need to know definitively how to move forward. We cannot wait any longer. Please put us on the same program as the rest of the state.

HB-1286-HD-1
Submitted on: 2/16/2021 12:13:56 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Steve O'Neal	Individual	Oppose	No

Comments:

Dear Honorable Leaders,

Thank you for your service.

If you allow this bill to move forward you will force all islands to directly contradict the new, as of Feb 2nd, explicit CDC travel guidelines - which were issued after this bill was conceived.

I suspect largely because of the new variants that have entered the United States, and now Hawaii, the CDC explicitly recommends against all non-essential travel at this time.

But if travel is done, the CDC now explicitly recommends that a traveler quarantines for several days and then get a second test to exit.

Moving this bill forward will force all islands to go against these newly clarified guidelines. Is this your intention?

(https://www.cdc.gov/coronavirus/2019-ncov/travelers/travel-during-covid19.html)

Secondly, the emergence of several virus variants in recent weeks is so concerning that the following has happened in the last week.

Britain, in spite of 20% of their population already having gotten their first vaccine shot, just limited travel from 33 countries, now requiring all travelers from those countries to quarantine for 10 days in a government sanctioned hotel. Not just to quarantine, but to quarantine in designated monitored hotels, at the travelers expense. And there is no option of testing out early with a 2nd test. Scotland is now requiring mandatory hotel quarantine for travelers coming from outside of the UK or Ireland.

And lastly, South Africa just shocked the world last week when they halted their vaccination rollout over concerns that it is less effective against their variant.

Hawaii's vaccination program needs to outrun the arrival of variants that can only get here by slipping through our Safe Travels program, as we now know the UK variant has now done.

Don't jump the gun with this odd bill that, if anything, seems retaliatory toward one small island and in service of tourism's interests, not our citizen's health interests. Given the limited vaccine supply, give our vaccination program time to get the head start it needs to succeed.

Mahalo

HB-1286-HD-1
Submitted on: 2/16/2021 12:15:08 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Alton Couturier	Individual	Oppose	No

Comments:

Dear Hawai'i State Legislature:

With as many as seven (7) Covid-19 variants detected in the US (National Public Radio this am), it is incumbent on the legislature to narrow the entry of people who may be actively shedding virus--or worse--developing mutant strains. Kaua'i County in particular has done an exemplary job of keeping case counts and fatalities low and in efficiently rolling out vaccine to residents. The county mayors and district health officers are uniquely positioned to understand the issues facing their populations--and addressing them. Dr. Fauci and others warn that this could get worse in the next month or so as the UK variant begins to dominate in the next couple of months. This is not the time to relax health guidance. Thank you.

HB-1286-HD-1
Submitted on: 2/16/2021 12:19:00 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Deborah Camara	Individual	Oppose	No

Comments:

I strongly oppose House Bill HB1286 which will override counties ability to make their own decisions and govern themselves regarding COVID travel rules. It eliminates the right of a County to establish COVID travel rules and is bad public policy.

HB-1286-HD-1
Submitted on: 2/16/2021 12:27:13 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Chad Taniguchi	Individual	Oppose	No

Comments:

Please do NOT pass HB1286. It is the wrong solution to a hastily defined problem. Instead of using this crisis opportunity to revision tourism, it depends on the failed old model that resulted in way-over tourism.

Kauaʻi has the healthiest covid population in the state, and one of the best in the world. Listening to scientists, Mayor Kawakami looked to his roots and chose to prioritize health. The Council and citizens support this.

Similarly, **t**he Phuket Tourist Association announced plans to reopen their island after 70% of their population is vaccinated - in October 2021. “The safety of the people gets priority because tourists come and go but locals live here.”

Could the legislature research how places like Phuket are trying to support their residentsʻ economic survival until tourism reopens?

And how to use State/County budget/resources and State/County staff to accellerate a shift from tourism overdependence to a balanced economy, including local agriculture?

How can a significant number of hotel workers be supported in agriculture? Our future economy WILL involve less movement of people and things by airplane to Hawaiʻi.

We are awaiting the leadership of visionaries in the Legislature and administration who can see the future clearly. And can enact legislation to make it happen.

Do not punish Kauaʻi county for its leadership supported by its citizens.

HB-1286-HD-1
Submitted on: 2/16/2021 12:28:38 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Dana Wilke	Individual	Oppose	No

Comments:

1. Please do not change the travel rules to correspond with the other islands. We feel the reason our numbers have been low is because of these restrictions. Our Ohana has been able to stay in tier 4 because our mayor (who we love!) has put our safety before money.

HB-1286-HD-1
Submitted on: 2/16/2021 12:30:15 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
James Lee	Individual	Oppose	No

Comments:

As a resident of Kauai, I oppose this bill.Our Mayor& his team has kept us safe during this Pandemic by opting out of the Safe Travel program. I do not want to take away the option away from our local rule.Our Islands are different, with different resourses, one size fits all does not work!!!!

HB-1286-HD-1
Submitted on: 2/16/2021 12:31:05 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Lee Evslin	Individual	Oppose	No

Comments:

Testimony in Opposition to HB 1286

I am Lee Evslin, M.D. testifying in strong opposition to HB 1286. I have lived and worked as a physician on Kaua`i since 1979 and have served as the CEO of Wilcox Hospital and Kaua`i Medical Clinic. I am well aware of our limited medical care delivery system. I stand in opposition to this bill for the following reasons.

I am Michael W. Schwartz, M.D. testifying in strong opposition to HB 1286. I am a professor of Medicine at the University of Washington and a physician-scientist with a 30-year history of providing patient care while also running a productive research program that has generated >260 peer-reviewed publications. As a part-time resident of Kauai, I am aware of the limits inherent in medical care delivery on Kauai, especially where intensive care and mechanical ventilation are concerned. I stand in opposition to this bill for the following reasons.

- The majority of experts in the world appear to be united in applauding the worldwide decrease in COVID and pleading for great caution over the next several months.
- Variants seem to be spreading everywhere. There is a true race between immunizations and the spreading of these variants.
- The UK variant played a significant role in the UK's surge in cases.
- The UK variant is now doubling every 10 days on the US mainland. It is in Hawai`i already and will come in greater numbers with more trans-Pacific travelers. It is thought to be 30-50% more communicable.
- The science is very clear that a Safe Travels program, relying on a single pretest, will miss 30-40% of those infected because the test cannot pick up people in the early days of the infection.
- Since leaving the Safe Travels Program, Kaua`i returned to virtually no cases and Maui, while staying in the program, changed from having about 1% of the state's cases to having 18% of the state's cases.
- Kauai's cases per 100,000 is one of the best ratios in the country and is allowing us to safely further open our schools and businesses.
- In several months, we will be in a much better position to know where the state and country stand with the disease and our most vulnerable and susceptible will be immunized.

Kaua`i should not be forced to abandon almost a year of sacrifice when we may be so close to the end and the risk is so great. Please stand in opposition to this bill. Let Kaua`i continue to safely open its schools and further immunize the frontlines and the vulnerable. Let the leadership on Kaua`i make the necessary decisions about opening as we all learn together over the vital next two months.

Mahalo,

Lee A. Evslin, M.D.
Kapaa, Hi

Michael W. Schwartz, M.D., Kilauea, Hi

HB-1286-HD-1
Submitted on: 2/16/2021 12:33:19 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Erik Tanigawa	Individual	Support	No

Comments:

As a Kauai business owner , we need the help of our governor to change our travel restrictions to one state order . Kauai cannot be without visitors any longer. We, the people and businesses have done so much to keep our island safe. It is now time to open our Island to pre testing travlers . Resort bubbles don't work and are restricted to certain resorts with very few success for anyone. Kauai needs to open or kauai people and businesses should be supported by those who keep us restricted.

HB-1286-HD-1
Submitted on: 2/16/2021 12:35:05 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Silvina Rubinstein	Individual	Oppose	No

Comments:

I firmly oppose HB 1286. A "cookie cutter" approach does not take into consideration the resources or lack of resources for each one of our islands. Kauai has been successful in controlling the spread of COVID-19 because our mayor, Derek Kawakami took the necessary measures to prevent the spread of this horrible disease and protect our health.

This is our reality on Kauai:

- A a small percentage of our population has so far had access to the vaccine. We are stuck in group 1b, due to insufficient vaccines.
- About 6% of our population are Kupuna over 75 and we are still trying to ensure vaccines for that group, teachers and essential workers, without a clear timeline as to when we will enter into group 1c.
- Group 1c has individuals over 65 years old and 20.7% of the population of Kauai is over 65 years old, which means at this point, individuals like myself are not protected.
- In addition the medical field announced that the worst is still to come as the virus has mutated and those mutations have now spread through the mainland.
-

So, I want you to answer this question? How can you as legislators can in good conscience, propose a piece of legislation that will increase the risk for those of us who live in an island with insufficient medical resources?

I urge you to consider the differences between our islands and the individual needs of our communities. There will be a time for safe travel under different rules, but we are not there yet.

Respectfully submitted by

Silvina Rubinstein

Kalaheo, Kauai, District 16

HB-1286-HD-1
Submitted on: 2/16/2021 12:35:24 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Julia Paul	Individual	Oppose	No

Comments:

We need to allow counties in Hawaii to each make their own decisions. Gov Ige is not Akamai enough to protect Hawaii. His decisions are motivated by big business. Just have to follow the money. Protect and preserve home rule now.

HB-1286-HD-1
Submitted on: 2/16/2021 12:36:16 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Duncan Forgey	Individual	Oppose	No

Comments:

As a multiple property owner and tax payer living on Kauai, I feel it is imperative to allow our Mayor, Council and residents to create their own policy regarding access to the island during this emergency. As is proven by our success in controlling the Virus, the county of Kauai is capable of creating the proper environment to keep residents safe. We opted out of the previous dictates from the Legislature resulting in control of the spread of the virus. Yes, our businesses have suffered like the other islands, but the community has rallied to do everything we can to help each other in the true spirit of Aloha and Ohana. Each island is different and Kauai throughout the long history of Hawaii has been independent from the other islands. Give us the opportunity to show how success can be acheived under Mayor Kawakami and our council. I strongly oppose a one law fits all approach. The state motto, "Ua mau ke ea o ka 'aina i ka pono", says the life of the land is perpetuated in righteousness. It says nothing about tourism and hurting our land.

HB-1286-HD-1
Submitted on: 2/16/2021 12:40:49 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Dionne Hamberg	Individual	Support	No

Comments:

I am in support of Kaua`i reopening and participating in the State's Safe Travels Program. I feel that we need to adjust to our new normal as COVID doesn't seem to leaving any time soon. Our people need to be allowed to return to work and begin healing our economy. Mahalo!

February 16, 2021

COMMITTEE ON JUDICIARY & HAWAIIAN AFFAIRS
Rep. Mark M. Nakashima, Chair

Regarding: HB1286

We are writing to ask you to please vote no on HB1286 for these reasons:

1. This bill does not help to contain the virus nor does it help to boost the economy. We understand the pandemic has been an economic disaster for Hawai'i. Improving Hawai'i's economy is about letting visitors in while keeping the virus out. Kaua'i's approach does exactly that.

2. This bill targets and limits each island's ability to react to island-specific problems. The islands need to retain local authority in order to respond to local circumstances. We wouldn't legislate this way in response to a hurricane. We shouldn't legislate this way in response to a pandemic.

3. Kaua'i's medical resources are limited. We can't allow our eleven ICU beds to be overwhelmed by Covid patients.

We think O'ahu should consider following Kaua'i's example but we understand it's not our place to make decisions for O'ahu just as it is not *your* place to make that decision for us.

Thank you committee Chair and members for your time and attention.

Sincerely,

Wendy Graetz
Jim Hoglen
Kalaheo, Kaua'i
fortoomuchmail@yahoo.com

HB-1286-HD-1
Submitted on: 2/16/2021 12:46:04 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Russell Winkelman	Individual	Support	No

Comments:

I am in support of a statewide policy on travel restrictions. This should not be left up to the Mayors. I support Mayor Kawakami but this should be a statewide policy.

HB-1286-HD-1
Submitted on: 2/16/2021 12:53:55 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
MICHAEL MCGINNIS	Individual	Support	No

Comments:

While I do not generally support the State government taking authority from local officials, in this instance I do. Kauai's economy has been decimated by the pandemic. We are vaccinating our most vulnerable members, and the data from the Safe Travels Program shows that visitor travel-related Covid cases are minor in comparison to community spread and returning resident travel vectors.

Our mayor is unwilling to rejoin the Safe Travels Program, so I feel our only recourse is HB1286. Please help Kauai to rejoin the Safe Travels Program by passing this bill.

HB-1286-HD-1
Submitted on: 2/16/2021 1:01:25 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Jessica Castillo	Individual	Support	No

Comments:

I understand the need to keep us safe. It is something I do not take lightly. I have appreciated the safety of our island while the world around us has been collapsing but I also recognize our island depends on tourism. I think we can still be safe by allowing a negative test 72 hours prior to their arrival and if we see changes, we can always go back to enforcing the quarantine. Mahalo

HB-1286-HD-1
Submitted on: 2/16/2021 1:05:10 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Stephanie Whiting	Individual	Oppose	No

Comments:

I am a residen of Kauai. Our Mayor and Chief Medical Officer have kept this island healthy and safe during the pandemic due to their wise choice of COVID-19 strategies. They should be allowed to continue safeguard planning for Kauai. A look at the individual Hawaii Counties COVID infection rates plainly shows the efficacy of Kauai‘s pandemic strategies.

HB-1286-HD-1
Submitted on: 2/16/2021 1:13:42 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Lisa Kerman	Individual	Support	No

Comments:

February 16, 2021

To The House Committee on Judiciary and Hawaiian Affairs,

I am in strong support of HB 1286.

The public and economic health of the residents of Kaua'i has plummeted since the Covid lockdowns began. There has been an increase of suicide, homelessness, domestic violence, drug and alcohol consumption and peoples mental health is being extremely compromised. Childen are failing in school due to closures, and people are having an extremely difficult time finding the financial resources to cover rent, mortgages, food, medical, dental, certain needed services and other expenses.

People have become extremely depressed because of the lack of purpose in their lives. They're feeling as though they're no longer contributing to society through their work place, due to the fact that businesses have been closing down throughout this past year, many never to open back up again. The tourism dollars
that support local business has virtually dissapeared since the Covid lockdowns began.

We must open up the island as the other main Hawaiian Islands have done. This Bill will allow Kaua'i to reopen to tourist and inter island travelers, with much more user friendly traveling requirements, just as the other islands have done.

Please support HB1286 and support the people of Kaua'i in getting our economy back.

Thank you,

Lisa Kerman-P.O. Box 1011-Kilauea-HI-96754

hike2heaven@yahoo.com

I

HB-1286-HD-1
Submitted on: 2/16/2021 1:19:26 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Dr. Mark Olson	Individual	Oppose	No

Comments:

I strongly oppose HB 1286 and request that you vote to oppose it.

No state should be telling any of its counties that it's COVID rules are too restrictive. The state should be setting the floor, not the ceiling, on restrictions designed to protect the health of its citizens. Kaua'i made its own rules based on reason and science, which is why Kaua'i has been so successful and has zero COVID cases right now. Kauai's children have had school in person fir all of 2021. During the Fall of 2020, Kauai's children had to go online for school because Kaua'i briefly adopted the state's sub-adequate rules that are against science and common sense. This negatively impacted those children in ways that will affect their whole lives, all due to abiding by rules that benefited no one.

We are told that this bill will bring economic recovery, and that having different rules confuses tourists. This is false. This is propaganda. Scapegoating Kaua'i for doing what's smart and responsible is not acceptable, and it's a harmful fantasy to be pushing that uniformity will magically improve the economy. Economic recovery can't happen if children are at home and parents can't work. Economic recovery can't happen if the tourists that arrive are the ones who aren't willing to respect each county's medical capacity by getting a second test after arriving.

It's normalcy that will drive economic recovery, and the best way to normalcy is to bring down the case counts as Kaua'i has deftly done. If we want to have uniform rules, then the conversation that we should be having is getting the whole state to adopt Kauai's smart, science-based rules, not to be defending a county's autonomy to make its own smart rules.

Please vote to oppose this bill. Thank you.

HB-1286-HD-1
Submitted on: 2/16/2021 1:22:57 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Lisa Kerman	Individual	Support	No

Comments:

February 16, 2021

To The House Committee on Judiciary and Hawaiian Affairs,

I am in strong support of HB 1286.

The public and economic health of the residents of Kaua'i has plummeted since the Covid lockdowns began. There has been an increase of suicide, homelessness, domestic violence, drug and alcohol consumption and peoples mental health is being extremely compromised. Childen are failing in school due to closures, and people are having an extremely difficult time finding the financial resources to cover rent, mortgages, food, medical, dental, certain needed services and other expenses.

People have become extremely depressed because of the lack of purpose in their lives. They're feeling as though they're no longer contributing to society through their work place, due to the fact that businesses have been closing down throughout this past year, many never to open back up again. The tourism dollars
that support local business has virtually dissapeared since the Covid lockdowns began.

We must open up the island as the other main Hawaiian Islands have done. This Bill will allow Kaua'i to reopen to tourist and inter island travelers, with much more user friendly traveling requirements, just as the other islands have done.

Please support HB1286 and support the people of Kaua'i in getting our economy back.

Thank you,

Lisa Kerman-P.O. Box 1011-Kilauea-HI-96754

hike2heaven@yahoo.com

I

HB-1286-HD-1
Submitted on: 2/16/2021 1:25:50 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Robin Shannon	Individual	Oppose	No

Comments:

Please vote no on HB1286. Travelers are managing just fine following the specific rules of Kauai and it is keeping us safe. Our hotel occupancy percent is no different than the other islands. Traditionally the islands have been able to decide things that are better for their specific island. By letting such a significant thing as the pandemic be something that sets a precedence to control what we do specifically to protect ourselves is wrong. It did not work before when we didn't have extra rules for travelers. We learned from that experience and were able to control the spread by going back to a more severe quarantine.

We have been given a gift of the best place in the US to live virtually covid free, please let us stay that way. Our value as a very safe travel destination is one reason we are still attracting travelers, no matter the extra restrictions. Please help keep us safe by not voting to have the islands all follow the same rules. We are all different.

Frank O. Hay
kokee@okauai.com

16. February 2021
The Honorable Members of the House of Representatives
Hawaii State Capitol
Honolulu, Oahu, Hawaii 96813

MEETING IN HONOLULU on February 17, 2021: House Bill 1286, Relating to Travel

TESTIMONY IN OPPOSITION TO THE PROPOSED Statewide Safe Travels Program Exemption; COVID-19; Quarantine

Aloha,

I have been a resident of Hawaii for almost sixty years and a proud resident of the island of Kauai for almost fifty. My extended family and I have closely observed and applauded the relative success with which Kauai has avoided the pandemic, while other – perhaps less careful – islands have been and continue to be overwhelmed.

Our relative success is due, in large part, to the strong and timely decisions made by our mayor, appropriate to the island and protecting our small community. I believe that it would be a serious mistake to compromise the "shield" we now have protecting the community.

The current House Draft would likely result in additional cases of the pandemic on our island by opening it up beyond the reasonable limits currently in force. Therefore I submit that it is highly unjustified for the State to prevent Mayor Kawakami from protecting the residents of Kauai as he knows best.

Thank you for this opportunity to testify on this important matter.

Very truly yours,

268 Hua Place, Wailua Mauka, Kapaa, Kauai, Hawaii 96746-9608
(808) 635-3226

HB-1286-HD-1
Submitted on: 2/16/2021 1:41:31 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Koohan Paik	Individual	Oppose	No

Comments:

STRONGLY OPPOSE

Testimony on H.B. 1286-HD1 "Relating To Travel"—Revised

Lee Altenberg, Ph.D.
Graduate Faculty of Ecology, Evolution, and Conservation Biology
Adj Full Professor of Mathematics
Adj Full Professor of Information and Computer Sciences
University of Hawai'i at Mānoa

Member of the Hawai'i Applied Pandemic Modeling Work Group
Member, Models of Infectious Disease Agent Study (MIDAS Network)
Member, Hawai'i COVID-19 Healthcare Provider Taskforce

TESTIFYING AS AN INDIVIDUAL

February 16, 2021

A science-based response to the discovery of community transmission of the B.1.1.7 (UK) variant of SARS-CoV-2 requires the following:

1. An acknowledgement that travelers infected with B.1.1.7 penetrated the Safe Travels program undetected and infected residents of Hawai'i.

2. An assessment of the consequences of this penetration: what will happen to epidemic in Hawai'i due to the estimated 50% greater reproduction number of B.1.1.7 over the common SARS-CoV-2 variants already present in Hawai'i.

3. An assessment of the possibilities still remaining for different policy choices to alter the outcome of the pandemic with establishment of novel SARS-CoV-2 variants in Hawai'i; in particular

4. Can anything be done to halt the new epidemic that would be caused by growth of the B.1.1.7?

HB 1286 lacks each of these science-based responses. Instead, it attempts to solve the problem of the pandemic's decimation of Hawaii's visitor industry by stripping the Governor and all other state actors of their ability to quarantine travelers with a negative SARS-CoV-2 test. This bill would lock-in a policy for Hawai'i that already is counter to the scientific consensus as represented by the CDC policy on international travel. Because the

pandemic still in an emergent state, there are likely to be further changes to the scientific consensus. HB 1286 prevents the Governor or other authorities from responding to changes in the scientific consensus as they emerge. Such a change would require the time it takes legislative action to repeal HB 1286. This leaves the state incapable of timely response to new scientific understandings of the pandemic.

1 Models of the B.1.1.7 Variant in Hawai‘i

Recent studies of the B.1.1.7 variant indicate it is some 50% more lethal than the common SARS-CoV-2 variants. But the greatest concern is its estimated 35% to 55% greater reproduction number. This greater infectivity means that even in populations whose non-pharmaceutical interventions (NPIs) have lowered the reproduction of the common variants to a degree that would end the epidemic, the B.1.1.7 may be able to grow exponentially.

In case the Hawai‘i leadership has not explored models of what this means for the state, I present an exploration here. These results are neither predictions nor projections, because they sensitively depend on biological properties that have not been sharply determined yet. Rather, these figures are IF-THEN statements: IF certain assumptions are true, THEN here is how the epidemic plays out.

Figure 1 shows a projection of the number of daily cases of the variants that have been in Hawai‘i previously. The decline in the number of infections since January 2021 translate to a reproduction number $R_t = 0.91$. If we assume this number continues to hold, and we include the reduction in transmission from vaccinations, we see that there is a rapid reduction in daily cases over the next three months. The decline is relatively insensitive to the rate of vaccination. We will contrast the projection for the common variants with what happens when B.1.1.7 is established in Hawai‘i.



Figure 1: Projected number of daily cases of common SARS-CoV-2 variants present in Hawai‘i based on rate of decline since January 2021.

In Figure 2 we see the dynamics of daily B.1.1.7 variant case numbers in Hawai‘i under the best case assumptions: That the variant reproduction number is 35% greater than the current variants, that there was only one case on February 1, 2021, and that the vaccines reduce transmission by 95%. The four curves plot the case numbers for four different rates of vaccination of the two-dose vaccines per day: 5,000, 7,500, 10,000, and 12,500. We see that even at the lowest vaccination rate, the number of B.1.1.7 infections never exceeds 12 per day. Under this scenario, the variants are of little concern for the state.



Figure 2: Projected number of daily cases of B.1.1.7 SARS-CoV-2 variant in Hawai‘i under best-case assumptions on greater infectivity and cases as of Feb. 1.

However, the epidemic dynamics are extremely sensitive to how much more infectious the B.1.1.7 variant. While some estimates place it as much as 70% more infective, a consensus higher end is for 55% greater reproduction number. The consequences of such infectivity are explored next.

We see in Figure 3 the dynamics of B.1.1.7 under the assumption of 55% greater reproduction number assuming a single case on February 1, 2021. Now we see that there is great sensitivity to having too few vaccinations per day, where the number at 5,000 per day are triple what they are at 7,500 per day. Under vaccination rates that have been stated as targets, the B.1.1.7 daily case numbers by summer are similar to the case numbers in the summer of 2020.

If, however, there were 10 cases of B.1.1.7 in Hawai‘i on February 1, under these same assumptions we see catastrophic growth of B.1.1.7 by May, 2021, as shown in Figure 4. Even at a rate of 12,500 vaccinations per day, by May the number of daily cases of B.1.1.7 exceeds 400. At the current rate of 7,500 vaccinations per day, the number of daily cases exceeds 1,000 by June, 2021.



Figure 3: Projected number of daily cases of B.1.1.7 SARS-CoV-2 variant in Hawai'i under worst-case assumptions on greater infectivity, but assuming only one case as of Feb. 1.



Figure 4: Projected number of daily cases of B.1.1.7 SARS-CoV-2 variant in Hawai'i under worst-case assumption on greater infectivity, assuming 10 cases as of Feb. 1.

```
Block[{days = 300, popSize = 1 416 000., alreadyInfected = 25 943, alreadyVaccinated = 157 018 / 2 },
  vacR = 0.95;
  initCases = 10;
  b117Rt = 1.55 * wildtypeRt; (* 1.35 1.45 1.55 * wildtypeR; *)
  immunityTime = 28 + 14;
  wtDailyCases = Table[wtFeb1 * wildtypeRt ^ (t / serialInterval), {t, days}]; (* Approx *)
  caseInstTrajTab = Table[
    dailyCases = Table[0, days]; caseTotals = Table[0, days];
    dailyCases[[1]] = caseTotals[[1]] = initCases;
    vacNumbers = Table[alreadyVaccinated + t * dayVacs, {t, days}];
    Do[
     dailyCases[[t]] = dailyCases[[t - 1]] *
       (b117Rt *
          (1 - (alreadyInfected + wtDailyCases[[t - 1]] + caseTotals[[t - 1]] + vacR
                (vacNumbers[[Max[1, t - immunityTime] ]] / 2) ) / popSize) ) ^ (1 / serialInterval);
     caseTotals[[t]] = caseTotals[[t - 1]] +  dailyCases[[t]] + wtDailyCases[[t - 1]], {t, 2, days}];
    dailyCases, {dayVacs, 5000, 12 500, 2500}];
 ];
DateListPlot[TimeSeries[Tp@caseInstTrajTab, {"Feb 1, 2021"}], PlotRange → {0, All},
 AspectRatio → 0.618]
```



Figure 5: The *Mathematica* code for the model used here is presented.

2 Conclusions

The exploration of the dynamics of B.1.1.7 infections in Hawai‘i show that they range from benign to catastrophic under the range of infectivity, initial case numbers, and vaccinations rates that are currently in the realm of possibility. The implication is that the state government needs to adopt policy that allows it to quickly adapt to the developing science of the variants. If it becomes clear that keeping the variants out of Hawai‘i until sufficient vaccinations have been given is necessary to avoid further lockdowns and loss of life, the state needs to be able to invoke stronger quarantine measures. HB 1286 blocks the state from taking such actions to strengthen quarantine, and should be therefore opposed.

HB-1286-HD-1
Submitted on: 2/16/2021 1:50:46 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Carly Clement	Individual	Support	No

Comments:

Working for a resort in Waikiki that has remained open during the pandemic, I have personally been able to see how ever-changing messaging across the various counties causes confusion and hesitation for visitors traveling to the state.

While I recognize the importance of “home rule” and allowing the county mayors to decide what is best for their communities, the lack of cohesion in rules for travelers and returning residents to Hawai‘i has led to significant confusion, further harming an industry already suffering an unprecedented economic downturn. As such, I strongly support House Bill 1286

HB-1286-HD-1
Submitted on: 2/16/2021 1:51:25 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Branch Lotspeich	Individual	Oppose	No

Comments:

I strongly oppose HB1286.

My wife and I are in our 70's â€‹and â€‹â€‹have lived on Kauai for 14 years. We are not yet eligibleâ€‹ for the Covid-19 vaccination, so we literally fear for our lives because of the Covid-19 virus. â€‹ â€‹The first few months Mayor Kawakami closed down our island and we were safe.

Our Mayor â€‹analyzeâ€‹sâ€‹ â€‹the science on Covid-19, listens to the medical experts and then makes decisions that have resulted in an extremely low infection rate. Note that from â€‹last â€‹March to Oct 15 â€‹there â€‹were â€‹only â€‹60â€‹ cases on Kauaiâ€‹. â€‹As soon as tourism opened up, it doubled in a monthâ€‹ and we had our first deathâ€‹.â€‹ He then restricted travel to Kauai again and we now have near 0 new cases per day and only 1 active case as of today.

â€‹For this reason Iâ€‹ greatly fear that if the State is allowed to overrule Mayor Kawakami we will again face a dramatic increase of life threatening Covid-19 cases and my wife and I, our friends and neighbors will no longer be safe.

This is truly a life threatening decision your committee is about to make.

I understand the economic consequences of restricted travel and as vaccinations are more available only then will we be able to get our economy rebooted.

â€‹In the meantime, let's protect the lives of our residents.

I oppose HB1286 for these reasons and strongly urge you to vote against it.

Respectfully,

Branch Lotspeich

Kilauea, Kauai

HB-1286-HD-1
Submitted on: 2/16/2021 1:52:20 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Lisa Downer	Individual	Support	No

Comments:

I am in support of this bill as I live on Kauai and, like many others, am suffering due to the lack of tourism on island. I am a small business owner and it is near impossible for business to pick up without tourism. The different rules make is super confusing and frustrating for visitors attempting to visit our island and they are reluctant to book trips not knowing if and when rules will change. This has been devastating to so many.

Testimony Re HB 1286, Draft 1
by JoAnn A. Yukimura
Before the Committee on Judiciary and Hawaiian Affairs
State House of Representatives
February 9, 2021

Chair Nakashima and Committee Members:

Good afternoon! Mahalo for this opportunity to testify on HB 1286, Draft 1.

I want to acknowledge at the outset, the economic hardship that many are going through--be they businesses or families. It is heartbreaking to see the existence of something you have worked for your whole life threatened with closure. It is terribly scary to be food or housing insecure.

We all want to end this nightmare. Where we differ, is how to end it.

Back in May of last year as we all grappled with the impacts of the 14-day quarantine wisely instituted by Governor Ige, I, along with a group of doctors, scientists and community leaders on Kauaʻi, saw that what was needed was a safe way to welcome visitors back. We knew that the quarantine was the right solution for the moment, but wouldn't work as a long term solution. We wanted visitors, but we didnʻt want the coronavirus, which spreads by travel. We wanted visitors, but not at the expense of the health and wellbeing of our community. We started looking for a science-based solution.

We completed our report in mid-June, and presented our recommendations to Mayor Kawakami in June, 2020 and to Governor Ige in early August, 2020.

Our science-based report was entitled, "A Plan for Safely Reopening Hawaiʻi: Kauaʻi as a Model." You can read here. It recommends a pre-departure test, a 6-day quarantine and release on the 7th day with a negative second test. The basic approach of a quarantine and second test has been validated many times all over the world.[1]

Unlike the government of Australia and the organizers for the Grand Slam who creatively and conscientiously followed the science to success, certain political, visitor industry, and medical leaders in Hawaiʻi chose the easier but not science-based way.

[1] CDC Travel Recommendations for Americans returning from foreign travel, "Shorter quarantine could prevent coronavirus outbreaks," " Germany requires 2-covid-tests-and quarantine"

When the state, including Kaua‘i, was reopened on October 15, 2020, using the State‘s one-test plan, Mayor Kawakami, in consultation with DOH‘s Kauai District Health Director, Dr. Berreman, instituted a second voluntary test for visitors and returning residents. While the numbers were small and the timing of the second test was not optimum for detecting infections, it was in the right direction, and the lessons learned were invaluable.

We learned that on Kaua‘i, the State‘s one-test plan missed about 9 infected travelers per 1,000 incoming travelers. (without a second test, the other counties could not as easily or accurately determine this figure). This learning led to the development of the “bubble resort” which requires a second test to exit the bubble.

We also learned that official COVID statistics, announced daily, do not include visitors found to be positive in Hawai‘i if their test was a pre-departure test done outside of Hawai‘i, even though the visitors are COVID positive while in the state. Kaua‘i County since that time, has tracked and reported those numbers, but it is the only county to do so.[2] This lack of careful tracking and reporting allows some to argue that travel does not have as big an impact in Oahu, Hawaii and Maui counties as it actually does.

As documented below, the State‘s one-test travel policy is not safe--by scientific analysis, by hard data provided by Kaua‘i’s careful tracking of its experience under the 1-test plan, and by CDC guidelines.

Based on the biology of the coronavirus, Infected people don’t usually test positive until Day 4 or 5 after exposure when the viral shedding becomes detectable. Therefore, tne pretravel negative test does not mean a traveler is safe. A significant number of travelers test positive *after* arrival, seeding spread in Hawaii.

Prior to October 15, when the state‘s plan went into effect, 60 COVID cases had been recorded on Kaua‘i in the first seven months of the pandemic. One month after the state‘s plan took effect, Kaua‘i’s COVID caseload doubled to 120. Eighty percent of the post-reopening cases were incoming travelers, half visitors and half returning residents. (Please note that my objections to the travel plan are not due only to the impacts of visitors who come through the defective screening; the one-test plan is detrimental to

[2] On February 16, 2021, official state COVID statistics show Kaua‘i‘s total COVID caseload at 181; Kaua‘i County‘s reporting shows a total caseload of 210. In the other counties in Hawai‘i, these travel-related infections are not reported. Often, they are not even registered because there is no second test by which to detect these infections.

the health of our families when returning residents are led to believe that they are safe based on one pre-departure test.)

HB 1286, Draft 1 would force Kaua‘i to go against a Centers for Disease Control recommendation. For U.S. citizens returning to America (a category of travelers akin to returning residents or visitors to Hawai‘i), the CDC states**: "Testing before and after travel is a critical layer to slow the introduction and spread of COVID-19."** It recommends a pre-departure test, a second test between 3-5 days after arrival, and post arrival quarantine for 7 days.

The only rationale I have heard for HB 1286 is that potential visitors are confused when there are different rules for different counties. To approve this bill based on that reason would validate the widely held perception identified in a recent Omnitrak poll wherein 67% of Hawaii residents polled said that Hawai‘i "is being run for tourists at the expense of local people."

Mayor Kawakami‘s creative and courageous efforts to follow the science have brought Kaua‘i to the point (1 new case in the last 14 days) where it‘s non-tourism economy has been able to operate without much COVID-induced restraint. Face-to-face schools and sports are starting again. Residents re getting their hair cut, their nails done. They are scheduling their dental checks and elective surgeries. If we can keep the coronavirus at bay with a safe way for screening incoming travelers--both visitors and returning residents--sustained economic recovery can truly begin.

The truth is, as Hawai‘i economist Paul Brewbaker has said, "You don‘t solve the economic problem until the epidemiological problem is solved."

Kaua‘i is on the verge of solving its coronavirus problem. Any legislation that forces Kaua‘i to comply with the 1-test plan, will set us backward--toward disease, potential death and economic recession. HB 1286, Draft 1 would have grave consequences for my lifelong home and community on Kaua‘i.

I humbly request--I sincerely urge--that you hold HB 1286, Draft 1 in committee.

Mahalo nui loa.

HB-1286-HD-1
Submitted on: 2/16/2021 1:57:18 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
james trujillo	Individual	Oppose	No

Comments:

Aloha Representatives,
Thank you for the opportunity to provide tesitimony in opposition to HB1286.
While the desire to provide a statewide travel program is laudable the effects may have less than ideal outcomes. We are faced with severe shortages of medical resources on the island of Kaua'i if an outbreak of CV19 were to impact our community. Mayor Kawakami has tried to manage the issues accordingly and HB1286 reduces the chief officer of the county's ability to implement strategies that will reduce the risk of exposure to residents from travel related CV19 transmission. Please do not restrict the mayors of Hawai'i ability to protect thier island residents from CV19 exposure by passing HB1286. Please kill this bill and let neighbor island Mayors decide what is best for their local jurisdiction.
Mahalo for considering this testimony in opposition to HB 1286

With respect & aloha,

James G Trujillo
PO Box 33
Kapa'a, HI

96746

HB-1286-HD-1
Submitted on: 2/16/2021 1:58:19 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Kapono Chong-Hanssen	Individual	Oppose	No

Comments:

Aloha kakou,

As a Kanaka Maoli and the medical director for the Native Hawaiian Health Care systems branch for Kaua`I, HoÊ½Å• la LÄ• hui HawaiÊ½i, and the only federall qualified health center on the island, KauaÊ½i Community Health Center, I continue to oppose HB1286's prioritization of the tourism economy over the public safety of residents. The memory of the infectious epidemics that devastated the Native Hawaiian population in the 19th century still weigh heavily on our conscience as the measles epidemic did on Queen Liliuokalani's when she immediately shut down all ports in 1881 after small pox was found on a ship. This decision was extemely unpopular amongst the American business people who eventually overthrew the Hawaiian Kingdom illegally. Similar to the assertions made by businessmen in the late 19th century that Native Hawaiians have no way to sustain ourselves without their money, we are once again being told by many politicians today that until our hospital systems become overwhelemed, we must accept the risks of allowing this pandemic to enter our land because Hawai`i has no way to sustain itself without the highly tourism dependent economy the state has built over the past few decades. This assertion bristles the hair of many Kanaka Maoli, and brings us back to the days of the overthrow when the song *Kaulana Na Pua,* also known as the *Mele `Ai Pohaku (Rock-eating song)*, proudly pronounced: *'A'ole mÄ• kou a'e minamina I ka pu'u kÄ• lÄ• o ke aupuni. Ua lawa mÄ• kou i ka pÅ• haku I ka 'ai kamaha'o o ka Ä• ina.*

We do not value the government's sums of money. We are satisfied with the stones, astonishing food of the land.

With the inspiration of our last queen informing my role as the medical director for the only federally qualified health center on Kauai, I am extremely proud of what our island has done to protect our residents while also doing our best to support the most economically vulnerable at the same time. Through these efforts, our island's epidemic curve remained essentially flat while the counties where the "Safe Travels" program's

limited ability to prevent the introduction of the virus led to a clear January surge that has only recently decreased again. Our local economy was also unhindered by being able to remain in Tier 4 while Oahu climbed to Tier 2 restrictions, and our residents seeking hope in the face of the pandemic were ensured the opportunity for some socialization and activities such as youth sports. We achieved this success through collaboration at the county level while our state leaders were unable to coordinate a similar plan at the state level despite clear advice from the department of health regarding the benefit of the second test. Kaua`i continues to enjoy the benefits of effective county level collaboration and opting out of "Safe Travels" by our ability to focus most of our public health efforts on vaccinating our population towards herd immunity rather than contact tracing and other efforts to manage the smoldering pandemic. To have HB1286 now force Kaua`i to accept the current, surge-prone "Safe Travels" plan after nearly a year of dedication to developing a program that has proven to be effective in comparison to the other counties is difficult to stomach.

The justifications for why this bill should be accepted focus solely on the needs of the traveler despite CDC advice not to travel at this time. Furthermore, the idea that the "confusion" created by allowing the counties to institute their own travel protocols will hurt the tourism appeal of Hawai`i in the long run could only be believed by somebody who does not truly appeciate what our islands have to offer. For those of us who love our land, we know that respectful visitors will return when aloha can be shared freely again. Unfortunately, my local representative co-introduced this bill and in her recent newsletter to her constiutents she cited affordable testing as another reason for this bill to be passed. I can affirm that affordable, rapid testing is currently available in the realm of $25-30 per test, and through collaboration with colleagues at the Hawaii Toursim Authority and local tourism focused businesses we have begun to strategize ways to appeal to more travelers while ensuring continued safety in the face of the dangerous COVID-19 variants that threaten to undo all of our vaccination efforts as occurred in South Africa after the emergence of B.1.351 strain's resistance to the Astra-Zeneca vaccine forced the country to abandon the one million dose vaccination effort they had planned for February.

Should more dangerous variants be found in Hawai`i, aggressive local intervention may be needed to prevent spread as has been demonstrated by countries successful in preventing pandemic surges such as Australia recently did with a complete lockdown of Perth after one case of community spread. HB1286 seeks to do the opposite and force the entire state to conform to the lowest standard of travel safety currently being offered in Hawai`i. This approach is premature at best and foolish at worst based on the scientific evidence and pattern of recurrent surges worldwide. At this point, we are in a race to vaccinate our population to achieve herd immunity before our own plans can be derailed by the emergence of a dangerous or resistant variant, but we now must also race against the state of Hawai`i's insatiable appetite for tourism that continues to prioritize one aspect of the economy over the lives of our residents. I urge you to let us continue the work we have done on Kaua`i to ensure public safety and safely reopen our travel economy through collaboration with our department of health, health care systems, local businesses and the Hawai`i Tourism Authority, which we have already

begun. Perhaps our work will eventually benefit the entire state as the challenge of managing travel in the face of the COVID-19 virus variants will likely persist for years to come.

`o au me ka ha`aha`ah,

Damien Kapono Chong-Hanssen, MD

Medical Director - HoÊ½Å• la LÄ• hui HawaiÊ½i/KauaÊ½i Community Health Center

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

February 16, 2021

To: *Committee on Judiciary and Hawaiian Affairs*
Honorable Rep. Mark M. Nakashima, Chair, and committee members

From: Nancy J Budd

Re: TESTIMONY IN **OPPOSITION** TO **HB1286**

Aloha Chair Nakashima and committee members,

HB 1286 removes the power of each island's Mayor to opt out of the "Safe Travels" program and also appears to remove the governor's ability to take emergency action in the face of a surge in COVID-19 cases. It further suggests that a single pre-arrival test is the only requirement to avoid quarantine. *This would force each county to ignore CDC travel guidelines which call for a second test after arrival and a short quarantine*.

A single pre-arrival test misses 30-40% of those infected. With the confirmation of virulent variants in the islands, this matter could not be more critical. By allowing the virus to continue to spread (in counties other than Kaua`i), the single pre-arrival test plan is actually delaying economic recovery. Please note that in 2020 and in early 2021 (to date), Kauai's hotel occupancy was essentially equal to all other counties. Kauai`s use of quarantine "bubbles", which require a negative test before leaving the bubble resort, has reduced the quarantine to a bare minimum for visitors and is proving popular. Why punish Kaua`i?

Kaua`i island has a total of 9 ICU beds for any and all patients in need of them, not just those suffering from life-threatening cases of COVID-19. Expanding capacity to cope with a surge in COVID cases on Kaua`i is challenging, if not impossible, as both critical care infrastructure and trained personnel are extremely limited resources on Kaua`i.

The underlying assumption of HB 1286 appears to be that by easing travel restrictions on tourists state-wide our economy will become robust, outweighing the significant concerns of medical experts.

By allowing greater numbers of infected persons into the State (including increasing numbers of those carrying the mutant strains) we will, instead, likely end up with another lockdown of our economy and significantly greater numbers of deaths- a lose-lose proposition on a grand scale. And we will have neither a healthy economy nor a healthy population.

Dr. Anthony Fauci, in an interview with Terry Gross a few days ago, stated that "*no one should be travelling*." He urges us to *avoid all travel* unless it is absolutely necessary, vaccinate as many people as quickly and efficiently as possible, and double-down on public health measures. It is critical that we in Hawaii follow this advice. We need to manage our tourism re-opening as an integral part of our public health plan which must allow the Mayor of each County the latitude and power to protect its residents. Let us continue the vaccination roll-out and keep our schools and businesses open without the fear of lock-down and another spike in cases we do not have the resources to respond to.

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/16/2021 2:03:16 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
ROBERT DAY	Individual	Oppose	No

Comments:

The leaders on Kauai have kept its citizens safe fron COVID-19 and I would like it kept that way. This state is unique in that the various counties are separated by a large body of water. Kauai is a small county with limited medical resources and therefore cannot afford a large outbreak of the virus. Our local leaders know what is good for Kauai and they have done an excellent job so far so let them continue to make policy for Kauai.

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/16/2021 2:19:09 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Serafina Gajate	Individual	Oppose	No

Comments:

STOP GIVING TOURISTS EXEMPTIONS!! It's our local communities that suffer when we allow visitors to circumvent the rules of health and safety just to make a quick buck. The pre and post flight testing a have been PROVEN to give false negatives, or to not catch a very early infection that a traveler might have just caught on the flight over. Please, prioritize the health and safety of our local community over the desire to make money off the tourism industry. Enough is enough. Our lives are more important.

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/16/2021 2:29:10 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Alissa Coen	Individual	Support	No

Comments:

I am writing to you as a constituent and in my capacity as Director of Food & Bevereage for the Koloa Landing Resort at Poipu.

Kauai's economy has suffered the greatest of all of the islands due to County restrictions on travel. This has resulted in thousands of lost jobs and permanently closed businesses. While we have remained opened through the pandemic, much of our team has been furloughed and the remaining employed continue to experience incredible financial loss due to pay cuts and loss of hours.

For the well being of the island residents mental health and stability, it is time to re-join the safe travels program and re-start our economy.

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/16/2021 2:32:06 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Keegan Pleas	Individual	Oppose	No

Comments:

This bill seems to be retaliatory in nature against certain counties who have chosen to not take part in the Safe Travels program or those who have decided to amend portions of the program to fit their needs. The passing of this bill will be detrimental to the populations of those counties due to increased COVID-19 transmissions where there were previously very low case counts.

Speaking for Kauai specifically, we have been blessed with very low case counts due to the diligence of our mayor's decision to opt out of the Safe Travels program. Allowing visitors to be exempt from quarantine will result in increased numbers which will cause an unnecessary increased risk to our kupuna and "at-risk" groups. Looking back at the brief period which we opened to travelers, you can easily see the correlation between the increased visitors and increase in cases.

I strongly oppose this bill for the sake of the health of the population of Kauai.

Mahalo.

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/16/2021 2:35:16 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Anne Thurston	Individual	Oppose	No

Comments:

I strongly oppose this bill. Kaua'i has a low incidence of COVID precisely because our mayor has had the freedom to introduce measures to protect our population as necessary. To interfer with this ability would put us at unnecessary risk and would be very distressing for our population, especially at a time when there are new and litle understood variants.

Please do not pass this bill.

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/16/2021 2:44:27 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
John R. Gordines	Individual	Oppose	No

Comments:

I do not support this bill as it takes away the powers of our mayors to individually do what is best for their respective communities.

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/16/2021 2:47:47 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Alicia Humiston	Individual	Support	No

Comments:

This will help standardize the islands entry requirements during this trying time.

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/16/2021 2:58:22 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Ikaika Sarkissian	Individual	Comments	No

Comments:

I would like to go on record of stating that I'm half in and half out in support of this bill. I want it noted that the only reason for my consideration toward support for hb1286 would be due to our Dr. Josh Green's belief through applied science that he himself would do no harm as to his sworn oath he took when he graduated medical school. If the proverbial Poop hits the fan, let it be on Dr. Green's conscience. Please. Thank you for your time.

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/16/2021 4:02:01 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
April C McLean	Individual	Comments	No

Comments:

I STRONGLY OPPOSE HB 1286.

Invoking a blanket provocation of behavior for ALL islands is neither backed by science nor the constitution. Health issue in normal human existence, therefore there should NOT be a blanket legislation to address public health concerns. The same can be said about masks and if you need the "research" to back this information please email me and I will gladly forward the information to you.

You must remember, that ANY actions that you decide upon WITHOUT the full backing of the majority of your constituents, you are then subject to legal issues such as crimes against humanity, and treason for opposing actions of the Constitution.

I pray that you do the right thing. This should be voted upon PUBLICLY amongst the people of every island.

Thank you.

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/16/2021 4:46:50 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Maria Hacker	Individual	Oppose	No

Comments:

Aloha, I oppose Bill HB1286 for the following reasons.
The CDC recommends no non essential travel.
This Bill will make it less confusing for visitors and others choosing to travel in a Pandemic, This is ridiculous. The Covid Virus is a very fluid situation. Things are changing not only daily but hourly. There is so much that is unknown but we are supposed to make things less confusing when clearly travel has proven to be a spreader by the fact that countries that have closed their borders to travel are now flourishing.
When the Hawaii States Epidemiologist says that her recommendation is two tests not one for the safest practice for travel into our state, this Bill makes no sense. This Bill usurps our Mayors ability to protect Kauai's residents in a Pandemic. It's proven that countries that have shut their borders to travel like Australia, New Zealand & Bali have very few deaths from this virus, we should be following that model not the model that has achieved close to half a million deaths. You should be thinking of ways to protect our residents health not ways to bring in more virus to all our islands. I oppose this Bill that's Backed by the Hotel and Travel industries, since when do these industries dictate what's best for my health.
This Bill comes on the heels of a new variant none the less! Meanwhile Tahiti, French Polynesia is closing its borders to travel to protect their citizens from this new variant. I oppose this one size fits all approach that is headed for disaster.

What is the goal here? To make it less confusing for travelers to our islands when the CDC says no to non essential travel so as to stop spreading this virus from state to state? It's interesting that Josh Green and Governor Ige approved a 10 day quarantine from the original 14 day quarantine to follow the CDC guidelines but not the guideline that states its best not to travel at this time. This is cherry picking at its very finest. This Bill is not in the best interest of the health of our island of Kauai. I oppose this Bill and advise that Oahu should be following our lead on safe travel not vice versa. Health before commerce because with a sick community there will be no commerce.

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/16/2021 5:33:14 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Alan Koons	Individual	Support	No

Comments:

I support this bill. Kauai should have been opened to tourism months ago. The county is struggling to survive and most businesses won't rebound at this point.

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/16/2021 5:56:49 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Terrie Hayes	Individual	Oppose	No

Comments:

I oppose HB1286! Kauai is unique and should be treated as such! We have few Covid cases

as we have been cautious. Those that come are tested and should continue to be.

DUE TO THE NEW VARIANTS, we should continue our behavior!

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/16/2021 8:15:42 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Danielle Davis	Individual	Support	No

Comments:

With only one active case on the island and numbers looking relativily good on all the other islands we need to open us back up to the Travel Safe Program. I understand the need to proctect our county and appreciate the efforts however no tourism is hurting us just as bad! We need to help open our island back up so we as an island can become econmically stable as well as healthy.

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/16/2021 9:08:43 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Elizabeth Hood	Individual	Oppose	No

Comments:

I'm from Kauai, grew up there my whole life, my family all still lives there and I haven't been home in over a year because I want to keep my family safe. COVID has been devastating and too many lives have been lost for selfish reasons, money and profit over life. Kauai healthcare resources do not have the infrastructure to handle a widespread covid outbreak places like LA struggled to manage it, how would Wilcox?! Reopening now without testing and mandatory quarantine ONLY serves mainland business owners and tourists who treat our island like a amusement park to use and abuse with no care for the locals and native Hawaiian people and culture. We survived Iniki we can survive this, wait till our keiki are back in school and our kÅ«puna are vaccinated, no profit is worth a life. Aloha.

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/17/2021 3:16:04 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Danny Hashimoto	Individual	Support	No

Comments:

Aloha,

Please support this Bill. It is very important that Kaua'i, particularly, be able to allow visitors and returning residents under the Safetravels program that is uniform throughout Hawai'i.

Mahalo,

Danny Hashimoto

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/17/2021 7:53:49 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
George White	Individual	Oppose	No

Comments:

Aloha Chair Nakashima, Vice-Chair Matayoshi and Members -

I write in strong opposition to HB1286, HD1, relating to establishing a statewide mandate related to the State's "SafeTravels" program.

This bill appears to have one express purpose, to preempt the existing authority of each county Mayor to opt-out of the existing "Safe Travels" program, while hamstringing the Governor from expeditiously exercising his existing emergency power in the future. State policy in this situation should set the minimum standards - the floor not the ceiling - as to what counties are able to do to protect and promote their communities.

Many experts have provided testimony to you regarding the pernicious imperfect nature of the existing "Safe Travels" program. The comparison between Kauai and other counties' approach to regulation of arriving travelers is invaluable and indicative that it is premature to mandate loosening restrictions related to incoming travelers to our shores. Balancing the need to protect public health while pushing to jumpstart our state's economy is a tenuous and unenviable task. It is important however, to not upend a system that has worked better than it hasn't, and continue to take a measured rational approach based in science and data, and by the guidance of experts...not politicians.

CDC guidance currently discourages travel and explicitly recommends stricter protocols than our current "Safe Travels" program provides for. As this ever-evolving response to COVID-19 has shown, travel policies regulating the influx of virus vectors into Hawaii should not be legislatively 'set in stone' as proposed in this bill. Even HI-EMA, the State agency that has skillfully coordinated the entirety of our emergency response to COVID-19, has testified that this measure is not needed. Many have also opined that the current situation is a "fluid" one, necessitating for greater flexibility in response (not less), especially given the arrival and presence of more worrisome variants, as well as our evolving progress with vaccinations.

We are at a critical juncture in our response to this crisis, and it is a heavy burden for you as policymakers to help steer us towards a safe and revitalized Hawaii. This bill, however, is a distraction and deflection from your critical work and should be deferred.

Mahalo for this opportunity to provide testimony.

Respectfully -
George White

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/17/2021 7:55:06 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Nanea Lo	Individual	Oppose	No

Comments:

Hello,

My name is Nanea Lo and I'm writing to strongly oppose HB1286.

“The travel rules are not “too confusing,” they’re exclusive. They exclude those who want easy and full access without personal responsibility or having to pay attention to the rules. Those vacationers can find ample accommodations elsewhere in a place that is not quite as worried about health and safety. Florida is beautiful this time of year.” Lee Cataluna Civil Beat “Kauai Should Get Special Rules Because It Is Special"

"Though the passage of HB1286 also prevents Maui, Honolulu, and Hawaii County from doing the same, it was introduced specifically to stop Kauai County...This is the unvarnished truth." Gary Hooser Garden Island Newspaper “House bill seeks to prohibit county COVID travel rules (HB1286 Unpacked)”

Please oppose this bill.

me ke aloha ‘Ä• ina,

Nanea Lo

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/17/2021 8:07:47 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
ellen sofio	Individual	Oppose	No

Comments:

Testimony on HB 1286

Ellen Sofio M.D.

2/7/21

I am writing to strongly oppose passage of HB1286. The pre-travel testing program this bill seeks to force on the entire state without possibility of exemption is inherently unsafe, based on a pre-travel PCR test which is known to miss up to 30% of positive cases. The surveillance of this program last fall involved the inappropriate use of a BD Veritor rapid antigen test designed for use during the first 5 days of suspected symptomatic COVID 19, and never tested or expressly intended in its emergency use authorization for one time surveillance testing of asymptomatic individuals, which is how it was recklessly used.

According to UH epidemiologist Dewolfe Miller who was allegedly overseeing the surveillance, the protocol was "written for me by rear Admiral Louis Tripoli of the Indo-Pacific command". The Navy and the DOD apparently had a vested interest in guaranteeing that the pre-travel testing program would get the green light, putting a non-epidemiologist physician in charge of the protocol and permitting the use of an insensitive test in a setting it was clearly not designed for.

Even with this faulty protocol, the surveillance detected missed positive cases in 7 out of 1,000 cases, seven times the predicted rate of 1 in 1,000. With 10,000 arriving travelers daily that would mean 70 undetected positive cases getting off planes here without quarantine obligations per day. 20,000 arrivals would mean 140 per day and 30,000 would rise to 210 missed positive COVID 19 cases entering our island communities per day. This is completely unacceptable, and its consequences were made evident in the

alarming surge that occurred on Kauaʻi immediately after it was briefly adopted there prior to Mayor Kawakamiʻs wise decision to opt out.

With recent vaccine and antibody resistant viral escape mutations from South Africa and spontaneous similar occurrence in a subset of the UK variant in the UK (E484K) it becomes even more dangerous and irresponsible to perpetrate this dangerous program on our island population. Rather than being standardized, the unsafe “safe” travels program should be shut down completely to spare Hawaii potential third and ongoing waves caused by the current more contagious, more lethal and vaccine resistant variants which are sure to enter and exponentially multiply if they are not kept out and decisively suppressed with lock down measures, devastating our communities here.

I strongly oppose this bill which will deprive many vulnerable island residents of the protective quarantine. At a time when the UK and Scotland are imposing 10 day mandatory hotel quarantines on those entering from 33 red zoned nations and Germany has instituted road blockades as well as air travel bans to suppress the growth of these exponentially dangerous variants, I would characterize this bill and the pre-travel testing program it seeks to expand as incompetent at best and criminally negligent at worst.

We are all grieving pre-pandemic life. Kauaʻi, like our entire state back in the early days of the pandemic, has virtually eliminated the virus and resumed a semblance of normality for itʻs adults and alike with social gatherings and in person school. This is what we all clearly miss and yearn for. Instead of forcing travel on Kauaʻi, we should be barring flights and locking down to win the battle on all the islands in a similar way to what they have.

The safety of our population and protecting the resilience of our sustainable local economy is much more important long term in the face of this viral scourge than a mainland controlled tourist industry or the perpetual harms done to military and civilians alike by perpetual aggressive mass movements but the DOD.

Anyone who genuinely cares about the long term well being of our island community must vote decisively against HB 1286. Mahalo for your kind attention.

Ellen Sofio M.D

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/17/2021 9:28:32 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
lance nash	forourrights.com	Oppose	No

Comments:

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/17/2021 10:23:20 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Nancy Mitchell	Individual	Oppose	No

Comments:

As a retired Registered Nurse living here on Maui I am vehemently opposed to this bill. . All islands are not equal in terms of many things , but the largest is health resources. Maui has ONE acute care Hospital which runs at near maximum capacity most times and especially now. Maui County now has similar if not more tourism than Maui . We need the ability to flex our needs at a moments notice in order to stave off a surge. This bill would eliminate that possiblity. Our Vaccination rate for Maui County is dismal for 75 year and up kupuna.I am 65 and Husband is 73. & we like many of our friends cannot get a vaccine. Until vaccination is improved, the House has no business passing this bill. And with unknown effects of the variants , more trouble is coming. Look at Europe ! Some of the newer vaccines are NOT effective against at least one of the variant strains. CDC still recommends NOT traveling on 2/9/2021 - NOTHING scientifiically points to opening up JUST YET ! I implore you all to not let this Bill go through at this time, We need to watch and observe and wait for the experts and not LG GREEN or the legislature ! You are in over your heads and need to listen to Science before choosing only money , and revenue and chatter from the Tourism Authority . Don't play with our health and our lives .

Mahalo,

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/17/2021 10:41:26 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
W David P Carey	Individual	Support	No

Comments:

It is essential to create clarity for the testing process for visitors that want to come to Hawaii. Bringing back our visitors is critical to bringing back needed jobs and generating much needed tax revenue.

As a former hospitiality executive I cannot urge you enough to promote a return to economic stability. I support HB1286 HD1
David Carey

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/17/2021 10:48:57 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Nancy Viemeister	Individual	Support	No

Comments:

Aloha,

I would like to submit testimony in support of this bill. I wokr in the hospitality industry as a manger and I have seen first hand how Kaua'i being closed has affected my employees. I have had to stop scheduling them, they then have to start filling for UI again and we all know how much of a mess that it. The island was doing so well and I was able to hire a bunch of previous employees that we laid off and they were working and making money and not filling for UI. Unfortunately with Mayor Kawakami closing our island and making it hard for tourists to come, they have had to start over and a lot of them are waiting for thei much needed UI. And I have a lot of employees who have children that they need to take care of. Reducing their hours also affects their health insurance which is a big burden. It is also a heavy weight on my shoulders knowing that my hard working employees are going through. I see that the other islands have been working well with pre-travel testing and visitors arriving on the islands. And it seems to be working very well so I really hope that Kauai can be afforded the opportunity to have the same chance. This island desperately needs tourism. There are so many small businesses that cannot and have not been able to sustain staying open without visitors on island. I urge lawmakers to pass this bill so that Kaua'i can open it's doors and welcome tourists again.

Mahalo for your time,

Nancy Viemeister

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/17/2021 10:50:04 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Lisa A Kim	Individual	Support	No

Comments:

Testimony of

Lisa A. Kim

Owner of L.A.K. Enterprises (Marketing Firm) and Restauranteur

Committee on Judiciary and Hawaiian Affairs

House Bill 1286: Relating to Statewide Safe Travels Program Exemption; COVID-19; Quarantine

TO: Chair Nakashima and members of the Committee

I would like to express my support for House Bill 1286 to bring a unified, cohesive Safe Travels Program.

We have all seen the confusion that has arisen with various safe travel plans from each of the Hawaiian Islands. It has even reached the national news stating that Hawaii wants the visitors to return but we cannot seem to work together to have ONE plan. This is quite an embarrassment.

The confusion and strict requirements have severely deterred Kama'aina from traveling to the neighbor islands and visitors from out-of-state to come to Hawaii. A nucleic acid amplification test (NAAT) is only accepted by the state but not a rapid test that was distributed during surge testing. With a rapid test, results can be received quickly and

there is a minimum or no cost. Paying $150.00 for the NAAT test is deterring residents from traveling to the neighbor islands and visitors from entering the state.

There is much confusion on several issues regarding the pre-test and quarantine. Who should or should not have to quarantine? Where do you receive the tests if you are not in Hawaii? What is the difference between a NAAT and rapid test? What are the total costs for testing? Is proof of a negative test in writing accepted? These are just some of the questions that are being raised and if there was one plan, this would eliminated such a gray area.

As a restaurant who lost her business completely due to COVID-19, I know firsthand what the negative affects are from the virus. We are all looking at our elected officials to ease the burden on the residents and businesses and create a unified Safe Travels Program.

Thank you.

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/17/2021 11:03:50 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Kris Anderson	Individual	Support	No

Comments:

HB 1286 must be approved for the sake of the community here on Kauai. I had to leave the island to find work on the mainland and after 7 months I have returned. I have returned to a very sad situation in the hospitality industry with hotels closed, my favorite restaurants closed, friends gone due to lack of income, and an overall extremely depressed economy. If the safe travels program works on Oahu, Maui, and the Big Island it will work here on Kauai. Please pass HB1286 and allow us all to return to normal!

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/17/2021 11:32:14 AM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Linda Kay Ross	Individual	Oppose	No

Comments:

they never even isolated the virus...listen to recent NBC interview with chinese epitiomologist..no evidence that this COVID virus even exits, much less make a test for it, a vaccine or need to wear mask, lockdowns, or ruining our economy/lives!!!

please re-think your loyatly...when it all comes to light...do you really want to be standing with the dark?

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/17/2021 12:02:19 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Dr. Robert Abell	Individual	Support	No

Comments:

To Those Concerned,

I are writing to express my support for HB 1286 HD1. Kaua'i needs to open back up so that this island can bring back tourism to help our local businesses. Kaua'i is not different from our neighboring islands and we do not need extra testing to be safe. The numbers and statistics just don't show the need for these extreme measures.

I have personally experienced how Kaua'i testing has prevented tourism. My wife and I recently were on the Mainland for 3 weeks. In order to avoid being quarantined for 10 days on Kaua'i we stayed on Oahu for 3 days and then retested, but our results were not avaliable when we boarded the plane to Kaua'i. We were placed in quarantine and 12 hours later our results came in which I uploaded to the SafeTravel website and received our exemptions on Friday morning. Even though we were exempt the National Guard showed up at our house on Saturday, the next Monday, Wednedsay and Thursday. Each time we had to prove that we were exempt. I asked them to be taken off the list. I emailed KEMA on Monday and Wednesday and still was visited on Thursday. At this point I called mayor's office and was given KEMA's phone number and explained the problem. Finally this issue was resolved. Fortunately, we were home every time the National Guard checked on us (even though we were out of quarentine). I asked KEMA what would have happened if we were not home and was told they would probably call the police. What is most alarmly about this is that ONLY 3 people where in quarentine during this time and 2 of the 3 were my wife and I. In no way do we blame the National Guard who were only doing their job and they were extremely respectful and understanding.

Why would anyone want to go through this for a vacation? This is wrong!

Why can I fly to Oahu or any other island and have my negative test, but on Kaua'i I have to spend extra time and money ($240 for my wife and I to have 2 CoVID tests each) just for the privilege of coming back to my home. The excuse of keeping our hospitals from being overwhelmed does not make sense. We have always flown emergency or hard to treat patients to Oahu anyway, so how is that any different with CoVID patients?

Thank you for your consideration in this manner.

Robert Abell

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/17/2021 12:06:33 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Lorraine Larzabal	Individual	Support	No

Comments:

YES, WE WANT TRAVEL REGULATIONS UNIFORM ACROSS ALL COUNTIES.â€‹

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/17/2021 12:46:10 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
L. J. Akins	Individual	Support	No

Comments:

Keep the laws regarding covid testing the same for all islands.

ALSO- remove testing required for flights between islands!

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/17/2021 1:06:23 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Susan Tsao	Individual	Support	No

Comments:

We need to see all business open back up now more than ever especially Kauai!

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/17/2021 1:16:18 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Darrell Edwards	Individual	Support	No

Comments:

The Safe Travels Program is an ongoing and celebrated success that has worked so well for all of Hawaii when in effect (even on Kauai). Kauai opting out created that much more confusion for travelers. Many people with reservations to visit Kauai and and/or multiple islands have cancelled their reservations, because they were uncertain about all of the different rules, and when/if the rules would change again. This not only hurt Kauai's economy, but the State's as well, with many people cancelling their trips to other islands and Hawaii in general. Kauai opting out of the Safe Travels program further destroyed it's already fragile economy, as well as put thousands of more people out of work, closed more businesses, had more people file for unemployment, etc. Kauai has the lowest new case counts in Hawaii, and Hawaii has the lowest case counts in the Country. How is this justifiable to continue to compromise Hawaii's future when everyone here is working so hard to keep our case counts so low? The Covid new case and hospitalization rates are as low or lower than before the Safe Travels program started! There is no justification not to have a uniform policy for all of Hawaii, so that the visitors and returning residents can get a negative test, then travel to any of the Hawaii islands without trying to figure out the different rules and potentially delaying/cancelling their trips until things are easier/clarified!

Please, help give some stability to Hawaii and pass this bill for the sake of Hawaii's residents, visitors and economic recovery. Aloha!

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

Honorable Senators, Representatives, Governor, Mayors, and Councilmembers:

I submitted testimony on February 15th comparing Kaua'i's cases before and after October 15th when Hawai'i's 14-day quarantine travel restrictions were lifted. I also listed numbers for cases and deaths statewide and by Counties. I then compared Kaua'i's numbers for cases and deaths with the other Counties, and presented what Kaua'i's numbers would be at other islands' rates.

Today I compared Hawai'i state numbers with mainland cases and deaths. I calculated mainland numbers by subtracting Hawai'i numbers from total US data. I looked at subtracting Alaska as well, but their rate of confirmed cases was comparable to the overall US rates (one case per 13 residents). I determined the following:

	Current #s	If computed at mainland ratios
Hawai'i statewide cases	26,935	121,193
Statewide deaths	427	2,139
Big Island cases	2,217	17,249
Big Island deaths	53	304
Kaua'i cases	179	6,261
Kaua'i deaths	1	110
Maui County cases	2,094	14,330
Maui County deaths	29	253
O'ahu cases	21,650	83,418
O'ahu deaths	341	1,472

As we can see, Hawai'i would be in a world of hurt if we were on par with the mainland. I would prefer that we wait until more of our citizens are vaccinated – like the hotel and restaurant workers and businesses – before opening up our state with relaxed travel regulations.

Attached is a spreadsheet of calculations used to determine above numbers.
Thank you again for your service .. Susan Oakley, Kaua'i

US Statistics

329,484,123	US population per 2020 Census [1]
332,243,017	Current US population per WorldOMeter [2]
	US population minus Hawai'i population
28,438,566	US COVID-19 cases per WorldOMeter [3]
11.68	Per capita rate of US cases
501,891	US COVID-19 deaths per WorldOMeter [3]
661.98	Per capita rate of US deaths

Hawai'i State Statistics

1,415,872	Hawai'i Population per 2020 Census [1]
0.42972%	Hawai'i as % of US Population
26,935	Hawai'i COVID-19 Cases [4]
0.094713%	Hawai'i Cases as % of US Cases
52.57	Per capita rate of cases
427	Hawai'i COVID-19 Deaths [4]
0.085078%	Hawai'i Deaths as % of US Deaths
3,315.86	Per capita rate of deaths

Mainland Statistics

328,077,117	US population minus Hawai'i population
28,411,631	US cases minus Hawai'i cases
11.547	Per capita rate of cases of mainland population
501,464	US deaths minus Hawai'i deaths
654.24	Per capita rate of deaths of mainland population

Kaua'i County Statistics

72,293	Kaua'i Population per 2020 Census [1]
179	Kaua'i COVID-19 cases [4]
403.87	Per capita rate of Kaua'i cases
1	Kaua'i COVID-19 deaths [4]
72,293	Per capita rate of Kaua'i deaths
1,343,579	Hawai'i minus Kaua'i population
26,756	Hawai'i cases minus Kaua'i cases
50	Per capita rate of state minus Kaua'i cases
0.006645628	Kaua'i cases as % of Hawai'i cases
426	Hawai'i deaths minus Kaua'i deaths
3,154	Per capita rate of state minus Kaua'i deaths
0.234192%	Kaua'i deaths as % of Hawai'i deaths

Hawai'i State population per 2020 Census [1]	1,415,872
Hawai'i State COVID-19 Cases [4]	26,935
Hawai'i State cases at mainland ratio	121,193
Hawai'i COVID-19 Deaths [4]	427
Hawai'i State deaths at mainland ratio	2,139

Maui County population per 2020 Census [1]	167,417
Maui County cases as of noon Feb 17 [4]	2,094
Maui County cases at mainland ratio	14,330
Maui County deaths as of noon Feb 17 [4]	29
Maui County deaths at mainland ratio	253

O'ahu population per 2020 Census [1]	974,563
O'ahu cases as of noon Feb 17 [4]	21,650
O'ahu cases at mainland ratio	83,418
O'ahu deaths as of noon Feb 17 [4]	341
O'ahu deaths at mainland ratio	1,472

Hawai'i County population per 2020 Census [1]	201,513
Hawai'i County cases as of noon Feb 17 [4]	2,217
Hawai'i County cases at mainland ratio	17,249
Hawai'i County deaths as of noon Feb 17 [4]	53
Hawai'i County deaths at mainland ratio	304

Kaua'i County population per 2020 Census [1]	72,293
Kaua'i COVID-19 cases [4]	179
Kaua'i cases at mainland ratio	6,261
Kaua'i COVID-19 deaths [4]	1
Kaua'i deaths at mainland ratio	110

1) https://www.census.gov/quickfacts/fact/table/mauicountyhawaii,honolulucountyhawaii,kauaicountyhawaii,hawaiicountyhawaii,HI,US/PST045219

2) https://www.worldometers.info/world-population/us-population/

3) https://www.worldometers.info/coronavirus/country/us/

4) https://health.hawaii.gov/coronavirusdisease2019/what-you-should-know/current-situation-in-hawaii/

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/17/2021 1:48:29 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Kristin Matsuda	Individual	Support	No

Comments:

I echo the sentiments expressed by Representative Morikawa. Additionally, it just seems that HI's elected leaders arbitrarily select when we will be united as a "state" (like when the statewide teachers union HSTA benefits by keeping all the state's public schools in shutdown-mode while Kauai has impressively low COVID numbers that would otherwise dictate that our schools be OPEN) and when we will not (like when Mayor Kawakami gets to play community hero while really just allowing a select few to enjoy our Garden Island at the expense of everyone else). It's time to open and get back to normal for inter-island travel. You have a had a year to figure this out. Time to try something new and unifying that doesn't involve fear, division, over-legislating, or over-regulating.

LATE *Testimony submitted late may not be considered by the Committee for decision making purposes.

HB-1286-HD-1
Submitted on: 2/17/2021 3:02:00 PM
Testimony for JHA on 2/17/2021 2:00:00 PM

Submitted By	Organization	Testifier Position	Present at Hearing
Laurie Puglia	Individual	Support	No

Comments:

I support this bill..Time to open up Kauai. Livelihoods are being destroyed.